https://biobriefs.com/m-a-activity-and-takeout BioBriefs en 2026-11-05T16:32:27Z M&A activity and takeout speculation https://biobriefs.com/biopharma-licensing-and-china-business BioBriefs en 2026-11-05T16:32:27Z Biopharma licensing and China business development https://biobriefs.com/china-regulatory-crackdown-on-investigator BioBriefs en 2026-11-05T16:32:27Z China regulatory crackdown on investigator-initiated trials https://biobriefs.com/dealmaking-and-financing-for-early BioBriefs en 2026-11-05T16:32:27Z Dealmaking and financing for early-stage oncology/immune startups https://biobriefs.com/big-clinical-outcomes-and-label BioBriefs en 2026-11-05T16:32:27Z Big clinical outcomes and label expansion in metabolic disease https://biobriefs.com/clinical-efficacy-signal-from-real BioBriefs en 2026-11-05T16:32:27Z Clinical efficacy signal from real-world and comparative trials https://biobriefs.com/immunotherapy-and-monoclonal-antibody-pipeline BioBriefs en 2026-11-05T16:32:27Z Immunotherapy and monoclonal antibody pipeline readouts https://biobriefs.com/genetic-medicine-early-clinical-data BioBriefs en 2026-11-05T16:32:27Z Genetic medicine: early clinical data and trial momentum https://biobriefs.com/biopharma-staffing-and-strategic-restructuring BioBriefs en 2026-11-05T16:32:27Z Biopharma staffing and strategic restructuring https://biobriefs.com/clinical-development-setbacks-and-pivotal BioBriefs en 2026-11-05T16:32:27Z Clinical development setbacks and pivotal study outcomes https://biobriefs.com/astrazeneca-poised-for-major-takeout BioBriefs en 2026-11-05T14:32:17Z AstraZeneca poised for major takeout of Rhythm Pharmaceuticals over Imcivree momentum https://biobriefs.com/abbvie-pays-for-nxeras-gut BioBriefs en 2026-11-05T14:32:17Z AbbVie pays for Nxera’s gut-restricted EP4 agonist for IBD https://biobriefs.com/t-therapeutics-lands-133m-megafunding BioBriefs en 2026-11-05T14:32:17Z T-Therapeutics lands $133M megafunding for bispecifics targeting undruggable cancer and autoimmune disease https://biobriefs.com/alethio-therapeutics-secures-90m-series BioBriefs en 2026-11-05T14:32:17Z Alethio Therapeutics secures $90M Series A for first-in-class G6B antibody in essential thrombocythemia https://biobriefs.com/clinical-ai-for-trials-boehringer BioBriefs en 2026-11-05T14:32:17Z Clinical AI for trials: Boehringer Ingelheim and Microsoft explore AI ‘digital patient twins’ to cut control-group burden https://biobriefs.com/recursion-eyes-2027-pivotal-trial BioBriefs en 2026-11-05T14:32:17Z Recursion eyes 2027 pivotal trial after positive Phase Ib/II FAP data for REC-4881 https://biobriefs.com/cell-and-gene-therapy-manufacturing BioBriefs en 2026-11-05T14:32:17Z Cell and gene therapy manufacturing: standardization and equipment-scale monitoring get sharper attention https://biobriefs.com/regulatory-and-policy-ireland-opens BioBriefs en 2026-11-05T14:32:17Z Regulatory and policy: Ireland opens COMBINE pathway for drug-device combination trial authorizations https://biobriefs.com/muscular-dystrophy-setback-serviers-sevasemten BioBriefs en 2026-11-05T14:32:17Z Muscular dystrophy setback: Servier’s sevasemten fails pivotal Becker trial https://biobriefs.com/obesity-market-data-novos-wegovy BioBriefs en 2026-11-05T14:32:17Z Obesity market data: Novo’s Wegovy pill performance lifts outlook, but Europe launch timing shifts https://biobriefs.com/china-regulatory-crackdown-slows-investigator BioBriefs en 2026-11-05T10:32:10Z China regulatory crackdown slows investigator-initiated trials https://biobriefs.com/rare-blood-cancer-antibody-advances BioBriefs en 2026-11-05T10:32:10Z Rare blood cancer antibody advances after $90M funding https://biobriefs.com/autoimmunity-and-cancer-tcr-platform BioBriefs en 2026-11-05T10:32:10Z Autoimmunity and cancer TCR platform pulls $133M with major pharma support https://biobriefs.com/ai-assisted-trial-design-and BioBriefs en 2026-11-05T10:32:10Z AI-assisted trial design and documentation automation enters clinical workflows https://biobriefs.com/big-pharma-licensing-deal-expands BioBriefs en 2026-11-05T10:32:10Z Big pharma licensing deal expands in China with $7B upside https://biobriefs.com/phase-3-data-sonesitatug-vedotin BioBriefs en 2026-11-05T10:32:10Z Phase 3 data: sonesitatug vedotin doubles overall survival in CLDN18.2 gastric cancer https://biobriefs.com/camauzestrant-fda-approval-ties-ctdna BioBriefs en 2026-11-05T10:32:10Z Camauzestrant FDA approval ties ctDNA-guided switching to ESR1 mutation timing https://biobriefs.com/sickle-cell-gene-editing-kamau BioBriefs en 2026-11-05T10:32:10Z Sickle cell gene editing: Kamau shares first RESTORE cohort data https://biobriefs.com/vertex-eyes-runway-for-iga BioBriefs en 2026-11-05T10:32:10Z Vertex eyes runway for IgA nephropathy amid FDA decision focus https://biobriefs.com/lonza-expands-us-cdmo-footprint BioBriefs en 2026-11-05T10:32:10Z Lonza expands US CDMO footprint by buying Merck KGaA sites https://biobriefs.com/rare-blood-cancer-funding-surge BioBriefs en 2026-11-05T09:32:16Z Rare blood cancer funding surge https://biobriefs.com/large-scale-tcr-platform-backing BioBriefs en 2026-11-05T09:32:16Z Large-scale TCR platform backing in immune oncology and autoimmunity https://biobriefs.com/trial-stage-machine-learning-and BioBriefs en 2026-11-05T09:32:16Z Trial-stage machine learning and AI to accelerate evidence generation https://biobriefs.com/regulatory-milestone-first-in-class BioBriefs en 2026-11-05T09:32:16Z Regulatory milestone: first-in-class DNA plasmid immunotherapy approval https://biobriefs.com/phase-3-oncology-readout-claudin BioBriefs en 2026-11-05T09:32:16Z Phase 3 oncology readout: claudin 18.2 ADC extends survival https://biobriefs.com/cdmo-capacity-expansion-via-merck BioBriefs en 2026-11-05T09:32:16Z CDMO capacity expansion via Merck KGaA site acquisition https://biobriefs.com/clinical-stage-gene-editing-data BioBriefs en 2026-11-05T09:32:16Z Clinical-stage gene editing data in sickle cell https://biobriefs.com/cdmo-and-automation-building-blocks BioBriefs en 2026-11-05T09:32:16Z CDMO and automation: building blocks for scaling manufacturing https://biobriefs.com/immune-prevention-updates-vrc01-durability BioBriefs en 2026-11-05T09:32:16Z Immune prevention updates: VRC01 durability and breakthrough infections https://biobriefs.com/platform-and-funding-human-cell BioBriefs en 2026-11-05T09:32:16Z Platform and funding: human cell models scale-up financing https://biobriefs.com/clinical-trial-results-in-oncology BioBriefs en 2026-11-05T04:32:39Z Clinical trial results in oncology: CLDN18.2 ADC shows OS gain in phase 3 gastric cancer https://biobriefs.com/ai-and-clinical-trials-boehringer BioBriefs en 2026-11-05T04:32:39Z AI and clinical trials: Boehringer and Microsoft pursue ‘digital patient twins’ https://biobriefs.com/corporate-deals-and-manufacturing-capacity BioBriefs en 2026-11-05T04:32:39Z Corporate deals and manufacturing capacity: Lonza expands US CDMO footprint via Merck KGaA sites https://biobriefs.com/fda-and-regulatory-policy-comment BioBriefs en 2026-11-05T04:32:39Z FDA and regulatory policy: Comment fight over Treasury plan to add biotech and pharma to the COINS Act https://biobriefs.com/drug-development-pipeline-recursion-prepares BioBriefs en 2026-11-05T04:32:39Z Drug development pipeline: Recursion prepares 2027 registrational trial for MEK1/2 inhibitor in FAP https://biobriefs.com/corporate-finance-and-staffing-ultragenyx BioBriefs en 2026-11-05T04:32:39Z Corporate finance and staffing: Ultragenyx cuts staff and axes a Wilson disease gene therapy program https://biobriefs.com/regulatory-and-clinical-development-phase BioBriefs en 2026-11-05T04:32:39Z Regulatory and clinical development: Phase 3 tacrolimus monotherapy trial in older kidney transplant recipients https://biobriefs.com/corporate-transactions-in-drug-discovery BioBriefs en 2026-11-05T04:32:39Z Corporate transactions in drug discovery: AbbVie licenses Nxera’s EP4 receptor agonist program for gut-targeted IBD https://biobriefs.com/ai-in-drug-discovery-operations BioBriefs en 2026-11-05T04:32:39Z AI in drug discovery operations: Anthropic details clinical-trial AI plans with BMS and Enveda https://biobriefs.com/precision-medicine-and-approvals-in BioBriefs en 2026-11-05T04:32:39Z Precision medicine and approvals in oncology: FDA approval positions ctDNA-guided switching for ESR1-mutant HR+/HER2– breast cancer https://biobriefs.com/fda-user-fee-renewal-faces BioBriefs en 2026-11-04T21:32:13Z FDA user-fee renewal faces sharper political scrutiny https://biobriefs.com/phase-3-adc-extends-survival BioBriefs en 2026-11-04T21:32:13Z Phase 3 ADC extends survival in CLDN18.2 gastroesophageal cancer https://biobriefs.com/serviers-sevasemten-fails-pivotal-becker BioBriefs en 2026-11-04T21:32:13Z Servier’s sevasemten fails pivotal Becker muscular dystrophy readout https://biobriefs.com/kamau-therapeutics-shares-first-clinical BioBriefs en 2026-11-04T21:32:13Z Kamau Therapeutics shares first clinical readouts from revamped sickle cell gene editing https://biobriefs.com/boehringer-ingelheim-lands-backloaded-7b BioBriefs en 2026-11-04T21:32:13Z Boehringer Ingelheim lands backloaded $7B-plus ADC deal in China https://biobriefs.com/hhs-loosens-access-rules-for BioBriefs en 2026-11-04T21:32:13Z HHS loosens access rules for six unapproved gray-market peptides https://biobriefs.com/lung-cancer-risk-biomarker-shows BioBriefs en 2026-11-04T21:32:13Z Lung cancer risk biomarker shows diagnostic separation in pooled analysis https://biobriefs.com/alamar-and-nightingale-health-launch BioBriefs en 2026-11-04T21:32:13Z Alamar and Nightingale Health launch UK Biobank proteomics trial for neurodegeneration risk https://biobriefs.com/novos-obesity-franchise-gets-another BioBriefs en 2026-11-04T21:32:13Z Novo’s obesity franchise gets another boost as Wegovy pill clears Wall Street tests https://biobriefs.com/cell-therapy-manufacturing-apheresis-standardization BioBriefs en 2026-11-04T21:32:13Z Cell therapy manufacturing: apheresis standardization urged to reduce variability https://biobriefs.com/fda-moves-in-huntingtons-gene BioBriefs en 2026-11-04T16:31:52Z FDA moves in Huntington’s gene therapy review clock https://biobriefs.com/global-cardiometabolic-care-inflammation-markers BioBriefs en 2026-11-04T16:31:52Z Global cardiometabolic care: inflammation markers track higher events in atherosclerotic disease https://biobriefs.com/big-pharma-licensing-push-into BioBriefs en 2026-11-04T16:31:52Z Big Pharma licensing push into China oncology https://biobriefs.com/company-level-portfolio-cleanup-sanofi BioBriefs en 2026-11-04T16:31:52Z Company-level portfolio cleanup: Sanofi drops a STAT6 degrader program https://biobriefs.com/biotech-funding-bit-bio-raises BioBriefs en 2026-11-04T16:31:52Z Biotech funding: bit.bio raises Series D to scale human cell models https://biobriefs.com/inflatable-clinical-signal-ultrasensitive-proteomics BioBriefs en 2026-11-04T16:31:52Z Inflatable clinical signal: ultrasensitive proteomics enters large UK Biobank risk study https://biobriefs.com/precision-trial-engineering-anthropic-outlines BioBriefs en 2026-11-04T16:31:52Z Precision trial engineering: Anthropic outlines AI workflow for clinical development bottlenecks https://biobriefs.com/regulatory-changes-widen-gray-market BioBriefs en 2026-11-04T16:31:52Z Regulatory changes widen gray-market peptide access via compounding discretion https://biobriefs.com/gene-editing-in-sickle-cell BioBriefs en 2026-11-04T16:31:52Z Gene editing in sickle cell: Kamau Therapeutics reports early RESTORE trial readout ahead of ASH https://biobriefs.com/cancer-precision-fda-approves-talazoparib BioBriefs en 2026-11-04T16:31:52Z Cancer precision: FDA approves talazoparib plus enzalutamide for HRR-mutated mAPMN/S prostate cancer https://biobriefs.com/fda-greenlights-parp-based-combo BioBriefs en 2026-11-04T14:32:55Z FDA greenlights PARP-based combo for HRR-mutated prostate cancer https://biobriefs.com/uniqure-wins-fda-acceptance-with BioBriefs en 2026-11-04T14:32:55Z UniQure wins FDA acceptance with Huntington’s gene therapy review date https://biobriefs.com/recursion-pushes-toward-pivotal-trial BioBriefs en 2026-11-04T14:32:55Z Recursion pushes toward pivotal trial after positive Phase Ib/II FAP data https://biobriefs.com/uniqure-review-date-adds-urgency BioBriefs en 2026-11-04T14:32:55Z UniQure review date adds urgency as investors watch Huntington’s gene-therapy path https://biobriefs.com/camizestrant-approval-enables-ctdna-guided BioBriefs en 2026-11-04T14:32:55Z Camizestrant approval enables ctDNA-guided endocrine switching in advanced breast cancer https://biobriefs.com/contract-manufacturing-shuffle-lonza-expands BioBriefs en 2026-11-04T14:32:55Z Contract manufacturing shuffle: Lonza expands US footprint with Merck KGaA CDMO deal https://biobriefs.com/boehringer-and-sino-biopharmaceutical-enter BioBriefs en 2026-11-04T14:32:55Z Boehringer and Sino Biopharmaceutical enter large ADC/TCE cancer deal https://biobriefs.com/abbvie-bets-on-nxeras-gut BioBriefs en 2026-11-04T14:32:55Z AbbVie bets on Nxera’s gut-targeting EP4 program for IBD https://biobriefs.com/asset-and-portfolio-setbacks-serviers BioBriefs en 2026-11-04T14:32:55Z Asset and portfolio setbacks: Servier’s muscular dystrophy drug fails pivotal trial https://biobriefs.com/biotech-m-a-and-restructuring BioBriefs en 2026-11-04T14:32:55Z Biotech M&A and restructuring: Karyopharm set to sell in bankruptcy process https://biobriefs.com/regulatory-approval-oncology-precision-medicine BioBriefs en 2026-11-04T10:32:24Z Regulatory approval: oncology precision medicine and biomarker-led switching https://biobriefs.com/regulatory-approval-prostate-cancer-combination BioBriefs en 2026-11-04T10:32:24Z Regulatory approval: prostate cancer combination therapy in HRR-mutated metastatic disease https://biobriefs.com/regulatory-timeline-huntingtons-disease-gene BioBriefs en 2026-11-04T10:32:24Z Regulatory timeline: Huntington’s disease gene therapy moves toward potential approval date https://biobriefs.com/regulatory-and-clinical-setbacks-muscular BioBriefs en 2026-11-04T10:32:24Z Regulatory and clinical setbacks: muscular dystrophy pivotal trial fails after major acquisition https://biobriefs.com/commercial-deals-china-biotech-sells BioBriefs en 2026-11-04T10:32:24Z Commercial deals: China biotech sells Japan rights for Phase 3 thyroid eye disease drug https://biobriefs.com/clinical-pipeline-update-recursion-targets BioBriefs en 2026-11-04T10:32:24Z Clinical pipeline update: Recursion targets FAP registrational path after positive mid-stage data https://biobriefs.com/drug-r-d-partnerships-abbvie BioBriefs en 2026-11-04T10:32:24Z Drug R&D partnerships: AbbVie and Brise expand migraine pipeline with two preclinical programs https://biobriefs.com/manufacturing-and-supply-chain-lonza BioBriefs en 2026-11-04T10:32:24Z Manufacturing and supply chain: Lonza expands US CDMO footprint via Merck KGaA asset sale https://biobriefs.com/research-platform-and-partnerships-uk BioBriefs en 2026-11-04T10:32:24Z Research platform and partnerships: UK Biobank proteomics study expands Alzheimer’s and neurodegeneration biomarker discovery https://biobriefs.com/health-policy-enforcement-ftc-warning BioBriefs en 2026-11-04T10:32:24Z Health policy enforcement: FTC warning letters target healthcare marketing practices https://biobriefs.com/fda-approvals-in-oncology-and BioBriefs en 2026-11-04T09:32:03Z FDA approvals in oncology and gene therapy https://biobriefs.com/clinical-trial-setbacks-in-neuromuscular BioBriefs en 2026-11-04T09:32:03Z Clinical trial setbacks in neuromuscular disease https://biobriefs.com/biotech-financing-and-new-company BioBriefs en 2026-11-04T09:32:03Z Biotech financing and new company launches in rare disease genetics https://biobriefs.com/big-pharma-licensing-deals-in BioBriefs en 2026-11-04T09:32:03Z Big pharma licensing deals in migraine drug development https://biobriefs.com/cdmo-consolidation-reshapes-us-manufacturing BioBriefs en 2026-11-04T09:32:03Z CDMO consolidation reshapes US manufacturing footprint https://biobriefs.com/fetal-real-world-platform-expansion BioBriefs en 2026-11-04T09:32:03Z Fetal/real-world platform expansion in neurodegeneration proteomics https://biobriefs.com/alzheimers-and-diabetes-biology-research BioBriefs en 2026-11-04T09:32:03Z Alzheimer’s and diabetes biology research signals and drug discovery concepts https://biobriefs.com/regulatory-and-pipeline-readouts-in BioBriefs en 2026-11-04T09:32:03Z Regulatory and pipeline readouts in rare oncology and genetics https://biobriefs.com/orphan-device-and-drug-device BioBriefs en 2026-11-04T09:32:03Z Orphan-device and drug-device regulatory pathway updates in Europe https://biobriefs.com/health-policy-oversight-affecting-biotech BioBriefs en 2026-11-04T09:32:03Z Health policy oversight affecting biotech commercialization https://biobriefs.com/huntingtons-disease-gene-therapy-moves BioBriefs en 2026-11-04T04:32:22Z Huntington’s disease gene therapy moves toward FDA decision https://biobriefs.com/sickle-cell-drug-faces-fda BioBriefs en 2026-11-04T04:32:22Z Sickle cell drug faces FDA review timing delay after safety data submission https://biobriefs.com/oncology-approval-expands-parp-inhibitor BioBriefs en 2026-11-04T04:32:22Z Oncology approval expands PARP inhibitor use with targeted hormone therapy https://biobriefs.com/biotech-restructures-after-scrapping-a BioBriefs en 2026-11-04T04:32:22Z Biotech restructures after scrapping a gene therapy program https://biobriefs.com/phase-3-muscular-dystrophy-attempt BioBriefs en 2026-11-04T04:32:22Z Phase 3 muscular dystrophy attempt ends in failure for a high-profile buyer https://biobriefs.com/m-a-reshapes-cdmo-footprint BioBriefs en 2026-11-04T04:32:22Z M&A reshapes CDMO footprint in the US https://biobriefs.com/regulatory-frameworks-for-drug-device BioBriefs en 2026-11-04T04:32:22Z Regulatory frameworks for drug–device combination studies get an EU pilot route https://biobriefs.com/abbvie-licensed-migraine-platform-deal BioBriefs en 2026-11-04T04:32:22Z AbbVie-licensed migraine platform deal announced https://biobriefs.com/genetics-platform-for-alzheimers-risk BioBriefs en 2026-11-04T04:32:22Z Genetics platform for Alzheimer’s risk study scales to tens of thousands of samples https://biobriefs.com/fabry-disease-enzyme-replacement-deal BioBriefs en 2026-11-04T04:32:22Z Fabry disease enzyme replacement deal extends to subcutaneous development https://biobriefs.com/muscular-dystrophy-setback-for-servier BioBriefs en 2026-11-03T21:32:53Z Muscular dystrophy setback for Servier after large acquisition https://biobriefs.com/fda-approval-expands-ctdna-guided BioBriefs en 2026-11-03T21:32:53Z FDA approval expands ctDNA-guided switching in breast cancer https://biobriefs.com/new-registrational-pathway-after-positive BioBriefs en 2026-11-03T21:32:53Z New registrational pathway after positive mid-stage FAP data at Recursion https://biobriefs.com/fda-sets-pdufa-date-for BioBriefs en 2026-11-03T21:32:53Z FDA sets PDUFA date for uniQure Huntington’s gene therapy https://biobriefs.com/uniqure-review-timeline-moves-forward BioBriefs en 2026-11-03T21:32:53Z UniQure review timeline moves forward amid related trading reaction https://biobriefs.com/lonza-expands-us-cdmo-footprint BioBriefs en 2026-11-03T21:32:53Z Lonza expands US CDMO footprint by acquiring Merck KGaA sites https://biobriefs.com/fda-delays-decision-on-agios BioBriefs en 2026-11-03T21:32:53Z FDA delays decision on Agios sickle cell sNDA https://biobriefs.com/fda-approval-extends-hrr-mutated BioBriefs en 2026-11-03T21:32:53Z FDA approval extends HRR-mutated prostate cancer treatment with talazoparib https://biobriefs.com/drug-device-regulation-shift-ireland BioBriefs en 2026-11-03T21:32:53Z Drug-device regulation shift: Ireland opens COMBINE trial authorization https://biobriefs.com/new-biotech-financing-setara-launches BioBriefs en 2026-11-03T21:32:53Z New biotech financing: Setara launches with $90M to pursue genetics at scale https://biobriefs.com/fda-approval-expands-parp-inhibitor BioBriefs en 2026-11-03T16:32:13Z FDA approval expands PARP inhibitor use in HRR-mutant mHSPC https://biobriefs.com/uniqures-huntingtons-gene-therapy-enters BioBriefs en 2026-11-03T16:32:13Z uniQure’s Huntington’s gene therapy enters formal FDA review for May 1 https://biobriefs.com/abbvie-and-brise-lock-in BioBriefs en 2026-11-03T16:32:13Z AbbVie and Brise lock in up to $757m for preclinical migraine programs https://biobriefs.com/lonza-expands-u-s-cdmo BioBriefs en 2026-11-03T16:32:13Z Lonza expands U.S. CDMO footprint via Merck KGaA network sale https://biobriefs.com/new-fabry-enzyme-replacement-licensing BioBriefs en 2026-11-03T16:32:13Z New Fabry enzyme replacement licensing deal for HM15421/GC1134A https://biobriefs.com/agios-mitapivat-snda-decision-pushed BioBriefs en 2026-11-03T16:32:13Z Agios mitapivat sNDA decision pushed as FDA requests REMS assessment data https://biobriefs.com/brighter-fda-partially-holds-bright BioBriefs en 2026-11-03T16:32:13Z Brighter? FDA partially holds Bright Minds seizure drug after mouse toxicity findings https://biobriefs.com/setara-launches-with-90m-to BioBriefs en 2026-11-03T16:32:13Z Setara launches with $90m to build genetics-driven rare disease-to-common condition strategy https://biobriefs.com/cell-free-protein-synthesis-plus BioBriefs en 2026-11-03T16:32:13Z Cell-free protein synthesis plus AI automation boosts enzyme manufacturing https://biobriefs.com/stem-cell-biology-identifies-long BioBriefs en 2026-11-03T16:32:13Z Stem cell biology identifies long-lived dormant blood stem cell reserve https://biobriefs.com/fda-approval-precision-oncology-combo BioBriefs en 2026-11-03T14:32:56Z FDA approval – precision oncology combo therapy https://biobriefs.com/fda-review-timeline-huntingtons-gene BioBriefs en 2026-11-03T14:32:56Z FDA review timeline – Huntington’s gene therapy https://biobriefs.com/cdmo-m-a-lonza-expands BioBriefs en 2026-11-03T14:32:56Z CDMO M&A – Lonza expands US footprint from Merck KGaA https://biobriefs.com/biopharma-licensing-astellas-bets-on BioBriefs en 2026-11-03T14:32:56Z Biopharma licensing – Astellas bets on Audax IL-12 program https://biobriefs.com/clinical-update-mitapivat-snda-faces BioBriefs en 2026-11-03T14:32:56Z Clinical update – mitapivat sNDA faces FDA delay in sickle cell https://biobriefs.com/deals-biomarin-expands-fabry-franchise BioBriefs en 2026-11-03T14:32:56Z Deals – BioMarin expands Fabry franchise with LA-GLA ERT option https://biobriefs.com/therapeutics-regulatory-groundwork-for-individualized BioBriefs en 2026-11-03T14:32:56Z Therapeutics – regulatory groundwork for individualized gene editing https://biobriefs.com/health-tech-policy-hhs-loosens BioBriefs en 2026-11-03T14:32:56Z Health tech policy – HHS loosens health IT certification oversight https://biobriefs.com/biotech-investing-new-startup-emerges BioBriefs en 2026-11-03T14:32:56Z Biotech investing – new startup emerges from Jazz/Actio deal with $90M https://biobriefs.com/cdmo-and-biosimilars-fresenius-ramps BioBriefs en 2026-11-03T14:32:56Z CDMO and biosimilars – Fresenius ramps with WuXi/Fresenius partnership https://biobriefs.com/regulatory-milestones-for-gene-therapies BioBriefs en 2026-11-03T10:31:47Z Regulatory milestones for gene therapies https://biobriefs.com/oncology-approvals-expand-targeted-combination BioBriefs en 2026-11-03T10:31:47Z Oncology approvals expand targeted combination options https://biobriefs.com/cardiopulmonary-science-links-inflammation-to BioBriefs en 2026-11-03T10:31:47Z Cardiopulmonary science links inflammation to cognitive decline https://biobriefs.com/company-dealmaking-reshapes-manufacturing-and BioBriefs en 2026-11-03T10:31:47Z Company dealmaking reshapes manufacturing and rare disease portfolios https://biobriefs.com/cdmo-and-biosimilars-manufacturing-partnerships BioBriefs en 2026-11-03T10:31:47Z CDMO and biosimilars manufacturing partnerships https://biobriefs.com/oncology-pipeline-signals-at-esmo BioBriefs en 2026-11-03T10:31:47Z Oncology pipeline signals at ESMO https://biobriefs.com/immuno-oncology-licensing-investment BioBriefs en 2026-11-03T10:31:47Z Immuno-oncology licensing investment https://biobriefs.com/finance-and-restructuring-in-blood BioBriefs en 2026-11-03T10:31:47Z Finance and restructuring in blood cancer biotech https://biobriefs.com/single-cell-ai-analytics-moves BioBriefs en 2026-11-03T10:31:47Z Single-cell AI analytics moves into the lab workflow https://biobriefs.com/health-tech-and-biotech-funding BioBriefs en 2026-11-03T10:31:47Z Health tech and biotech funding activity https://biobriefs.com/fda-greenlights-new-parp-inhibitor BioBriefs en 2026-11-03T09:31:58Z FDA greenlights new PARP inhibitor combo for HRR-mutated mAPMN/S prostate cancer https://biobriefs.com/huntingtons-gene-therapy-clears-key BioBriefs en 2026-11-03T09:31:58Z Huntington’s gene therapy clears key FDA review step under PDUFA clock https://biobriefs.com/agios-sickle-cell-snda-delayed BioBriefs en 2026-11-03T09:31:58Z Agios’ sickle cell sNDA delayed as FDA requests REMS-related information https://biobriefs.com/astellas-expands-il-12-investment BioBriefs en 2026-11-03T09:31:58Z Astellas expands IL-12 investment via option on Audax’s DAX-044 program https://biobriefs.com/biomarin-lines-up-fabry-ert BioBriefs en 2026-11-03T09:31:58Z BioMarin lines up Fabry ERT candidate with up to $475m partner deal https://biobriefs.com/setara-launches-with-90m-after BioBriefs en 2026-11-03T09:31:58Z Setara launches with $90m after Jazz acquisition of Actio—TRPV4 inhibitor enters clinic https://biobriefs.com/crispr-activation-boosted-by-mechanical BioBriefs en 2026-11-03T09:31:58Z CRISPR activation boosted by mechanical stimulation to reprogram cells into neurons https://biobriefs.com/fda-action-advances-a-gene BioBriefs en 2026-11-03T09:31:58Z FDA action advances a gene-editing regulatory framework for individualized rare disease therapies https://biobriefs.com/wuxi-biologics-and-fresenius-set BioBriefs en 2026-11-03T09:31:58Z WuXi Biologics and Fresenius set biosimilars pact ahead of scale-up phase https://biobriefs.com/karyopharm-to-sell-itself-through BioBriefs en 2026-11-03T09:31:58Z Karyopharm to sell itself through bankruptcy process as it weighs merger path https://biobriefs.com/fda-greenlights-talazoparib-enzalutamide-for BioBriefs en 2026-11-03T04:32:06Z FDA greenlights talazoparib + enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer https://biobriefs.com/fda-sets-may-1-review BioBriefs en 2026-11-03T04:32:06Z FDA sets May 1 review date for uniQure’s Huntington gene therapy (iezuntirgene inilparvovec) https://biobriefs.com/fda-delays-agios-decision-on BioBriefs en 2026-11-03T04:32:06Z FDA delays Agios decision on mitapivat sNDA for sickle cell disease pending REMS assessment https://biobriefs.com/biotech-dealmaking-biomarin-signs-up BioBriefs en 2026-11-03T04:32:06Z Biotech dealmaking: BioMarin signs up to as much as $475m for long-acting Fabry enzyme replacement therapy candidate https://biobriefs.com/large-biosimilars-push-wuxi-biologics BioBriefs en 2026-11-03T04:32:06Z Large biosimilars push: WuXi Biologics and Fresenius expand bets ahead of the biosimilar wave https://biobriefs.com/setara-launches-from-jazzs-actio BioBriefs en 2026-11-03T04:32:06Z Setara launches from Jazz’s Actio acquisition with $90m to pursue genetics-driven rare disease programs https://biobriefs.com/cardiovascular-drug-development-graviton-teams BioBriefs en 2026-11-03T04:32:06Z Cardiovascular drug development: Graviton teams with Sam Waksal to pursue ROCK2 therapies for pulmonary arterial hypertension https://biobriefs.com/immuno-oncology-translational-research-chemotherapy BioBriefs en 2026-11-03T04:32:06Z Immuno-oncology translational research: chemotherapy may act as an adjuvant for viral-vector cancer vaccines https://biobriefs.com/gene-editing-regulation-fda-draft BioBriefs en 2026-11-03T04:32:06Z Gene editing regulation: FDA draft guidance defines BLA submissions for individualized genome editing products https://biobriefs.com/bio-ai-tools-for-single BioBriefs en 2026-11-03T04:32:06Z Bio-AI tools for single-cell workflows: Sentira brings Claude-powered agentic analysis to 10x Chromium https://biobriefs.com/us-regulatory-decision-in-rare BioBriefs en 2026-11-02T21:32:45Z US regulatory decision in rare pediatric tumor immunotherapy https://biobriefs.com/huntingtons-gene-therapy-clears-fda BioBriefs en 2026-11-02T21:32:45Z Huntington’s gene therapy clears FDA review gate https://biobriefs.com/oncology-fda-decision-for-combination BioBriefs en 2026-11-02T21:32:45Z Oncology FDA decision for combination therapy in HRR-mutant metastatic prostate cancer https://biobriefs.com/regulatory-timing-for-sickle-cell BioBriefs en 2026-11-02T21:32:45Z Regulatory timing for sickle cell drug amid REMS question https://biobriefs.com/biosimilar-expansion-deal-tied-to BioBriefs en 2026-11-02T21:32:45Z Biosimilar expansion deal tied to projected market growth https://biobriefs.com/fabry-disease-deal-expands-enzyme BioBriefs en 2026-11-02T21:32:45Z Fabry disease deal expands enzyme replacement modalities https://biobriefs.com/gene-editing-regulation-roadmap-for BioBriefs en 2026-11-02T21:32:45Z Gene editing regulation roadmap for individualized genome therapies https://biobriefs.com/deck-reshuffle-in-hematology-as BioBriefs en 2026-11-02T21:32:45Z Deck reshuffle in hematology as Karyopharm seeks bankruptcy sale https://biobriefs.com/robotic-microsurgery-expands-with-new BioBriefs en 2026-11-02T21:32:45Z Robotic microsurgery expands with new funding and neurodegeneration exploration https://biobriefs.com/early-readouts-for-immunology-drug BioBriefs en 2026-11-02T21:32:45Z Early readouts for immunology drug contest against established eczema leaders https://biobriefs.com/huntingtons-gene-therapy-regulatory-milestone BioBriefs en 2026-11-02T16:32:07Z Huntington’s gene therapy regulatory milestone https://biobriefs.com/sickle-cell-drug-faces-fda BioBriefs en 2026-11-02T16:32:07Z Sickle cell drug faces FDA timing and safety-structure questions https://biobriefs.com/cardio-biotech-collaboration-targets-rock2 BioBriefs en 2026-11-02T16:32:07Z Cardio biotech collaboration targets ROCK2 for PAH and related disease https://biobriefs.com/gene-editing-regulation-for-individualized BioBriefs en 2026-11-02T16:32:07Z Gene editing regulation for individualized therapies https://biobriefs.com/biologic-exclusivity-rollover-meets-biosimilar BioBriefs en 2026-11-02T16:32:07Z Biologic exclusivity rollover meets biosimilar competition realities https://biobriefs.com/fabry-enzyme-replacement-therapy-deal BioBriefs en 2026-11-02T16:32:07Z Fabry enzyme replacement therapy deal expands delivery differentiation https://biobriefs.com/immunology-pipeline-readout-in-eczema BioBriefs en 2026-11-02T16:32:07Z Immunology pipeline readout in eczema benchmark season https://biobriefs.com/adc-efficacy-readout-in-her2 BioBriefs en 2026-11-02T16:32:07Z ADC efficacy readout in HER2-low breast cancer https://biobriefs.com/robotic-microsurgery-expands-toward-new BioBriefs en 2026-11-02T16:32:07Z Robotic microsurgery expands toward new indications https://biobriefs.com/setara-launches-with-clinic-stage BioBriefs en 2026-11-02T16:32:07Z Setara launches with clinic-stage rare disease lead https://biobriefs.com/regulatory-framework-for-individualized-gene BioBriefs en 2026-11-02T14:32:41Z Regulatory framework for individualized gene editing https://biobriefs.com/big-pharma-deal-for-next BioBriefs en 2026-11-02T14:32:41Z Big pharma deal for next-gen Fabry enzyme therapy https://biobriefs.com/phase-3-win-for-her2 BioBriefs en 2026-11-02T14:32:41Z Phase 3 win for Her2-low ADC in HORIZON-Breast06 https://biobriefs.com/eczema-readout-builds-pressure-on BioBriefs en 2026-11-02T14:32:41Z Eczema readout builds pressure on Kymera’s mid-stage program https://biobriefs.com/cardiopulmonary-targeting-collaboration-for-rock2 BioBriefs en 2026-11-02T14:32:41Z Cardiopulmonary targeting collaboration for ROCK2 drugs https://biobriefs.com/startup-financing-for-robotic-microsurgery BioBriefs en 2026-11-02T14:32:41Z Startup financing for robotic microsurgery and exploratory neuro work https://biobriefs.com/biotech-startup-funding-for-rare BioBriefs en 2026-11-02T14:32:41Z Biotech startup funding for rare disease and clinic pipeline https://biobriefs.com/health-systems-financing-startup-raises BioBriefs en 2026-11-02T14:32:41Z Health systems financing startup raises Series A https://biobriefs.com/pricing-and-access-policy-shift BioBriefs en 2026-11-02T14:32:41Z Pricing and access policy shift in the U.S. market https://biobriefs.com/ebola-outbreak-scale-and-tracking BioBriefs en 2026-11-02T14:32:41Z Ebola outbreak scale and tracking challenges in DRC https://biobriefs.com/mfn-adoption-reshapes-u-s BioBriefs en 2026-11-02T10:32:40Z MFN adoption reshapes U.S. drug launch economics, spreads across global pricing frameworks https://biobriefs.com/genmabs-petosemtamab-plus-keytruda-posts BioBriefs en 2026-11-02T10:32:40Z Genmab’s petosemtamab plus Keytruda posts positive late-stage readout in PD-L1–positive first-line head and neck cancer https://biobriefs.com/fda-issues-draft-guidance-to BioBriefs en 2026-11-02T10:32:40Z FDA issues draft guidance to define approval pathway for individualized human genome editing products https://biobriefs.com/biomarin-expands-fabry-pipeline-with BioBriefs en 2026-11-02T10:32:40Z BioMarin expands Fabry pipeline with up to $475m deal for HM15421/GC1134A long-acting ERT https://biobriefs.com/kymera-readies-eczema-trial-data BioBriefs en 2026-11-02T10:32:40Z Kymera readies eczema trial data as investors gauge its shot at the Dupixent immunology throne https://biobriefs.com/setara-biosciences-launches-with-90m BioBriefs en 2026-11-02T10:32:40Z Setara Biosciences launches with $90m and a clinic-stage drug after Jazz-linked deal flow https://biobriefs.com/mmi-banks-125m-to-scale BioBriefs en 2026-11-02T10:32:40Z MMI banks $125m to scale Symani robotic microsurgery and explore Alzheimer’s applications https://biobriefs.com/midstream-health-closes-series-a BioBriefs en 2026-11-02T10:32:40Z Midstream Health closes Series A to bolster financial stability for health systems https://biobriefs.com/horizon-breast06-trastuzumab-rezetecan-improves BioBriefs en 2026-11-02T10:32:40Z HORIZON-Breast06: trastuzumab rezetecan improves progression-free survival in HER2-low advanced breast cancer https://biobriefs.com/scientists-quantify-a-rise-in BioBriefs en 2026-11-02T10:32:40Z Scientists quantify a rise in fabricated references, highlighting escalating integrity risks across biomedical publishing https://biobriefs.com/gene-editing-regulation-for-individualized BioBriefs en 2026-11-02T09:32:38Z Gene editing regulation for individualized therapies https://biobriefs.com/late-stage-efficacy-win-in BioBriefs en 2026-11-02T09:32:38Z Late-stage efficacy win in head and neck cancer https://biobriefs.com/phase-3-confirmation-for-her2 BioBriefs en 2026-11-02T09:32:38Z Phase 3 confirmation for HER2-low breast cancer ADC https://biobriefs.com/funding-for-new-healthcare-finance BioBriefs en 2026-11-02T09:32:38Z Funding for new healthcare finance infrastructure https://biobriefs.com/microsurgery-expansion-and-experimental-alzheimers BioBriefs en 2026-11-02T09:32:38Z Microsurgery expansion and experimental Alzheimer’s application https://biobriefs.com/biotech-dealmaking-and-seedling-pipeline BioBriefs en 2026-11-02T09:32:38Z Biotech dealmaking and seedling pipeline launch backed by new financing https://biobriefs.com/scientific-integrity-signals-fabricated-references BioBriefs en 2026-11-02T09:32:38Z Scientific integrity signals: fabricated references in biomedical publishing https://biobriefs.com/peer-review-ethics-scrutiny-editor BioBriefs en 2026-11-02T09:32:38Z Peer review ethics scrutiny: editor–author conflicts at major open-access publishers https://biobriefs.com/translational-lab-workflow-blood-based BioBriefs en 2026-11-02T09:32:38Z Translational lab workflow: blood-based amyloid testing guidance https://biobriefs.com/tools-for-protein-biologics-manufacturing BioBriefs en 2026-11-02T09:32:38Z Tools for protein biologics manufacturing: LC-MS-assisted bispecific purification https://biobriefs.com/gene-editing-regulation BioBriefs en 2026-11-02T04:32:11Z Gene editing regulation https://biobriefs.com/late-stage-oncology-readout BioBriefs en 2026-11-02T04:32:11Z Late-stage oncology readout https://biobriefs.com/merger-fueled-oncology-win BioBriefs en 2026-11-02T04:32:11Z Merger-fueled oncology win https://biobriefs.com/rare-disease-biotech-funding-and BioBriefs en 2026-11-02T04:32:11Z Rare disease biotech funding and clinic entry https://biobriefs.com/robotics-microsurgery-expansion BioBriefs en 2026-11-02T04:32:11Z Robotics microsurgery expansion https://biobriefs.com/digital-health-platform-funding BioBriefs en 2026-11-02T04:32:11Z Digital health platform funding https://biobriefs.com/biotech-tooling-and-analytics-product BioBriefs en 2026-11-02T04:32:11Z Biotech tooling and analytics (product-focused) https://biobriefs.com/regulated-lab-equipment-for-data BioBriefs en 2026-11-02T04:32:11Z Regulated lab equipment for data integrity https://biobriefs.com/workforce-and-education-removed-as BioBriefs en 2026-11-02T04:32:11Z Workforce and education (removed as low-impact for industry news) https://biobriefs.com/scientific-integrity-and-research-ecosystem BioBriefs en 2026-11-02T04:32:11Z Scientific integrity and research ecosystem (removed as low-impact for biotech industry operations) https://biobriefs.com/gene-editing-regulation-moves-toward BioBriefs en 2026-11-01T21:32:46Z Gene editing regulation moves toward individualized genome-variation within a single BLA https://biobriefs.com/late-stage-oncology-win-adds BioBriefs en 2026-11-01T21:32:46Z Late-stage oncology win adds momentum for bispecific petosemtamab combinations https://biobriefs.com/phase-3-horizon-breast06-confirms BioBriefs en 2026-11-01T21:32:46Z Phase 3 HORIZON-Breast06 confirms PFS lift for trastuzumab rezetecan in HER2-low https://biobriefs.com/fda-advisory-panel-questions-whether BioBriefs en 2026-11-01T21:32:46Z FDA advisory panel questions whether atropine can shift decision-making on Sydnexis https://biobriefs.com/fdas-november-docket-spotlights-ivonescimab BioBriefs en 2026-11-01T21:32:46Z FDA’s November docket spotlights ivonescimab and multiple potential PD-1 x VEGF decisions https://biobriefs.com/setara-raises-fresh-capital-to BioBriefs en 2026-11-01T21:32:46Z Setara raises fresh capital to start a lead drug program in rare disease and beyond https://biobriefs.com/mmi-expands-symani-robotic-microsurgery BioBriefs en 2026-11-01T21:32:46Z MMI expands Symani robotic microsurgery after Series D funding https://biobriefs.com/public-equity-debut-pressure-hits BioBriefs en 2026-11-01T21:32:46Z Public equity debut pressure hits biotech IPOs amid NASDAQ weakness https://biobriefs.com/strand-therapeutics-begins-dosing-in BioBriefs en 2026-11-01T21:32:46Z Strand Therapeutics begins dosing in systemic programmable mRNA program https://biobriefs.com/gene-editing-data-flare-meets BioBriefs en 2026-11-01T21:32:46Z Gene-editing data flare meets ESGCT congress readouts and FDA comment window https://biobriefs.com/rare-disease-biotech-launches-with BioBriefs en 2026-11-01T16:32:40Z Rare disease biotech launches with seed funding and early clinical pipeline https://biobriefs.com/robotics-and-ai-expand-beyond BioBriefs en 2026-11-01T16:32:40Z Robotics and AI expand beyond surgery into new therapeutic applications https://biobriefs.com/phase-3-adc-delivers-major BioBriefs en 2026-11-01T16:32:40Z Phase 3 ADC delivers major progression-free survival gain in HER2-low breast cancer https://biobriefs.com/genmabs-petosemtamab-combo-posts-another BioBriefs en 2026-11-01T16:32:40Z Genmab’s petosemtamab combo posts another late-stage win in PD-L1+ head and neck cancer https://biobriefs.com/fda-pushes-a-scalable-path BioBriefs en 2026-11-01T16:32:40Z FDA pushes a scalable path for personalized gene therapies via ‘plug and play’ approvals https://biobriefs.com/regulatory-calendar-tightens-around-november BioBriefs en 2026-11-01T16:32:40Z Regulatory calendar tightens around November PDUFAs and a key PD-1 x VEGF bispecific https://biobriefs.com/atropine-for-pediatric-myopia-fails BioBriefs en 2026-11-01T16:32:40Z Atropine for pediatric myopia fails to sway FDA advisors on Sydnexis evidence https://biobriefs.com/pbm-transparency-rule-finalized-disclosures BioBriefs en 2026-11-01T16:32:40Z PBM transparency rule finalized—disclosures expected to drive employer contract leverage https://biobriefs.com/ai-ready-immune-dataset-scales BioBriefs en 2026-11-01T16:32:40Z AI-ready immune dataset scales multimodal drug discovery inputs https://biobriefs.com/funding-backs-one-time-kidney BioBriefs en 2026-11-01T16:32:40Z Funding backs one-time kidney gene therapy concept for ADPKD https://biobriefs.com/her2-low-adc-delivers-major BioBriefs en 2026-11-01T14:32:17Z HER2-low ADC delivers major PFS win in phase 3 HORIZON-Breast06 https://biobriefs.com/genmabs-petosemtamab-plus-keytruda-posts BioBriefs en 2026-11-01T14:32:17Z Genmab’s petosemtamab plus Keytruda posts survival benefit in PD-L1–positive head and neck cancer https://biobriefs.com/fda-advances-plug-and-play BioBriefs en 2026-11-01T14:32:17Z FDA advances “plug and play” approvals for personalized gene therapies https://biobriefs.com/dol-finalizes-sweeping-pbm-compensation BioBriefs en 2026-11-01T14:32:17Z DOL finalizes sweeping PBM compensation disclosure rule https://biobriefs.com/sydnexis-pediatric-myopia-fda-advisors BioBriefs en 2026-11-01T14:32:17Z Sydnexis pediatric myopia: FDA advisors hold out for more evidence despite atropine practice patterns https://biobriefs.com/launch-price-and-access-gap BioBriefs en 2026-11-01T14:32:17Z Launch-price and access gap persists for outpatient drugs https://biobriefs.com/opentrons-raises-40m-to-scale BioBriefs en 2026-11-01T14:32:17Z Opentrons raises $40M to scale AI-enabled lab automation https://biobriefs.com/parse-and-nomic-build-cascade BioBriefs en 2026-11-01T14:32:17Z Parse and Nomic build “Cascade” multimodal immune dataset for pharma AI modeling https://biobriefs.com/fox-chase-identifies-ano6-as BioBriefs en 2026-11-01T14:32:17Z Fox Chase identifies ANO6 as a driver of pancreatic tumor lipid supply and immune suppression https://biobriefs.com/parse-updates-editor-author-conflict BioBriefs en 2026-11-01T14:32:17Z Parse-updates: Editor–author conflict checks uncover thousands of policy breaches at PLOS and MDPI https://biobriefs.com/oncology-genmabs-petosemtamab-combo-posts BioBriefs en 2026-11-01T10:31:53Z Oncology: Genmab’s petosemtamab combo posts another late-stage win in head and neck cancer https://biobriefs.com/regulation-fda-advances-a-plug BioBriefs en 2026-11-01T10:31:53Z Regulation: FDA advances a “plug and play” pathway for personalized gene therapies https://biobriefs.com/cell-therapy-safety-regulatory-gilead BioBriefs en 2026-11-01T10:31:53Z Cell therapy safety/regulatory: Gilead flags partial clinical hold after CAR-T ICANS cases https://biobriefs.com/m-a-and-pipeline-shift BioBriefs en 2026-11-01T10:31:53Z M&A and pipeline shift: Sanofi seeks late-stage and commercial acquisitions to offset Dupixent pressure https://biobriefs.com/pbm-oversight-dol-finalizes-sweeping BioBriefs en 2026-11-01T10:31:53Z PBM oversight: DOL finalizes sweeping disclosure rule affecting employer contracts https://biobriefs.com/immunology-data-for-drug-discovery BioBriefs en 2026-11-01T10:31:53Z Immunology data for drug discovery: Parse and Nomic launch 100M-cell immune response dataset https://biobriefs.com/clinical-translation-fox-chase-team BioBriefs en 2026-11-01T10:31:53Z Clinical translation: Fox Chase team identifies ANO6 as a pancreatic cancer driver and immunosuppression lever https://biobriefs.com/therapeutics-funding-dren-bio-raises BioBriefs en 2026-11-01T10:31:53Z Therapeutics funding: Dren Bio raises $350M to advance CD94 antibody dibotatug toward commercialization https://biobriefs.com/genomics-automation-opentrons-lands-40m BioBriefs en 2026-11-01T10:31:53Z Genomics automation: Opentrons lands $40M Series E for AI-enabled lab robotics infrastructure https://biobriefs.com/public-markets-bambusa-therapeutics-raises BioBriefs en 2026-11-01T10:31:53Z Public markets: Bambusa Therapeutics raises IPO cash as it targets immunology’s monoclonal ceiling https://biobriefs.com/oncology-trial-readout-drives-market BioBriefs en 2026-11-01T09:31:38Z Oncology trial readout drives market repricing at Genmab https://biobriefs.com/fda-sets-a-regulatory-pathway BioBriefs en 2026-11-01T09:31:38Z FDA sets a regulatory pathway for personalized 'plug and play' gene therapies https://biobriefs.com/fda-advisory-gatekeeping-atropine-use BioBriefs en 2026-11-01T09:31:38Z FDA advisory gatekeeping: atropine use doesn’t sway Sydnexis review for pediatric myopia https://biobriefs.com/gilead-pauses-car-t-after BioBriefs en 2026-11-01T09:31:38Z Gilead pauses CAR-T after ICANS signals trigger partial clinical hold https://biobriefs.com/sanofi-pivots-toward-later-stage BioBriefs en 2026-11-01T09:31:38Z Sanofi pivots toward later-stage and commercial M&A to blunt Dupixent decline risk https://biobriefs.com/abbvie-posts-another-quarter-of BioBriefs en 2026-11-01T09:31:38Z AbbVie posts another quarter of beats and signals preference for bolt-on deals https://biobriefs.com/drug-access-icer-finds-high BioBriefs en 2026-11-01T09:31:38Z Drug access: ICER finds high launch prices paired with slow outpatient fills https://biobriefs.com/pbm-transparency-labor-finalizes-sweeping BioBriefs en 2026-11-01T09:31:38Z PBM transparency: Labor finalizes sweeping disclosure rule https://biobriefs.com/lab-automation-funding-opentrons-raises BioBriefs en 2026-11-01T09:31:38Z Lab automation funding: Opentrons raises Series E for autonomous experiment workflows https://biobriefs.com/immunology-data-infrastructure-parse-and BioBriefs en 2026-11-01T09:31:38Z Immunology data infrastructure: Parse and Nomic launch a 100M-cell multimodal immune dataset https://biobriefs.com/fda-expands-framework-for-personalized BioBriefs en 2026-11-01T04:31:57Z FDA expands framework for personalized gene therapies https://biobriefs.com/pbm-transparency-rule-finalized-targeting BioBriefs en 2026-11-01T04:31:57Z PBM transparency rule finalized, targeting compensation and rebates https://biobriefs.com/genmabs-petosemtamab-keytruda-posts-late BioBriefs en 2026-11-01T04:31:57Z Genmab’s petosemtamab + Keytruda posts late-stage win in PD-L1+ head and neck cancer https://biobriefs.com/sanofi-plans-to-shift-toward BioBriefs en 2026-11-01T04:31:57Z Sanofi plans to shift toward late-stage and commercial M&A as Dupixent cliff nears https://biobriefs.com/opentrons-raises-40m-series-e BioBriefs en 2026-11-01T04:31:57Z Opentrons raises $40M Series E to expand autonomous lab execution https://biobriefs.com/parse-and-nomic-launch-100m BioBriefs en 2026-11-01T04:31:57Z Parse and Nomic launch 100M-cell immune dataset for multimodal AI drug discovery https://biobriefs.com/dren-bio-closes-350m-to BioBriefs en 2026-11-01T04:31:57Z Dren Bio closes $350M to advance CD94 antibody dibotatug toward commercialization https://biobriefs.com/astellas-inks-up-to-1 BioBriefs en 2026-11-01T04:31:57Z Astellas inks up to $1.34B option deal for Audax’s DAX-044 IL-12 tumor-focused fusion https://biobriefs.com/bambusa-and-aspen-ipos-bring BioBriefs en 2026-11-01T04:31:57Z Bambusa and Aspen IPOs bring new capital amid Nasdaq volatility https://biobriefs.com/cold-agglutinin-disease-review-reframes BioBriefs en 2026-11-01T04:31:57Z Cold agglutinin disease review reframes complement-driven care and where sutimlimab fits https://biobriefs.com/head-and-neck-cancer-petosemtamab BioBriefs en 2026-10-31T21:31:53Z Head and neck cancer—petosemtamab plus Keytruda posts late-stage win https://biobriefs.com/regulatory-fda-proposes-plug-and BioBriefs en 2026-10-31T21:31:53Z Regulatory—FDA proposes ‘plug and play’ approvals for personalized gene therapies https://biobriefs.com/clinical-pipeline-gilead-pauses-car BioBriefs en 2026-10-31T21:31:53Z Clinical pipeline—Gilead pauses CAR-T trials after ICANS cases https://biobriefs.com/ophthalmology-regulation-fda-advisory-panel BioBriefs en 2026-10-31T21:31:53Z Ophthalmology/Regulation—FDA advisory panel weighs Sydnexis atropine strategy for pediatric myopia https://biobriefs.com/late-stage-oversight-labor-finalizes BioBriefs en 2026-10-31T21:31:53Z Late-stage oversight—Labor finalizes sweeping PBM disclosure rule https://biobriefs.com/biopharma-earnings-and-capital-allocation BioBriefs en 2026-10-31T21:31:53Z Biopharma earnings and capital allocation—AbbVie beat supports bolt-on deal posture https://biobriefs.com/drug-pipeline-and-gene-therapy BioBriefs en 2026-10-31T21:31:53Z Drug pipeline and gene-therapy investment—Dren Bio closes $350M for dibotatug toward commercialization https://biobriefs.com/immunology-data-infrastructure-parse-and BioBriefs en 2026-10-31T21:31:53Z Immunology data infrastructure—Parse and Nomic build 100M-cell immune multimodal dataset https://biobriefs.com/clinical-trials-and-technology-strand BioBriefs en 2026-10-31T21:31:53Z Clinical trials and technology—Strand begins first-patient dosing of systemic programmable mRNA therapy https://biobriefs.com/lab-automation-funding-opentrons-raises BioBriefs en 2026-10-31T21:31:53Z Lab automation funding—Opentrons raises $40M Series E to expand autonomous lab infrastructure https://biobriefs.com/genmabs-bispecific-hits-late-stage BioBriefs en 2026-10-31T16:32:53Z Genmab’s bispecific hits late-stage goals in first-line head and neck cancer https://biobriefs.com/fda-sets-rules-for-plug BioBriefs en 2026-10-31T16:32:53Z FDA sets rules for “plug and play” personalized gene therapies https://biobriefs.com/drugmakers-accelerate-m-a-math BioBriefs en 2026-10-31T16:32:53Z Drugmakers accelerate M&A math as Dupixent’s patent cliff looms https://biobriefs.com/astrazeneca-signals-restructuring-savings-with BioBriefs en 2026-10-31T16:32:53Z AstraZeneca signals restructuring savings with R&D and trials possibly shifted https://biobriefs.com/abbvie-keeps-beating-estimates-and BioBriefs en 2026-10-31T16:32:53Z AbbVie keeps beating estimates and signals preference for bolt-on deals https://biobriefs.com/opentrons-raises-40m-to-scale BioBriefs en 2026-10-31T16:32:53Z Opentrons raises $40M to scale autonomous lab robotics infrastructure https://biobriefs.com/parse-and-nomic-build-a BioBriefs en 2026-10-31T16:32:53Z Parse and Nomic build a 100M-cell AI-ready immune dataset for target discovery https://biobriefs.com/astellas-options-il-12-fusion BioBriefs en 2026-10-31T16:32:53Z Astellas options IL-12 fusion for tumor-selective immune activation https://biobriefs.com/venture-funding-backs-one-time BioBriefs en 2026-10-31T16:32:53Z Venture funding backs one-time gene therapy bet in ADPKD https://biobriefs.com/dren-bio-raises-350m-to BioBriefs en 2026-10-31T16:32:53Z Dren Bio raises $350M to push CD94-targeting antibody toward market https://biobriefs.com/head-and-neck-cancer-trial BioBriefs en 2026-10-31T14:31:52Z Head and neck cancer trial success for Genmab’s petosemtamab plus Keytruda https://biobriefs.com/fda-plug-and-play-pathway BioBriefs en 2026-10-31T14:31:52Z FDA ‘plug-and-play’ pathway for personalized gene therapies https://biobriefs.com/fda-calendar-november-pd-1 BioBriefs en 2026-10-31T14:31:52Z FDA calendar: November PD-1 x VEGF bispecific ivonescimab PDUFA spotlight https://biobriefs.com/pbm-transparency-department-of-labor BioBriefs en 2026-10-31T14:31:52Z PBM transparency: Department of Labor finalizes sweeping disclosure rule https://biobriefs.com/atropine-and-pediatric-myopia-fda BioBriefs en 2026-10-31T14:31:52Z Atropine and pediatric myopia: FDA advisory panel backs more evidence for Sydnexis https://biobriefs.com/innovation-capital-opentrons-raises-40m BioBriefs en 2026-10-31T14:31:52Z Innovation capital: Opentrons raises $40M Series E for autonomous lab automation https://biobriefs.com/immune-discovery-dataset-buildout-parse BioBriefs en 2026-10-31T14:31:52Z Immune discovery dataset buildout: Parse and Nomic create 100M-cell Cascade https://biobriefs.com/cell-therapy-and-ipo-calendar BioBriefs en 2026-10-31T14:31:52Z Cell therapy and IPO calendar: Aspen Neuroscience and Bambusa debut raise cash https://biobriefs.com/rare-disease-funding-dren-bio BioBriefs en 2026-10-31T14:31:52Z Rare disease funding: Dren Bio banks $350M to advance dibotatug https://biobriefs.com/immuno-oncology-deal-astellas-options BioBriefs en 2026-10-31T14:31:52Z Immuno-oncology deal: Astellas options Audax IL-12 fusion DAX-044 https://biobriefs.com/fda-considers-new-approach-for BioBriefs en 2026-10-31T10:31:34Z FDA considers new approach for rare-disease personalized gene therapies https://biobriefs.com/pbms-face-sweeping-federal-transparency BioBriefs en 2026-10-31T10:31:34Z PBMs face sweeping federal transparency requirements https://biobriefs.com/drug-pricing-and-patient-access BioBriefs en 2026-10-31T10:31:34Z Drug pricing and patient access gaps persist despite real-world affordability efforts https://biobriefs.com/astrazeneca-outlines-restructuring-tied-to BioBriefs en 2026-10-31T10:31:34Z AstraZeneca outlines restructuring tied to R&D and trial shifts https://biobriefs.com/fdas-complex-advisory-debate-stalls BioBriefs en 2026-10-31T10:31:34Z FDAs complex advisory debate stalls pediatric myopia decision https://biobriefs.com/sanofi-prepares-for-dupixent-patent BioBriefs en 2026-10-31T10:31:34Z Sanofi prepares for Dupixent patent cliff with deal-seeking R&D focus https://biobriefs.com/car-t-setback-gilead-reports BioBriefs en 2026-10-31T10:31:34Z CAR-T setback: Gilead reports partial clinical hold after ICANS cases https://biobriefs.com/opentrons-raises-series-e-to BioBriefs en 2026-10-31T10:31:34Z Opentrons raises Series E to scale autonomous lab robotics https://biobriefs.com/multimodal-immune-dataset-partnership-targets BioBriefs en 2026-10-31T10:31:34Z Multimodal immune dataset partnership targets target discovery bottleneck https://biobriefs.com/dren-bio-funds-late-stage BioBriefs en 2026-10-31T10:31:34Z Dren Bio funds late-stage push for dibotatug antibody in rare hematologic cancers https://biobriefs.com/fda-modernizes-personalized-gene-therapy BioBriefs en 2026-10-31T09:32:54Z FDA modernizes personalized gene-therapy approvals for rare mutations https://biobriefs.com/fda-advisors-push-for-stronger BioBriefs en 2026-10-31T09:32:54Z FDA advisors push for stronger proof in pediatric myopia drug review https://biobriefs.com/multiple-pdufas-looming-as-fda BioBriefs en 2026-10-31T09:32:54Z Multiple PDUFAs looming as FDA readies November approvals https://biobriefs.com/sanofi-signals-late-phase-and BioBriefs en 2026-10-31T09:32:54Z Sanofi signals late-phase and commercial M&A as Dupixent faces the patent cliff https://biobriefs.com/abbvie-keeps-momentum-as-management BioBriefs en 2026-10-31T09:32:54Z AbbVie keeps momentum as management favors bolt-on acquisitions https://biobriefs.com/dren-bio-raises-350m-to BioBriefs en 2026-10-31T09:32:54Z Dren Bio raises $350M to push CD94-targeted antibody toward market https://biobriefs.com/opentrons-scales-autonomous-lab-automation BioBriefs en 2026-10-31T09:32:54Z Opentrons scales autonomous lab automation after $40M Series E https://biobriefs.com/parse-and-nomic-build-a BioBriefs en 2026-10-31T09:32:54Z Parse and Nomic build a 100M-cell multimodal immune dataset for drug discovery https://biobriefs.com/pbms-face-sweeping-transparency-requirements BioBriefs en 2026-10-31T09:32:54Z PBMs face sweeping transparency requirements under DOL’s final rule https://biobriefs.com/clinical-infrastructure-and-patient-access BioBriefs en 2026-10-31T09:32:54Z Clinical infrastructure and patient access metrics spotlight affordability gaps https://biobriefs.com/gene-therapies-move-toward-plug BioBriefs en 2026-10-31T04:32:19Z Gene therapies move toward “plug-and-play” approvals for rare-mutation variants https://biobriefs.com/pbms-face-sweeping-transparency-rule BioBriefs en 2026-10-31T04:32:19Z PBMs face sweeping transparency rule as contract leverage shifts to employers https://biobriefs.com/big-pharma-pivots-as-dupixents BioBriefs en 2026-10-31T04:32:19Z Big pharma pivots as Dupixent’s patent cliff looms: M&A and pricing strategy at Sanofi https://biobriefs.com/autonomous-experimentation-and-ai-enabled BioBriefs en 2026-10-31T04:32:19Z Autonomous experimentation and AI-enabled lab robotics advance with Opentrons Series E https://biobriefs.com/parse-and-nomic-build-massive BioBriefs en 2026-10-31T04:32:19Z Parse and Nomic build massive immune dataset to accelerate target discovery https://biobriefs.com/new-immunology-startups-reach-the BioBriefs en 2026-10-31T04:32:19Z New immunology startups reach the public markets as IPOs extend IPO streak https://biobriefs.com/targeted-immune-oncology-deal-astellas BioBriefs en 2026-10-31T04:32:19Z Targeted immune-oncology deal: Astellas options Audax’s IL-12 fusion asset https://biobriefs.com/antibody-therapy-funding-dren-bio BioBriefs en 2026-10-31T04:32:19Z Antibody therapy funding: Dren Bio banks $350M to advance dibotatug https://biobriefs.com/big-deal-in-data-to BioBriefs en 2026-10-31T04:32:19Z Big deal in data-to-therapy strategy: engineered immune cells move toward solid-tumor trials https://biobriefs.com/fda-moves-toward-approval-pathway BioBriefs en 2026-10-30T21:32:50Z FDA moves toward approval pathway for personalized gene therapies https://biobriefs.com/us-final-rule-targets-pbm BioBriefs en 2026-10-30T21:32:50Z US final rule targets PBM compensation transparency for employer plans https://biobriefs.com/astrazeneca-commits-to-major-restructuring BioBriefs en 2026-10-30T21:32:50Z AstraZeneca commits to major restructuring as it targets R&D and trials reallocation https://biobriefs.com/abbvie-posts-q3-beat-as BioBriefs en 2026-10-30T21:32:50Z AbbVie posts Q3 beat as management prioritizes bolt-on acquisitions https://biobriefs.com/sanofi-looks-to-dealmaking-to BioBriefs en 2026-10-30T21:32:50Z Sanofi looks to dealmaking to offset Dupixent patent cliff https://biobriefs.com/car-t-development-faces-regulatory BioBriefs en 2026-10-30T21:32:50Z CAR-T development faces regulatory and trial interruptions at Gilead https://biobriefs.com/opentrons-expands-robotics-and-ai BioBriefs en 2026-10-30T21:32:50Z Opentrons expands robotics and AI tools with new Series E funding https://biobriefs.com/parse-and-nomic-back-a BioBriefs en 2026-10-30T21:32:50Z Parse and Nomic back a massive multimodal immune dataset for drug discovery https://biobriefs.com/new-biotech-funding-for-rare BioBriefs en 2026-10-30T21:32:50Z New biotech funding for rare blood cancer antibody developer https://biobriefs.com/setara-spins-out-rare-disease BioBriefs en 2026-10-30T21:32:50Z Setara spins out rare-disease pipeline after Actio sale to Jazz https://biobriefs.com/rare-disease-venture-funding-dren BioBriefs en 2026-10-30T16:32:43Z Rare-disease venture funding: Dren Bio’s $350M drive to commercialization https://biobriefs.com/immuno-oncology-dealmaking-astellas-options BioBriefs en 2026-10-30T16:32:43Z Immuno-oncology dealmaking: Astellas options Audax’s IL-12 fusion DAX-044 https://biobriefs.com/regulatory-and-clinical-program-disruptions BioBriefs en 2026-10-30T16:32:43Z Regulatory and clinical program disruptions: Gilead’s CAR-T partial clinical hold after ICANS https://biobriefs.com/big-pharma-cost-and-r BioBriefs en 2026-10-30T16:32:43Z Big pharma cost and R&D shifts: AstraZeneca restructuring hints at trial and R&D cutbacks https://biobriefs.com/ip-and-rare-disease-strategy BioBriefs en 2026-10-30T16:32:43Z IP and rare-disease strategy: FDA’s Fit-for-Purpose Rare Disease Framework gets BIO support https://biobriefs.com/cold-agglutinin-disease-sutimlimab-era BioBriefs en 2026-10-30T16:32:43Z Cold agglutinin disease: sutimlimab-era care mapped as first approved drug reshapes treatment https://biobriefs.com/rare-disease-startup-formation-setara BioBriefs en 2026-10-30T16:32:43Z Rare disease startup formation: Setara spins out Actio pipeline with $90M https://biobriefs.com/biopharma-markets-aspen-neuroscience-and BioBriefs en 2026-10-30T16:32:43Z Biopharma markets: Aspen Neuroscience and Bambusa debut with large IPOs https://biobriefs.com/oncology-diagnostics-innovation-b7-h4 BioBriefs en 2026-10-30T16:32:43Z Oncology diagnostics innovation: B7-H4 ADC puxitatug posts early responses in first-in-human trial https://biobriefs.com/us-healthcare-policy-new-labor BioBriefs en 2026-10-30T16:32:43Z US healthcare policy: new Labor Department PBM disclosure rule takes aim at middlemen fees https://biobriefs.com/dren-bio-secures-large-private BioBriefs en 2026-10-30T14:32:08Z Dren Bio secures large private financing to advance CD94 antibody toward commercialization https://biobriefs.com/astellas-and-audax-strike-il BioBriefs en 2026-10-30T14:32:08Z Astellas and Audax strike IL-12 fusion deal to seed next immuno-oncology pipeline https://biobriefs.com/aspen-neuroscience-prepares-for-ipo BioBriefs en 2026-10-30T14:32:08Z Aspen Neuroscience prepares for IPO amid Parkinson’s cell therapy push https://biobriefs.com/sanofi-sidesteps-major-overhaul-as BioBriefs en 2026-10-30T14:32:08Z Sanofi sidesteps major overhaul as Dupixent patent cliff approaches https://biobriefs.com/astrazeneca-accelerates-cost-actions-to BioBriefs en 2026-10-30T14:32:08Z AstraZeneca accelerates cost actions to fund pipeline investment https://biobriefs.com/regulatory-and-healthcare-policy-pressure BioBriefs en 2026-10-30T14:32:08Z Regulatory and healthcare policy pressure points for biotech employers and reimbursements https://biobriefs.com/a-new-spotlight-on-palliative BioBriefs en 2026-10-30T14:32:08Z A new spotlight on palliative care measurement under CMS https://biobriefs.com/ai-driven-drug-discovery-leadership BioBriefs en 2026-10-30T14:32:08Z AI-driven drug discovery leadership: Anthropic exec on biopharma partnerships and M&A https://biobriefs.com/uk-biobank-restarts-access-after BioBriefs en 2026-10-30T14:32:08Z UK Biobank restarts access after massive data breach https://biobriefs.com/rare-hematology-buy-in-cold BioBriefs en 2026-10-30T14:32:08Z Rare hematology buy-in: cold agglutinin disease treatment mapping highlights sutimlimab era https://biobriefs.com/astrazeneca-cost-cutting-to-fund BioBriefs en 2026-10-30T10:32:54Z AstraZeneca cost-cutting to fund pipeline https://biobriefs.com/biomarin-pays-70m-for-long BioBriefs en 2026-10-30T10:32:54Z BioMarin pays $70M for long-acting Fabry enzyme replacement rights https://biobriefs.com/frontiers-retracts-stem-cell-exosome BioBriefs en 2026-10-30T10:32:54Z Frontiers retracts stem-cell exosome fracture paper over image integrity https://biobriefs.com/uk-biobank-restores-access-after BioBriefs en 2026-10-30T10:32:54Z UK Biobank restores access after major data leak https://biobriefs.com/first-in-human-b7-h4 BioBriefs en 2026-10-30T10:32:54Z First-in-human B7-H4 ADC posts early tumor shrinkage signals https://biobriefs.com/amr-threat-data-cdc-quantifies BioBriefs en 2026-10-30T10:32:54Z AMR threat data – CDC quantifies infections and deaths https://biobriefs.com/cold-agglutinin-disease-sutimlimab-era BioBriefs en 2026-10-30T10:32:54Z Cold agglutinin disease – sutimlimab era and first approved drug review https://biobriefs.com/sepsis-heart-injury-biomarkers-combine BioBriefs en 2026-10-30T10:32:54Z Sepsis heart injury biomarkers combine modestly https://biobriefs.com/ipsc-free-sensing-ultrasound-enhances BioBriefs en 2026-10-30T10:32:54Z iPSC-free sensing: Ultrasound enhances ovarian tumor discrimination in pilot https://biobriefs.com/mendelian-quality-gene-therapy-platform BioBriefs en 2026-10-30T10:32:54Z Mendelian-quality gene therapy platform debate – gene editing demand vs sparse data https://biobriefs.com/astrazeneca-pipeline-investment-via-major BioBriefs en 2026-10-30T09:31:54Z AstraZeneca pipeline investment via major restructuring https://biobriefs.com/merger-market-new-clinical-oncology BioBriefs en 2026-10-30T09:31:54Z Merger-market: new clinical oncology readouts drive deal chatter https://biobriefs.com/rare-disease-regulation-fda-expands BioBriefs en 2026-10-30T09:31:54Z Rare-disease regulation: FDA expands fit-for-purpose framework https://biobriefs.com/ipo-window-for-cell-therapy BioBriefs en 2026-10-30T09:31:54Z IPO window for cell therapy and early-stage biotech https://biobriefs.com/new-cell-therapy-readout-il BioBriefs en 2026-10-30T09:31:54Z New cell therapy readout: IL-6-responsive CAR macrophages plus CAR-T https://biobriefs.com/oncology-imaging-standardization-china-issues BioBriefs en 2026-10-30T09:31:54Z Oncology imaging standardization: China issues national PET guideline https://biobriefs.com/diagnostics-innovation-imaging-based-cardiac BioBriefs en 2026-10-30T09:31:54Z Diagnostics innovation: imaging-based cardiac amyloidosis shifts away from biopsy https://biobriefs.com/immuno-oncology-target-strategy-gene BioBriefs en 2026-10-30T09:31:54Z Immuno-oncology target strategy: gene signatures linked to PD-1 blockade response https://biobriefs.com/oncology-drug-mechanism-risk-pan BioBriefs en 2026-10-30T09:31:54Z Oncology drug mechanism risk: pan-RAS inhibitor shows vascular signals but no cardiac endpoints at Phase 3 scale https://biobriefs.com/cold-agglutinin-disease-new-treatment BioBriefs en 2026-10-30T09:31:54Z Cold agglutinin disease: new treatment landscape mapped https://biobriefs.com/fda-and-regulator-adjacent-policy BioBriefs en 2026-10-30T04:31:45Z FDA- and regulator-adjacent policy update: peptide compounding expanded despite objections https://biobriefs.com/uk-biobank-restores-access-after BioBriefs en 2026-10-30T04:31:45Z UK Biobank restores access after major data breach https://biobriefs.com/fda-linked-rare-disease-framework BioBriefs en 2026-10-30T04:31:45Z FDA-linked rare-disease framework support draws industry comment https://biobriefs.com/biomarin-pays-70m-for-long BioBriefs en 2026-10-30T04:31:45Z BioMarin pays $70M for long-acting Fabry enzyme replacement expansion https://biobriefs.com/clinical-and-translational-oncology-il BioBriefs en 2026-10-30T04:31:45Z Clinical and translational oncology: IL-6-responsive CAR macrophages enhance CAR-T activity https://biobriefs.com/rare-disease-and-trial-design BioBriefs en 2026-10-30T04:31:45Z Rare-disease and trial design: ACO-SWITCH protocol tracks transthyretin after tafamidis-to-acoramidis switch https://biobriefs.com/oncology-cyclin-k-degradation-reverses BioBriefs en 2026-10-30T04:31:45Z Oncology: Cyclin K degradation reverses HIV latency in cell models and patient-derived cells https://biobriefs.com/diagnostics-and-medical-ai-uk BioBriefs en 2026-10-30T04:31:45Z Diagnostics and medical AI: UK-Grown beans? (excluded) – Instead: Seoul? (excluded) https://biobriefs.com/drug-discovery-and-cancer-biology BioBriefs en 2026-10-30T04:31:45Z Drug discovery and cancer biology: tumor vasculature functions as an immune-regulatory hub https://biobriefs.com/diagnostic-ai-for-pathology-pituitary BioBriefs en 2026-10-30T04:31:45Z Diagnostic AI for pathology: Pituitary subtype detection from routine slides using deep learning https://biobriefs.com/biopharma-licensing-and-pipeline-expansion BioBriefs en 2026-10-29T21:32:33Z Biopharma licensing and pipeline expansion https://biobriefs.com/regulatory-framework-shift-for-rare BioBriefs en 2026-10-29T21:32:33Z Regulatory framework shift for rare disease drug development https://biobriefs.com/regulatory-controversy-hhs-peptide-compounding BioBriefs en 2026-10-29T21:32:33Z Regulatory controversy: HHS peptide compounding enforcement discretion https://biobriefs.com/oncology-therapeutics-immune-checkpoint-strategy BioBriefs en 2026-10-29T21:32:33Z Oncology therapeutics: immune checkpoint strategy shows survival signal https://biobriefs.com/cellular-therapy-imaging-pet-ct BioBriefs en 2026-10-29T21:32:33Z Cellular therapy imaging: PET/CT findings track CAR T response https://biobriefs.com/ai-in-oncology-workflows-genomics BioBriefs en 2026-10-29T21:32:33Z AI in oncology workflows: genomics from single-cell Hi-C https://biobriefs.com/immunotherapy-engineering-il-6-responsive BioBriefs en 2026-10-29T21:32:33Z Immunotherapy engineering: IL-6-responsive CAR macrophages boost CAR T https://biobriefs.com/drug-discovery-governance-quality-and BioBriefs en 2026-10-29T21:32:33Z Drug discovery governance: quality and risk assessment for digital twins in pharma https://biobriefs.com/infection-and-antimicrobial-resistance-policy BioBriefs en 2026-10-29T21:32:33Z Infection and antimicrobial resistance policy: CDC quantifies US AMR burden https://biobriefs.com/clinical-product-and-data-balanced BioBriefs en 2026-10-29T21:32:33Z Clinical product and data: balanced drug regimen improves LDL with manageable enzymes https://biobriefs.com/merger-and-acquisition-ferring-to BioBriefs en 2026-10-29T16:32:01Z Merger and acquisition: Ferring to buy Gameto https://biobriefs.com/regulatory-and-policy-hhs-allows BioBriefs en 2026-10-29T16:32:01Z Regulatory and policy: HHS allows compounding of six experimental peptides https://biobriefs.com/oncology-genmab-shares-surge-on BioBriefs en 2026-10-29T16:32:01Z Oncology: Genmab shares surge on head-and-neck cancer trial success https://biobriefs.com/oncology-immunotherapy-cimavax-egf-plus BioBriefs en 2026-10-29T16:32:01Z Oncology (immunotherapy): CIMAvax-EGF plus nivolumab posts survival signal in advanced NSCLC https://biobriefs.com/hematologic-oncology-timdarpacept-plus-azacitidine BioBriefs en 2026-10-29T16:32:01Z Hematologic oncology: Timdarpacept plus azacitidine shows 72.7% response in CMML https://biobriefs.com/clinical-safety-and-research-integrity BioBriefs en 2026-10-29T16:32:01Z Clinical safety and research integrity: BMC Neuroscience issues expression of concern over diabetes drug neurogenesis images https://biobriefs.com/regenerative-medicine-immunology-vagus-nerve BioBriefs en 2026-10-29T16:32:01Z Regenerative medicine / immunology: Vagus nerve stimulation shows 10-year safety and remission durability in Crohn’s disease https://biobriefs.com/molecular-oncology-nsun2-suppresses-cd8 BioBriefs en 2026-10-29T16:32:01Z Molecular oncology: NSUN2 suppresses CD8 recruitment and blocks anti-PD-1 efficacy in lung adenocarcinoma https://biobriefs.com/biotech-funding-and-corporate-strategy BioBriefs en 2026-10-29T16:32:01Z Biotech funding and corporate strategy: Flagship Pioneering merges three AI drug-discovery startups into Etcelera https://biobriefs.com/vaccinology-infectious-disease-egf-depleting BioBriefs en 2026-10-29T16:32:01Z Vaccinology / infectious disease: EGF-depleting vaccine plus nivolumab survival signal? (excluded) — replacing with H9N2 epitope mapping for diagnostics https://biobriefs.com/regulatory-and-policy-shift-for BioBriefs en 2026-10-29T14:31:56Z Regulatory and policy shift for experimental peptides https://biobriefs.com/big-pharma-deal-in-fertility BioBriefs en 2026-10-29T14:31:56Z Big pharma deal in fertility cell engineering https://biobriefs.com/corporate-restructuring-to-build-an BioBriefs en 2026-10-29T14:31:56Z Corporate restructuring to build an AI drug discovery platform https://biobriefs.com/immunotherapy-signal-in-advanced-nsclc BioBriefs en 2026-10-29T14:31:56Z Immunotherapy signal in advanced NSCLC with an EGF-depleting vaccine https://biobriefs.com/longevity-science-funding-european-push BioBriefs en 2026-10-29T14:31:56Z Longevity science funding: European push for secretome OA therapy https://biobriefs.com/clinical-safety-signals-and-infection BioBriefs en 2026-10-29T14:31:56Z Clinical safety signals and infection scrutiny ahead of an FDA decision for Vertex https://biobriefs.com/clinical-trial-response-in-cmml BioBriefs en 2026-10-29T14:31:56Z Clinical trial response in CMML using a SIRPα-Fc fusion plus azacitidine https://biobriefs.com/regimen-reconsideration-low-dose-aspirin BioBriefs en 2026-10-29T14:31:56Z Regimen reconsideration: low-dose aspirin association in sepsis mortality https://biobriefs.com/diagnostics-remote-digital-slide-reading BioBriefs en 2026-10-29T14:31:56Z Diagnostics: remote digital slide reading for thyroid cytology https://biobriefs.com/drug-delivery-platform-research-hybrid BioBriefs en 2026-10-29T14:31:56Z Drug delivery platform research: hybrid extracellular vesicles to overcome EV limits https://biobriefs.com/regulatory-milestone-for-rsv-prevention BioBriefs en 2026-10-29T10:31:42Z Regulatory milestone for RSV prevention https://biobriefs.com/big-biotech-m-a BioBriefs en 2026-10-29T10:31:42Z Big biotech M&A https://biobriefs.com/immuno-oncology-target-discovery-in BioBriefs en 2026-10-29T10:31:42Z Immuno-oncology target discovery in solid tumors https://biobriefs.com/therapy-durability-and-safety-in BioBriefs en 2026-10-29T10:31:42Z Therapy durability and safety in atopic dermatitis https://biobriefs.com/oncology-mechanism-linking-tumor-microenvironment BioBriefs en 2026-10-29T10:31:42Z Oncology mechanism linking tumor microenvironment to drug resistance https://biobriefs.com/car-nk-immunotherapy-engineering-roundup BioBriefs en 2026-10-29T10:31:42Z CAR-NK immunotherapy engineering roundup https://biobriefs.com/glucagon-like-immune-and-safety BioBriefs en 2026-10-29T10:31:42Z Glucagon-like immune and safety signal in diabetes drug class https://biobriefs.com/antiviral-therapy-signal-for-long BioBriefs en 2026-10-29T10:31:42Z Antiviral therapy signal for Long COVID risk reduction https://biobriefs.com/clinical-validation-gap-for-machine BioBriefs en 2026-10-29T10:31:42Z Clinical validation gap for machine learning medicine https://biobriefs.com/translational-cardiology-imaging-risk-marker BioBriefs en 2026-10-29T10:31:42Z Translational cardiology imaging risk marker after stenting https://biobriefs.com/m-a-ferring-to-acquire BioBriefs en 2026-10-29T09:31:53Z M&A: Ferring to acquire Gameto for up to $1.38B https://biobriefs.com/oncology-tagmokitug-interim-data-in BioBriefs en 2026-10-29T09:31:53Z Oncology: Tagmokitug interim data in esophageal squamous cell carcinoma https://biobriefs.com/cardiovascular-glp-1-subject-level BioBriefs en 2026-10-29T09:31:53Z Cardiovascular: GLP-1 subject-level analysis finds no raised suicide risk https://biobriefs.com/imaging-diagnostics-positron-emission-mammography BioBriefs en 2026-10-29T09:31:53Z Imaging/Diagnostics: Positron emission mammography vs standard imaging for multifocal disease https://biobriefs.com/immunology-cell-biology-rabies-matrix BioBriefs en 2026-10-29T09:31:53Z Immunology/Cell biology: Rabies matrix protein suppresses ferroptosis via RGS4 axis https://biobriefs.com/regenerative-medicine-stem-cells-new BioBriefs en 2026-10-29T09:31:53Z Regenerative medicine/Stem cells: New small-molecule protocol generates human iPSCs from cord cells https://biobriefs.com/clinical-safety-evidence-sacituzumab-tirumotecan BioBriefs en 2026-10-29T09:31:53Z Clinical safety evidence: Sacituzumab tirumotecan adverse events appear front-loaded but manageable https://biobriefs.com/ai-in-medicine-reasoning-models BioBriefs en 2026-10-29T09:31:53Z AI in medicine: Reasoning models raise false positives in diagnosis workflows https://biobriefs.com/public-health-policy-hhs-announces BioBriefs en 2026-10-29T09:31:53Z Public health policy: HHS announces limited enforcement discretion for certain peptide bulk drugs https://biobriefs.com/regulatory-clinical-innovation-single-dose BioBriefs en 2026-10-29T09:31:53Z Regulatory/Clinical innovation: Single-dose RSV antibody clesrovimab approved and provides first-season protection https://biobriefs.com/rsv-antibody-protection-in-infants BioBriefs en 2026-10-29T04:32:02Z RSV antibody protection in infants https://biobriefs.com/diabetes-megastudy-retatrutide-beats-ozempic BioBriefs en 2026-10-29T04:32:02Z Diabetes megastudy: retatrutide beats Ozempic head-to-head https://biobriefs.com/fda-lays-out-a-gene BioBriefs en 2026-10-29T04:32:02Z FDA lays out a gene-editing approval pathway for individualized therapies https://biobriefs.com/hhs-expands-enforcement-discretion-for BioBriefs en 2026-10-29T04:32:02Z HHS expands enforcement discretion for unapproved wellness peptides https://biobriefs.com/biotech-industry-economics-and-workforce BioBriefs en 2026-10-29T04:32:02Z Biotech industry economics and workforce footprint https://biobriefs.com/formation-bio-raises-600m-fund BioBriefs en 2026-10-29T04:32:02Z Formation Bio raises $600M fund to scale AI-driven asset strategy https://biobriefs.com/tagmokitug-in-ccr8-program-posts BioBriefs en 2026-10-29T04:32:02Z Tagmokitug in CCR8 program posts interim ESCC activity https://biobriefs.com/gene-editing-and-immune-therapy BioBriefs en 2026-10-29T04:32:02Z Gene editing and immune therapy engineering: compact multiplexing Cas12m platform https://biobriefs.com/triple-negative-breast-cancer-microenvironment BioBriefs en 2026-10-29T04:32:02Z Triple-negative breast cancer microenvironment: neutrophils shift metabolism in vitro https://biobriefs.com/coughing-fear-not-cardiac-arrest BioBriefs en 2026-10-29T04:32:02Z Coughing fear? not—cardiac arrest resuscitation workflow improves survival https://biobriefs.com/retatrutide-beats-ozempic-in-head BioBriefs en 2026-10-28T21:31:59Z Retatrutide beats Ozempic in head-to-head Phase 3 https://biobriefs.com/fda-sets-a-path-for BioBriefs en 2026-10-28T21:31:59Z FDA sets a path for personalized gene editing approvals https://biobriefs.com/coherus-posts-interim-tagmokitug-data BioBriefs en 2026-10-28T21:31:59Z Coherus posts interim tagmokitug data in esophageal squamous cell carcinoma https://biobriefs.com/hhs-loosens-enforcement-for-compounded BioBriefs en 2026-10-28T21:31:59Z HHS loosens enforcement for compounded wellness peptides https://biobriefs.com/formation-bio-raises-600m-fund BioBriefs en 2026-10-28T21:31:59Z Formation Bio raises $600M fund for AI asset acquisition strategy https://biobriefs.com/new-crispra-platform-uses-compact BioBriefs en 2026-10-28T21:31:59Z New CRISPRa platform uses compact Cas12m in a single AAV vector https://biobriefs.com/tagging-ferroptosis-pathways-in-cancer BioBriefs en 2026-10-28T21:31:59Z Tagging ferroptosis pathways in cancer: new ferroptosis regulators and biomarkers https://biobriefs.com/microbial-immunity-in-dengue-challenge BioBriefs en 2026-10-28T21:31:59Z Microbial immunity in dengue challenge trials clarifies secondary infection risk https://biobriefs.com/ai-assisted-brain-bleed-detection BioBriefs en 2026-10-28T21:31:59Z AI-assisted brain bleed detection improves sensitivity after real-world feedback https://biobriefs.com/clinical-trial-design-and-access BioBriefs en 2026-10-28T21:31:59Z Clinical trial design and access: care coverage barriers take center stage at BIO event https://biobriefs.com/diabetes-glp-1-gip-competition BioBriefs en 2026-10-28T16:33:52Z Diabetes GLP-1/GIP competition heats up https://biobriefs.com/fda-sets-a-plug-and BioBriefs en 2026-10-28T16:33:52Z FDA sets a ‘plug and play’ pathway for gene therapies https://biobriefs.com/biotech-ai-benchmarks-move-into BioBriefs en 2026-10-28T16:33:52Z Biotech AI benchmarks move into production-grade evaluation https://biobriefs.com/ai-drug-r-d-funding BioBriefs en 2026-10-28T16:33:52Z AI drug R&D funding accelerates in China https://biobriefs.com/biogen-faces-investor-pressure-ahead BioBriefs en 2026-10-28T16:33:52Z Biogen faces investor pressure ahead of lupus catalyst readouts https://biobriefs.com/manufacturing-disruption-threatens-cancer-supply BioBriefs en 2026-10-28T16:33:52Z Manufacturing disruption threatens cancer supply in India https://biobriefs.com/astellas-makes-option-move-in BioBriefs en 2026-10-28T16:33:52Z Astellas makes option move in IL-12 immuno-oncology from Audax https://biobriefs.com/healthcare-policy-pressure-returns-on BioBriefs en 2026-10-28T16:33:52Z Healthcare policy pressure returns on affordability https://biobriefs.com/gene-therapy-mindset-grows-around BioBriefs en 2026-10-28T16:33:52Z Gene therapy mindset grows around personalized subsets https://biobriefs.com/biotech-ai-governance-and-commercialization BioBriefs en 2026-10-28T16:33:52Z Biotech AI governance and commercialization scrutiny https://biobriefs.com/regulatory-and-competitive-move-in BioBriefs en 2026-10-28T14:32:03Z Regulatory and competitive move in type 2 diabetes drug class https://biobriefs.com/ai-drug-discovery-funding-in BioBriefs en 2026-10-28T14:32:03Z AI drug discovery funding in China https://biobriefs.com/global-rare-disease-distribution-and BioBriefs en 2026-10-28T14:32:03Z Global rare disease distribution and access in APAC https://biobriefs.com/corporate-restructuring-and-deal-accounting BioBriefs en 2026-10-28T14:32:03Z Corporate restructuring and deal accounting pressure in large pharma https://biobriefs.com/clinical-and-regulatory-progress-for BioBriefs en 2026-10-28T14:32:03Z Clinical and regulatory progress for brain-penetrant PARP inhibition https://biobriefs.com/immuno-oncology-licensing-astellas-option BioBriefs en 2026-10-28T14:32:03Z Immuno-oncology licensing: Astellas option on Audax preclinical IL-12 asset https://biobriefs.com/digital-health-governance-under-clinician BioBriefs en 2026-10-28T14:32:03Z Digital health governance under clinician and regulator pressure https://biobriefs.com/ai-tool-evaluation-failure-in BioBriefs en 2026-10-28T14:32:03Z AI tool evaluation failure in real-world settings https://biobriefs.com/real-world-deployment-uplift-for BioBriefs en 2026-10-28T14:32:03Z Real-world deployment uplift for brain bleed detection AI https://biobriefs.com/insect-repellent-chemistry-lead-that BioBriefs en 2026-10-28T14:32:03Z Insect repellent chemistry lead that ties to biomedical materials https://biobriefs.com/regulatory-and-clinical-trial-readouts BioBriefs en 2026-10-28T10:32:05Z Regulatory and clinical trial readouts—cell therapy and platform missteps https://biobriefs.com/big-pharma-deal-digestion-valuation BioBriefs en 2026-10-28T10:32:05Z Big Pharma deal digestion—valuation reset after late-stage failure https://biobriefs.com/vc-capital-and-market-access BioBriefs en 2026-10-28T10:32:05Z VC capital and market access—funding flows stay concentrated https://biobriefs.com/oncology-imaging-and-biomarkers-earlier BioBriefs en 2026-10-28T10:32:05Z Oncology imaging and biomarkers—earlier detection and better risk models https://biobriefs.com/immuno-oncology-biology-new-resistance BioBriefs en 2026-10-28T10:32:05Z Immuno-oncology biology—new resistance mechanisms and combinability angles https://biobriefs.com/novel-therapeutic-platforms-targeted-delivery BioBriefs en 2026-10-28T10:32:05Z Novel therapeutic platforms—targeted delivery and radiotherapy concepts https://biobriefs.com/immunotherapy-in-inherited-disease-patient BioBriefs en 2026-10-28T10:32:05Z Immunotherapy in inherited disease—patient attitudes shape development risk https://biobriefs.com/real-world-evidence-and-clinical BioBriefs en 2026-10-28T10:32:05Z Real-world evidence and clinical dosing—routine care signals https://biobriefs.com/ai-in-medicine-tool-performance BioBriefs en 2026-10-28T10:32:05Z AI in medicine—tool performance gains tempered by validation limits https://biobriefs.com/anti-infectives-and-diagnostics-drug BioBriefs en 2026-10-28T10:32:05Z Anti-infectives and diagnostics—drug development and diagnostic performance gaps https://biobriefs.com/late-stage-regulatory-and-market BioBriefs en 2026-10-28T09:32:57Z Late-stage regulatory and market impact https://biobriefs.com/cell-therapy-setbacks-and-strategic BioBriefs en 2026-10-28T09:32:57Z Cell therapy setbacks and strategic retrenchment https://biobriefs.com/immunology-oncology-biomarker-driven-precision BioBriefs en 2026-10-28T09:32:57Z Immunology-oncology: biomarker-driven precision strategies https://biobriefs.com/cancer-therapeutics-imaging-and-target BioBriefs en 2026-10-28T09:32:57Z Cancer therapeutics: imaging and target selection https://biobriefs.com/oncology-biomarkers-ferroptosis-and-diagnostics BioBriefs en 2026-10-28T09:32:57Z Oncology biomarkers: ferroptosis and diagnostics https://biobriefs.com/oncology-genomics-drug-resistance-and BioBriefs en 2026-10-28T09:32:57Z Oncology genomics: drug-resistance and therapeutic targeting https://biobriefs.com/infectious-disease-diagnostics-and-stewardship BioBriefs en 2026-10-28T09:32:57Z Infectious disease diagnostics and stewardship https://biobriefs.com/diabetes-and-cardiometabolic-risk-real BioBriefs en 2026-10-28T09:32:57Z Diabetes and cardiometabolic risk: real-world safety and outcomes https://biobriefs.com/neuroscience-and-ai-enabled-biomarkers BioBriefs en 2026-10-28T09:32:57Z Neuroscience and AI-enabled biomarkers https://biobriefs.com/biotech-funding-and-capital-markets BioBriefs en 2026-10-28T09:32:57Z Biotech funding and capital markets momentum https://biobriefs.com/cell-therapy-shutdown-after-deaths BioBriefs en 2026-10-28T04:32:10Z Cell therapy shutdown after deaths and durability questions https://biobriefs.com/oncology-targeted-radiotherapy-approach-moves BioBriefs en 2026-10-28T04:32:10Z Oncology: targeted radiotherapy approach moves into mice for PD-L1-positive TNBC https://biobriefs.com/regulatory-and-pipeline-fda-drafts BioBriefs en 2026-10-28T04:32:10Z Regulatory and pipeline: FDA drafts faster pathway for personalized gene therapies https://biobriefs.com/dealmaking-and-fertility-innovation-ferring BioBriefs en 2026-10-28T04:32:10Z Dealmaking and fertility innovation: Ferring to acquire Gameto https://biobriefs.com/public-markets-biotech-ipo-activity BioBriefs en 2026-10-28T04:32:10Z Public markets: biotech IPO activity stays hot despite mixed index moves https://biobriefs.com/novel-vaccine-strategy-merck-and BioBriefs en 2026-10-28T04:32:10Z Novel vaccine strategy: Merck and Moderna personalized melanoma mRNA data https://biobriefs.com/biopharma-finance-vc-funding-remains BioBriefs en 2026-10-28T04:32:10Z Biopharma finance: VC funding remains concentrated in top US hubs https://biobriefs.com/precision-medicine-governance-proposals-to BioBriefs en 2026-10-28T04:32:10Z Precision medicine governance: proposals to overhaul ClinicalTrials.gov usability and data quality https://biobriefs.com/diagnostics-and-translational-ai-caution BioBriefs en 2026-10-28T04:32:10Z Diagnostics and translational AI: caution on AI performance without external validation https://biobriefs.com/cardiology-real-world-data-on BioBriefs en 2026-10-28T04:32:10Z Cardiology: real-world data on mavacamten in obstructive HCM https://biobriefs.com/cell-therapy-shutdown-after-fatal BioBriefs en 2026-10-27T21:32:48Z Cell therapy shutdown after fatal safety signals https://biobriefs.com/ferring-moves-into-next-gen BioBriefs en 2026-10-27T21:32:48Z Ferring moves into next-gen IVF with Gameto acquisition https://biobriefs.com/fda-draft-guidance-for-faster BioBriefs en 2026-10-27T21:32:48Z FDA draft guidance for faster approvals of personalized gene therapies https://biobriefs.com/clinical-trial-safety-disclosure-bms BioBriefs en 2026-10-27T21:32:48Z Clinical trial safety disclosure: BMS confirms a death in MS CAR T study https://biobriefs.com/new-oral-glp-1-route BioBriefs en 2026-10-27T21:32:48Z New oral GLP-1 route raises cash for pivotal obesity trials https://biobriefs.com/alzheimers-biomarkers-ptau217-fails-to BioBriefs en 2026-10-27T21:32:48Z Alzheimer’s biomarkers: pTau217 fails to forecast key outcomes https://biobriefs.com/diagnostics-and-evidence-genomic-confirmation BioBriefs en 2026-10-27T21:32:48Z Diagnostics and evidence: Genomic confirmation of lineage in rare pediatric/clinical settings https://biobriefs.com/clinical-translation-of-trial-registries BioBriefs en 2026-10-27T21:32:48Z Clinical translation of trial registries: reform push for ClinicalTrials.gov https://biobriefs.com/immune-oncology-biomarker-and-monitoring BioBriefs en 2026-10-27T21:32:48Z Immune/oncology biomarker and monitoring: tumor-informed ctDNA matches imaging https://biobriefs.com/industry-and-governance-sentiment-fda BioBriefs en 2026-10-27T21:32:48Z Industry and governance sentiment: FDA leadership shift lifts regulatory mood https://biobriefs.com/fda-gene-therapy-pathway-draft BioBriefs en 2026-10-27T16:31:50Z FDA gene-therapy pathway draft guidance https://biobriefs.com/spac-backed-move-to-fund BioBriefs en 2026-10-27T16:31:50Z SPAC-backed move to fund oral GLP-1 clinical program https://biobriefs.com/autoimmune-cell-therapy-setback-prompts BioBriefs en 2026-10-27T16:31:50Z Autoimmune cell therapy setback prompts wind-down https://biobriefs.com/bristol-myers-reports-fatal-event BioBriefs en 2026-10-27T16:31:50Z Bristol Myers reports fatal event in MS CAR-T study https://biobriefs.com/antibiotic-resistance-resistance-to-ceftazidime BioBriefs en 2026-10-27T16:31:50Z Antibiotic resistance: resistance to ceftazidime-avibactam in carbapenem-resistant Pseudomonas https://biobriefs.com/court-ruling-blocks-novo-effort BioBriefs en 2026-10-27T16:31:50Z Court ruling blocks Novo effort to stop Lilly obesity drug ads https://biobriefs.com/liquid-biopsy-tech-mass-spectrometry BioBriefs en 2026-10-27T16:31:50Z Liquid biopsy tech: mass spectrometry detects myeloma M-protein without sequencing https://biobriefs.com/cancer-imaging-biomarkers-tau-pet BioBriefs en 2026-10-27T16:31:50Z Cancer imaging/biomarkers: tau PET rates flag faster PSP decline https://biobriefs.com/epidemiology-lyme-incidence-in-europe BioBriefs en 2026-10-27T16:31:50Z Epidemiology: Lyme incidence in Europe far exceeds surveillance estimates https://biobriefs.com/health-systems-ai-governance-why BioBriefs en 2026-10-27T16:31:50Z Health systems/AI governance: why models still miss the bedside https://biobriefs.com/regulatory-and-market-sentiment-after BioBriefs en 2026-10-27T14:32:33Z Regulatory and market sentiment after FDA leadership changes https://biobriefs.com/roche-expands-adc-pipeline-via BioBriefs en 2026-10-27T14:32:33Z Roche expands ADC pipeline via Hansoh licensing and collaboration https://biobriefs.com/car-t-safety-signal-disclosed BioBriefs en 2026-10-27T14:32:33Z CAR-T safety signal disclosed in multiple sclerosis trial https://biobriefs.com/point-of-care-car-t BioBriefs en 2026-10-27T14:32:33Z Point-of-care CAR-T expands to pediatric leukemia in 14 days https://biobriefs.com/experimental-vaccine-boosts-immune-clearance BioBriefs en 2026-10-27T14:32:33Z Experimental vaccine boosts immune clearance in HPV16 tumor model https://biobriefs.com/manufacturing-and-data-infrastructure-for BioBriefs en 2026-10-27T14:32:33Z Manufacturing and data infrastructure for genomic submissions https://biobriefs.com/synthetic-cofactor-biocatalysis-ai-designed BioBriefs en 2026-10-27T14:32:33Z Synthetic cofactor biocatalysis: AI-designed enzymes for cheaper reagents https://biobriefs.com/genomics-and-ai-for-oncology BioBriefs en 2026-10-27T14:32:33Z Genomics and AI for oncology: explainable metastasis detection in microscopy https://biobriefs.com/rare-pediatric-ocular-pain-procedure BioBriefs en 2026-10-27T14:32:33Z Rare pediatric ocular pain procedure tested in randomized trial https://biobriefs.com/fetal-monitoring-innovation-extracellular-vesicle BioBriefs en 2026-10-27T14:32:33Z Fetal monitoring innovation: extracellular vesicle biomarkers for oxygenation https://biobriefs.com/multiple-myeloma-style-biotech-shift BioBriefs en 2026-10-27T10:31:46Z Multiple myeloma–style biotech shift: mRNA cancer vaccine hits Phase 3 endpoint https://biobriefs.com/car-t-safety-bms-confirms BioBriefs en 2026-10-27T10:31:46Z CAR T safety: BMS confirms death in multiple sclerosis trial https://biobriefs.com/cardiomyopathy-mavacamten-shows-sharp-outflow BioBriefs en 2026-10-27T10:31:46Z Cardiomyopathy: mavacamten shows sharp outflow-gradient reduction in real-world China data https://biobriefs.com/obesity-pipeline-financing-corxel-lines BioBriefs en 2026-10-27T10:31:46Z Obesity pipeline financing: Corxel lines up SPAC to commercialize oral GLP-1 program https://biobriefs.com/regulatory-and-device-pathway-university BioBriefs en 2026-10-27T10:31:46Z Regulatory and device pathway: University of Michigan suction-agitation system clears FDA for lung clot removal https://biobriefs.com/ai-clinical-trials-operations-astrazeneca BioBriefs en 2026-10-27T10:31:46Z AI + clinical trials operations: AstraZeneca teams with Oracle for recruitment acceleration using real-world data https://biobriefs.com/precision-oncology-first-line-trastuzumab BioBriefs en 2026-10-27T10:31:46Z Precision oncology: first-line trastuzumab deruxtecan extends PFS in HER2-mutant lung cancer https://biobriefs.com/fda-clinical-economics-cost-effectiveness BioBriefs en 2026-10-27T10:31:46Z FDA/clinical economics: cost-effectiveness fails for inavolisib in China despite negotiated price cut https://biobriefs.com/theranostics-pipeline-reality-check-evidence BioBriefs en 2026-10-27T10:31:46Z Theranostics pipeline reality check: evidence-gated roadmap for PET tracer translation https://biobriefs.com/trial-safety-signal-in-car BioBriefs en 2026-10-27T10:31:46Z Trial safety signal in CAR T programs: additional fatality disclosed and monitored https://biobriefs.com/cancer-vaccine-phase-3-milestone BioBriefs en 2026-10-27T09:33:01Z Cancer vaccine Phase 3 milestone signals pivot in personalized mRNA oncology https://biobriefs.com/roche-advances-first-line-her2 BioBriefs en 2026-10-27T09:33:01Z Roche advances first-line HER2-mutant lung cancer with DESTINY-Lung04 https://biobriefs.com/merck-and-kelun-targeted-chemo BioBriefs en 2026-10-27T09:33:01Z Merck and Kelun targeted chemo-ADC reports survival benefit in advanced endometrial cancer https://biobriefs.com/ai-recruitment-partnership-targets-earlier BioBriefs en 2026-10-27T09:33:01Z AI recruitment partnership targets earlier clinical trial enrollment at AstraZeneca https://biobriefs.com/biotech-dealmaking-bms-leads-series BioBriefs en 2026-10-27T09:33:01Z Biotech dealmaking—BMS leads Series E for AI drug developer Pathos AI https://biobriefs.com/clinical-evidence-in-severe-infection BioBriefs en 2026-10-27T09:33:01Z Clinical evidence in severe infection—Ceftazidime–avibactam mortality signal narrows after adjustment https://biobriefs.com/immunotherapy-safety-real-world-analysis BioBriefs en 2026-10-27T09:33:01Z Immunotherapy safety—real-world analysis quantifies liver injury burden on checkpoint inhibitors https://biobriefs.com/ai-in-radiology-lightweight-neural BioBriefs en 2026-10-27T09:33:01Z AI in radiology—lightweight neural network differentiates bacterial vs viral pneumonia https://biobriefs.com/regulatory-market-access-canadas-reliance BioBriefs en 2026-10-27T09:33:01Z Regulatory/market access—Canada’s reliance rule faces pediatric shortage concerns https://biobriefs.com/spac-and-pipeline-momentum-corxel BioBriefs en 2026-10-27T09:33:01Z SPAC and pipeline momentum—Corxel prepares to go public for oral GLP-1 obesity Phase 3 https://biobriefs.com/fda-clearance-for-lung-clot BioBriefs en 2026-10-27T04:32:44Z FDA clearance for lung clot thrombectomy device https://biobriefs.com/ai-and-real-world-data BioBriefs en 2026-10-27T04:32:44Z AI and real-world data partnerships to speed oncology and other trial recruitment https://biobriefs.com/emerging-obesity-pipeline-corxel-to BioBriefs en 2026-10-27T04:32:44Z Emerging obesity pipeline: Corxel to go public via SPAC ahead of oral GLP-1 Phase 3 https://biobriefs.com/bristol-myers-leads-series-e BioBriefs en 2026-10-27T04:32:44Z Bristol Myers leads Series E for AI drug-discovery platform Pathos AI https://biobriefs.com/esmo-readout-sacituzumab-tirumotecan-cuts BioBriefs en 2026-10-27T04:32:44Z ESMO readout: sacituzumab tirumotecan cuts death risk in advanced endometrial cancer https://biobriefs.com/crispr-promoter-editing-for-rice BioBriefs en 2026-10-27T04:32:44Z CRISPR promoter editing for rice water-use efficiency https://biobriefs.com/clinical-oncology-trial-zipalertinib-plus BioBriefs en 2026-10-27T04:32:44Z Clinical oncology trial: zipalertinib plus chemotherapy extends PFS in EGFR exon 20 NSCLC https://biobriefs.com/liquid-biopsy-screening-pathfinder-2 BioBriefs en 2026-10-27T04:32:44Z Liquid biopsy screening: PATHFINDER 2 finds more cancers with Galleri, but no mortality proof https://biobriefs.com/car-t-platform-modular-car BioBriefs en 2026-10-27T04:32:44Z CAR T platform: modular CAR T cells can accept engineered adaptors after treatment https://biobriefs.com/south-africa-biopharma-sovereignty-push BioBriefs en 2026-10-27T04:32:44Z South Africa biopharma sovereignty push: Immobazyme raises seed funding to scale recombinant protein manufacturing https://biobriefs.com/fda-clearance-for-lung-clot BioBriefs en 2026-10-26T21:32:56Z FDA clearance for lung clot removal device https://biobriefs.com/liquid-biopsy-and-imaging-for BioBriefs en 2026-10-26T21:32:56Z Liquid biopsy and imaging for cancer detection and staging https://biobriefs.com/new-obesity-pipeline-financing-and BioBriefs en 2026-10-26T21:32:56Z New obesity pipeline financing and market access https://biobriefs.com/ai-partnerships-for-faster-clinical BioBriefs en 2026-10-26T21:32:56Z AI partnerships for faster clinical trial recruitment https://biobriefs.com/large-funding-for-ai-drug BioBriefs en 2026-10-26T21:32:56Z Large funding for AI drug discovery platform https://biobriefs.com/company-disclosures-anthropic-life-sciences BioBriefs en 2026-10-26T21:32:56Z Company disclosures: Anthropic life sciences expansion https://biobriefs.com/cancer-immunotherapy-and-targeted-oncology BioBriefs en 2026-10-26T21:32:56Z Cancer immunotherapy and targeted oncology outcomes https://biobriefs.com/neurology-early-biomarkers-and-prediction BioBriefs en 2026-10-26T21:32:56Z Neurology: early biomarkers and prediction in neurodegeneration https://biobriefs.com/oncology-biomarkers-and-care-personalization BioBriefs en 2026-10-26T21:32:56Z Oncology biomarkers and care personalization in CAR T-cell therapy https://biobriefs.com/rare-source-device-for-brain BioBriefs en 2026-10-26T21:32:56Z Rare-source device for brain injury detection in emergency care https://biobriefs.com/adc-efficacy-signals-and-next BioBriefs en 2026-10-26T16:32:34Z ADC efficacy signals and next-step decisions https://biobriefs.com/late-stage-trial-readouts-reshape BioBriefs en 2026-10-26T16:32:34Z Late-stage trial readouts reshape oncology expectations https://biobriefs.com/cancer-vaccine-milestone-sets-a BioBriefs en 2026-10-26T16:32:34Z Cancer vaccine milestone sets a new regulatory timeline https://biobriefs.com/company-funding-signals-and-ai BioBriefs en 2026-10-26T16:32:34Z Company funding signals and AI drug-discovery scaling https://biobriefs.com/esmo-oncology-highlights-kras-inhibitors BioBriefs en 2026-10-26T16:32:34Z ESMO oncology highlights: KRAS inhibitors and competitive pressure https://biobriefs.com/regulatory-and-pricing-pressure-reshapes BioBriefs en 2026-10-26T16:32:34Z Regulatory and pricing pressure reshapes launch timing https://biobriefs.com/drug-development-setback-pfizer-ends BioBriefs en 2026-10-26T16:32:34Z Drug development setback: Pfizer ends a GIPR antagonist program https://biobriefs.com/real-world-evidence-supports-psma BioBriefs en 2026-10-26T16:32:34Z Real-world evidence supports PSMA radioligand in practice https://biobriefs.com/trial-outcomes-expand-treatment-options BioBriefs en 2026-10-26T16:32:34Z Trial outcomes expand treatment options in relapsed SCLC https://biobriefs.com/infrastructure-and-workflow-ai-admin BioBriefs en 2026-10-26T16:32:34Z Infrastructure and workflow: AI-admin tooling enters clinical imaging pipelines https://biobriefs.com/cancer-vaccines-moderna-merck-phase BioBriefs en 2026-10-26T14:33:28Z Cancer vaccines: Moderna/ Merck Phase 3 readout at ESMO https://biobriefs.com/egfr-mutant-lung-cancer-tagrisso BioBriefs en 2026-10-26T14:33:28Z EGFR-mutant lung cancer: Tagrisso resistance strategies and ADC competition https://biobriefs.com/small-cell-lung-cancer-b7 BioBriefs en 2026-10-26T14:33:28Z Small-cell lung cancer: B7-H3 ADC shows survival benefit https://biobriefs.com/ai-drug-development-bms-led BioBriefs en 2026-10-26T14:33:28Z AI drug development: BMS-led Series E for Pathos AI https://biobriefs.com/pancreatic-cancer-incyte-esmo-update BioBriefs en 2026-10-26T14:33:28Z Pancreatic cancer: Incyte ESMO update supports late-stage push https://biobriefs.com/biotech-m-a-risk-and BioBriefs en 2026-10-26T14:33:28Z Biotech M&A risk and dealmaking: CAR-T death and major partnership payments https://biobriefs.com/biotech-funding-corxel-plans-us BioBriefs en 2026-10-26T14:33:28Z Biotech funding: Corxel plans US IPO via SPAC https://biobriefs.com/clinical-pipeline-progress-zidesamtinib-posts BioBriefs en 2026-10-26T14:33:28Z Clinical pipeline progress: zidesamtinib posts Phase I/II activity in ROS1+ NSCLC https://biobriefs.com/regulatory-evidence-framing-eu-considerations BioBriefs en 2026-10-26T14:33:28Z Regulatory/evidence framing: EU considerations after FDA alignment https://biobriefs.com/market-backdrop-ipo-comeback-and BioBriefs en 2026-10-26T14:33:28Z Market backdrop: IPO comeback and deal volume pressure https://biobriefs.com/personalized-mrna-cancer-vaccine-reaches BioBriefs en 2026-10-26T10:32:59Z Personalized mRNA cancer vaccine reaches pivotal efficacy readout https://biobriefs.com/late-stage-efficacy-expands-in BioBriefs en 2026-10-26T10:32:59Z Late-stage efficacy expands in biliary cancer via PD-1xVEGF bispecific https://biobriefs.com/checkpoint-inhibitor-combination-data-boost BioBriefs en 2026-10-26T10:32:59Z Checkpoint inhibitor combination data boost in relapsed small-cell lung cancer https://biobriefs.com/biotech-funding-and-deal-momentum BioBriefs en 2026-10-26T10:32:59Z Biotech funding and deal momentum returns amid licensing and M&A shifts https://biobriefs.com/cost-effectiveness-pressure-hits-ivonescimab BioBriefs en 2026-10-26T10:32:59Z Cost-effectiveness pressure hits ivonescimab pricing in China https://biobriefs.com/real-world-evidence-strengthens-confidence BioBriefs en 2026-10-26T10:32:59Z Real-world evidence strengthens confidence in PSMA radioligand therapy https://biobriefs.com/hospital-antibiotic-policy-shift-h2 BioBriefs en 2026-10-26T10:32:59Z Hospital antibiotic policy shift: H2 blockers linked to lower C. difficile risk https://biobriefs.com/new-late-line-lung-cancer BioBriefs en 2026-10-26T10:32:59Z New late-line lung cancer option: zipalertinib improves outcomes in EGFR exon 20 NSCLC https://biobriefs.com/early-cancer-detection-pet-trial BioBriefs en 2026-10-26T10:32:59Z Early cancer detection: PET trial to find primary tumors in cancer of unknown primary https://biobriefs.com/advanced-brain-imaging-ai-wins BioBriefs en 2026-10-26T10:32:59Z Advanced brain imaging AI wins grant-backed workflow integration https://biobriefs.com/personalized-cancer-vaccines-post-phase BioBriefs en 2026-10-26T09:32:48Z Personalized cancer vaccines post–Phase 3 milestone https://biobriefs.com/b7-h3-antibody-drug-conjugate BioBriefs en 2026-10-26T09:32:48Z B7-H3 antibody-drug conjugate delivers survival gain in relapsed small-cell lung cancer https://biobriefs.com/ivonescimab-vs-pembrolizumab-in-pd BioBriefs en 2026-10-26T09:32:48Z Ivonescimab vs pembrolizumab in PD-L1-positive advanced lung cancer https://biobriefs.com/merck-and-moderna-personalized-cancer BioBriefs en 2026-10-26T09:32:48Z Merck and Moderna personalized cancer vaccines—ESMO follow-through https://biobriefs.com/company-finance-and-market-access BioBriefs en 2026-10-26T09:32:48Z Company finance and market access: obesity assets re-evaluated after paradigm shifts https://biobriefs.com/biotech-capital-markets-ipo-surge BioBriefs en 2026-10-26T09:32:48Z Biotech capital markets: IPO surge alongside weaker licensing and deal flow https://biobriefs.com/next-gen-drug-development-targets BioBriefs en 2026-10-26T09:32:48Z Next-gen drug development targets: HIF-1α glycolysis axis in hepatocellular carcinoma https://biobriefs.com/diagnostics-in-cancer-care-pet BioBriefs en 2026-10-26T09:32:48Z Diagnostics in cancer care: PET trial to locate primaries in cancer of unknown primary https://biobriefs.com/practical-clinical-evidence-real-world BioBriefs en 2026-10-26T09:32:48Z Practical clinical evidence: real-world PSMA radioligand therapy outcomes https://biobriefs.com/regulatory-adjacent-care-platform-telehealth BioBriefs en 2026-10-26T09:32:48Z Regulatory-adjacent care platform: telehealth expands hormone therapy offering https://biobriefs.com/late-stage-oncology-data-lift BioBriefs en 2026-10-26T04:32:09Z Late-stage oncology data lift competitive positioning for targeted and immuno combinations https://biobriefs.com/biomarker-and-imaging-signals-push BioBriefs en 2026-10-26T04:32:09Z Biomarker and imaging signals push earlier relapse detection in solid tumors https://biobriefs.com/infectious-disease-real-world-and BioBriefs en 2026-10-26T04:32:09Z Infectious disease real-world and clinical evidence informs stewardship decisions https://biobriefs.com/translational-neurology-targets-nad-and BioBriefs en 2026-10-26T04:32:09Z Translational neurology targets NAD+ and neuroinflammation pathways https://biobriefs.com/reproductive-health-biomarkers-and-cervical BioBriefs en 2026-10-26T04:32:09Z Reproductive health biomarkers and cervical cancer screening signals https://biobriefs.com/device-and-ai-enabled-care BioBriefs en 2026-10-26T04:32:09Z Device and AI-enabled care coordination enters specialty and outpatient pathways https://biobriefs.com/antimicrobial-delivery-and-prevention-catheter BioBriefs en 2026-10-26T04:32:09Z Antimicrobial delivery and prevention: catheter infections and hospital protocols https://biobriefs.com/from-bench-to-clinical-pipelines BioBriefs en 2026-10-26T04:32:09Z From bench to clinical pipelines: oncology molecular targets and new precision candidates https://biobriefs.com/reinforcing-evidence-for-cardiovascular-and BioBriefs en 2026-10-26T04:32:09Z Reinforcing evidence for cardiovascular and kidney risk management using monitoring and clinical decision tools https://biobriefs.com/biomarker-innovation-in-als-and BioBriefs en 2026-10-26T04:32:09Z Biomarker innovation in ALS and neurodegeneration signals emerging years before symptoms https://biobriefs.com/phase-3-updates-reshape-first BioBriefs en 2026-10-25T21:32:09Z Phase 3 updates reshape first-line lung cancer maintenance choices https://biobriefs.com/immuno-oncology-regimens-post-surgery BioBriefs en 2026-10-25T21:32:09Z Immuno-oncology regimens post-surgery deliver durable colon cancer control https://biobriefs.com/new-phase-3-data-target BioBriefs en 2026-10-25T21:32:09Z New Phase 3 data target hard-to-treat small-cell lung cancer with ADC and maintenance strategies https://biobriefs.com/car-t-therapy-efficacy-is BioBriefs en 2026-10-25T21:32:09Z CAR T therapy efficacy is consistent; survival depends sharply on where lymphoma sits https://biobriefs.com/evidence-expands-on-ctdna-as BioBriefs en 2026-10-25T21:32:09Z Evidence expands on ctDNA as a prognosis tool, while clinical utility remains disputed https://biobriefs.com/algorithmic-fairness-meets-privacy-constraints BioBriefs en 2026-10-25T21:32:09Z Algorithmic fairness meets privacy constraints in high-stakes decision systems https://biobriefs.com/diabetes-kidney-risk-models-move BioBriefs en 2026-10-25T21:32:09Z Diabetes kidney risk models move into primary care workflows https://biobriefs.com/transforming-mrna-delivery-storage-buffers BioBriefs en 2026-10-25T21:32:09Z Transforming mRNA delivery: storage buffers can change real-world performance https://biobriefs.com/first-us-enrollment-begins-in BioBriefs en 2026-10-25T21:32:09Z First US enrollment begins in pulmonary artery denervation trial https://biobriefs.com/translational-imaging-advances-collagen-targeted BioBriefs en 2026-10-25T21:32:09Z Translational imaging advances: collagen-targeted MRI spots tiny lung tumors and metastases https://biobriefs.com/lu-psma-real-world-validation BioBriefs en 2026-10-25T16:32:50Z Lu-PSMA real-world validation expands evidence base for prostate cancer radioligand therapy https://biobriefs.com/phase-3-small-cell-lung BioBriefs en 2026-10-25T16:32:50Z Phase 3 small-cell lung cancer results: anti–B7-H3 ADC takes on topotecan in relapsed disease https://biobriefs.com/new-nsclc-biology-and-pipeline BioBriefs en 2026-10-25T16:32:50Z New NSCLC biology and pipeline: ivonescimab claims interim OS advantage over pembrolizumab in PD-L1 positive disease https://biobriefs.com/checkpoint-innovation-meets-esmo-competition BioBriefs en 2026-10-25T16:32:50Z Checkpoint innovation meets ESMO competition: Merck and AstraZeneca report targeted lung cancer regimen gains https://biobriefs.com/fda-style-safety-pressure-mounts BioBriefs en 2026-10-25T16:32:50Z FDA-style safety pressure mounts in autoimmune CAR-T as BMS reports death in early trial https://biobriefs.com/arpa-h-backs-room-temperature BioBriefs en 2026-10-25T16:32:50Z ARPA-H backs room-temperature storage approach for therapeutic cells with cyborg-like polymer gels https://biobriefs.com/cell-therapy-logistics-and-manufacturing BioBriefs en 2026-10-25T16:32:50Z Cell therapy logistics and manufacturing confidence: Fractyl’s Revita device hits a clinical goal but faces sharp market reaction https://biobriefs.com/biotech-financing-lycia-therapeutics-raises BioBriefs en 2026-10-25T16:32:50Z Biotech financing: Lycia Therapeutics raises $317M via IPO for inflammation platform tied to Nobel-winning science https://biobriefs.com/regenerative-and-anti-infective-engineering BioBriefs en 2026-10-25T16:32:50Z Regenerative and anti-infective engineering: collagen-targeted MRI agent moves toward FDA testing https://biobriefs.com/trial-data-at-scale-car BioBriefs en 2026-10-25T16:32:50Z Trial data at scale: CAR-T day-14 risk scoring identifies low infection subgroup https://biobriefs.com/phase-3-immunotherapy-in-relapsed BioBriefs en 2026-10-25T14:32:11Z Phase 3 immunotherapy in relapsed small-cell lung cancer https://biobriefs.com/phase-3-readout-boosts-first BioBriefs en 2026-10-25T14:32:11Z Phase 3 readout boosts first-line EGFR exon 20 therapy https://biobriefs.com/targeted-therapy-adds-survival-signal BioBriefs en 2026-10-25T14:32:11Z Targeted therapy adds survival signal in ROS1-positive NSCLC https://biobriefs.com/hospital-scale-evidence-psma-radioligand BioBriefs en 2026-10-25T14:32:11Z Hospital-scale evidence: PSMA radioligand therapy holds up in routine care https://biobriefs.com/immunotherapy-after-surgery-reshapes-dmmr BioBriefs en 2026-10-25T14:32:11Z Immunotherapy after surgery reshapes dMMR colorectal cancer https://biobriefs.com/biomarker-driven-immunotherapy-stratification-in BioBriefs en 2026-10-25T14:32:11Z Biomarker-driven immunotherapy stratification in ESCC https://biobriefs.com/regulatory-free-operational-milestone-telehealth BioBriefs en 2026-10-25T14:32:11Z Regulatory-free operational milestone: telehealth changes CAR-T care burden signals https://biobriefs.com/major-deal-gilead-buys-oral BioBriefs en 2026-10-25T14:32:11Z Major deal: Gilead buys oral IL-23R program to expand IBD immunology pipeline https://biobriefs.com/clinical-safety-concern-bristol-myers BioBriefs en 2026-10-25T14:32:11Z Clinical safety concern: Bristol Myers autoimmune CAR-T death reported https://biobriefs.com/clinical-evidence-meets-precision-ops BioBriefs en 2026-10-25T14:32:11Z Clinical evidence meets precision ops: adaptive sampling speeds pediatric cancer genome profiling https://biobriefs.com/clinical-trial-readouts-at-esmo BioBriefs en 2026-10-25T10:32:14Z Clinical trial readouts at ESMO: melanoma immunotherapy combos https://biobriefs.com/oncology-pipeline-first-u-s BioBriefs en 2026-10-25T10:32:14Z Oncology pipeline: first U.S. uptake signals and biomarker-driven strategy shifts https://biobriefs.com/regulatory-and-economic-access-pressure BioBriefs en 2026-10-25T10:32:14Z Regulatory and economic access pressure: cost-effectiveness tests reshape adoption https://biobriefs.com/immunotherapy-safety-signals-autoimmune-car BioBriefs en 2026-10-25T10:32:14Z Immunotherapy safety signals: autoimmune CAR-T death and program pause context https://biobriefs.com/ibd-m-a-gilead-buys BioBriefs en 2026-10-25T10:32:14Z IBD M&A: Gilead buys oral IL-23R program to expand inflammation pipeline https://biobriefs.com/cancer-genomics-and-precision-oncology BioBriefs en 2026-10-25T10:32:14Z Cancer genomics and precision oncology: AI maps vulnerabilities in MSS colorectal cancer https://biobriefs.com/kidney-care-delivery-clinical-decision BioBriefs en 2026-10-25T10:32:14Z Kidney care delivery: clinical decision support embedded in primary care records https://biobriefs.com/microbiome-immune-mechanisms-in-cancer BioBriefs en 2026-10-25T10:32:14Z Microbiome-immune mechanisms in cancer adverse effects: diet shapes immunotherapy toxicity https://biobriefs.com/antibiotic-resistance-surveillance-e-coli BioBriefs en 2026-10-25T10:32:14Z Antibiotic resistance surveillance: E. coli resistance genes flagged in Chinese watershed waters https://biobriefs.com/diagnostics-and-biomarker-engineering-blood BioBriefs en 2026-10-25T10:32:14Z Diagnostics and biomarker engineering: blood cutoffs identify brain injury missed by CT https://biobriefs.com/regulatory-and-market-access-u BioBriefs en 2026-10-25T09:32:20Z Regulatory and market access: U.S. restriction proposal tightens China biotech investment pathways https://biobriefs.com/pipeline-expansion-via-major-dealmaking BioBriefs en 2026-10-25T09:32:20Z Pipeline expansion via major dealmaking: Gilead buys oral IL-23R program from PepStar https://biobriefs.com/oncology-breakthrough-signal-amgens-imdelltra BioBriefs en 2026-10-25T09:32:20Z Oncology breakthrough signal: Amgen’s Imdelltra plus Imfinzi cuts death risk in small-cell lung cancer https://biobriefs.com/precision-immunotherapy-duration-short-course BioBriefs en 2026-10-25T09:32:20Z Precision immunotherapy duration: Short-course nivolumab plus ipilimumab shows no recurrences in dMMR colon cancer https://biobriefs.com/neuro-oncology-translational-tooling-adaptive BioBriefs en 2026-10-25T09:32:20Z Neuro-oncology translational tooling: Adaptive sampling speeds whole-genome sequencing for pediatric cancer https://biobriefs.com/imaging-based-triage-innovation-blood BioBriefs en 2026-10-25T09:32:20Z Imaging-based triage innovation: Blood protein cutoffs flag traumatic brain injury that CT can miss https://biobriefs.com/car-t-safety-signal-bristol BioBriefs en 2026-10-25T09:32:20Z CAR-T safety signal: Bristol Myers reports death in autoimmune CAR-T trial https://biobriefs.com/clinical-oncology-discovery-ai-map BioBriefs en 2026-10-25T09:32:20Z Clinical oncology discovery: AI map iPhenMap identifies drug vulnerabilities in microsatellite-stable colorectal cancer https://biobriefs.com/biomarker-led-strategy-in-hematology BioBriefs en 2026-10-25T09:32:20Z Biomarker-led strategy in hematology: Gene expression signals predict refractory AML to 7+3 https://biobriefs.com/vaccine-supply-disruption-guinea-bissau BioBriefs en 2026-10-25T09:32:20Z Vaccine supply disruption: Guinea-Bissau authorities halt planned hepatitis B birth-dose trial after police raid https://biobriefs.com/policy-u-s-restricts-new BioBriefs en 2026-10-25T04:33:41Z Policy: U.S. restricts new investment into Chinese biotech under COINS framework https://biobriefs.com/transaction-gilead-to-buy-pepstars BioBriefs en 2026-10-25T04:33:41Z Transaction: Gilead to buy PepStar’s oral IL-23R inhibitor platform for $1.275B upfront https://biobriefs.com/clinical-safety-bristol-myers-discloses BioBriefs en 2026-10-25T04:33:41Z Clinical safety: Bristol Myers discloses death in autoimmune CAR-T trial https://biobriefs.com/oncology-efficacy-tango-and-revolution BioBriefs en 2026-10-25T04:33:41Z Oncology efficacy: Tango and Revolution combine to drive 82% response in advanced pancreatic cancer https://biobriefs.com/oncology-dealmaking-zymeworks-licenses-trispecific BioBriefs en 2026-10-25T04:33:41Z Oncology dealmaking: Zymeworks licenses trispecific DLL3 T cell engager to Roche for up to $813M https://biobriefs.com/oncology-precision-biomarker-tumor-pd BioBriefs en 2026-10-25T04:33:41Z Oncology precision biomarker: Tumor PD-L1 score predicts longer survival in gastric cancer on chemotherapy alone https://biobriefs.com/oncology-modeling-and-diagnostics-ai BioBriefs en 2026-10-25T04:33:41Z Oncology modeling and diagnostics: AI maps vulnerabilities in microsatellite-stable colorectal cancer using multi-omics https://biobriefs.com/cell-therapy-research-risk-model BioBriefs en 2026-10-25T04:33:41Z Cell therapy research: Risk model identifies low-infection subgroup by Day 14 after CD19 CAR-T https://biobriefs.com/diagnostics-and-safety-ai-review BioBriefs en 2026-10-25T04:33:41Z Diagnostics and safety: AI review shows high accuracy but major transparency gaps for brain tumor MRI tools https://biobriefs.com/regulatory-and-policy-adjacent-consensus BioBriefs en 2026-10-25T04:33:41Z Regulatory and policy-adjacent consensus: UK panel supports disease-modifying therapy access for ventilated SMA patients https://biobriefs.com/u-s-investment-restrictions-on BioBriefs en 2026-10-24T21:32:51Z U.S. investment restrictions on China biotech move toward rulemaking https://biobriefs.com/gilead-expands-oral-il-23r BioBriefs en 2026-10-24T21:32:51Z Gilead expands oral IL-23R pipeline with PepStar acquisition https://biobriefs.com/new-ceo-no-pathos-series BioBriefs en 2026-10-24T21:32:51Z New CEO? No—Pathos’ Series E backs AI drug development expansion into neurology https://biobriefs.com/modern-mrna-melanoma-vaccine-data BioBriefs en 2026-10-24T21:32:51Z Modern mRNA melanoma vaccine data leak forces early release https://biobriefs.com/esmo-amgens-imdelltra-regimen-cuts BioBriefs en 2026-10-24T21:32:51Z ESMO: Amgen’s Imdelltra regimen cuts death risk in small-cell lung cancer https://biobriefs.com/clinical-risk-signal-bristol-myers BioBriefs en 2026-10-24T21:32:51Z Clinical risk signal: Bristol Myers autoimmune CAR-T trial death reported https://biobriefs.com/star-therapeutics-returns-with-fresh BioBriefs en 2026-10-24T21:32:51Z Star Therapeutics returns with fresh $200M after spinout exits https://biobriefs.com/esmo-tango-and-revolution-medicines BioBriefs en 2026-10-24T21:32:51Z ESMO: Tango and Revolution Medicines targetable combo posts 82% tumor responses in pancreatic cancer https://biobriefs.com/roche-bets-on-zymeworks-trispecific BioBriefs en 2026-10-24T21:32:51Z Roche bets on Zymeworks trispecific TCE with up to $813M deal https://biobriefs.com/ai-and-protein-markers-refine BioBriefs en 2026-10-24T21:32:51Z AI and protein markers refine clinical selection in esophageal cancer immunochemotherapy https://biobriefs.com/merck-and-moderna-advance-personalized BioBriefs en 2026-10-24T16:32:02Z Merck and Moderna advance personalized melanoma mRNA vaccine in Phase 3 https://biobriefs.com/gilead-expands-oral-il-23r BioBriefs en 2026-10-24T16:32:02Z Gilead expands oral IL-23R pipeline with $1.275B PepStar acquisition https://biobriefs.com/regulators-fda-grants-accelerated-approval BioBriefs en 2026-10-24T16:32:02Z Regulators: FDA grants accelerated approval for dostarlimab in MSI-H/dMMR rectal cancer https://biobriefs.com/safety-signal-in-autoimmune-car BioBriefs en 2026-10-24T16:32:02Z Safety signal in autoimmune CAR-T: Bristol Myers reports patient death https://biobriefs.com/esmo-amgens-imdelltra-with-imfinzi BioBriefs en 2026-10-24T16:32:02Z ESMO: Amgen’s Imdelltra with Imfinzi halves death risk in first-line small cell lung cancer https://biobriefs.com/corporate-finance-pathos-ai-drug BioBriefs en 2026-10-24T16:32:02Z Corporate finance: Pathos AI drug developer raises $237M and expands into neurology https://biobriefs.com/policy-shock-u-s-treasury BioBriefs en 2026-10-24T16:32:02Z Policy shock: U.S. Treasury proposes major limits on outbound investment in Chinese biotech https://biobriefs.com/oncology-discovery-ai-maps-microsatellite BioBriefs en 2026-10-24T16:32:02Z Oncology discovery: AI maps microsatellite-stable colorectal cancer vulnerabilities https://biobriefs.com/clinical-signal-in-car-t BioBriefs en 2026-10-24T16:32:02Z Clinical signal in CAR-T risk stratification: Day 14 infection score after CD19 therapy https://biobriefs.com/regulatory-and-infrastructure-eqt-to BioBriefs en 2026-10-24T16:32:02Z Regulatory and infrastructure: EQT to take Qiagen private in $12.1B deal https://biobriefs.com/us-regulatory-and-trial-results BioBriefs en 2026-10-24T14:32:32Z US regulatory and trial results in oncology https://biobriefs.com/autoimmune-car-t-safety-scrutiny BioBriefs en 2026-10-24T14:32:32Z Autoimmune CAR-T safety scrutiny deepens https://biobriefs.com/pulmonary-hypertension-first-us-patients BioBriefs en 2026-10-24T14:32:32Z Pulmonary hypertension: first US patients enter denervation trial https://biobriefs.com/deals-and-funding-shaping-biopharma BioBriefs en 2026-10-24T14:32:32Z Deals and funding shaping biopharma momentum https://biobriefs.com/oncology-discovery-targeted-combination-signals BioBriefs en 2026-10-24T14:32:32Z Oncology discovery: targeted combination signals in early pancreatic cancer data https://biobriefs.com/biotech-finance-and-market-access BioBriefs en 2026-10-24T14:32:32Z Biotech finance and market access: AI drugmaker raises a major Series E https://biobriefs.com/regulatory-and-policy-proposed-us BioBriefs en 2026-10-24T14:32:32Z Regulatory and policy: proposed US rules could restrict investment into China biotech https://biobriefs.com/immunotherapy-pipeline-il-23r-oral BioBriefs en 2026-10-24T14:32:32Z Immunotherapy pipeline: IL-23R oral pathway moves forward via deal flow https://biobriefs.com/fda-approvals-outside-oncology-antibiotic BioBriefs en 2026-10-24T14:32:32Z FDA approvals outside oncology: antibiotic and infection innovation in preclinical forms https://biobriefs.com/diagnostic-and-workflow-innovation-ai BioBriefs en 2026-10-24T14:32:32Z Diagnostic and workflow innovation: AI-linked proteomics and rapid WGS for pediatric cancer https://biobriefs.com/melanoma-adjuvant-vaccine-results-arrive BioBriefs en 2026-10-24T10:32:13Z Melanoma adjuvant vaccine results arrive early amid data-leak fallout https://biobriefs.com/u-s-fda-accelerates-approval BioBriefs en 2026-10-24T10:32:13Z U.S. FDA accelerates approval for dostarlimab in biomarker-defined rectal cancer https://biobriefs.com/autoimmune-car-t-trial-death BioBriefs en 2026-10-24T10:32:13Z Autoimmune CAR-T trial death renews safety scrutiny across the class https://biobriefs.com/gilead-expands-oral-il-23r BioBriefs en 2026-10-24T10:32:13Z Gilead expands oral IL-23R program via PepStar acquisition https://biobriefs.com/roche-and-zymeworks-ink-large BioBriefs en 2026-10-24T10:32:13Z Roche and Zymeworks ink large licensing deal for preclinical trispecific TCE https://biobriefs.com/eqt-agrees-to-take-qiagen BioBriefs en 2026-10-24T10:32:13Z EQT agrees to take Qiagen private in $12.1B diagnostics tools deal https://biobriefs.com/pathos-raises-and-expands-beyond BioBriefs en 2026-10-24T10:32:13Z Pathos raises and expands beyond oncology with BMS partnership https://biobriefs.com/lycia-files-for-ipo-after BioBriefs en 2026-10-24T10:32:13Z Lycia files for IPO after aftermarket surge; protein-degrader strategy spotlighted https://biobriefs.com/preclinical-glaucoma-nanovesicle-gel-delivers BioBriefs en 2026-10-24T10:32:13Z Preclinical glaucoma nanovesicle gel delivers dual-drug eye pressure reduction in rabbits https://biobriefs.com/first-in-us-pulmonary-artery BioBriefs en 2026-10-24T10:32:13Z First-in-US pulmonary artery denervation patient enrollment begins https://biobriefs.com/regulatory-fda-accelerated-approval-for BioBriefs en 2026-10-24T09:32:07Z Regulatory: FDA accelerated approval for first-line rectal cancer https://biobriefs.com/clinical-outcomes-moderna-merck-mrna BioBriefs en 2026-10-24T09:32:07Z Clinical outcomes: Moderna–Merck mRNA melanoma vaccine data leak and show 42% risk reduction https://biobriefs.com/biopharma-dealmaking-gilead-buys-pepstars BioBriefs en 2026-10-24T09:32:07Z Biopharma dealmaking: Gilead buys PepStar’s oral IL-23R inhibitor program for $1.275B https://biobriefs.com/car-t-safety-bristol-myers BioBriefs en 2026-10-24T09:32:07Z CAR-T safety: Bristol Myers reports patient death in autoimmune CAR-T trial https://biobriefs.com/oncology-pipeline-targeted-ras-inhibitor BioBriefs en 2026-10-24T09:32:07Z Oncology pipeline: Targeted RAS inhibitor daraxonrasib shows survival benefit across pancreatic cancer subgroups https://biobriefs.com/oncology-immunotherapy-roche-licenses-zymeworks BioBriefs en 2026-10-24T09:32:07Z Oncology immunotherapy: Roche licenses Zymeworks’ DLL3 trispecific T cell engager for up to $813M https://biobriefs.com/corporate-finance-eqt-to-take BioBriefs en 2026-10-24T09:32:07Z Corporate/finance: EQT to take Qiagen private in €10.8B cash deal https://biobriefs.com/ai-in-medicine-ct-radiomics BioBriefs en 2026-10-24T09:32:07Z AI in medicine: ct-radiomics model separates Talaromyces marneffei from tuberculosis in HIV patients https://biobriefs.com/health-policy-and-markets-treasury BioBriefs en 2026-10-24T09:32:07Z Health policy and markets: Treasury proposes major restrictions on U.S. investment in Chinese biotech https://biobriefs.com/drug-development-and-manufacturing-lilly BioBriefs en 2026-10-24T09:32:07Z Drug development and manufacturing: Lilly breaks ground on $6.5B Houston site for oral GLP-1 production https://biobriefs.com/huntingtons-rnai-therapy-shows-early BioBriefs en 2026-10-24T04:31:53Z Huntington’s RNAi therapy shows early target knockdown https://biobriefs.com/autoimmune-car-t-trial-death BioBriefs en 2026-10-24T04:31:53Z Autoimmune CAR-T trial death raises safety scrutiny https://biobriefs.com/roche-signs-up-zymeworks-for BioBriefs en 2026-10-24T04:31:53Z Roche signs up Zymeworks for DLL3 T-cell engager https://biobriefs.com/gilead-buys-pepstar-oral-il BioBriefs en 2026-10-24T04:31:53Z Gilead buys PepStar oral IL-23R inhibitor for $1.275B https://biobriefs.com/fda-accelerates-dostarlimab-for-msi BioBriefs en 2026-10-24T04:31:53Z FDA accelerates dostarlimab for MSI-H/dMMR locally advanced rectal cancer https://biobriefs.com/moderna-and-merck-melanoma-vaccine BioBriefs en 2026-10-24T04:31:53Z Moderna and Merck melanoma vaccine data land after leak https://biobriefs.com/us-proposes-to-restrict-outbound BioBriefs en 2026-10-24T04:31:53Z US proposes to restrict outbound investment in China biotech https://biobriefs.com/windward-bio-files-for-nasdaq BioBriefs en 2026-10-24T04:31:53Z Windward Bio files for Nasdaq IPO https://biobriefs.com/lycia-therapeutics-prices-protein-degrader BioBriefs en 2026-10-24T04:31:53Z Lycia Therapeutics prices protein-degrader IPO https://biobriefs.com/alcon-buys-neurotech-pharma-for BioBriefs en 2026-10-24T04:31:53Z Alcon buys Neurotech Pharma for $550M to expand cell therapy in eye https://biobriefs.com/cancer-vaccines-and-trial-data BioBriefs en 2026-10-23T21:31:49Z Cancer vaccines and trial data at ESMO: Moderna–Merck melanoma readout https://biobriefs.com/autoimmune-car-t-safety-bristol BioBriefs en 2026-10-23T21:31:49Z Autoimmune CAR-T safety: Bristol Myers reports death and paused program context https://biobriefs.com/gilead-expands-oral-ibd-inflammation BioBriefs en 2026-10-23T21:31:49Z Gilead expands oral IBD inflammation pipeline with PepStar IL-23R asset deal https://biobriefs.com/partnering-and-licensing-roche-taps BioBriefs en 2026-10-23T21:31:49Z Partnering and licensing: Roche taps Zymeworks for DLL3 trispecific TCE https://biobriefs.com/ai-driven-drug-discovery-funding BioBriefs en 2026-10-23T21:31:49Z AI-driven drug discovery funding: Pathos closes $237M Series E https://biobriefs.com/clinical-oncology-pipeline-tango-reports BioBriefs en 2026-10-23T21:31:49Z Clinical oncology pipeline: Tango reports 82% response in advanced pancreatic cancer combo https://biobriefs.com/neuroscience-and-obesity-metabolic-tech BioBriefs en 2026-10-23T21:31:49Z Neuroscience and obesity-metabolic tech: wirelessly powered ECHO electrocatalytic implant https://biobriefs.com/regulatory-and-policy-risk-treasury BioBriefs en 2026-10-23T21:31:49Z Regulatory and policy risk: Treasury proposes major restrictions on U.S. investment in China biotech https://biobriefs.com/industrial-and-medical-tools-dealmaking BioBriefs en 2026-10-23T21:31:49Z Industrial and medical tools dealmaking: EQT to acquire Qiagen for $12.1B and take company private https://biobriefs.com/regenerative-eye-therapy-expansion-alcon BioBriefs en 2026-10-23T21:31:49Z Regenerative eye therapy expansion: Alcon buys Neurotech Pharma for $550M https://biobriefs.com/melanoma-mrna-vaccine-checkpoint-inhibitor BioBriefs en 2026-10-23T16:32:08Z Melanoma mRNA vaccine + checkpoint inhibitor efficacy update https://biobriefs.com/regulatory-approval-dostarlimab-accelerated-in BioBriefs en 2026-10-23T16:32:08Z Regulatory approval: dostarlimab accelerated in biomarker-defined rectal cancer https://biobriefs.com/dealmaking-roche-licenses-dll3-trispecific BioBriefs en 2026-10-23T16:32:08Z Dealmaking: Roche licenses DLL3 trispecific T-cell engager from Zymeworks https://biobriefs.com/inflammation-pipeline-gilead-buys-oral BioBriefs en 2026-10-23T16:32:08Z Inflammation pipeline: Gilead buys oral IL-23R inhibitor program from PepStar https://biobriefs.com/oncology-early-signals-tango-advances BioBriefs en 2026-10-23T16:32:08Z Oncology early signals: Tango advances PRMT5 inhibitor combo in MTAP-deleted pancreatic cancer https://biobriefs.com/antibody-engineering-fibrin-shield-disruption BioBriefs en 2026-10-23T16:32:08Z Antibody engineering: fibrin-shield disruption improves abscess infection control https://biobriefs.com/ai-biotech-funding-pathos-raises BioBriefs en 2026-10-23T16:32:08Z AI biotech funding: Pathos raises $237M and expands beyond oncology into Alzheimer’s https://biobriefs.com/protein-degrader-ipo-lycia-prices BioBriefs en 2026-10-23T16:32:08Z Protein degrader IPO: Lycia prices $318M public offering https://biobriefs.com/u-s-policy-treasury-proposes BioBriefs en 2026-10-23T16:32:08Z U.S. policy: Treasury proposes restrictions on outbound investment in Chinese biotech https://biobriefs.com/corporate-m-a-eqt-to BioBriefs en 2026-10-23T16:32:08Z Corporate M&A: EQT to buy Qiagen for $12.1B and take it private https://biobriefs.com/oncology-precision-combo-data-for BioBriefs en 2026-10-23T14:32:51Z Oncology — precision combo data for MTAP-deleted pancreatic cancer https://biobriefs.com/immuno-oncology-roche-deal-for BioBriefs en 2026-10-23T14:32:51Z Immuno-oncology — Roche deal for DLL3 trispecific T-cell engager https://biobriefs.com/fda-regulatory-accelerated-approval-for BioBriefs en 2026-10-23T14:32:51Z FDA regulatory — accelerated approval for dostarlimab in MSI-H/dMMR rectal cancer https://biobriefs.com/huntingtons-disease-alnylam-reports-mutant BioBriefs en 2026-10-23T14:32:51Z Huntington’s disease — Alnylam reports mutant huntingtin knockdown in early brezosiran study https://biobriefs.com/therapeutic-oncology-new-evidence-from BioBriefs en 2026-10-23T14:32:51Z Therapeutic oncology — new evidence from pancreatic cancer meeting as companies pivot at ESMO https://biobriefs.com/neuro-vision-cell-therapy-alcon BioBriefs en 2026-10-23T14:32:51Z Neuro/vision cell therapy — Alcon to buy Neurotech Pharma for $550M https://biobriefs.com/antibody-skin-inflammation-abbvie-late BioBriefs en 2026-10-23T14:32:51Z Antibody/skin inflammation — AbbVie late-stage success, but market expectations missed https://biobriefs.com/oncology-whole-genome-liquid-biopsy BioBriefs en 2026-10-23T14:32:51Z Oncology — whole-genome liquid biopsy signals recurrence months before imaging https://biobriefs.com/china-policy-proposed-coins-rule BioBriefs en 2026-10-23T14:32:51Z China policy — proposed COINS rule would sharply limit U.S. investments in Chinese biotech https://biobriefs.com/deal-and-financing-pathos-raises BioBriefs en 2026-10-23T14:32:51Z Deal and financing — Pathos raises $237M Series E led by Bristol Myers Squibb https://biobriefs.com/huntingtons-disease-rna-knockdown-advances BioBriefs en 2026-10-23T10:32:43Z Huntington’s disease RNA knockdown advances https://biobriefs.com/melanoma-mrna-vaccine-hits-phase BioBriefs en 2026-10-23T10:32:43Z Melanoma mRNA vaccine hits Phase 3 endpoints amid market reaction https://biobriefs.com/fda-grants-accelerated-approval-for BioBriefs en 2026-10-23T10:32:43Z FDA grants accelerated approval for MSI-H/dMMR rectal cancer https://biobriefs.com/hidradenitis-suppurativa-antibody-trial-lands BioBriefs en 2026-10-23T10:32:43Z Hidradenitis suppurativa antibody trial lands Phase 3 win but misses expectations https://biobriefs.com/dealmaking-eqt-to-take-qiagen BioBriefs en 2026-10-23T10:32:43Z Dealmaking: EQT to take Qiagen private for about $12.1B https://biobriefs.com/inflammation-gilead-expands-china-footprint BioBriefs en 2026-10-23T10:32:43Z Inflammation: Gilead expands China footprint with IL-23 Phase 1 asset https://biobriefs.com/ipo-lycia-prices-318m-for BioBriefs en 2026-10-23T10:32:43Z IPO: Lycia prices $318M for protein-degrading allergy and autoimmune pipeline https://biobriefs.com/regulatory-and-policy-us-draft BioBriefs en 2026-10-23T10:32:43Z Regulatory and policy: US draft outbound investment rules threaten cross-border biotech deals https://biobriefs.com/antiviral-and-platform-research-cryo BioBriefs en 2026-10-23T10:32:43Z Antiviral and platform research: cryo-EM reveals Andes hantavirus receptor binding mechanism https://biobriefs.com/ai-in-biomedical-discovery-openai BioBriefs en 2026-10-23T10:32:43Z AI in biomedical discovery: OpenAI and PerturbAI launch reasoning agents https://biobriefs.com/huntingtons-disease-early-gene-silencing BioBriefs en 2026-10-23T09:31:58Z Huntington’s disease — early gene-silencing signal for brezosiran https://biobriefs.com/melanoma-moderna-and-mercks-personalized BioBriefs en 2026-10-23T09:31:58Z Melanoma — Moderna and Merck’s personalized mRNA vaccine hits phase 3 endpoints https://biobriefs.com/regulatory-approval-accelerated-green-light BioBriefs en 2026-10-23T09:31:58Z Regulatory approval — accelerated green light for dostarlimab in MSI-H/dMMR locally advanced rectal cancer https://biobriefs.com/biopharma-dealmaking-gilead-pays-upfront BioBriefs en 2026-10-23T09:31:58Z Biopharma dealmaking — Gilead pays upfront for early oral IL-23 asset from PepStar https://biobriefs.com/diagnostics-and-tools-m-a BioBriefs en 2026-10-23T09:31:58Z Diagnostics and tools M&A — EQT agrees to acquire Qiagen for $12.1B and take it private https://biobriefs.com/oncology-innovation-and-pipeline-signals BioBriefs en 2026-10-23T09:31:58Z Oncology innovation and pipeline signals — Racura’s MYC-targeted cancer strategy https://biobriefs.com/cell-therapy-commercialization-alcon-buys BioBriefs en 2026-10-23T09:31:58Z Cell therapy commercialization — Alcon buys Neurotech Pharmaceuticals for $550M to expand Encelto access https://biobriefs.com/protein-degradation-lycia-prices-318m BioBriefs en 2026-10-23T09:31:58Z Protein degradation — Lycia prices $318M IPO for Graves’ and allergic pipeline https://biobriefs.com/regulatory-and-investment-policy-treasury BioBriefs en 2026-10-23T09:31:58Z Regulatory and investment policy — Treasury proposal threatens China biotech deal activity https://biobriefs.com/healthcare-economics-2025-drug-launch BioBriefs en 2026-10-23T09:31:58Z Healthcare economics — 2025 drug launch prices exceed $250,000 and access lags https://biobriefs.com/melanoma-mrna-vaccine-pivotal-trial BioBriefs en 2026-10-23T04:33:17Z Melanoma mRNA vaccine pivotal trial results and next regulatory steps https://biobriefs.com/fda-accelerates-dostarlimab-in-biomarker BioBriefs en 2026-10-23T04:33:17Z FDA accelerates dostarlimab in biomarker-defined locally advanced rectal cancer https://biobriefs.com/qiagen-heads-to-12-1b BioBriefs en 2026-10-23T04:33:17Z Qiagen heads to $12.1B EQT buyout, moving diagnostics and life-science tools to private ownership https://biobriefs.com/alcon-bets-on-ocular-cell BioBriefs en 2026-10-23T04:33:17Z Alcon bets on ocular cell therapy with $550M Neurotech acquisition https://biobriefs.com/gilead-pays-1-28b-upfront BioBriefs en 2026-10-23T04:33:17Z Gilead pays $1.28B upfront to PepStar for oral IL-23 Phase 1 asset https://biobriefs.com/lycia-launches-as-a-new BioBriefs en 2026-10-23T04:33:17Z Lycia launches as a new protein degrader public company via $318M IPO https://biobriefs.com/investment-restrictions-treasury-drafts-rules BioBriefs en 2026-10-23T04:33:17Z Investment restrictions: Treasury drafts rules to curb US biotech dealmaking tied to China https://biobriefs.com/protein-engineering-uw-and-nvidia BioBriefs en 2026-10-23T04:33:17Z Protein engineering: UW and Nvidia unveil open-source protein design model https://biobriefs.com/translational-virology-cryo-em-and BioBriefs en 2026-10-23T04:33:17Z Translational virology: cryo-EM and AI-designed scaffolds map Andes hantavirus receptor binding https://biobriefs.com/diabetes-technology-wireless-implant-uses BioBriefs en 2026-10-23T04:33:17Z Diabetes technology: wireless implant uses electrocatalysis to metabolize glucose in mice https://biobriefs.com/regulatory-approvals-in-oncology BioBriefs en 2026-10-22T21:32:06Z Regulatory approvals in oncology https://biobriefs.com/cancer-vaccine-efficacy-readout-pressure BioBriefs en 2026-10-22T21:32:06Z Cancer vaccine efficacy readout pressure https://biobriefs.com/biopharma-supply-chain-scaling-for BioBriefs en 2026-10-22T21:32:06Z Biopharma supply chain scaling for oral GLP-1s https://biobriefs.com/mega-deal-life-sciences-tools BioBriefs en 2026-10-22T21:32:06Z Mega-deal: life-sciences tools and diagnostics go private https://biobriefs.com/large-cap-cell-therapy-expansion BioBriefs en 2026-10-22T21:32:06Z Large-cap cell therapy expansion via acquisition https://biobriefs.com/late-stage-success-with-market BioBriefs en 2026-10-22T21:32:06Z Late-stage success with market disappointment in dermatology https://biobriefs.com/diabetes-technology-wireless-implant-eliminates BioBriefs en 2026-10-22T21:32:06Z Diabetes technology: wireless implant eliminates glucose in situ https://biobriefs.com/ai-for-protein-design-open BioBriefs en 2026-10-22T21:32:06Z AI for protein design: open model from UW and Nvidia https://biobriefs.com/cell-therapy-and-neurotechnology-retinal BioBriefs en 2026-10-22T21:32:06Z Cell therapy and neurotechnology: retinal implant integration strategy https://biobriefs.com/genai-governance-and-medical-oversight BioBriefs en 2026-10-22T21:32:06Z GenAI governance and medical oversight https://biobriefs.com/regulatory-approvals-and-pipeline-moves BioBriefs en 2026-10-22T16:33:30Z Regulatory approvals and pipeline moves https://biobriefs.com/major-deals-in-therapeutics-and BioBriefs en 2026-10-22T16:33:30Z Major deals in therapeutics and diagnostics https://biobriefs.com/ai-policy-and-healthcare-evidence BioBriefs en 2026-10-22T16:33:30Z AI policy and healthcare evidence standards https://biobriefs.com/fda-guidance-and-clinical-trials BioBriefs en 2026-10-22T16:33:30Z FDA guidance and clinical trials outcomes framework https://biobriefs.com/regulatory-and-political-risk-for BioBriefs en 2026-10-22T16:33:30Z Regulatory and political risk for China-biotech investment https://biobriefs.com/corporate-and-governance-shifts-in BioBriefs en 2026-10-22T16:33:30Z Corporate and governance shifts in big pharma and biotech https://biobriefs.com/cell-and-gene-therapy-expansion BioBriefs en 2026-10-22T16:33:30Z Cell and gene therapy expansion through acquisitions https://biobriefs.com/immunotherapy-safety-signals-in-real BioBriefs en 2026-10-22T16:33:30Z Immunotherapy safety signals in real-world Alzheimer’s use https://biobriefs.com/long-term-biomarker-and-cellular BioBriefs en 2026-10-22T16:33:30Z Long-term biomarker and cellular diagnostics innovation https://biobriefs.com/cell-therapy-for-viral-hepatitis BioBriefs en 2026-10-22T16:33:30Z Cell therapy for viral hepatitis—FDA clearance https://biobriefs.com/regulatory-approvals-in-oncology-and BioBriefs en 2026-10-22T14:33:25Z Regulatory approvals in oncology and infectious disease https://biobriefs.com/biotech-dealmaking-acquisitions-partnerships-and BioBriefs en 2026-10-22T14:33:25Z Biotech dealmaking: acquisitions, partnerships, and funding https://biobriefs.com/phase-3-momentum-and-pipeline BioBriefs en 2026-10-22T14:33:25Z Phase 3 momentum and pipeline readouts in inflammation and targeted therapy https://biobriefs.com/neuroinflammation-and-neurodegeneration-new-imaging BioBriefs en 2026-10-22T14:33:25Z Neuroinflammation and neurodegeneration: new imaging and biomarker angles https://biobriefs.com/ai-and-digital-health-oversight BioBriefs en 2026-10-22T14:33:25Z AI and digital health oversight: FDA guidance and clinical implementation challenges https://biobriefs.com/clinical-trial-and-dosing-signals BioBriefs en 2026-10-22T14:33:25Z Clinical trial and dosing signals: cardiometabolic and infectious disease studies https://biobriefs.com/immunotherapy-and-biomarker-measurement-cell BioBriefs en 2026-10-22T14:33:25Z Immunotherapy and biomarker measurement: cell health and imaging triage https://biobriefs.com/gene-therapy-and-molecular-therapeutics BioBriefs en 2026-10-22T14:33:25Z Gene therapy and molecular therapeutics: early clinical progress and platform choices https://biobriefs.com/safety-and-real-world-performance BioBriefs en 2026-10-22T14:33:25Z Safety and real-world performance: lecanemab ARIA and adverse-event profiling https://biobriefs.com/rare-diseases-and-inflammation-early BioBriefs en 2026-10-22T14:33:25Z Rare diseases and inflammation: early clinical exploration and trial design https://biobriefs.com/regulatory-approval-hepatitis-b-functional BioBriefs en 2026-10-22T10:32:55Z Regulatory approval – hepatitis B, functional cure https://biobriefs.com/clinical-development-cns-oncology-device BioBriefs en 2026-10-22T10:32:55Z Clinical development – CNS-oncology device funding https://biobriefs.com/partnerships-and-ai-drug-delivery BioBriefs en 2026-10-22T10:32:55Z Partnerships and AI drug delivery – Lilly and METiS https://biobriefs.com/biotech-funding-and-pipeline-trigemx BioBriefs en 2026-10-22T10:32:55Z Biotech funding and pipeline – TriGemX SPAC transaction https://biobriefs.com/r-d-update-roche-pipeline BioBriefs en 2026-10-22T10:32:55Z R&D update – Roche pipeline reshuffle and Phase 3 confidence messaging https://biobriefs.com/clinical-efficacy-oral-immune-modulating BioBriefs en 2026-10-22T10:32:55Z Clinical efficacy – oral immune-modulating pill in uveitis https://biobriefs.com/fda-and-trial-operations-ai BioBriefs en 2026-10-22T10:32:55Z FDA and trial operations – AI protocol checker for clinical sponsors https://biobriefs.com/safety-and-signal-evaluation-lecanemab BioBriefs en 2026-10-22T10:32:55Z Safety and signal evaluation – lecanemab real-world ARIA meta-analysis https://biobriefs.com/biotech-finance-rezera-files-for BioBriefs en 2026-10-22T10:32:55Z Biotech finance – Rezera files for IPO to fund NLRP3 program https://biobriefs.com/phase-3-late-stage-context BioBriefs en 2026-10-22T10:32:55Z Phase 3/late-stage context – Roivant and late-stage franchise signaling https://biobriefs.com/fda-approval-hepatitis-b-functional BioBriefs en 2026-10-22T09:33:55Z FDA approval: hepatitis B functional-cure strategy https://biobriefs.com/neurology-biotech-organ-implant-cancer BioBriefs en 2026-10-22T09:33:55Z Neurology biotech: organ-implant cancer monitoring funding https://biobriefs.com/dealmaking-ai-driven-lipid-nanoparticle BioBriefs en 2026-10-22T09:33:55Z Dealmaking: AI-driven lipid nanoparticle delivery partnership at Lilly https://biobriefs.com/oncology-phase-2-3-immunotherapy BioBriefs en 2026-10-22T09:33:55Z Oncology: Phase 2/3 immunotherapy trial launches in US biliary tract cancer https://biobriefs.com/rare-disease-ambrose-acquisition-of BioBriefs en 2026-10-22T09:33:55Z Rare disease: Ambrose acquisition of ilofotase alfa from AM-Pharma https://biobriefs.com/oncology-fda-approval-and-real BioBriefs en 2026-10-22T09:33:55Z Oncology: FDA approval and real-world safety for lecanemab https://biobriefs.com/immuno-oncology-biomarker-buoyant-mass BioBriefs en 2026-10-22T09:33:55Z Immuno-oncology biomarker: buoyant mass predicts checkpoint response https://biobriefs.com/company-ipo-rezera-files-for BioBriefs en 2026-10-22T09:33:55Z Company/IPO: Rezera files for IPO to back NLRP3 work in PAD https://biobriefs.com/regulatory-clinical-operations-mhra-to BioBriefs en 2026-10-22T09:33:55Z Regulatory, clinical operations: MHRA to build AI protocol checker https://biobriefs.com/bankable-validation-roche-automated-p BioBriefs en 2026-10-22T09:33:55Z Bankable validation: Roche automated p-tau217 amyloid testing in Taiwan https://biobriefs.com/fda-clears-hepatitis-b-program BioBriefs en 2026-10-22T04:33:44Z FDA clears hepatitis B program promising a functional cure https://biobriefs.com/lecanemab-real-world-data-quantify BioBriefs en 2026-10-22T04:33:44Z Lecanemab real-world data quantify ARIA risk https://biobriefs.com/roivants-lisraya-posts-phase-3 BioBriefs en 2026-10-22T04:33:44Z Roivant’s Lisraya posts Phase 3 win in non-infectious uveitis https://biobriefs.com/alzheimers-triage-blood-algorithm-cuts BioBriefs en 2026-10-22T04:33:44Z Alzheimer’s triage blood algorithm cuts amyloid PET use https://biobriefs.com/whole-genome-liquid-biopsy-detects BioBriefs en 2026-10-22T04:33:44Z Whole-genome liquid biopsy detects lung cancer recurrence early https://biobriefs.com/nist-quantum-sensors-sharpen-nuclear BioBriefs en 2026-10-22T04:33:44Z NIST quantum sensors sharpen nuclear monitoring measurements https://biobriefs.com/severe-malaria-sevuparin-identifies-3 BioBriefs en 2026-10-22T04:33:44Z Severe malaria: sevuparin identifies 3 mg/kg as tolerable dose https://biobriefs.com/interventional-imaging-brain-mri-surveillance BioBriefs en 2026-10-22T04:33:44Z Interventional imaging: brain MRI surveillance improves cognition in SCLC trial https://biobriefs.com/technology-investment-alcon-expands-eye BioBriefs en 2026-10-22T04:33:44Z Technology investment: Alcon expands eye portfolio via Neurotech acquisition https://biobriefs.com/clinical-device-funding-brain-implant BioBriefs en 2026-10-22T04:33:44Z Clinical device funding: brain implant startup Coherence raises for glioblastoma trial https://biobriefs.com/fda-approval-hepatitis-b-functional BioBriefs en 2026-10-21T21:31:47Z FDA approval – hepatitis B functional cure drug https://biobriefs.com/dealmaking-ai-led-delivery-partnership BioBriefs en 2026-10-21T21:31:47Z Dealmaking – AI-led delivery partnership at Lilly https://biobriefs.com/biotech-funding-brain-implant-cancer BioBriefs en 2026-10-21T21:31:47Z Biotech funding – brain-implant cancer startup Coherence raises seed https://biobriefs.com/clinical-readout-roivants-lisraya-advances BioBriefs en 2026-10-21T21:31:47Z Clinical readout – Roivant’s Lisraya advances in non-infectious uveitis https://biobriefs.com/r-d-validation-mit-method BioBriefs en 2026-10-21T21:31:47Z R&D validation – MIT method predicts response to immune checkpoint therapy https://biobriefs.com/m-a-ambrose-acquires-ilofotase BioBriefs en 2026-10-21T21:31:47Z M&A – Ambrose acquires ilofotase alfa candidate for hypophosphatasia https://biobriefs.com/pipeline-and-evidence-arkus-kidney BioBriefs en 2026-10-21T21:31:47Z Pipeline and evidence – Arkus kidney cancer update and next trials https://biobriefs.com/ai-drug-discovery-asimov-automates BioBriefs en 2026-10-21T21:31:47Z AI + drug discovery – Asimov automates vector design with agents and bio-foundation models https://biobriefs.com/device-innovation-and-regulatory-pathway BioBriefs en 2026-10-21T21:31:47Z Device innovation and regulatory pathway – drug-coated balloon rescue case https://biobriefs.com/cyber-operational-biosafety-morocco-pilot BioBriefs en 2026-10-21T21:31:47Z Cyber/operational biosafety – Morocco pilot identifies staffing as the main gap https://biobriefs.com/hepatitis-b-functional-cure-approval BioBriefs en 2026-10-21T16:31:42Z Hepatitis B functional-cure approval https://biobriefs.com/roivant-rare-disease-and-autoimmune BioBriefs en 2026-10-21T16:31:42Z Roivant rare-disease and autoimmune drug momentum https://biobriefs.com/ai-driven-drug-delivery-partnership BioBriefs en 2026-10-21T16:31:42Z AI-driven drug delivery partnership https://biobriefs.com/alcon-acquisition-signals-renewed-appetite BioBriefs en 2026-10-21T16:31:42Z Alcon acquisition signals renewed appetite in ophthalmic therapeutics https://biobriefs.com/hiv-long-term-treatment-durability BioBriefs en 2026-10-21T16:31:42Z HIV long-term treatment durability in dolutegravir/rilpivirine https://biobriefs.com/sevuparin-dose-selected-for-severe BioBriefs en 2026-10-21T16:31:42Z Sevuparin dose selected for severe pediatric malaria https://biobriefs.com/arcus-kidney-cancer-data-and BioBriefs en 2026-10-21T16:31:42Z Arcus kidney cancer data and TriGemX funding pathway https://biobriefs.com/dual-trials-expand-roivants-inflammatory BioBriefs en 2026-10-21T16:31:42Z Dual trials expand Roivant’s inflammatory eye franchise https://biobriefs.com/alcon-north-american-growth-and BioBriefs en 2026-10-21T16:31:42Z Alcon-North American growth and AI trial operations partnership https://biobriefs.com/dose-and-safety-move-heterologous BioBriefs en 2026-10-21T16:31:42Z Dose-and-safety move: heterologous immunotherapy platform in lymphoma https://biobriefs.com/fda-accelerates-immunotherapy-adoption-in BioBriefs en 2026-10-21T14:32:28Z FDA accelerates immunotherapy adoption in rectal cancer https://biobriefs.com/roche-and-hansoh-deepen-cancer BioBriefs en 2026-10-21T14:32:28Z Roche and Hansoh deepen cancer ADC pipeline with multi-program deal https://biobriefs.com/roivant-led-lisraya-posts-phase BioBriefs en 2026-10-21T14:32:28Z Roivant-led Lisraya posts Phase 3 win in non-infectious uveitis https://biobriefs.com/gsk-ionis-antiviral-bepirovirsen-earns BioBriefs en 2026-10-21T14:32:28Z GSK, Ionis antiviral bepirovirsen earns early FDA approval for functional cure https://biobriefs.com/ambrose-acquires-phase-ii-ready BioBriefs en 2026-10-21T14:32:28Z Ambrose acquires Phase II-ready ilofotase alfa from AM-Pharma in $181m deal https://biobriefs.com/clinical-trial-starts-in-severe BioBriefs en 2026-10-21T14:32:28Z Clinical trial starts in severe pediatric malaria with sevuparin dose selection https://biobriefs.com/cell-therapy-for-uveal-melanoma BioBriefs en 2026-10-21T14:32:28Z Cell therapy for uveal melanoma heads toward wider oncology interest https://biobriefs.com/targeted-ai-tool-seeks-regulatory BioBriefs en 2026-10-21T14:32:28Z Targeted AI tool seeks regulatory-grade treatment planning checks for radiation https://biobriefs.com/cancer-program-set-to-be BioBriefs en 2026-10-21T14:32:28Z Cancer program set to be tested in U.S. Phase 2/3: ivonescimab in biliary tract cancer https://biobriefs.com/roivant-usp-partnership-expands-where BioBriefs en 2026-10-21T14:32:28Z Roivant/USP partnership expands where NGS automation fits into clinical genomics https://biobriefs.com/gsk-secures-accelerated-fda-expansion BioBriefs en 2026-10-21T10:31:35Z GSK secures accelerated FDA expansion for Jemperli in rectal cancer https://biobriefs.com/gileads-emvistegrast-posts-phase-2 BioBriefs en 2026-10-21T10:31:35Z Gilead’s emvistegrast posts Phase 2 ulcerative colitis efficacy, targets Phase 3 https://biobriefs.com/roche-and-hansoh-expand-cancer BioBriefs en 2026-10-21T10:31:35Z Roche and Hansoh expand cancer ADC collaboration to new programs https://biobriefs.com/ambrose-buys-ilofotase-alfa-hpp BioBriefs en 2026-10-21T10:31:35Z Ambrose buys ilofotase alfa HPP asset from AM-Pharma https://biobriefs.com/phase-2-single-arm-results BioBriefs en 2026-10-21T10:31:35Z Phase 2 single-arm results: orelabrutinib plus R-CDOP hits strong response in high-risk DLBCL with CNS relapse https://biobriefs.com/ai-assisted-imaging-adaptive-models BioBriefs en 2026-10-21T10:31:35Z AI-assisted imaging: adaptive models recalibrate under retinal dataset shift https://biobriefs.com/model-warning-explainable-ml-adds BioBriefs en 2026-10-21T10:31:35Z Model warning: explainable ML adds risk ranking but not clear mortality edge in acute heart failure https://biobriefs.com/takara-bio-and-spt-labtech BioBriefs en 2026-10-21T10:31:35Z Takara Bio and SPT Labtech automate SMART-seq NGS workflows https://biobriefs.com/genai-regulation-fda-official-says BioBriefs en 2026-10-21T10:31:35Z GenAI regulation: FDA official says AI tools may need physician-level assessment https://biobriefs.com/fda-confidence-shifts-jemperli-label BioBriefs en 2026-10-21T10:31:35Z FDA confidence shifts: Jemperli label expansion meets rapid colorectal competitive cycle https://biobriefs.com/roche-hansoh-expands-adc-pipeline BioBriefs en 2026-10-21T09:33:02Z Roche-Hansoh expands ADC pipeline with new partnership https://biobriefs.com/gsk-gets-fda-accelerated-approval BioBriefs en 2026-10-21T09:33:02Z GSK gets FDA accelerated approval for rectal cancer label expansion https://biobriefs.com/gilead-pushes-oral-a4b7-integrin BioBriefs en 2026-10-21T09:33:02Z Gilead pushes oral a4b7 integrin blocker deeper after Phase 2 signal in ulcerative colitis https://biobriefs.com/ambrose-buys-am-pharmas-ilofotase BioBriefs en 2026-10-21T09:33:02Z Ambrose buys AM-Pharma’s ilofotase alfa for rare disease HPP https://biobriefs.com/orelabrutinib-plus-r-cdop-delivers BioBriefs en 2026-10-21T09:33:02Z Orelabrutinib plus R-CDOP delivers strong induction response in high-risk DLBCL https://biobriefs.com/uk-home-to-point-of BioBriefs en 2026-10-21T09:33:02Z UK home to point-of-care monitoring registries linking transfusion decisions to outcomes https://biobriefs.com/takara-bio-and-spt-labtech BioBriefs en 2026-10-21T09:33:02Z Takara Bio and SPT Labtech extend automation for SMART-Seq library prep https://biobriefs.com/cost-plus-rare-disease-model BioBriefs en 2026-10-21T09:33:02Z Cost-plus rare disease model pushes into European rare disease market via platform base https://biobriefs.com/rap-219-epilepsy-drug-finds BioBriefs en 2026-10-21T09:33:02Z RAP-219 epilepsy drug finds success signal in bipolar trial https://biobriefs.com/pando-bioscience-expands-enzyme-engineering BioBriefs en 2026-10-21T09:33:02Z Pando Bioscience expands enzyme-engineering push with ultra-high-throughput AI screening https://biobriefs.com/regulatory-approval-and-label-expansion BioBriefs en 2026-10-21T04:32:29Z Regulatory approval and label expansion https://biobriefs.com/late-stage-inflammatory-bowel-disease BioBriefs en 2026-10-21T04:32:29Z Late-stage inflammatory bowel disease pipeline momentum https://biobriefs.com/biotech-business-development-adc-partnership BioBriefs en 2026-10-21T04:32:29Z Biotech business development: ADC partnership expansion https://biobriefs.com/biopharma-dealmaking-and-pipeline-expansion BioBriefs en 2026-10-21T04:32:29Z Biopharma dealmaking and pipeline expansion in rare hematology https://biobriefs.com/trial-pipeline-milestone-at-esmo BioBriefs en 2026-10-21T04:32:29Z Trial pipeline milestone at ESMO for small-cell lung cancer https://biobriefs.com/regulatory-and-governance-for-ai BioBriefs en 2026-10-21T04:32:29Z Regulatory and governance for AI-enabled clinical tools https://biobriefs.com/biotech-funding-compliance-and-data BioBriefs en 2026-10-21T04:32:29Z Biotech funding: compliance and data platforms https://biobriefs.com/ngs-automation-partnerships-for-clinical BioBriefs en 2026-10-21T04:32:29Z NGS automation partnerships for clinical genomics workflows https://biobriefs.com/platform-innovation-enzymology-with-ultra BioBriefs en 2026-10-21T04:32:29Z Platform innovation: enzymology with ultra-high-throughput screening and AI https://biobriefs.com/biotech-pipeline-and-market-readthrough BioBriefs en 2026-10-21T04:32:29Z Biotech pipeline and market readthrough: Epkinly and ADC outlook https://biobriefs.com/fda-accelerates-jemperli-label-for BioBriefs en 2026-10-20T21:31:51Z FDA accelerates Jemperli label for rectal cancer https://biobriefs.com/genmab-bets-on-epkinly-and BioBriefs en 2026-10-20T21:31:51Z Genmab bets on Epkinly and ADC pipeline as Darzalex revenue cliff nears https://biobriefs.com/gilead-advances-oral-a4b7-integrin BioBriefs en 2026-10-20T21:31:51Z Gilead advances oral a4β7 integrin asset emvistegrast after SWIFT Phase 2 win https://biobriefs.com/merck-kgaa-expands-rare-disease BioBriefs en 2026-10-20T21:31:51Z Merck KGaA expands rare-disease hematology with Silence Therapeutics deal https://biobriefs.com/china-partnership-roche-and-hansoh BioBriefs en 2026-10-20T21:31:51Z China partnership: Roche and Hansoh co-develop antibody-drug conjugates https://biobriefs.com/pfizer-ends-phase-2-trial BioBriefs en 2026-10-20T21:31:51Z Pfizer ends Phase 2 trial of autoimmune program https://biobriefs.com/lab-to-market-compliance-readily BioBriefs en 2026-10-20T21:31:51Z Lab-to-market compliance: Readily raises $11M for compliance intelligence https://biobriefs.com/labcorp-expands-diagnostics-with-bioreference BioBriefs en 2026-10-20T21:31:51Z Labcorp expands diagnostics with BioReference acquisition https://biobriefs.com/regulatory-policy-tension-manufacturers-push BioBriefs en 2026-10-20T21:31:51Z Regulatory/policy tension: manufacturers push for 340B transparency https://biobriefs.com/vaccine-variant-detection-raman-barcodes BioBriefs en 2026-10-20T21:31:51Z Vaccine/variant detection: Raman barcodes distinguish SARS-CoV-2 variants https://biobriefs.com/inflammation-inflammatory-bowel-disease-pipeline BioBriefs en 2026-10-20T16:32:06Z Inflammation / Inflammatory bowel disease pipeline momentum https://biobriefs.com/biotech-dealmaking-rare-disease-rna BioBriefs en 2026-10-20T16:32:06Z Biotech dealmaking: rare disease RNA platform expansion https://biobriefs.com/diagnostics-m-a-broaden-prostate BioBriefs en 2026-10-20T16:32:06Z Diagnostics M&A: broaden prostate cancer risk testing footprint https://biobriefs.com/oncology-pipeline-antibody-like-immune BioBriefs en 2026-10-20T16:32:06Z Oncology pipeline: antibody-like immune engineering enters early clinical testing https://biobriefs.com/rna-drugs-regulation-and-safety BioBriefs en 2026-10-20T16:32:06Z RNA drugs regulation and safety evidence base https://biobriefs.com/regulatory-policy-risk-fda-compounding BioBriefs en 2026-10-20T16:32:06Z Regulatory-policy risk: FDA compounding expansion for peptides under White House review https://biobriefs.com/cybersecurity-threat-targeting-the-biotech BioBriefs en 2026-10-20T16:32:06Z Cybersecurity threat targeting the biotech ecosystem https://biobriefs.com/technology-r-d-clinical-long BioBriefs en 2026-10-20T16:32:06Z Technology R&D: clinical long-read genomics data platform expands https://biobriefs.com/clinical-operational-diagnostics-ai-backed BioBriefs en 2026-10-20T16:32:06Z Clinical/operational diagnostics: AI-backed imaging and workflow tools https://biobriefs.com/corporate-portfolio-astrazeneca-hires-oracle BioBriefs en 2026-10-20T16:32:06Z Corporate/portfolio: AstraZeneca hires Oracle for clinical trial recruitment https://biobriefs.com/mercks-1-3b-move-into BioBriefs en 2026-10-20T14:32:02Z Merck’s $1.3B move into late-stage rare blood siRNA for polycythemia vera https://biobriefs.com/labcorp-expands-fda-cleared-4kscore BioBriefs en 2026-10-20T14:32:02Z Labcorp expands FDA-cleared 4Kscore prostate test reach via $722M BioReference acquisition https://biobriefs.com/phase-3-readout-eases-fda BioBriefs en 2026-10-20T14:32:02Z Phase 3 readout eases FDA efficacy doubts for Disc’s bitopertin in erythropoietic protoporphyria https://biobriefs.com/us-policy-shift-implications-hepatitis BioBriefs en 2026-10-20T14:32:02Z US policy shift implications: hepatitis B protection could weaken under delayed infant vaccination https://biobriefs.com/new-clinical-evidence-for-early BioBriefs en 2026-10-20T14:32:02Z New clinical evidence for early viral protection: Sabin-strain inactivated polio vaccine shows broad infant responses https://biobriefs.com/rna-editing-platform-advance-engineered BioBriefs en 2026-10-20T14:32:02Z RNA editing platform advance: engineered human AGO2 enables higher C-to-U editing with comparable off-target profiles https://biobriefs.com/aav3b-antibodies-may-block-eligibility BioBriefs en 2026-10-20T14:32:02Z AAV3B antibodies may block eligibility for liver-directed gene therapy https://biobriefs.com/uk-biobank-immune-profiling-expansion BioBriefs en 2026-10-20T14:32:02Z UK Biobank immune profiling expansion: IMU Biosciences selected to generate 100M+ immune data points https://biobriefs.com/cardiac-diagnostics-caix-pet-ct BioBriefs en 2026-10-20T14:32:02Z Cardiac diagnostics: CAIX PET/CT finds most lesions in prospective clear-cell kidney cancer study https://biobriefs.com/biopharma-sentiment-lifts-after-downturn BioBriefs en 2026-10-20T14:32:02Z Biopharma sentiment lifts after downturn: BPSI Q3 2026 reaches positive territory https://biobriefs.com/rna-therapeutics-and-m-a BioBriefs en 2026-10-20T10:32:02Z RNA therapeutics and M&A reshuffle rare-disease pipelines https://biobriefs.com/diagnostics-consolidation-and-expanding-prostate BioBriefs en 2026-10-20T10:32:02Z Diagnostics consolidation and expanding prostate risk testing access https://biobriefs.com/clinical-progress-in-rare-disease BioBriefs en 2026-10-20T10:32:02Z Clinical progress in rare disease: EPP Phase 3 hits FDA concerns https://biobriefs.com/early-cancer-detection-and-response BioBriefs en 2026-10-20T10:32:02Z Early cancer detection and response monitoring through liquid biopsy microRNAs https://biobriefs.com/ai-in-oncology-and-biomarker BioBriefs en 2026-10-20T10:32:02Z AI in oncology and biomarker staging moves toward clinical workflows https://biobriefs.com/regulatory-signal-for-peptide-compounding BioBriefs en 2026-10-20T10:32:02Z Regulatory signal for peptide compounding access under White House review https://biobriefs.com/new-phase-i-iia-car BioBriefs en 2026-10-20T10:32:02Z New Phase I/IIa CAR T in solid tumors targets GD2 in Thailand https://biobriefs.com/product-development-exosome-delivery-and BioBriefs en 2026-10-20T10:32:02Z Product development: exosome delivery and bone regeneration in preclinical models https://biobriefs.com/merger-and-collaboration-for-large BioBriefs en 2026-10-20T10:32:02Z Merger and collaboration for large-scale immune profiling in UK Biobank https://biobriefs.com/cybersecurity-threat-targets-biotech-conference BioBriefs en 2026-10-20T10:32:02Z Cybersecurity threat targets biotech conference gatekeeping https://biobriefs.com/merck-kgaa-expands-rnai-with BioBriefs en 2026-10-20T09:31:56Z Merck KGaA expands RNAi with Silence Therapeutics buyout https://biobriefs.com/disc-medicine-records-phase-3 BioBriefs en 2026-10-20T09:31:56Z Disc Medicine records Phase 3 win as bitopertin clears FDA efficacy doubts https://biobriefs.com/estuary-biotherapeutics-raises-103m-to BioBriefs en 2026-10-20T09:31:56Z Estuary Biotherapeutics raises $103m to bring kidney-targeted AAV gene therapy to clinic https://biobriefs.com/ai-genomics-meets-real-world BioBriefs en 2026-10-20T09:31:56Z AI genomics meets real-world data: PacBio and Verily extend long-read collaboration https://biobriefs.com/nk-immune-surveillance-in-prostate BioBriefs en 2026-10-20T09:31:56Z NK/immune surveillance in prostate cancer: liquid biopsy miR-302/367 axis reshapes macrophages https://biobriefs.com/botanical-cancer-staging-two-plasma BioBriefs en 2026-10-20T09:31:56Z Botanical cancer staging: two plasma proteins stage Alzheimer’s and predict decline https://biobriefs.com/vaccine-strategy-in-outbreak-settings BioBriefs en 2026-10-20T09:31:56Z Vaccine strategy in outbreak settings: Vaxchora shows high effectiveness in Mayotte https://biobriefs.com/aav-delivery-for-fibrosis-singapores BioBriefs en 2026-10-20T09:31:56Z AAV delivery for fibrosis: Singapore’s A*STAR and HistoIndex join forces for fibrotic disease screening https://biobriefs.com/continuous-innovation-in-manufacturing-oak BioBriefs en 2026-10-20T09:31:56Z Continuous innovation in manufacturing: Oak Ridge joins BioMADE to scale domestic biomanufacturing https://biobriefs.com/security-alert-for-biotech-proofpoint BioBriefs en 2026-10-20T09:31:56Z Security alert for biotech: Proofpoint flags fake conference front used for malware https://biobriefs.com/rna-therapeutics-dealmaking-accelerates-in BioBriefs en 2026-10-20T04:31:41Z RNA therapeutics dealmaking accelerates in rare blood disease https://biobriefs.com/biotech-funding-targets-kidney-gene BioBriefs en 2026-10-20T04:31:41Z Biotech funding targets kidney gene therapy with local delivery platform https://biobriefs.com/clinical-trial-result-boosts-oral BioBriefs en 2026-10-20T04:31:41Z Clinical trial result boosts oral ulcerative colitis remission push https://biobriefs.com/first-in-human-gd2-car BioBriefs en 2026-10-20T04:31:41Z First-in-human GD2 CAR T trial opens for pediatric-solid-tumor targeting https://biobriefs.com/new-phase-3-readout-adds BioBriefs en 2026-10-20T04:31:41Z New Phase 3 readout adds a second chance after prior FDA rejection https://biobriefs.com/diagnostics-plasma-markers-move-toward BioBriefs en 2026-10-20T04:31:41Z Diagnostics: plasma markers move toward ALS screening precision https://biobriefs.com/digital-health-and-ai-in BioBriefs en 2026-10-20T04:31:41Z Digital health and AI in medicine: governance and safety remain unresolved https://biobriefs.com/regulatory-and-product-safety-measles BioBriefs en 2026-10-20T04:31:41Z Regulatory and product safety: measles and mumps vaccine viruses show anti-tumor synergy https://biobriefs.com/rna-delivery-and-manufacturing-preformed BioBriefs en 2026-10-20T04:31:41Z RNA delivery and manufacturing: preformed vesicles accelerate personalized dosing https://biobriefs.com/cybersecurity-intersects-life-sciences-operations BioBriefs en 2026-10-20T04:31:41Z Cybersecurity intersects life sciences operations https://biobriefs.com/merck-kgaa-buys-rnai-biotech BioBriefs en 2026-10-19T21:32:03Z Merck KGaA buys RNAi biotech Silence Therapeutics https://biobriefs.com/sanofi-partners-with-scionxbio-for BioBriefs en 2026-10-19T21:32:03Z Sanofi partners with ScionxBio for long-acting RNA discovery screening https://biobriefs.com/a-star-and-histoindex-team BioBriefs en 2026-10-19T21:32:03Z A*STAR and HistoIndex team up to accelerate fibrosis drug development https://biobriefs.com/estuary-biotherapeutics-raises-103m-for BioBriefs en 2026-10-19T21:32:03Z Estuary Biotherapeutics raises $103M for kidney-targeted AAV gene therapy in ADPKD https://biobriefs.com/nouscom-lands-135m-series-d BioBriefs en 2026-10-19T21:32:03Z Nouscom lands $135M Series D to advance neoantigen cancer interception https://biobriefs.com/car-t-moves-into-solid BioBriefs en 2026-10-19T21:32:03Z CAR T moves into solid tumors with first-in-human GD2 trial in Thailand https://biobriefs.com/gileads-oral-a4b7-inhibitor-emvistegrast BioBriefs en 2026-10-19T21:32:03Z Gilead’s oral α4β7 inhibitor emvistegrast shows Phase 2 remission signal in ulcerative colitis https://biobriefs.com/ai-tutoring-for-nursing-improves BioBriefs en 2026-10-19T21:32:03Z AI tutoring for nursing improves NCLEX-style reasoning performance https://biobriefs.com/imu-biosciences-and-uk-biobank BioBriefs en 2026-10-19T21:32:03Z IMU Biosciences and UK Biobank expand large-scale immune profiling https://biobriefs.com/china-restricts-foreign-biotech-acquisitions BioBriefs en 2026-10-19T21:32:03Z China restricts foreign biotech acquisitions – reported policy shift https://biobriefs.com/merck-kgaa-expands-rnai-pipeline BioBriefs en 2026-10-19T16:33:52Z Merck KGaA expands RNAi pipeline with Silence Therapeutics buyout https://biobriefs.com/chinas-moves-to-restrict-foreign BioBriefs en 2026-10-19T16:33:52Z China’s moves to restrict foreign biotech acquisitions https://biobriefs.com/oral-immunotherapy-in-ulcerative-colitis BioBriefs en 2026-10-19T16:33:52Z Oral immunotherapy in ulcerative colitis heats up as Gilead reports Phase 2 win https://biobriefs.com/single-dose-antibody-clears-siv BioBriefs en 2026-10-19T16:33:52Z Single-dose antibody clears SIV reservoirs in infant macaques https://biobriefs.com/estuary-biotherapeutics-raises-103m-for BioBriefs en 2026-10-19T16:33:52Z Estuary Biotherapeutics raises $103M for kidney-targeted AAV gene therapy in ADPKD https://biobriefs.com/new-guidance-for-measles-and BioBriefs en 2026-10-19T16:33:52Z New guidance for measles and mumps strains shows potential cancer cytotoxic synergy https://biobriefs.com/zilurgisertib-atebrioz-wins-fda-approval BioBriefs en 2026-10-19T16:33:52Z Zilurgisertib (Atebrioz) wins FDA approval as first ALK2 inhibitor for FOP https://biobriefs.com/clinical-recurrence-dynamics-in-multiply BioBriefs en 2026-10-19T16:33:52Z Clinical recurrence dynamics in multiply recurrent intracranial germ cell tumors https://biobriefs.com/roches-15b-adc-partnership-with BioBriefs en 2026-10-19T16:33:52Z Roche’s $15B ADC partnership with Hansoh signals scale-up in China oncology alliances https://biobriefs.com/stem-cell-exosomes-deliver-a BioBriefs en 2026-10-19T16:33:52Z Stem cell exosomes deliver a microRNA that halts kidney scarring in preclinical models https://biobriefs.com/genetic-medicines-dealmaking-merck-kgaa BioBriefs en 2026-10-19T14:32:46Z Genetic medicines dealmaking: Merck KGaA buys Silence Therapeutics for siRNA pipeline expansion https://biobriefs.com/inflammatory-bowel-disease-abbvie-advances BioBriefs en 2026-10-19T14:32:46Z Inflammatory bowel disease: AbbVie advances Skyrizi combo with ABBV-466 win in Crohn’s https://biobriefs.com/infectious-disease-diagnostics-ai-pipeline BioBriefs en 2026-10-19T14:32:46Z Infectious disease & diagnostics: AI pipeline audits tuberculosis resistance signals https://biobriefs.com/cancer-immunotherapy-expansion-marengos-invikafusp BioBriefs en 2026-10-19T14:32:46Z Cancer immunotherapy expansion: Marengo’s invikafusp alfa earns expanded FDA fast track for TMB-H solid tumors https://biobriefs.com/car-t-safety-profiling-car BioBriefs en 2026-10-19T14:32:46Z CAR-T safety profiling: CAR-HEMATOTOX score forecasts blood-cell crashes https://biobriefs.com/oncology-translational-progress-nouscom-raises BioBriefs en 2026-10-19T14:32:46Z Oncology translational progress: Nouscom raises $135M to advance lead cancer interception vaccine https://biobriefs.com/diagnostics-access-transplant-metagenomic-sequencing BioBriefs en 2026-10-19T14:32:46Z Diagnostics & access: Transplant metagenomic sequencing flags hidden donor-derived transmission https://biobriefs.com/regenerative-and-chronic-wound-biology BioBriefs en 2026-10-19T14:32:46Z Regenerative and chronic wound biology: Autophagy framed as master switch for wound healing https://biobriefs.com/diabetes-and-metabolic-risk-finerenone BioBriefs en 2026-10-19T14:32:46Z Diabetes and metabolic risk: Finerenone slows kidney decline in non-diabetic CKD real-world cohort https://biobriefs.com/rna-drug-delivery-innovation-scionxbio BioBriefs en 2026-10-19T14:32:46Z RNA & drug delivery innovation: ScionxBio links Sanofi candidates to long-acting RNA screening platform https://biobriefs.com/cancer-interception-immunotherapy-gets-major BioBriefs en 2026-10-19T10:32:52Z Cancer interception immunotherapy gets major funding and early data milestone https://biobriefs.com/regulatory-and-labeling-shake-up BioBriefs en 2026-10-19T10:32:52Z Regulatory and labeling shake-up for inhaled treprostinil IP dispute https://biobriefs.com/fda-expands-fast-track-status BioBriefs en 2026-10-19T10:32:52Z FDA expands fast-track status for pan-tumor T-cell agonist in TMB-H https://biobriefs.com/precision-immunotherapy-meets-safety-signal BioBriefs en 2026-10-19T10:32:52Z Precision immunotherapy meets safety signal in IL-6 blockade https://biobriefs.com/car-t-toxicity-risk-stratification BioBriefs en 2026-10-19T10:32:52Z CAR-T toxicity risk stratification gets a new predictive score https://biobriefs.com/biotech-scale-leap-in-continuous BioBriefs en 2026-10-19T10:32:52Z Biotech-scale leap in continuous brain monitoring guidelines for first responders https://biobriefs.com/neoadjuvant-immunochemotherapy-may-reduce-recurrence BioBriefs en 2026-10-19T10:32:52Z Neoadjuvant immunochemotherapy may reduce recurrence in esophageal cancer https://biobriefs.com/regenerative-cell-therapy-early-stem BioBriefs en 2026-10-19T10:32:52Z Regenerative cell therapy: early stem cell transplants improve outcomes in Shwachman-Diamond https://biobriefs.com/translational-hearing-tech-reaches-underserved BioBriefs en 2026-10-19T10:32:52Z Translational hearing tech reaches underserved populations with community delivery model https://biobriefs.com/diagnostic-imaging-acceleration-one-minute BioBriefs en 2026-10-19T10:32:52Z Diagnostic imaging acceleration: one-minute total-body PET/CT delivers quality in EQUIP https://biobriefs.com/cancer-immunotherapy-financing-and-trial BioBriefs en 2026-10-19T09:31:41Z Cancer immunotherapy financing and trial-readout momentum https://biobriefs.com/inflammatory-bowel-disease-gileads-phase BioBriefs en 2026-10-19T09:31:41Z Inflammatory bowel disease: Gilead’s Phase 2 emvistegrast shows remission signal https://biobriefs.com/regulatory-new-fast-track-expansion BioBriefs en 2026-10-19T09:31:41Z Regulatory: new Fast Track expansion for Marengo’s invikafusp alfa https://biobriefs.com/oncology-and-biomarkers-early-response BioBriefs en 2026-10-19T09:31:41Z Oncology and biomarkers: early response signals emerge in HCC https://biobriefs.com/car-t-safety-predictable-hematologic BioBriefs en 2026-10-19T09:31:41Z CAR-T safety: predictable hematologic toxicity risk scoring https://biobriefs.com/company-legal-settlement-impacting-pulmonary BioBriefs en 2026-10-19T09:31:41Z Company legal settlement impacting pulmonary arterial hypertension product label https://biobriefs.com/regenerative-medicine-early-stem-cell BioBriefs en 2026-10-19T09:31:41Z Regenerative medicine: early stem cell transplants improve survival in Shwachman-Diamond syndrome https://biobriefs.com/rare-infectious-disease-and-diagnostics BioBriefs en 2026-10-19T09:31:41Z Rare infectious disease and diagnostics: rapid TB resistance prediction with audit controls https://biobriefs.com/clinical-trial-design-and-cmc BioBriefs en 2026-10-19T09:31:41Z Clinical trial design and CMC planning: guidance on when to engage CDMOs https://biobriefs.com/health-system-and-funding-ecosystem BioBriefs en 2026-10-19T09:31:41Z Health system and funding ecosystem: Saudi Arabia ramps biotech buildout https://biobriefs.com/fda-fast-track-immuno-oncology BioBriefs en 2026-10-19T04:32:31Z FDA fast-track immuno-oncology expand https://biobriefs.com/liquidia-udly-united-settlement-reshapes BioBriefs en 2026-10-19T04:32:31Z Liquidia-Udly United settlement reshapes PH-ILD label https://biobriefs.com/company-financing-for-rare-endocrine BioBriefs en 2026-10-19T04:32:31Z Company financing for rare endocrine therapy https://biobriefs.com/ai-and-ct-biomarkers-move BioBriefs en 2026-10-19T04:32:31Z AI-and-CT biomarkers move toward noninvasive oncology decisions https://biobriefs.com/single-cell-insights-into-aml BioBriefs en 2026-10-19T04:32:31Z Single-cell insights into AML relapse after transplant https://biobriefs.com/car-t-toxicities-gut-persistence BioBriefs en 2026-10-19T04:32:31Z CAR-T toxicities: gut persistence drives severe intestinal inflammation https://biobriefs.com/clinical-trial-sparing-chemotherapy-in BioBriefs en 2026-10-19T04:32:31Z Clinical trial: sparing chemotherapy in early breast cancer https://biobriefs.com/microfluidic-protein-engineering-scale-up BioBriefs en 2026-10-19T04:32:31Z Microfluidic protein engineering scale-up https://biobriefs.com/clinical-delivery-systems-solusome-improves BioBriefs en 2026-10-19T04:32:31Z Clinical delivery systems: Solusome improves oral bioavailability https://biobriefs.com/diagnostics-and-epidemiology-low-cost BioBriefs en 2026-10-19T04:32:31Z Diagnostics and epidemiology: low-cost CRISPR test for Babesia https://biobriefs.com/capped-us-hospital-scrutiny-on BioBriefs en 2026-10-18T21:31:42Z Capped US hospital scrutiny on CAR-T intestinal toxicity https://biobriefs.com/diasome-outlines-phase-3-readiness BioBriefs en 2026-10-18T21:31:42Z Diasome outlines Phase 3 readiness for hepatocyte-targeted HDV-insulin in type 1 diabetes https://biobriefs.com/liquidia-settles-with-united-therapeutics BioBriefs en 2026-10-18T21:31:42Z Liquidia settles with United Therapeutics, narrows Yutrepia label https://biobriefs.com/ehr-driven-latent-tb-screening BioBriefs en 2026-10-18T21:31:42Z EHR-driven latent TB screening under California’s mandate https://biobriefs.com/ai-on-ct-scans-to BioBriefs en 2026-10-18T21:31:42Z AI on CT scans to forecast bladder cancer recurrence https://biobriefs.com/hiv-two-drug-therapy-reaches BioBriefs en 2026-10-18T21:31:42Z HIV: two-drug therapy reaches lymph node reservoirs on trial imaging https://biobriefs.com/cell-therapy-manufacturing-research-subcutaneous BioBriefs en 2026-10-18T21:31:42Z Cell therapy manufacturing research: subcutaneous CAR-T cognition signals by age https://biobriefs.com/oncology-discovery-usp15-dependency-in BioBriefs en 2026-10-18T21:31:42Z Oncology discovery: USP15 dependency in ovarian cancer https://biobriefs.com/neuroscience-oncology-stroke-driven-microenvironment BioBriefs en 2026-10-18T21:31:42Z Neuroscience oncology: stroke-driven microenvironment programs accelerate glioma https://biobriefs.com/pediatric-infectious-disease-phoenix-sepsis BioBriefs en 2026-10-18T21:31:42Z Pediatric infectious disease: Phoenix Sepsis Criteria outperforms procalcitonin https://biobriefs.com/clinical-development-and-trial-readouts BioBriefs en 2026-10-18T16:31:36Z Clinical development and trial readouts in oncology https://biobriefs.com/drug-discovery-and-platform-advances BioBriefs en 2026-10-18T16:31:36Z Drug discovery and platform advances in targeted oncology biology https://biobriefs.com/immunotherapy-and-cell-therapy-manufacturing BioBriefs en 2026-10-18T16:31:36Z Immunotherapy and cell therapy manufacturing models https://biobriefs.com/infectious-disease-hiv-research-and BioBriefs en 2026-10-18T16:31:36Z Infectious disease: HIV research and screening execution https://biobriefs.com/antibiotics-antimicrobial-stewardship-and-diagnostics BioBriefs en 2026-10-18T16:31:36Z Antibiotics, antimicrobial stewardship, and diagnostics https://biobriefs.com/cardiovascular-and-rehabilitation-outcomes-in BioBriefs en 2026-10-18T16:31:36Z Cardiovascular and rehabilitation outcomes in real-world settings https://biobriefs.com/ai-in-healthcare-clinician-workflows BioBriefs en 2026-10-18T16:31:36Z AI in healthcare: clinician workflows, imaging, and patient monitoring https://biobriefs.com/rare-disease-and-pipeline-funding BioBriefs en 2026-10-18T16:31:36Z Rare disease and pipeline funding: OMass raises for endocrine drug candidate https://biobriefs.com/diabetes-care-and-metabolic-risk BioBriefs en 2026-10-18T16:31:36Z Diabetes care and metabolic risk mechanisms https://biobriefs.com/regulatory-and-clinical-policy-signals BioBriefs en 2026-10-18T16:31:36Z Regulatory and clinical policy signals in TB and oncology supportive care https://biobriefs.com/funding-for-lgbtq-behavioral-health BioBriefs en 2026-10-18T14:32:35Z Funding for LGBTQ+ behavioral health platform https://biobriefs.com/in-vivo-car-t-as BioBriefs en 2026-10-18T14:32:35Z In vivo CAR-T as next-gen universal immune therapy concept https://biobriefs.com/car-t-off-the-shelf BioBriefs en 2026-10-18T14:32:35Z CAR-T off-the-shelf outcomes tied to immune rejection and CAR T fitness https://biobriefs.com/manufacturing-and-access-gap-for BioBriefs en 2026-10-18T14:32:35Z Manufacturing and access gap for antibiotic delivery https://biobriefs.com/clinical-imaging-biomarkers-for-high BioBriefs en 2026-10-18T14:32:35Z Clinical imaging biomarkers for high-risk disease https://biobriefs.com/oncology-pipeline-signal-cdk7-inhibition BioBriefs en 2026-10-18T14:32:35Z Oncology pipeline signal: CDK7 inhibition in resistant HR+/HER2− breast cancer https://biobriefs.com/gene-targeted-hiv-therapy-penetrates BioBriefs en 2026-10-18T14:32:35Z Gene-targeted HIV therapy penetrates lymph node reservoirs https://biobriefs.com/immune-checkpoint-therapy-monitoring-for BioBriefs en 2026-10-18T14:32:35Z Immune checkpoint therapy monitoring for liver transplant recurrence risk https://biobriefs.com/velosource-expansion-with-upmc-enterprises BioBriefs en 2026-10-18T14:32:35Z VeloSource expansion with UPMC Enterprises investment https://biobriefs.com/antibiotic-stewardship-vaccination-linked-to BioBriefs en 2026-10-18T14:32:35Z Antibiotic stewardship: vaccination linked to reduced antibiotic use https://biobriefs.com/ai-drug-discovery-and-targeted BioBriefs en 2026-10-18T10:31:29Z AI drug discovery and targeted cancer therapeutics https://biobriefs.com/hiv-treatment-optimization-via-drug BioBriefs en 2026-10-18T10:31:29Z HIV treatment optimization via drug penetration and regimen strategies https://biobriefs.com/cell-therapy-engineering-and-immune BioBriefs en 2026-10-18T10:31:29Z Cell therapy engineering and immune control in CAR T https://biobriefs.com/immunotherapy-and-immune-checkpoint-biomarker BioBriefs en 2026-10-18T10:31:29Z Immunotherapy and immune-checkpoint biomarker refinement https://biobriefs.com/myopia-therapeutics-atropine-eye-drops BioBriefs en 2026-10-18T10:31:29Z Myopia therapeutics: atropine eye drops show stronger slowing effect https://biobriefs.com/cancer-diagnostics-and-rapid-tissue BioBriefs en 2026-10-18T10:31:29Z Cancer diagnostics and rapid tissue-to-decision tools https://biobriefs.com/neutrophil-immune-evasion-mechanisms-in BioBriefs en 2026-10-18T10:31:29Z Neutrophil/immune evasion mechanisms in cancer https://biobriefs.com/sepsis-and-organ-injury-prediction BioBriefs en 2026-10-18T10:31:29Z Sepsis and organ-injury prediction using AI models https://biobriefs.com/lung-and-radiation-oncology-safety BioBriefs en 2026-10-18T10:31:29Z Lung and radiation oncology safety: radiotherapy triggers herpes reactivation https://biobriefs.com/diabetic-foot-and-amputation-outcomes BioBriefs en 2026-10-18T10:31:29Z Diabetic foot and amputation outcomes predicted by routine lab tests https://biobriefs.com/hiv-prevention-access-and-real BioBriefs en 2026-10-18T09:32:42Z HIV prevention access and real-world adherence barriers https://biobriefs.com/two-drug-hiv-therapy-reaches BioBriefs en 2026-10-18T09:32:42Z Two-drug HIV therapy reaches lymph node reservoirs https://biobriefs.com/covid-19-immunity-wanes-with BioBriefs en 2026-10-18T09:32:42Z COVID-19 immunity wanes with rising community transmission https://biobriefs.com/home-based-monitoring-can-cut BioBriefs en 2026-10-18T09:32:42Z Home-based monitoring can cut postoperative complications – only with clinician review https://biobriefs.com/cancer-surgery-choice-reshapes-long BioBriefs en 2026-10-18T09:32:42Z Cancer surgery choice reshapes long-term colorectal cancer risk after appendicitis https://biobriefs.com/proximal-biomarker-inflammation-index-plus BioBriefs en 2026-10-18T09:32:42Z Proximal biomarker: inflammation index plus staging predicts lung cancer survival https://biobriefs.com/off-the-shelf-car-t BioBriefs en 2026-10-18T09:32:42Z Off-the-shelf CAR T success depends on immune rejection and CAR T cell fitness https://biobriefs.com/mount-sinai-wins-20-7m BioBriefs en 2026-10-18T09:32:41Z Mount Sinai wins $20.7M to build next-generation respiratory mRNA vaccine platform https://biobriefs.com/checkpoint-inhibition-side-effects-are BioBriefs en 2026-10-18T09:32:41Z Checkpoint inhibition side effects are not equal for survival https://biobriefs.com/rapid-point-of-care-diagnostics BioBriefs en 2026-10-18T09:32:41Z Rapid point-of-care diagnostics: microfluidic platform enables multidimensional profiling https://biobriefs.com/glioblastoma-drug-development-shifts-toward BioBriefs en 2026-10-18T04:32:18Z Glioblastoma drug development shifts toward biomarker-guided combinations https://biobriefs.com/new-diagnostic-signal-for-blood BioBriefs en 2026-10-18T04:32:18Z New diagnostic signal for blood cancers and risk stratification https://biobriefs.com/targeted-crispr-screen-identifies-a BioBriefs en 2026-10-18T04:32:18Z Targeted CRISPR screen identifies a vulnerability in GNAQ-mutant eye cancer https://biobriefs.com/immunotherapy-resistance-biology-resurfaces-as BioBriefs en 2026-10-18T04:32:18Z Immunotherapy-resistance biology resurfaces as a cancer treatment limiter https://biobriefs.com/h5n1-vaccine-platform-funding-and BioBriefs en 2026-10-18T04:32:18Z H5N1 vaccine platform funding and early clinical path https://biobriefs.com/pr3-anca-pulmonary-renal-syndrome BioBriefs en 2026-10-18T04:32:18Z PR3-ANCA pulmonary-renal syndrome sees rituximab rescue after standard failure https://biobriefs.com/peripheral-artery-disease-burden-ties BioBriefs en 2026-10-18T04:32:18Z Peripheral artery disease burden ties to metabolic risk signals in China https://biobriefs.com/cagrisema-meta-analysis-adds-dose BioBriefs en 2026-10-18T04:32:18Z CagriSema meta-analysis adds dose-specific efficacy signal in type 2 diabetes https://biobriefs.com/microfluidic-point-of-care-platform BioBriefs en 2026-10-18T04:32:18Z Microfluidic point-of-care platform boosts multi-analyte diagnostic performance https://biobriefs.com/antibiotic-use-reduction-from-vaccination BioBriefs en 2026-10-18T04:32:18Z Antibiotic use reduction from vaccination programs – global review https://biobriefs.com/precision-immunotherapy-in-solid-tumors BioBriefs en 2026-10-17T21:31:34Z Precision immunotherapy in solid tumors https://biobriefs.com/targeting-cancer-lipid-remodeling-to BioBriefs en 2026-10-17T21:31:34Z Targeting cancer lipid remodeling to overcome gemcitabine resistance https://biobriefs.com/clinical-trial-signal-in-resistant BioBriefs en 2026-10-17T21:31:34Z Clinical trial signal in resistant HR+/HER2- breast cancer https://biobriefs.com/early-escalation-strategy-fails-in BioBriefs en 2026-10-17T21:31:34Z Early escalation strategy fails in septic shock https://biobriefs.com/new-biomarker-route-in-hpv BioBriefs en 2026-10-17T21:31:34Z New biomarker route in HPV-negative head and neck cancer https://biobriefs.com/from-diagnosis-to-stewardship-penicillin BioBriefs en 2026-10-17T21:31:34Z From diagnosis to stewardship: penicillin allergy delabeling push https://biobriefs.com/cell-death-pathway-uncovered-as BioBriefs en 2026-10-17T21:31:34Z Cell death pathway uncovered as therapeutic lever in pulmonary fibrosis https://biobriefs.com/delivering-antibiotics-to-the-eye BioBriefs en 2026-10-17T21:31:34Z Delivering antibiotics to the eye through the cornea https://biobriefs.com/digital-health-in-pediatrics-universal BioBriefs en 2026-10-17T21:31:34Z Digital health in pediatrics: universal psychosocial screening scaled https://biobriefs.com/real-world-antimicrobial-stewardship-impact BioBriefs en 2026-10-17T21:31:34Z Real-world antimicrobial stewardship impact in hospital pediatrics https://biobriefs.com/regulatory-greenlights-and-approval-driven BioBriefs en 2026-10-17T16:31:37Z Regulatory greenlights and approval-driven oncology momentum https://biobriefs.com/precision-diagnostic-tools-for-oncology BioBriefs en 2026-10-17T16:31:37Z Precision diagnostic tools for oncology selection https://biobriefs.com/immunotherapy-patient-stratification-by-blood BioBriefs en 2026-10-17T16:31:37Z Immunotherapy patient stratification by blood biomarkers https://biobriefs.com/transplant-medicine-moves-toward-biomarker BioBriefs en 2026-10-17T16:31:37Z Transplant medicine moves toward biomarker-defined rejection surveillance https://biobriefs.com/car-t-relapse-biology-surfaces BioBriefs en 2026-10-17T16:31:37Z CAR-T relapse biology surfaces a potential RNA biomarker https://biobriefs.com/sepsis-detection-and-the-long BioBriefs en 2026-10-17T16:31:37Z Sepsis detection and the long road to certified diagnostics https://biobriefs.com/antibiotic-stewardship-and-dosing-precision BioBriefs en 2026-10-17T16:31:37Z Antibiotic stewardship and dosing precision in early life https://biobriefs.com/real-world-evidence-reshapes-asthma BioBriefs en 2026-10-17T16:31:37Z Real-world evidence reshapes asthma biologic selection https://biobriefs.com/nursing-workflow-intelligence-for-oncology BioBriefs en 2026-10-17T16:31:37Z Nursing workflow intelligence for oncology toxicity prevention https://biobriefs.com/cell-death-biology-and-mitochondrial BioBriefs en 2026-10-17T16:31:37Z Cell death biology and mitochondrial vulnerability as cancer therapy strategy https://biobriefs.com/sepsis-biology-and-potential-precision BioBriefs en 2026-10-17T14:31:44Z Sepsis biology and potential precision targets https://biobriefs.com/neural-data-analytics-for-icu BioBriefs en 2026-10-17T14:31:44Z Neural data analytics for ICU deterioration risk https://biobriefs.com/gut-microbiome-shifts-tied-to BioBriefs en 2026-10-17T14:31:44Z Gut microbiome shifts tied to diet-derived toxins and aging https://biobriefs.com/allergy-diagnostics-quality-control-for BioBriefs en 2026-10-17T14:31:44Z Allergy diagnostics quality control for multiplex IgE panels https://biobriefs.com/machine-learning-for-earlier-kidney BioBriefs en 2026-10-17T14:31:44Z Machine learning for earlier kidney injury detection in ICU time series https://biobriefs.com/hyperacusis-intervention-using-gamified-sound BioBriefs en 2026-10-17T14:31:44Z Hyperacusis intervention using gamified sound training https://biobriefs.com/car-t-relapse-biomarker-from BioBriefs en 2026-10-17T14:31:44Z CAR-T relapse biomarker from pre-treatment RNA splicing signals https://biobriefs.com/primary-care-and-clinical-delivery BioBriefs en 2026-10-17T14:31:44Z Primary care and clinical delivery constraints for rehabilitation access https://biobriefs.com/biotech-regulation-and-real-world BioBriefs en 2026-10-17T14:31:44Z Biotech regulation and real-world adoption of AI in hospitals https://biobriefs.com/targeted-therapy-in-myotonic-generalized BioBriefs en 2026-10-17T14:31:44Z Targeted therapy in myotonic/generalized myasthenia: sequencing and crisis management https://biobriefs.com/pan-european-pancreatic-cancer-approval BioBriefs en 2026-10-17T10:31:45Z Pan-European pancreatic cancer approval momentum https://biobriefs.com/fda-us-centre-therapies-and BioBriefs en 2026-10-17T10:31:45Z FDA/US-Centre therapies and the business of AI-enabled diagnostics https://biobriefs.com/ipo-and-funding-rnai-bets BioBriefs en 2026-10-17T10:31:45Z IPO and funding: RNAi bets expand beyond the liver https://biobriefs.com/brain-stimulation-analytics-how-fast BioBriefs en 2026-10-17T10:31:45Z Brain stimulation analytics: how fast-growing deep-target techniques compare https://biobriefs.com/cancer-precision-oncology-digital-pathology BioBriefs en 2026-10-17T10:31:45Z Cancer precision oncology: digital pathology improves tumor DNA yield https://biobriefs.com/neurodegeneration-and-biomarker-discovery-parkinsons BioBriefs en 2026-10-17T10:31:45Z Neurodegeneration and biomarker discovery: Parkinson’s blood immune signature tied to Alzheimer co-pathology https://biobriefs.com/clinical-evidence-nuance-thrombectomy-benefits BioBriefs en 2026-10-17T10:31:45Z Clinical evidence nuance: thrombectomy benefits in extended windows https://biobriefs.com/hidradenitis-suppurativa-biologics-reshape-clot BioBriefs en 2026-10-17T10:31:45Z Hidradenitis suppurativa: biologics reshape clot risk and outcomes https://biobriefs.com/antibiotic-stewardship-evidence-shorter-poet BioBriefs en 2026-10-17T10:31:45Z Antibiotic stewardship evidence: shorter POET II regimens for endocarditis https://biobriefs.com/r-d-and-manufacturing-infrastructure BioBriefs en 2026-10-17T10:31:45Z R&D and manufacturing infrastructure: GMP platform for extracellular vesicles https://biobriefs.com/company-ipo-and-financing-to BioBriefs en 2026-10-17T09:32:19Z Company IPO and financing to expand RNAi beyond liver https://biobriefs.com/eu-regulatory-nods-for-next BioBriefs en 2026-10-17T09:32:19Z EU regulatory nods for next-gen obesity and pancreatic cancer drugs https://biobriefs.com/astrazeneca-and-insitro-partner-on BioBriefs en 2026-10-17T09:32:19Z AstraZeneca and insitro partner on AI-driven target discovery in cardiometabolic disease https://biobriefs.com/portugal-like-precision-genomics-digital BioBriefs en 2026-10-17T09:32:19Z Portugal-like precision genomics: digital extraction improves tumor DNA yield for sequencing https://biobriefs.com/cancer-genome-analysis-toolkit-targets BioBriefs en 2026-10-17T09:32:19Z Cancer genome analysis toolkit targets extrachromosomal DNA chaos https://biobriefs.com/cell-free-dna-assay-for BioBriefs en 2026-10-17T09:32:19Z Cell-free DNA assay for earlier detection of heart transplant rejection https://biobriefs.com/modernizing-car-t-for-solid BioBriefs en 2026-10-17T09:32:19Z Modernizing CAR-T for solid tumors with new engineering and cost strategies https://biobriefs.com/danaher-and-nvidia-team-up BioBriefs en 2026-10-17T09:32:19Z Danaher and NVIDIA team up for autonomous lab workflows https://biobriefs.com/ai-reliability-warning-hospitals-deploy BioBriefs en 2026-10-17T09:32:19Z AI reliability warning: hospitals deploy faster than regulators can verify https://biobriefs.com/clinical-research-flags-antibiotic-stopping BioBriefs en 2026-10-17T09:32:19Z Clinical research flags antibiotic stopping strategy in infective endocarditis https://biobriefs.com/regulatory-and-clinical-trial-signals BioBriefs en 2026-10-17T04:32:19Z Regulatory and clinical trial signals in musculoskeletal and liver disease https://biobriefs.com/rnai-ipos-and-delivery-strategies BioBriefs en 2026-10-17T04:32:19Z RNAi IPOs and delivery strategies move into late-stage competition https://biobriefs.com/ai-and-diagnostic-workflows-precision BioBriefs en 2026-10-17T04:32:19Z AI and diagnostic workflows: precision pathology, imaging triage, and seizure risk https://biobriefs.com/car-t-and-immune-oncology BioBriefs en 2026-10-17T04:32:19Z CAR-T and immune-oncology: early-stage durability signals and engineered next steps https://biobriefs.com/inflammation-biology-and-targeted-drug BioBriefs en 2026-10-17T04:32:19Z Inflammation biology and targeted drug opportunities emerge from computational-to-bench links https://biobriefs.com/sepsis-and-critical-care-diagnostics BioBriefs en 2026-10-17T04:32:19Z Sepsis and critical care diagnostics: turning biomarkers into certified decisions https://biobriefs.com/rare-disease-gene-therapies-non BioBriefs en 2026-10-17T04:32:19Z Rare disease gene therapies: non-dilutive funding via FDA rare pediatric PRVs https://biobriefs.com/drug-safety-stewardship-and-antimicrobial BioBriefs en 2026-10-17T04:32:19Z Drug safety, stewardship, and antimicrobial resistance surveillance in hospitals https://biobriefs.com/neurotherapeutics-and-device-based-care BioBriefs en 2026-10-17T04:32:19Z Neurotherapeutics and device-based care: brain stimulation, BCI, and new measurement tools https://biobriefs.com/metabolic-and-immune-regulation-cross BioBriefs en 2026-10-17T04:32:19Z Metabolic and immune regulation: cross-disease targets and early pipeline cues https://biobriefs.com/european-glp-1-expansion BioBriefs en 2026-10-16T21:32:28Z European GLP-1 expansion https://biobriefs.com/ai-enabled-target-discovery-dealmaking BioBriefs en 2026-10-16T21:32:28Z AI-enabled target discovery dealmaking https://biobriefs.com/rnai-public-market-push BioBriefs en 2026-10-16T21:32:28Z RNAi public-market push https://biobriefs.com/therapeutic-plasma-exchange-safety-in BioBriefs en 2026-10-16T21:32:28Z Therapeutic plasma exchange safety in pediatrics https://biobriefs.com/car-t-clinical-signal-in BioBriefs en 2026-10-16T21:32:28Z CAR-T clinical signal in myeloma https://biobriefs.com/rare-pediatric-prv-monetization-by BioBriefs en 2026-10-16T21:32:28Z Rare pediatric PRV monetization by Ultragenyx https://biobriefs.com/clinical-evidence-for-left-atrial BioBriefs en 2026-10-16T21:32:28Z Clinical evidence for left atrial appendage occlusion https://biobriefs.com/immuno-oncology-target-biology-in BioBriefs en 2026-10-16T21:32:28Z Immuno-oncology target biology in T-cell exhaustion https://biobriefs.com/diagnostic-ai-for-infant-hip BioBriefs en 2026-10-16T21:32:28Z Diagnostic AI for infant hip dysplasia https://biobriefs.com/regulatory-scrutiny-of-peptide-compounding BioBriefs en 2026-10-16T21:32:28Z Regulatory scrutiny of peptide compounding and label updates https://biobriefs.com/regulatory-and-trial-decisions-in BioBriefs en 2026-10-16T16:31:51Z Regulatory and trial decisions in oncology https://biobriefs.com/eu-approval-for-oral-glp BioBriefs en 2026-10-16T16:31:51Z EU approval for oral GLP-1 expands obesity pipeline https://biobriefs.com/ai-drug-discovery-funding-and BioBriefs en 2026-10-16T16:31:51Z AI drug discovery funding and IPO activity https://biobriefs.com/large-biotech-financing-for-gene BioBriefs en 2026-10-16T16:31:51Z Large biotech financing for gene therapy in inherited kidney disease https://biobriefs.com/ipo-wave-in-rnai-drug BioBriefs en 2026-10-16T16:31:51Z IPO wave in RNAi drug development https://biobriefs.com/fda-rare-disease-regulatory-reset BioBriefs en 2026-10-16T16:31:51Z FDA rare disease regulatory reset framework https://biobriefs.com/clinical-update-in-car-t BioBriefs en 2026-10-16T16:31:51Z Clinical update in CAR-T for multiple myeloma https://biobriefs.com/funding-for-ai-enabled-target BioBriefs en 2026-10-16T16:31:51Z Funding for AI-enabled target discovery collaboration (AZ + insitro) https://biobriefs.com/rare-disease-voucher-monetization-to BioBriefs en 2026-10-16T16:31:51Z Rare disease voucher monetization to fund gene therapy pipeline https://biobriefs.com/rna-based-flu-vaccine-dosing BioBriefs en 2026-10-16T16:31:51Z RNA-based flu vaccine dosing interval improves immunogenicity https://biobriefs.com/fda-rare-disease-review-overhaul BioBriefs en 2026-10-16T14:32:43Z FDA rare-disease review overhaul signals regulatory reset https://biobriefs.com/ai-enabled-diagnostics-and-radiology BioBriefs en 2026-10-16T14:32:43Z AI-enabled diagnostics and radiology tools move toward clinical evaluation https://biobriefs.com/regenerative-and-gene-therapy-funding BioBriefs en 2026-10-16T14:32:43Z Regenerative and gene therapy funding accelerates outside the liver https://biobriefs.com/rnai-dealmaking-heats-up-as BioBriefs en 2026-10-16T14:32:43Z RNAi dealmaking heats up as Roche expands beyond the liver https://biobriefs.com/solid-tumor-car-t-pushes BioBriefs en 2026-10-16T14:32:43Z Solid-tumor CAR-T pushes into early clinical readouts https://biobriefs.com/imaging-and-decision-tools-aim BioBriefs en 2026-10-16T14:32:43Z Imaging and decision tools aim to improve cancer surgery selection https://biobriefs.com/vaccines-and-dosing-schedules-advance BioBriefs en 2026-10-16T14:32:43Z Vaccines and dosing schedules advance for H5N1 self-amplifying mRNA https://biobriefs.com/microbiology-and-bloodstream-infections-highlight BioBriefs en 2026-10-16T14:32:43Z Microbiology and bloodstream infections highlight risk in high-acuity oncology populations https://biobriefs.com/clinical-safety-and-standards-fda BioBriefs en 2026-10-16T14:32:43Z Clinical safety and standards: FDA and evidence-quality pressure continues https://biobriefs.com/neuro-and-autoimmune-interplay-rare BioBriefs en 2026-10-16T14:32:43Z Neuro and autoimmune interplay: rare immune toxicities mapped in immunotherapy https://biobriefs.com/ipo-momentum-in-ai-enabled BioBriefs en 2026-10-16T10:32:12Z IPO momentum in AI-enabled RNAi and RNA therapeutics https://biobriefs.com/fda-rare-disease-review-overhaul BioBriefs en 2026-10-16T10:32:12Z FDA rare-disease review overhaul https://biobriefs.com/venture-and-capital-formation-for BioBriefs en 2026-10-16T10:32:12Z Venture and capital formation for biotech pipelines https://biobriefs.com/rare-pediatric-gene-therapy-monetization BioBriefs en 2026-10-16T10:32:12Z Rare pediatric gene therapy monetization via FDA PRVs https://biobriefs.com/r-d-dealmaking-roche-expands BioBriefs en 2026-10-16T10:32:12Z R&D dealmaking: Roche expands RNAi obesity pipeline in China https://biobriefs.com/clinical-signals-in-oncology-durable BioBriefs en 2026-10-16T10:32:12Z Clinical signals in oncology: durable responses in low-grade serous ovarian cancer https://biobriefs.com/ai-enabled-diagnostics-preoperative-cancer BioBriefs en 2026-10-16T10:32:12Z AI-enabled diagnostics: preoperative cancer risk models gain trial-scale validation https://biobriefs.com/therapeutics-for-rare-pediatric-neurology BioBriefs en 2026-10-16T10:32:12Z Therapeutics for rare pediatric neurology: sugar-based therapy for GLUT1 deficiency https://biobriefs.com/drug-safety-and-execution-capa BioBriefs en 2026-10-16T10:32:12Z Drug safety and execution: CAPA signals on surgical imaging and treatment decision limits https://biobriefs.com/regeneration-and-cell-therapy-egg BioBriefs en 2026-10-16T10:32:12Z Regeneration and cell therapy: egg-cell inspired biomaterial protects islet cells from immune attack https://biobriefs.com/rare-disease-regulation-reset-at BioBriefs en 2026-10-16T09:33:16Z Rare disease regulation reset at FDA https://biobriefs.com/rare-disease-biotech-funding-for BioBriefs en 2026-10-16T09:33:16Z Rare disease biotech funding for ACTH-related and interferon programs https://biobriefs.com/ai-enabled-sirna-collaboration-targets BioBriefs en 2026-10-16T09:33:16Z AI-enabled siRNA collaboration targets obesity via ALK7 RNAi https://biobriefs.com/phase-1-durability-readout-for BioBriefs en 2026-10-16T09:33:16Z Phase 1 durability readout for self-amplifying mRNA H5N1 vaccine https://biobriefs.com/omics-linked-prediction-of-immunotherapy BioBriefs en 2026-10-16T09:33:16Z Omics-linked prediction of immunotherapy response in lung cancer https://biobriefs.com/first-human-target-engagement-signals BioBriefs en 2026-10-16T09:33:16Z First human target-engagement signals for CNS siRNA https://biobriefs.com/car-t-durability-signal-in BioBriefs en 2026-10-16T09:33:16Z CAR-T durability signal in relapsed/refractory myeloma https://biobriefs.com/fda-guidance-shift-for-ema BioBriefs en 2026-10-16T09:33:16Z FDA guidance shift for EMA trial advice continuity https://biobriefs.com/new-pooled-evidence-for-guideline BioBriefs en 2026-10-16T09:33:16Z New pooled evidence for guideline-adherent nurse care to reduce alcohol harm https://biobriefs.com/ipo-cash-for-ai-oncology BioBriefs en 2026-10-16T09:33:16Z IPO cash for AI oncology platform and discovery pipeline https://biobriefs.com/rare-disease-drug-development-funding BioBriefs en 2026-10-16T04:31:56Z Rare disease drug development funding https://biobriefs.com/ai-enabled-target-discovery-deals BioBriefs en 2026-10-16T04:31:56Z AI-enabled target discovery deals https://biobriefs.com/big-financing-for-ai-oncology BioBriefs en 2026-10-16T04:31:56Z Big financing for AI oncology biotech via IPO https://biobriefs.com/regulatory-fda-rare-disease-review BioBriefs en 2026-10-16T04:31:56Z Regulatory: FDA rare disease review overhaul https://biobriefs.com/early-clinical-signal-in-immune BioBriefs en 2026-10-16T04:31:56Z Early clinical signal in immune-oncology: ubamatamab in low-grade serous ovarian cancer https://biobriefs.com/clinical-microbiome-intervention-in-crohns BioBriefs en 2026-10-16T04:31:56Z Clinical microbiome intervention in Crohn’s disease https://biobriefs.com/gene-therapy-safety-immune-signal BioBriefs en 2026-10-16T04:31:56Z Gene therapy safety/immune signal in DMD https://biobriefs.com/u-s-pediatric-critical-care BioBriefs en 2026-10-16T04:31:56Z U.S. pediatric critical care: validated simple septic shock risk score https://biobriefs.com/rare-and-high-mortality-complication BioBriefs en 2026-10-16T04:31:56Z Rare and high-mortality complication after AF ablation https://biobriefs.com/cell-therapy-platform-resurgence-of BioBriefs en 2026-10-16T04:31:56Z Cell therapy platform: resurgence of Galapagos CAR-T through Armed Cell/Lakefront Biotherapeutics https://biobriefs.com/rare-disease-regulation-reset-at BioBriefs en 2026-10-15T21:31:58Z Rare disease regulation reset at FDA https://biobriefs.com/private-financing-and-pipeline-momentum BioBriefs en 2026-10-15T21:31:58Z Private financing and pipeline momentum for rare disease specialist OMass https://biobriefs.com/ai-drug-discovery-expansion-astrazeneca BioBriefs en 2026-10-15T21:31:58Z AI drug discovery expansion: AstraZeneca and insitro partnership https://biobriefs.com/vaccine-pivot-after-phase-2b BioBriefs en 2026-10-15T21:31:58Z Vaccine pivot after Phase 2b failure: Osivax https://biobriefs.com/cancer-therapeutics-under-scrutiny-verastem BioBriefs en 2026-10-15T21:31:58Z Cancer therapeutics under scrutiny: Verastem KRAS inhibitor early data https://biobriefs.com/device-maker-alliance-stryker-backs BioBriefs en 2026-10-15T21:31:58Z Device-maker alliance: Stryker backs CMR Surgical robot push https://biobriefs.com/ai-evidence-gap-in-radiopharmaceutical BioBriefs en 2026-10-15T21:31:58Z AI evidence gap in radiopharmaceutical therapy https://biobriefs.com/clinical-trial-platform-ultra-early BioBriefs en 2026-10-15T21:31:58Z Clinical trial platform: Ultra-early vasopressin timing signal in septic shock https://biobriefs.com/translational-oncology-imaging-and-decision BioBriefs en 2026-10-15T21:31:58Z Translational oncology imaging and decision support: FET-PET/MRI trial https://biobriefs.com/company-innovation-in-data-infrastructure BioBriefs en 2026-10-15T21:31:58Z Company innovation in data infrastructure: Illumina BioInsight platform https://biobriefs.com/fda-regulatory-approach-for-rare BioBriefs en 2026-10-15T16:32:58Z FDA regulatory approach for rare diseases https://biobriefs.com/rare-disease-financing-and-clinical BioBriefs en 2026-10-15T16:32:58Z Rare-disease financing and clinical pipeline momentum https://biobriefs.com/ai-in-regulatory-science BioBriefs en 2026-10-15T16:32:58Z AI in regulatory science https://biobriefs.com/protein-drug-design-collaboration-for BioBriefs en 2026-10-15T16:32:58Z Protein drug design collaboration for metabolic disease https://biobriefs.com/cell-therapy-revival-under-new BioBriefs en 2026-10-15T16:32:58Z Cell therapy revival under new management https://biobriefs.com/vxrd-pipeline-gene-directed-alzheimers BioBriefs en 2026-10-15T16:32:58Z VXRD pipeline: gene-directed Alzheimer’s protein suppression https://biobriefs.com/device-era-antimicrobial-resistance-threat BioBriefs en 2026-10-15T16:32:58Z Device-era antimicrobial resistance threat in hospitals https://biobriefs.com/ai-driven-imaging-for-clinical BioBriefs en 2026-10-15T16:32:58Z AI-driven imaging for clinical decision support https://biobriefs.com/car-t-control-switch-for BioBriefs en 2026-10-15T16:32:58Z CAR-T control switch for solid tumor safety https://biobriefs.com/bioprocessing-and-scale-up-controlling BioBriefs en 2026-10-15T16:32:58Z Bioprocessing and scale-up: controlling lipid nanoparticles https://biobriefs.com/ai-designed-obesity-therapeutics-move BioBriefs en 2026-10-15T14:32:45Z AI-designed obesity therapeutics move from platform to preclinical programs https://biobriefs.com/funding-orbimed-secures-major-new BioBriefs en 2026-10-15T14:32:45Z Funding: OrbiMed secures major new life-sciences capital for global investing https://biobriefs.com/cell-therapy-manufacturing-rapid-car BioBriefs en 2026-10-15T14:32:45Z Cell therapy manufacturing: rapid CAR-T expansion strategy aims to reduce turnaround risk https://biobriefs.com/drug-development-risk-vanda-pauses BioBriefs en 2026-10-15T14:32:45Z Drug development risk: Vanda pauses female-led Phase 3 program after late-stage failure https://biobriefs.com/clinical-neuroscience-gene-therapy-and BioBriefs en 2026-10-15T14:32:45Z Clinical neuroscience: gene therapy and BBB-targeted strategies converge on CNS drug delivery https://biobriefs.com/oncology-finance-and-pipeline-competition BioBriefs en 2026-10-15T14:32:45Z Oncology finance and pipeline competition: Verastem doubles down on KRAS-adjacent strategy https://biobriefs.com/regulatory-shift-ema-makes-eu BioBriefs en 2026-10-15T14:32:45Z Regulatory shift: EMA makes EU-level trial advice pilot permanent https://biobriefs.com/molecular-diagnostics-urine-based-cxcl10 BioBriefs en 2026-10-15T14:32:45Z Molecular diagnostics: urine-based CXCL10 aims to flag kidney transplant rejection and infection at one year https://biobriefs.com/antimicrobial-resistance-irans-carbapenem-resistant BioBriefs en 2026-10-15T14:32:45Z Antimicrobial resistance: Iran’s carbapenem-resistant Klebsiella reaches half of clinical isolates https://biobriefs.com/discovery-and-platform-engineered-cas13a BioBriefs en 2026-10-15T14:32:45Z Discovery and platform: engineered Cas13a improvement targets HIV and other RNA viruses detection https://biobriefs.com/iambic-therapeutics-launches-with-150m BioBriefs en 2026-10-15T10:31:56Z Iambic Therapeutics launches with $150M IPO to build an AI-driven oncology pipeline https://biobriefs.com/oxford-based-omass-therapeutics-raises BioBriefs en 2026-10-15T10:31:56Z Oxford-based OMass Therapeutics raises $310M to challenge leading genetic adrenal disorder players https://biobriefs.com/pfizer-and-enodia-strike-licensing BioBriefs en 2026-10-15T10:31:56Z Pfizer and Enodia strike licensing collaboration to develop Sec61 inhibitors https://biobriefs.com/ema-locks-in-eu-level BioBriefs en 2026-10-15T10:31:56Z EMA locks in EU-level trial advice pilot as permanent option for sponsors https://biobriefs.com/triple-therapy-plus-hepatic-arterial BioBriefs en 2026-10-15T10:31:56Z Triple therapy plus hepatic arterial infusion roughly doubles survival in advanced liver cancer with portal vein tumor thrombosis https://biobriefs.com/arrowheads-aro-mapt-shows-early BioBriefs en 2026-10-15T10:31:56Z Arrowhead’s ARO-MAPT shows early human tau knockdown with brain-shuttle target engagement https://biobriefs.com/verastem-steps-up-pancreatic-cancer BioBriefs en 2026-10-15T10:31:56Z Verastem steps up pancreatic cancer push with VS-7375 data, CEO departure, and $250M raise https://biobriefs.com/new-rule-linking-drug-penetration BioBriefs en 2026-10-15T10:31:56Z New rule linking drug penetration to shortened tuberculosis regimens aims to explain Phase 3 failures https://biobriefs.com/healthleap-raises-38m-to-expand BioBriefs en 2026-10-15T10:31:56Z Healthleap raises $38M to expand EHR-based AI screening for overlooked inpatient conditions https://biobriefs.com/tiny-genetic-switches-maternally-driven BioBriefs en 2026-10-15T10:31:56Z Tiny genetic switches: maternally driven tauopathy and SRSF1 rejuvenation highlight splicing-linked neurobiology https://biobriefs.com/ipo-capital-raises-in-ai BioBriefs en 2026-10-15T09:33:00Z IPO & capital raises in AI-driven oncology https://biobriefs.com/adverse-event-research-after-transfusions BioBriefs en 2026-10-15T09:33:00Z Adverse-event research after transfusions in thalassemia https://biobriefs.com/transplant-science-milestone-cryopreserved-pig BioBriefs en 2026-10-15T09:33:00Z Transplant science milestone: cryopreserved pig kidneys recover after long storage https://biobriefs.com/regulatory-shift-in-the-eu BioBriefs en 2026-10-15T09:33:00Z Regulatory shift in the EU clinical advice process https://biobriefs.com/immunotherapy-chemoradiation-sequencing-in-nasopharyngeal BioBriefs en 2026-10-15T09:33:00Z Immunotherapy–chemoradiation sequencing in nasopharyngeal cancer https://biobriefs.com/mechanism-linked-therapy-target-in BioBriefs en 2026-10-15T09:33:00Z Mechanism-linked therapy target in lung cancer cuproptosis https://biobriefs.com/oncology-clinical-trial-signal-triple BioBriefs en 2026-10-15T09:33:00Z Oncology clinical trial signal: triple therapy extends survival in liver cancer with portal vein clots https://biobriefs.com/drug-delivery-translational-manufacturing-arrowhead BioBriefs en 2026-10-15T09:33:00Z Drug delivery & translational manufacturing: Arrowhead brain shuttle target engagement https://biobriefs.com/tech-to-clinic-pharmacists-embedded BioBriefs en 2026-10-15T09:33:00Z Tech-to-clinic: pharmacists embedded in primary care for opioid use disorder https://biobriefs.com/kidney-therapeutics-potassium-binder-enables BioBriefs en 2026-10-15T09:33:00Z Kidney therapeutics: potassium binder enables full RAAS inhibitor dosing in CKD with heart failure https://biobriefs.com/regulatory-and-policy-ema-trial BioBriefs en 2026-10-15T04:32:41Z Regulatory and policy—EMA trial advice becomes permanent https://biobriefs.com/company-dealmaking-pfizer-partners-with BioBriefs en 2026-10-15T04:32:41Z Company dealmaking—Pfizer partners with Enodia on Sec61 inhibitors https://biobriefs.com/oncology-rapid-manufacturing-car-t BioBriefs en 2026-10-15T04:32:41Z Oncology—Rapid manufacturing CAR-T in early clinical testing https://biobriefs.com/psychedelics-compass-pathways-signals-cautious BioBriefs en 2026-10-15T04:32:41Z Psychedelics—Compass Pathways signals cautious rollout for potential FDA-era launch https://biobriefs.com/clinical-innovation-potassium-binder-helps BioBriefs en 2026-10-15T04:32:41Z Clinical innovation—Potassium binder helps CKD heart-failure patients reach full RAAS inhibitor doses https://biobriefs.com/regulatory-and-evidence-biofabrication-of BioBriefs en 2026-10-15T04:32:41Z Regulatory and evidence—Biofabrication of trial recruitment information across social platforms https://biobriefs.com/virology-and-immunology-mrna-delivered BioBriefs en 2026-10-15T04:32:41Z Virology and immunology—mRNA-delivered bispecific antibodies show broad SARS-CoV-2 neutralization https://biobriefs.com/infectious-disease-drug-resistant-fungus BioBriefs en 2026-10-15T04:32:41Z Infectious disease—Drug-resistant fungus Candida auris surges in US surveillance data https://biobriefs.com/drug-discovery-arrowheads-rnai-brain BioBriefs en 2026-10-15T04:32:41Z Drug discovery—Arrowhead’s RNAi brain-targeting program lowers tau in early human data https://biobriefs.com/r-d-platform-and-funding BioBriefs en 2026-10-15T04:32:41Z R&D platform and funding—Soufflé Therapeutics raises $135M for multiple RNA medicines https://biobriefs.com/regulatory-ema-permanent-trial-advice BioBriefs en 2026-10-14T21:31:59Z Regulatory: EMA permanent trial advice pilot https://biobriefs.com/rare-disease-financing-ultragenyx-sells BioBriefs en 2026-10-14T21:31:59Z Rare disease financing: Ultragenyx sells priority review vouchers https://biobriefs.com/ai-x-clinical-trials-platform BioBriefs en 2026-10-14T21:31:59Z AI x clinical trials: platform effects on trial information sharing https://biobriefs.com/obesity-investing-zealand-partners-with BioBriefs en 2026-10-14T21:31:59Z Obesity investing: Zealand partners with Generate Biomedicines https://biobriefs.com/alzheimers-therapeutics-arrowhead-targets-tau BioBriefs en 2026-10-14T21:31:59Z Alzheimer’s therapeutics: Arrowhead targets tau with brain-reaching RNAi https://biobriefs.com/gene-therapy-preclinical-proof-aav BioBriefs en 2026-10-14T21:31:59Z Gene therapy preclinical proof: AAV delivered at CSF source for hydrocephalus https://biobriefs.com/immunotherapy-platform-mit-lipid-nanoparticles BioBriefs en 2026-10-14T21:31:59Z Immunotherapy platform: MIT lipid nanoparticles reprogram NK cells in vivo https://biobriefs.com/m-a-and-platform-licensing BioBriefs en 2026-10-14T21:31:59Z M&A and platform licensing: Pfizer collaborates with Enodia on Sec61 inhibitors https://biobriefs.com/trial-readout-potassium-binder-enables BioBriefs en 2026-10-14T21:31:59Z Trial readout: potassium binder enables full RAAS inhibitor dosing in CKD+HF https://biobriefs.com/trial-financing-and-portfolio-moves BioBriefs en 2026-10-14T21:31:59Z Trial financing and portfolio moves: Soufflé Therapeutics raises $135M for RNA medicines https://biobriefs.com/sec61-inhibition-sprint-pfizer-and BioBriefs en 2026-10-14T16:32:50Z Sec61 inhibition sprint: Pfizer and Enodia expand target validation https://biobriefs.com/obesity-licensing-and-cashflow-roche BioBriefs en 2026-10-14T16:32:50Z Obesity licensing and cashflow: Roche backs ALK7 RNAi via Rona https://biobriefs.com/gene-therapy-cash-engineering-ultragenyx BioBriefs en 2026-10-14T16:32:50Z Gene therapy cash engineering: Ultragenyx sells rare pediatric PRV https://biobriefs.com/ai-in-alzheimers-adjacent-tau BioBriefs en 2026-10-14T16:32:50Z AI in Alzheimer’s-adjacent tau biology: Arrowhead’s brain-targeting RNAi tau knockdown https://biobriefs.com/car-t-control-for-solid BioBriefs en 2026-10-14T16:32:50Z CAR-T control for solid tumors: genetic switch activates only on tumor contact https://biobriefs.com/rna-therapeutics-funding-souffle-therapeutics BioBriefs en 2026-10-14T16:32:50Z RNA therapeutics funding: Soufflé Therapeutics raises $135 million https://biobriefs.com/rare-childhood-cancer-roadmap-experts BioBriefs en 2026-10-14T16:32:50Z Rare childhood cancer roadmap: experts prioritize targets for desmoplastic small round cell tumor https://biobriefs.com/vertex-era-economics-nih-grant BioBriefs en 2026-10-14T16:32:50Z Vertex-era economics: NIH grant transparency plan triggers scientific ire https://biobriefs.com/antibiotic-resistance-containment-five-year BioBriefs en 2026-10-14T16:32:50Z Antibiotic resistance containment: five-year surveillance shows divergent superbug trends https://biobriefs.com/ust-diagnostic-ai-in-neonatal BioBriefs en 2026-10-14T16:32:50Z UST: diagnostic AI in neonatal care trains across hospitals without data sharing https://biobriefs.com/deal-activity-reshapes-oncology-platform BioBriefs en 2026-10-14T14:32:14Z Deal activity reshapes oncology platform bets https://biobriefs.com/strategic-capital-and-manufacturing-scale BioBriefs en 2026-10-14T14:32:14Z Strategic capital and manufacturing scale-up in the US https://biobriefs.com/obesity-pharma-investment-accelerates-via BioBriefs en 2026-10-14T14:32:14Z Obesity pharma investment accelerates via AI-designed therapeutics https://biobriefs.com/targeted-immunology-and-cellular-engineering BioBriefs en 2026-10-14T14:32:14Z Targeted immunology and cellular engineering in early human data https://biobriefs.com/first-in-human-gene-medicines BioBriefs en 2026-10-14T14:32:14Z First-in-human gene medicines expand with Prime Editing in patient cells https://biobriefs.com/regulatory-market-access-shifts-for BioBriefs en 2026-10-14T14:32:14Z Regulatory/market access shifts for global rare disease financing https://biobriefs.com/clinical-trial-failure-in-obesity BioBriefs en 2026-10-14T14:32:14Z Clinical trial failure in obesity: risk signal for near-term GLP-1 pill strategy https://biobriefs.com/regulatory-scrutiny-and-real-world BioBriefs en 2026-10-14T14:32:14Z Regulatory scrutiny and real-world safety debate in rare disease https://biobriefs.com/synthetic-biology-platform-expands-with BioBriefs en 2026-10-14T14:32:14Z Synthetic biology platform expands with Pfizer Sec61 inhibitor collaboration https://biobriefs.com/cybersecurity-and-clinical-ai-safety BioBriefs en 2026-10-14T14:32:14Z Cybersecurity and clinical AI safety: auditing medical models in production https://biobriefs.com/obesity-rnai-deal-accelerates-metabolic BioBriefs en 2026-10-14T10:32:18Z Obesity RNAi deal accelerates metabolic pipeline https://biobriefs.com/enabling-science-sec61-targeting-collaboration BioBriefs en 2026-10-14T10:32:18Z Enabling science: Sec61 targeting collaboration with Pfizer https://biobriefs.com/immunotherapy-engineered-car-t-advances BioBriefs en 2026-10-14T10:32:18Z Immunotherapy: engineered CAR T advances with faster manufacturing https://biobriefs.com/fda-clearance-for-cuffless-continuous BioBriefs en 2026-10-14T10:32:18Z FDA clearance for cuffless continuous blood pressure wearable https://biobriefs.com/obesity-drug-trial-readout-verdivas BioBriefs en 2026-10-14T10:32:18Z Obesity drug trial readout: Verdiva’s Phase 2 terminated https://biobriefs.com/biologics-manufacturing-ucb-commits-2b BioBriefs en 2026-10-14T10:32:18Z Biologics manufacturing: UCB commits $2B US campus https://biobriefs.com/synthetic-biology-and-rare-disease BioBriefs en 2026-10-14T10:32:18Z Synthetic biology and rare disease gene editing: prime editing in patient stem cells https://biobriefs.com/antimicrobial-resistance-cdc-says-candida BioBriefs en 2026-10-14T10:32:18Z Antimicrobial resistance: CDC says Candida auris cases double https://biobriefs.com/cancer-immunotherapy-dual-il-17 BioBriefs en 2026-10-14T10:32:18Z Cancer immunotherapy: dual IL-17 blocker bimekizumab durability https://biobriefs.com/regulatory-and-policy-nih-grant BioBriefs en 2026-10-14T10:32:18Z Regulatory and policy: NIH grant score concealment proposal sparks backlash https://biobriefs.com/obesity-rnai-push-expands-at BioBriefs en 2026-10-14T09:33:22Z Obesity RNAi push expands at Roche https://biobriefs.com/car-t-innovation-accelerates-manufacturing BioBriefs en 2026-10-14T09:33:22Z CAR T innovation accelerates manufacturing cycle https://biobriefs.com/enodia-and-pfizer-team-up BioBriefs en 2026-10-14T09:33:22Z Enodia and Pfizer team up on Sec61 small-molecule inhibitors https://biobriefs.com/fda-clears-cuffless-wearable-blood BioBriefs en 2026-10-14T09:33:22Z FDA clears cuffless wearable blood pressure ring https://biobriefs.com/hospital-fungal-threat-escalates-candida BioBriefs en 2026-10-14T09:33:22Z Hospital fungal threat escalates: Candida auris doubles https://biobriefs.com/phase-i-immune-activation-imm60 BioBriefs en 2026-10-14T09:33:22Z Phase I immune activation: IMM60 shows safety in advanced cancers https://biobriefs.com/machine-learning-car-t-for BioBriefs en 2026-10-14T09:33:22Z Machine learning CAR T for real-world monitoring https://biobriefs.com/sfts-patient-risk-stratification-moves BioBriefs en 2026-10-14T09:33:22Z SFTS patient risk stratification moves to early biomarkers https://biobriefs.com/prv-liquidity-deal-ultragenyx-sells BioBriefs en 2026-10-14T09:33:22Z PRV liquidity deal: Ultragenyx sells rare pediatric voucher https://biobriefs.com/nih-grant-process-faces-pushback BioBriefs en 2026-10-14T09:33:22Z NIH grant process faces pushback over hidden scores https://biobriefs.com/obesity-r-d-dealmaking-roche BioBriefs en 2026-10-14T04:32:43Z Obesity R&D dealmaking: Roche extends RNAi strategy in ALK7 https://biobriefs.com/fda-clearance-cuffless-continuous-blood BioBriefs en 2026-10-14T04:32:43Z FDA clearance: cuffless continuous blood pressure tracking hits market https://biobriefs.com/immunotherapy-and-cell-engineering-new BioBriefs en 2026-10-14T04:32:43Z Immunotherapy and cell engineering: new CAR T approach with OX40 boost and rapid manufacturing https://biobriefs.com/car-nk-in-vivo-engineering BioBriefs en 2026-10-14T04:32:43Z CAR-NK in vivo engineering: lipid nanoparticles reprogram NK cells to attack tumors https://biobriefs.com/virus-host-interplay-reverse-order BioBriefs en 2026-10-14T04:32:43Z Virus-host interplay: reverse order bacterial immunity as a new DNA-editing blueprint https://biobriefs.com/antibiotic-resistance-and-infection-control BioBriefs en 2026-10-14T04:32:43Z Antibiotic resistance and infection control: Candida auris cases surge in US and globally https://biobriefs.com/oncology-biology-and-resistance-kras BioBriefs en 2026-10-14T04:32:43Z Oncology biology and resistance: KRAS tumors crank out adenosine to blunt immune attack https://biobriefs.com/virology-and-drug-development-scarb2 BioBriefs en 2026-10-14T04:32:43Z Virology and drug development: SCARB2 mimic blocks enteroviruses in vitro and in neonatal mice https://biobriefs.com/oncology-diagnostics-proteomics-aging-clocks BioBriefs en 2026-10-14T04:32:43Z Oncology diagnostics: proteomics aging clocks enter a clinical trial as biomarkers https://biobriefs.com/regulatory-and-policy-nih-considers BioBriefs en 2026-10-14T04:32:43Z Regulatory and policy: NIH considers hiding grant impact scores, drawing researcher ire https://biobriefs.com/regulatory-and-trial-outcome-signals BioBriefs en 2026-10-13T21:33:07Z Regulatory and trial outcome signals https://biobriefs.com/biopharma-deals-and-partnerships BioBriefs en 2026-10-13T21:33:07Z Biopharma deals and partnerships https://biobriefs.com/obesity-target-validation-and-rnai BioBriefs en 2026-10-13T21:33:07Z Obesity target validation and RNAi expansion https://biobriefs.com/immuno-oncology-and-drug-resistance BioBriefs en 2026-10-13T21:33:07Z Immuno-oncology and drug-resistance biology https://biobriefs.com/gene-editing-and-precision-cell BioBriefs en 2026-10-13T21:33:07Z Gene editing and precision cell therapy manufacturing https://biobriefs.com/clinical-biomarkers-and-monitoring-tools BioBriefs en 2026-10-13T21:33:07Z Clinical biomarkers and monitoring tools https://biobriefs.com/regimen-science-dosing-and-endpoints BioBriefs en 2026-10-13T21:33:07Z Regimen science: dosing and endpoints in trial programs https://biobriefs.com/healthcare-systems-and-access-constraints BioBriefs en 2026-10-13T21:33:07Z Healthcare systems and access constraints https://biobriefs.com/manufacturing-and-translational-formulation-innovation BioBriefs en 2026-10-13T21:33:07Z Manufacturing and translational formulation innovation https://biobriefs.com/digital-health-and-ai-clinical BioBriefs en 2026-10-13T21:33:07Z Digital health and AI clinical deployment https://biobriefs.com/roche-doubles-down-on-rnai BioBriefs en 2026-10-13T16:33:24Z Roche doubles down on RNAi obesity with Rona deal https://biobriefs.com/beams-base-editing-rare-disease BioBriefs en 2026-10-13T16:33:24Z Beam’s base-editing rare disease trial shares first patient data https://biobriefs.com/fda-approved-rare-pediatric-prv BioBriefs en 2026-10-13T16:33:24Z FDA-approved rare pediatric PRV monetization boosts Ultragenyx funding runway https://biobriefs.com/clinical-setback-for-syndax-in BioBriefs en 2026-10-13T16:33:24Z Clinical setback for Syndax in idiopathic pulmonary fibrosis https://biobriefs.com/bri-stol-myers-reports-mixed BioBriefs en 2026-10-13T16:33:24Z Bri​stol Myers reports mixed Phase 3 readouts for lung disease candidate admilparant https://biobriefs.com/m-a-viatris-to-buy BioBriefs en 2026-10-13T16:33:24Z M&A: Viatris to buy Pacira for $1.65B, expands non-opioid pain portfolio https://biobriefs.com/fda-approves-asahi-kaseis-hovilpri BioBriefs en 2026-10-13T16:33:24Z FDA approves Asahi Kasei’s Hovilpri after AiCuris acquisition https://biobriefs.com/ucb-locks-in-future-us BioBriefs en 2026-10-13T16:33:24Z UCB locks in future US biologics manufacturing capacity in Georgia https://biobriefs.com/cancer-immunology-nk-cells-may BioBriefs en 2026-10-13T16:33:24Z Cancer immunology: NK cells may mediate pembrolizumab responses in low-HLA colorectal cancer https://biobriefs.com/neuro-oncology-biomarker-scrutiny-mgmt BioBriefs en 2026-10-13T16:33:24Z Neuro-oncology biomarker scrutiny: MGMT methylation testing faces a standardization gap https://biobriefs.com/rare-disease-gene-therapy-monetization BioBriefs en 2026-10-13T14:31:52Z Rare disease gene therapy monetization https://biobriefs.com/obesity-dealmaking-with-roche BioBriefs en 2026-10-13T14:31:52Z Obesity dealmaking with Roche https://biobriefs.com/regulatory-fda-approval-for-novel BioBriefs en 2026-10-13T14:31:52Z Regulatory: FDA approval for novel HSV oral therapy https://biobriefs.com/clinical-celiac-dosing-data-spotlight BioBriefs en 2026-10-13T14:31:52Z Clinical: celiac dosing data spotlight CD122 approach https://biobriefs.com/biotech-financing-undecimals-sirna-spinout BioBriefs en 2026-10-13T14:31:52Z Biotech financing: Undecimal’s siRNA spinout https://biobriefs.com/clinical-failure-syndax-ends-niktimvo BioBriefs en 2026-10-13T14:31:52Z Clinical failure: Syndax ends Niktimvo IPF program https://biobriefs.com/big-pharma-m-a-viatris BioBriefs en 2026-10-13T14:31:52Z Big pharma M&A: Viatris to buy Pacira for $1.65 billion https://biobriefs.com/biopharma-leadership-change-bausch-lomb BioBriefs en 2026-10-13T14:31:52Z Biopharma leadership change: Bausch + Lomb CEO exit https://biobriefs.com/cancer-therapeutics-nk-cell-engineering BioBriefs en 2026-10-13T14:31:52Z Cancer therapeutics: NK cell engineering with LNPs https://biobriefs.com/late-stage-oncology-keynote-966 BioBriefs en 2026-10-13T14:31:52Z Late-stage oncology: KEYNOTE-966 follow-up in biliary tract cancer https://biobriefs.com/roche-obesity-licensing-deal-in BioBriefs en 2026-10-13T10:32:34Z Roche obesity licensing deal in ALK7 inhibition https://biobriefs.com/market-turbulence-for-allogeneic-car BioBriefs en 2026-10-13T10:32:34Z Market turbulence for allogeneic CAR-T and strategic review https://biobriefs.com/regulatory-approval-for-new-oral BioBriefs en 2026-10-13T10:32:34Z Regulatory approval for new oral herpes therapy via acquisition https://biobriefs.com/biopharma-deals-viatris-to-acquire BioBriefs en 2026-10-13T10:32:34Z Biopharma deals: Viatris to acquire Pacira https://biobriefs.com/safety-controversy-around-neurocrines-vykat BioBriefs en 2026-10-13T10:32:34Z Safety controversy around Neurocrine’s Vykat in Prader-Willi syndrome https://biobriefs.com/celiac-disease-cd122-targeting-shows BioBriefs en 2026-10-13T10:32:34Z Celiac disease: CD122 targeting shows early Phase I results https://biobriefs.com/oncology-trial-immunotherapy-durability-holds BioBriefs en 2026-10-13T10:32:34Z Oncology trial: immunotherapy durability holds in biliary cancer https://biobriefs.com/fda-clears-rapid-urine-test BioBriefs en 2026-10-13T10:32:34Z FDA clears rapid urine test for invasive aspergillosis https://biobriefs.com/cell-therapy-donor-derived-cd19 BioBriefs en 2026-10-13T10:32:34Z Cell therapy: donor-derived CD19 CAR-T after transplant failure https://biobriefs.com/patent-asset-and-payer-policy BioBriefs en 2026-10-13T10:32:34Z Patent/asset and payer policy pressures in US biotech https://biobriefs.com/biotech-market-and-m-a BioBriefs en 2026-10-13T09:31:49Z Biotech market and M&A / capital-access headwinds https://biobriefs.com/regulatory-and-safety-scrutiny-for BioBriefs en 2026-10-13T09:31:49Z Regulatory and safety scrutiny for approved rare-disease and antiviral medicines https://biobriefs.com/oncology-clinical-readouts-immuno-oncology BioBriefs en 2026-10-13T09:31:49Z Oncology clinical readouts: immuno-oncology, radiation strategies, and imaging-adjacent tools https://biobriefs.com/cell-therapy-and-precision-immunotherapy BioBriefs en 2026-10-13T09:31:49Z Cell therapy and precision immunotherapy preclinical/clinical pipeline signals https://biobriefs.com/infectious-disease-countermeasures-diagnostics-and BioBriefs en 2026-10-13T09:31:49Z Infectious disease countermeasures: diagnostics and trial-adjacent prevention https://biobriefs.com/biomarkers-and-diagnostics-for-precision BioBriefs en 2026-10-13T09:31:49Z Biomarkers and diagnostics for precision oncology https://biobriefs.com/novel-immunotherapy-targets-and-mechanisms BioBriefs en 2026-10-13T09:31:49Z Novel immunotherapy targets and mechanisms in inflammation and cancer https://biobriefs.com/neurodegeneration-biology-early-risk-genes BioBriefs en 2026-10-13T09:31:49Z Neurodegeneration biology: early risk genes, imaging correlates, and mechanistic brakes https://biobriefs.com/regenerative-medicine-and-wound-healing BioBriefs en 2026-10-13T09:31:49Z Regenerative medicine and wound healing technologies https://biobriefs.com/manufacturing-and-platform-moves-formulation BioBriefs en 2026-10-13T09:31:49Z Manufacturing and platform moves: formulation translation and AI-enabled rapid design https://biobriefs.com/allogeneic-car-t-retreat-and BioBriefs en 2026-10-13T04:32:44Z Allogeneic CAR-T retreat and trial halts https://biobriefs.com/fda-approval-for-asahi-kaseis BioBriefs en 2026-10-13T04:32:44Z FDA approval for Asahi Kasei’s oral HSV pill after big deal https://biobriefs.com/bristol-myers-mixed-phase-3 BioBriefs en 2026-10-13T04:32:44Z Bristol Myers’ mixed Phase 3 readouts for lung fibrosis and RayzeBio https://biobriefs.com/cms-2026-drug-pricing-rule BioBriefs en 2026-10-13T04:32:44Z CMS 2026 drug pricing rule raises manufacturer reporting load https://biobriefs.com/new-trial-evidence-doubles-survival BioBriefs en 2026-10-13T04:32:44Z New trial evidence doubles survival for small cell lung cancer brain metastases https://biobriefs.com/radiotherapy-intensification-after-brain-metastasis BioBriefs en 2026-10-13T04:32:44Z Radiotherapy intensification after brain metastasis surgery reduces recurrence https://biobriefs.com/fda-cleared-rapid-urine-test BioBriefs en 2026-10-13T04:32:44Z FDA-cleared rapid urine test for invasive aspergillosis https://biobriefs.com/meta-analysis-hemoglobin-transfusion-threshold BioBriefs en 2026-10-13T04:32:44Z Meta-analysis: hemoglobin transfusion threshold may improve acute brain injury outcomes https://biobriefs.com/health-data-policy-companion-diagnostics BioBriefs en 2026-10-13T04:32:44Z Health-data policy: companion diagnostics bridging validation for pembrolizumab https://biobriefs.com/new-diagnostics-or-care-laser BioBriefs en 2026-10-13T04:32:44Z New diagnostics or care: laser-powered beads to detect colorectal cancer biomarker quickly https://biobriefs.com/regulatory-approval-for-new-hsv BioBriefs en 2026-10-12T21:32:33Z Regulatory approval for new HSV therapy https://biobriefs.com/oncology-radiosurgery-fractionation-improves-brain BioBriefs en 2026-10-12T21:32:33Z Oncology: radiosurgery fractionation improves brain metastasis outcomes https://biobriefs.com/immuno-oncology-diagnostics-companion-diagnostics BioBriefs en 2026-10-12T21:32:33Z Immuno-oncology diagnostics: companion diagnostics validated for pembrolizumab in dMMR/MSI-H https://biobriefs.com/merck-ophthalmology-remigromig-posts-mixed BioBriefs en 2026-10-12T21:32:33Z Merck ophthalmology: remigromig posts mixed pivotal results in diabetic macular edema https://biobriefs.com/market-access-and-reimbursement-policy BioBriefs en 2026-10-12T21:32:33Z Market access and reimbursement policy pressure on US biopharma innovation https://biobriefs.com/cell-therapy-financing-aspen-neuroscience BioBriefs en 2026-10-12T21:32:33Z Cell therapy financing: Aspen Neuroscience files for IPO https://biobriefs.com/microbiology-and-clinical-diagnostics-rapid BioBriefs en 2026-10-12T21:32:33Z Microbiology and clinical diagnostics: rapid urine test wins FDA clearance for invasive aspergillosis https://biobriefs.com/company-deal-viatris-to-acquire BioBriefs en 2026-10-12T21:32:33Z Company deal: Viatris to acquire Pacira in $1.65 billion transaction https://biobriefs.com/clinical-evidence-concentrated-u-500 BioBriefs en 2026-10-12T21:32:33Z Clinical evidence: concentrated U-500 insulin integrated into tubeless automated insulin delivery https://biobriefs.com/immunotherapy-durability-keynote-966-benefit BioBriefs en 2026-10-12T21:32:33Z Immunotherapy durability: KEYNOTE-966 benefit holds after three years in biliary tract cancer https://biobriefs.com/bristol-myers-squibb-pipeline-phase BioBriefs en 2026-10-12T16:32:00Z Bristol Myers Squibb pipeline: Phase 3 momentum for fibrosis and RayzeBio https://biobriefs.com/fda-and-regulatory-approvals-herpes BioBriefs en 2026-10-12T16:32:00Z FDA and regulatory approvals: Herpes drug cleared after acquisition https://biobriefs.com/cancer-immunotherapy-endurance-keynote-966 BioBriefs en 2026-10-12T16:32:00Z Cancer immunotherapy endurance: KEYNOTE-966 3-year durability in biliary tract cancer https://biobriefs.com/turnaround-in-super-early-diagnostics BioBriefs en 2026-10-12T16:32:00Z Turnaround in super-early diagnostics: Urine test gets FDA clearance for invasive aspergillosis https://biobriefs.com/telemedicine-impact-virtual-urgent-care BioBriefs en 2026-10-12T16:32:00Z Telemedicine impact: virtual urgent care keeps most patients out of ED https://biobriefs.com/regulatory-facing-oncology-care-multiple BioBriefs en 2026-10-12T16:32:00Z Regulatory-facing oncology care: multiple groups validate biomarker strategies https://biobriefs.com/car-t-escalation-after-transplant BioBriefs en 2026-10-12T16:32:00Z CAR-T escalation after transplant failure: donor-derived CD19 responses https://biobriefs.com/drug-dosing-optimization-for-difficult BioBriefs en 2026-10-12T16:32:00Z Drug dosing optimization for difficult infections: high-dose sulbactam exposure targets https://biobriefs.com/cell-and-gene-therapy-industry BioBriefs en 2026-10-12T16:32:00Z Cell and gene therapy industry: Aspen Neuroscience files for IPO https://biobriefs.com/clinical-imaging-shift-liquid-biopsy BioBriefs en 2026-10-12T16:32:00Z Clinical imaging shift: liquid biopsy and CT-based predictions expand triage tools https://biobriefs.com/regulatory-and-evidence-updates-for BioBriefs en 2026-10-12T14:32:01Z Regulatory and evidence updates for diagnostics and tumor-agnostic oncology https://biobriefs.com/phase-3-and-higher-evidence BioBriefs en 2026-10-12T14:32:01Z Phase 3 and higher evidence reshaping cancer and radiation strategies https://biobriefs.com/immuno-oncology-biomarkers-and-translational BioBriefs en 2026-10-12T14:32:01Z Immuno-oncology biomarkers and translational ex vivo testing https://biobriefs.com/molecular-drivers-of-therapy-resistance BioBriefs en 2026-10-12T14:32:01Z Molecular drivers of therapy resistance and immune evasion in cancer https://biobriefs.com/drug-safety-toxicity-and-precision BioBriefs en 2026-10-12T14:32:01Z Drug safety, toxicity, and precision risk signals across clinical care https://biobriefs.com/evidence-on-imaging-and-ai BioBriefs en 2026-10-12T14:32:01Z Evidence on imaging and AI-driven patient selection for oncology https://biobriefs.com/nicu-care-practices-revisiting-rooming BioBriefs en 2026-10-12T14:32:01Z NICU care practices: revisiting rooming strategies https://biobriefs.com/pediatric-and-maternal-care-precision BioBriefs en 2026-10-12T14:32:01Z Pediatric and maternal care: precision dosing and clinical trial evidence https://biobriefs.com/technology-transfer-and-formulation-science BioBriefs en 2026-10-12T14:32:01Z Technology transfer and formulation science moving toward the clinic https://biobriefs.com/major-funding-and-corporate-deal BioBriefs en 2026-10-12T14:32:01Z Major funding and corporate deal activity in biotech https://biobriefs.com/regulatory-validated-diagnostics-for-tumor BioBriefs en 2026-10-12T10:32:01Z Regulatory-validated diagnostics for tumor-agnostic oncology https://biobriefs.com/new-imaging-marker-for-brain BioBriefs en 2026-10-12T10:32:01Z New imaging marker for brain metastasis radiosurgery outcomes https://biobriefs.com/carving-out-safer-and-more BioBriefs en 2026-10-12T10:32:01Z Carving out safer and more scalable IVF protocols https://biobriefs.com/translational-particle-engineering-for-drug BioBriefs en 2026-10-12T10:32:01Z Translational particle engineering for drug formulation https://biobriefs.com/fda-cleared-rapid-diagnostic-for BioBriefs en 2026-10-12T10:32:01Z FDA-cleared rapid diagnostic for invasive aspergillosis https://biobriefs.com/clinical-trial-signal-enhanced-lung BioBriefs en 2026-10-12T10:32:01Z Clinical trial signal: enhanced lung cancer management via immune-guided blood testing https://biobriefs.com/targeting-tnf-survival-biology-with BioBriefs en 2026-10-12T10:32:01Z Targeting TNF survival biology with a new molecular switch https://biobriefs.com/oncology-immunobiology-mda5-turns-immune BioBriefs en 2026-10-12T10:32:01Z Oncology immunobiology: MDA5 turns immune evasion into a druggable vulnerability https://biobriefs.com/cancer-resistance-and-metabolism-leflunomide BioBriefs en 2026-10-12T10:32:01Z Cancer resistance and metabolism: leflunomide reverses SMARCD1-driven kidney tumor mitochondrial changes https://biobriefs.com/ai-accelerated-design-of-rna BioBriefs en 2026-10-12T10:32:01Z AI-accelerated design of RNA therapeutics using an automated lipid nanoparticle platform https://biobriefs.com/translational-whole-virus-flu-vaccine BioBriefs en 2026-10-12T09:32:04Z Translational whole-virus flu vaccine moves into early humans https://biobriefs.com/fda-cleared-rapid-urine-testing BioBriefs en 2026-10-12T09:32:04Z FDA-cleared rapid urine testing for invasive aspergillosis https://biobriefs.com/car-t-safety-signal-liver BioBriefs en 2026-10-12T09:32:04Z CAR T safety signal: liver injury linked to early cytokine release https://biobriefs.com/durable-brain-metastasis-control-via BioBriefs en 2026-10-12T09:32:04Z Durable brain metastasis control via multi-fraction radioactive tiles https://biobriefs.com/companion-diagnostics-validated-for-pembrolizumab BioBriefs en 2026-10-12T09:32:04Z Companion diagnostics validated for pembrolizumab across dMMR/MSI-H tumors https://biobriefs.com/semaglutide-pancreatic-cancer-risk-checked BioBriefs en 2026-10-12T09:32:04Z Semaglutide pancreatic-cancer risk checked in Nordic registry data https://biobriefs.com/ai-assisted-tumor-biology-ct BioBriefs en 2026-10-12T09:32:04Z AI-assisted tumor biology: ct-based model distinguishes benign from malignant sacral tumors https://biobriefs.com/whole-virus-vaccination-signal-reinforced BioBriefs en 2026-10-12T09:32:04Z Whole-virus vaccination signal reinforced by first-in-human PET probe for PARP-1 https://biobriefs.com/immune-evasion-mechanism-pinned-on BioBriefs en 2026-10-12T09:32:04Z Immune evasion mechanism pinned on MDA5 in Nature Communications cancer study https://biobriefs.com/diagnostics-and-adoption-pooled-sputum BioBriefs en 2026-10-12T09:32:04Z Diagnostics and adoption: pooled sputum testing halves TB costs with Xpert Ultra cartridges https://biobriefs.com/regulatory-validated-tumor-agnostic-diagnostics BioBriefs en 2026-10-12T04:33:10Z Regulatory-validated tumor-agnostic diagnostics for pembrolizumab https://biobriefs.com/semaglutide-pancreatic-cancer-risk-cleared BioBriefs en 2026-10-12T04:33:10Z Semaglutide pancreatic cancer risk cleared by Nordic registry mandate https://biobriefs.com/fda-clearance-for-rapid-urine BioBriefs en 2026-10-12T04:33:10Z FDA clearance for rapid urine testing in invasive aspergillosis https://biobriefs.com/clinical-safety-and-early-signals BioBriefs en 2026-10-12T04:33:10Z Clinical safety and early signals for new cancer therapy roginolisib https://biobriefs.com/ai-ready-tumor-diagnostics-cdx BioBriefs en 2026-10-12T04:33:10Z AI-ready tumor diagnostics: CDx-like improvement claims backed by algorithms https://biobriefs.com/cancer-immunotherapy-ex-vivo-testing BioBriefs en 2026-10-12T04:33:10Z Cancer immunotherapy ex vivo testing platform keeps immune cells functional https://biobriefs.com/hospital-infection-control-asymptomatic-c BioBriefs en 2026-10-12T04:33:10Z Hospital infection control: asymptomatic C. difficile carriers dominate spread https://biobriefs.com/heart-failure-technology-remote-glucose BioBriefs en 2026-10-12T04:33:10Z Heart failure technology: remote glucose control with robotic exoskeleton walking https://biobriefs.com/cancer-care-delivery-virtual-family BioBriefs en 2026-10-12T04:33:10Z Cancer care delivery: virtual family rounds expand participation in NICU https://biobriefs.com/new-diagnostic-style-ai-for BioBriefs en 2026-10-12T04:33:10Z New diagnostic-style AI for diabetic foot ulcer imaging with explainability https://biobriefs.com/fda-cleared-tb-diagnostic-tool BioBriefs en 2026-10-11T21:32:16Z FDA-cleared TB diagnostic tool https://biobriefs.com/companion-diagnostics-bridging-for-tumor BioBriefs en 2026-10-11T21:32:16Z Companion diagnostics bridging for tumor-agnostic immunotherapy https://biobriefs.com/phase-1-cancer-trial-readout BioBriefs en 2026-10-11T21:32:16Z Phase 1 cancer trial readout for conformation-selective PI3Kδ inhibition https://biobriefs.com/drug-development-bridging-form-rollout BioBriefs en 2026-10-11T21:32:16Z Drug development: bridging form rollout for dual-release levodopa https://biobriefs.com/oncology-biomarker-breakthrough-image-ready BioBriefs en 2026-10-11T21:32:16Z Oncology biomarker breakthrough: image-ready PARP-1 PET reaches first-in-human https://biobriefs.com/cancer-immunology-platform-tumor-slices BioBriefs en 2026-10-11T21:32:16Z Cancer immunology platform: tumor slices maintain immune functionality for drug testing https://biobriefs.com/infectious-disease-diagnostics-rapid-testing BioBriefs en 2026-10-11T21:32:16Z Infectious disease diagnostics: rapid testing through smartphone urine images for TB adherence https://biobriefs.com/neuroscience-and-neurobiology-microglia-trogocytosis BioBriefs en 2026-10-11T21:32:16Z Neuroscience and neurobiology: microglia trogocytosis protects neurons in Parkinson’s https://biobriefs.com/clinical-trial-and-drug-performance BioBriefs en 2026-10-11T21:32:16Z Clinical trial and drug performance in stroke care: tirofiban fails in p16-negative head-to-head setting https://biobriefs.com/immunology-and-cancer-microenvironment-mmp14 BioBriefs en 2026-10-11T21:32:16Z Immunology and cancer microenvironment: MMP14 generates immune-excluding tumor shield https://biobriefs.com/regulatory-clinical-development-pi3kd-inhibitor BioBriefs en 2026-10-11T16:32:28Z Regulatory/Clinical development: PI3Kδ inhibitor roginolisib shows early survival signal in metastatic uveal melanoma https://biobriefs.com/oncology-trial-readouts-neoadjuvant-pyrotinib BioBriefs en 2026-10-11T16:32:28Z Oncology trial readouts: neoadjuvant pyrotinib-based HER2 regimen matches trastuzumab–pertuzumab https://biobriefs.com/oncology-biomarkers-and-imaging-ai BioBriefs en 2026-10-11T16:32:28Z Oncology biomarkers and imaging: AI-enabled PET probe reaches first human evaluation for PARP-1 https://biobriefs.com/infectious-disease-diagnostics-regulation-rapid BioBriefs en 2026-10-11T16:32:28Z Infectious disease diagnostics/regulation: rapid urine test for invasive aspergillosis wins FDA clearance https://biobriefs.com/antimicrobial-resistance-and-hospital-epidemiology BioBriefs en 2026-10-11T16:32:28Z Antimicrobial resistance and hospital epidemiology: asymptomatic C. difficile carriers drive most transmission in cancer wards https://biobriefs.com/neuroimmunology-in-cancer-immune-engaging BioBriefs en 2026-10-11T16:32:28Z Neuroimmunology in cancer: immune-engaging strategy evolves with dendritic-cell support for gastric tumors https://biobriefs.com/clinical-guidance-and-drug-formulation BioBriefs en 2026-10-11T16:32:28Z Clinical guidance and drug formulation: dual-release levodopa wins expert consensus for Parkinson’s motor fluctuations https://biobriefs.com/genomics-and-precision-oncology-dll3 BioBriefs en 2026-10-11T16:32:27Z Genomics and precision oncology: DLL3 emerges as a drug target validated in cervical cancer organoids https://biobriefs.com/safety-side-effects-in-oncology BioBriefs en 2026-10-11T16:32:27Z Safety/side effects in oncology: nivolumab-induced hypophysitis characterised in largest case synthesis https://biobriefs.com/microbiome-and-immunotherapy-gut-bacteria BioBriefs en 2026-10-11T16:32:27Z Microbiome and immunotherapy: gut bacteria influence fever after mRNA vaccination https://biobriefs.com/regulatory-clinical-rollouts BioBriefs en 2026-10-11T14:31:58Z Regulatory + clinical rollouts https://biobriefs.com/cancer-drug-development-first-in BioBriefs en 2026-10-11T14:31:58Z Cancer drug development + first-in-human progress https://biobriefs.com/imaging-ai-in-oncology-promising BioBriefs en 2026-10-11T14:31:58Z Imaging AI in oncology (promising but uneven validation) https://biobriefs.com/new-target-discovery-in-aggressive BioBriefs en 2026-10-11T14:31:58Z New target discovery in aggressive cervical cancer https://biobriefs.com/precision-oncology-biomarkers-diagnostics BioBriefs en 2026-10-11T14:31:58Z Precision oncology biomarkers + diagnostics https://biobriefs.com/antibiotics-antimicrobial-resistance BioBriefs en 2026-10-11T14:31:58Z Antibiotics + antimicrobial resistance https://biobriefs.com/oncology-immunotherapy-safety-signals BioBriefs en 2026-10-11T14:31:58Z Oncology immunotherapy safety signals https://biobriefs.com/clinical-practice-diagnostics-fda-cleared BioBriefs en 2026-10-11T14:31:58Z Clinical practice + diagnostics: FDA-cleared rapid test https://biobriefs.com/antiviral-drug-repurposing-mechanism-insight BioBriefs en 2026-10-11T14:31:58Z Antiviral + drug repurposing mechanism insight https://biobriefs.com/health-equity-care-access-consequences BioBriefs en 2026-10-11T14:31:58Z Health equity + care access consequences (high-impact systems issue) https://biobriefs.com/oncology-her2-neoadjuvant-pill-matches BioBriefs en 2026-10-11T10:31:33Z Oncology – HER2 neoadjuvant pill matches antibody standard https://biobriefs.com/neuroinflammation-nivolumab-linked-hypophysitis-mapping BioBriefs en 2026-10-11T10:31:33Z Neuroinflammation – Nivolumab-linked hypophysitis mapping https://biobriefs.com/cell-therapy-radiation-strategy-preserves BioBriefs en 2026-10-11T10:31:33Z Cell therapy – Radiation strategy preserves CAR T effect in brain lymphoma https://biobriefs.com/infection-diagnostics-care-ct-vs BioBriefs en 2026-10-11T10:31:33Z Infection diagnostics & care – CT vs angiography for hemoptysis planning https://biobriefs.com/endocrinology-aging-consensus-roadmap-for BioBriefs en 2026-10-11T10:31:33Z Endocrinology & aging – Consensus roadmap for palliative cancer care https://biobriefs.com/metformin-chemo-toxicity-lymphatic-vessel BioBriefs en 2026-10-11T10:31:33Z Metformin & chemo toxicity – Lymphatic vessel protection in models https://biobriefs.com/clinical-trials-weekly-vs-every BioBriefs en 2026-10-11T10:31:33Z Clinical trials – Weekly vs every-three-week cisplatin acute toxicity https://biobriefs.com/immunotherapy-safety-car-t-liver BioBriefs en 2026-10-11T10:31:33Z Immunotherapy safety – CAR T liver injury linked to cytokine release syndrome https://biobriefs.com/ophthalmology-innovation-optogenetic-therapy-shows BioBriefs en 2026-10-11T10:31:33Z Ophthalmology innovation – Optogenetic therapy shows vision gains https://biobriefs.com/battery-biotech-adjacent-manufacturing-tech BioBriefs en 2026-10-11T10:31:33Z Battery/biotech-adjacent manufacturing tech – Lithium surface standardization https://biobriefs.com/clinical-trial-and-consensus-updates BioBriefs en 2026-10-11T09:32:23Z Clinical trial and consensus updates in Parkinson’s disease https://biobriefs.com/imaging-and-diagnostics-breast-tb BioBriefs en 2026-10-11T09:32:23Z Imaging and diagnostics: breast, TB, and cancer risk stratification https://biobriefs.com/hiv-and-infectious-disease-immune BioBriefs en 2026-10-11T09:32:23Z HIV and infectious disease: immune engineering, long-term burden, and evolving surveillance https://biobriefs.com/immuno-oncology-biology-and-tumor BioBriefs en 2026-10-11T09:32:23Z Immuno-oncology biology and tumor microenvironment mechanisms https://biobriefs.com/car-t-and-radiation-platform BioBriefs en 2026-10-11T09:32:23Z CAR T and radiation: platform-level evidence for combination strategies https://biobriefs.com/rare-and-high-burden-diseases BioBriefs en 2026-10-11T09:32:23Z Rare and high-burden diseases: maternal-newborn care and congenital conditions https://biobriefs.com/cancer-treatment-evidence-dosing-strategy BioBriefs en 2026-10-11T09:32:23Z Cancer treatment evidence: dosing strategy and predictive imaging markers https://biobriefs.com/diabetes-and-metabolic-risk-drug BioBriefs en 2026-10-11T09:32:23Z Diabetes and metabolic risk: drug safety signals and early warning biomarkers https://biobriefs.com/neurology-and-immunology-crossovers-alzheimers BioBriefs en 2026-10-11T09:32:23Z Neurology and immunology crossovers: Alzheimer’s detection and post-COVID symptom stratification https://biobriefs.com/biotech-platform-and-translational-science BioBriefs en 2026-10-11T09:32:23Z Biotech platform and translational science: AI and open-source tools for clinical research workflows https://biobriefs.com/ophthalmology-neurovascular-protection-and-ai BioBriefs en 2026-10-11T04:32:05Z Ophthalmology—neurovascular protection and AI detection in diabetic eye disease https://biobriefs.com/immuno-oncology-biology-tumor-delivery BioBriefs en 2026-10-11T04:32:05Z Immuno-oncology biology—tumor delivery, resistance, and immune microenvironment rewiring https://biobriefs.com/genetic-and-cellular-mechanisms-in BioBriefs en 2026-10-11T04:32:05Z Genetic and cellular mechanisms in cancer progression—RNA marks, immune evasion, and new vulnerabilities https://biobriefs.com/clinical-and-real-world-healthcare BioBriefs en 2026-10-11T04:32:05Z Clinical and real-world healthcare evidence—therapy safety, diagnostic signals, and adoption in practice https://biobriefs.com/ophthalmology-therapeutics-device-led-gene BioBriefs en 2026-10-11T04:32:05Z Ophthalmology therapeutics—device-led gene and drug approaches https://biobriefs.com/infectious-disease-and-vaccines-targeted BioBriefs en 2026-10-11T04:32:05Z Infectious disease and vaccines—targeted prevention and diagnostic performance https://biobriefs.com/nephrology-and-diabetes-complications-biomarkers BioBriefs en 2026-10-11T04:32:05Z Nephrology and diabetes complications—biomarkers, mechanisms, and perioperative risk https://biobriefs.com/regenerative-medicine-and-stem-cell BioBriefs en 2026-10-11T04:32:05Z Regenerative medicine and stem cell approaches—platforms and translational signals https://biobriefs.com/ai-in-drug-and-diagnostics BioBriefs en 2026-10-11T04:32:05Z AI in drug and diagnostics pipelines—validation, explainability, and clinical governance https://biobriefs.com/neuroscience-and-neurodegeneration-tau-filament BioBriefs en 2026-10-11T04:32:05Z Neuroscience and neurodegeneration—tau filament structure and early biomarkers https://biobriefs.com/fda-review-and-kras-specified BioBriefs en 2026-10-10T21:32:20Z FDA review and KRAS-specified response concerns https://biobriefs.com/biotech-ipo-momentum-with-immune BioBriefs en 2026-10-10T21:32:20Z Biotech IPO momentum with immune modulation focus https://biobriefs.com/regulatory-guidance-reshapes-clinical-care BioBriefs en 2026-10-10T21:32:20Z Regulatory guidance reshapes clinical care in nephrology https://biobriefs.com/clinical-trial-result-on-thyroid BioBriefs en 2026-10-10T21:32:20Z Clinical trial result on thyroid hot-flash safety https://biobriefs.com/real-world-delivery-of-amyloid BioBriefs en 2026-10-10T21:32:20Z Real-world delivery of amyloid therapies via community neurologists https://biobriefs.com/mechanism-and-drug-resistance-in BioBriefs en 2026-10-10T21:32:20Z Mechanism and drug-resistance in oral cancer ferroptosis escape https://biobriefs.com/preclinical-rna-therapy-for-colorectal BioBriefs en 2026-10-10T21:32:20Z Preclinical RNA therapy for colorectal cancer via miR-124 vesicles https://biobriefs.com/matched-cohorts-link-residual-tumor BioBriefs en 2026-10-10T21:32:20Z Matched cohorts link residual tumor burden to survival in esophageal cancer https://biobriefs.com/in-vivo-device-trial-vagus BioBriefs en 2026-10-10T21:32:20Z In vivo device trial: vagus nerve stimulation for cancer-related wasting https://biobriefs.com/diagnostics-and-adherence-insulin-safety BioBriefs en 2026-10-10T21:32:20Z Diagnostics and adherence: insulin safety gaps in US safety-net clinics https://biobriefs.com/regulatory-backed-cell-therapy-momentum BioBriefs en 2026-10-10T16:32:12Z Regulatory-backed cell therapy momentum https://biobriefs.com/immunology-ipo-deal-flow-accelerates BioBriefs en 2026-10-10T16:32:12Z Immunology IPO deal flow accelerates https://biobriefs.com/oncology-and-diagnostic-imaging-new BioBriefs en 2026-10-10T16:32:12Z Oncology and diagnostic imaging—new tools forecast outcomes https://biobriefs.com/clinical-trial-readouts-hot-flashes BioBriefs en 2026-10-10T16:32:12Z Clinical trial readouts—hot flashes safety and efficacy signal https://biobriefs.com/drug-discovery-science-rna-chemical BioBriefs en 2026-10-10T16:32:12Z Drug discovery science—RNA chemical tags and ferroptosis escape https://biobriefs.com/infectious-disease-epidemiology-c-difficile BioBriefs en 2026-10-10T16:32:12Z Infectious disease epidemiology—C. difficile spread is mostly silent https://biobriefs.com/ai-in-diagnostics-risk-stratification BioBriefs en 2026-10-10T16:32:12Z AI in diagnostics—risk stratification from routine imaging https://biobriefs.com/immunotherapy-toxicity-neurotoxicity-risk-tied BioBriefs en 2026-10-10T16:32:12Z Immunotherapy toxicity—neurotoxicity risk tied to immune signatures https://biobriefs.com/clinical-operations-and-infection-control BioBriefs en 2026-10-10T16:32:12Z Clinical operations and infection control—venous line infection burden https://biobriefs.com/pharma-pipeline-regulatory-landscape-adjuvant BioBriefs en 2026-10-10T16:32:12Z Pharma pipeline/regulatory landscape—adjuvant strategy primes respiratory immunity https://biobriefs.com/fda-approval-immuno-oncology-in BioBriefs en 2026-10-10T14:31:44Z FDA approval – immuno-oncology in colorectal cancer https://biobriefs.com/ipo-momentum-in-cell-therapy BioBriefs en 2026-10-10T14:31:44Z IPO momentum in cell therapy – Aspen and Bambusa launch path https://biobriefs.com/early-clinical-signal-and-safety BioBriefs en 2026-10-10T14:31:44Z Early clinical signal and safety in immune modulation – TRex Bio IPO https://biobriefs.com/drug-outcome-trial-stroke-subtype BioBriefs en 2026-10-10T14:31:44Z Drug outcome trial – stroke subtype fails to beat standard antiplatelet https://biobriefs.com/precision-imaging-biomarkers-spectral-ct BioBriefs en 2026-10-10T14:31:44Z Precision imaging biomarkers – spectral CT predicts lymphoma treatment failure https://biobriefs.com/cell-gene-editing-living-patient BioBriefs en 2026-10-10T14:31:44Z Cell/gene editing – living patient tumor models for Duchenne https://biobriefs.com/clinical-trial-and-guideline-shift BioBriefs en 2026-10-10T14:31:44Z Clinical trial and guideline shift – hormone therapy first-line for hot flashes https://biobriefs.com/ai-in-cardiology-routine-ecg BioBriefs en 2026-10-10T14:31:44Z AI in cardiology – routine ECG flags coronary disease risk https://biobriefs.com/sepsis-and-device-infection-burden BioBriefs en 2026-10-10T14:31:44Z Sepsis and device infection burden – central line bloodstream infections https://biobriefs.com/drug-delivery-platform-vesicles-that BioBriefs en 2026-10-10T14:31:44Z Drug delivery platform – vesicles that sense hydrostatic pressure https://biobriefs.com/regulatory-and-ipo-momentum-in BioBriefs en 2026-10-10T10:32:29Z Regulatory and IPO momentum in immunology and oncology https://biobriefs.com/fda-approval-advances-immune-checkpoint BioBriefs en 2026-10-10T10:32:29Z FDA approval advances immune checkpoint therapy in dMMR colon cancer https://biobriefs.com/clinical-evidence-update-perioperative-use BioBriefs en 2026-10-10T10:32:29Z Clinical evidence update: perioperative use of GLP-1 drugs before thyroid surgery https://biobriefs.com/first-in-human-testing-for BioBriefs en 2026-10-10T10:32:29Z First-in-human testing for noninvasive neuromodulation in cancer wasting https://biobriefs.com/cancer-immunology-mechanisms-malignant-ascites BioBriefs en 2026-10-10T10:32:29Z Cancer immunology mechanisms: malignant ascites immune profiling and therapy-enabling biology https://biobriefs.com/digital-health-and-ai-in BioBriefs en 2026-10-10T10:32:29Z Digital health and AI in care delivery: reducing inequity and improving clinical documentation https://biobriefs.com/ai-enabled-diagnostics-heart-and BioBriefs en 2026-10-10T10:32:29Z AI-enabled diagnostics: heart and cancer imaging without major workflow disruption https://biobriefs.com/infectious-disease-care-evidence-on BioBriefs en 2026-10-10T10:32:29Z Infectious disease care: evidence on resistance and treatment gaps https://biobriefs.com/translational-immunotherapy-engineering-moving-beyond BioBriefs en 2026-10-10T10:32:29Z Translational immunotherapy engineering: moving beyond conventional targets in oncology https://biobriefs.com/open-science-pipeline-new-computation BioBriefs en 2026-10-10T10:32:29Z Open science pipeline: new computation for mutation detection in regulatory DNA https://biobriefs.com/regulatory-clinical-update-in-oncology BioBriefs en 2026-10-10T09:33:07Z Regulatory/clinical update in oncology and immunotherapy https://biobriefs.com/ipo-momentum-for-immune-modulating BioBriefs en 2026-10-10T09:33:07Z IPO momentum for immune-modulating cell therapy and inflammation targets https://biobriefs.com/clinical-trial-signal-in-head BioBriefs en 2026-10-10T09:33:07Z Clinical trial signal in head and neck cancer via chemo-immunotherapy de-escalation https://biobriefs.com/new-drug-performance-signal-in BioBriefs en 2026-10-10T09:33:07Z New drug performance signal in rare hematology via complement inhibition in pregnancy https://biobriefs.com/ai-enabled-diagnostic-tools-moving BioBriefs en 2026-10-10T09:33:07Z AI-enabled diagnostic tools moving toward screening workflows https://biobriefs.com/precision-immunology-and-cancer-biology BioBriefs en 2026-10-10T09:33:07Z Precision immunology and cancer biology: resistance and tumor-immune interactions https://biobriefs.com/new-targeted-microbiology-and-antimicrobial BioBriefs en 2026-10-10T09:33:07Z New targeted microbiology and antimicrobial adjunct concept https://biobriefs.com/ai-and-healthcare-operations-systematic BioBriefs en 2026-10-10T09:33:07Z AI and healthcare operations: systematic performance on nursing workloads and care delivery https://biobriefs.com/clinical-evidence-for-glp-1 BioBriefs en 2026-10-10T09:33:07Z Clinical evidence for GLP-1 use around surgery in diabetes patients https://biobriefs.com/public-health-and-infectious-disease BioBriefs en 2026-10-10T09:33:07Z Public health and infectious disease: malaria control signal and surveillance methods https://biobriefs.com/regulators-expand-immunotherapy-options-in BioBriefs en 2026-10-10T04:31:34Z Regulators expand immunotherapy options in solid tumors https://biobriefs.com/biotech-ipos-underscore-renewed-appetite BioBriefs en 2026-10-10T04:31:34Z Biotech IPOs underscore renewed appetite for immune-focused pipelines https://biobriefs.com/clinical-trial-data-reshape-preoperative BioBriefs en 2026-10-10T04:31:34Z Clinical trial data reshape preoperative head-and-neck strategies https://biobriefs.com/oncology-biology-identifies-new-immune BioBriefs en 2026-10-10T04:31:34Z Oncology biology identifies new immune escape levers https://biobriefs.com/new-translational-approaches-for-delivering BioBriefs en 2026-10-10T04:31:34Z New translational approaches for delivering targeted gene therapy https://biobriefs.com/cancer-diagnostics-blood-based-ratios BioBriefs en 2026-10-10T04:31:34Z Cancer diagnostics: blood-based ratios point to earlier risk stratification https://biobriefs.com/on-device-or-ai-enabled BioBriefs en 2026-10-10T04:31:34Z On-device or AI-enabled diagnostics inch toward deployment but validation gaps remain https://biobriefs.com/new-mechanistic-cancer-targeting-strategies BioBriefs en 2026-10-10T04:31:34Z New mechanistic cancer-targeting strategies emerge from molecular reviews https://biobriefs.com/neurology-therapeutics-engineered-protein-therapy BioBriefs en 2026-10-10T04:31:34Z Neurology therapeutics: engineered protein therapy targets Fragile X circuitry https://biobriefs.com/drug-safety-and-discovery-tooling BioBriefs en 2026-10-10T04:31:34Z Drug safety and discovery tooling: novel screening and analytics expand capabilities https://biobriefs.com/regulatory-approvals-and-pricing-moves BioBriefs en 2026-10-09T21:33:04Z Regulatory approvals and pricing moves in oncology and radiopharmaceuticals https://biobriefs.com/biotech-ipos-and-capital-formation BioBriefs en 2026-10-09T21:33:04Z Biotech IPOs and capital formation for immune and hypertension programs https://biobriefs.com/targeted-therapeutics-and-biomarkers-predicting BioBriefs en 2026-10-09T21:33:04Z Targeted therapeutics and biomarkers—predicting immunotherapy benefit in lung cancer https://biobriefs.com/clinical-trial-efficacy-in-oncology BioBriefs en 2026-10-09T21:33:04Z Clinical trial efficacy in oncology—ADC and PARP combinations https://biobriefs.com/imaging-and-pathology-ai-mismatch BioBriefs en 2026-10-09T21:33:04Z Imaging and pathology AI—mismatch between accuracy and real-world readiness https://biobriefs.com/cell-and-gene-pipeline-in BioBriefs en 2026-10-09T21:33:04Z Cell and gene pipeline: in vivo CAR-T durability update https://biobriefs.com/vaccine-and-infectious-disease-antibody BioBriefs en 2026-10-09T21:33:04Z Vaccine and infectious disease—antibody escape and Long COVID mechanistic failure https://biobriefs.com/regulatory-and-compliance-oversight-for BioBriefs en 2026-10-09T21:33:04Z Regulatory and compliance oversight for pharma disclosures https://biobriefs.com/venture-funding-matchpoint-and-immune BioBriefs en 2026-10-09T21:33:04Z Venture funding: Matchpoint and immune-oncology oral chemistry https://biobriefs.com/evidence-gaps-and-diagnostics-limited BioBriefs en 2026-10-09T21:33:04Z Evidence gaps and diagnostics: limited benefit of delayed PET for lung nodules https://biobriefs.com/regulatory-signals-and-drug-company BioBriefs en 2026-10-09T16:31:57Z Regulatory signals and drug-company disclosures https://biobriefs.com/fda-approval-for-adjuvant-immunotherapy BioBriefs en 2026-10-09T16:31:57Z FDA approval for adjuvant immunotherapy in colorectal cancer https://biobriefs.com/oral-immune-targeting-startup-funding BioBriefs en 2026-10-09T16:31:57Z Oral immune targeting startup funding surge https://biobriefs.com/ipo-activity-and-treg-directed BioBriefs en 2026-10-09T16:31:57Z IPO activity and Treg-directed immune drug programs https://biobriefs.com/precision-microbiome-and-cancer-immune BioBriefs en 2026-10-09T16:31:57Z Precision microbiome and cancer immune modulation via gut-liver access https://biobriefs.com/cell-therapy-pathway-development-for BioBriefs en 2026-10-09T16:31:57Z Cell therapy pathway development for longer storage and shipping https://biobriefs.com/quantum-cellulose-new-approaches-to BioBriefs en 2026-10-09T16:31:57Z Quantum-cellulose: new approaches to drug-delivery translational formulation https://biobriefs.com/clinical-oncology-and-imaging-tracking BioBriefs en 2026-10-09T16:31:57Z Clinical oncology and imaging: tracking treatment response with new biomarkers https://biobriefs.com/cell-death-and-immune-escape BioBriefs en 2026-10-09T16:31:57Z Cell death and immune escape mechanisms in cancer https://biobriefs.com/antibody-drug-conjugate-patient-selection BioBriefs en 2026-10-09T16:31:57Z Antibody-drug conjugate patient selection beyond antigen staining https://biobriefs.com/regulatory-approvals-in-oncology BioBriefs en 2026-10-09T14:32:45Z Regulatory approvals in oncology https://biobriefs.com/biotech-ipo-pipeline-and-market BioBriefs en 2026-10-09T14:32:45Z Biotech IPO pipeline and market funding momentum https://biobriefs.com/large-pharma-dealmaking-for-pain BioBriefs en 2026-10-09T14:32:45Z Large pharma dealmaking for pain therapeutics https://biobriefs.com/venture-funding-for-oral-autoimmune BioBriefs en 2026-10-09T14:32:45Z Venture funding for oral autoimmune small molecules https://biobriefs.com/immunotherapy-strategy-shift-in-long BioBriefs en 2026-10-09T14:32:45Z Immunotherapy strategy shift in Long COVID https://biobriefs.com/cell-therapy-platform-data-update BioBriefs en 2026-10-09T14:32:45Z Cell therapy platform data update https://biobriefs.com/new-private-funding-for-hospital BioBriefs en 2026-10-09T14:32:45Z New private funding for hospital capacity and labor management https://biobriefs.com/fda-oversight-tightening-sec-fda BioBriefs en 2026-10-09T14:32:45Z FDA oversight tightening: SEC-FDA information sharing https://biobriefs.com/roches-new-approach-to-china BioBriefs en 2026-10-09T14:32:45Z Roche’s new approach to China innovation partnerships https://biobriefs.com/arpa-h-funding-for-room BioBriefs en 2026-10-09T14:32:45Z ARPA-H funding for room-temperature stabilization of cell therapies https://biobriefs.com/fda-approval-and-adjuvant-strategy BioBriefs en 2026-10-09T10:31:51Z FDA approval and adjuvant strategy for dMMR stage III colon cancer https://biobriefs.com/biopharma-dealmaking-in-oncology-and BioBriefs en 2026-10-09T10:31:51Z Biopharma dealmaking in oncology and pain https://biobriefs.com/cutting-the-time-and-complexity BioBriefs en 2026-10-09T10:31:51Z Cutting the time and complexity of Treg manufacturing via IPO-funded expansion https://biobriefs.com/long-term-in-vivo-bcma BioBriefs en 2026-10-09T10:31:51Z Long-term in vivo BCMA CAR-T safety and durability update https://biobriefs.com/microbiome-linked-mechanism-for-post BioBriefs en 2026-10-09T10:31:51Z Microbiome-linked mechanism for post-vaccine fever risk https://biobriefs.com/company-pipeline-signal-molecular-glue BioBriefs en 2026-10-09T10:31:51Z Company pipeline signal: molecular glue collaboration in China https://biobriefs.com/arpa-h-funding-to-stabilize BioBriefs en 2026-10-09T10:31:51Z ARPA-H funding to stabilize cell therapies without refrigeration https://biobriefs.com/major-trial-design-shift-oral BioBriefs en 2026-10-09T10:31:51Z Major trial design shift: oral low-dose antiplatelet combo in minor stroke https://biobriefs.com/advances-in-biosensing-magnetic-tracer BioBriefs en 2026-10-09T10:31:51Z Advances in biosensing: magnetic tracer for sentinel node mapping in ovarian cancer https://biobriefs.com/new-cancer-biomarker-direction-blood BioBriefs en 2026-10-09T10:31:51Z New cancer biomarker direction: blood proteomics to measure tumor hypoxia and predict radiotherapy benefit https://biobriefs.com/new-oncology-approvals-and-label BioBriefs en 2026-10-09T09:32:05Z New oncology approvals and label expansions https://biobriefs.com/big-pharma-dealmaking-in-pain BioBriefs en 2026-10-09T09:32:05Z Big pharma dealmaking in pain and China partnering https://biobriefs.com/cell-therapy-durability-updates-and BioBriefs en 2026-10-09T09:32:05Z Cell therapy durability updates and the in vivo CAR-T direction https://biobriefs.com/clinical-trial-readouts-in-solid BioBriefs en 2026-10-09T09:32:05Z Clinical trial readouts in solid tumors and targeted approaches https://biobriefs.com/diagnostic-innovation-in-oncology-imaging BioBriefs en 2026-10-09T09:32:05Z Diagnostic innovation in oncology imaging https://biobriefs.com/fda-and-regulatory-oversight-sec BioBriefs en 2026-10-09T09:32:05Z FDA and regulatory oversight: SEC-FDA disclosure coordination https://biobriefs.com/government-funding-for-cell-therapy BioBriefs en 2026-10-09T09:32:05Z Government funding for cell-therapy cold chain stabilization https://biobriefs.com/biotech-ipo-appetite-and-new BioBriefs en 2026-10-09T09:32:05Z Biotech IPO appetite and new market entries https://biobriefs.com/sequencing-and-diagnostics-rapid-pathogen BioBriefs en 2026-10-09T09:32:05Z Sequencing and diagnostics: rapid pathogen and immune profiling tools https://biobriefs.com/venture-and-startup-financing-in BioBriefs en 2026-10-09T09:32:05Z Venture and startup financing in biotech-enabling tech https://biobriefs.com/fda-sec-oversight-alignment-reshapes BioBriefs en 2026-10-09T04:32:19Z FDA-SEC oversight alignment reshapes pharma disclosure risk https://biobriefs.com/roche-and-defand-therapeutics-take BioBriefs en 2026-10-09T04:32:19Z Roche and Defand Therapeutics take a molecular-glue discovery collaboration approach in China https://biobriefs.com/viatris-to-acquire-pacira-in BioBriefs en 2026-10-09T04:32:19Z Viatris to acquire Pacira in $1.65B non-opioid pain deal https://biobriefs.com/bristol-myers-zenbexus-gets-fda BioBriefs en 2026-10-09T04:32:19Z Bristol Myers’ Zenbexus gets FDA accelerated approval; trial shows 51% progression reduction https://biobriefs.com/in-vivo-bcma-car-t BioBriefs en 2026-10-09T04:32:19Z In vivo BCMA CAR-T follow-up updates safety and durability limits https://biobriefs.com/argenx-hits-sjogrens-phase-3 BioBriefs en 2026-10-09T04:32:19Z Argenx hits Sjögren’s Phase 3 futility; broader pipeline signals diverge https://biobriefs.com/hiv-prevention-antibody-escape-vrc01 BioBriefs en 2026-10-09T04:32:19Z HIV prevention antibody escape: VRC01 selects low-frequency mutations https://biobriefs.com/general-medicine-launches-to-turn BioBriefs en 2026-10-09T04:32:19Z General Medicine launches to turn patient data into a unified healthcare store https://biobriefs.com/covid-contact-tracing-automation-slashes BioBriefs en 2026-10-09T04:32:19Z COVID contact tracing automation slashes labor by 99.8% at a South Korean hospital https://biobriefs.com/vaginal-to-blood-targeting-a BioBriefs en 2026-10-09T04:32:19Z Vaginal-to-blood targeting: a blood-based methylation panel for esophageal cancer detection https://biobriefs.com/fda-accelerated-approval-reshapes-multiple BioBriefs en 2026-10-08T21:33:26Z FDA accelerated approval reshapes multiple myeloma outcomes https://biobriefs.com/viatris-1-65b-pacira-acquisition BioBriefs en 2026-10-08T21:33:26Z Viatris’ $1.65B Pacira acquisition accelerates non-opioid pain buildout https://biobriefs.com/roche-shifts-from-licensing-to BioBriefs en 2026-10-08T21:33:26Z Roche shifts from licensing to early invention with Defand Therapeutics https://biobriefs.com/arpa-h-funds-room-temperature BioBriefs en 2026-10-08T21:33:26Z ARPA-H funds room-temperature biostabilization for cell therapies https://biobriefs.com/caribou-biosciences-winds-down-allogeneic BioBriefs en 2026-10-08T21:33:26Z Caribou Biosciences winds down allogeneic CAR T programs https://biobriefs.com/roche-vs-halozyme-patent-dispute BioBriefs en 2026-10-08T21:33:26Z Roche vs Halozyme patent dispute blocks subcutaneous Keytruda in Europe https://biobriefs.com/eu-moves-to-rebuild-clinical BioBriefs en 2026-10-08T21:33:26Z EU moves to rebuild clinical trials database for Biotech Act compliance https://biobriefs.com/argenx-stumbles-in-sjogrens-phase BioBriefs en 2026-10-08T21:33:26Z Argenx stumbles in Sjögren’s Phase 3 as Vyvgart misses placebo https://biobriefs.com/antibody-validation-and-reproducibility-face BioBriefs en 2026-10-08T21:33:26Z Antibody validation and reproducibility face renewed scrutiny https://biobriefs.com/cold-chain-breakthrough-for-pediatric BioBriefs en 2026-10-08T21:33:26Z Cold-chain breakthrough for pediatric heart transplants after circulatory death https://biobriefs.com/regulatory-approvals-and-late-stage BioBriefs en 2026-10-08T16:32:41Z Regulatory approvals and late-stage trial outcomes https://biobriefs.com/strategic-licensing-and-major-biotech BioBriefs en 2026-10-08T16:32:41Z Strategic licensing and major biotech deal activity https://biobriefs.com/big-data-and-ai-governance BioBriefs en 2026-10-08T16:32:41Z Big data and AI governance in biotech and clinical research https://biobriefs.com/car-t-and-next-wave BioBriefs en 2026-10-08T16:32:41Z CAR-T and next-wave cell therapy shakeups https://biobriefs.com/clinical-pipeline-oncology-diagnostics-and BioBriefs en 2026-10-08T16:32:41Z Clinical pipeline: oncology diagnostics and therapeutic signals https://biobriefs.com/metabolic-and-endocrine-therapeutics-beyond BioBriefs en 2026-10-08T16:32:41Z Metabolic and endocrine therapeutics beyond GLP-1 https://biobriefs.com/neurodegeneration-and-late-stage-neurology BioBriefs en 2026-10-08T16:32:41Z Neurodegeneration and late-stage neurology progress https://biobriefs.com/infectious-disease-diagnostics-and-antimicrobial BioBriefs en 2026-10-08T16:32:41Z Infectious disease diagnostics and antimicrobial-resistance signals https://biobriefs.com/cutting-edge-cell-biology-and BioBriefs en 2026-10-08T16:32:41Z Cutting-edge cell biology and translational mechanisms https://biobriefs.com/platforms-and-productivity-manufacturing-robotics BioBriefs en 2026-10-08T16:32:41Z Platforms and productivity: manufacturing robotics and digital transformation https://biobriefs.com/roche-deepens-china-drugmaking-push BioBriefs en 2026-10-08T14:31:40Z Roche deepens China drugmaking push via molecular glue discovery deal https://biobriefs.com/genentech-and-alector-agree-on BioBriefs en 2026-10-08T14:31:40Z Genentech and Alector agree on $1.27B Parkinson’s enzyme replacement program https://biobriefs.com/argenxs-vyvgart-fails-in-sjogrens BioBriefs en 2026-10-08T14:31:40Z Argenx’s Vyvgart fails in Sjögren’s Phase 3, stock drops https://biobriefs.com/eu-court-blocks-subcutaneous-keytruda BioBriefs en 2026-10-08T14:31:40Z EU court blocks subcutaneous Keytruda in multiple countries https://biobriefs.com/caribou-biosciences-ends-late-stage BioBriefs en 2026-10-08T14:31:40Z Caribou Biosciences ends late-stage allogeneic CAR-T path and shuts down https://biobriefs.com/regulatory-and-policy-pressure-eu BioBriefs en 2026-10-08T14:31:40Z Regulatory and policy pressure: EU CTIS overhaul for Biotech Act compliance https://biobriefs.com/big-pharma-faces-fresh-pricing BioBriefs en 2026-10-08T14:31:40Z Big pharma faces fresh pricing litigation in US Medicare MFN pilot https://biobriefs.com/therapy-pipeline-update-cervance-reports BioBriefs en 2026-10-08T14:31:40Z Therapy pipeline update: Cervance reports Phase 3 solengepras win in Parkinson’s off-time reduction https://biobriefs.com/capital-markets-matchpoint-therapeutics-raises BioBriefs en 2026-10-08T14:31:40Z Capital markets: Matchpoint Therapeutics raises $150M Series B with Novartis-linked background https://biobriefs.com/biotech-funding-and-dealmaking-multiply BioBriefs en 2026-10-08T14:31:40Z Biotech funding and dealmaking: multiply Labs scales robotic cell therapy manufacturing https://biobriefs.com/car-t-pipeline-shutdowns-and BioBriefs en 2026-10-08T10:32:21Z CAR-T pipeline shutdowns and funding access for cell therapy https://biobriefs.com/regulatory-and-pricing-pressure-reshapes BioBriefs en 2026-10-08T10:32:21Z Regulatory and pricing pressure reshapes pharma business models https://biobriefs.com/eu-clinical-trial-database-overhaul BioBriefs en 2026-10-08T10:32:21Z EU clinical trial database overhaul for Biotech Act compliance https://biobriefs.com/dealmaking-roche-expands-china-degraders BioBriefs en 2026-10-08T10:32:21Z Dealmaking: Roche expands China degraders footprint https://biobriefs.com/generative-ai-for-antibody-discovery BioBriefs en 2026-10-08T10:32:21Z Generative AI for antibody discovery: platform capabilities expand https://biobriefs.com/clinical-update-obesity-drugs-and BioBriefs en 2026-10-08T10:32:21Z Clinical update: obesity drugs and longer-term payer impact https://biobriefs.com/fda-approvals-and-rare-disease BioBriefs en 2026-10-08T10:32:21Z FDA approvals and rare disease commercial strategy https://biobriefs.com/ai-tools-meet-oncology-precision BioBriefs en 2026-10-08T10:32:21Z AI tools meet oncology: precision imaging for treatment planning https://biobriefs.com/clinical-trial-outcome-parkinsons-add BioBriefs en 2026-10-08T10:32:21Z Clinical trial outcome: Parkinson’s add-on pill reduces off-time https://biobriefs.com/antimicrobial-resistance-surveillance-resistance-genes BioBriefs en 2026-10-08T10:32:21Z Antimicrobial resistance surveillance: resistance genes spread in hospital wards https://biobriefs.com/regulatory-and-policy-shifts-affecting BioBriefs en 2026-10-08T09:31:57Z Regulatory and policy shifts affecting biotech operations https://biobriefs.com/oncology-fda-approval-and-tumor BioBriefs en 2026-10-08T09:31:57Z Oncology: FDA approval and tumor biology advances https://biobriefs.com/cell-therapy-car-t-trial BioBriefs en 2026-10-08T09:31:57Z Cell therapy: CAR-T trial terminations and strategic exits https://biobriefs.com/immunology-and-inflammation-mechanistic-switches BioBriefs en 2026-10-08T09:31:57Z Immunology and inflammation: mechanistic switches and immune-targeting strategies https://biobriefs.com/machine-learning-in-biotech-clinical BioBriefs en 2026-10-08T09:31:57Z Machine learning in biotech: clinical imaging, validation, and interpretability https://biobriefs.com/rare-disease-and-rare-drug BioBriefs en 2026-10-08T09:31:57Z Rare disease and rare-drug commercialization https://biobriefs.com/digital-health-and-reimbursement-adjacent BioBriefs en 2026-10-08T09:31:57Z Digital health and reimbursement-adjacent adoption https://biobriefs.com/clinical-evidence-updates-diabetes-and BioBriefs en 2026-10-08T09:31:57Z Clinical evidence updates: diabetes and cardiovascular risk signals https://biobriefs.com/cell-and-gene-therapy-engineered BioBriefs en 2026-10-08T09:31:57Z Cell and gene therapy: engineered interventions entering new disease contexts https://biobriefs.com/immuno-oncology-mechanisms-and-radiosensitivity BioBriefs en 2026-10-08T09:31:57Z Immuno-oncology mechanisms and radiosensitivity https://biobriefs.com/fda-and-regulatory-actions-reshape BioBriefs en 2026-10-08T04:31:50Z FDA and regulatory actions reshape pancreatic cancer and immunotherapy landscape https://biobriefs.com/caribou-exits-off-the-shelf BioBriefs en 2026-10-08T04:31:50Z Caribou exits off-the-shelf CAR-T after funding failure https://biobriefs.com/genentech-and-alector-strike-a BioBriefs en 2026-10-08T04:31:50Z Genentech and Alector strike a major Parkinson’s collaboration on enzyme replacement https://biobriefs.com/diabetes-and-obesity-drugs-keep BioBriefs en 2026-10-08T04:31:50Z Diabetes and obesity drugs keep delivering real-world cardiovascular signal https://biobriefs.com/cell-therapy-and-immunotherapy-trials BioBriefs en 2026-10-08T04:31:50Z Cell therapy and immunotherapy trials face mixed momentum in neurology and oncology https://biobriefs.com/regulatory-and-compliance-scrutiny-accelerates BioBriefs en 2026-10-08T04:31:50Z Regulatory and compliance scrutiny accelerates around diagnostics and privacy https://biobriefs.com/ema-ctis-overhaul-looms-under BioBriefs en 2026-10-08T04:31:50Z EMA/CTIS overhaul looms under proposed EU Biotech Act https://biobriefs.com/food-allergy-biotech-prepares-ipo BioBriefs en 2026-10-08T04:31:50Z Food-allergy biotech prepares IPO to fund IgE-targeted therapies https://biobriefs.com/diagnostics-and-imaging-ai-move BioBriefs en 2026-10-08T04:31:50Z Diagnostics and imaging AI move toward earlier cancer staging https://biobriefs.com/cell-biology-insights-open-new BioBriefs en 2026-10-08T04:31:50Z Cell biology insights open new therapeutic targets across inflammation and immune evasion https://biobriefs.com/regulatory-and-pricing-pressure-on BioBriefs en 2026-10-07T21:32:01Z Regulatory and pricing pressure on pharma https://biobriefs.com/cell-therapy-funding-crunch-forces BioBriefs en 2026-10-07T21:32:01Z Cell therapy funding crunch forces strategic retreat https://biobriefs.com/strategic-investment-and-ipo-momentum BioBriefs en 2026-10-07T21:32:01Z Strategic investment and IPO momentum in biopharma https://biobriefs.com/clinical-trial-readouts-reshaping-parkinsons BioBriefs en 2026-10-07T21:32:01Z Clinical trial readouts reshaping Parkinson’s add-on treatment https://biobriefs.com/cellular-and-immunology-mechanisms-in BioBriefs en 2026-10-07T21:32:01Z Cellular and immunology mechanisms in immune protection at birth https://biobriefs.com/oncology-biomarkers-liver-metastases-and BioBriefs en 2026-10-07T21:32:01Z Oncology biomarkers: liver metastases and outcome divergence in pancreatic cancer https://biobriefs.com/biotech-platform-analytics-and-digital BioBriefs en 2026-10-07T21:32:01Z Biotech platform analytics and digital biology funding for virtual cell models https://biobriefs.com/genetic-diagnosis-refinement-in-friedreich BioBriefs en 2026-10-07T21:32:01Z Genetic diagnosis refinement in Friedreich ataxia https://biobriefs.com/ai-enabled-clinical-imaging-for BioBriefs en 2026-10-07T21:32:01Z AI-enabled clinical imaging for cancer detection and surgical triage https://biobriefs.com/biomanufacturing-and-process-control-via BioBriefs en 2026-10-07T21:32:01Z Biomanufacturing and process control via electrical monitoring https://biobriefs.com/biopharma-licensing-and-big-deal BioBriefs en 2026-10-07T16:32:08Z Biopharma licensing and big-deal partnerships https://biobriefs.com/clinical-stage-wins-and-near BioBriefs en 2026-10-07T16:32:08Z Clinical-stage wins and near-misses in oncology https://biobriefs.com/car-t-and-allogeneic-cell BioBriefs en 2026-10-07T16:32:08Z CAR-T and allogeneic cell therapy setbacks https://biobriefs.com/biotech-public-market-moves BioBriefs en 2026-10-07T16:32:08Z Biotech public-market moves https://biobriefs.com/regulatory-and-policy-pressure-on BioBriefs en 2026-10-07T16:32:08Z Regulatory and policy pressure on drug pricing transparency https://biobriefs.com/fundraising-for-next-generation-cell BioBriefs en 2026-10-07T16:32:08Z Fundraising for next-generation cell manufacturing https://biobriefs.com/big-trial-outcomes-in-cns BioBriefs en 2026-10-07T16:32:08Z Big trial outcomes in CNS drug development https://biobriefs.com/fda-linked-review-updates-and BioBriefs en 2026-10-07T16:32:08Z FDA-linked review updates and pipeline readouts in rare disease https://biobriefs.com/new-clinical-stage-diagnostics-and BioBriefs en 2026-10-07T16:32:08Z New clinical-stage diagnostics and evidence generation for immuno-oncology https://biobriefs.com/cellular-and-molecular-immunology-drug BioBriefs en 2026-10-07T16:32:08Z Cellular and molecular immunology drug target discovery https://biobriefs.com/parkinsons-disease-pipeline-update BioBriefs en 2026-10-07T14:31:44Z Parkinson’s disease pipeline update https://biobriefs.com/biopharma-dealmaking-and-platform-financing BioBriefs en 2026-10-07T14:31:44Z Biopharma dealmaking and platform financing https://biobriefs.com/biotech-exits-and-funding-crunch BioBriefs en 2026-10-07T14:31:44Z Biotech exits and funding crunch https://biobriefs.com/ai-governance-and-implementation-readiness BioBriefs en 2026-10-07T14:31:44Z AI governance and implementation readiness for healthcare https://biobriefs.com/healthcare-ai-infrastructure-and-reliability BioBriefs en 2026-10-07T14:31:44Z Healthcare AI infrastructure and reliability approaches https://biobriefs.com/open-data-push-for-ai BioBriefs en 2026-10-07T14:31:44Z Open data push for AI models in biology https://biobriefs.com/biotech-clinical-strategy-deepfakes-detection BioBriefs en 2026-10-07T14:31:44Z Biotech clinical strategy: deepfakes detection with privacy https://biobriefs.com/glp-1-cardiovascular-outcomes-in BioBriefs en 2026-10-07T14:31:44Z GLP-1 cardiovascular outcomes in sleep apnea https://biobriefs.com/oncology-drug-development-first-line BioBriefs en 2026-10-07T14:31:44Z Oncology drug development: first-line DLBCL win for Epkinly https://biobriefs.com/biotech-funding-landscape-forbion-raises BioBriefs en 2026-10-07T14:31:44Z Biotech funding landscape: Forbion raises €2.3B for new VC funds https://biobriefs.com/parkinsons-enzyme-replacement-licensing-and BioBriefs en 2026-10-07T10:32:02Z Parkinson’s enzyme replacement licensing and brain delivery push https://biobriefs.com/car-t-finance-shock-forces BioBriefs en 2026-10-07T10:32:02Z CAR-T finance shock forces Caribou to stop programs https://biobriefs.com/first-line-lymphoma-win-sets BioBriefs en 2026-10-07T10:32:02Z First-line lymphoma win sets up potential bispecific showdown https://biobriefs.com/shionogi-expands-rare-disease-portfolio BioBriefs en 2026-10-07T10:32:01Z Shionogi expands rare-disease portfolio via IntraBio acquisition https://biobriefs.com/regulatory-and-market-access-friction BioBriefs en 2026-10-07T10:32:01Z Regulatory and market-access friction: FTC targets price transparency failures https://biobriefs.com/vaccine-antibiotic-era-biology-ozone BioBriefs en 2026-10-07T10:32:01Z Vaccine/antibiotic-era biology: ozone/UV treatment may raise hormone disruption risk https://biobriefs.com/new-oncology-imaging-ai-and BioBriefs en 2026-10-07T10:32:01Z New oncology imaging AI and decision tools push toward pre-biopsy risk stratification https://biobriefs.com/clinical-trials-and-real-world BioBriefs en 2026-10-07T10:32:01Z Clinical trials and real-world evidence: epkinly/cell and radiopharma winners reshape care https://biobriefs.com/heme-bleeding-disorder-startup-funding BioBriefs en 2026-10-07T10:32:01Z Heme/bleeding disorder startup funding: oral therapy program launches https://biobriefs.com/foundational-biotech-innovation-non-invasive BioBriefs en 2026-10-07T10:32:01Z Foundational biotech innovation: non-invasive temporal interference for disorders of consciousness https://biobriefs.com/crispr-car-t-shutdown-at BioBriefs en 2026-10-07T09:31:49Z CRISPR CAR-T shutdown at Caribou after capital shortfall https://biobriefs.com/shionogi-buys-intrabio-to-expand BioBriefs en 2026-10-07T09:31:49Z Shionogi buys IntraBio to expand rare-disease portfolio https://biobriefs.com/phase-3-setbacks-for-arrivent BioBriefs en 2026-10-07T09:31:49Z Phase 3 setbacks for ArriVent lung cancer drug https://biobriefs.com/first-line-lymphoma-win-for BioBriefs en 2026-10-07T09:31:49Z First-line lymphoma win for Epkinly in Phase 3 https://biobriefs.com/hhs-launches-surpass-to-accelerate BioBriefs en 2026-10-07T09:31:49Z HHS launches SURPASS to accelerate adaptive clinical trial design https://biobriefs.com/ge-healthcare-to-acquire-sofie BioBriefs en 2026-10-07T09:31:49Z GE HealthCare to acquire Sofie Biosciences to expand PET radiopharmaceutical manufacturing https://biobriefs.com/living-pharmas-controllers-that-keep BioBriefs en 2026-10-07T09:31:49Z Living Pharmas: controllers that keep drug levels on target in the brain https://biobriefs.com/rougetx-raises-58m-to-develop BioBriefs en 2026-10-07T09:31:49Z RougeTx raises $58M to develop oral small molecule for HHT https://biobriefs.com/forbion-expands-biotech-vc-with BioBriefs en 2026-10-07T09:31:49Z Forbion expands biotech VC with €2.3B across two new funds https://biobriefs.com/arrivent-approvals-and-policy-signals BioBriefs en 2026-10-07T09:31:49Z ArriVent, approvals, and policy signals converge on cancer and pricing https://biobriefs.com/fda-approval-and-label-expansion BioBriefs en 2026-10-07T04:31:50Z FDA approval and label expansion for CLL first-line therapy https://biobriefs.com/caribou-pulls-back-on-allogeneic BioBriefs en 2026-10-07T04:31:50Z Caribou pulls back on allogeneic CAR-T programs amid financing pressure https://biobriefs.com/shionogi-expands-rare-disease-portfolio BioBriefs en 2026-10-07T04:31:50Z Shionogi expands rare-disease portfolio with IntraBio acquisition https://biobriefs.com/epkinly-wins-first-line-dlbcl BioBriefs en 2026-10-07T04:31:50Z Epkinly wins first-line DLBCL phase 3 and sets up a Roche head-to-head https://biobriefs.com/fda-fast-track-pilot-aims BioBriefs en 2026-10-07T04:31:50Z FDA fast-track pilot aims to reduce IND bottlenecks for clinical entry https://biobriefs.com/hhs-launches-surpass-to-use BioBriefs en 2026-10-07T04:31:50Z HHS launches SURPASS to use digital twins and adaptive controls for faster seamless trials https://biobriefs.com/ge-healthcare-buys-sofie-biosciences BioBriefs en 2026-10-07T04:31:50Z GE HealthCare buys Sofie Biosciences to expand U.S. radiopharmaceutical manufacturing https://biobriefs.com/carcinoma-immune-evasion-biology-highlighted BioBriefs en 2026-10-07T04:31:50Z Carcinoma immune evasion biology highlighted by SPP1 as a tumor “master switch” https://biobriefs.com/engineering-safer-earlier-diagnoses-with BioBriefs en 2026-10-07T04:31:50Z Engineering safer, earlier diagnoses with AI on imaging for gastric and prostate cancer https://biobriefs.com/drug-discovery-platform-funding-sensible BioBriefs en 2026-10-07T04:31:50Z Drug discovery platform funding: Sensible Biotechnologies secures $47M for naturally modified mRNA https://biobriefs.com/frontline-lymphoma-win-for-epkinly BioBriefs en 2026-10-06T21:31:53Z Frontline lymphoma win for Epkinly in first-line DLBCL https://biobriefs.com/fda-grants-frontline-cll-label BioBriefs en 2026-10-06T21:31:53Z FDA grants frontline CLL label expansion for Jaypirca (pirtobrutinib) https://biobriefs.com/vaxcytes-vax-31-clears-phase BioBriefs en 2026-10-06T21:31:53Z Vaxcyte’s VAX-31 clears Phase 3 endpoints in pneumococcal vaccine https://biobriefs.com/ge-healthcare-to-buy-sofie BioBriefs en 2026-10-06T21:31:53Z GE HealthCare to buy Sofie Biosciences to expand US PET radiopharmaceutical manufacturing https://biobriefs.com/caribou-pauses-development-and-reviews BioBriefs en 2026-10-06T21:31:53Z Caribou pauses development and reviews strategic alternatives for CAR-T programs https://biobriefs.com/arrivents-furmonertinib-fails-phase-3 BioBriefs en 2026-10-06T21:31:53Z ArriVent’s furmonertinib fails Phase 3 in EGFR exon 20 insertion lung cancer https://biobriefs.com/large-scale-fundraisings-forbion-lands BioBriefs en 2026-10-06T21:31:53Z Large-scale fundraisings: Forbion lands €2.3B for two new VC funds https://biobriefs.com/clinical-trials-infrastructure-hhs-launches BioBriefs en 2026-10-06T21:31:53Z Clinical trials infrastructure: HHS launches SURPASS to speed seamless trials https://biobriefs.com/fda-regulatory-process-expedited-ind BioBriefs en 2026-10-06T21:31:53Z FDA regulatory process: expedited IND pilot program 'Operation TrialBlazer' https://biobriefs.com/softer-regulatory-oversight-signals-back BioBriefs en 2026-10-06T21:31:53Z Softer regulatory oversight signals: 'back to basics' SEC enforcement shift https://biobriefs.com/fda-approval-expands-targeted-therapy BioBriefs en 2026-10-06T16:32:11Z FDA approval expands targeted therapy options in frontline CLL https://biobriefs.com/vaxcytes-pneumococcal-phase-3-readout BioBriefs en 2026-10-06T16:32:11Z Vaxcyte’s pneumococcal Phase 3 readout sets up a new late-cycle market showdown https://biobriefs.com/abbvie-and-genmab-extend-bispecific BioBriefs en 2026-10-06T16:32:11Z AbbVie and Genmab extend bispecific success into newly diagnosed DLBCL https://biobriefs.com/shionogi-doubles-down-on-rare BioBriefs en 2026-10-06T16:32:11Z Shionogi doubles down on rare diseases with $2B IntraBio acquisition https://biobriefs.com/gene-therapy-and-cell-therapy BioBriefs en 2026-10-06T16:32:11Z Gene therapy and cell therapy durability and safety become sharper policy signals https://biobriefs.com/ge-healthcare-expands-u-s BioBriefs en 2026-10-06T16:32:11Z GE HealthCare expands U.S. PET radiopharmaceutical manufacturing footprint https://biobriefs.com/fda-and-hhs-push-to BioBriefs en 2026-10-06T16:32:11Z FDA and HHS push to accelerate clinical trial start-up bottlenecks https://biobriefs.com/drug-development-risk-trial-failure BioBriefs en 2026-10-06T16:32:11Z Drug development risk: trial failure hits ArriVent’s exon 20 lung cancer program https://biobriefs.com/biotech-funding-and-platform-scale BioBriefs en 2026-10-06T16:32:11Z Biotech funding and platform scale-up: Sensible Biotechnologies raises to build mRNA manufacturing engine https://biobriefs.com/cell-therapy-platform-and-delivery BioBriefs en 2026-10-06T16:32:11Z Cell therapy platform and delivery tech: lipid nanoparticles move CAR instructions without viral vectors https://biobriefs.com/fda-approval-expands-first-line BioBriefs en 2026-10-06T14:32:16Z FDA approval expands first-line targeted therapy in CLL/SLL https://biobriefs.com/ge-healthcare-builds-u-s BioBriefs en 2026-10-06T14:32:16Z GE HealthCare builds U.S. radiopharma capacity via Sofie Biosciences acquisition https://biobriefs.com/shionogi-doubles-down-on-rare BioBriefs en 2026-10-06T14:32:16Z Shionogi doubles down on rare disease with $2B IntraBio buy https://biobriefs.com/car-t-pathway-safety-guidance BioBriefs en 2026-10-06T14:32:16Z CAR-T pathway safety guidance incorporates oral health practices https://biobriefs.com/vaxcytes-pneumococcal-vaccine-clears-phase BioBriefs en 2026-10-06T14:32:16Z Vaxcyte’s pneumococcal vaccine clears Phase 3 endpoints and lifts shares https://biobriefs.com/new-oncology-trial-evidence-reshapes BioBriefs en 2026-10-06T14:32:16Z New oncology trial evidence reshapes bladder cancer chemo sensitivity https://biobriefs.com/fda-expedites-ind-reviews-to BioBriefs en 2026-10-06T14:32:16Z FDA expedites IND reviews to reduce barriers for trial entry https://biobriefs.com/corporate-financing-accelerates-next-gen BioBriefs en 2026-10-06T14:32:16Z Corporate financing accelerates next-gen mRNA manufacturing platform https://biobriefs.com/clinical-data-and-real-world BioBriefs en 2026-10-06T14:32:16Z Clinical data and real-world evidence reinforce immunotherapy timing in breast cancer https://biobriefs.com/biotech-vc-and-ipo-activity BioBriefs en 2026-10-06T14:32:16Z Biotech VC and IPO activity highlights continued capital interest in targeted oncology assets https://biobriefs.com/fda-approval-expands-targeted-therapy BioBriefs en 2026-10-06T10:32:16Z FDA approval expands targeted therapy for untreated CLL https://biobriefs.com/phase-3-win-lifts-vaxcytes BioBriefs en 2026-10-06T10:32:16Z Phase 3 win lifts Vaxcyte’s pneumococcal vaccine—shares surge https://biobriefs.com/company-strategy-shionogi-expands-rare BioBriefs en 2026-10-06T10:32:16Z Company strategy: Shionogi expands rare-disease footprint with $2B IntraBio deal https://biobriefs.com/new-biotech-financing-rougetx-launches BioBriefs en 2026-10-06T10:32:16Z New biotech financing: RougeTx launches with $58M Series A for once-daily HHT https://biobriefs.com/regulatory-acceleration-fda-launches-expedited BioBriefs en 2026-10-06T10:32:16Z Regulatory acceleration: FDA launches expedited IND pilot tied to clinical bottleneck reduction https://biobriefs.com/payer-policy-and-access-medicaid BioBriefs en 2026-10-06T10:32:16Z Payer/policy and access: Medicaid patients abandon GLP-1 weight-loss therapy quickly https://biobriefs.com/clinical-evidence-psma-pet-ct BioBriefs en 2026-10-06T10:32:16Z Clinical evidence: PSMA PET/CT improves detection before biopsy in MRI-negative men https://biobriefs.com/trial-data-realism-clinical-risk BioBriefs en 2026-10-06T10:32:16Z Trial data realism: clinical risk scores cannot replace neurofilament biomarkers in ALS https://biobriefs.com/new-therapy-evidence-glp-1 BioBriefs en 2026-10-06T10:32:16Z New therapy evidence: GLP-1 receptor agonists linked to survival after traumatic brain injury surgery https://biobriefs.com/health-systems-and-operations-mount BioBriefs en 2026-10-06T10:32:16Z Health systems and operations: Mount Sinai deploys real-time EHR-to-EDC to cut trial data entry https://biobriefs.com/regulatory-approval-expands-targeted-therapy BioBriefs en 2026-10-06T09:33:02Z Regulatory approval expands targeted therapy in CLL https://biobriefs.com/pneumococcal-vaccine-phase-3-success BioBriefs en 2026-10-06T09:33:02Z Pneumococcal vaccine Phase 3 success pressures incumbents https://biobriefs.com/car-t-and-transplant-therapy BioBriefs en 2026-10-06T09:33:02Z CAR-T and transplant therapy-associated blood cancer risk characterization https://biobriefs.com/health-systems-and-commercialization-ai BioBriefs en 2026-10-06T09:33:02Z Health systems and commercialization: AI/real-world data validate early breast cancer immunotherapy https://biobriefs.com/rare-disease-m-a-and BioBriefs en 2026-10-06T09:33:02Z Rare disease M&A and platform moves: Shionogi expands with IntraBio https://biobriefs.com/manufacturing-and-regulatory-process-fda BioBriefs en 2026-10-06T09:33:02Z Manufacturing and regulatory process: FDA pauses hemophilia A drug review https://biobriefs.com/clinical-pipeline-and-oncology-mri BioBriefs en 2026-10-06T09:33:02Z Clinical pipeline and oncology: MRI-backed monitoring of early disease progression in breast cancer trials https://biobriefs.com/diagnostics-innovation-contrast-enhanced-ultrasound BioBriefs en 2026-10-06T09:33:02Z Diagnostics innovation: contrast-enhanced ultrasound expands lung cancer biopsy options https://biobriefs.com/fda-and-trial-administration-streamlined BioBriefs en 2026-10-06T09:33:02Z FDA and trial administration: streamlined IND pathway pilot aims to accelerate first-in-human starts https://biobriefs.com/imaging-guided-precision-in-urology BioBriefs en 2026-10-06T09:33:02Z Imaging-guided precision in urology: PSMA PET/CT biopsy detects clinically significant disease missed by MRI https://biobriefs.com/fda-decision-expands-frontline-cll BioBriefs en 2026-10-06T04:32:16Z FDA decision expands frontline CLL treatment https://biobriefs.com/rare-disease-m-a-accelerates BioBriefs en 2026-10-06T04:32:16Z Rare-disease M&A accelerates with Shionogi IntraBio deal https://biobriefs.com/pneumococcal-vaccine-phase-3-success BioBriefs en 2026-10-06T04:32:16Z Pneumococcal vaccine Phase 3 success sets up competitive pressure https://biobriefs.com/immune-engineering-guidance-updates-for BioBriefs en 2026-10-06T04:32:16Z Immune engineering guidance updates for severe autoimmune CAR T use https://biobriefs.com/new-clinical-imaging-approach-for BioBriefs en 2026-10-06T04:32:16Z New clinical imaging approach for follow-up after aneurysm rupture https://biobriefs.com/ai-validation-in-therapeutics-nerve BioBriefs en 2026-10-06T04:32:16Z AI validation in therapeutics: nerve stimulation modeling open-source https://biobriefs.com/gene-therapy-hearing-milestone-highlights BioBriefs en 2026-10-06T04:32:16Z Gene therapy hearing milestone highlights ongoing AAV progress https://biobriefs.com/regulatory-accelerant-fda-launches-expedited BioBriefs en 2026-10-06T04:32:16Z Regulatory accelerant: FDA launches expedited IND pilot for bottlenecks https://biobriefs.com/company-exit-genentechs-global-ai BioBriefs en 2026-10-06T04:32:16Z Company exit: Genentech’s global AI drug discovery head leaves https://biobriefs.com/funding-sensible-bio-raises-to BioBriefs en 2026-10-06T04:32:16Z Funding: Sensible Bio raises to build mRNA manufacturing platform https://biobriefs.com/fda-expands-frontline-cll-use BioBriefs en 2026-10-05T21:31:59Z FDA expands frontline CLL use of noncovalent BTK inhibitor https://biobriefs.com/shionogi-doubles-down-on-rare BioBriefs en 2026-10-05T21:31:59Z Shionogi doubles down on rare disease with IntraBio deal https://biobriefs.com/roche-and-alector-restart-parkinsons BioBriefs en 2026-10-05T21:31:59Z Roche and Alector restart Parkinson’s push with $100M upfront https://biobriefs.com/fda-uses-manufacturing-fixes-as BioBriefs en 2026-10-05T21:31:59Z FDA uses manufacturing fixes as trigger for hemophilia A review delay https://biobriefs.com/breye-raises-series-a-to BioBriefs en 2026-10-05T21:31:59Z Breye raises Series A to advance oral therapy for diabetic retinopathy https://biobriefs.com/vaxcyte-bets-on-next-gen BioBriefs en 2026-10-05T21:31:59Z Vaxcyte bets on next-gen pneumococcal vaccine in Phase 3 https://biobriefs.com/fda-launches-expedited-ind-pilot BioBriefs en 2026-10-05T21:31:59Z FDA launches expedited IND pilot to speed early trial entry https://biobriefs.com/swiss-clinical-trials-decline-as BioBriefs en 2026-10-05T21:31:59Z Swiss clinical trials decline as approvals and data laws slow access https://biobriefs.com/trial-adherence-fades-quickly-for BioBriefs en 2026-10-05T21:31:59Z Trial adherence fades quickly for Medicaid patients on GLP-1 weight-loss drugs https://biobriefs.com/bristol-myers-faces-analyst-pressure BioBriefs en 2026-10-05T21:31:59Z Bristol Myers faces analyst pressure over pipeline timing risk https://biobriefs.com/pneumococcal-vaccine-phase-3-win BioBriefs en 2026-10-05T16:31:49Z Pneumococcal vaccine Phase 3 win for Vaxcyte https://biobriefs.com/regulatory-expansion-for-jaypirca-in BioBriefs en 2026-10-05T16:31:49Z Regulatory expansion for Jaypirca in CLL https://biobriefs.com/rare-disease-dealmaking-shionogi-acquires BioBriefs en 2026-10-05T16:31:49Z Rare disease dealmaking: Shionogi acquires IntraBio for $2B https://biobriefs.com/neuroscience-collaboration-roche-pays-100m BioBriefs en 2026-10-05T16:31:49Z Neuroscience collaboration: Roche pays $100M upfront to Alector https://biobriefs.com/rare-kidney-and-liver-rare BioBriefs en 2026-10-05T16:31:49Z Rare kidney and liver rare disease co-development: CSL and Alentis https://biobriefs.com/funding-maturing-diabetic-retinopathy-pipeline BioBriefs en 2026-10-05T16:31:49Z Funding: maturing diabetic retinopathy pipeline with Breye Series A https://biobriefs.com/vaccine-and-oncology-mrd-strategy BioBriefs en 2026-10-05T16:31:49Z Vaccine and oncology MRD strategy: Signatera-guided trial AFT-70 NAVIGATE https://biobriefs.com/epigenetic-cancer-biology-irosustat-shows BioBriefs en 2026-10-05T16:31:49Z Epigenetic cancer biology: irosustat shows oral efficacy in resistant malaria https://biobriefs.com/rare-ocular-biomarker-discovery-for BioBriefs en 2026-10-05T16:31:49Z Rare ocular biomarker discovery for diabetic eye disease https://biobriefs.com/machine-learning-drug-r-d BioBriefs en 2026-10-05T16:31:49Z Machine-learning drug R&D: OrganoIDNet tracks CAR T activity in patient tumor organoids https://biobriefs.com/vaxcytes-phase-3-pneumococcal-vaccine BioBriefs en 2026-10-05T14:31:51Z Vaxcyte’s Phase 3 pneumococcal vaccine hit raises competitive stakes https://biobriefs.com/mrd-blood-monitoring-takes-aim BioBriefs en 2026-10-05T14:31:51Z MRD blood monitoring takes aim at toxicity reduction in early breast cancer https://biobriefs.com/csl-and-alentis-strike-a BioBriefs en 2026-10-05T14:31:51Z CSL and Alentis strike a rare mega-collaboration on rare fibrosis indications https://biobriefs.com/tarlatamab-expands-into-real-world BioBriefs en 2026-10-05T14:31:51Z Tarlatamab expands into real-world intracranial response for SCLC https://biobriefs.com/ai-and-biology-join-forces BioBriefs en 2026-10-05T14:31:51Z AI and biology join forces on in-cell RNA-to-DNA barcoding https://biobriefs.com/a-proteomics-map-identifies-subtypes BioBriefs en 2026-10-05T14:31:51Z A proteomics map identifies subtypes and a new driver in cervical cancer https://biobriefs.com/lung-cancer-biology-reveals-c BioBriefs en 2026-10-05T14:31:51Z Lung cancer biology reveals c-MET shapes immune suppression in spatial niches https://biobriefs.com/car-t-tracking-in-patient BioBriefs en 2026-10-05T14:31:51Z CAR T tracking in patient organoids gets real-time AI monitoring https://biobriefs.com/frailty-icu-biomarkers-and-prediction BioBriefs en 2026-10-05T14:31:51Z Frailty, ICU biomarkers, and prediction tools sharpen clinical risk models https://biobriefs.com/molecular-glue-drug-discovery-points BioBriefs en 2026-10-05T14:31:51Z Molecular glue drug discovery points to VAV1 degradation for blood cancers and autoimmunity https://biobriefs.com/immuno-oncology-and-car-t BioBriefs en 2026-10-05T10:31:50Z Immuno-oncology and CAR T monitoring in live tissue https://biobriefs.com/biopharma-partnerships-in-kidney-and BioBriefs en 2026-10-05T10:31:50Z Biopharma partnerships in kidney and liver fibrosis https://biobriefs.com/oncology-real-world-effectiveness-for BioBriefs en 2026-10-05T10:31:50Z Oncology real-world effectiveness for SCLC brain metastases https://biobriefs.com/clinical-trial-signal-for-resistance BioBriefs en 2026-10-05T10:31:50Z Clinical trial signal for resistance exercise in breast-cancer lymphedema https://biobriefs.com/ai-enabled-early-detection-in BioBriefs en 2026-10-05T10:31:50Z AI-enabled early detection in gastroenterology endoscopy https://biobriefs.com/real-world-cardiovascular-ai-for BioBriefs en 2026-10-05T10:31:50Z Real-world cardiovascular AI for AF ablation response https://biobriefs.com/computational-drug-discovery-meets-safety BioBriefs en 2026-10-05T10:31:50Z Computational drug discovery meets safety/feasibility for RNA-LNPs https://biobriefs.com/genome-sequencing-outperforms-standard-testing BioBriefs en 2026-10-05T10:31:50Z Genome sequencing outperforms standard testing for developmental disorders https://biobriefs.com/covid-19-vaccine-effectiveness-in BioBriefs en 2026-10-05T10:31:50Z COVID-19 vaccine effectiveness in dialysis patients https://biobriefs.com/biotech-industry-tariffs-raise-compliance BioBriefs en 2026-10-05T10:31:50Z Biotech industry: tariffs raise compliance and innovation uncertainty https://biobriefs.com/mrna-cancer-vaccine-response-extends BioBriefs en 2026-10-05T09:31:49Z mRNA cancer vaccine response extends to melanoma recurrence signals https://biobriefs.com/regulatory-and-market-pressure-us BioBriefs en 2026-10-05T09:31:49Z Regulatory and market pressure: US biotech tariffs increase uncertainty for innovators https://biobriefs.com/ai-redesigns-manufacturing-and-accelerates BioBriefs en 2026-10-05T09:31:49Z AI redesigns manufacturing and accelerates early drug development cycles https://biobriefs.com/clinical-genomics-genome-sequencing-outperforms BioBriefs en 2026-10-05T09:31:49Z Clinical genomics: genome sequencing outperforms standard testing in developmental disorders https://biobriefs.com/precision-oncology-mrna-and-advanced BioBriefs en 2026-10-05T09:31:49Z Precision oncology: mRNA and advanced modalities keep expanding beyond classic biomarker pipelines https://biobriefs.com/cardiovascular-imaging-ai-ct-clinical BioBriefs en 2026-10-05T09:31:49Z Cardiovascular imaging AI: CT/clinical models forecast who benefits from AF ablation https://biobriefs.com/biotech-partnering-csl-agrees-to BioBriefs en 2026-10-05T09:31:49Z Biotech partnering: CSL agrees to pay $355M upfront to co-develop Alentis anti-fibrosis drug https://biobriefs.com/neuro-oncology-real-world-evidence BioBriefs en 2026-10-05T09:31:49Z Neuro-oncology real-world evidence: tarlatamab intracranial activity in SCLC brain metastases https://biobriefs.com/diagnostics-ai-stomach-lining-visibility BioBriefs en 2026-10-05T09:31:49Z Diagnostics AI: stomach-lining visibility scoring boosts early gastric cancer detection https://biobriefs.com/oncology-imaging-tool-performance-mri BioBriefs en 2026-10-05T09:31:49Z Oncology imaging tool performance: MRI radiomics forecasts breast cancer chemotherapy response https://biobriefs.com/csl-locks-in-355m-to BioBriefs en 2026-10-05T04:31:44Z CSL locks in $355M to co-develop Alentis fibrosis drug https://biobriefs.com/tarlatamab-shows-intracranial-activity-in BioBriefs en 2026-10-05T04:31:44Z Tarlatamab shows intracranial activity in real-world E-SCLC https://biobriefs.com/metabolite-based-stroke-injury-pathway BioBriefs en 2026-10-05T04:31:44Z Metabolite-based stroke injury pathway sharpens prognosis signals https://biobriefs.com/mind-diet-trial-links-metabolic BioBriefs en 2026-10-05T04:31:44Z MIND diet trial links metabolic changes to antioxidant and mood benefits in type 2 diabetes https://biobriefs.com/blockchain-backed-ai-targets-financial BioBriefs en 2026-10-05T04:31:44Z Blockchain-backed AI targets financial crime with 96% accuracy claims https://biobriefs.com/exome-wide-epigenetic-validation-flags BioBriefs en 2026-10-05T04:31:44Z Exome-wide epigenetic validation flags pitfalls after aneurysm rupture https://biobriefs.com/artificial-immune-reset-startup-ai3bio BioBriefs en 2026-10-05T04:31:44Z Artificial immune reset startup ai3Bio pivots to inflammatory T cells https://biobriefs.com/fda-data-show-rising-harm BioBriefs en 2026-10-05T04:31:44Z FDA data show rising harm reports for sleep apnea oral appliances https://biobriefs.com/belgian-randomized-trial-strengthens-genome BioBriefs en 2026-10-05T04:31:44Z Belgian randomized trial strengthens genome sequencing for developmental disorders https://biobriefs.com/real-world-ipsc-modeling-gets BioBriefs en 2026-10-05T04:31:44Z Real-world iPSC modeling gets a long-read genome resource https://biobriefs.com/deal-and-financing-signals-in BioBriefs en 2026-10-04T21:32:14Z Deal and financing signals in pharma https://biobriefs.com/regenerative-autophagy-control-in-disease BioBriefs en 2026-10-04T21:32:14Z Regenerative autophagy control in disease biology https://biobriefs.com/autophagy-master-regulator-becomes-drug BioBriefs en 2026-10-04T21:32:14Z Autophagy master regulator becomes drug target https://biobriefs.com/cancer-imaging-biomarkers-for-relapse BioBriefs en 2026-10-04T21:32:14Z Cancer imaging biomarkers for relapse prediction https://biobriefs.com/precision-delivery-and-computational-screening BioBriefs en 2026-10-04T21:32:14Z Precision delivery and computational screening for RNA-LNPs https://biobriefs.com/clinical-protocol-optimization-in-oncology BioBriefs en 2026-10-04T21:32:14Z Clinical protocol optimization in oncology imaging https://biobriefs.com/drug-safety-and-surveillance-signals BioBriefs en 2026-10-04T21:32:14Z Drug-safety and surveillance signals in biologics https://biobriefs.com/innovative-clinical-strategy-in-hematologic BioBriefs en 2026-10-04T21:32:14Z Innovative clinical strategy in hematologic oncology https://biobriefs.com/regimen-timing-and-combination-rationale BioBriefs en 2026-10-04T21:32:14Z Regimen timing and combination rationale in breast cancer https://biobriefs.com/drug-delivery-and-biosafety-for BioBriefs en 2026-10-04T21:32:14Z Drug-delivery and biosafety for nanomedicine https://biobriefs.com/oncology-immunotherapy-chemo-improves-outcomes BioBriefs en 2026-10-04T16:31:39Z Oncology: immunotherapy + chemo improves outcomes in recurrent cervical cancer https://biobriefs.com/neurology-intranasal-bmp2-6-aims BioBriefs en 2026-10-04T16:31:39Z Neurology: intranasal BMP2/6 aims to slow dopamine neuron loss in Parkinson’s models https://biobriefs.com/hematology-oncology-trials-kidney-aimed BioBriefs en 2026-10-04T16:31:39Z Hematology/Oncology trials: kidney-aimed immunotherapy and first-line signals in CLL https://biobriefs.com/medical-imaging-and-diagnostics-breath BioBriefs en 2026-10-04T16:31:39Z Medical imaging and diagnostics: breath test reaches high accuracy for lung cancer detection https://biobriefs.com/cancer-biomarkers-and-risk-models BioBriefs en 2026-10-04T16:31:39Z Cancer biomarkers and risk models: emotional distress predicts survival in lung cancer surgery patients https://biobriefs.com/regenerative-neuroprotective-engineering-engineered-exosomes BioBriefs en 2026-10-04T16:31:39Z Regenerative/neuroprotective engineering: engineered exosomes for spinal cord injury https://biobriefs.com/rare-disease-therapy-approach-gene BioBriefs en 2026-10-04T16:31:39Z Rare disease therapy approach: gene-targeted complement silencing in myasthenia gravis https://biobriefs.com/glp-1-obesity-evidence-nih BioBriefs en 2026-10-04T16:31:39Z GLP-1 obesity evidence: NIH backs $4M study on weight regain after stopping GLP-1 drugs https://biobriefs.com/platform-innovation-single-clone-selection BioBriefs en 2026-10-04T16:31:39Z Platform/innovation: single-clone selection improves manufacturability for cell therapy https://biobriefs.com/regulatory-science-fda-plans-to BioBriefs en 2026-10-04T16:31:39Z Regulatory science: FDA plans to add aging and longevity to FARS update https://biobriefs.com/parkinsons-disease-protein-therapy BioBriefs en 2026-10-04T14:31:45Z Parkinson’s disease protein therapy https://biobriefs.com/cancer-care-quality-and-survival BioBriefs en 2026-10-04T14:31:45Z Cancer care quality and survival signals from patient experience https://biobriefs.com/next-generation-prostate-cancer-diagnostics BioBriefs en 2026-10-04T14:31:45Z Next-generation prostate cancer diagnostics and therapy targeting VEGF biology https://biobriefs.com/genomics-and-cell-fate-immune BioBriefs en 2026-10-04T14:31:45Z Genomics and cell fate: immune system boundary reshaped https://biobriefs.com/complement-inhibition-therapy-in-myasthenia BioBriefs en 2026-10-04T14:31:45Z Complement inhibition therapy in myasthenia gravis https://biobriefs.com/cardiometabolic-and-cardiovascular-drug-strategy BioBriefs en 2026-10-04T14:31:45Z Cardiometabolic and cardiovascular drug strategy: GLP-1 discontinuation weight regain https://biobriefs.com/oncology-engineering-improved-liver-mri BioBriefs en 2026-10-04T14:31:45Z Oncology engineering: improved liver MRI for ablation monitoring https://biobriefs.com/neonatal-vascular-access-standardization-in BioBriefs en 2026-10-04T14:31:45Z Neonatal vascular access standardization in Europe https://biobriefs.com/regulatory-science-fda-pushes-aging BioBriefs en 2026-10-04T14:31:45Z Regulatory science: FDA pushes aging and longevity endpoints https://biobriefs.com/biotech-funding-and-pipeline-pressure BioBriefs en 2026-10-04T14:31:45Z Biotech funding and pipeline pressure in CAR-T https://biobriefs.com/fda-regulatory-science-for-aging BioBriefs en 2026-10-04T10:31:45Z FDA regulatory science for aging and longevity https://biobriefs.com/clinical-oncology-new-evidence-in BioBriefs en 2026-10-04T10:31:45Z Clinical oncology: new evidence in metastatic breast cancer and breast cancer care de-escalation https://biobriefs.com/fda-backed-trial-modernization-and BioBriefs en 2026-10-04T10:31:45Z FDA-backed trial modernization and accelerated clinical development https://biobriefs.com/biotech-finance-circles-raises-to BioBriefs en 2026-10-04T10:31:45Z Biotech finance: Circles raises to advance cyclin D1 program https://biobriefs.com/regulatory-and-company-execution-risk BioBriefs en 2026-10-04T10:31:45Z Regulatory and company execution risk: Aviceda to wind down after Phase 2 failure https://biobriefs.com/immuno-oncology-strategy-complement-footprints BioBriefs en 2026-10-04T10:31:45Z Immuno-oncology strategy: complement footprints and macrophages https://biobriefs.com/hematology-pirtobrutinib-data-and-the BioBriefs en 2026-10-04T10:31:45Z Hematology: pirtobrutinib data and the CLL treatment order debate https://biobriefs.com/diagnostics-breath-testing-for-lung BioBriefs en 2026-10-04T10:31:45Z Diagnostics: breath testing for lung cancer with high reported accuracy https://biobriefs.com/ir-oncology-particulate-delivery-to BioBriefs en 2026-10-04T10:31:45Z IR/oncology: particulate delivery to treat breast cancer liver metastases https://biobriefs.com/cellular-therapy-manufacturing-and-portfolio BioBriefs en 2026-10-04T10:31:45Z Cellular therapy manufacturing and portfolio momentum: CAR engineering and trial updates https://biobriefs.com/aviceda-therapeutics-winds-down-after BioBriefs en 2026-10-04T09:32:26Z Aviceda Therapeutics winds down after Phase 2 miss https://biobriefs.com/fda-regulatory-science-flags-aging BioBriefs en 2026-10-04T09:32:26Z FDA regulatory science flags aging and longevity for next FARS update https://biobriefs.com/clinical-trial-funding-and-modernization BioBriefs en 2026-10-04T09:32:26Z Clinical trial funding and modernization: FDA opens CDER trial modernization office https://biobriefs.com/fda-safety-scrutiny-expands-in BioBriefs en 2026-10-04T09:32:26Z FDA safety scrutiny expands in biologics database after hair-loss signal https://biobriefs.com/deal-momentum-novartis-expands-in BioBriefs en 2026-10-04T09:32:26Z Deal momentum: Novartis expands in vivo autoimmune T-cell targeting with Abogen https://biobriefs.com/funding-circle-raises-92-5m BioBriefs en 2026-10-04T09:32:26Z Funding: Circle raises $92.5M to move cyclin D1 program ahead https://biobriefs.com/oncology-pipeline-reads-immix-interim BioBriefs en 2026-10-04T09:32:26Z Oncology pipeline reads: Immix interim data drives $125M offering https://biobriefs.com/cancer-innovation-stealth-cancer-vaccine BioBriefs en 2026-10-04T09:32:26Z Cancer innovation: stealth cancer vaccine approach using camouflaged nanoparticles https://biobriefs.com/hematology-trial-landscape-pirtobrutinib-sequence BioBriefs en 2026-10-04T09:32:26Z Hematology trial landscape: pirtobrutinib sequence debate in CLL https://biobriefs.com/clinical-evidence-glp-1-weight BioBriefs en 2026-10-04T09:32:26Z Clinical evidence: GLP-1 weight-loss discontinuation triggers NIH-backed study https://biobriefs.com/autoimmune-rna-therapeutics-scaled-by BioBriefs en 2026-10-04T04:31:44Z Autoimmune RNA therapeutics scaled by big pharma dealmaking https://biobriefs.com/biotech-funding-anacardio-advances-an BioBriefs en 2026-10-04T04:31:44Z Biotech funding: AnaCardio advances an oral heart-failure candidate into Phase IIb https://biobriefs.com/clinical-oncology-giredestrant-plus-everolimus BioBriefs en 2026-10-04T04:31:44Z Clinical oncology: Giredestrant plus everolimus extends survival in metastatic breast cancer https://biobriefs.com/regulatory-and-innovation-policy-fda BioBriefs en 2026-10-04T04:31:44Z Regulatory and innovation policy: FDA signals aging and longevity as FARS focus https://biobriefs.com/biopharma-deal-pipeline-ai-pathology BioBriefs en 2026-10-04T04:31:44Z Biopharma deal pipeline: AI pathology partnerships for NSCLC companion diagnostics https://biobriefs.com/federal-funding-environment-nih-issues BioBriefs en 2026-10-04T04:31:44Z Federal funding environment: NIH issues fewer grant awards amid process opacity https://biobriefs.com/biopharma-pipeline-failure-aviceda-to BioBriefs en 2026-10-04T04:31:44Z Biopharma pipeline failure: Aviceda to shut down after Phase 2 setback https://biobriefs.com/imaging-innovation-pet-based-metabolic BioBriefs en 2026-10-04T04:31:44Z Imaging innovation: PET-based metabolic scoring improves lymphoma risk stratification https://biobriefs.com/car-t-manufacturing-economics-convergence BioBriefs en 2026-10-04T04:31:44Z CAR-T manufacturing economics: convergence on syn/engineering for persistence and immune effects https://biobriefs.com/clinical-pain-and-anxiety-care BioBriefs en 2026-10-04T04:31:44Z Clinical pain and anxiety care: randomized trial supports intranasal sedative spray in children https://biobriefs.com/novartis-expands-china-origin-mrna BioBriefs en 2026-10-03T21:31:45Z Novartis expands China-origin mRNA T-cell engager deal https://biobriefs.com/phase-3-evera-confirms-oral BioBriefs en 2026-10-03T21:31:45Z Phase 3 evERA confirms oral giredestrant plus everolimus survival gain in metastatic breast cancer https://biobriefs.com/biotech-financing-immix-car-t BioBriefs en 2026-10-03T21:31:45Z Biotech financing: Immix CAR-T offering follows interim NEXICART-2 amyloidosis response https://biobriefs.com/clinical-development-funding-anacardio-raises BioBriefs en 2026-10-03T21:31:45Z Clinical development funding: AnaCardio raises €62.5M for oral AC01 in advanced HFrEF https://biobriefs.com/regulatory-science-fda-to-highlight BioBriefs en 2026-10-03T21:31:45Z Regulatory science: FDA to highlight aging and longevity in next FARS update https://biobriefs.com/ai-in-clinical-diagnostics-imagene BioBriefs en 2026-10-03T21:31:45Z AI in clinical diagnostics: Imagene and CellCarta expand AI pathology CDx partnership for NSCLC https://biobriefs.com/cancer-care-targeted-therapy-regimen BioBriefs en 2026-10-03T21:31:45Z Cancer care: targeted therapy regimen delivers 97% event-free survival signal in early-stage Hodgkin lymphoma https://biobriefs.com/bioethics-and-evidence-standards-ai BioBriefs en 2026-10-03T21:31:45Z Bioethics and evidence standards: AI in the operating room faces “evidence not ready” critique https://biobriefs.com/biopharma-funding-and-platform-building BioBriefs en 2026-10-03T21:31:45Z Biopharma funding and platform building: Parakeet Health raises $10M for conversational agentic platform https://biobriefs.com/genetic-tool-for-cancer-sampling BioBriefs en 2026-10-03T21:31:45Z Genetic tool for cancer sampling: “Genetic barcodes” show tumor heterogeneity missed by biopsies https://biobriefs.com/fda-regulatory-modernization-for-clinical BioBriefs en 2026-10-03T16:31:40Z FDA regulatory modernization for clinical trials https://biobriefs.com/ai-powered-immunology-and-drug BioBriefs en 2026-10-03T16:31:40Z AI-powered immunology and drug discovery dealmaking https://biobriefs.com/cancer-immunotherapy-pipeline-financing BioBriefs en 2026-10-03T16:31:40Z Cancer immunotherapy pipeline financing https://biobriefs.com/biotech-startup-funding-and-lead BioBriefs en 2026-10-03T16:31:40Z Biotech startup funding and lead reprioritization https://biobriefs.com/regulatory-scrutiny-and-trial-failure BioBriefs en 2026-10-03T16:31:40Z Regulatory scrutiny and trial-failure outcomes in ophthalmology https://biobriefs.com/new-clinical-trial-results-in BioBriefs en 2026-10-03T16:31:40Z New clinical trial results in CLL and treatment sequencing questions https://biobriefs.com/heart-failure-therapeutics-funding-for BioBriefs en 2026-10-03T16:31:40Z Heart failure therapeutics funding for late-stage preparation https://biobriefs.com/ai-pathology-collaboration-to-speed BioBriefs en 2026-10-03T16:31:40Z AI pathology collaboration to speed companion diagnostics https://biobriefs.com/trade-and-pharma-manufacturing-expansion BioBriefs en 2026-10-03T16:31:40Z Trade and pharma manufacturing expansion https://biobriefs.com/us-vaccine-litigation-risk-for BioBriefs en 2026-10-03T16:31:40Z US vaccine litigation risk for Pfizer https://biobriefs.com/mrna-in-autoimmune-targeting-novartis BioBriefs en 2026-10-03T14:32:45Z mRNA in autoimmune targeting: Novartis-Abogen deal reshapes next wave https://biobriefs.com/regulatory-update-fda-opens-clinical BioBriefs en 2026-10-03T14:32:45Z Regulatory update: FDA opens clinical trial modernization office https://biobriefs.com/geographic-atrophy-retreat-aviceda-winds BioBriefs en 2026-10-03T14:32:45Z Geographic atrophy retreat: Aviceda winds down after Phase 2 failure https://biobriefs.com/clinical-development-funding-anacardio-raises BioBriefs en 2026-10-03T14:32:45Z Clinical development funding: AnaCardio raises to advance oral heart failure therapy https://biobriefs.com/oncology-efficacy-signal-immix-interim BioBriefs en 2026-10-03T14:32:45Z Oncology efficacy signal: Immix interim NXC-201 readout drives capital market action https://biobriefs.com/clinical-failure-in-cancer-immunotherapy BioBriefs en 2026-10-03T14:32:45Z Clinical failure in cancer immunotherapy: IDO1 inhibitor plus melanoma vaccine misses target https://biobriefs.com/regulatory-and-trial-evidence-for BioBriefs en 2026-10-03T14:32:45Z Regulatory and trial evidence for precision oncology: MRI-based sarcoma response prediction https://biobriefs.com/ai-diagnostics-and-companion-diagnostics BioBriefs en 2026-10-03T14:32:45Z AI + diagnostics and companion diagnostics: CellCarta and Imagene expand NSCLC CDx workflow partnership https://biobriefs.com/clinical-infrastructure-and-oncology-operations BioBriefs en 2026-10-03T14:32:45Z Clinical infrastructure and oncology operations: trial-recruitment ‘momentum’ after referral https://biobriefs.com/rare-disease-genomics-and-gene BioBriefs en 2026-10-03T14:32:45Z Rare disease genomics and gene editing: Intellia’s lonvoguran ziclumeran gets BLA approval https://biobriefs.com/large-pharma-expands-china-fueled BioBriefs en 2026-10-03T10:31:52Z Large pharma expands China-fueled immunology pipeline https://biobriefs.com/novartis-licenses-abogens-mrna-t BioBriefs en 2026-10-03T10:31:52Z Novartis licenses Abogen’s mRNA T-cell engager for autoimmune reset https://biobriefs.com/aviceda-shuts-down-after-geographic BioBriefs en 2026-10-03T10:31:52Z Aviceda shuts down after geographic atrophy Phase 2 failure https://biobriefs.com/nih-grantmaking-hits-multi-year BioBriefs en 2026-10-03T10:31:52Z NIH grantmaking hits multi-year low as award counts fall https://biobriefs.com/fda-expands-longevity-agenda-in BioBriefs en 2026-10-03T10:31:52Z FDA expands longevity agenda in updated FARS framework https://biobriefs.com/fda-opens-clinical-trial-modernization BioBriefs en 2026-10-03T10:31:52Z FDA opens clinical trial modernization office in CDER https://biobriefs.com/corporate-financing-anacardio-raises-to BioBriefs en 2026-10-03T10:31:52Z Corporate financing: AnaCardio raises to advance oral heart failure drug into Phase 2b https://biobriefs.com/biotech-investing-immix-presses-forward BioBriefs en 2026-10-03T10:31:52Z Biotech investing: Immix presses forward after NXC-201 interim readout and launches offering https://biobriefs.com/clinical-milestone-lonvoguran-ziclumeran-clears BioBriefs en 2026-10-03T10:31:52Z Clinical milestone: Lonvoguran ziclumeran clears Phase 3 and wins HAE BLA approval https://biobriefs.com/regulatory-focus-pfizers-litfulo-pivots BioBriefs en 2026-10-03T10:31:52Z Regulatory focus: Pfizer’s Litfulo pivots toward vitiligo market authorization https://biobriefs.com/in-vivo-gene-editing-scores BioBriefs en 2026-10-03T09:31:45Z In vivo gene editing scores US approval for hereditary angioedema https://biobriefs.com/big-pharma-locks-in-next BioBriefs en 2026-10-03T09:31:45Z Big Pharma locks in next-gen autoimmune mRNA engager programs https://biobriefs.com/sanofi-and-regeneron-extend-long BioBriefs en 2026-10-03T09:31:45Z Sanofi and Regeneron extend long-acting immunology strategy https://biobriefs.com/circuit-level-data-and-ai BioBriefs en 2026-10-03T09:31:45Z Circuit-level data and AI validation partnerships move toward NSCLC companion diagnostics https://biobriefs.com/fda-builds-a-dedicated-clinical BioBriefs en 2026-10-03T09:31:45Z FDA builds a dedicated clinical trial modernization office in CDER https://biobriefs.com/new-funds-back-late-stage BioBriefs en 2026-10-03T09:31:45Z New funds back late-stage-ready heart failure program https://biobriefs.com/clinical-pipeline-hit-signals-aviceda BioBriefs en 2026-10-03T09:31:45Z Clinical pipeline hit signals Aviceda shutdown after Phase 2 failure https://biobriefs.com/oncology-biomarkers-blood-inflammation-scores BioBriefs en 2026-10-03T09:31:45Z Oncology biomarkers: blood inflammation scores forecast spread in vulvar cancer https://biobriefs.com/neoadjuvant-strategy-delivers-real-world BioBriefs en 2026-10-03T09:31:45Z Neoadjuvant strategy delivers real-world tumor response gains in rectal cancer https://biobriefs.com/nih-grantmaking-issues-fewer-awards BioBriefs en 2026-10-03T09:31:45Z NIH grantmaking issues: fewer awards despite stable obligations https://biobriefs.com/regulatory-acceleration-for-longevity-and BioBriefs en 2026-10-03T04:31:43Z Regulatory acceleration for longevity and clinical trial modernization https://biobriefs.com/large-pharma-revenue-bets-on BioBriefs en 2026-10-03T04:31:43Z Large pharma revenue bets on next-generation immuno-oncology and autoimmune platforms https://biobriefs.com/oncology-diagnostics-and-trial-enabling BioBriefs en 2026-10-03T04:31:43Z Oncology diagnostics and trial-enabling AI move toward clinical development https://biobriefs.com/crispr-approval-for-hereditary-angioedema BioBriefs en 2026-10-03T04:31:43Z CRISPR approval for hereditary angioedema and implications for genome-editing durability https://biobriefs.com/funding-clinical-stage-heart-failure BioBriefs en 2026-10-03T04:31:43Z Funding: clinical-stage heart failure program advances into Phase IIb readiness https://biobriefs.com/regulatory-and-market-signals-pfizers BioBriefs en 2026-10-03T04:31:43Z Regulatory and market signals: Pfizer’s Phase 3 vitiligo pill heads toward FDA and EMA submissions https://biobriefs.com/immunology-dealmaking-sanofi-extends-regeneron BioBriefs en 2026-10-03T04:31:43Z Immunology dealmaking: Sanofi extends Regeneron antibody alliance toward next-gen Dupixent successors https://biobriefs.com/us-policy-pressure-nih-grant BioBriefs en 2026-10-03T04:31:43Z US policy pressure: NIH grant awards fall while funding uncertainty persists https://biobriefs.com/company-pipeline-risk-aviceda-winds BioBriefs en 2026-10-03T04:31:43Z Company pipeline risk: Aviceda winds down after Phase 2 setback https://biobriefs.com/clinical-caution-on-therapy-timing BioBriefs en 2026-10-03T04:31:43Z Clinical caution on therapy timing and immune-related risks https://biobriefs.com/crispr-approval-in-hereditary-angioedema BioBriefs en 2026-10-02T21:32:09Z CRISPR approval in hereditary angioedema https://biobriefs.com/large-pharma-licensing-abogen-mrna BioBriefs en 2026-10-02T21:32:09Z Large pharma licensing: Abogen mRNA T-cell engager for autoimmune disease https://biobriefs.com/regulatory-science-shift-fda-fars BioBriefs en 2026-10-02T21:32:09Z Regulatory science shift: FDA FARS update to address aging and longevity https://biobriefs.com/clinical-fail-impacting-development-plans BioBriefs en 2026-10-02T21:32:09Z Clinical fail impacting development plans: Aviceda shuts down after Phase 2 miss https://biobriefs.com/heart-failure-funding-round-for BioBriefs en 2026-10-02T21:32:09Z Heart failure funding round for oral calcium-sensitizing agent https://biobriefs.com/immunology-deal-expansion-sanofi-and BioBriefs en 2026-10-02T21:32:09Z Immunology deal expansion: Sanofi and Regeneron deepen long-acting antibody pipeline https://biobriefs.com/clinical-efficacy-signal-pfizers-tilrekimig BioBriefs en 2026-10-02T21:32:09Z Clinical efficacy signal: Pfizer’s tilrekimig posts strong Phase 2 eczema clearance https://biobriefs.com/oncology-imaging-and-biomarker-ai BioBriefs en 2026-10-02T21:32:09Z Oncology imaging and biomarker AI: PSMA PET tracer finds prostate-to-liver cancer crossover use https://biobriefs.com/clinical-pipeline-attrition-and-portfolio BioBriefs en 2026-10-02T21:32:09Z Clinical pipeline attrition and portfolio risk: Lilly reduces investment in Foghorn synthetic lethality program https://biobriefs.com/biotech-innovation-funding-parakeet-health BioBriefs en 2026-10-02T21:32:09Z Biotech innovation funding: Parakeet Health raises $10M for automated patient outreach https://biobriefs.com/big-pharma-strikes-major-rna BioBriefs en 2026-10-02T16:32:25Z Big pharma strikes major RNA deal for autoimmune T-cell engager https://biobriefs.com/phase-2-readout-lifts-pfizer BioBriefs en 2026-10-02T16:32:25Z Phase 2 readout lifts Pfizer into stronger eczema competition https://biobriefs.com/crispr-therapy-secures-fda-bla BioBriefs en 2026-10-02T16:32:25Z CRISPR therapy secures FDA BLA approval for hereditary angioedema https://biobriefs.com/new-biotech-funding-anacardio-pushes BioBriefs en 2026-10-02T16:32:25Z New Biotech funding: AnaCardio pushes oral HFrEF drug to Phase IIb https://biobriefs.com/immuno-oncology-fails-to-deliver BioBriefs en 2026-10-02T16:32:25Z Immuno-oncology fails to deliver expected T-cell boost in melanoma https://biobriefs.com/clinical-study-challenges-use-of BioBriefs en 2026-10-02T16:32:25Z Clinical study challenges use of home AI for pediatric sleep apnea screening https://biobriefs.com/ai-pathology-partnerships-push-nsclc BioBriefs en 2026-10-02T16:32:25Z AI pathology partnerships push NSCLC companion diagnostic programs forward https://biobriefs.com/hospital-bedside-innovation-tiny-drug BioBriefs en 2026-10-02T16:32:25Z Hospital bedside innovation: tiny drug-eluting implant cuts glaucoma drops in real-world data https://biobriefs.com/precision-immunology-gut-microbes-may BioBriefs en 2026-10-02T16:32:25Z Precision immunology: Gut microbes may shape response via regulatory B cells https://biobriefs.com/platform-capability-talus-bio-releases BioBriefs en 2026-10-02T16:32:25Z Platform capability: Talus Bio releases structure-free AI model for unstructured proteome binding https://biobriefs.com/novartis-and-abogen-deepen-rna BioBriefs en 2026-10-02T14:31:51Z Novartis and Abogen deepen RNA-platform autoimmune ambitions https://biobriefs.com/in-vivo-crispr-earns-fda BioBriefs en 2026-10-02T14:31:51Z In-vivo CRISPR earns FDA clearance for hereditary angioedema https://biobriefs.com/anacardio-raises-fresh-capital-for BioBriefs en 2026-10-02T14:31:51Z AnaCardio raises fresh capital for Phase IIb advanced heart failure program https://biobriefs.com/immune-checkpoint-targeting-shows-mixed BioBriefs en 2026-10-02T14:31:51Z Immune checkpoint targeting shows mixed efficacy – IDO1 inhibitor plus vaccine disappoints in melanoma https://biobriefs.com/sanofi-and-regeneron-expand-next BioBriefs en 2026-10-02T14:31:51Z Sanofi and Regeneron expand next-generation Dupixent-style immunology pipeline https://biobriefs.com/lilly-delivers-another-obesity-cardiometabolic BioBriefs en 2026-10-02T14:31:51Z Lilly delivers another obesity-cardiometabolic differentiation with amylin–GLP-1/GIP combo https://biobriefs.com/abogen-and-rna-platform-deal BioBriefs en 2026-10-02T14:31:51Z Abogen and RNA platform deal confirmation – second reporting thread https://biobriefs.com/venture-backing-for-risk-limited BioBriefs en 2026-10-02T14:31:51Z Venture backing for risk-limited heart failure oral therapy https://biobriefs.com/fda-safety-clinical-signal-in BioBriefs en 2026-10-02T14:31:51Z FDA safety/clinical signal in advanced cancer immunotherapy adverse event tracking https://biobriefs.com/policymaker-shift-hhs-launches-programs BioBriefs en 2026-10-02T14:31:51Z Policymaker shift: HHS launches programs to speed clinical trials in response to foreign competition https://biobriefs.com/regulatory-milestone-in-vivo-crispr BioBriefs en 2026-10-02T10:32:06Z Regulatory milestone: in vivo CRISPR for hereditary angioedema https://biobriefs.com/immunology-dealmaking-sanofi-and-regeneron BioBriefs en 2026-10-02T10:32:06Z Immunology dealmaking: Sanofi and Regeneron expand long-acting antibody pipeline https://biobriefs.com/clinical-development-lilly-advances-amylin BioBriefs en 2026-10-02T10:32:06Z Clinical development: Lilly advances amylin–tirzepatide combination data https://biobriefs.com/ai-drug-discovery-infrastructure-talus BioBriefs en 2026-10-02T10:32:06Z AI + drug discovery infrastructure: Talus Bio launches structure-free binding model https://biobriefs.com/biotech-finance-kallyope-rebrands-as BioBriefs en 2026-10-02T10:32:06Z Biotech finance: Kallyope rebrands as TriGemX and secures $94M https://biobriefs.com/regulatory-policy-us-hhs-launches BioBriefs en 2026-10-02T10:32:06Z Regulatory/policy: US HHS launches programs to speed clinical trials https://biobriefs.com/rare-disease-oncology-fda-approval BioBriefs en 2026-10-02T10:32:06Z Rare disease/oncology: FDA approval is not the only signal—radioligand and imaging progress https://biobriefs.com/oncology-cryoablation-shows-promise-for BioBriefs en 2026-10-02T10:32:06Z Oncology: cryoablation shows promise for oligoprogressive disease https://biobriefs.com/safety-pharmacovigilance-immune-checkpoint-blockade BioBriefs en 2026-10-02T10:32:06Z Safety pharmacovigilance: immune checkpoint blockade linked to rare platelet disorder https://biobriefs.com/venture-startups-parakeet-health-raises BioBriefs en 2026-10-02T10:32:06Z Venture/startups: Parakeet Health raises $10M for AI patient outreach automation https://biobriefs.com/gene-editing-approval-for-hereditary BioBriefs en 2026-10-02T09:31:46Z Gene editing approval for hereditary angioedema https://biobriefs.com/us-policy-to-speed-up BioBriefs en 2026-10-02T09:31:46Z US policy to speed up clinical trials https://biobriefs.com/major-immunology-partnership-expansion-around BioBriefs en 2026-10-02T09:31:46Z Major immunology partnership expansion around Dupixent targets https://biobriefs.com/trigemx-funding-and-rebrand-for BioBriefs en 2026-10-02T09:31:46Z TriGemX funding and rebrand for migraine therapy development https://biobriefs.com/large-venture-bet-for-gene BioBriefs en 2026-10-02T09:31:46Z Large venture bet for gene therapy and clinical pipeline timelines https://biobriefs.com/fda-and-clinical-pipeline-watch BioBriefs en 2026-10-02T09:31:46Z FDA and clinical pipeline watch for late-2026 decisions https://biobriefs.com/precision-oncology-imaging-guidance-for BioBriefs en 2026-10-02T09:31:46Z Precision oncology imaging guidance for prostate cancer https://biobriefs.com/clinical-efficacy-signal-for-venetoclax BioBriefs en 2026-10-02T09:31:46Z Clinical efficacy signal for venetoclax combination in Waldenström’s https://biobriefs.com/oncology-clinical-trial-signal-chemotherapy BioBriefs en 2026-10-02T09:31:46Z Oncology clinical trial signal: chemotherapy plus checkpoint in lung cancer https://biobriefs.com/energy-and-biotech-adjacent-manufacturing BioBriefs en 2026-10-02T09:31:46Z Energy and biotech-adjacent manufacturing: CHO cell selection platform https://biobriefs.com/regulatory-approval-and-late-stage BioBriefs en 2026-10-02T04:31:51Z Regulatory approval and late-stage progress https://biobriefs.com/immunology-partnerships-to-extend-blockbuster BioBriefs en 2026-10-02T04:31:51Z Immunology partnerships to extend blockbuster momentum https://biobriefs.com/clinical-safety-signals-in-immunotherapy BioBriefs en 2026-10-02T04:31:51Z Clinical safety signals in immunotherapy https://biobriefs.com/biomanufacturing-process-innovation BioBriefs en 2026-10-02T04:31:51Z Biomanufacturing process innovation https://biobriefs.com/ai-enabled-clinical-diagnostics-and BioBriefs en 2026-10-02T04:31:51Z AI-enabled clinical diagnostics and risk stratification https://biobriefs.com/oncology-immunotherapy-delivery-and-response BioBriefs en 2026-10-02T04:31:51Z Oncology: immunotherapy delivery and response signals https://biobriefs.com/oncology-real-world-immunotherapy-safety BioBriefs en 2026-10-02T04:31:51Z Oncology: real-world immunotherapy safety and treatment dynamics https://biobriefs.com/rare-disease-and-targeted-therapeutics BioBriefs en 2026-10-02T04:31:51Z Rare disease and targeted therapeutics https://biobriefs.com/policy-and-trial-acceleration-in BioBriefs en 2026-10-02T04:31:51Z Policy and trial acceleration in the US https://biobriefs.com/biotech-funding-and-commercial-traction BioBriefs en 2026-10-02T04:31:51Z Biotech funding and commercial traction https://biobriefs.com/genome-editing-approval-lands-for BioBriefs en 2026-10-01T21:31:50Z Genome editing approval lands for hereditary angioedema https://biobriefs.com/sanofi-and-regeneron-expand-long BioBriefs en 2026-10-01T21:31:50Z Sanofi and Regeneron expand long-acting immunology push beyond Dupixent https://biobriefs.com/us-launches-simulation-augmented-trial BioBriefs en 2026-10-01T21:31:50Z US launches simulation-augmented trial framework to speed clinical development https://biobriefs.com/major-immunotherapy-safety-signal-emerges BioBriefs en 2026-10-01T21:31:50Z Major immunotherapy safety signal emerges from global drug safety databases https://biobriefs.com/new-real-world-evidence-for BioBriefs en 2026-10-01T21:31:50Z New real-world evidence for a leukemia BTK inhibitor in China https://biobriefs.com/ai-boosts-precision-oncology-workflows BioBriefs en 2026-10-01T21:31:50Z AI boosts precision oncology workflows by reading H&E slides https://biobriefs.com/trial-data-feed-into-next BioBriefs en 2026-10-01T21:31:50Z Trial data feed into next-gen obesity pipeline as Regeneron reports muscle regain signals at EASD https://biobriefs.com/new-health-tech-funding-supports BioBriefs en 2026-10-01T21:31:50Z New health-tech funding supports AI patient outreach automation https://biobriefs.com/neuroscience-imaging-innovation-targets-seizure BioBriefs en 2026-10-01T21:31:50Z Neuroscience-imaging innovation targets seizure risk stratification in gliomas https://biobriefs.com/space-manufacturing-gets-major-capital BioBriefs en 2026-10-01T21:31:50Z Space manufacturing gets major capital for drug production in orbit https://biobriefs.com/sanofi-and-regeneron-expand-long BioBriefs en 2026-10-01T16:32:15Z Sanofi and Regeneron expand long-acting immunology pipeline https://biobriefs.com/hhs-launches-surpass-and-arpa BioBriefs en 2026-10-01T16:32:15Z HHS launches SURPASS and ARPA-H initiatives to speed clinical trials https://biobriefs.com/hibernating-hamsters-reveal-histone-rewiring BioBriefs en 2026-10-01T16:32:15Z Hibernating hamsters reveal histone rewiring during torpor https://biobriefs.com/regulatory-turnaround-attempt-atara-and BioBriefs en 2026-10-01T16:32:15Z Regulatory turnaround attempt: Atara and Pierre Fabre resubmit Ebvallo https://biobriefs.com/lilly-exits-foghorn-synthetic-lethality BioBriefs en 2026-10-01T16:32:15Z Lilly exits Foghorn synthetic lethality collaboration https://biobriefs.com/abbvies-zuilokibart-moves-toward-phase BioBriefs en 2026-10-01T16:32:15Z AbbVie’s zuilokibart moves toward Phase 3 in atopic dermatitis https://biobriefs.com/invivyd-posts-phase-3-safety BioBriefs en 2026-10-01T16:32:15Z Invivyd posts Phase 3 safety results for low-dose Covid antibody VYD2311 https://biobriefs.com/genomics-and-diagnostics-tb-profiler BioBriefs en 2026-10-01T16:32:15Z Genomics and diagnostics: TB-Profiler upgrade uses 171,000 genomes https://biobriefs.com/clinical-development-trigemx-bio-targets BioBriefs en 2026-10-01T16:32:15Z Clinical development: triGemX Bio targets migraine with Phase 3 program after rebrand https://biobriefs.com/venture-and-health-operations-parakeet BioBriefs en 2026-10-01T16:32:15Z Venture and health operations: Parakeet Health raises $10M for automated patient outreach https://biobriefs.com/obesity-drug-execution-risk-and BioBriefs en 2026-10-01T14:32:28Z Obesity drug execution risk and late-stage readouts https://biobriefs.com/glp-1-side-effect-scrutiny BioBriefs en 2026-10-01T14:32:28Z GLP-1 side-effect scrutiny widens beyond the gut https://biobriefs.com/china-biotech-regulatory-headwinds-ebvallo BioBriefs en 2026-10-01T14:32:28Z China biotech regulatory headwinds: Ebvallo faces another FDA path https://biobriefs.com/neuroimmune-oncology-car-macrophage-checkpoint BioBriefs en 2026-10-01T14:32:28Z Neuroimmune oncology: CAR macrophage checkpoint target emerges https://biobriefs.com/microbiome-signals-in-cancer-biology BioBriefs en 2026-10-01T14:32:28Z Microbiome signals in cancer biology and treatment adverse events https://biobriefs.com/antibiotic-resistance-diagnostics-and-faster BioBriefs en 2026-10-01T14:32:28Z Antibiotic resistance diagnostics and faster susceptibility testing https://biobriefs.com/biotech-dealmaking-sanofi-expands-regeneron BioBriefs en 2026-10-01T14:32:28Z Biotech dealmaking: Sanofi expands Regeneron immunology footprint https://biobriefs.com/cell-therapy-and-manufacturing-economics BioBriefs en 2026-10-01T14:32:28Z Cell therapy and manufacturing economics: BioNTech shuts mRNA sites https://biobriefs.com/clinical-evidence-for-access-acceleration BioBriefs en 2026-10-01T14:32:28Z Clinical evidence for access acceleration in oncology https://biobriefs.com/base-editing-ip-dispute-escalates BioBriefs en 2026-10-01T14:32:28Z Base editing IP dispute escalates in rare disease field https://biobriefs.com/obesity-drug-partnerships-and-next BioBriefs en 2026-10-01T10:31:58Z Obesity drug partnerships and next-gen weekly oral metabolic programs https://biobriefs.com/regulatory-reset-attempts-for-cell BioBriefs en 2026-10-01T10:31:58Z Regulatory reset attempts for cell therapy approvals (Ebvallo) https://biobriefs.com/inflammation-and-immunology-deal-making BioBriefs en 2026-10-01T10:31:58Z Inflammation and immunology deal-making from established pharma alliances https://biobriefs.com/fda-starts-review-of-roches BioBriefs en 2026-10-01T10:31:58Z FDA starts review of Roche’s MS oral drug fenebrutinib https://biobriefs.com/clinical-stage-al-amyloidosis-immu BioBriefs en 2026-10-01T10:31:58Z Clinical-stage AL amyloidosis: Immu​nixes? CAR-T durability signal https://biobriefs.com/obesity-drug-clinical-progress-and BioBriefs en 2026-10-01T10:31:58Z Obesity drug clinical progress and next-wave amylin analogs https://biobriefs.com/gene-therapy-durability-questions-in BioBriefs en 2026-10-01T10:31:58Z Gene therapy durability questions in Huntington’s disease https://biobriefs.com/pharma-big-deals-and-regulatory BioBriefs en 2026-10-01T10:31:58Z Pharma big deals and regulatory uncertainty: Summit Therapeutics oncology investment https://biobriefs.com/car-t-manufacturing-bottlenecks-and BioBriefs en 2026-10-01T10:31:58Z CAR-T manufacturing bottlenecks and predictive control frameworks https://biobriefs.com/antibody-developability-data-collaboration-to BioBriefs en 2026-10-01T10:31:58Z Antibody developability data collaboration to speed biotherapeutic translation https://biobriefs.com/obesity-and-diabetes-pipeline-dealmaking BioBriefs en 2026-10-01T09:31:50Z Obesity and diabetes pipeline dealmaking https://biobriefs.com/fda-scrutiny-and-regulatory-reversals BioBriefs en 2026-10-01T09:31:50Z FDA scrutiny and regulatory reversals in cell therapy https://biobriefs.com/car-t-platform-engineering-and BioBriefs en 2026-10-01T09:31:50Z CAR-T platform engineering and next-generation manufacturing https://biobriefs.com/clinical-evidence-moves-the-needle BioBriefs en 2026-10-01T09:31:50Z Clinical evidence moves the needle in oncology https://biobriefs.com/fda-advisory-and-evidence-generation BioBriefs en 2026-10-01T09:31:50Z FDA advisory and evidence-generation policy shifts https://biobriefs.com/large-scale-data-diagnostics-and BioBriefs en 2026-10-01T09:31:50Z Large-scale data, diagnostics, and disease detection via AI https://biobriefs.com/immunology-translational-research-immune-checkpoints BioBriefs en 2026-10-01T09:31:50Z Immunology translational research: immune checkpoints and engineered cells https://biobriefs.com/biopharma-industry-moves-manufacturing-and BioBriefs en 2026-10-01T09:31:50Z Biopharma industry moves: manufacturing and platform bets https://biobriefs.com/metabolic-immunology-and-first-in BioBriefs en 2026-10-01T09:31:50Z Metabolic immunology and first-in-human prep: inflammation in new targets https://biobriefs.com/competitive-litigation-in-genome-editing BioBriefs en 2026-10-01T09:31:50Z Competitive litigation in genome editing https://biobriefs.com/obesity-drug-breakthroughs-and-next BioBriefs en 2026-10-01T04:32:01Z Obesity drug breakthroughs and next-gen GLP-1 competition https://biobriefs.com/regulatory-setbacks-and-reversals-in BioBriefs en 2026-10-01T04:32:01Z Regulatory setbacks and reversals in fibrosis: Bristol Myers and FDA scrutiny https://biobriefs.com/car-t-and-cell-therapy BioBriefs en 2026-10-01T04:32:01Z CAR-T and cell therapy scale-up bottlenecks https://biobriefs.com/cell-therapy-resubmissions-after-fda BioBriefs en 2026-10-01T04:32:01Z Cell therapy resubmissions after FDA reversals: Atara and Pierre Fabre’s Ebvallo https://biobriefs.com/bio-manufacturing-in-space-vardas BioBriefs en 2026-10-01T04:32:01Z Bio-manufacturing in space: Varda’s $251M Series D https://biobriefs.com/antibody-developability-data-collaboration BioBriefs en 2026-10-01T04:32:01Z Antibody developability data collaboration https://biobriefs.com/weight-loss-ai-growth-in BioBriefs en 2026-10-01T04:32:01Z Weight-loss AI: Growth in GLP-1 compounded use raises scrutiny https://biobriefs.com/huntington-gene-therapy-durability-concerns BioBriefs en 2026-10-01T04:32:01Z Huntington gene therapy durability concerns: UniQure’s AMT-130 update https://biobriefs.com/us-regulatory-framework-and-evidence BioBriefs en 2026-10-01T04:32:01Z US regulatory framework and evidence standards: EMA pushes back on rigid trial-count logic https://biobriefs.com/immune-biology-chemotherapy-driven-senescence BioBriefs en 2026-10-01T04:32:01Z Immune biology—chemotherapy-driven senescence and senolytics rationale https://biobriefs.com/us-regulatory-push-to-accelerate BioBriefs en 2026-09-30T21:32:36Z US regulatory push to accelerate AI-enabled clinical trials https://biobriefs.com/fda-review-momentum-for-next BioBriefs en 2026-09-30T21:32:36Z FDA review momentum for next-generation MS oral therapy https://biobriefs.com/bristol-myers-fibrosis-drug-readout BioBriefs en 2026-09-30T21:32:36Z Bristol Myers fibrosis-drug readout clouds as patient death emerges https://biobriefs.com/astrazeneca-deepens-summit-therapeutics-cancer BioBriefs en 2026-09-30T21:32:36Z AstraZeneca deepens Summit Therapeutics cancer strategy with $2B equity investment https://biobriefs.com/obesity-pipeline-stakes-rise-as BioBriefs en 2026-09-30T21:32:36Z Obesity pipeline stakes rise as Lilly and peers post high-impact weight-loss efficacy https://biobriefs.com/uniqure-huntington-gene-therapy-follow BioBriefs en 2026-09-30T21:32:36Z UniQure Huntington gene-therapy follow-up raises durability questions https://biobriefs.com/china-biopharma-ip-risk-surfaces BioBriefs en 2026-09-30T21:32:36Z China biopharma IP risk surfaces as Beam sues for base-editing theft https://biobriefs.com/regulatory-and-manufacturing-pressure-drives BioBriefs en 2026-09-30T21:32:36Z Regulatory and manufacturing pressure drives Cell-and gene therapy reroute at Atara and Pierre Fabre https://biobriefs.com/fertility-market-attention-grows-but BioBriefs en 2026-09-30T21:32:36Z Fertility market attention grows, but biotech’s operational focus remains trial execution and access https://biobriefs.com/car-t-economics-and-manufacturing BioBriefs en 2026-09-30T21:32:36Z CAR-T economics and manufacturing bottlenecks remain central as companies pursue scalable delivery https://biobriefs.com/fda-scrutiny-and-revised-clinical BioBriefs en 2026-09-30T16:31:54Z FDA scrutiny and revised clinical evidence for cell therapy approvals https://biobriefs.com/obesity-pipeline-escalation-as-lillys BioBriefs en 2026-09-30T16:31:54Z Obesity pipeline escalation as Lilly’s retatrutide posts phase 3 weight-loss benchmarks https://biobriefs.com/mercks-multi-billion-oncology-licensing BioBriefs en 2026-09-30T16:31:54Z Merck’s multi-billion oncology licensing bet on KRAS G12D molecular glue from China https://biobriefs.com/astrazeneca-invests-2b-in-summits BioBriefs en 2026-09-30T16:31:54Z AstraZeneca invests $2B in Summit’s PD-1/VEGF bispecific and sets ADC combination trials https://biobriefs.com/novo-renews-obesity-expansion-with BioBriefs en 2026-09-30T16:31:54Z Novo renews obesity expansion with a weekly oral GLP-1/GIP license from Hengrui https://biobriefs.com/biotech-ip-litigation-escalates-as BioBriefs en 2026-09-30T16:31:54Z Biotech IP litigation escalates as Beam sues rival base-editing claims https://biobriefs.com/huntington-gene-therapy-durability-review BioBriefs en 2026-09-30T16:31:54Z Huntington gene therapy durability review pressures UniQure as four-year data show waning effect https://biobriefs.com/biontech-to-close-german-manufacturing BioBriefs en 2026-09-30T16:31:54Z BioNTech to close German manufacturing sites after failing to find buyers https://biobriefs.com/car-t-manufacturing-bottleneck-becomes BioBriefs en 2026-09-30T16:31:54Z CAR-T manufacturing bottleneck becomes a focus for predictive control platforms https://biobriefs.com/regulatory-flexibility-debate-ema-argues BioBriefs en 2026-09-30T16:31:54Z Regulatory flexibility debate: EMA argues against rigid one-trial standards while referencing FDA https://biobriefs.com/lilly-elevates-obesity-and-diabetes BioBriefs en 2026-09-30T14:32:31Z Lilly elevates obesity-and-diabetes triple-agonist momentum at EASD https://biobriefs.com/lillys-triumph-2-results-set BioBriefs en 2026-09-30T14:32:31Z Lilly’s TRIUMPH-2 results set a new weight-loss benchmark in phase 3 https://biobriefs.com/merck-biocentury-2-13b-kras BioBriefs en 2026-09-30T14:32:31Z Merck-BIOCENTURY: $2.13B KRAS G12D molecular glue deal from SciBrunch https://biobriefs.com/astrazeneca-loads-2b-into-summits BioBriefs en 2026-09-30T14:32:31Z AstraZeneca loads $2B into Summit’s PD-1/VEGF bispecific for ADC combinations https://biobriefs.com/regulatory-setback-merck-and-daiichi BioBriefs en 2026-09-30T14:32:31Z Regulatory setback: Merck and Daiichi withdraw B7-H3 ADC BLA for extensive-stage SCLC https://biobriefs.com/beam-escalates-ip-fight-over BioBriefs en 2026-09-30T14:32:31Z Beam escalates IP fight over base editing tech tied to YolTech and Serapha https://biobriefs.com/uniqures-huntington-gene-therapy-durability BioBriefs en 2026-09-30T14:32:31Z UniQure’s Huntington gene therapy durability concerns deepen at four-year follow-up https://biobriefs.com/fda-decision-risk-free-otsuka BioBriefs en 2026-09-30T14:32:31Z FDA decision risk-free? Otsuka and Ionis report phase III win in FUS-ALS https://biobriefs.com/venture-and-platform-buildout-tiny BioBriefs en 2026-09-30T14:32:31Z Venture and platform buildout: Tiny Health raises $33M to expand microbiome testing https://biobriefs.com/data-infrastructure-for-antibodies-ginkgo BioBriefs en 2026-09-30T14:32:31Z Data infrastructure for antibodies: Ginkgo Datapoints and Apheris launch Developability Consortium https://biobriefs.com/obesity-breakthrough-lillys-retatrutide-posts BioBriefs en 2026-09-30T10:32:01Z Obesity breakthrough: Lilly’s retatrutide posts Phase 3 “high-water mark” https://biobriefs.com/astrazeneca-bets-on-summits-pd BioBriefs en 2026-09-30T10:32:01Z AstraZeneca bets on Summit’s PD-1/VEGF bispecific for ADC combinations https://biobriefs.com/regulatory-rollback-merck-and-daiichi BioBriefs en 2026-09-30T10:32:01Z Regulatory rollback: Merck and Daiichi withdraw BLA for ifinatamab deruxtecan in SCLC https://biobriefs.com/kras-g12d-molecular-glue-licensing BioBriefs en 2026-09-30T10:32:01Z KRAS G12D molecular glue licensing: Merck seals SciBrunch deal https://biobriefs.com/obesity-pipeline-expansion-via-china BioBriefs en 2026-09-30T10:32:01Z Obesity pipeline expansion via China-to-Global deal: Novo licenses Hengrui’s weekly oral GLP-1/GIP agonist https://biobriefs.com/phase-3-win-in-wet BioBriefs en 2026-09-30T10:32:01Z Phase 3 win in wet AMD: Kodiak advances longer-interval tarcocimab tedromer and tabirafusp tedromer https://biobriefs.com/beam-vs-yoltech-serapha-alleged BioBriefs en 2026-09-30T10:32:01Z Beam vs. YolTech/Serapha: alleged base-editing trade secret theft fuels new legal fight https://biobriefs.com/uniqure-huntington-gene-therapy-durability BioBriefs en 2026-09-30T10:32:01Z UniQure Huntington gene therapy durability concern after four-year readout https://biobriefs.com/apheris-and-ginkgo-form-antibody BioBriefs en 2026-09-30T10:32:01Z Apheris and Ginkgo form Antibody Developability Consortium to de-risk manufacturing https://biobriefs.com/ai-proteomics-accelerate-molecular-glue BioBriefs en 2026-09-30T10:32:01Z AI + proteomics accelerate molecular glue discovery targeting VAV1 https://biobriefs.com/obesity-drug-pipelines-surge-with BioBriefs en 2026-09-30T09:31:55Z Obesity drug pipelines surge with late-stage results and weekly dosing bets https://biobriefs.com/big-pharma-doubles-down-on BioBriefs en 2026-09-30T09:31:55Z Big Pharma doubles down on PD-1/VEGF bispecific combinations https://biobriefs.com/merck-ramps-precision-oncology-licensing BioBriefs en 2026-09-30T09:31:55Z Merck ramps precision oncology licensing for KRAS G12D molecular glue https://biobriefs.com/regulatory-setbacks-thin-the-fda BioBriefs en 2026-09-30T09:31:55Z Regulatory setbacks thin the FDA pipeline calendar for antibody-drug conjugates https://biobriefs.com/uniqures-huntington-gene-therapy-durability BioBriefs en 2026-09-30T09:31:55Z UniQure’s Huntington gene therapy durability comes under renewed scrutiny https://biobriefs.com/scibrunch-and-vav1-molecular-glue BioBriefs en 2026-09-30T09:31:55Z SciBrunch and VAV1 molecular glue science points toward faster targeted protein degradation https://biobriefs.com/astrazenecas-adc-plus-bispecific-strategy BioBriefs en 2026-09-30T09:31:55Z AstraZeneca’s ADC-plus-bispecific strategy expands through Summit equity and clinical planning https://biobriefs.com/merck-and-scibrunch-intellectual-property BioBriefs en 2026-09-30T09:31:55Z Merck and SciBrunch intellectual-property and deal momentum intersects with precision oncology licensing https://biobriefs.com/link-cell-names-leadership-for BioBriefs en 2026-09-30T09:31:55Z Link Cell names leadership for CAR T start-up focused on scalable autoimmune cell therapy https://biobriefs.com/new-trial-ready-and-investor BioBriefs en 2026-09-30T09:31:55Z New trial-ready and investor-backed platforms in immune and metabolic disease https://biobriefs.com/next-gen-obesity-drugs-score BioBriefs en 2026-09-30T04:31:54Z Next-gen obesity drugs score major late-stage efficacy milestones https://biobriefs.com/big-pharma-doubles-down-on BioBriefs en 2026-09-30T04:31:54Z Big Pharma doubles down on precision oncology with KRAS-targeted molecular glues https://biobriefs.com/astrazeneca-places-2b-equity-bet BioBriefs en 2026-09-30T04:31:54Z AstraZeneca places $2B equity bet on PD-1/VEGF bispecific strategy https://biobriefs.com/novo-and-hengrui-expand-the BioBriefs en 2026-09-30T04:31:54Z Novo and Hengrui expand the weekly obesity tablet race https://biobriefs.com/beam-escalates-base-editing-disputes BioBriefs en 2026-09-30T04:31:54Z Beam escalates base editing disputes with trade-secret lawsuit https://biobriefs.com/regulatory-setback-hits-b7-h3 BioBriefs en 2026-09-30T04:31:54Z Regulatory setback hits B7-H3 ADC path in small-cell lung cancer https://biobriefs.com/uniqure-reports-waning-durability-signals BioBriefs en 2026-09-30T04:31:54Z UniQure reports waning durability signals for Huntington’s gene therapy https://biobriefs.com/car-t-expansion-and-governance BioBriefs en 2026-09-30T04:31:54Z CAR-T expansion and governance pressures surface in lupus and manufacturing https://biobriefs.com/precision-data-platforms-for-antibody BioBriefs en 2026-09-30T04:31:54Z Precision data platforms for antibody developability get industry-scale traction https://biobriefs.com/novel-immune-resetting-biotech-emerges BioBriefs en 2026-09-30T04:31:54Z Novel immune-resetting biotech emerges from stealth with funding and a T-cell targeting platform https://biobriefs.com/astrazeneca-stakes-2b-on-summits BioBriefs en 2026-09-29T21:31:54Z AstraZeneca stakes $2B on Summit’s PD-1/VEGF bispecific for combo oncology https://biobriefs.com/beam-therapeutics-sues-over-alleged BioBriefs en 2026-09-29T21:31:54Z Beam Therapeutics sues over alleged base-editing trade secret theft https://biobriefs.com/uniqures-huntington-gene-therapy-faces BioBriefs en 2026-09-29T21:31:54Z UniQure’s Huntington gene therapy faces durability concerns https://biobriefs.com/novo-buys-into-chinas-hengrui BioBriefs en 2026-09-29T21:31:54Z Novo buys into China’s Hengrui weekly oral obesity drug (HRS-1596) https://biobriefs.com/merck-adds-400m-upfront-for BioBriefs en 2026-09-29T21:31:54Z Merck adds $400M upfront for SciBrunch KRAS G12D program https://biobriefs.com/fda-ema-shift-on-evidence BioBriefs en 2026-09-29T21:31:54Z FDA/EMA shift on evidence expectations: focus moves beyond trial counts https://biobriefs.com/eu-regulator-leadership-emer-cooke BioBriefs en 2026-09-29T21:31:54Z EU regulator leadership: Emer Cooke reiterates gender gaps in trials https://biobriefs.com/car-t-scalability-push-link BioBriefs en 2026-09-29T21:31:54Z CAR-T scalability push: Link Cell appoints new CEO and ties to BMS https://biobriefs.com/ai-guided-optimization-enables-thermostable BioBriefs en 2026-09-29T21:31:54Z AI-guided optimization enables thermostable mRNA vaccine formulations https://biobriefs.com/earendil-labs-lands-1-5b BioBriefs en 2026-09-29T21:31:54Z Earendil Labs lands $1.5B Genentech discovery deal for oncology bispecifics https://biobriefs.com/als-precision-medicine-milestone BioBriefs en 2026-09-29T16:31:32Z ALS precision medicine milestone https://biobriefs.com/obesity-pipeline-intensifies-with-china BioBriefs en 2026-09-29T16:31:32Z Obesity pipeline intensifies with China-sourced innovation https://biobriefs.com/merck-expands-kras-g12d-bets BioBriefs en 2026-09-29T16:31:32Z Merck expands KRAS G12D bets via SciBrunch https://biobriefs.com/astrazeneca-takes-equity-stake-and BioBriefs en 2026-09-29T16:31:32Z AstraZeneca takes equity stake and adds clinical collaboration with Summit https://biobriefs.com/gene-therapy-durability-under-scrutiny BioBriefs en 2026-09-29T16:31:32Z Gene therapy durability under scrutiny in Huntington’s https://biobriefs.com/regulatory-setbacks-hit-b7-h3 BioBriefs en 2026-09-29T16:31:32Z Regulatory setbacks hit B7-H3 ADC in small-cell lung cancer https://biobriefs.com/ophthalmology-phase-iii-breakthrough-for BioBriefs en 2026-09-29T16:31:32Z Ophthalmology Phase III breakthrough for Kodiak’s wet AMD franchise https://biobriefs.com/fda-adds-a-new-parkinsons BioBriefs en 2026-09-29T16:31:32Z FDA adds a new Parkinson’s pill option https://biobriefs.com/clinical-evidence-focus-ema-weighs BioBriefs en 2026-09-29T16:31:32Z Clinical evidence focus: EMA weighs in on “one pivotal study” debate https://biobriefs.com/new-capital-for-immune-reprogramming BioBriefs en 2026-09-29T16:31:32Z New capital for immune reprogramming in Tregs https://biobriefs.com/astrazeneca-expands-summits-pd-1 BioBriefs en 2026-09-29T14:31:51Z AstraZeneca expands Summit’s PD-1/VEGF platform with $2B equity investment https://biobriefs.com/novo-licenses-weekly-oral-glp BioBriefs en 2026-09-29T14:31:51Z Novo licenses weekly oral GLP-1/GIP weight-loss drug candidate from Hengrui https://biobriefs.com/kodiaks-phase-3-dual-readouts BioBriefs en 2026-09-29T14:31:51Z Kodiak’s Phase 3 dual readouts propel wet AMD drugs toward potential FDA submission https://biobriefs.com/fda-backs-anacardios-heart-failure BioBriefs en 2026-09-29T14:31:51Z FDA backs AnaCardio’s heart failure drug runway after $70.9M Series B https://biobriefs.com/mirum-delivers-phase-3-hdv BioBriefs en 2026-09-29T14:31:51Z Mirum delivers Phase 3 HDV and secures additional regulatory progress via Atebrioz and brelovitug https://biobriefs.com/abbvies-juvmo-wins-fda-approval BioBriefs en 2026-09-29T14:31:51Z AbbVie’s Juvmo wins FDA approval as a new oral Parkinson’s option https://biobriefs.com/merck-expands-kras-g12d-business BioBriefs en 2026-09-29T14:31:51Z Merck expands KRAS G12D business with $2.13B SciBrunch license https://biobriefs.com/egetis-gets-fda-approval-for BioBriefs en 2026-09-29T14:31:51Z Egetis gets FDA approval for tiratricol in rare X-linked genetic disease https://biobriefs.com/veeva-launches-claude-powered-ai BioBriefs en 2026-09-29T14:31:51Z Veeva launches Claude-powered AI agent to accelerate clinical trial study configuration https://biobriefs.com/adicet-shows-remission-signals-in BioBriefs en 2026-09-29T14:31:51Z Adicet shows remission signals in off-the-shelf CAR-T for lupus https://biobriefs.com/eye-care-phase-3-readouts BioBriefs en 2026-09-29T10:31:33Z Eye care Phase 3 readouts strengthen Kodiak’s dosing-durability thesis https://biobriefs.com/regulatory-approvals-expand-mirums-hepatitis BioBriefs en 2026-09-29T10:31:33Z Regulatory approvals expand Mirum’s hepatitis delta franchise https://biobriefs.com/big-pharma-bets-on-summits BioBriefs en 2026-09-29T10:31:33Z Big Pharma bets on Summit’s PD-1xVEGF bispecific for ADC combinations https://biobriefs.com/adicets-allogeneic-car-t-reports BioBriefs en 2026-09-29T10:31:33Z Adicet’s allogeneic CAR-T reports lupus signal as shares slide https://biobriefs.com/fda-clears-dreameds-cgm-driven BioBriefs en 2026-09-29T10:31:33Z FDA clears DreaMed’s CGM-driven insulin automation for Type 2 https://biobriefs.com/merck-locks-kras-g12d-licensing BioBriefs en 2026-09-29T10:31:33Z Merck locks KRAS G12D licensing rights from SciBrunch https://biobriefs.com/novo-expands-its-pipeline-via BioBriefs en 2026-09-29T10:31:33Z Novo expands its pipeline via $2.6B GLP-1/GIP preclinical deal with Hengrui https://biobriefs.com/nutshell-wins-fda-ind-clearance BioBriefs en 2026-09-29T10:31:33Z Nutshell wins FDA IND clearance for NRF2 degrader NTS-231 https://biobriefs.com/vasomune-completes-enrollment-in-phase BioBriefs en 2026-09-29T10:31:33Z Vasomune completes enrollment in Phase 2a pegevongitide program for pneumonia/ARDS https://biobriefs.com/veeva-launches-ai-agent-to BioBriefs en 2026-09-29T10:31:33Z Veeva launches AI agent to accelerate clinical trial study configuration https://biobriefs.com/astrazeneca-deepens-bet-on-summits BioBriefs en 2026-09-29T09:31:19Z AstraZeneca deepens bet on Summit’s PD-1xVEGF bispecific and triggers ADC combo plans https://biobriefs.com/fda-clears-dreamed-cgm-driven BioBriefs en 2026-09-29T09:31:19Z FDA clears DreaMed CGM-driven insulin dosing tool for Type 2 dual regimens https://biobriefs.com/egetis-wins-fda-approval-for BioBriefs en 2026-09-29T09:31:19Z Egetis wins FDA approval for tiratricol in a rare X-linked genetic disease https://biobriefs.com/kodiaks-phase-3-readout-restores BioBriefs en 2026-09-29T09:31:19Z Kodiak’s Phase 3 readout restores Eylea-equivalent durability claims in wet AMD https://biobriefs.com/fda-approval-and-phase-3 BioBriefs en 2026-09-29T09:31:19Z FDA approval and Phase 3 momentum for Mirum’s Atebrioz and brelovitug in hepatitis delta https://biobriefs.com/car-t-in-lupus-adicets BioBriefs en 2026-09-29T09:31:19Z CAR-T in lupus: Adicet’s off-the-shelf prula-cel shows complete kidney responses in early data https://biobriefs.com/merck-strikes-a-2-13b BioBriefs en 2026-09-29T09:31:19Z Merck strikes a $2.13B KRAS G12D license deal with SciBrunch https://biobriefs.com/vasomune-completes-enrollment-for-fast BioBriefs en 2026-09-29T09:31:19Z Vasomune completes enrollment for Fast Track-pegevongitide Phase 2a in pneumonia/ARDS https://biobriefs.com/veeva-launches-an-ai-agent BioBriefs en 2026-09-29T09:31:19Z Veeva launches an AI agent to generate faster EDC and study build configurations https://biobriefs.com/scynexis-wins-barda-contract-for BioBriefs en 2026-09-29T09:31:19Z Scynexis wins BARDA contract for antifungal development of SCY-247 https://biobriefs.com/rare-disease-fda-approval-for BioBriefs en 2026-09-29T04:31:36Z Rare-disease FDA approval for Egetis’ emcitate (tiratricol) https://biobriefs.com/merck-expands-kras-g12d-pipeline BioBriefs en 2026-09-29T04:31:36Z Merck expands KRAS G12D pipeline with SciBrunch license https://biobriefs.com/kodiak-posts-double-phase-3 BioBriefs en 2026-09-29T04:31:36Z Kodiak posts double Phase 3 win for wet AMD candidates vs Eylea https://biobriefs.com/mirum-secures-fda-approval-for BioBriefs en 2026-09-29T04:31:36Z Mirum secures FDA approval for Atebrioz (zilurgisertib) and posts positive Phase 3 HDV data https://biobriefs.com/abbvie-wins-fda-approval-for BioBriefs en 2026-09-29T04:31:36Z AbbVie wins FDA approval for tavapadon (Juvmo) in Parkinson’s disease https://biobriefs.com/clinical-stage-momentum-adicets-off BioBriefs en 2026-09-29T04:31:36Z Clinical stage momentum: Adicet’s off-the-shelf CAR-T shows remission signals in lupus https://biobriefs.com/regulatory-setback-merck-and-daiichi BioBriefs en 2026-09-29T04:31:36Z Regulatory setback: Merck and Daiichi withdraw B7-H3 ADC filing in extensive-stage SCLC https://biobriefs.com/eye-drug-developer-kodiak-phase BioBriefs en 2026-09-29T04:31:36Z Eye-drug developer Kodiak: Phase 3 endpoint discussion intensifies https://biobriefs.com/fda-clears-ind-for-nutshells BioBriefs en 2026-09-29T04:31:36Z FDA clears IND for Nutshell’s NRF2 degrader NTS-231 https://biobriefs.com/ai-in-clinical-operations-veeva BioBriefs en 2026-09-29T04:31:36Z AI in clinical operations: Veeva launches an agent to build trial study configuration https://biobriefs.com/kras-g12d-licensing-deal BioBriefs en 2026-09-28T21:31:42Z KRAS G12D licensing deal https://biobriefs.com/wet-amd-phase-3-readouts BioBriefs en 2026-09-28T21:31:42Z Wet AMD Phase 3 readouts for Kodiak https://biobriefs.com/hepatitis-d-phase-3-catalyst BioBriefs en 2026-09-28T21:31:42Z Hepatitis D Phase 3 catalyst and pipeline execution https://biobriefs.com/alzheimers-tauopathy-immune-targeting-in BioBriefs en 2026-09-28T21:31:42Z Alzheimer’s tauopathy immune targeting in mice https://biobriefs.com/off-the-shelf-car-t BioBriefs en 2026-09-28T21:31:42Z Off-the-shelf CAR-T for lupus reaches 1-year remission signals https://biobriefs.com/regulatory-setback-for-b7-h3 BioBriefs en 2026-09-28T21:31:42Z Regulatory setback for B7-H3 ADC in SCLC https://biobriefs.com/fda-ind-clearance-for-nrf2 BioBriefs en 2026-09-28T21:31:42Z FDA IND clearance for NRF2 degrader NTS-231 https://biobriefs.com/vasomune-phase-2a-enrollment-completion BioBriefs en 2026-09-28T21:31:42Z Vasomune Phase 2a enrollment completion in pneumonia/ARDS https://biobriefs.com/barda-contract-supports-antifungal-scy BioBriefs en 2026-09-28T21:31:42Z BARDA contract supports antifungal SCY-247 development https://biobriefs.com/clinical-trial-execution-automation-and BioBriefs en 2026-09-28T21:31:42Z Clinical trial execution automation and governance tools https://biobriefs.com/ophthalmology-phase-3-win-for BioBriefs en 2026-09-28T16:31:22Z Ophthalmology: Phase 3 win for Kodiak’s aflibercept competitor https://biobriefs.com/autoimmune-disease-allogeneic-car-t BioBriefs en 2026-09-28T16:31:22Z Autoimmune disease: allogeneic CAR-T shows remission signals in lupus nephritis https://biobriefs.com/regulatory-fda-ind-clearance-for BioBriefs en 2026-09-28T16:31:22Z Regulatory: FDA IND clearance for Nutshell’s NRF2 degrader https://biobriefs.com/infectious-disease-scynexis-wins-barda BioBriefs en 2026-09-28T16:31:22Z Infectious disease: Scynexis wins BARDA funding for antifungal development https://biobriefs.com/respiratory-critical-care-vasomune-completes BioBriefs en 2026-09-28T16:31:22Z Respiratory critical care: Vasomune completes Phase 2a enrollment for Tie2-targeting therapy https://biobriefs.com/regulatory-and-pipeline-discontinuation-roche BioBriefs en 2026-09-28T16:31:22Z Regulatory and pipeline discontinuation: Roche pulls obesity antibody after interim failure https://biobriefs.com/biotech-investing-and-dealmaking-merck BioBriefs en 2026-09-28T16:31:22Z Biotech investing and dealmaking: Merck licenses KRAS G12D inhibitor https://biobriefs.com/immunotherapy-in-lung-cancer-merck BioBriefs en 2026-09-28T16:31:22Z Immunotherapy in lung cancer: Merck and Daiichi halt FDA filing after pushback https://biobriefs.com/hepatology-mirum-posts-phase-3 BioBriefs en 2026-09-28T16:31:22Z Hepatology: Mirum posts Phase 3 hepatitis delta win https://biobriefs.com/clinical-development-mirums-atebrioz-pill BioBriefs en 2026-09-28T16:31:22Z Clinical development: Mirum’s Atebrioz pill gains FDA approval for FOP https://biobriefs.com/regulatory-approvals-in-parkinsons-disease BioBriefs en 2026-09-28T14:31:30Z Regulatory approvals in Parkinson’s disease https://biobriefs.com/r-d-setbacks-in-lung BioBriefs en 2026-09-28T14:31:30Z R&D setbacks in lung cancer ADCs https://biobriefs.com/anticancer-licensing-kras-g12d-deals BioBriefs en 2026-09-28T14:31:30Z Anticancer licensing—KRAS G12D deals at scale https://biobriefs.com/ophthalmology-trial-readouts-for-aflibercept BioBriefs en 2026-09-28T14:31:30Z Ophthalmology trial readouts for aflibercept-matched therapies https://biobriefs.com/obesity-drug-development-reversals-at BioBriefs en 2026-09-28T14:31:30Z Obesity drug development reversals at Roche https://biobriefs.com/hepatitis-delta-phase-3-win BioBriefs en 2026-09-28T14:31:30Z Hepatitis delta—Phase 3 win to challenge Gilead https://biobriefs.com/rare-disease-fda-approval-for BioBriefs en 2026-09-28T14:31:30Z Rare disease—FDA approval for fibrodysplasia ossificans progressiva https://biobriefs.com/public-private-r-d-funding BioBriefs en 2026-09-28T14:31:30Z Public-private R&D funding—BARDA contract for antifungals https://biobriefs.com/ai-in-clinical-trials-automation BioBriefs en 2026-09-28T14:31:30Z AI in clinical trials—automation with cost impact signals https://biobriefs.com/therapeutic-innovation-ai-built-thermostable BioBriefs en 2026-09-28T14:31:30Z Therapeutic innovation—AI-built thermostable mRNA vaccines https://biobriefs.com/fda-approval-for-rare-disease BioBriefs en 2026-09-28T10:31:18Z FDA approval for rare disease oral/injectable pipeline https://biobriefs.com/regulatory-setback-on-oncology-accelerated BioBriefs en 2026-09-28T10:31:18Z Regulatory setback on oncology accelerated approval pathway https://biobriefs.com/company-level-legal-outcome-impacting BioBriefs en 2026-09-28T10:31:18Z Company-level legal outcome impacting capital expectations https://biobriefs.com/thermostable-rna-vaccine-formulation-using BioBriefs en 2026-09-28T10:31:18Z Thermostable RNA vaccine formulation using AI-driven design https://biobriefs.com/lnp-engineering-for-large-rna BioBriefs en 2026-09-28T10:31:18Z LNP engineering for large RNA cargo and tissue targeting https://biobriefs.com/self-amplifying-rna-vaccine-resistance BioBriefs en 2026-09-28T10:31:18Z Self-amplifying RNA vaccine resistance to intracellular defenses https://biobriefs.com/ai-assisted-clinical-monitoring-to BioBriefs en 2026-09-28T10:31:18Z AI-assisted clinical monitoring to reduce trial cost and inefficiency https://biobriefs.com/crispr-nuclease-engineering-accelerates-genome BioBriefs en 2026-09-28T10:31:18Z CRISPR nuclease engineering accelerates genome editing performance https://biobriefs.com/clinical-monitoring-and-decision-support BioBriefs en 2026-09-28T10:31:18Z Clinical monitoring and decision support for oncology response uncertainty https://biobriefs.com/operational-readiness-as-a-bottleneck BioBriefs en 2026-09-28T10:31:18Z Operational readiness as a bottleneck for moving therapies to market https://biobriefs.com/regulatory-setback-for-next-gen BioBriefs en 2026-09-28T09:31:19Z Regulatory setback for next-gen lung cancer ADC filing https://biobriefs.com/fda-nod-for-mirums-oral BioBriefs en 2026-09-28T09:31:19Z FDA nod for Mirum’s oral pill in FOP https://biobriefs.com/ai-monitoring-claims-cost-savings BioBriefs en 2026-09-28T09:31:19Z AI monitoring claims cost savings in oncology trials https://biobriefs.com/court-ruling-turns-nektars-lilly BioBriefs en 2026-09-28T09:31:19Z Court ruling turns Nektar’s Lilly deal dispute into a market test https://biobriefs.com/next-gen-dopamine-therapy-gets BioBriefs en 2026-09-28T09:31:19Z Next-gen dopamine therapy gets FDA green light https://biobriefs.com/rna-vaccine-thermal-stability-breakthrough BioBriefs en 2026-09-28T09:31:19Z RNA vaccine thermal stability breakthrough https://biobriefs.com/ai-native-biotech-investors-refocus BioBriefs en 2026-09-28T09:31:19Z AI-native biotech investors refocus on clinical execution https://biobriefs.com/glp-1-marketing-shift-from BioBriefs en 2026-09-28T09:31:19Z GLP-1 marketing shift from medical obesity to lifestyle positioning https://biobriefs.com/operational-constraint-emerges-as-a BioBriefs en 2026-09-28T09:31:19Z Operational constraint emerges as a biopharma bottleneck https://biobriefs.com/carbon-reduction-therapy-strategy-sparks BioBriefs en 2026-09-28T09:31:19Z Carbon reduction therapy strategy sparks long-term arthritis interest https://biobriefs.com/fda-approvals-for-rare-disease BioBriefs en 2026-09-28T04:31:20Z FDA approvals for rare disease therapeutics https://biobriefs.com/oncology-treatment-modeling-and-ai BioBriefs en 2026-09-28T04:31:20Z Oncology treatment modeling and AI clinical guidance https://biobriefs.com/regulatory-fallout-for-oncology-antibody BioBriefs en 2026-09-28T04:31:20Z Regulatory fallout for oncology antibody-drug conjugates https://biobriefs.com/court-ruling-reshapes-nektars-dispute BioBriefs en 2026-09-28T04:31:20Z Court ruling reshapes Nektar’s dispute with Eli Lilly https://biobriefs.com/clinical-monitoring-automation-and-trial BioBriefs en 2026-09-28T04:31:20Z Clinical monitoring automation and trial cost efficiency https://biobriefs.com/crispr-platform-engineering-delivers-major BioBriefs en 2026-09-28T04:31:20Z CRISPR platform engineering delivers major performance gains https://biobriefs.com/new-radiotherapy-evidence-in-metastatic BioBriefs en 2026-09-28T04:31:20Z New radiotherapy evidence in metastatic colorectal cancer https://biobriefs.com/cell-therapy-monitoring-finds-hidden BioBriefs en 2026-09-28T04:31:20Z Cell therapy monitoring finds hidden cardiovascular risk https://biobriefs.com/car-t-immune-cell-engineering BioBriefs en 2026-09-28T04:31:20Z CAR-T/immune-cell engineering advances for solid tumors https://biobriefs.com/protein-biomarker-and-screening-tools BioBriefs en 2026-09-28T04:31:20Z Protein biomarker and screening tools to improve cancer risk stratification https://biobriefs.com/regulatory-approval-in-rare-disease BioBriefs en 2026-09-27T21:31:26Z Regulatory approval in rare disease https://biobriefs.com/biotech-litigation-and-partnership-fallout BioBriefs en 2026-09-27T21:31:26Z Biotech litigation and partnership fallout https://biobriefs.com/oncology-trial-data-in-colorectal BioBriefs en 2026-09-27T21:31:26Z Oncology trial data in colorectal liver metastases https://biobriefs.com/oncology-trial-data-endometrial-cancer BioBriefs en 2026-09-27T21:31:26Z Oncology trial data: endometrial cancer after immunotherapy https://biobriefs.com/drug-pipeline-bla-withdrawal-in BioBriefs en 2026-09-27T21:31:26Z Drug pipeline: BLA withdrawal in SCLC https://biobriefs.com/cell-therapy-safety-signals-in BioBriefs en 2026-09-27T21:31:26Z Cell therapy safety signals in real-world cohorts https://biobriefs.com/clinical-oncology-support-tool-switching BioBriefs en 2026-09-27T21:31:26Z Clinical oncology support tool: switching treatment milestone https://biobriefs.com/cell-engineering-review-for-solid BioBriefs en 2026-09-27T21:31:26Z Cell engineering review for solid tumors and metabolic rewiring https://biobriefs.com/bioengineering-and-platform-validation-engineered BioBriefs en 2026-09-27T21:31:26Z Bioengineering and platform validation: engineered CRISPR nuclease https://biobriefs.com/ai-enabled-oncology-decision-support BioBriefs en 2026-09-27T21:31:26Z AI-enabled oncology decision support https://biobriefs.com/regulatory-approvals-first-in-class BioBriefs en 2026-09-27T16:31:30Z Regulatory approvals: first-in-class gene-editing candidates and chronic disease innovation https://biobriefs.com/oncology-targeted-combinations-after-immunotherapy BioBriefs en 2026-09-27T16:31:30Z Oncology: targeted combinations after immunotherapy failure https://biobriefs.com/oncology-ferroptosis-and-mechanistic-cell BioBriefs en 2026-09-27T16:31:30Z Oncology: ferroptosis and mechanistic cell-death biology https://biobriefs.com/cell-therapy-real-world-adverse BioBriefs en 2026-09-27T16:31:30Z Cell therapy: real-world adverse effects after treatment https://biobriefs.com/immunology-and-infection-intracellular-e BioBriefs en 2026-09-27T16:31:30Z Immunology and infection: intracellular E. coli clearance mechanism behind Uro-Vaxom-like therapy https://biobriefs.com/ai-in-drug-development-protein BioBriefs en 2026-09-27T16:31:30Z AI in drug development: protein and disease modeling breakthroughs https://biobriefs.com/clinical-biomarkers-simple-blood-tests BioBriefs en 2026-09-27T16:31:30Z Clinical biomarkers: simple blood tests in oncology risk stratification https://biobriefs.com/fda-and-rare-disease-new BioBriefs en 2026-09-27T16:31:30Z FDA and rare disease: new approval expanding treatment options https://biobriefs.com/biopharma-financing-ipo-and-capital BioBriefs en 2026-09-27T16:31:30Z Biopharma financing: IPO and capital formation momentum https://biobriefs.com/genomics-and-molecular-pathology-splicing BioBriefs en 2026-09-27T16:31:30Z Genomics and molecular pathology: splicing-related survival across cancers https://biobriefs.com/regulatory-approvals-and-first-in BioBriefs en 2026-09-27T14:31:20Z Regulatory approvals and first-in-class therapies https://biobriefs.com/oncology-drug-pipeline-setbacks-and BioBriefs en 2026-09-27T14:31:20Z Oncology drug pipeline setbacks and course corrections https://biobriefs.com/ipo-and-capital-formation-in BioBriefs en 2026-09-27T14:31:20Z IPO and capital formation in biopharma https://biobriefs.com/corporate-litigation-with-licensing-implications BioBriefs en 2026-09-27T14:31:20Z Corporate litigation with licensing implications https://biobriefs.com/drug-development-strategy-in-alzheimers BioBriefs en 2026-09-27T14:31:20Z Drug development strategy in Alzheimer’s disease https://biobriefs.com/partnership-and-licensing-for-drug BioBriefs en 2026-09-27T14:31:20Z Partnership and licensing for drug delivery platforms https://biobriefs.com/car-t-expansion-beyond-blood BioBriefs en 2026-09-27T14:31:20Z CAR-T expansion beyond blood cancers https://biobriefs.com/cell-therapy-safety-signals-and BioBriefs en 2026-09-27T14:31:20Z Cell therapy safety signals and real-world complications https://biobriefs.com/regulatory-framework-updates-for-cmc BioBriefs en 2026-09-27T14:31:20Z Regulatory framework updates for CMC submissions https://biobriefs.com/fda-policy-on-evidence-requirements BioBriefs en 2026-09-27T14:31:20Z FDA policy on evidence requirements https://biobriefs.com/regulatory-approvals BioBriefs en 2026-09-27T10:31:24Z Regulatory approvals https://biobriefs.com/court-rulings-and-ip-disputes BioBriefs en 2026-09-27T10:31:24Z Court rulings and IP disputes https://biobriefs.com/clinical-pipeline-oncology-and-immune BioBriefs en 2026-09-27T10:31:24Z Clinical pipeline: oncology and immune escape https://biobriefs.com/cell-therapy-and-immune-engineering BioBriefs en 2026-09-27T10:31:24Z Cell therapy and immune engineering https://biobriefs.com/funding-and-capital-formation BioBriefs en 2026-09-27T10:31:24Z Funding and capital formation https://biobriefs.com/antibiotics-resistance-and-diagnostics BioBriefs en 2026-09-27T10:31:24Z Antibiotics, resistance, and diagnostics https://biobriefs.com/drug-development-biomarker-and-ai BioBriefs en 2026-09-27T10:31:24Z Drug development: biomarker and AI-supported risk tools https://biobriefs.com/emerging-modalities-editing-and-gene BioBriefs en 2026-09-27T10:31:24Z Emerging modalities: editing and gene therapeutics https://biobriefs.com/cns-and-mental-health-depression BioBriefs en 2026-09-27T10:31:24Z CNS and mental health: depression mechanisms and screening https://biobriefs.com/clinical-trial-and-treatment-strategies BioBriefs en 2026-09-27T10:31:24Z Clinical trial and treatment strategies in cancer https://biobriefs.com/regulatory-approvals-and-label-expansions BioBriefs en 2026-09-27T09:31:32Z Regulatory approvals and label expansions https://biobriefs.com/drug-delivery-licensing-deals BioBriefs en 2026-09-27T09:31:32Z Drug delivery licensing deals https://biobriefs.com/high-profile-biopharma-litigation-outcomes BioBriefs en 2026-09-27T09:31:32Z High-profile biopharma litigation outcomes https://biobriefs.com/major-ipos-and-public-market BioBriefs en 2026-09-27T09:31:32Z Major IPOs and public-market momentum https://biobriefs.com/cell-therapy-clinical-execution-and BioBriefs en 2026-09-27T09:31:32Z Cell therapy clinical execution and supportive care https://biobriefs.com/oncology-strategy-chemo-immunotherapy-and BioBriefs en 2026-09-27T09:31:32Z Oncology strategy: chemo-immunotherapy and resistance mechanisms https://biobriefs.com/microbiology-and-antimicrobial-resistance-risk BioBriefs en 2026-09-27T09:31:32Z Microbiology and antimicrobial resistance risk https://biobriefs.com/imaging-diagnostics-and-predictive-analytics BioBriefs en 2026-09-27T09:31:32Z Imaging, diagnostics, and predictive analytics in clinical care https://biobriefs.com/translational-cancer-biology-precision-targets BioBriefs en 2026-09-27T09:31:32Z Translational cancer biology: precision targets and novel engineering https://biobriefs.com/cell-therapy-safety-hemodynamic-complications BioBriefs en 2026-09-27T09:31:32Z Cell therapy safety: hemodynamic complications after treatment https://biobriefs.com/fda-approvals-expand-parkinsons-and BioBriefs en 2026-09-27T04:31:33Z FDA approvals expand Parkinson’s and kidney-cancer options https://biobriefs.com/clinical-readouts-from-hematology-and BioBriefs en 2026-09-27T04:31:33Z Clinical readouts from hematology and oncology pipelines https://biobriefs.com/dealmaking-big-pharma-expands-partnerships BioBriefs en 2026-09-27T04:31:33Z Dealmaking: big pharma expands partnerships and licensing reach https://biobriefs.com/biotech-litigation-nektar-wins-damages BioBriefs en 2026-09-27T04:31:33Z Biotech litigation: Nektar wins damages from Eli Lilly https://biobriefs.com/ipo-momentum-returns-rna-therapeutics BioBriefs en 2026-09-27T04:31:33Z IPO momentum returns: RNA therapeutics go public with major raises https://biobriefs.com/biology-mechanism-crispr-editing-leaves BioBriefs en 2026-09-27T04:31:33Z Biology mechanism: CRISPR editing leaves mosaic DNA effects https://biobriefs.com/cancer-microenvironment-and-immune-escape BioBriefs en 2026-09-27T04:31:33Z Cancer microenvironment and immune escape: new targets emerge https://biobriefs.com/cellular-therapies-and-oncology-workflow BioBriefs en 2026-09-27T04:31:33Z Cellular therapies and oncology workflow: imaging and safety signals https://biobriefs.com/antimicrobial-resistance-and-diagnostics-faster BioBriefs en 2026-09-27T04:31:33Z Antimicrobial resistance and diagnostics: faster detection and stewardship pressure https://biobriefs.com/cancer-therapy-engineering-car-nk BioBriefs en 2026-09-27T04:31:33Z Cancer therapy engineering: CAR-NK signaling rewired for durability https://biobriefs.com/regulatory-approvals BioBriefs en 2026-09-26T21:31:15Z Regulatory approvals https://biobriefs.com/ipo-and-market-financing BioBriefs en 2026-09-26T21:31:15Z IPO and market financing https://biobriefs.com/partnerships-and-licensing-drug-delivery BioBriefs en 2026-09-26T21:31:15Z Partnerships and licensing (drug delivery) https://biobriefs.com/oncology-immunotherapy-and-car-t BioBriefs en 2026-09-26T21:31:15Z Oncology—immunotherapy and CAR-T expansion https://biobriefs.com/clinical-data-drug-safety-and BioBriefs en 2026-09-26T21:31:15Z Clinical data—drug safety and real-world complications after cell therapy https://biobriefs.com/regimen-and-safety-identifying-biomarkers BioBriefs en 2026-09-26T21:31:15Z Regimen and safety—identifying biomarkers for amiodarone lung toxicity https://biobriefs.com/oncology-imaging-and-recurrence-risk BioBriefs en 2026-09-26T21:31:15Z Oncology—imaging and recurrence risk tools https://biobriefs.com/drug-development-and-manufacturing-scaling BioBriefs en 2026-09-26T21:31:15Z Drug development and manufacturing—scaling siRNA formulations https://biobriefs.com/fda-and-clinical-pipeline-ind BioBriefs en 2026-09-26T21:31:15Z FDA and clinical pipeline—IND approvals and rare-disease progress https://biobriefs.com/patent-and-legal-outcomes-biotech BioBriefs en 2026-09-26T21:31:15Z Patent and legal outcomes—biotech disputes https://biobriefs.com/fda-approvals-and-product-launches BioBriefs en 2026-09-26T16:31:31Z FDA approvals and product launches https://biobriefs.com/regulatory-approvals-for-ultra-rare BioBriefs en 2026-09-26T16:31:31Z Regulatory approvals for ultra-rare disease medicines https://biobriefs.com/regulatory-and-pipeline-expansion-in BioBriefs en 2026-09-26T16:31:31Z Regulatory and pipeline expansion in oncology (kidney cancer) https://biobriefs.com/biopharma-ipo-momentum-and-market BioBriefs en 2026-09-26T16:31:31Z Biopharma IPO momentum and market entry for RNAi https://biobriefs.com/biotech-financing-and-deal-flow BioBriefs en 2026-09-26T16:31:31Z Biotech financing and deal flow supporting R&D https://biobriefs.com/biotech-disputes-and-courtroom-wins BioBriefs en 2026-09-26T16:31:31Z Biotech disputes and courtroom wins affecting collaboration value https://biobriefs.com/early-stage-gene-editing-and BioBriefs en 2026-09-26T16:31:31Z Early-stage gene editing and platform IND milestones https://biobriefs.com/car-t-and-cell-therapy BioBriefs en 2026-09-26T16:31:31Z CAR-T and cell therapy pipeline review focus https://biobriefs.com/scientific-advance-targeting-bacterial-persistence BioBriefs en 2026-09-26T16:31:31Z Scientific advance: targeting bacterial persistence in recurrent UTIs https://biobriefs.com/drug-discovery-platform-strategy-mutating BioBriefs en 2026-09-26T16:31:31Z Drug discovery platform strategy: mutating bacteriophages at genome scale https://biobriefs.com/fda-approval-expands-treatment-options BioBriefs en 2026-09-26T14:31:23Z FDA approval expands treatment options for FGFR2-rearranged bile duct cancer https://biobriefs.com/fda-backed-decision-advances-multi BioBriefs en 2026-09-26T14:31:23Z FDA-backed decision advances multi-cancer blood test scrutiny https://biobriefs.com/ipo-adarx-prices-446-3m BioBriefs en 2026-09-26T14:31:23Z IPO: ADARx prices $446.3M debut to expand RNAi pipeline https://biobriefs.com/lilly-extends-china-innovation-drive BioBriefs en 2026-09-26T14:31:23Z Lilly extends China innovation drive with Innocare discovery-stage deal https://biobriefs.com/drug-development-and-manufacturing-jnc BioBriefs en 2026-09-26T14:31:23Z Drug development and manufacturing: JNC showcases large-pore cellulose media for bigger biologics and viral vectors https://biobriefs.com/biopharma-funding-enveda-raises-311m BioBriefs en 2026-09-26T14:31:23Z Biopharma funding: Enveda raises $311M series E for plant-discovered molecules https://biobriefs.com/clinical-and-regulatory-milestone-fda BioBriefs en 2026-09-26T14:31:23Z Clinical and regulatory milestone: FDA approval of AATD prime editor PM-647 https://biobriefs.com/healthcare-policy-and-regulation-fda BioBriefs en 2026-09-26T14:31:23Z Healthcare policy and regulation: FDA seeks more clarity on when one pivotal trial is enough https://biobriefs.com/patent-litigation-nektar-wins-90m BioBriefs en 2026-09-26T14:31:23Z Patent litigation: Nektar wins $90M in Lilly rezpeg licensing dispute https://biobriefs.com/biopharma-industry-dispute-and-reputational BioBriefs en 2026-09-26T14:31:23Z Biopharma industry dispute and reputational risk: Lilly targeted after GLP-1 press release language criticism https://biobriefs.com/regulatory-approvals-oncology BioBriefs en 2026-09-26T10:31:26Z Regulatory approvals: oncology https://biobriefs.com/major-drugmaking-dealmaking-china-licensing BioBriefs en 2026-09-26T10:31:26Z Major drugmaking dealmaking: China licensing and discovery pacts https://biobriefs.com/big-pharma-partnering-drug-delivery BioBriefs en 2026-09-26T10:31:26Z Big pharma partnering: drug delivery technology acquisition https://biobriefs.com/judicial-outcomes-licensing-dispute-damages BioBriefs en 2026-09-26T10:31:26Z Judicial outcomes: licensing dispute damages https://biobriefs.com/capital-markets-rnai-ipo-and BioBriefs en 2026-09-26T10:31:26Z Capital markets: RNAi IPO and AbbVie-linked funding https://biobriefs.com/fda-approvals-endocrine-and-pipeline BioBriefs en 2026-09-26T10:31:26Z FDA approvals: endocrine and pipeline competition https://biobriefs.com/clinical-stage-oncology-updates-pancreatic BioBriefs en 2026-09-26T10:31:26Z Clinical-stage oncology updates: pancreatic cancer regimen evidence https://biobriefs.com/engineering-and-platform-science-optimized BioBriefs en 2026-09-26T10:31:26Z Engineering and platform science: optimized phage mutagenesis for antimicrobial resistance https://biobriefs.com/fda-regulatory-policy-when-one BioBriefs en 2026-09-26T10:31:26Z FDA/Regulatory policy: when one pivotal trial may be enough https://biobriefs.com/biotech-financing-growth-stage-plant BioBriefs en 2026-09-26T10:31:26Z Biotech financing: growth-stage plant-discovery drug platform https://biobriefs.com/fda-greenlights-new-oncology-medicine BioBriefs en 2026-09-26T09:31:33Z FDA greenlights new oncology medicine in cholangiocarcinoma https://biobriefs.com/adarxs-ipo-brings-rnai-biotech BioBriefs en 2026-09-26T09:31:33Z ADARx’s IPO brings RNAi biotech to public markets with AbbVie support https://biobriefs.com/merck-expands-welireg-use-with BioBriefs en 2026-09-26T09:31:33Z Merck expands Welireg use with new kidney-cancer combination https://biobriefs.com/novo-and-nanexa-ink-long BioBriefs en 2026-09-26T09:31:33Z Novo and Nanexa ink long-acting drug delivery deal worth up to $1.3B https://biobriefs.com/lilly-pays-up-to-3 BioBriefs en 2026-09-26T09:31:33Z Lilly pays up to $3.35B to access InnoCare discovery platform https://biobriefs.com/oncolytic-virotherapy-gains-spotlight-with BioBriefs en 2026-09-26T09:31:33Z Oncolytic virotherapy gains spotlight with engineered vaccinia candidate https://biobriefs.com/car-t-expands-deeper-into BioBriefs en 2026-09-26T09:31:33Z CAR-T expands deeper into autoimmune and solid-tumor territory https://biobriefs.com/global-anticancer-testing-fda-advisory BioBriefs en 2026-09-26T09:31:33Z Global anticancer testing: FDA advisory panel backs Galleri with concerns over follow-up use https://biobriefs.com/regulatory-pathway-question-when-one BioBriefs en 2026-09-26T09:31:33Z Regulatory pathway question: when one pivotal trial can be enough https://biobriefs.com/lps-safety-review-supports-controlled BioBriefs en 2026-09-26T09:31:33Z LPS safety review supports controlled human inflammation research https://biobriefs.com/fda-approvals-oncology BioBriefs en 2026-09-26T04:31:24Z FDA approvals – oncology https://biobriefs.com/ipo-and-market-access-rna BioBriefs en 2026-09-26T04:31:24Z IPO and market access – RNA therapeutics https://biobriefs.com/m-a-and-litigation-nektar BioBriefs en 2026-09-26T04:31:24Z M&A and litigation – Nektar vs Eli Lilly https://biobriefs.com/partnerships-cardiometabolic-drug-delivery BioBriefs en 2026-09-26T04:31:24Z Partnerships – cardiometabolic drug delivery https://biobriefs.com/clinical-pipeline-alzheimers-psychosis-setback BioBriefs en 2026-09-26T04:31:24Z Clinical pipeline – Alzheimer’s psychosis setback and Phase 3 path https://biobriefs.com/platform-and-drug-discovery-computational BioBriefs en 2026-09-26T04:31:24Z Platform and drug discovery – computational biology and translation https://biobriefs.com/cell-therapy-durable-autoimmune-benefit BioBriefs en 2026-09-26T04:31:24Z Cell therapy – durable autoimmune benefit in CAR-T https://biobriefs.com/diagnostics-and-early-detection-multicancer BioBriefs en 2026-09-26T04:31:24Z Diagnostics and early detection – multicancer screening policy risk https://biobriefs.com/research-and-translational-oncology-tumor BioBriefs en 2026-09-26T04:31:24Z Research and translational oncology – tumor microenvironment and metastasis biology https://biobriefs.com/manufacturing-and-cdmo-capacity-ema BioBriefs en 2026-09-26T04:31:24Z Manufacturing and CDMO capacity – EMA GMP certification in biologics https://biobriefs.com/fda-approvals-in-oncology-and BioBriefs en 2026-09-25T21:31:31Z FDA approvals in oncology and rare disease https://biobriefs.com/rnai-ipo-debut-and-public BioBriefs en 2026-09-25T21:31:31Z RNAi IPO debut and public-market momentum https://biobriefs.com/big-dealmaking-lilly-expands-china BioBriefs en 2026-09-25T21:31:31Z Big dealmaking: Lilly expands China reach with InnoCare pact https://biobriefs.com/car-t-in-rare-autoimmune BioBriefs en 2026-09-25T21:31:31Z CAR T in rare autoimmune disease: Kyverna gains durable signal https://biobriefs.com/lilly-nanexa-delivery-deal-ties BioBriefs en 2026-09-25T21:31:31Z Lilly-Nanexa delivery deal ties to longer-acting obesity injectables https://biobriefs.com/chromatography-and-bioprocessing-scale-up BioBriefs en 2026-09-25T21:31:31Z Chromatography and bioprocessing scale-up via SFC partnerships https://biobriefs.com/company-test-to-market-prime BioBriefs en 2026-09-25T21:31:31Z Company test-to-market: Prime Medicine’s in vivo Prime Editor clears FDA IND https://biobriefs.com/drug-platform-innovation-crispr-based BioBriefs en 2026-09-25T21:31:31Z Drug platform innovation: CRISPR-based genome-wide mutagenesis for phages https://biobriefs.com/biotech-litigation-nektar-wins-damages BioBriefs en 2026-09-25T21:31:31Z Biotech litigation: Nektar wins damages in Lilly rezpeg dispute https://biobriefs.com/clinical-pipeline-execution-merck-expands BioBriefs en 2026-09-25T21:31:31Z Clinical pipeline execution: Merck expands Welireg use with FDA approval in kidney cancer https://biobriefs.com/regulatory-approval-onswik-once-weekly BioBriefs en 2026-09-25T16:31:36Z Regulatory approval: Onswik once-weekly insulin pen clears FDA https://biobriefs.com/regulatory-approval-merck-expands-welireg BioBriefs en 2026-09-25T16:31:36Z Regulatory approval: Merck expands Welireg use for advanced RCC https://biobriefs.com/fda-decision-lyrfigtu-wins-approval BioBriefs en 2026-09-25T16:31:36Z FDA decision: Lyrfigtu wins approval for FGFR2 fusion cholangiocarcinoma https://biobriefs.com/china-to-western-dealmaking-lilly BioBriefs en 2026-09-25T16:31:36Z China-to-Western dealmaking: Lilly signs up to $3.35B with InnoCare https://biobriefs.com/biosimilar-regulatory-roadmap-fda-lays BioBriefs en 2026-09-25T16:31:36Z Biosimilar regulatory roadmap: FDA lays out strategy for interchangeable products https://biobriefs.com/ai-biomed-diagnostics-transparent-ai BioBriefs en 2026-09-25T16:31:36Z AI-biomed diagnostics: Transparent AI hits 95% accuracy choosing immunotherapy in HNSCC https://biobriefs.com/oncology-ai-early-warning-ct BioBriefs en 2026-09-25T16:31:36Z Oncology AI early-warning: CT model flags immunotherapy pneumonitis risk https://biobriefs.com/platform-deals-roche-genentech-inks BioBriefs en 2026-09-25T16:31:36Z Platform deals: Roche Genentech inks $1.5B bispecific pact with Earendil https://biobriefs.com/clinical-innovation-prime-medicine-pm BioBriefs en 2026-09-25T16:31:36Z Clinical innovation: Prime Medicine PM-647 wins IND for in vivo prime editing in AATD https://biobriefs.com/investment-and-pipeline-finance-enveda BioBriefs en 2026-09-25T16:31:36Z Investment and pipeline finance: Enveda banks $311M Series E for AI-driven drugs https://biobriefs.com/fda-approval-fgfr2-targeted-bile BioBriefs en 2026-09-25T14:31:38Z FDA approval—FGFR2-targeted bile duct cancer therapy https://biobriefs.com/clinical-pipeline-merck-expands-welireg BioBriefs en 2026-09-25T14:31:38Z Clinical pipeline—Merck expands Welireg use with Lenvima combo https://biobriefs.com/big-deals-roche-and-earendil BioBriefs en 2026-09-25T14:31:38Z Big deals—Roche and Earendil expand bispecific antibody effort https://biobriefs.com/strategic-funding-enveda-banks-311m BioBriefs en 2026-09-25T14:31:38Z Strategic funding—Enveda banks $311M Series E for AI drug discovery https://biobriefs.com/ipo-momentum-adarx-prices-446m BioBriefs en 2026-09-25T14:31:38Z IPO momentum—ADARx prices $446M RNAi debut and adds AbbVie backing https://biobriefs.com/biopharma-deals-lilly-deepens-china BioBriefs en 2026-09-25T14:31:38Z Biopharma deals—Lilly deepens China innovation with InnoCare pact https://biobriefs.com/fda-advisory-grail-galleri-panel BioBriefs en 2026-09-25T14:31:38Z FDA advisory—Grail Galleri panel vote advances multi-cancer screening https://biobriefs.com/cell-therapy-update-kyverna-reports BioBriefs en 2026-09-25T14:31:38Z Cell therapy update—Kyverna reports 1-year autoimmune CAR-T benefit https://biobriefs.com/gene-therapy-sarepta-settles-regenxbio BioBriefs en 2026-09-25T14:31:38Z Gene therapy—Sarepta settles Regenxbio claims https://biobriefs.com/ai-and-biosecurity-anthropics-wet BioBriefs en 2026-09-25T14:31:38Z AI and biosecurity—Anthropic’s wet lab discovery with gene-editing-like system https://biobriefs.com/fda-approves-first-in-class BioBriefs en 2026-09-25T10:31:23Z FDA approves first-in-class-like oral therapy for FGFR2-driven bile duct cancer https://biobriefs.com/rnai-ipo-surge-adarx-prices BioBriefs en 2026-09-25T10:31:23Z RNAi IPO surge: ADARx prices upsized offering with AbbVie backstop https://biobriefs.com/eli-lilly-deepens-china-innovation BioBriefs en 2026-09-25T10:31:23Z Eli Lilly deepens China innovation push with new InnoCare R&D pact https://biobriefs.com/roche-and-genentech-launch-a BioBriefs en 2026-09-25T10:31:23Z Roche and Genentech launch a $1.5B bispecific deal with Earendil Labs https://biobriefs.com/big-pharma-shifts-exit-dynamics BioBriefs en 2026-09-25T10:31:23Z Big Pharma shifts exit dynamics: CGT spending rises as acquisitions replace IPOs https://biobriefs.com/envedas-series-e-underscores-ai BioBriefs en 2026-09-25T10:31:23Z Enveda’s Series E underscores AI-led plant chemistry as clinical capital target https://biobriefs.com/fda-advisory-panel-advances-grail BioBriefs en 2026-09-25T10:31:23Z FDA advisory panel advances Grail Galleri; safety and effectiveness debated https://biobriefs.com/igan-competition-heats-up-roche BioBriefs en 2026-09-25T10:31:23Z IgAN competition heats up: Roche sefaxersen clears phase 3 goal https://biobriefs.com/biotech-and-regulatory-ecosystem-hhs BioBriefs en 2026-09-25T10:31:23Z Biotech and regulatory ecosystem: HHS weighs how to regulate islet cell products for T1 diabetes https://biobriefs.com/therapy-success-proof-in-autoimmune BioBriefs en 2026-09-25T10:31:23Z Therapy success proof in autoimmune CAR-T: Kyverna reports 1-year miv-cel results https://biobriefs.com/regulatory-approval-oncology-therapeutics BioBriefs en 2026-09-25T09:31:17Z Regulatory approval – oncology therapeutics https://biobriefs.com/clinical-trial-immunotherapy-plus-epigenetic BioBriefs en 2026-09-25T09:31:17Z Clinical trial – immunotherapy plus epigenetic strategy in bile duct cancer https://biobriefs.com/capital-markets-ipos-in-rna BioBriefs en 2026-09-25T09:31:17Z Capital markets – IPOs in RNA interference https://biobriefs.com/strategic-deals-roche-genentech-expands BioBriefs en 2026-09-25T09:31:17Z Strategic deals – Roche Genentech expands bispecific discovery with Earendil https://biobriefs.com/strategic-partnership-envida-raises-series BioBriefs en 2026-09-25T09:31:17Z Strategic partnership – Envida raises Series E to scale AI plant-and-microbe drug discovery https://biobriefs.com/regulatory-and-policy-fda-commissioner BioBriefs en 2026-09-25T09:31:17Z Regulatory and policy – FDA commissioner nomination and vaccine stance https://biobriefs.com/cybersecurity-and-health-tech-hospital BioBriefs en 2026-09-25T09:31:17Z Cybersecurity and health tech – hospital AI training and data governance https://biobriefs.com/platform-innovation-ai-enabled-biopsy BioBriefs en 2026-09-25T09:31:17Z Platform innovation – AI-enabled biopsy planning pilot https://biobriefs.com/clinical-oncology-diagnostics-multi-cancer BioBriefs en 2026-09-25T09:31:17Z Clinical oncology diagnostics – multi-cancer blood test scrutiny https://biobriefs.com/autoimmune-car-t-long-term BioBriefs en 2026-09-25T09:31:17Z Autoimmune CAR-T – long-term safety and efficacy update https://biobriefs.com/fda-approvals-fgfr2-fusion-cholangiocarcinoma BioBriefs en 2026-09-25T04:31:24Z FDA approvals: FGFR2 fusion cholangiocarcinoma https://biobriefs.com/fda-advisory-panel-backs-grails BioBriefs en 2026-09-25T04:31:24Z FDA advisory panel backs Grail’s multicancer blood test https://biobriefs.com/rnai-ipo-adarx-prices-446m BioBriefs en 2026-09-25T04:31:24Z RNAi IPO: ADARx prices $446M offering with AbbVie support https://biobriefs.com/strategic-finance-envedas-311m-series BioBriefs en 2026-09-25T04:31:24Z Strategic finance: Enveda’s $311M Series E for AI-driven nature-derived drugs https://biobriefs.com/biotech-dealmaking-roche-joins-discovery BioBriefs en 2026-09-25T04:31:24Z Biotech dealmaking: Roche joins discovery sprint with Atavistik and Earendil https://biobriefs.com/autoimmune-car-t-kyverna-reports BioBriefs en 2026-09-25T04:31:24Z Autoimmune CAR-T: Kyverna reports one-year miv-cel data https://biobriefs.com/immunotherapy-innovation-nanoparticles-reprogram-scar BioBriefs en 2026-09-25T04:31:24Z Immunotherapy innovation: nanoparticles reprogram scar-driving tumor macrophages https://biobriefs.com/cns-drug-discovery-earendil-lands BioBriefs en 2026-09-25T04:31:24Z CNS drug discovery: Earendil lands $1.5B Genentech collaboration https://biobriefs.com/bioprocessing-sartorius-nmpc-boosts-continuous BioBriefs en 2026-09-25T04:31:24Z Bioprocessing: Sartorius NMPC boosts continuous CHO perfusion productivity https://biobriefs.com/regulatory-leadership-fda-nominee-heidi BioBriefs en 2026-09-25T04:31:24Z Regulatory leadership: FDA nominee Heidi Overton affirms vaccine and mifepristone safety https://biobriefs.com/fda-advisory-panel-backs-grails BioBriefs en 2026-09-24T21:31:33Z FDA advisory panel backs Grail’s multi-cancer blood test https://biobriefs.com/fda-decision-elevars-lirafugratinib-approved BioBriefs en 2026-09-24T21:31:33Z FDA decision: Elevar’s lirafugratinib approved for FGFR2-rearranged bile duct cancer https://biobriefs.com/lilly-expands-china-innovation-pipeline BioBriefs en 2026-09-24T21:31:33Z Lilly expands China innovation pipeline via InnoCare deal https://biobriefs.com/kyverna-reports-1-year-durability BioBriefs en 2026-09-24T21:31:33Z Kyverna reports 1-year durability data for autoimmune CAR-T https://biobriefs.com/fda-advisory-spotlight-on-overtons BioBriefs en 2026-09-24T21:31:33Z FDA advisory spotlight on Overton’s confirmation – vaccines and mifepristone under Senate scrutiny https://biobriefs.com/elephants-in-the-room-mercks BioBriefs en 2026-09-24T21:31:33Z Elephants in the room: Merck’s Brunello DME study lifts Wnt strategy while analysts weigh safety https://biobriefs.com/novo-and-lilly-rivalry-fda BioBriefs en 2026-09-24T21:31:33Z Novo and Lilly rivalry: FDA approves Eli Lilly’s once-weekly insulin pen https://biobriefs.com/biopharma-financing-and-platform-momentum BioBriefs en 2026-09-24T21:31:33Z Biopharma financing and platform momentum: Enveda’s $311M Series E https://biobriefs.com/sarepta-settles-regenxbio-gene-therapy BioBriefs en 2026-09-24T21:31:33Z Sarepta settles Regenxbio gene therapy claims; continues gene-therapy legal and funding landscape https://biobriefs.com/fda-approvals-in-oncology BioBriefs en 2026-09-24T16:31:32Z FDA approvals in oncology https://biobriefs.com/fda-actions-in-diabetes-care BioBriefs en 2026-09-24T16:31:32Z FDA actions in diabetes care https://biobriefs.com/ophthalmology-drug-momentum-after-merck BioBriefs en 2026-09-24T16:31:32Z Ophthalmology drug momentum after Merck deal https://biobriefs.com/cell-therapy-long-term-efficacy BioBriefs en 2026-09-24T16:31:32Z Cell therapy long-term efficacy and FDA readiness https://biobriefs.com/alzheimers-phase-2-failure-prompting BioBriefs en 2026-09-24T16:31:32Z Alzheimer’s: Phase 2 failure prompting Phase 3 changes https://biobriefs.com/autoimmune-checkpoint-regulatory-strategy-signals BioBriefs en 2026-09-24T16:31:32Z Autoimmune checkpoint/regulatory strategy signals in M&A commentary https://biobriefs.com/drug-discovery-deals-and-platform BioBriefs en 2026-09-24T16:31:32Z Drug discovery deals and platform expansion https://biobriefs.com/ai-driven-biotech-funding-and BioBriefs en 2026-09-24T16:31:32Z AI-driven biotech funding and IPO momentum https://biobriefs.com/clinical-diagnostics-multi-cancer-blood BioBriefs en 2026-09-24T16:31:32Z Clinical diagnostics: multi-cancer blood test advances in FDA review https://biobriefs.com/gene-therapy-litigation-settlement BioBriefs en 2026-09-24T16:31:32Z Gene therapy litigation settlement https://biobriefs.com/ai-drug-discovery-funding-and BioBriefs en 2026-09-24T14:31:44Z AI drug discovery funding and platform momentum https://biobriefs.com/fda-advisory-panel-clears-multi BioBriefs en 2026-09-24T14:31:44Z FDA advisory panel clears multi-cancer blood test, setting up next regulatory step https://biobriefs.com/roche-and-ionis-score-phase BioBriefs en 2026-09-24T14:31:44Z Roche and Ionis score Phase 3 progress in IgA nephropathy https://biobriefs.com/kyverna-pushes-autoimmune-car-t BioBriefs en 2026-09-24T14:31:44Z Kyverna pushes autoimmune CAR-T durability with 1-year data tied to FDA submission https://biobriefs.com/iambic-files-for-nasdaq-ipo BioBriefs en 2026-09-24T14:31:44Z Iambic files for Nasdaq IPO as AI drug discovery meets robotics https://biobriefs.com/lilly-expands-china-footprint-with BioBriefs en 2026-09-24T14:31:44Z Lilly expands China footprint with another InnoCare pact https://biobriefs.com/amicus-vet-leadership-transition-at BioBriefs en 2026-09-24T14:31:44Z Amicus vet leadership transition at Travere Therapeutics https://biobriefs.com/immunovant-ends-cutaneous-lupus-fcrn BioBriefs en 2026-09-24T14:31:44Z Immunovant ends cutaneous lupus FcRn program after Phase 2 setback https://biobriefs.com/roivants-lupus-fcrn-fails-in BioBriefs en 2026-09-24T14:31:44Z Roivant’s lupus FcRn fails in Phase 2b for an FcRn drug https://biobriefs.com/merck-scores-pivotal-win-in BioBriefs en 2026-09-24T14:31:44Z Merck scores pivotal win in $3B eye-disease candidate https://biobriefs.com/autoimmune-car-t-long-term BioBriefs en 2026-09-24T10:31:43Z Autoimmune CAR-T long-term efficacy package for FDA https://biobriefs.com/cancer-screening-test-advances-through BioBriefs en 2026-09-24T10:31:43Z Cancer screening test advances through FDA advisory gate https://biobriefs.com/iga-nephropathy-rivalry-heats-up BioBriefs en 2026-09-24T10:31:43Z IgA nephropathy rivalry heats up with late-stage wins https://biobriefs.com/car-t-data-recalibration-amid BioBriefs en 2026-09-24T10:31:43Z CAR-T data recalibration amid autoimmune safety scrutiny https://biobriefs.com/ai-native-drug-discovery-funding BioBriefs en 2026-09-24T10:31:43Z AI-native drug discovery funding boosts clinical pipeline https://biobriefs.com/robot-assisted-surgery-governance-update BioBriefs en 2026-09-24T10:31:43Z Robot-assisted surgery governance update in China https://biobriefs.com/cell-therapy-platform-collaboration-for BioBriefs en 2026-09-24T10:31:43Z Cell therapy platform collaboration for patient-matched pancreatic models https://biobriefs.com/ai-at-the-bedside-and BioBriefs en 2026-09-24T10:31:43Z AI at the bedside and diagnostics: bloodstream and imaging workflow advances https://biobriefs.com/med-tech-innovation-funding-and BioBriefs en 2026-09-24T10:31:43Z Med-tech innovation funding and regulatory momentum in interventional devices https://biobriefs.com/at-home-screening-startup-raises BioBriefs en 2026-09-24T10:31:43Z At-home screening startup raises Series A https://biobriefs.com/fda-adjacent-progress-for-multi BioBriefs en 2026-09-24T09:32:06Z FDA-adjacent progress for multi-cancer blood screening https://biobriefs.com/clinical-phase-3-momentum-in BioBriefs en 2026-09-24T09:32:06Z Clinical Phase 3 momentum in IgA nephropathy with Roche’s mRNA-targeting candidate https://biobriefs.com/otsuka-and-ionis-chase-another BioBriefs en 2026-09-24T09:32:06Z Otsuka and Ionis chase another precision-ALS milestone in FUS-associated disease https://biobriefs.com/ai-platform-capital-raises-as BioBriefs en 2026-09-24T09:32:06Z AI platform capital raises as clinical programs expand https://biobriefs.com/ai-drug-design-startup-basecamp BioBriefs en 2026-09-24T09:32:06Z AI drug design startup Basecamp lands large Series C for in-vivo cell therapies https://biobriefs.com/genetic-medicines-mutation-agnostic-crispr BioBriefs en 2026-09-24T09:32:06Z Genetic medicines: mutation-agnostic CRISPR therapy framework heads toward clinic https://biobriefs.com/m-a-and-portfolio-reshaping BioBriefs en 2026-09-24T09:32:06Z M&A and portfolio reshaping in neurodegeneration and rare disease https://biobriefs.com/new-device-round-at-home BioBriefs en 2026-09-24T09:32:06Z New device round: at-home HPV screening moves forward with Series A financing https://biobriefs.com/device-sector-funding-anaconda-raises BioBriefs en 2026-09-24T09:32:06Z Device sector funding: Anaconda raises $56 million for stroke catheter trial work https://biobriefs.com/industry-funding-and-strategy-envedas BioBriefs en 2026-09-24T09:32:06Z Industry funding and strategy: Enveda’s and ecosystem competition widen for AI drug discovery https://biobriefs.com/regulatory-green-light-for-multi BioBriefs en 2026-09-24T04:31:52Z Regulatory green light for multi-cancer blood screening https://biobriefs.com/clinical-phase-3-momentum-in BioBriefs en 2026-09-24T04:31:52Z Clinical phase 3 momentum in IgA nephropathy https://biobriefs.com/phase-3-win-in-fus BioBriefs en 2026-09-24T04:31:52Z Phase 3 win in FUS-ALS with antisense therapy https://biobriefs.com/big-pharma-betting-on-ai BioBriefs en 2026-09-24T04:31:52Z Big Pharma betting on AI splicing platform https://biobriefs.com/ai-drug-discovery-startup-locks BioBriefs en 2026-09-24T04:31:52Z AI drug discovery startup locks in major Series E funding https://biobriefs.com/platform-partnership-to-link-patient BioBriefs en 2026-09-24T04:31:52Z Platform partnership to link patient biology with 3D pancreatic cancer models https://biobriefs.com/med-tech-collaboration-expands-across BioBriefs en 2026-09-24T04:31:52Z Med-tech collaboration expands across drug development lifecycle https://biobriefs.com/fda-ind-clearance-for-systimmunes BioBriefs en 2026-09-24T04:31:52Z FDA IND clearance for Systimmune’s immunotherapy bispecific https://biobriefs.com/cgt-collaboration-shifts-toward-shared BioBriefs en 2026-09-24T04:31:52Z CGT collaboration shifts toward shared infrastructure https://biobriefs.com/ai-cell-therapy-design-startup BioBriefs en 2026-09-24T04:31:52Z AI cell therapy design startup raises Series C https://biobriefs.com/phase-3-wins-reshape-iga BioBriefs en 2026-09-23T21:31:56Z Phase 3 wins reshape IgA nephropathy competition with mRNA-targeted assets https://biobriefs.com/otsuka-and-ionis-score-phase BioBriefs en 2026-09-23T21:31:56Z Otsuka and Ionis score Phase 3 win in FUS-ALS, pushing for expedited regulator talks https://biobriefs.com/amgens-sjogrens-therapy-hits-phase BioBriefs en 2026-09-23T21:31:56Z Amgen’s Sjögren’s therapy hits Phase 3 objectives after Horizon acquisition https://biobriefs.com/ai-drugmakers-accelerate-with-megafunding BioBriefs en 2026-09-23T21:31:56Z AI drugmakers accelerate with megafunding rounds and deeper clinical pipeline commitments https://biobriefs.com/radiopharma-consolidation-and-isotope-supply BioBriefs en 2026-09-23T21:31:56Z Radiopharma consolidation and isotope supply control moves to center stage https://biobriefs.com/ind-clearances-and-platform-advances BioBriefs en 2026-09-23T21:31:56Z IND clearances and platform advances push next-generation T-cell engagers toward first-in-human trials https://biobriefs.com/process-innovation-targets-higher-productivity BioBriefs en 2026-09-23T21:31:56Z Process innovation targets higher productivity and cost control in biologics manufacturing https://biobriefs.com/u-s-fda-adviser-scrutiny BioBriefs en 2026-09-23T21:31:56Z U.S. FDA adviser scrutiny hits Grail multi-cancer blood test effectiveness questions https://biobriefs.com/cybersecurity-and-ai-validation-concerns BioBriefs en 2026-09-23T21:31:56Z Cybersecurity and AI validation concerns surface in clinical deployment risk https://biobriefs.com/digital-health-and-clinical-infrastructure BioBriefs en 2026-09-23T21:31:56Z Digital health and clinical infrastructure: MHRA warns eHR gaps can sink UK trial participation https://biobriefs.com/enveda-mega-round-drives-ai BioBriefs en 2026-09-23T16:32:13Z Enveda mega-round drives AI-native pipeline into later-stage development https://biobriefs.com/ai-drug-design-startup-basecamp BioBriefs en 2026-09-23T16:32:13Z AI drug-design startup Basecamp lands major funding for in vivo cell therapies https://biobriefs.com/immunovant-stops-phase-2-imvt BioBriefs en 2026-09-23T16:32:13Z Immunovant stops Phase 2 IMVT-1402 program after cutaneous lupus failure https://biobriefs.com/novartis-accelerates-radioligand-therapy-pipeline BioBriefs en 2026-09-23T16:32:13Z Novartis accelerates radioligand therapy pipeline via $900M Boomray licensing https://biobriefs.com/telix-and-itm-to-merge BioBriefs en 2026-09-23T16:32:13Z Telix and ITM to merge to scale radiopharmaceutical manufacturing and supply https://biobriefs.com/amgen-posts-phase-3-success BioBriefs en 2026-09-23T16:32:13Z Amgen posts Phase 3 success in Sjögren’s with dazodalibep after Horizon acquisition https://biobriefs.com/adagene-wins-china-ind-clearance BioBriefs en 2026-09-23T16:32:13Z Adagene wins China IND clearance for ADG-138 HER2×CD3 bispecific T-cell engager https://biobriefs.com/boehringer-expands-variant-bio-deal BioBriefs en 2026-09-23T16:32:13Z Boehringer expands Variant Bio deal into cardiovascular applications https://biobriefs.com/fda-ind-cleared-for-systimmune BioBriefs en 2026-09-23T16:32:13Z FDA IND cleared for Systimmune bispecific SI-B037 targeting immunosuppression https://biobriefs.com/genetic-and-manufacturing-oversight-mhra BioBriefs en 2026-09-23T16:32:13Z Genetic and manufacturing oversight: MHRA warns eHR noncompliance can derail UK clinical trials https://biobriefs.com/regulatory-acceleration-and-trial-infrastructure BioBriefs en 2026-09-23T14:31:59Z Regulatory acceleration and trial infrastructure https://biobriefs.com/kidney-disease-drug-wins-and BioBriefs en 2026-09-23T14:31:59Z Kidney disease drug wins and race for faster approvals https://biobriefs.com/big-pharma-licensing-deals-reshape BioBriefs en 2026-09-23T14:31:59Z Big pharma licensing deals reshape oncology target discovery https://biobriefs.com/ai-drug-design-funding-accelerates BioBriefs en 2026-09-23T14:31:59Z AI drug design funding accelerates in vivo reprogramming ambitions https://biobriefs.com/rare-disease-and-gene-therapy BioBriefs en 2026-09-23T14:31:59Z Rare disease and gene therapy momentum in ophthalmology https://biobriefs.com/cell-and-organoid-engineering-pushes BioBriefs en 2026-09-23T14:31:59Z Cell and organoid engineering pushes oncology translation https://biobriefs.com/gene-therapy-and-gene-editing BioBriefs en 2026-09-23T14:31:59Z Gene therapy and gene editing tools move toward earlier feasibility https://biobriefs.com/immunology-and-oncology-targeted-mechanisms BioBriefs en 2026-09-23T14:31:59Z Immunology and oncology: targeted mechanisms and emerging therapeutics https://biobriefs.com/radiopharma-consolidation-and-manufacturing-scale BioBriefs en 2026-09-23T14:31:59Z Radiopharma consolidation and manufacturing scale-up https://biobriefs.com/clinical-and-late-stage-autoimmune BioBriefs en 2026-09-23T14:31:59Z Clinical and late-stage autoimmune development signals https://biobriefs.com/kidney-disease-roche-and-vertex BioBriefs en 2026-09-23T10:31:50Z Kidney disease: Roche and Vertex advance late-stage programs toward approval https://biobriefs.com/ophthalmology-gene-therapy-beacon-pushes BioBriefs en 2026-09-23T10:31:50Z Ophthalmology gene therapy: Beacon pushes laruparetigene zovaparvovec toward BLA https://biobriefs.com/autoimmunity-amgens-dazodalibep-hits-phase BioBriefs en 2026-09-23T10:31:50Z Autoimmunity: Amgen’s dazodalibep hits Phase 3 bar in Sjögren’s https://biobriefs.com/immunology-oncology-new-checkpoint-biology BioBriefs en 2026-09-23T10:31:50Z Immunology oncology: New checkpoint biology explains PD-1 resistance in gastric cancer https://biobriefs.com/ai-and-clinical-safety-framework BioBriefs en 2026-09-23T10:31:50Z AI and clinical safety: Framework flags hidden failure modes in medical language models https://biobriefs.com/clinical-operations-and-regulation-fda BioBriefs en 2026-09-23T10:31:50Z Clinical operations and regulation: FDA pilots site activation support for faster Phase I starts https://biobriefs.com/radiopharmaceuticals-telix-to-acquire-itm BioBriefs en 2026-09-23T10:31:50Z Radiopharmaceuticals: Telix to acquire ITM, consolidating isotope and manufacturing capacity https://biobriefs.com/radiopharma-pipeline-otsuka-and-ionis BioBriefs en 2026-09-23T10:31:50Z Radiopharma pipeline: Otsuka and Ionis position for ALS expedited discussions after Phase 3 endpoint https://biobriefs.com/neuroinflammation-new-stem-cell-secretome BioBriefs en 2026-09-23T10:31:50Z Neuroinflammation: New stem-cell secretome strategy targets skin aging via mitophagy https://biobriefs.com/microbiome-and-immunometabolism-gut-metabolites BioBriefs en 2026-09-23T10:31:50Z Microbiome and immunometabolism: Gut metabolites reach bone cells through AKT1-linked signaling https://biobriefs.com/late-stage-wins-in-rare BioBriefs en 2026-09-23T09:31:53Z Late-stage wins in rare ophthalmology gene therapy https://biobriefs.com/big-pharma-partnerships-expand-in BioBriefs en 2026-09-23T09:31:53Z Big pharma partnerships expand in RNA splicing and precision oncology https://biobriefs.com/radiopharma-consolidation-accelerates-with-telix BioBriefs en 2026-09-23T09:31:53Z Radiopharma consolidation accelerates with Telix/ITM merger https://biobriefs.com/regulatory-pressure-on-clinical-data BioBriefs en 2026-09-23T09:31:53Z Regulatory pressure on clinical data workflows: MHRA warns on eHR compliance https://biobriefs.com/us-moves-to-streamline-early BioBriefs en 2026-09-23T09:31:53Z US moves to streamline early drug trials via FDA IND pilot https://biobriefs.com/fda-review-outcome-delayed-in BioBriefs en 2026-09-23T09:31:53Z FDA review outcome delayed in biliary cancer as Compass reports further trial request https://biobriefs.com/autoimmune-innovation-amgen-claims-phase BioBriefs en 2026-09-23T09:31:53Z Autoimmune innovation: Amgen claims Phase 3 progress in Sjögren’s https://biobriefs.com/drug-discovery-investment-regcell-raises BioBriefs en 2026-09-23T09:31:53Z Drug discovery investment: Regcell raises $66M to move Nobel-linked Treg platform to clinic https://biobriefs.com/pipeline-setback-in-oncology-worsening BioBriefs en 2026-09-23T09:31:53Z Pipeline setback in oncology: Worsening safety profile clouds Celldex hives readout https://biobriefs.com/obesity-therapeutics-broaden-into-psychiatric BioBriefs en 2026-09-23T09:31:53Z Obesity therapeutics broaden into psychiatric and addiction indications https://biobriefs.com/autoimmune-drug-trial-readouts-and BioBriefs en 2026-09-23T04:31:40Z Autoimmune drug trial readouts and regulatory timing https://biobriefs.com/radiopharma-consolidation-and-manufacturing-scale BioBriefs en 2026-09-23T04:31:40Z Radiopharma consolidation and manufacturing scale https://biobriefs.com/clinical-advances-in-genomics-led BioBriefs en 2026-09-23T04:31:40Z Clinical advances in genomics-led ocular gene therapy https://biobriefs.com/fda-accelerates-oncology-drug-pathway BioBriefs en 2026-09-23T04:31:40Z FDA accelerates oncology drug pathway decisions under new trial requirements https://biobriefs.com/new-funding-for-immune-reprogramming BioBriefs en 2026-09-23T04:31:40Z New funding for immune reprogramming and precision regulatory T-cell therapy https://biobriefs.com/fda-approval-expands-treatment-options BioBriefs en 2026-09-23T04:31:40Z FDA approval expands treatment options for ultra-rare neurologic disease https://biobriefs.com/oncology-microbiology-platform-expands-toward BioBriefs en 2026-09-23T04:31:40Z Oncology microbiology platform expands toward IND-enabling studies https://biobriefs.com/clinical-development-acceleration-via-fdas BioBriefs en 2026-09-23T04:31:40Z Clinical development acceleration via FDA’s QRI-assisted IND pilot https://biobriefs.com/cell-therapy-and-gene-therapy BioBriefs en 2026-09-23T04:31:40Z Cell therapy and gene therapy manufacturing software upgrades https://biobriefs.com/regulatory-and-healthcare-operations-trial BioBriefs en 2026-09-23T04:31:40Z Regulatory and healthcare operations: trial conduct hinges on EHR compliance https://biobriefs.com/autoimmune-therapy-advancement-in-sjogrens BioBriefs en 2026-09-22T21:32:43Z Autoimmune therapy advancement in Sjögren’s disease https://biobriefs.com/fda-decision-pressure-on-als BioBriefs en 2026-09-22T21:32:43Z FDA decision pressure on ALS drug pathway https://biobriefs.com/radiopharma-consolidation-accelerates-with-telix BioBriefs en 2026-09-22T21:32:43Z Radiopharma consolidation accelerates with Telix–ITM merger https://biobriefs.com/emerging-gene-therapy-approval-track BioBriefs en 2026-09-22T21:32:43Z Emerging gene therapy approval track in X-linked retinitis pigmentosa https://biobriefs.com/rna-splicing-deal-bets-on BioBriefs en 2026-09-22T21:32:43Z RNA splicing deal bets on precision oncology targets https://biobriefs.com/regulatory-pressure-on-chronic-hives BioBriefs en 2026-09-22T21:32:43Z Regulatory pressure on chronic hives therapy safety https://biobriefs.com/chronic-kidney-disease-label-push BioBriefs en 2026-09-22T21:32:43Z Chronic kidney disease label push hinges on urine response data at Vertex https://biobriefs.com/regulatory-and-trial-execution-risks BioBriefs en 2026-09-22T21:32:43Z Regulatory and trial execution risks in early-stage research timelines https://biobriefs.com/fda-pilot-program-targets-faster BioBriefs en 2026-09-22T21:32:43Z FDA pilot program targets faster Phase I starts https://biobriefs.com/glp-1-gip-obesity-franchise BioBriefs en 2026-09-22T21:32:42Z GLP-1/GIP obesity franchise expands with longer-interval maintenance data and wider pipeline bets https://biobriefs.com/obesity-drug-dosing-durability-at BioBriefs en 2026-09-22T16:32:36Z Obesity drug dosing durability at Viking https://biobriefs.com/radiopharma-consolidation-drive-telix-and BioBriefs en 2026-09-22T16:32:36Z Radiopharma consolidation drive: Telix and ITM https://biobriefs.com/immune-therapy-safety-signal-clouds BioBriefs en 2026-09-22T16:32:36Z Immune therapy safety signal clouds Celldex’s chronic hives drug https://biobriefs.com/regulatory-and-clinical-momentum-for BioBriefs en 2026-09-22T16:32:36Z Regulatory and clinical momentum for Otsuka/Ionis ALS therapy https://biobriefs.com/gene-therapy-milestone-in-x BioBriefs en 2026-09-22T16:32:36Z Gene therapy milestone in X-linked retinitis pigmentosa https://biobriefs.com/immunology-dealmaking-boehringer-and-envisagenics BioBriefs en 2026-09-22T16:32:36Z Immunology dealmaking: Boehringer and Envisagenics https://biobriefs.com/clinical-development-pivot-risk-for BioBriefs en 2026-09-22T16:32:36Z Clinical development pivot risk for Cue Biopharma in chronic hives https://biobriefs.com/fda-regulatory-modernization-nonanimal-testing BioBriefs en 2026-09-22T16:32:36Z FDA regulatory modernization: nonanimal testing flexibility https://biobriefs.com/biotech-ipo-pipeline-ai-drug BioBriefs en 2026-09-22T16:32:36Z Biotech IPO pipeline: AI drug discovery and precision immunology debut efforts https://biobriefs.com/gene-therapy-manufacturing-scale-andelyn BioBriefs en 2026-09-22T16:32:36Z Gene therapy manufacturing scale: Andelyn supports Fayuvi commercial supply https://biobriefs.com/fda-and-regulatory-momentum-for BioBriefs en 2026-09-22T14:32:07Z FDA and regulatory momentum for rare-disease and precision therapies https://biobriefs.com/radiopharmaceutical-consolidation-escalates BioBriefs en 2026-09-22T14:32:07Z Radiopharmaceutical consolidation escalates https://biobriefs.com/gene-therapy-hits-pivotal-regulatory BioBriefs en 2026-09-22T14:32:07Z Gene therapy hits pivotal/regulatory inflection in XLRP https://biobriefs.com/boehringer-and-envisagenics-lock-in BioBriefs en 2026-09-22T14:32:07Z Boehringer and Envisagenics lock in a major multi-target AI oncology pact https://biobriefs.com/glp-1-gip-and-related BioBriefs en 2026-09-22T14:32:07Z GLP-1/GIP and related metabolic pipeline readouts https://biobriefs.com/chronic-hives-immunology-advances-with BioBriefs en 2026-09-22T14:32:07Z Chronic hives immunology advances, with Cue’s next trial path clarifying https://biobriefs.com/fda-pre-ind-and-trial BioBriefs en 2026-09-22T14:32:07Z FDA pre-IND and trial-start modernization via site pairing https://biobriefs.com/ai-driven-drug-discovery-partnerships BioBriefs en 2026-09-22T14:32:07Z AI-driven drug discovery partnerships keep expanding into alternative biology https://biobriefs.com/cell-therapy-and-regenerative-medicine BioBriefs en 2026-09-22T14:32:07Z Cell therapy and regenerative medicine funding support in Canada https://biobriefs.com/clinical-documentation-and-healthcare-ops BioBriefs en 2026-09-22T14:32:07Z Clinical documentation and healthcare ops: AI adoption measured https://biobriefs.com/radiopharma-consolidation-accelerates-with-telix BioBriefs en 2026-09-22T10:31:50Z Radiopharma consolidation accelerates with Telix/ITM https://biobriefs.com/beacons-xlrp-gene-therapy-surges BioBriefs en 2026-09-22T10:31:50Z Beacon’s XLRP gene therapy surges toward FDA review https://biobriefs.com/fda-advisory-momentum-for-grails BioBriefs en 2026-09-22T10:31:50Z FDA/Advisory momentum for Grail’s multi-cancer blood test https://biobriefs.com/fda-approval-expands-pediatric-vascular BioBriefs en 2026-09-22T10:31:50Z FDA approval expands pediatric vascular anomaly care with safer dosing signals https://biobriefs.com/intrabio-secures-fda-nod-for BioBriefs en 2026-09-22T10:31:50Z Intrabio secures FDA nod for ataxia-telangiectasia treatment https://biobriefs.com/new-fda-pilot-program-targets BioBriefs en 2026-09-22T10:31:50Z New FDA pilot program targets faster Phase I IND start-up https://biobriefs.com/beacons-earlier-bla-staging-after BioBriefs en 2026-09-22T10:31:50Z Beacon’s earlier BLA staging after pivotal ocular gene therapy win https://biobriefs.com/infixions-nf1-strategy-wins-bio BioBriefs en 2026-09-22T10:31:50Z iNFixion’s NF1 strategy wins BIO startup recognition https://biobriefs.com/stem-cell-network-backs-rejuvenrx BioBriefs en 2026-09-22T10:31:50Z Stem Cell Network backs RejuvenRx with inaugural Canadian investment https://biobriefs.com/alkermes-orexin-agonist-signals-adhd BioBriefs en 2026-09-22T10:31:50Z Alkermes’ orexin agonist signals ADHD efficacy in early trial https://biobriefs.com/grail-cancer-detection-test-heads BioBriefs en 2026-09-22T09:31:35Z Grail cancer detection test heads into FDA advisory scrutiny https://biobriefs.com/beacons-xlrp-gene-therapy-clears BioBriefs en 2026-09-22T09:31:35Z Beacon’s XLRP gene therapy clears pivotal hurdle https://biobriefs.com/radiopharma-consolidation-accelerates-with-telix BioBriefs en 2026-09-22T09:31:35Z Radiopharma consolidation accelerates with Telix–ITM mega-deal https://biobriefs.com/fda-moves-to-streamline-phase BioBriefs en 2026-09-22T09:31:35Z FDA moves to streamline Phase I setup via sponsor-site IND prep https://biobriefs.com/nih-grant-oversight-proposals-spark BioBriefs en 2026-09-22T09:31:35Z NIH grant oversight proposals spark Capitol Hill backlash https://biobriefs.com/alkermes-orexin-agonist-posts-early BioBriefs en 2026-09-22T09:31:35Z Alkermes orexin agonist posts early ADHD signal https://biobriefs.com/cue-pushes-forward-after-phase BioBriefs en 2026-09-22T09:31:35Z Cue pushes forward after Phase 2 chronic hives rebound https://biobriefs.com/chugai-targets-next-gen-hemlibra BioBriefs en 2026-09-22T09:31:35Z Chugai targets next-gen Hemlibra follow-on with NXT007 https://biobriefs.com/intrabio-gets-fda-approval-for BioBriefs en 2026-09-22T09:31:35Z IntraBio gets FDA approval for ataxia-telangiectasia treatment https://biobriefs.com/fda-updates-nonanimal-testing-rules BioBriefs en 2026-09-22T09:31:35Z FDA updates nonanimal testing rules for preclinical programs https://biobriefs.com/radiopharma-m-a-accelerates-into BioBriefs en 2026-09-22T04:31:50Z Radiopharma M&A accelerates into scale and supply control https://biobriefs.com/fda-early-phase-process-change BioBriefs en 2026-09-22T04:31:50Z FDA early-phase process change – faster path from IND to first-in-human https://biobriefs.com/grail-cancer-blood-test-fda BioBriefs en 2026-09-22T04:31:50Z Grail cancer blood test: FDA advisory materials stoke optimism https://biobriefs.com/gene-therapy-progress-in-rare BioBriefs en 2026-09-22T04:31:50Z Gene therapy progress in rare eye disease and a new ataxia-telangiectasia option https://biobriefs.com/china-and-opioid-like-soft BioBriefs en 2026-09-22T04:31:50Z China and opioid-like ‘soft rules’ for early evidence of new biotech pipelines https://biobriefs.com/u-s-clinical-biotech-funding BioBriefs en 2026-09-22T04:31:50Z U.S. clinical biotech funding infrastructure: direct early-stage capital in Canada https://biobriefs.com/precision-immunology-electra-expands-into BioBriefs en 2026-09-22T04:31:50Z Precision immunology: Electra expands into precision immune therapies with IPO funding https://biobriefs.com/regulatory-science-and-product-policy BioBriefs en 2026-09-22T04:31:50Z Regulatory science and product policy: FDA shifts guidance on nonanimal preclinical testing https://biobriefs.com/u-s-nih-governance-under BioBriefs en 2026-09-22T04:31:50Z U.S. NIH governance under scrutiny – reported political control over grants https://biobriefs.com/quant-heavy-radiopharma-and-market BioBriefs en 2026-09-22T04:31:50Z Quant-heavy radiopharma and market structure: Novo signals pipeline expectations amid patent cliff concerns https://biobriefs.com/radiopharmaceuticals-consolidation-and-manufacturing-scale BioBriefs en 2026-09-21T21:31:59Z Radiopharmaceuticals consolidation and manufacturing scale https://biobriefs.com/fda-moves-to-reduce-friction BioBriefs en 2026-09-21T21:31:59Z FDA moves to reduce friction in early-phase trial starts https://biobriefs.com/grails-mult-cancer-blood-test BioBriefs en 2026-09-21T21:31:59Z Grail’s mult-cancer blood test draws FDA advisory committee scrutiny https://biobriefs.com/ocular-gene-therapy-steps-closer BioBriefs en 2026-09-21T21:31:59Z Ocular gene therapy steps closer to review for XLRP https://biobriefs.com/immunology-drugdata-lifts-cues-chronic BioBriefs en 2026-09-21T21:31:59Z Immunology drugdata lifts Cue’s chronic hives program despite share drop https://biobriefs.com/fda-approves-second-rare-disease BioBriefs en 2026-09-21T21:31:59Z FDA approves second rare-disease indication for Intrabio’s ataxia-telangiectasia therapy https://biobriefs.com/regulatory-and-policy-threat-to BioBriefs en 2026-09-21T21:31:59Z Regulatory and policy threat to NIH grant oversight becomes a focal point https://biobriefs.com/novo-doubles-down-on-launch BioBriefs en 2026-09-21T21:31:59Z Novo doubles down on launch pipeline as investors question strategy https://biobriefs.com/reimbursement-focused-decision-meeting-for BioBriefs en 2026-09-21T21:31:59Z Reimbursement-focused decision meeting for blood-based cancer detection https://biobriefs.com/biopharma-finance-leadership-reshuffles-at BioBriefs en 2026-09-21T21:31:59Z Biopharma finance leadership reshuffles at multiple clinical-stage companies https://biobriefs.com/radiopharmaceuticals-m-a-reshapes-supply BioBriefs en 2026-09-21T16:32:45Z Radiopharmaceuticals M&A reshapes supply and scale https://biobriefs.com/rare-disease-gene-therapy-scores BioBriefs en 2026-09-21T16:32:45Z Rare disease gene therapy scores pivotal win toward submission https://biobriefs.com/ataxia-telangiectasia-gets-first-approval BioBriefs en 2026-09-21T16:32:45Z Ataxia-telangiectasia gets first approval under new mechanism https://biobriefs.com/adhd-signal-emerges-for-orexin BioBriefs en 2026-09-21T16:32:45Z ADHD signal emerges for orexin agonists in early clinical data https://biobriefs.com/midstage-immunology-win-for-chronic BioBriefs en 2026-09-21T16:32:45Z Midstage immunology win for chronic hives competitor effort https://biobriefs.com/immunology-reverse-mergers-push-public BioBriefs en 2026-09-21T16:32:45Z Immunology reverse mergers push public-market alternatives https://biobriefs.com/precision-immune-therapy-funding-accelerates BioBriefs en 2026-09-21T16:32:45Z Precision immune therapy funding accelerates late preclinical work https://biobriefs.com/precision-gene-modulation-advances-for BioBriefs en 2026-09-21T16:32:45Z Precision gene modulation advances for chronic HBV https://biobriefs.com/oral-metabolic-assets-low-dose BioBriefs en 2026-09-21T16:32:45Z Oral metabolic assets: low-dose CagriSema data ahead of key decision https://biobriefs.com/ipo-pipeline-continues-with-sirna BioBriefs en 2026-09-21T16:32:45Z IPO pipeline continues with siRNA Phase 3 plans https://biobriefs.com/radiopharmaceutical-m-a-escalates BioBriefs en 2026-09-21T14:32:27Z Radiopharmaceutical M&A escalates https://biobriefs.com/electras-ipo-fuels-precision-immune BioBriefs en 2026-09-21T14:32:27Z Electra’s IPO fuels precision immune therapy push https://biobriefs.com/gene-therapy-trial-lifts-beacon BioBriefs en 2026-09-21T14:32:27Z Gene therapy trial lifts Beacon toward FDA path https://biobriefs.com/immunology-challenger-cue-advances-chronic BioBriefs en 2026-09-21T14:32:27Z Immunology challenger Cue advances chronic hives readout https://biobriefs.com/alkermes-explores-orexin-agonist-for BioBriefs en 2026-09-21T14:32:27Z Alkermes explores orexin agonist for ADHD https://biobriefs.com/reverse-mergers-return-as-ipo BioBriefs en 2026-09-21T14:32:27Z Reverse mergers return as IPO window thins https://biobriefs.com/biotech-ipo-pipeline-adarx-and BioBriefs en 2026-09-21T14:32:27Z Biotech IPO pipeline: ADARx and TRex Bio/Retension lineup https://biobriefs.com/drug-delivery-and-immunology-cd8 BioBriefs en 2026-09-21T14:32:27Z Drug delivery and immunology: CD8-free? (early) not applicable; MASH, chronic hives excluded—Focus on GLP-1 infrastructure readiness https://biobriefs.com/genetic-engine-cln8-clarifies-lipid BioBriefs en 2026-09-21T14:32:27Z Genetic engine: CLN8 clarifies lipid recycling defect in Batten disease https://biobriefs.com/preclinical-oncology-dual-t-cell BioBriefs en 2026-09-21T14:32:27Z Preclinical oncology: dual T-cell activation revisits checkpoint resistance https://biobriefs.com/biotech-immunology-chronic-spontaneous-urticaria BioBriefs en 2026-09-21T10:32:00Z Biotech immunology: chronic spontaneous urticaria https://biobriefs.com/gene-therapy-in-rare-eye BioBriefs en 2026-09-21T10:32:00Z Gene therapy in rare eye disease: XLRP https://biobriefs.com/radiopharmaceuticals-dealmaking-telix-and-itm BioBriefs en 2026-09-21T10:32:00Z Radiopharmaceuticals dealmaking: Telix and ITM https://biobriefs.com/biopharma-m-a-reverse-mergers BioBriefs en 2026-09-21T10:32:00Z Biopharma M&A: reverse mergers into public markets https://biobriefs.com/precision-immunology-elecetra-ipo-funding BioBriefs en 2026-09-21T10:32:00Z Precision immunology: Elecetra IPO funding https://biobriefs.com/glp-1-and-metabolic-care BioBriefs en 2026-09-21T10:32:00Z GLP-1 and metabolic care infrastructure https://biobriefs.com/early-clinical-data-lillys-brenipatide BioBriefs en 2026-09-21T10:32:00Z Early clinical data: Lilly’s brenipatide https://biobriefs.com/oncology-biomarker-and-platform-proof BioBriefs en 2026-09-21T10:32:00Z Oncology: biomarker and platform proof points https://biobriefs.com/digital-health-and-monitoring-europe BioBriefs en 2026-09-21T10:32:00Z Digital health and monitoring: Europe CGM accuracy milestone https://biobriefs.com/health-system-delivery-whole-patient BioBriefs en 2026-09-21T10:32:00Z Health system delivery: whole-patient support in oncology https://biobriefs.com/radiopharmaceuticals-m-a-reshapes-competitive BioBriefs en 2026-09-21T09:31:44Z Radiopharmaceuticals M&A reshapes competitive landscape https://biobriefs.com/gene-therapy-scores-pivotal-win BioBriefs en 2026-09-21T09:31:44Z Gene therapy scores pivotal win in rare eye disease https://biobriefs.com/precision-immunology-ipos-bring-fresh BioBriefs en 2026-09-21T09:31:44Z Precision immunology IPOs bring fresh capital to early pipelines https://biobriefs.com/diabetes-technology-milestone-in-europe BioBriefs en 2026-09-21T09:31:44Z Diabetes technology milestone in Europe https://biobriefs.com/clinical-trial-progress-in-immunology BioBriefs en 2026-09-21T09:31:44Z Clinical trial progress in immunology—Xolair challenger advances https://biobriefs.com/oncology-and-ai-biomarkers-turning BioBriefs en 2026-09-21T09:31:44Z Oncology and AI biomarkers—turning immune signals into prognosis https://biobriefs.com/precision-oncology-platform-design-personal BioBriefs en 2026-09-21T09:31:44Z Precision oncology platform design—personal neoantigen vaccine proof-of-concept https://biobriefs.com/cell-engineering-advances-car-t BioBriefs en 2026-09-21T09:31:44Z Cell engineering advances CAR-T signaling https://biobriefs.com/institutional-shift-whole-patient-oncology BioBriefs en 2026-09-21T09:31:44Z Institutional shift—whole-patient oncology support models https://biobriefs.com/glp-1-rollout-confronts-payer BioBriefs en 2026-09-21T09:31:44Z GLP-1 rollout confronts payer and primary-care readiness https://biobriefs.com/radiopharmaceuticals-m-a-accelerates-scale BioBriefs en 2026-09-21T04:31:55Z Radiopharmaceuticals—M&A accelerates scale after FDA setback https://biobriefs.com/precision-immunology-ipos-funding-appetite BioBriefs en 2026-09-21T04:31:55Z Precision immunology IPOs—Funding appetite returns to early-stage platforms https://biobriefs.com/glp-1-gip-in-cns BioBriefs en 2026-09-21T04:31:55Z GLP-1/GIP in CNS and immune pathways—Lilly expands brenipatide dose-finding https://biobriefs.com/car-t-engineering-tetraspanin-boosts BioBriefs en 2026-09-21T04:31:55Z CAR-T engineering—Tetraspanin boosts IL-2 signaling to reinvigorate potency https://biobriefs.com/cancer-immunotherapy-durable-antibody-response BioBriefs en 2026-09-21T04:31:55Z Cancer immunotherapy—Durable antibody response mapped through personalized neoantigen vaccine https://biobriefs.com/targeted-oncology-bispecific-antibody-cadonilimab BioBriefs en 2026-09-21T04:31:55Z Targeted oncology—Bispecific antibody cadonilimab gains survival edge in gastric cancer https://biobriefs.com/next-gen-diagnostics-fapi-04 BioBriefs en 2026-09-21T04:31:55Z Next-gen diagnostics—FAPI-04 PET/CT outperforms FDG for liver metastases https://biobriefs.com/rare-disease-cln8-revealed-as BioBriefs en 2026-09-21T04:31:55Z Rare disease—CLN8 revealed as key enzyme in lysosomal lipid recycling https://biobriefs.com/device-regulation-caresens-air-first BioBriefs en 2026-09-21T04:31:55Z Device regulation—CareSens Air first CGM to meet proposed Europe accuracy criteria https://biobriefs.com/aortic-disease-in-marfan-syndrome BioBriefs en 2026-09-21T04:31:55Z Aortic disease in Marfan syndrome—TRPV4 emerges as disease-relevant target https://biobriefs.com/lilly-expands-brenipatides-early-clinical BioBriefs en 2026-09-20T21:32:01Z Lilly expands brenipatide’s early clinical footprint beyond metabolic disease https://biobriefs.com/fda-style-momentum-for-gene BioBriefs en 2026-09-20T21:32:01Z FDA-style momentum for gene-therapy approvals: Ultragenyx clears MPS IIIA milestone https://biobriefs.com/ema-lifts-multiple-european-approvals BioBriefs en 2026-09-20T21:32:01Z EMA lifts multiple European approvals amid expanding oncology and dermatology pipeline https://biobriefs.com/bavarian-nordic-leadership-transition-lands BioBriefs en 2026-09-20T21:32:01Z Bavarian Nordic leadership transition lands after Sanofi executive appointment https://biobriefs.com/microbiology-and-car-t-safety BioBriefs en 2026-09-20T21:32:01Z Microbiology and CAR-T safety: fatal toxicities test autoimmune CAR-T risk thesis https://biobriefs.com/regulators-and-oversight-change-in BioBriefs en 2026-09-20T21:32:01Z Regulators and oversight: change in approach to clinical recommendations after USPSTF leadership overhaul https://biobriefs.com/anthropic-opens-a-wet-lab BioBriefs en 2026-09-20T21:32:01Z Anthropic opens a wet lab in the Bay Area, spotlighting real-world biology execution https://biobriefs.com/funding-for-digital-health-ayble BioBriefs en 2026-09-20T21:32:01Z Funding for digital health: Ayble Health raises $16M to expand virtual digestive care https://biobriefs.com/clinical-innovation-platform-neuron-targeted BioBriefs en 2026-09-20T21:32:01Z Clinical innovation platform: neuron-targeted exosomes linked to shingles chronic pain mechanisms https://biobriefs.com/ai-in-biomedical-publishing-signatures BioBriefs en 2026-09-20T21:32:01Z AI in biomedical publishing: signatures of AI-assisted writing jump to near-ubiquity https://biobriefs.com/fda-approval-for-first-in BioBriefs en 2026-09-20T16:31:57Z FDA approval for first-in-class gene therapy in Sanfilippo A https://biobriefs.com/fda-lifts-lid-on-lillys BioBriefs en 2026-09-20T16:31:57Z FDA lifts lid on Lilly’s oral SERD combination for breast cancer https://biobriefs.com/ema-chmp-recommends-multiple-therapies BioBriefs en 2026-09-20T16:31:57Z EMA CHMP recommends multiple therapies including hemophilia A preventive and ovarian cancer https://biobriefs.com/ultragenyx-clears-a-regulatory-hurdle BioBriefs en 2026-09-20T16:31:57Z Ultragenyx clears a regulatory hurdle for MPS IIIA after prior FDA denial https://biobriefs.com/lillys-brenipatide-posts-early-phase BioBriefs en 2026-09-20T16:31:57Z Lilly’s brenipatide posts early Phase I dose-selection data for CNS and addiction-adjacent disorders https://biobriefs.com/neuron-targeted-exosomes-linked-to BioBriefs en 2026-09-20T16:31:56Z Neuron-targeted exosomes linked to shingles chronic pain mechanism https://biobriefs.com/car-t-safety-fatal-toxicities BioBriefs en 2026-09-20T16:31:56Z CAR T safety: fatal toxicities test the autoimmune risk model https://biobriefs.com/bavarian-nordic-names-new-ceo BioBriefs en 2026-09-20T16:31:56Z Bavarian Nordic names new CEO after Sanofi background leadership move https://biobriefs.com/ai-wet-lab-push-anthropic BioBriefs en 2026-09-20T16:31:56Z AI wet-lab push: Anthropic confirms Bay Area lab while limiting drug-discovery claims https://biobriefs.com/virtual-digestive-health-startup-ayble BioBriefs en 2026-09-20T16:31:56Z Virtual digestive health startup Ayble raises $16M for clinical expansion https://biobriefs.com/fda-approval-first-disease-modifying BioBriefs en 2026-09-20T14:31:40Z FDA approval: first disease-modifying gene therapy for Sanfilippo A https://biobriefs.com/fda-decision-lillys-oral-serd BioBriefs en 2026-09-20T14:31:40Z FDA decision: Lilly’s oral SERD combo moves into second-line breast cancer https://biobriefs.com/fda-regulatory-stance-agency-says BioBriefs en 2026-09-20T14:31:40Z FDA regulatory stance: agency says initial drug rejections have fallen https://biobriefs.com/clinical-safety-signal-xenon-pauses BioBriefs en 2026-09-20T14:31:40Z Clinical safety signal: Xenon pauses azetukalner depression trials https://biobriefs.com/company-pipeline-regulatory-timing-xenon BioBriefs en 2026-09-20T14:31:40Z Company pipeline/regulatory timing: Xenon NDA for focal onset seizures under FDA review https://biobriefs.com/neuroscience-discovery-neuron-targeted-exosomes BioBriefs en 2026-09-20T14:31:40Z Neuroscience discovery: neuron-targeted exosomes implicated in chronic shingles pain https://biobriefs.com/company-leadership-bavarian-nordic-appoints BioBriefs en 2026-09-20T14:31:40Z Company leadership: Bavarian Nordic appoints Tarja Stenvall as CEO https://biobriefs.com/bioprocess-innovation-gbi-biomanufacturing-to BioBriefs en 2026-09-20T14:31:40Z Bioprocess innovation: GBI Biomanufacturing to launch SmartScale GMP for first-in-human https://biobriefs.com/biopharma-funding-electra-upsizes-ipo BioBriefs en 2026-09-20T14:31:40Z Biopharma funding: Electra upsizes IPO after pricing https://biobriefs.com/health-policy-all-states-sign BioBriefs en 2026-09-20T14:31:40Z Health policy: all states sign up for Medicaid “most favored nation” pricing model https://biobriefs.com/fda-gene-therapy-approval-for BioBriefs en 2026-09-20T10:31:46Z FDA gene therapy approval for Sanfilippo syndrome type A https://biobriefs.com/lilly-expands-glp-1-franchise BioBriefs en 2026-09-20T10:31:46Z Lilly expands GLP-1 franchise with Brenipatide Phase 1 dose selection https://biobriefs.com/fda-approval-for-lillys-oral BioBriefs en 2026-09-20T10:31:46Z FDA approval for Lilly’s oral SERD combination in breast cancer https://biobriefs.com/car-t-safety-risk-assessment BioBriefs en 2026-09-20T10:31:46Z CAR T safety risk assessment: autoimmune mechanisms and IEC-HS https://biobriefs.com/xenon-pharmaceuticals-pauses-depression-trials BioBriefs en 2026-09-20T10:31:46Z Xenon Pharmaceuticals pauses depression trials over neuropsychiatric adverse events https://biobriefs.com/european-regulator-momentum-ema-chmp BioBriefs en 2026-09-20T10:31:46Z European regulator momentum: EMA CHMP endorses eight new medicines https://biobriefs.com/european-regulator-backs-novo-hemophilia BioBriefs en 2026-09-20T10:31:46Z European regulator backs Novo hemophilia A preventive therapy https://biobriefs.com/electra-therapeutics-launches-350m-ipo BioBriefs en 2026-09-20T10:31:46Z Electra Therapeutics launches $350M IPO for sHLH monoclonal antibody program https://biobriefs.com/cms-expands-access-model-to BioBriefs en 2026-09-20T10:31:46Z CMS expands ACCESS model to additional chronic conditions https://biobriefs.com/venture-backed-neuroscience-spinout-targets BioBriefs en 2026-09-20T10:31:46Z Venture-backed neuroscience spinout targets Parkinson’s apathy https://biobriefs.com/gene-therapy-approval-for-sanfilippo BioBriefs en 2026-09-20T09:31:57Z Gene therapy approval for Sanfilippo type A https://biobriefs.com/lillys-oral-serd-expands-breast BioBriefs en 2026-09-20T09:31:57Z Lilly’s oral SERD expands breast cancer options https://biobriefs.com/lillys-brenipatide-posts-early-cns BioBriefs en 2026-09-20T09:31:57Z Lilly’s brenipatide posts early CNS and psychiatric dosing data https://biobriefs.com/car-t-safety-focus-on BioBriefs en 2026-09-20T09:31:57Z CAR T safety focus on autoimmune risk https://biobriefs.com/ultragenyx-pricing-and-gene-therapy BioBriefs en 2026-09-20T09:31:57Z Ultragenyx pricing and gene-therapy market implications https://biobriefs.com/xenon-pauses-depression-trial-over BioBriefs en 2026-09-20T09:31:57Z Xenon pauses depression trial over neuropsychiatric adverse events https://biobriefs.com/ema-backs-multiple-new-medicines BioBriefs en 2026-09-20T09:31:57Z EMA backs multiple new medicines including ovarian cancer and HS https://biobriefs.com/bioprocessing-scale-up-gmp-smartscale BioBriefs en 2026-09-20T09:31:57Z Bioprocessing scale-up: GMP SmartScale platform launch https://biobriefs.com/neuroscience-drug-development-spinout-targets BioBriefs en 2026-09-20T09:31:57Z Neuroscience drug development spinout targets Parkinson’s apathy https://biobriefs.com/lilly-expands-cns-research-partnership BioBriefs en 2026-09-20T09:31:57Z Lilly expands CNS research partnership with QurCan https://biobriefs.com/fda-greenlights-first-disease-modifying BioBriefs en 2026-09-20T04:31:38Z FDA greenlights first disease-modifying gene therapy for Sanfilippo A https://biobriefs.com/fda-approves-lillys-oral-serd BioBriefs en 2026-09-20T04:31:38Z FDA approves Lilly’s oral SERD combination for second-line breast cancer https://biobriefs.com/clinical-safety-signal-triggers-xenon BioBriefs en 2026-09-20T04:31:38Z Clinical safety signal triggers Xenon pause in depression trials https://biobriefs.com/biotech-ipos-and-fundraising-momentum BioBriefs en 2026-09-20T04:31:38Z Biotech IPOs and fundraising momentum continue https://biobriefs.com/lilly-expands-cns-and-inflammation BioBriefs en 2026-09-20T04:31:38Z Lilly expands CNS-and-inflammation strategy with QurCan deal https://biobriefs.com/eu-regulator-backs-novo-hemophilia BioBriefs en 2026-09-20T04:31:38Z EU regulator backs Novo hemophilia A preventive drug and multiple medicines https://biobriefs.com/ultragenyx-approval-extends-europe-wide BioBriefs en 2026-09-20T04:31:38Z Ultragenyx approval extends Europe-wide rare disease trajectory https://biobriefs.com/ariadne-bio-spinout-targets-parkinsons BioBriefs en 2026-09-20T04:31:38Z Ariadne Bio spinout targets Parkinson’s apathy with non-hallucinogenic 5-HT2A agonist https://biobriefs.com/novo-doubles-down-on-ai BioBriefs en 2026-09-20T04:31:38Z Novo doubles down on AI-powered oral drugs via $1.4B Orbis partnership https://biobriefs.com/bioprocessing-innovation-smart-gmp-scale BioBriefs en 2026-09-20T04:31:38Z Bioprocessing innovation: smart GMP scale-up and benchtop virus filtration https://biobriefs.com/fda-clears-first-disease-modifying BioBriefs en 2026-09-19T21:31:44Z FDA clears first disease-modifying gene therapy for Sanfilippo A https://biobriefs.com/lilly-wins-fda-nod-for BioBriefs en 2026-09-19T21:31:44Z Lilly wins FDA nod for oral SERD combination in second-line breast cancer https://biobriefs.com/xenon-pauses-depression-trials-after BioBriefs en 2026-09-19T21:31:44Z Xenon pauses depression trials after neuropsychiatric adverse events https://biobriefs.com/lilly-expands-cns-addiction-relevant BioBriefs en 2026-09-19T21:31:44Z Lilly expands CNS addiction-relevant GLP-1/GIP program with brenipatide Phase 1 dose-selection data https://biobriefs.com/ema-chmp-recommends-hemophilia-a BioBriefs en 2026-09-19T21:31:44Z EMA CHMP recommends hemophilia A preventive drug plus seven other medicines https://biobriefs.com/electra-lifts-350m-in-upsized BioBriefs en 2026-09-19T21:31:44Z Electra lifts $350M in upsized IPO for late-stage pan-SIRP immunology drug https://biobriefs.com/bristol-myers-drops-100m-orum BioBriefs en 2026-09-19T21:31:44Z Bristol Myers drops $100M Orum degrader-antibody conjugate after Phase 1 readout https://biobriefs.com/diverse-biopharma-funding-picture-and BioBriefs en 2026-09-19T21:31:44Z Diverse biopharma funding picture and IPO momentum https://biobriefs.com/new-venture-ariadne-bio-spins BioBriefs en 2026-09-19T21:31:44Z New venture Ariadne Bio spins out to pursue non-hallucinogenic 5-HT2A agonism for Parkinson’s apathy https://biobriefs.com/regulatory-and-reimbursement-policy-pressure BioBriefs en 2026-09-19T21:31:44Z Regulatory and reimbursement policy pressure: Medicaid drug model and ACCESS expansion https://biobriefs.com/fda-approvals-sanfilippo-gene-therapy BioBriefs en 2026-09-19T16:31:43Z FDA approvals: Sanfilippo gene therapy lands approval after manufacturing hurdles https://biobriefs.com/ema-moves-chmp-backs-eight BioBriefs en 2026-09-19T16:31:43Z EMA moves: CHMP backs eight new medicines including hemophilia A prevention https://biobriefs.com/biopharma-setbacks-xenon-pauses-depression BioBriefs en 2026-09-19T16:31:43Z Biopharma setbacks: Xenon pauses depression trial after neuropsychiatric adverse events https://biobriefs.com/biotech-financing-electra-upsizes-ipo BioBriefs en 2026-09-19T16:31:43Z Biotech financing: Electra upsizes IPO to raise $350 million https://biobriefs.com/ai-meets-the-wet-lab BioBriefs en 2026-09-19T16:31:43Z AI meets the wet lab: Anthropic confirms Bay Area lab but denies drug discovery use https://biobriefs.com/oral-drug-innovation-novo-and BioBriefs en 2026-09-19T16:31:43Z Oral drug innovation: Novo and Orbis Medicines agree $1.4 billion collaboration https://biobriefs.com/biotech-spinout-palomar-labs-launches BioBriefs en 2026-09-19T16:31:43Z Biotech spinout: Palomar Labs launches Ariadne Bio for non-hallucinogenic Parkinson’s apathy https://biobriefs.com/platform-science-and-process-tech BioBriefs en 2026-09-19T16:31:43Z Platform science and process tech: new GMP manufacturing path for early biologics https://biobriefs.com/bioprocess-analytics-model-free-spectroscopy BioBriefs en 2026-09-19T16:31:43Z Bioprocess analytics: model-free spectroscopy aims to cut real-time protein testing costs https://biobriefs.com/startup-funding-ayble-health-raises BioBriefs en 2026-09-19T16:31:43Z Startup funding: Ayble Health raises $16 million for a virtual digestive clinic https://biobriefs.com/regulatory-approvals-in-rare-diseases BioBriefs en 2026-09-19T14:31:51Z Regulatory approvals in rare diseases https://biobriefs.com/us-regulatory-and-evidence-follow BioBriefs en 2026-09-19T14:31:51Z US regulatory and evidence-follow-through scrutiny https://biobriefs.com/european-regulatory-momentum-for-oncology BioBriefs en 2026-09-19T14:31:51Z European regulatory momentum for oncology and dermatology https://biobriefs.com/biopharma-ipo-and-late-stage BioBriefs en 2026-09-19T14:31:51Z Biopharma IPO and late-stage inflammation funding https://biobriefs.com/clinical-holds-in-psychiatric-cns BioBriefs en 2026-09-19T14:31:51Z Clinical holds in psychiatric CNS trials https://biobriefs.com/strategic-partnerships-for-oral-peptide BioBriefs en 2026-09-19T14:31:51Z Strategic partnerships for oral peptide and macrocycle drug discovery https://biobriefs.com/car-t-safety-and-autoimmune BioBriefs en 2026-09-19T14:31:51Z CAR-T safety and autoimmune trial risk controls https://biobriefs.com/neuroscience-investment-and-new-venture BioBriefs en 2026-09-19T14:31:51Z Neuroscience investment and new venture creation https://biobriefs.com/biopharma-funding-and-capital-market BioBriefs en 2026-09-19T14:31:51Z Biopharma funding and capital market conditions https://biobriefs.com/ai-biotech-infrastructure-for-wet BioBriefs en 2026-09-19T14:31:51Z AI-biotech infrastructure for wet lab work https://biobriefs.com/fda-gene-therapy-approval-for BioBriefs en 2026-09-19T10:31:23Z FDA gene therapy approval for Sanfilippo syndrome https://biobriefs.com/biopharma-ipo-window-electra-raises BioBriefs en 2026-09-19T10:31:23Z Biopharma IPO window: Electra raises for inflammation drug development https://biobriefs.com/xenon-depression-trial-pause-tied BioBriefs en 2026-09-19T10:31:23Z Xenon depression trial pause tied to neuropsychiatric events https://biobriefs.com/emerging-corporate-leadership-bavarian-nordic BioBriefs en 2026-09-19T10:31:23Z Emerging corporate leadership: Bavarian Nordic names Tarja Stenvall CEO https://biobriefs.com/cancer-immunotherapy-r-d-new BioBriefs en 2026-09-19T10:31:23Z Cancer immunotherapy R&D: new checkpoint molecule from Apeximmune and Erasmus MC https://biobriefs.com/cell-therapy-innovation-palomars-ariadne BioBriefs en 2026-09-19T10:31:23Z Cell therapy innovation: Palomar’s Ariadne Bio spins out for Parkinson’s apathy https://biobriefs.com/us-gene-editing-and-regulation BioBriefs en 2026-09-19T10:31:23Z US gene-editing and regulation: post-approval study follow-through concerns https://biobriefs.com/biotech-financing-and-funding-mithrl BioBriefs en 2026-09-19T10:31:23Z Biotech financing and funding: Mithrl raises for biomedical world model https://biobriefs.com/oral-biologics-dealmaking-novo-and BioBriefs en 2026-09-19T10:31:23Z Oral biologics dealmaking: Novo and Orbis expand macrocycle engine https://biobriefs.com/bioprocess-innovation-intensified-and-continuous BioBriefs en 2026-09-19T10:31:23Z Bioprocess innovation: intensified and continuous manufacturing training center https://biobriefs.com/fda-approval-first-disease-modifying BioBriefs en 2026-09-19T09:31:24Z FDA approval: first disease-modifying gene therapy for Sanfilippo syndrome type A https://biobriefs.com/eu-regulatory-review-chmp-backs BioBriefs en 2026-09-19T09:31:24Z EU regulatory review: CHMP backs multiple new therapies including hemophilia A preventive drug https://biobriefs.com/biopharma-funding-electras-upsized-ipo BioBriefs en 2026-09-19T09:31:24Z Biopharma funding: Electra’s upsized IPO fuels late-stage inflammation program https://biobriefs.com/xenon-pharmaceuticals-depression-trial-enrollment BioBriefs en 2026-09-19T09:31:24Z Xenon Pharmaceuticals: depression trial enrollment pause over neuropsychiatric adverse events https://biobriefs.com/cardiometabolic-oral-biologics-novo-and BioBriefs en 2026-09-19T09:31:24Z Cardiometabolic oral biologics: Novo and Orbis expand AI-enabled macrocycle platform deal to $1.4B https://biobriefs.com/immunology-platform-deal-roche-brings BioBriefs en 2026-09-19T09:31:24Z Immunology platform deal: Roche brings first partner into Dualitas’ bispecific discovery engine https://biobriefs.com/neurodegeneration-drug-discovery-ariadne-bio BioBriefs en 2026-09-19T09:31:24Z Neurodegeneration drug discovery: Ariadne Bio spinout targets Parkinson’s apathy with AB-300 https://biobriefs.com/bioprocessing-operations-sartorius-and-nibrt BioBriefs en 2026-09-19T09:31:24Z Bioprocessing operations: Sartorius and NIBRT set up training for intensified continuous manufacturing https://biobriefs.com/ai-biology-publishing-study-finds BioBriefs en 2026-09-19T09:31:24Z AI + biology publishing: study finds AI-assisted writing signatures now dominate biomedical papers https://biobriefs.com/biotech-innovation-funding-mithrl-raises BioBriefs en 2026-09-19T09:31:24Z Biotech innovation funding: Mithrl raises $20M to scale biomedical world model workflows https://biobriefs.com/fda-approval-first-disease-modifying BioBriefs en 2026-09-19T04:31:55Z FDA approval: first disease-modifying gene therapy for Sanfilippo A https://biobriefs.com/biopharma-pricing-policy-medicaid-most BioBriefs en 2026-09-19T04:31:55Z Biopharma pricing policy: Medicaid “most favored nation” expansion https://biobriefs.com/eleven-year-ipo-financing-cycle BioBriefs en 2026-09-19T04:31:55Z Eleven-year IPO/financing cycle: Electra’s $350M Nasdaq debut https://biobriefs.com/clinical-risk-event-xenon-pauses BioBriefs en 2026-09-19T04:31:55Z Clinical risk event: Xenon pauses depression program for neuropsychiatric events https://biobriefs.com/regulatory-chmp-backs-novos-hemophilia BioBriefs en 2026-09-19T04:31:55Z Regulatory: CHMP backs Novo’s hemophilia A preventive drug https://biobriefs.com/venture-and-reverse-merger-capital BioBriefs en 2026-09-19T04:31:55Z Venture and reverse merger capital: North Immunology raises $180M for eczema program https://biobriefs.com/partnership-roche-inks-up-to BioBriefs en 2026-09-19T04:31:55Z Partnership: Roche inks up to $1B screening deal with Dualitas https://biobriefs.com/neuropsychiatry-therapeutics-palomar-spins-out BioBriefs en 2026-09-19T04:31:55Z Neuropsychiatry therapeutics: Palomar spins out Ariadne Bio for Parkinson’s apathy https://biobriefs.com/manufacturing-operations-gbi-smartscale-gmp BioBriefs en 2026-09-19T04:31:55Z Manufacturing operations: GBI SmartScale GMP solutions for first-in-human timelines https://biobriefs.com/gene-editing-frontier-science-discovery BioBriefs en 2026-09-19T04:31:55Z Gene editing frontier science: discovery of CRISPR’s viral precursor https://biobriefs.com/fda-approvals-sanfilippo-gene-therapy BioBriefs en 2026-09-18T21:31:53Z FDA approvals: Sanfilippo gene therapy https://biobriefs.com/regulation-access-medicaid-pricing-model BioBriefs en 2026-09-18T21:31:53Z Regulation & access: Medicaid pricing model expansion https://biobriefs.com/biopharma-ipos-capital-markets-electras BioBriefs en 2026-09-18T21:31:53Z Biopharma IPOs & capital markets: Electra’s $350M raise https://biobriefs.com/cdmo-manufacturing-innovation-gbi-smartscale BioBriefs en 2026-09-18T21:31:53Z CDMO manufacturing innovation: GBI SmartScale GMP solutions https://biobriefs.com/cdmo-supply-resilience-raw-material BioBriefs en 2026-09-18T21:31:53Z CDMO supply resilience: Raw-material risk at BPI East https://biobriefs.com/reverse-m-a-new-public BioBriefs en 2026-09-18T21:31:53Z Reverse M&A & new public platforms: North Immunology deal and funding https://biobriefs.com/china-regulatory-progress-sino-biopharmaceutical BioBriefs en 2026-09-18T21:31:53Z China regulatory progress: Sino Biopharmaceutical filings https://biobriefs.com/biotech-startup-finance-mithrls-20m BioBriefs en 2026-09-18T21:31:53Z Biotech startup finance: Mithrl’s $20M Series A for biomedical world model https://biobriefs.com/neuro-innovation-ariadne-bio-spinout BioBriefs en 2026-09-18T21:31:53Z Neuro innovation: Ariadne Bio spinout for Parkinson’s apathy https://biobriefs.com/scientific-research-kidney-organoids-reveal BioBriefs en 2026-09-18T21:31:53Z Scientific research: kidney organoids reveal inflammatory drivers in diabetic kidney disease https://biobriefs.com/fda-gene-therapy-approvals-for BioBriefs en 2026-09-18T16:31:49Z FDA gene therapy approvals for ultra-rare disease https://biobriefs.com/company-clinical-trial-risk-depression BioBriefs en 2026-09-18T16:31:49Z Company clinical trial risk—depression pause tied to neuropsychiatric events https://biobriefs.com/fda-oversight-expansion-more-scrutiny BioBriefs en 2026-09-18T16:31:49Z FDA oversight expansion—more scrutiny of foreign clinical trial sites https://biobriefs.com/chinas-policy-push-for-global BioBriefs en 2026-09-18T16:31:49Z China’s policy push for global biopharma expansion https://biobriefs.com/ultra-rare-gene-therapy-economics BioBriefs en 2026-09-18T16:31:49Z Ultra-rare gene therapy economics—FDA approval vs pricing scrutiny https://biobriefs.com/ai-driven-oral-peptide-chemistry BioBriefs en 2026-09-18T16:31:49Z AI-driven oral peptide chemistry deal—Novo and Orbis commit up to $1.4 billion https://biobriefs.com/bispecific-antibody-discovery-roche-pays BioBriefs en 2026-09-18T16:31:49Z Bispecific antibody discovery—Roche pays Dualitas for large screening drive https://biobriefs.com/biotech-ipo-window-electra-therapeutics BioBriefs en 2026-09-18T16:31:49Z Biotech IPO window—Electra Therapeutics raises $350 million https://biobriefs.com/biotech-platform-financing-mithrl-raises BioBriefs en 2026-09-18T16:31:49Z Biotech platform financing—Mithrl raises $20 million for biomedical world model https://biobriefs.com/fda-and-industry-compliance-postmarket BioBriefs en 2026-09-18T16:31:49Z FDA and industry compliance—postmarket study follow-through gaps https://biobriefs.com/regulatory-approvals-first-in-class BioBriefs en 2026-09-18T14:32:09Z Regulatory approvals: first-in-class gene therapy for ultra-rare neurodegeneration https://biobriefs.com/big-pharma-deals-novo-and BioBriefs en 2026-09-18T14:32:09Z Big pharma deals: Novo and Orbis bet on oral macrocycle biologics https://biobriefs.com/biopharma-finance-electra-therapeutics-pulls BioBriefs en 2026-09-18T14:32:09Z Biopharma finance: Electra Therapeutics pulls in a hot IPO that targets inflammation https://biobriefs.com/trial-safety-xenon-pauses-phase BioBriefs en 2026-09-18T14:32:09Z Trial safety: Xenon pauses phase 3 depression enrollment after psychosis reports https://biobriefs.com/regulatory-oversight-fda-expands-scrutiny BioBriefs en 2026-09-18T14:32:09Z Regulatory oversight: FDA expands scrutiny of overseas clinical sites under resource constraints https://biobriefs.com/clinical-safety-and-evidence-generation BioBriefs en 2026-09-18T14:32:09Z Clinical safety and evidence generation: FDA postmarket studies still trailing original timelines https://biobriefs.com/ai-drug-development-virtual-biotech BioBriefs en 2026-09-18T14:32:09Z AI + drug development: virtual biotech using thousands of AI scientist agents https://biobriefs.com/funding-and-venture-mithrl-raises BioBriefs en 2026-09-18T14:32:09Z Funding and venture: Mithrl raises $20 million for an agentic biomedical world model https://biobriefs.com/discovery-platform-dealmaking-roche-taps BioBriefs en 2026-09-18T14:32:09Z Discovery platform dealmaking: Roche taps Dualitas for bispecific antibody screen up to $1 billion https://biobriefs.com/cell-therapy-manufacturing-cellares-expands BioBriefs en 2026-09-18T14:32:09Z Cell therapy manufacturing: Cellares expands CAR-T capacity with first Asia partnership https://biobriefs.com/fda-approval-gene-therapy-for BioBriefs en 2026-09-18T10:31:49Z FDA approval – gene therapy for Sanfilippo A https://biobriefs.com/biotech-ipo-surge-inflammation-player BioBriefs en 2026-09-18T10:31:49Z Biotech IPO surge – inflammation player Electra raises $350M https://biobriefs.com/big-pharma-licensing-exits-bms BioBriefs en 2026-09-18T10:31:49Z Big pharma licensing exits – BMS scraps $100M Orum degrader program https://biobriefs.com/ai-drug-discovery-partnership-novo BioBriefs en 2026-09-18T10:31:49Z AI–drug discovery partnership – Novo and Orbis sign up to $1.4B oral macrocycles deal https://biobriefs.com/ai-biosecurity-lawmakers-warn-of BioBriefs en 2026-09-18T10:31:49Z AI biosecurity – lawmakers warn of misuse pathways as AI accelerates biology https://biobriefs.com/fda-trial-acceleration-expedited-ind BioBriefs en 2026-09-18T10:31:49Z FDA trial acceleration – Expedited IND pilot under Operation Trialblazer https://biobriefs.com/orbis-and-roche-1b-style BioBriefs en 2026-09-18T10:31:49Z Orbis and Roche – $1B-style screening drive for immunology bispecifics https://biobriefs.com/ultragenyx-and-others-in-gene BioBriefs en 2026-09-18T10:31:49Z Ultragenyx and others in gene therapy pipeline – momentum after Sanfilippo https://biobriefs.com/ai-driven-oral-biologics-novo BioBriefs en 2026-09-18T10:31:49Z AI-driven oral biologics – Novo signs Anthropic collaboration to accelerate R&D https://biobriefs.com/cell-therapy-scale-up-cellares BioBriefs en 2026-09-18T10:31:49Z Cell therapy scale-up – Cellares and GenomeFrontier automate GF-CART01 manufacturing https://biobriefs.com/ai-driven-oral-cardiometabolic-drug BioBriefs en 2026-09-18T09:31:34Z AI-driven oral cardiometabolic drug discovery https://biobriefs.com/fda-greenlights-gene-therapy-for BioBriefs en 2026-09-18T09:31:34Z FDA greenlights gene therapy for Sanfilippo syndrome type A https://biobriefs.com/bms-drops-100m-orum-degrader BioBriefs en 2026-09-18T09:31:34Z BMS drops $100M Orum degrader-antibody conjugate after phase 1 readout https://biobriefs.com/electra-therapeutics-launches-after-upsized BioBriefs en 2026-09-18T09:31:34Z Electra Therapeutics launches after upsized inflammation IPO https://biobriefs.com/regulatory-oversight-fda-increases-foreign BioBriefs en 2026-09-18T09:31:34Z Regulatory oversight: FDA increases foreign clinical site inspection resources https://biobriefs.com/clinical-trials-acceleration-fda-launches BioBriefs en 2026-09-18T09:31:34Z Clinical trials acceleration: FDA launches Expedited IND pilot https://biobriefs.com/corporate-dealmaking-roche-signs-first BioBriefs en 2026-09-18T09:31:34Z Corporate dealmaking: Roche signs first partner for Dualitas’ bispecific screen https://biobriefs.com/oral-immunology-immunology-tech-molecular BioBriefs en 2026-09-18T09:31:34Z Oral immunology/immunology tech: Molecular Devices and STEMCELL automate organoid workflows https://biobriefs.com/funding-mithrl-raises-20m-to BioBriefs en 2026-09-18T09:31:34Z Funding: Mithrl raises $20M to scale an agentic biomedical model for R&D https://biobriefs.com/biotech-financing-and-pipeline-north BioBriefs en 2026-09-18T09:31:34Z Biotech financing and pipeline: North Immunology reverse merger raises $180M for eczema drug to clinic https://biobriefs.com/gene-therapy-approval-in-ultra BioBriefs en 2026-09-18T04:31:56Z Gene therapy approval in ultra-rare neurodegeneration https://biobriefs.com/reverse-merger-funding-for-next BioBriefs en 2026-09-18T04:31:56Z Reverse-merger funding for next-generation inflammation drugs https://biobriefs.com/big-ipo-momentum-in-biotech BioBriefs en 2026-09-18T04:31:56Z Big IPO momentum in biotech https://biobriefs.com/fda-oversight-focus-accelerate-early BioBriefs en 2026-09-18T04:31:56Z FDA oversight focus: accelerate early U.S. trials and expand foreign site audits https://biobriefs.com/massive-platform-deal-for-bispecific BioBriefs en 2026-09-18T04:31:56Z Massive platform deal for bispecific antibody discovery https://biobriefs.com/regenerative-and-inflammation-drug-development BioBriefs en 2026-09-18T04:31:56Z Regenerative and inflammation drug development support via RA-MAT designation https://biobriefs.com/precision-cell-therapy-manufacturing-automation BioBriefs en 2026-09-18T04:31:56Z Precision cell therapy manufacturing automation partnerships https://biobriefs.com/ai-in-biopharma-funding-for BioBriefs en 2026-09-18T04:31:56Z AI in biopharma: funding for biomedical world-model acceleration https://biobriefs.com/oncology-product-development-label-expansion BioBriefs en 2026-09-18T04:31:56Z Oncology product development: label expansion path for Roche T-cell engager https://biobriefs.com/molecular-tool-breakthrough-prime-assembly BioBriefs en 2026-09-18T04:31:56Z Molecular tool breakthrough: prime assembly enables targeted large DNA integration https://biobriefs.com/gene-therapy-approval-for-sanfilippo BioBriefs en 2026-09-17T21:31:59Z Gene therapy approval for Sanfilippo syndrome type A https://biobriefs.com/regulatory-push-on-faster-u BioBriefs en 2026-09-17T21:31:59Z Regulatory push on faster U.S. early clinical trials https://biobriefs.com/overseas-trial-oversight-and-tougher BioBriefs en 2026-09-17T21:31:59Z Overseas trial oversight and tougher scrutiny of foreign clinical data https://biobriefs.com/roche-bets-on-bispecific-discovery BioBriefs en 2026-09-17T21:31:59Z Roche bets on bispecific discovery via Dualitas platform https://biobriefs.com/novo-nordisk-expands-oral-macrocycle BioBriefs en 2026-09-17T21:31:59Z Novo Nordisk expands oral macrocycle push with Orbis deal https://biobriefs.com/novartis-expands-blood-brain-barrier BioBriefs en 2026-09-17T21:31:59Z Novartis expands blood-brain barrier delivery with Sironax platform https://biobriefs.com/cell-therapy-manufacturing-automation-in BioBriefs en 2026-09-17T21:31:59Z Cell therapy manufacturing automation in Asia https://biobriefs.com/ai-driven-biomedical-modeling-funding BioBriefs en 2026-09-17T21:31:59Z AI-driven biomedical modeling funding https://biobriefs.com/genome-engineering-advance-prime-assembly BioBriefs en 2026-09-17T21:31:59Z Genome engineering advance: prime assembly for targeted large DNA integration https://biobriefs.com/biotech-reverse-merger-financing-surge BioBriefs en 2026-09-17T21:31:59Z Biotech reverse merger financing surge: North Immunology https://biobriefs.com/regulatory-approvals-and-label-expansion BioBriefs en 2026-09-17T16:31:43Z Regulatory approvals and label expansion https://biobriefs.com/fda-oversight-tightening-and-clinical BioBriefs en 2026-09-17T16:31:43Z FDA oversight tightening and clinical-trial acceleration https://biobriefs.com/new-oncology-drug-approvals BioBriefs en 2026-09-17T16:31:43Z New oncology drug approvals https://biobriefs.com/oral-biologics-and-macrocycle-platform BioBriefs en 2026-09-17T16:31:43Z Oral biologics and macrocycle platform deals https://biobriefs.com/biotech-funding-for-ai-acceleration BioBriefs en 2026-09-17T16:31:43Z Biotech funding for AI acceleration and next-gen platforms https://biobriefs.com/immunology-reverse-merger-momentum BioBriefs en 2026-09-17T16:31:43Z Immunology reverse merger momentum https://biobriefs.com/bioprocess-training-and-continuous-manufacturing BioBriefs en 2026-09-17T16:31:43Z Bioprocess training and continuous manufacturing capability-building https://biobriefs.com/neuroscience-drug-and-platform-bets BioBriefs en 2026-09-17T16:31:43Z Neuroscience drug and platform bets: brain delivery and Parkinson’s mechanisms https://biobriefs.com/cell-and-gene-therapy-manufacturing BioBriefs en 2026-09-17T16:31:43Z Cell and gene therapy manufacturing automation partnerships https://biobriefs.com/immunology-checkpoint-and-targeted-preclinical BioBriefs en 2026-09-17T16:31:43Z Immunology checkpoint and targeted preclinical mechanism https://biobriefs.com/fda-approvals BioBriefs en 2026-09-17T14:32:22Z FDA approvals https://biobriefs.com/clinical-oncology-efficacy-in-hard BioBriefs en 2026-09-17T14:32:22Z Clinical oncology efficacy in hard-to-treat disease https://biobriefs.com/regulatory-shift-for-overseas-clinical BioBriefs en 2026-09-17T14:32:22Z Regulatory shift for overseas clinical trial oversight https://biobriefs.com/fda-accelerates-early-us-trial BioBriefs en 2026-09-17T14:32:22Z FDA accelerates early US trial starts https://biobriefs.com/big-biotech-licensing-and-platform BioBriefs en 2026-09-17T14:32:22Z Big biotech licensing and platform M&A—brain delivery https://biobriefs.com/big-pharma-dealmaking-bispecific-screening BioBriefs en 2026-09-17T14:32:22Z Big Pharma dealmaking—bispecific screening engine https://biobriefs.com/biotech-financings-oral-drug-phase BioBriefs en 2026-09-17T14:32:22Z Biotech financings—oral drug phase 3 push https://biobriefs.com/clinical-data-rna-splicing-approach BioBriefs en 2026-09-17T14:32:22Z Clinical data—RNA splicing approach in Huntington’s https://biobriefs.com/platform-strategy-regulatory-and-commercialization BioBriefs en 2026-09-17T14:32:22Z Platform/strategy—regulatory and commercialization for immune tolerance https://biobriefs.com/next-gen-genome-engineering-precise BioBriefs en 2026-09-17T14:32:22Z Next-gen genome engineering—precise large DNA integration https://biobriefs.com/bispecific-antibody-discovery-partnerships BioBriefs en 2026-09-17T10:32:13Z Bispecific antibody discovery partnerships https://biobriefs.com/brain-delivery-platform-deal BioBriefs en 2026-09-17T10:32:13Z Brain delivery platform deal https://biobriefs.com/fda-accelerates-early-us-trial BioBriefs en 2026-09-17T10:32:13Z FDA accelerates early US trial entry https://biobriefs.com/fda-tightens-scrutiny-of-foreign BioBriefs en 2026-09-17T10:32:13Z FDA tightens scrutiny of foreign clinical trial data https://biobriefs.com/us-immunology-trial-readout-dual BioBriefs en 2026-09-17T10:32:13Z US immunology trial readout – dual-acting PD-1/VEGF approach https://biobriefs.com/phase-3-funding-for-oral BioBriefs en 2026-09-17T10:32:12Z Phase 3 funding for oral thyroid eye disease therapy https://biobriefs.com/oncology-licensing-gsk-buys-global BioBriefs en 2026-09-17T10:32:12Z Oncology licensing – GSK buys global rights to trispecific T-cell engager https://biobriefs.com/prime-assembly-advances-large-dna BioBriefs en 2026-09-17T10:32:12Z Prime assembly advances large-DNA genome integration https://biobriefs.com/neurobiology-platform-xenocortical-mice-with BioBriefs en 2026-09-17T10:32:12Z Neurobiology platform – xenocortical mice with human neurons https://biobriefs.com/cell-therapy-manufacturing-automation-deal BioBriefs en 2026-09-17T10:32:12Z Cell therapy manufacturing automation deal https://biobriefs.com/regulatory-overhaul-for-faster-us BioBriefs en 2026-09-17T09:32:06Z Regulatory overhaul for faster US trial starts and tighter overseas scrutiny https://biobriefs.com/lunge-cancer-immunotherapy-readout-strengthens BioBriefs en 2026-09-17T09:32:06Z Lunge cancer immunotherapy readout strengthens ivonescimab competitive position https://biobriefs.com/novartis-buys-blood-brain-barrier BioBriefs en 2026-09-17T09:32:06Z Novartis buys blood-brain barrier platform from Sironax to advance brain delivery https://biobriefs.com/stem-cell-therapy-setback-triggers BioBriefs en 2026-09-17T09:32:06Z Stem cell therapy setback triggers Longeveron ‘review all options’ response https://biobriefs.com/designing-universal-gene-therapies-with BioBriefs en 2026-09-17T09:32:06Z Designing universal gene therapies with prime assembly improves targeted DNA integration https://biobriefs.com/funding-and-platform-scaling-for BioBriefs en 2026-09-17T09:32:06Z Funding and platform scaling for cell therapy manufacturing automation in Asia and the US https://biobriefs.com/investor-backed-oral-thyroid-eye BioBriefs en 2026-09-17T09:32:06Z Investor-backed oral thyroid eye disease challenger secures $123M to reach Phase 3 finish https://biobriefs.com/biosecurity-and-oversight-pressures-as BioBriefs en 2026-09-17T09:32:06Z Biosecurity and oversight pressures as AI expands biotech capabilities and risks https://biobriefs.com/neurodegeneration-biotech-huntingtons-rna-splicing BioBriefs en 2026-09-17T09:32:06Z Neurodegeneration biotech: Huntington’s RNA-splicing pill posts extension improvement https://biobriefs.com/genomic-immune-tolerance-startup-regcell BioBriefs en 2026-09-17T09:32:06Z Genomic immune tolerance startup RegCell raises $66M with AMED grant support https://biobriefs.com/regulatory-acceleration-fda-expedited-ind BioBriefs en 2026-09-17T06:34:24Z Regulatory acceleration: FDA Expedited IND Pilot https://biobriefs.com/fda-tightens-oversight-of-foreign BioBriefs en 2026-09-17T06:34:24Z FDA tightens oversight of foreign clinical trial data https://biobriefs.com/corporate-deal-novartis-buys-blood BioBriefs en 2026-09-17T06:34:24Z Corporate deal: Novartis buys blood-brain barrier delivery platform from Sironax https://biobriefs.com/clinical-readout-and-pipeline-milestone BioBriefs en 2026-09-17T06:34:24Z Clinical readout and pipeline milestone: Skyhawk’s RNA-splicing Huntington’s drug https://biobriefs.com/cell-therapy-manufacturing-cellares-and BioBriefs en 2026-09-17T06:34:24Z Cell therapy manufacturing: Cellares and GenomeFrontier scale automated GF-CART01 production https://biobriefs.com/regulatory-and-pipeline-strategy-gsk BioBriefs en 2026-09-17T06:34:24Z Regulatory and pipeline strategy: GSK expands China oncology with a new T-cell engager https://biobriefs.com/oncology-diagnostics-fda-clears-first BioBriefs en 2026-09-17T06:34:24Z Oncology diagnostics: FDA clears first glioma FET-PET radiopharmaceutical https://biobriefs.com/therapeutics-and-biosecurity-debate-ai BioBriefs en 2026-09-17T06:34:24Z Therapeutics and biosecurity debate: AI-enabled biological risk raises alarms in Congress https://biobriefs.com/genomic-engineering-prime-assembly-enables BioBriefs en 2026-09-17T06:34:24Z Genomic engineering: prime assembly enables precise integration of long DNA fragments https://biobriefs.com/funding-regcell-advances-immune-tolerance BioBriefs en 2026-09-17T06:34:24Z Funding: RegCell advances immune tolerance platform with $66M round https://biobriefs.com/regulatory-oversight-and-clinical-trial BioBriefs en 2026-09-17T04:32:41Z Regulatory oversight and clinical trial access https://biobriefs.com/ai-and-biosecurity-policy-scrutiny BioBriefs en 2026-09-17T04:32:41Z AI and biosecurity policy scrutiny https://biobriefs.com/big-pharma-deals-for-platform BioBriefs en 2026-09-17T04:32:41Z Big pharma deals for platform technologies https://biobriefs.com/clinical-trial-momentum-and-late BioBriefs en 2026-09-17T04:32:41Z Clinical trial momentum and late-stage financing for a thyroid eye disease competitor https://biobriefs.com/corporate-development-deal-for-multiple BioBriefs en 2026-09-17T04:32:41Z Corporate development deal for multiple myeloma trispecific T-cell engager https://biobriefs.com/new-regulatory-product-milestone-in BioBriefs en 2026-09-17T04:32:41Z New regulatory product milestone in radioligand imaging/therapy https://biobriefs.com/genome-engineering-innovation-with-broader BioBriefs en 2026-09-17T04:32:41Z Genome engineering innovation with broader targeting and potentially universal therapies https://biobriefs.com/cell-therapy-manufacturing-automation-collaboration BioBriefs en 2026-09-17T04:32:41Z Cell therapy manufacturing automation collaboration https://biobriefs.com/immune-tolerance-startup-funding BioBriefs en 2026-09-17T04:32:41Z Immune tolerance startup funding https://biobriefs.com/preclinical-anti-infective-innovation-using BioBriefs en 2026-09-17T04:32:41Z Preclinical anti-infective innovation using engineered prophylactic phage therapy https://biobriefs.com/fda-accelerates-early-clinical-development BioBriefs en 2026-09-16T21:32:51Z FDA accelerates early clinical development via expedited IND pilot https://biobriefs.com/regulatory-scrutiny-tightens-for-overseas BioBriefs en 2026-09-16T21:32:51Z Regulatory scrutiny tightens for overseas clinical data and trial sites https://biobriefs.com/novartis-buys-blood-brain-barrier BioBriefs en 2026-09-16T21:32:51Z Novartis buys blood-brain barrier platform from Sironax https://biobriefs.com/novo-and-anthropic-expand-ai BioBriefs en 2026-09-16T21:32:51Z Novo and Anthropic expand AI collaboration for drug development workflows https://biobriefs.com/prime-assembly-advances-universal-genome BioBriefs en 2026-09-16T21:32:51Z Prime Assembly advances universal genome integration concept https://biobriefs.com/sling-lands-123m-to-push BioBriefs en 2026-09-16T21:32:51Z Sling lands $123M to push oral thyroid eye disease candidate to Phase 3 https://biobriefs.com/gsk-commits-up-to-750m BioBriefs en 2026-09-16T21:32:51Z GSK commits up to $750M to acquire Chimagen T-cell engager for multiple myeloma https://biobriefs.com/sionna-therapeutics-cuts-workforce-after BioBriefs en 2026-09-16T21:32:51Z Sionna Therapeutics cuts workforce after cystic fibrosis trial failure https://biobriefs.com/regcell-raises-66m-to-take BioBriefs en 2026-09-16T21:32:51Z RegCell raises $66M to take Nobel-winning immune tolerance platform toward clinic https://biobriefs.com/skyhawk-reports-extension-benefit-for BioBriefs en 2026-09-16T21:32:51Z Skyhawk reports extension benefit for Huntington’s RNA-splicing pill and moves toward pivotal studies https://biobriefs.com/fda-expedites-early-stage-drug BioBriefs en 2026-09-16T16:33:05Z FDA expedites early-stage drug development https://biobriefs.com/regulatory-shift-fda-tightens-approach BioBriefs en 2026-09-16T16:33:05Z Regulatory shift: FDA tightens approach to early-stage China data https://biobriefs.com/fda-approvals-first-radioligand-generic BioBriefs en 2026-09-16T16:33:05Z FDA approvals: first radioligand generic enters market https://biobriefs.com/gsk-expands-china-oncology-bets BioBriefs en 2026-09-16T16:33:05Z GSK expands China oncology bets via Chimagen acquisition https://biobriefs.com/sling-therapeutics-advances-oral-tepezza BioBriefs en 2026-09-16T16:33:05Z Sling Therapeutics advances oral Tepezza rival for thyroid eye disease https://biobriefs.com/novartis-ends-als-program-after BioBriefs en 2026-09-16T16:33:05Z Novartis ends ALS program after Phase 2 failure https://biobriefs.com/a-new-in-vivo-human BioBriefs en 2026-09-16T16:33:05Z A new in vivo human-neuron model boosts neuropsychiatric research https://biobriefs.com/regcell-raises-non-dilutive-series BioBriefs en 2026-09-16T16:33:05Z RegCell raises non-dilutive + Series A to take immune tolerance platform into clinic https://biobriefs.com/chronic-pain-mechanism-exosomes-drive BioBriefs en 2026-09-16T16:33:05Z Chronic pain mechanism: exosomes drive persistent neuronal dysfunction after shingles https://biobriefs.com/slinging-the-pipeline-in-ai BioBriefs en 2026-09-16T16:33:05Z Slinging the pipeline in AI-driven drug discovery: Novo teams with Anthropic https://biobriefs.com/regulatory-acceleration BioBriefs en 2026-09-16T14:32:27Z Regulatory acceleration https://biobriefs.com/fda-approvals-and-major-regulatory BioBriefs en 2026-09-16T14:32:27Z FDA approvals and major regulatory milestones https://biobriefs.com/oncology-therapeutics-pipeline-wins-and BioBriefs en 2026-09-16T14:32:27Z Oncology therapeutics: pipeline wins and setbacks https://biobriefs.com/t-cell-engager-dealmaking-and BioBriefs en 2026-09-16T14:32:27Z T cell engager dealmaking and platform execution https://biobriefs.com/trial-readouts-across-cns-and BioBriefs en 2026-09-16T14:32:27Z Trial readouts across CNS and neurodegeneration https://biobriefs.com/biotech-funding-and-early-clinical BioBriefs en 2026-09-16T14:32:27Z Biotech funding and early clinical acceleration https://biobriefs.com/fda-and-biotech-operations-safety BioBriefs en 2026-09-16T14:32:27Z FDA and biotech operations: safety and manufacturing signals https://biobriefs.com/drug-pricing-contracts-and-policy BioBriefs en 2026-09-16T14:32:27Z Drug pricing, contracts, and policy pressure https://biobriefs.com/cancer-imaging-and-diagnostics-for BioBriefs en 2026-09-16T14:32:27Z Cancer imaging and diagnostics for neuro-oncology https://biobriefs.com/oncology-breakthroughs-adc-survival-signals BioBriefs en 2026-09-16T14:32:27Z Oncology breakthroughs: ADC survival signals in relapsed SCLC https://biobriefs.com/fda-expedited-ind-pathway BioBriefs en 2026-09-16T10:32:11Z FDA expedited IND pathway https://biobriefs.com/fda-pushes-tighter-scrutiny-of BioBriefs en 2026-09-16T10:32:11Z FDA pushes tighter scrutiny of China-origin early data https://biobriefs.com/radioligand-approvals-first-generic-and BioBriefs en 2026-09-16T10:32:11Z Radioligand approvals: first generic and renewed competitive pressure https://biobriefs.com/gsk-chimagen-trispecific-bet-for BioBriefs en 2026-09-16T10:32:11Z GSK- Chimagen trispecific bet for multiple myeloma https://biobriefs.com/vera-seeks-full-fda-approval BioBriefs en 2026-09-16T10:32:11Z Vera seeks full FDA approval after durable IgAN results https://biobriefs.com/scholar-rock-wins-sma-fda BioBriefs en 2026-09-16T10:32:11Z Scholar Rock wins SMA FDA approval for Isembyld https://biobriefs.com/telix-gets-first-glioma-fet BioBriefs en 2026-09-16T10:32:11Z Telix gets first glioma FET-PET imaging approval https://biobriefs.com/sionna-therapeutics-cuts-after-cystic BioBriefs en 2026-09-16T10:32:11Z Sionna Therapeutics cuts after cystic fibrosis setback https://biobriefs.com/teitur-trophics-peptide-tt-p34 BioBriefs en 2026-09-16T10:32:11Z Teitur Trophics peptide TT-P34 posts positive Phase I Parkinson’s signals https://biobriefs.com/shingles-after-pain-linked-to BioBriefs en 2026-09-16T10:32:11Z Shingles after-pain linked to exosome-driven neuronal dysfunction https://biobriefs.com/regulatory-acceleration-for-early-stage BioBriefs en 2026-09-16T09:32:41Z Regulatory acceleration for early-stage trials https://biobriefs.com/fda-greenlights-first-radioligand-generic BioBriefs en 2026-09-16T09:32:41Z FDA greenlights first radioligand generic https://biobriefs.com/biologics-regulation-and-drug-data BioBriefs en 2026-09-16T09:32:41Z Biologics regulation and drug-data scrutiny from China https://biobriefs.com/major-cns-immunology-platform-funding BioBriefs en 2026-09-16T09:32:41Z Major CNS immunology platform funding and leadership change https://biobriefs.com/big-pharma-bets-on-trispecific BioBriefs en 2026-09-16T09:32:41Z Big Pharma bets on trispecific T-cell engager for multiple myeloma https://biobriefs.com/trial-pipeline-lung-cancer-adc BioBriefs en 2026-09-16T09:32:41Z Trial pipeline: lung cancer ADC competition narrows https://biobriefs.com/regulatory-win-in-rare-neuromuscular BioBriefs en 2026-09-16T09:32:41Z Regulatory win in rare neuromuscular disease (SMA) https://biobriefs.com/biomarker-linked-mechanistic-neuroscience-tool BioBriefs en 2026-09-16T09:32:41Z Biomarker-linked mechanistic neuroscience tool: Alzheimer’s microprotein atlas https://biobriefs.com/mechanistic-immune-to-nerve-signaling BioBriefs en 2026-09-16T09:32:41Z Mechanistic immune-to-nerve signaling in post-shingles pain https://biobriefs.com/gsk-doubles-down-on-chimagen BioBriefs en 2026-09-16T09:32:41Z GSK doubles down on Chimagen with multiple-line ROS1 lung cancer asset move https://biobriefs.com/fda-clears-first-generic-radioligand BioBriefs en 2026-09-16T04:32:12Z FDA clears first generic radioligand equivalent to Lutathera https://biobriefs.com/gsks-multiple-myeloma-trispecific-gamble BioBriefs en 2026-09-16T04:32:12Z GSK’s multiple myeloma trispecific gamble gets major funding step https://biobriefs.com/fda-expedited-ind-pilot-rolls BioBriefs en 2026-09-16T04:32:12Z FDA expedited IND pilot rolls out under ‘Operation Trialblazer’ https://biobriefs.com/scholars-rocks-isembyld-wins-fda BioBriefs en 2026-09-16T04:32:12Z Scholars Rock’s Isembyld wins FDA approval for SMA https://biobriefs.com/telix-wins-fda-nod-for BioBriefs en 2026-09-16T04:32:12Z Telix wins FDA nod for first glioma FET-PET imaging agent https://biobriefs.com/gsks-ros1-nsclc-asset-posts BioBriefs en 2026-09-16T04:32:12Z GSK’s ROS1 NSCLC asset posts 94% ORR and pushes regulatory plans https://biobriefs.com/b7-h3-adcs-deliver-overall BioBriefs en 2026-09-16T04:32:12Z B7-H3 ADCs deliver overall survival gains in China trials of relapsed SCLC https://biobriefs.com/vera-lines-up-full-approval BioBriefs en 2026-09-16T04:32:12Z Vera lines up full approval push after strong 2-year IgAN Phase 3 results https://biobriefs.com/alzheimers-biology-gets-a-new BioBriefs en 2026-09-16T04:32:12Z Alzheimer’s biology gets a new resource: microprotein atlas of frontal cortex https://biobriefs.com/shingles-pain-mechanism-exosomes-drive BioBriefs en 2026-09-16T04:32:12Z Shingles pain mechanism: exosomes drive persistent neuronal dysfunction in PHN https://biobriefs.com/radiopharmaceutical-generics BioBriefs en 2026-09-15T21:32:32Z Radiopharmaceutical generics https://biobriefs.com/big-pharma-betting-on-next BioBriefs en 2026-09-15T21:32:32Z Big Pharma betting on next-gen T-cell engagers https://biobriefs.com/fda-rare-disease-trial-framework BioBriefs en 2026-09-15T21:32:32Z FDA rare-disease trial framework review https://biobriefs.com/fda-expedited-ind-pilot-to BioBriefs en 2026-09-15T21:32:32Z FDA expedited IND pilot to speed early trials https://biobriefs.com/rare-neuromuscular-approval-sma-gets BioBriefs en 2026-09-15T21:32:32Z Rare neuromuscular approval: SMA gets muscle-targeting therapy https://biobriefs.com/phase-3-durability-signal-for BioBriefs en 2026-09-15T21:32:32Z Phase 3 durability signal for CTLA-4 lung cancer therapy https://biobriefs.com/lung-cancer-adcs-and-os BioBriefs en 2026-09-15T21:32:32Z Lung cancer ADCs and OS wins in China https://biobriefs.com/major-biotech-exits-cellectis-shifts BioBriefs en 2026-09-15T21:32:32Z Major biotech exits: Cellectis shifts CAR-T strategy https://biobriefs.com/gsk-rnai-antibody-strategy-plus BioBriefs en 2026-09-15T21:32:32Z GSK RNAi/antibody strategy plus clinical uncertainty elsewhere (Q2 reset) https://biobriefs.com/clinical-research-mechanism-exosomes-as BioBriefs en 2026-09-15T21:32:32Z Clinical research mechanism: exosomes as driver of post-shingles nerve pain https://biobriefs.com/fda-accelerates-early-stage-clinical BioBriefs en 2026-09-15T16:32:30Z FDA accelerates early-stage clinical development with new investigational pilot https://biobriefs.com/new-fda-approvals-expand-treatment BioBriefs en 2026-09-15T16:32:30Z New FDA approvals expand treatment options in rare disease and diagnostic imaging https://biobriefs.com/late-stage-efficacy-wins-and BioBriefs en 2026-09-15T16:32:30Z Late-stage efficacy wins and setbacks reshape oncology readouts at WCLC https://biobriefs.com/astrazenecas-oral-serd-strategy-stumbles BioBriefs en 2026-09-15T16:32:30Z AstraZeneca’s oral SERD strategy stumbles again in first-line breast cancer https://biobriefs.com/biotech-restructurings-after-clinical-failures BioBriefs en 2026-09-15T16:32:30Z Biotech restructurings after clinical failures: Sionna shifts after CF setback https://biobriefs.com/new-financings-expand-precision-immunotherapy BioBriefs en 2026-09-15T16:32:30Z New financings expand precision immunotherapy pipelines https://biobriefs.com/corporate-pivots-in-cell-therapy BioBriefs en 2026-09-15T16:32:30Z Corporate pivots in cell therapy: Cellectis exits CAR-T to bet on in vivo editing https://biobriefs.com/epigenetics-and-hemoglobinopathy-development-fulcrum BioBriefs en 2026-09-15T16:32:30Z Epigenetics and hemoglobinopathy development: Fulcrum shuts PRC2 inhibitor program after regulatory concern https://biobriefs.com/diagnostic-and-imaging-ecosystem-expands BioBriefs en 2026-09-15T16:32:30Z Diagnostic and imaging ecosystem expands with new radiopharmaceutical approvals https://biobriefs.com/platform-and-assay-technology-faster BioBriefs en 2026-09-15T16:32:30Z Platform and assay technology: faster regulatory submissions via AI for trial data https://biobriefs.com/fda-accelerated-drug-development-pathway BioBriefs en 2026-09-15T14:33:37Z FDA accelerated drug-development pathway https://biobriefs.com/vera-therapeutics-pushes-igan-to BioBriefs en 2026-09-15T14:33:37Z Vera Therapeutics pushes IgAN to full approval https://biobriefs.com/pivotal-turns-for-multiple-cns BioBriefs en 2026-09-15T14:33:37Z Pivotal turns for multiple CNS and rare-disease programs https://biobriefs.com/phase-3-pressure-in-oral BioBriefs en 2026-09-15T14:33:37Z Phase 3 pressure in oral SERD breast cancer https://biobriefs.com/small-cell-lung-cancer-b7 BioBriefs en 2026-09-15T14:33:37Z Small-cell lung cancer: B7-H3 ADC survival signal in China https://biobriefs.com/cns-and-dataset-infrastructure-for BioBriefs en 2026-09-15T14:33:37Z CNS and dataset infrastructure for AI in biology https://biobriefs.com/precision-diagnostics-telix-gets-first BioBriefs en 2026-09-15T14:33:37Z Precision diagnostics: Telix gets first glioma FET-PET authorization in the U.S. https://biobriefs.com/biopharma-manufacturing-expansion-in-europe BioBriefs en 2026-09-15T14:33:37Z Biopharma manufacturing expansion in Europe https://biobriefs.com/cro-consolidation-for-discovery-to BioBriefs en 2026-09-15T14:33:37Z CRO consolidation for discovery-to-validation assays https://biobriefs.com/immunology-venture-nobel-winning-treg BioBriefs en 2026-09-15T14:33:37Z Immunology venture: Nobel-winning Treg work enters clinic https://biobriefs.com/regulatory-updates-psychedelics-at-the BioBriefs en 2026-09-15T10:32:21Z Regulatory updates: psychedelics at the FDA and real-world safeguards https://biobriefs.com/rare-disease-approvals-scholar-rock BioBriefs en 2026-09-15T10:32:21Z Rare disease approvals: Scholar Rock wins SMA go-ahead for muscle-targeted therapy https://biobriefs.com/oncology-ivonescimabs-latest-phase-3 BioBriefs en 2026-09-15T10:32:21Z Oncology: ivonescimab’s latest Phase 3 readouts aim to narrow the argument vs Keytruda https://biobriefs.com/oncology-roche-partner-medilink-reports BioBriefs en 2026-09-15T10:32:21Z Oncology: Roche partner MediLink reports Phase 3 OS benefit for B7-H3 ADC in relapsed SCLC https://biobriefs.com/womens-health-oncology-astrazenecas-etcamah BioBriefs en 2026-09-15T10:32:21Z Women’s health oncology: AstraZeneca’s Etcamah fails first-line expansion effort in Phase 3 https://biobriefs.com/oncology-pipeline-azs-camizestrant-setback BioBriefs en 2026-09-15T10:32:21Z Oncology pipeline: Az’s camizestrant setback sharpens ESR1 focus for oral SERDs https://biobriefs.com/biopharma-dealmaking-in-asia-solstices BioBriefs en 2026-09-15T10:32:21Z Biopharma dealmaking in Asia: Solstice’s $225M Series A and GLP-1 licensing for bofanglutide https://biobriefs.com/manufacturing-and-cro-services-single BioBriefs en 2026-09-15T10:32:21Z Manufacturing and CRO services: Single Cell Discoveries buys TATAA Biocenter to close validation gap https://biobriefs.com/ai-for-regulatory-submissions-nphase BioBriefs en 2026-09-15T10:32:21Z AI for regulatory submissions: nPhase targets faster clinical-trial paperwork conversion https://biobriefs.com/biopharma-economics-and-policy-pediatric BioBriefs en 2026-09-15T10:32:21Z Biopharma economics and policy: pediatric FDA priority review vouchers near record level as fees drop https://biobriefs.com/cancer-immunotherapy-financing-and-next BioBriefs en 2026-09-15T09:33:31Z Cancer immunotherapy financing and next trial launch https://biobriefs.com/depression-pipeline-hits-phase-2 BioBriefs en 2026-09-15T09:33:31Z Depression pipeline hits Phase 2 setback https://biobriefs.com/regulatory-approvals-first-in-class BioBriefs en 2026-09-15T09:33:31Z Regulatory approvals: first-in-class SMA therapy cleared by FDA https://biobriefs.com/fda-policy-reassessing-rare-disease BioBriefs en 2026-09-15T09:33:31Z FDA policy: reassessing rare-disease trial criteria https://biobriefs.com/china-phase-3-b7-h3 BioBriefs en 2026-09-15T09:33:31Z China Phase 3: B7-H3 ADCs post overall survival wins in relapsed SCLC https://biobriefs.com/oncology-roche-partner-medilink-posts BioBriefs en 2026-09-15T09:33:31Z Oncology: Roche partner MediLink posts Phase 3 OS benefit for Tam-Peli in China https://biobriefs.com/biotech-partnerships-and-platform-discovery BioBriefs en 2026-09-15T09:33:31Z Biotech partnerships and platform: discovery transcriptomics CRO acquisition https://biobriefs.com/regulatory-submissions-ai-platform-for BioBriefs en 2026-09-15T09:33:31Z Regulatory submissions: AI platform for clinical trial data-to-filing acceleration https://biobriefs.com/clinical-trial-results-in-neuromuscular BioBriefs en 2026-09-15T09:33:31Z Clinical trial results in neuromuscular disease: DM1 Phase 3 misses primary endpoint https://biobriefs.com/platform-therapeutics-pivot-cellectis-exits BioBriefs en 2026-09-15T09:33:31Z Platform therapeutics pivot: Cellectis exits CAR-T for in vivo gene editing https://biobriefs.com/regulatory-approvals-in-rare-neuromuscular BioBriefs en 2026-09-15T04:32:30Z Regulatory approvals in rare neuromuscular disease https://biobriefs.com/phase-3-oncology-readouts-reshape BioBriefs en 2026-09-15T04:32:30Z Phase 3 oncology readouts reshape second-line SCLC strategy https://biobriefs.com/phase-3-competitive-pressure-in BioBriefs en 2026-09-15T04:32:30Z Phase 3 competitive pressure in first-line breast cancer SERD strategy https://biobriefs.com/emerging-oncology-biomarkers-and-dual BioBriefs en 2026-09-15T04:32:30Z Emerging oncology biomarkers and dual-acting PD-1/VEGF competition https://biobriefs.com/fda-action-for-rare-disease BioBriefs en 2026-09-15T04:32:30Z FDA action for rare disease clinical trial design standards https://biobriefs.com/regulatory-ai-tooling-for-clinical BioBriefs en 2026-09-15T04:32:30Z Regulatory AI tooling for clinical submissions https://biobriefs.com/imaging-innovation-reaches-the-us BioBriefs en 2026-09-15T04:32:30Z Imaging innovation reaches the US market for glioma https://biobriefs.com/drug-development-outcomes-in-neuromuscular BioBriefs en 2026-09-15T04:32:30Z Drug development outcomes in neuromuscular antibody-oligonucleotide conjugates https://biobriefs.com/biotech-cro-consolidation-to-move BioBriefs en 2026-09-15T04:32:30Z Biotech CRO consolidation to move targets from discovery to validation https://biobriefs.com/company-pivots-and-platform-bets BioBriefs en 2026-09-15T04:32:30Z Company pivots and platform bets in gene editing and muscle biology https://biobriefs.com/fda-approval-first-myostatin-targeted BioBriefs en 2026-09-14T21:32:47Z FDA approval—first myostatin-targeted therapy expands SMA options https://biobriefs.com/late-stage-oncology-b7-h3 BioBriefs en 2026-09-14T21:32:47Z Late-stage oncology—B7-H3 ADCs press forward in relapsed small-cell lung cancer https://biobriefs.com/oncology-akeso-and-summit-move BioBriefs en 2026-09-14T21:32:47Z Oncology—Akeso and Summit move to shore up ivonescimab survival case https://biobriefs.com/regulatory-fda-seeks-input-on BioBriefs en 2026-09-14T21:32:47Z Regulatory—FDA seeks input on rare-disease trial criteria and endpoint selection https://biobriefs.com/clinical-failure-astrazenecas-oral-serd BioBriefs en 2026-09-14T21:32:47Z Clinical failure—AstraZeneca’s oral SERD Etcamah misses in first-line breast cancer https://biobriefs.com/regulatory-market-access-pediatric-priority BioBriefs en 2026-09-14T21:32:47Z Regulatory/market access—pediatric priority review vouchers near record highs https://biobriefs.com/ai-and-regulatory-operations-nphase BioBriefs en 2026-09-14T21:32:47Z AI and regulatory operations—nPhase promises faster clinical submissions https://biobriefs.com/biotech-funding-nara-health-secures BioBriefs en 2026-09-14T21:32:47Z Biotech funding—Nara Health secures $14M for third-party administration platform https://biobriefs.com/platform-buildout-single-cell-discoveries BioBriefs en 2026-09-14T21:32:47Z Platform buildout—Single Cell Discoveries acquires TATAA Biocenter https://biobriefs.com/business-realignment-cellectis-exits-car BioBriefs en 2026-09-14T21:32:47Z Business realignment—Cellectis exits CAR-T to pivot to in vivo gene editing https://biobriefs.com/regulatory-actions-in-neuro-rare BioBriefs en 2026-09-14T16:33:40Z Regulatory actions in neuro/rare disease https://biobriefs.com/oncology-trial-signals-wins-misses BioBriefs en 2026-09-14T16:33:40Z Oncology trial signals: wins, misses, and pipeline readouts https://biobriefs.com/fda-study-clearance-and-ind BioBriefs en 2026-09-14T16:33:40Z FDA study clearance and IND moves in gene/cell therapy https://biobriefs.com/biotech-pivot-and-strategic-transformation BioBriefs en 2026-09-14T16:33:40Z Biotech pivot and strategic transformation https://biobriefs.com/clinical-neuroscience-and-gene-epigenome BioBriefs en 2026-09-14T16:33:40Z Clinical neuroscience and gene/epigenome editing collaborations https://biobriefs.com/regulatory-and-commercial-stakes-in BioBriefs en 2026-09-14T16:33:40Z Regulatory and commercial stakes in obesity pharmacology https://biobriefs.com/ind-enabling-translational-immunology-and BioBriefs en 2026-09-14T16:33:40Z IND-enabling translational immunology and targeted platforms https://biobriefs.com/immunotherapy-delivery-and-dosing-optimization BioBriefs en 2026-09-14T16:33:40Z Immunotherapy delivery and dosing optimization signals https://biobriefs.com/corporate-strategy-and-manufacturing-capacity BioBriefs en 2026-09-14T16:33:40Z Corporate strategy and manufacturing capacity shift in vaccines https://biobriefs.com/psychedelics-in-anxiety-late-stage BioBriefs en 2026-09-14T16:33:40Z Psychedelics in anxiety: late-stage readouts and FDA path https://biobriefs.com/sma-drug-approval-apitegromab-isembyld BioBriefs en 2026-09-14T14:32:41Z SMA drug approval: apitegromab (Isembyld) https://biobriefs.com/novartis-late-stage-setback-del BioBriefs en 2026-09-14T14:32:41Z Novartis late-stage setback: del-desiran in HARBOR (DM1) + pipeline pressure https://biobriefs.com/definium-psychedelic-anxiety-program-second BioBriefs en 2026-09-14T14:32:41Z Definium psychedelic anxiety program: second Phase 3 win (DT120) https://biobriefs.com/oncology-trial-disappointment-astrazeneca-serd BioBriefs en 2026-09-14T14:32:41Z Oncology trial disappointment: AstraZeneca SERD Etcamah fails earlier-stage expansion study https://biobriefs.com/ipo-to-fund-late-stage BioBriefs en 2026-09-14T14:32:41Z IPO to fund late-stage inflammation program: Electra Therapeutics https://biobriefs.com/small-cell-lung-cancer-subcutaneous BioBriefs en 2026-09-14T14:32:41Z Small-cell lung cancer: subcutaneous tarlatamab (DeLLphi-308) early activity https://biobriefs.com/small-molecule-adc-efficacy-gap BioBriefs en 2026-09-14T14:32:41Z Small molecule ADC efficacy gap: MediLink/Roche Phase 3 B7-H3 ADC misses survival bar set by rival https://biobriefs.com/healthcare-policy-and-cost-risk BioBriefs en 2026-09-14T14:32:41Z Healthcare policy and cost risk: pharmaceutical tariffs compliance guidance still unclear https://biobriefs.com/diagnostics-real-world-efficacy-nefecon BioBriefs en 2026-09-14T14:32:41Z Diagnostics/real-world efficacy: Nefecon shows proteinuria reduction in IgA nephropathy https://biobriefs.com/biotech-capital-innovation-corporate-vc BioBriefs en 2026-09-14T14:32:41Z Biotech capital/innovation: corporate VC role in biopharma investing https://biobriefs.com/oncology-clinical-outcomes-and-pipeline BioBriefs en 2026-09-14T10:32:28Z Oncology clinical outcomes and pipeline readouts https://biobriefs.com/late-stage-setbacks-and-investor BioBriefs en 2026-09-14T10:32:28Z Late-stage setbacks and investor pressure in Big Pharma https://biobriefs.com/immuno-oncology-and-immune-engagement BioBriefs en 2026-09-14T10:32:28Z Immuno-oncology and immune engagement mechanisms https://biobriefs.com/glp-1-access-and-real BioBriefs en 2026-09-14T10:32:28Z GLP-1 access and real-world healthcare delivery https://biobriefs.com/biotech-venture-capital-structure-shifts BioBriefs en 2026-09-14T10:32:28Z Biotech venture capital structure shifts and funding mechanics https://biobriefs.com/ai-enabled-molecular-and-imaging BioBriefs en 2026-09-14T10:32:28Z AI-enabled molecular and imaging instrumentation advances https://biobriefs.com/clinical-research-in-neurodegeneration-and BioBriefs en 2026-09-14T10:32:28Z Clinical research in neurodegeneration and biomarkers https://biobriefs.com/diagnostic-and-data-tooling-for BioBriefs en 2026-09-14T10:32:28Z Diagnostic and data tooling for precision medicine https://biobriefs.com/drug-discovery-and-therapeutic-modality BioBriefs en 2026-09-14T10:32:28Z Drug discovery and therapeutic modality: AI for design and optimization https://biobriefs.com/early-clinical-development-in-immuno BioBriefs en 2026-09-14T10:32:28Z Early clinical development in immuno-oncology delivery https://biobriefs.com/clinical-trial-failures-reshape-rna BioBriefs en 2026-09-14T09:32:42Z Clinical trial failures reshape RNA-therapeutics bets https://biobriefs.com/immune-oncology-convenience-strategy-posts BioBriefs en 2026-09-14T09:32:42Z Immune-oncology convenience strategy posts early small-cell data https://biobriefs.com/precision-immunotherapy-combinations-face-mixed BioBriefs en 2026-09-14T09:32:42Z Precision immunotherapy combinations face mixed performance in lung cancer https://biobriefs.com/imaging-advances-faster-more-reliable BioBriefs en 2026-09-14T09:32:42Z Imaging advances: faster, more reliable digital pathology and membrane analysis https://biobriefs.com/diagnostics-and-device-innovation-for BioBriefs en 2026-09-14T09:32:42Z Diagnostics and device innovation for point-of-care performance https://biobriefs.com/ai-for-protein-understanding-scales BioBriefs en 2026-09-14T09:32:42Z AI for protein understanding scales genomics-era bottlenecks https://biobriefs.com/data-driven-oncology-care-better BioBriefs en 2026-09-14T09:32:42Z Data-driven oncology care: better staging signals and treatment targeting https://biobriefs.com/regulatory-and-evidence-quality-signals BioBriefs en 2026-09-14T09:32:42Z Regulatory and evidence quality signals: corrections and trial critique https://biobriefs.com/funding-and-platform-scaling-ai BioBriefs en 2026-09-14T09:32:42Z Funding and platform scaling: AI in health-adjacent innovation https://biobriefs.com/corporate-venture-capital-reshapes-biopharma BioBriefs en 2026-09-14T09:32:42Z Corporate venture capital reshapes biopharma financing dynamics https://biobriefs.com/phase-3-oncology-disappointment-and BioBriefs en 2026-09-14T04:32:08Z Phase 3 oncology disappointment and downstream corporate pressure https://biobriefs.com/ai-driven-membrane-mapping-for BioBriefs en 2026-09-14T04:32:08Z AI-driven membrane mapping for faster cell biology workflows https://biobriefs.com/cancer-immunotherapy-dosing-model-challenges BioBriefs en 2026-09-14T04:32:08Z Cancer immunotherapy dosing model challenges a key biomarker assumption https://biobriefs.com/targeted-immunotherapy-or-adc-combinations BioBriefs en 2026-09-14T04:32:08Z Targeted immunotherapy or ADC combinations fail to improve outcomes in PD-L1-high lung cancer https://biobriefs.com/early-clinical-signal-for-tarlatamab BioBriefs en 2026-09-14T04:32:08Z Early clinical signal for tarlatamab and regimen flexibility in small cell lung cancer https://biobriefs.com/sangamo-like-engineering-in-solid BioBriefs en 2026-09-14T04:32:08Z Sangamo-like engineering in solid tumors: ICOS-enhanced T-cell receptors https://biobriefs.com/pancreatic-cancer-platform-new-vein BioBriefs en 2026-09-14T04:32:08Z Pancreatic cancer platform: new vein-based diagnostic approach in hard-to-sample cases https://biobriefs.com/kidney-disease-management-real-world BioBriefs en 2026-09-14T04:32:08Z Kidney disease management: real-world evidence for Nefecon in IgA nephropathy https://biobriefs.com/antibody-drug-conjugates-meet-cost BioBriefs en 2026-09-14T04:32:08Z Antibody-Drug Conjugates meet cost-effectiveness in MSI-high colorectal cancer https://biobriefs.com/antibiotic-resistance-in-gonorrhea-surveillance BioBriefs en 2026-09-14T04:32:08Z Antibiotic resistance in gonorrhea: surveillance signals shift genetically https://biobriefs.com/late-stage-neuromuscular-pipeline-setback BioBriefs en 2026-09-13T21:32:32Z Late-stage neuromuscular pipeline setback and investor pressure at Novartis https://biobriefs.com/ai-driven-membrane-mapping-accelerates BioBriefs en 2026-09-13T21:32:32Z AI-driven membrane mapping accelerates cryo-ET workflows https://biobriefs.com/ai-powered-fall-prediction-funding BioBriefs en 2026-09-13T21:32:32Z AI-powered fall prediction funding signals continued appetite for digital health https://biobriefs.com/checkpoint-style-lung-cancer-strategy BioBriefs en 2026-09-13T21:32:32Z Checkpoint-style lung cancer strategy fails in first-line PD-L1 high disease https://biobriefs.com/new-small-molecule-strategy-targets BioBriefs en 2026-09-13T21:32:32Z New small-molecule strategy targets KRAS pathway limitations https://biobriefs.com/tarlatamab-dosing-schedule-exploration-in BioBriefs en 2026-09-13T21:32:32Z Tarlatamab dosing schedule exploration in small cell lung cancer https://biobriefs.com/immune-oncology-biomarker-and-pharmacokinetics BioBriefs en 2026-09-13T21:32:32Z Immune-oncology biomarker and pharmacokinetics question in pembrolizumab https://biobriefs.com/real-world-kidney-outcomes-for BioBriefs en 2026-09-13T21:32:32Z Real-world kidney outcomes for Nefecon expand beyond trials https://biobriefs.com/vaccine-immunogenicity-enhancement-with-mrna BioBriefs en 2026-09-13T21:32:32Z Vaccine immunogenicity enhancement with mRNA flu design https://biobriefs.com/sepsis-management-debate-plasma-transfusion BioBriefs en 2026-09-13T21:32:32Z Sepsis management debate: plasma transfusion evidence remains conflicting https://biobriefs.com/phase-3-oncology-readout-risk BioBriefs en 2026-09-13T16:32:01Z Phase 3 oncology readout risk for SELLAS (event-driven stock impact) https://biobriefs.com/checkpoint-inhibitor-strategy-stumble-in BioBriefs en 2026-09-13T16:32:01Z Checkpoint inhibitor strategy stumble in PD-L1-high metastatic lung cancer https://biobriefs.com/tarlatamab-dosing-interval-flexibility-emerges BioBriefs en 2026-09-13T16:32:01Z Tarlatamab dosing interval flexibility emerges in small cell lung cancer https://biobriefs.com/on-device-oncology-diagnostics-prostate BioBriefs en 2026-09-13T16:32:01Z On-device oncology diagnostics: prostate staging and liquid biopsy push https://biobriefs.com/lung-cancer-immunotherapy-patient-specific BioBriefs en 2026-09-13T16:32:01Z Lung cancer immunotherapy: patient-specific immune measurement shifts target identification https://biobriefs.com/hiv-cure-research-nk-cell BioBriefs en 2026-09-13T16:32:01Z HIV cure research: NK cell education imprints on HIV reservoirs https://biobriefs.com/diabetes-care-safety-operations-monitoring BioBriefs en 2026-09-13T16:32:01Z Diabetes care safety operations: monitoring older cancer patients on steroids https://biobriefs.com/car-t-and-engineered-tcr BioBriefs en 2026-09-13T16:32:01Z CAR-T and engineered TCR advances for solid tumors https://biobriefs.com/reproductive-and-neuroimmune-biology-prenatal BioBriefs en 2026-09-13T16:32:01Z Reproductive and neuroimmune biology: prenatal stress linked to cognitive changes via Galectin-3 https://biobriefs.com/translational-imaging-and-ai-workflow BioBriefs en 2026-09-13T16:32:01Z Translational imaging and AI workflow improvements: reducing pathology analysis burden https://biobriefs.com/immuno-oncology-checkpoint-combinations-dosing BioBriefs en 2026-09-13T14:32:28Z Immuno-oncology—checkpoint combinations, dosing assumptions and survival https://biobriefs.com/targeted-oncology-drug-resistance-immune BioBriefs en 2026-09-13T14:32:28Z Targeted oncology—drug resistance, immune evasion and biomarker biology https://biobriefs.com/gene-editing-and-precision-delivery BioBriefs en 2026-09-13T14:32:28Z Gene editing and precision delivery—improving specificity and getting payload into the right cells https://biobriefs.com/clinical-diagnostics-and-precision-imaging BioBriefs en 2026-09-13T14:32:28Z Clinical diagnostics and precision imaging—faster reads, better target confirmation https://biobriefs.com/oncology-clinical-trials-signals-for BioBriefs en 2026-09-13T14:32:28Z Oncology clinical trials—signals for new therapies and caution on negative or neutral reads https://biobriefs.com/immunology-and-cellular-engineering-boosting BioBriefs en 2026-09-13T14:32:28Z Immunology and cellular engineering—boosting T cells and reshaping immune landscapes https://biobriefs.com/antimicrobial-resistance-and-infectious-disease BioBriefs en 2026-09-13T14:32:28Z Antimicrobial resistance and infectious disease surveillance—measuring shifting resistance patterns https://biobriefs.com/cardiometabolic-and-kidney-clinical-measurements BioBriefs en 2026-09-13T14:32:28Z Cardiometabolic and kidney—clinical measurements and evidence for monitoring during therapy https://biobriefs.com/regenerative-and-drug-development-platforms BioBriefs en 2026-09-13T14:32:28Z Regenerative and drug development platforms—aging clocks and human-translatable endpoints https://biobriefs.com/biotech-investing-and-corporate-pipeline BioBriefs en 2026-09-13T14:32:28Z Biotech investing and corporate pipeline timing—market read-throughs on clinical event milestones https://biobriefs.com/small-cell-lung-cancer-immunotherapy BioBriefs en 2026-09-13T10:31:50Z Small cell lung cancer immunotherapy advances https://biobriefs.com/checkpoint-inhibitor-biology-under-scrutiny BioBriefs en 2026-09-13T10:31:50Z Checkpoint inhibitor biology under scrutiny https://biobriefs.com/cancer-immunotherapy-strategy-revisited BioBriefs en 2026-09-13T10:31:50Z Cancer immunotherapy strategy revisited https://biobriefs.com/new-clinical-signal-for-an BioBriefs en 2026-09-13T10:31:50Z New clinical signal for an IgA nephropathy therapy in the real world https://biobriefs.com/lung-cancer-trial-setback-for BioBriefs en 2026-09-13T10:31:50Z Lung cancer trial setback for antibody-drug plus PD-1 strategy https://biobriefs.com/sma-muscle-loss-drug-wins BioBriefs en 2026-09-13T10:31:50Z SMA muscle-loss drug wins FDA approval https://biobriefs.com/oncology-trial-design-and-outcome BioBriefs en 2026-09-13T10:31:50Z Oncology trial design and outcome interpretation debate https://biobriefs.com/cancer-genomics-and-treatment-resistance BioBriefs en 2026-09-13T10:31:50Z Cancer genomics and treatment resistance mechanisms https://biobriefs.com/surgical-and-clinical-workflow-optimization BioBriefs en 2026-09-13T10:31:50Z Surgical and clinical workflow optimization in oncology care https://biobriefs.com/ai-enabled-diagnostics-and-clinical BioBriefs en 2026-09-13T10:31:50Z AI-enabled diagnostics and clinical decision support https://biobriefs.com/fda-approval-sma-muscle-loss BioBriefs en 2026-09-13T09:32:50Z FDA approval – SMA muscle loss therapy https://biobriefs.com/oncology-immunotherapy-dosing-model-challenges BioBriefs en 2026-09-13T09:32:50Z Oncology – immunotherapy dosing model challenges PET-style assumptions https://biobriefs.com/immuno-oncology-early-clinical-signal BioBriefs en 2026-09-13T09:32:50Z Immuno-oncology – early clinical signal in small cell lung cancer https://biobriefs.com/oncology-pd-l1-high-phase BioBriefs en 2026-09-13T09:32:50Z Oncology – PD-L1-high phase 3 setback for ADC plus checkpoint inhibitor https://biobriefs.com/oncology-new-image-guided-ablation BioBriefs en 2026-09-13T09:32:50Z Oncology – new image-guided ablation approach for children https://biobriefs.com/biomarkers-diagnostics-real-world-evidence BioBriefs en 2026-09-13T09:32:50Z Biomarkers & diagnostics – real-world evidence for IgA nephropathy treatment https://biobriefs.com/neuroscience-alzheimers-blood-and-spinal BioBriefs en 2026-09-13T09:32:50Z Neuroscience – Alzheimer’s blood and spinal markers sequence plaques https://biobriefs.com/oncology-large-scale-canine-cancer BioBriefs en 2026-09-13T09:32:50Z Oncology – large-scale canine cancer molecular subtyping https://biobriefs.com/hematology-oncology-therapeutics-outpatient-delivery BioBriefs en 2026-09-13T09:32:50Z Hematology/Oncology therapeutics – outpatient delivery consensus for CPX-351 https://biobriefs.com/clinical-science-major-dataset-on BioBriefs en 2026-09-13T09:32:50Z Clinical science – major dataset on treatment-free benefit mismatch in colorectal immunotherapy economics https://biobriefs.com/fda-approval-for-spinal-muscular BioBriefs en 2026-09-13T04:32:30Z FDA approval for spinal muscular atrophy muscle-loss indication https://biobriefs.com/small-cell-lung-cancer-subcutaneous BioBriefs en 2026-09-13T04:32:30Z Small cell lung cancer: subcutaneous tarlatamab safety and early signals https://biobriefs.com/small-cell-lung-cancer-dosing BioBriefs en 2026-09-13T04:32:30Z Small cell lung cancer: dosing interval flexibility with tarlatamab https://biobriefs.com/clinical-trial-setback-sacituzumab-govitecan BioBriefs en 2026-09-13T04:32:30Z Clinical trial setback: sacituzumab govitecan plus pembrolizumab in PD-L1 high metastatic lung cancer https://biobriefs.com/real-world-safety-efficacy-nefecon BioBriefs en 2026-09-13T04:32:30Z Real-world safety/efficacy: Nefecon in IgA nephropathy https://biobriefs.com/antisense-vs-biology-receptor-occupancy BioBriefs en 2026-09-13T04:32:30Z Antisense vs. biology: receptor occupancy fails to predict pembrolizumab immune activation https://biobriefs.com/oncology-immunology-mechanism-t-cell BioBriefs en 2026-09-13T04:32:30Z Oncology immunology mechanism: T cell activation inside tumors can eliminate tumors independent of specificity https://biobriefs.com/big-tech-oncology-imaging-ai BioBriefs en 2026-09-13T04:32:30Z Big-tech oncology imaging/AI: PET imaging to confirm checkpoint inhibitor drug delivery to tumors https://biobriefs.com/oncology-safety-signal-hand-foot BioBriefs en 2026-09-13T04:32:30Z Oncology safety signal: hand-foot syndrome risk mapped across FDA safety reports https://biobriefs.com/biotech-deal-dynamics-solstice-225m BioBriefs en 2026-09-13T04:32:30Z Biotech deal dynamics: Solstice $225M neoadjuvant CTLA-4 program https://biobriefs.com/regulatory-approvals BioBriefs en 2026-09-12T21:32:22Z Regulatory approvals https://biobriefs.com/oncology-immunotherapy-and-trial-results BioBriefs en 2026-09-12T21:32:22Z Oncology – immunotherapy and trial results https://biobriefs.com/oncology-precision-imaging-for-treatment BioBriefs en 2026-09-12T21:32:22Z Oncology – precision imaging for treatment guidance https://biobriefs.com/biotech-finance-and-pipeline-risk BioBriefs en 2026-09-12T21:32:22Z Biotech finance and pipeline risk https://biobriefs.com/clinical-development-oncology-drug-combinations BioBriefs en 2026-09-12T21:32:22Z Clinical development – oncology drug combinations https://biobriefs.com/biotech-manufacturing-and-capacity-deals BioBriefs en 2026-09-12T21:32:22Z Biotech manufacturing and capacity deals https://biobriefs.com/clinical-development-gene-therapy-in BioBriefs en 2026-09-12T21:32:22Z Clinical development – gene therapy in SMA https://biobriefs.com/oncology-investigational-combination-with-checkpoint BioBriefs en 2026-09-12T21:32:22Z Oncology – investigational combination with checkpoint blockade https://biobriefs.com/health-technology-and-diagnostics BioBriefs en 2026-09-12T21:32:22Z Health technology and diagnostics https://biobriefs.com/virology-and-infectious-disease BioBriefs en 2026-09-12T21:32:22Z Virology and infectious disease https://biobriefs.com/fda-action-and-regulatory-milestones BioBriefs en 2026-09-12T16:32:23Z FDA action and regulatory milestones https://biobriefs.com/late-stage-oncology-readouts-and BioBriefs en 2026-09-12T16:32:23Z Late-stage oncology readouts and translational imaging guidance https://biobriefs.com/clinical-progress-and-expansion-in BioBriefs en 2026-09-12T16:32:23Z Clinical progress and expansion in rare disease gene therapy and blood cancers https://biobriefs.com/biotech-financing-and-commercialization-partnerships BioBriefs en 2026-09-12T16:32:23Z Biotech financing and commercialization partnerships https://biobriefs.com/high-impact-clinical-development-trial BioBriefs en 2026-09-12T16:32:23Z High-impact clinical development: trial reads, study timing, and risk https://biobriefs.com/new-oncology-mechanism-biology-with BioBriefs en 2026-09-12T16:32:23Z New oncology mechanism biology with translational implications https://biobriefs.com/advanced-diagnostics-and-biomarkers-for BioBriefs en 2026-09-12T16:32:23Z Advanced diagnostics and biomarkers for precision oncology https://biobriefs.com/neuro-and-rare-disease-therapeutics BioBriefs en 2026-09-12T16:32:23Z Neuro and rare disease therapeutics: gene delivery and functional recovery https://biobriefs.com/ai-driven-healthcare-tooling-with BioBriefs en 2026-09-12T16:32:23Z AI-driven healthcare tooling with clinical relevance https://biobriefs.com/massive-financing-and-commercialization-runway BioBriefs en 2026-09-12T16:32:23Z Massive financing and commercialization runway for gene therapy https://biobriefs.com/fda-approvals-sma-muscle-loss BioBriefs en 2026-09-12T14:32:24Z FDA approvals – SMA muscle loss therapy https://biobriefs.com/biotech-finance-cash-runway-for BioBriefs en 2026-09-12T14:32:24Z Biotech finance – cash runway for gene therapy & pipeline moves https://biobriefs.com/regulatory-cvot-setbacks-and-evolving BioBriefs en 2026-09-12T14:32:24Z Regulatory – CVOT setbacks and evolving target confidence in cardiology https://biobriefs.com/immuno-oncology-ctla-4-next BioBriefs en 2026-09-12T14:32:24Z Immuno-oncology – CTLA-4 next-generation launch https://biobriefs.com/clinical-development-antibody-drug-conjugate BioBriefs en 2026-09-12T14:32:24Z Clinical development – antibody-drug conjugate dosing step in EGFR-mutated lung cancer https://biobriefs.com/platform-manufacturing-improved-bioprocess-intensification BioBriefs en 2026-09-12T14:32:24Z Platform & manufacturing – improved bioprocess intensification licensing https://biobriefs.com/diagnostics-regulation-fda-clearance-delay BioBriefs en 2026-09-12T14:32:24Z Diagnostics regulation – FDA clearance delay for AI heart failure software https://biobriefs.com/m-a-axogen-to-acquire BioBriefs en 2026-09-12T14:32:24Z M&A – Axogen to acquire Biocircuit https://biobriefs.com/biomarker-strategy-liquid-biopsy-approach BioBriefs en 2026-09-12T14:32:24Z Biomarker strategy – liquid biopsy approach for NSCLC research https://biobriefs.com/device-monitoring-fda-breakthrough-status BioBriefs en 2026-09-12T14:32:24Z Device & monitoring – FDA breakthrough status for antibiotic monitoring patch https://biobriefs.com/sma-muscle-loss-therapy-gets BioBriefs en 2026-09-12T10:32:56Z SMA muscle-loss therapy gets FDA nod https://biobriefs.com/novartis-setbacks-spread-across-cardiovascular BioBriefs en 2026-09-12T10:32:56Z Novartis setbacks spread across cardiovascular and neuromuscular programs https://biobriefs.com/fda-signals-reconsideration-on-ai BioBriefs en 2026-09-12T10:32:56Z FDA signals reconsideration on AI-based cardiac decision support https://biobriefs.com/cancer-immunotherapy-and-regulatory-expansion BioBriefs en 2026-09-12T10:32:56Z Cancer immunotherapy and regulatory expansion: Bayer’s Hyrnuo label broadens https://biobriefs.com/samsung-biologics-locks-long-term BioBriefs en 2026-09-12T10:32:56Z Samsung Biologics locks long-term manufacturing deal https://biobriefs.com/dealmaking-and-funding-solstice-grows BioBriefs en 2026-09-12T10:32:56Z Dealmaking and funding: Solstice grows CTLA-4 oncology platform https://biobriefs.com/genome-engineering-continues-crispr-style BioBriefs en 2026-09-12T10:32:56Z Genome engineering continues: CRISPR-style epigenome rewiring for cancer https://biobriefs.com/cell-therapy-manufacturing-collaboration-in BioBriefs en 2026-09-12T10:32:56Z Cell therapy manufacturing collaboration in Japan https://biobriefs.com/clinical-trial-disruption-risk-persistent BioBriefs en 2026-09-12T10:32:56Z Clinical trial disruption risk: persistent cancer drug shortages https://biobriefs.com/ai-for-biosensing-wearable-vancomycin BioBriefs en 2026-09-12T10:32:56Z AI for biosensing: wearable vancomycin monitoring gets FDA breakthrough status https://biobriefs.com/fda-approvals-in-rare-diseases BioBriefs en 2026-09-12T09:32:27Z FDA approvals in rare diseases https://biobriefs.com/oncology-drug-development-setbacks-and BioBriefs en 2026-09-12T09:32:27Z Oncology drug development setbacks and label moves https://biobriefs.com/biotech-trial-readouts-and-regulatory BioBriefs en 2026-09-12T09:32:27Z Biotech trial readouts and regulatory review timelines https://biobriefs.com/clinical-holds-and-fda-regulatory BioBriefs en 2026-09-12T09:32:27Z Clinical holds and FDA regulatory interventions https://biobriefs.com/large-format-biotech-financing-and BioBriefs en 2026-09-12T09:32:27Z Large-format biotech financing and cash runway moves https://biobriefs.com/biopharma-capital-markets-and-public BioBriefs en 2026-09-12T09:32:27Z Biopharma capital markets and public-market re-pricing https://biobriefs.com/biomanufacturing-deals-and-capacity-expansion BioBriefs en 2026-09-12T09:32:27Z Biomanufacturing deals and capacity expansion https://biobriefs.com/cell-and-gene-therapy-manufacturing BioBriefs en 2026-09-12T09:32:27Z Cell and gene therapy manufacturing collaborations https://biobriefs.com/precision-immunotherapy-biology-in-breast BioBriefs en 2026-09-12T09:32:27Z Precision immunotherapy biology in breast cancer https://biobriefs.com/regulatory-frameworks-for-ai-in BioBriefs en 2026-09-12T09:32:27Z Regulatory frameworks for AI in healthcare https://biobriefs.com/regulatory-approvals-in-rare-disease BioBriefs en 2026-09-12T04:32:31Z Regulatory approvals in rare disease and oncology https://biobriefs.com/fda-setbacks-and-review-pauses BioBriefs en 2026-09-12T04:32:31Z FDA setbacks and review pauses for pharma programs https://biobriefs.com/biotech-financings-and-market-moves BioBriefs en 2026-09-12T04:32:31Z Biotech financings and market moves https://biobriefs.com/clinical-pipeline-acceleration-and-trial BioBriefs en 2026-09-12T04:32:31Z Clinical pipeline acceleration and trial design in immuno-oncology and beyond https://biobriefs.com/carried-therapeutic-platforms-and-commercialization BioBriefs en 2026-09-12T04:32:31Z Carried therapeutic platforms and commercialization partnerships https://biobriefs.com/cell-and-gene-therapy-manufacturing BioBriefs en 2026-09-12T04:32:31Z Cell and gene therapy manufacturing capacity partnerships https://biobriefs.com/medical-device-and-digital-health BioBriefs en 2026-09-12T04:32:31Z Medical device and digital health adoption—FDA and reimbursement signals https://biobriefs.com/new-biotech-platform-building-blocks BioBriefs en 2026-09-12T04:32:31Z New biotech platform building blocks—AI, imaging, and biosensing https://biobriefs.com/diabetes-and-metabolic-disease-pipeline BioBriefs en 2026-09-12T04:32:31Z Diabetes and metabolic disease pipeline—new real-world and preclinical bets https://biobriefs.com/biopharma-dealmaking-and-manufacturing-infrastructure BioBriefs en 2026-09-12T04:32:31Z Biopharma dealmaking and manufacturing infrastructure expansion https://biobriefs.com/fda-regulatory-decisions-oncology-neurology BioBriefs en 2026-09-11T21:32:58Z FDA regulatory decisions – oncology/neurology https://biobriefs.com/fda-regulatory-decisions-manufacturing-quality BioBriefs en 2026-09-11T21:32:58Z FDA regulatory decisions – manufacturing quality https://biobriefs.com/cancer-immunotherapy-financing-and-scaling BioBriefs en 2026-09-11T21:32:58Z Cancer immunotherapy financing and scaling https://biobriefs.com/gene-therapy-funding-momentum BioBriefs en 2026-09-11T21:32:58Z Gene therapy funding momentum https://biobriefs.com/biopharma-company-moves-m-a BioBriefs en 2026-09-11T21:32:58Z Biopharma company moves – M&A and strategic partnerships https://biobriefs.com/cell-therapy-manufacturing-japan-infrastructure BioBriefs en 2026-09-11T21:32:58Z Cell therapy manufacturing – Japan infrastructure https://biobriefs.com/device-innovation-antibiotic-monitoring BioBriefs en 2026-09-11T21:32:58Z Device innovation – antibiotic monitoring https://biobriefs.com/clinical-grade-pipeline-repricing-after BioBriefs en 2026-09-11T21:32:58Z Clinical-grade pipeline repricing after Phase 3 misses https://biobriefs.com/diagnostics-and-digital-clinical-decision BioBriefs en 2026-09-11T21:32:58Z Diagnostics and digital clinical decision support – FDA clearance risk https://biobriefs.com/business-to-biotech-dealmaking-biopharma BioBriefs en 2026-09-11T21:32:58Z Business-to-biotech dealmaking – biopharma commercialization pressure https://biobriefs.com/fda-device-pathway-for-real BioBriefs en 2026-09-11T16:32:53Z FDA device pathway for real-time antibiotic monitoring https://biobriefs.com/fda-review-timeline-changes-in BioBriefs en 2026-09-11T16:32:53Z FDA review timeline changes in metastatic colorectal cancer https://biobriefs.com/ai-driven-clinical-diagnostics-face BioBriefs en 2026-09-11T16:32:53Z AI-driven clinical diagnostics face FDA clearance headwinds https://biobriefs.com/alzheon-plans-major-fundraising-after BioBriefs en 2026-09-11T16:32:53Z Alzheon plans major fundraising after Phase 3 miss https://biobriefs.com/biotech-ipo-and-liquidity-backdrop BioBriefs en 2026-09-11T16:32:53Z Biotech IPO and liquidity backdrop shapes sector risk appetite https://biobriefs.com/private-investment-funds-keep-scaling BioBriefs en 2026-09-11T16:32:53Z Private investment funds keep scaling life sciences capital https://biobriefs.com/large-series-f-supports-dravet BioBriefs en 2026-09-11T16:32:53Z Large Series F supports Dravet gene therapy trial transition https://biobriefs.com/manufacturing-capacity-and-cdmo-partnerships BioBriefs en 2026-09-11T16:32:53Z Manufacturing capacity and CDMO partnerships drive production deals https://biobriefs.com/gene-therapy-financing-for-rare BioBriefs en 2026-09-11T16:32:53Z Gene therapy financing for rare pediatric epilepsy https://biobriefs.com/fda-and-regulatory-posture-on BioBriefs en 2026-09-11T16:32:53Z FDA and regulatory posture on AI in healthcare https://biobriefs.com/diabetes-drug-development-via-menin BioBriefs en 2026-09-11T14:32:57Z Diabetes drug development via menin inhibition spinout https://biobriefs.com/regulatory-setbacks-and-approval-expansions BioBriefs en 2026-09-11T14:32:57Z Regulatory setbacks and approval expansions for oncology and epilepsy https://biobriefs.com/contract-negotiation-pressure-at-karyopharm BioBriefs en 2026-09-11T14:32:57Z Contract negotiation pressure at Karyopharm amid Imdelltra expansion plans https://biobriefs.com/gene-therapy-pipeline-capital-injection BioBriefs en 2026-09-11T14:32:57Z Gene therapy pipeline capital injection in rare childhood epilepsy https://biobriefs.com/car-t-manufacturing-and-capacity BioBriefs en 2026-09-11T14:32:57Z CAR-T manufacturing and capacity buildout in Japan https://biobriefs.com/large-venture-pe-funding-in BioBriefs en 2026-09-11T14:32:57Z Large venture/PE funding in healthcare and life sciences platforms https://biobriefs.com/exosome-based-preclinical-strategy-in BioBriefs en 2026-09-11T14:32:57Z Exosome-based preclinical strategy in pancreatic cancer https://biobriefs.com/mrna-cancer-vaccine-manufacturing-constraints BioBriefs en 2026-09-11T14:32:57Z mRNA cancer vaccine manufacturing constraints https://biobriefs.com/fda-driven-shift-toward-agentic BioBriefs en 2026-09-11T14:32:57Z FDA-driven shift toward agentic medical AI development https://biobriefs.com/approval-of-first-in-human BioBriefs en 2026-09-11T14:32:57Z Approval of first-in-human therapy using radiopharmaceutical microlabeled system https://biobriefs.com/fda-regulatory-actions-on-psychedelics BioBriefs en 2026-09-11T10:32:31Z FDA regulatory actions on psychedelics and AI oversight https://biobriefs.com/clinical-trial-outcomes-and-holds BioBriefs en 2026-09-11T10:32:31Z Clinical trial outcomes and holds affecting late-stage and high-profile programs https://biobriefs.com/genetic-medicine-funding-surge-for BioBriefs en 2026-09-11T10:32:31Z Genetic medicine funding surge for Dravet and platform expansion https://biobriefs.com/cell-and-gene-therapy-manufacturing BioBriefs en 2026-09-11T10:32:31Z Cell and gene therapy manufacturing capacity in Japan https://biobriefs.com/cancer-immunotherapy-label-and-trial BioBriefs en 2026-09-11T10:32:31Z Cancer immunotherapy label and trial readouts reshape competitive landscape https://biobriefs.com/biotech-dealmaking-and-exits-assets BioBriefs en 2026-09-11T10:32:31Z Biotech dealmaking and exits: assets, acquisitions, and funds https://biobriefs.com/imaging-and-ai-diagnostics-face BioBriefs en 2026-09-11T10:32:31Z Imaging and AI diagnostics face regulatory headwinds and validation needs https://biobriefs.com/biotech-ipo-performance-and-capital BioBriefs en 2026-09-11T10:32:31Z Biotech IPO performance and capital market reopening https://biobriefs.com/regulatory-and-trial-ecosystem-shifts BioBriefs en 2026-09-11T10:32:31Z Regulatory and trial ecosystem shifts: FDA leadership continuity and clinical hold dynamics https://biobriefs.com/emerging-diabetes-genetics-to-clinics BioBriefs en 2026-09-11T10:32:31Z Emerging diabetes genetics-to-clinics strategy for menin inhibitors https://biobriefs.com/biotech-r-d-and-mechanistic BioBriefs en 2026-09-11T09:31:51Z Biotech R&D and mechanistic oncology findings https://biobriefs.com/precision-cardiometabolic-drug-setbacks-and BioBriefs en 2026-09-11T09:31:51Z Precision cardiometabolic drug setbacks and pipeline read-through https://biobriefs.com/fda-and-regulatory-leadership-moves BioBriefs en 2026-09-11T09:31:51Z FDA and regulatory leadership moves https://biobriefs.com/new-biotech-funding-for-genetic BioBriefs en 2026-09-11T09:31:51Z New biotech funding for genetic medicine https://biobriefs.com/fda-partial-holds-and-clinical BioBriefs en 2026-09-11T09:31:51Z FDA partial holds and clinical development interruptions https://biobriefs.com/regulatory-approvals-expanding-oncology-access BioBriefs en 2026-09-11T09:31:51Z Regulatory approvals expanding oncology access https://biobriefs.com/startups-and-platform-funding-in BioBriefs en 2026-09-11T09:31:51Z Startups and platform funding in cell and gene therapy manufacturing https://biobriefs.com/genetic-medicine-and-ocular-pipeline BioBriefs en 2026-09-11T09:31:51Z Genetic medicine and ocular pipeline momentum https://biobriefs.com/clinical-evidence-in-immuno-oncology BioBriefs en 2026-09-11T09:31:51Z Clinical evidence in immuno-oncology maintenance strategies https://biobriefs.com/ai-driven-diagnostics-and-regulatory BioBriefs en 2026-09-11T09:31:51Z AI-driven diagnostics and regulatory review delays https://biobriefs.com/regulatory-fda-oversight-and-label BioBriefs en 2026-09-11T04:32:11Z Regulatory: FDA oversight and label expansion https://biobriefs.com/immuno-oncology-new-ctla-4 BioBriefs en 2026-09-11T04:32:11Z Immuno-oncology: New CTLA-4 contender backed by $225M Series A https://biobriefs.com/oncology-cryoablation-analytics-and-failure BioBriefs en 2026-09-11T04:32:11Z Oncology: Cryoablation analytics and failure prediction https://biobriefs.com/diabetes-antibody-therapy-reverses-diabetic BioBriefs en 2026-09-11T04:32:11Z Diabetes: Antibody therapy reverses diabetic neuropathy in mice https://biobriefs.com/biopharma-deals-axogen-to-acquire BioBriefs en 2026-09-11T04:32:11Z Biopharma deals: Axogen to acquire Biocircuit for $200M https://biobriefs.com/cell-and-gene-therapy-manufacturing BioBriefs en 2026-09-11T04:32:11Z Cell and gene therapy manufacturing: Japan CAR T collaboration https://biobriefs.com/oncology-immunotherapy-limits-and-opportunity BioBriefs en 2026-09-11T04:32:11Z Oncology immunotherapy: Limits and opportunity in checkpoint biology https://biobriefs.com/ai-drug-development-arpa-h BioBriefs en 2026-09-11T04:32:11Z AI + drug development: ARPA-H ADVOCATE adds heart-disease and agentic tools https://biobriefs.com/oncology-multimodal-prediction-in-pancreatic BioBriefs en 2026-09-11T04:32:11Z Oncology: Multimodal prediction in pancreatic cancer for T-cell trapping https://biobriefs.com/biotech-funding-commercialization-models-reverse BioBriefs en 2026-09-11T04:32:11Z Biotech funding & commercialization models: reverse mergers surge https://biobriefs.com/fda-actions-reshape-oncology-treatment BioBriefs en 2026-09-10T21:32:40Z FDA actions reshape oncology treatment access https://biobriefs.com/oncology-pipeline-funding-fuels-new BioBriefs en 2026-09-10T21:32:40Z Oncology pipeline funding fuels new immunotherapy and gene-therapy bets https://biobriefs.com/clinical-setbacks-and-regulatory-holds BioBriefs en 2026-09-10T21:32:40Z Clinical setbacks and regulatory holds complicate epilepsy and neuromuscular R&D https://biobriefs.com/biotech-finance-and-m-a BioBriefs en 2026-09-10T21:32:40Z Biotech finance and M&A momentum returns with major capital raises https://biobriefs.com/device-and-diagnostics-regulation-hits BioBriefs en 2026-09-10T21:32:40Z Device and diagnostics regulation hits AI commercialization https://biobriefs.com/new-immunology-mechanisms-open-therapeutic BioBriefs en 2026-09-10T21:32:40Z New immunology mechanisms open therapeutic angles in cancer and rare disease https://biobriefs.com/car-t-and-precision-cell BioBriefs en 2026-09-10T21:32:40Z CAR T and precision cell therapy: manufacturing and clinical execution advances https://biobriefs.com/ai-and-biomedical-r-d BioBriefs en 2026-09-10T21:32:40Z AI and biomedical R&D: transparency, imaging, and platform-scale tools https://biobriefs.com/cancer-development-targeted-mechanisms-and BioBriefs en 2026-09-10T21:32:40Z Cancer development: targeted mechanisms and biomarker directions https://biobriefs.com/rare-disease-r-d-and BioBriefs en 2026-09-10T21:32:40Z Rare disease R&D and pediatric immunology signals move forward https://biobriefs.com/fda-oversight-and-regulatory-continuity BioBriefs en 2026-09-10T16:31:11Z FDA oversight and regulatory continuity https://biobriefs.com/clinical-setbacks-and-pipeline-reprioritization BioBriefs en 2026-09-10T16:31:11Z Clinical setbacks and pipeline reprioritization at Novartis and others https://biobriefs.com/trial-momentum-in-oncology-imdelltra BioBriefs en 2026-09-10T16:31:11Z Trial momentum in oncology: Imdelltra + Imfinzi and arlo-cel positioning https://biobriefs.com/ai-and-rare-disease-early BioBriefs en 2026-09-10T16:31:11Z AI and rare-disease early diagnosis: ARPA-H ADVOCATE rollout https://biobriefs.com/fda-clinical-hold-hits-biohaven BioBriefs en 2026-09-10T16:31:11Z FDA clinical hold hits Biohaven epilepsy program https://biobriefs.com/fda-approval-and-label-expansion BioBriefs en 2026-09-10T16:31:11Z FDA approval and label expansion for cancer therapy https://biobriefs.com/corporate-restructuring-in-biodev-takedas BioBriefs en 2026-09-10T16:31:11Z Corporate restructuring in biodev: Takeda’s R&D chief to retire https://biobriefs.com/new-money-for-life-sciences BioBriefs en 2026-09-10T16:31:11Z New money for life sciences: Luma’s $410M fund close and Encrypted’s $275M Series F https://biobriefs.com/new-biodev-licensing-and-platform BioBriefs en 2026-09-10T16:31:11Z New biodev licensing and platform expansion: Mucosal IgA, cationic antimicrobials, and deal-making https://biobriefs.com/biotech-financing-and-early-stage BioBriefs en 2026-09-10T16:31:11Z Biotech financing and early-stage launches: Twostep IND clearance and Moonwalk Series B https://biobriefs.com/fda-leadership-continuity-and-regulatory BioBriefs en 2026-09-10T14:32:32Z FDA leadership continuity and regulatory policy signals https://biobriefs.com/pipeline-derisking-in-multiple-myeloma BioBriefs en 2026-09-10T14:32:32Z Pipeline derisking in multiple myeloma cell therapy https://biobriefs.com/clinical-holds-and-trial-interruptions BioBriefs en 2026-09-10T14:32:32Z Clinical holds and trial interruptions in epilepsy drug development https://biobriefs.com/oncology-trial-updates-and-dose BioBriefs en 2026-09-10T14:32:32Z Oncology trial updates and dose strategy shifts in bladder cancer https://biobriefs.com/immunology-mmp-9-antibody-approach BioBriefs en 2026-09-10T14:32:32Z Immunology: MMP-9 antibody approach targets diabetic peripheral neuropathy https://biobriefs.com/gene-therapy-readiness-for-huntingtons BioBriefs en 2026-09-10T14:32:32Z Gene therapy readiness for Huntington’s readout https://biobriefs.com/funding-encrypted-series-f-for BioBriefs en 2026-09-10T14:32:32Z Funding: Encrypted series F for Dravet genetics program https://biobriefs.com/biotech-dealmaking-and-asset-acceleration BioBriefs en 2026-09-10T14:32:32Z Biotech dealmaking and asset acceleration in protein engineering and diagnostics https://biobriefs.com/china-regulatory-approvals-first-time BioBriefs en 2026-09-10T14:32:32Z China regulatory approvals: first-time clinic clearances for new modalities https://biobriefs.com/obesity-and-diabetes-expansion-via BioBriefs en 2026-09-10T14:32:32Z Obesity and diabetes expansion via new startups and spinouts https://biobriefs.com/fda-stability-and-leadership-continuity BioBriefs en 2026-09-10T10:31:32Z FDA stability and leadership continuity https://biobriefs.com/regulatory-access-and-courtroom-scrutiny BioBriefs en 2026-09-10T10:31:32Z Regulatory access and courtroom scrutiny over patient assistance https://biobriefs.com/fda-approval-for-next-generation BioBriefs en 2026-09-10T10:31:32Z FDA approval for next-generation SERD in breast cancer https://biobriefs.com/biotech-funding-drug-platform-moves BioBriefs en 2026-09-10T10:31:32Z Biotech funding: drug platform moves to clinic with major Series B https://biobriefs.com/genetic-medicine-encoded-books-additional BioBriefs en 2026-09-10T10:31:32Z Genetic medicine: Encoded books additional capital for Dravet program and manufacturing https://biobriefs.com/cancer-cell-therapy-amgens-bcma BioBriefs en 2026-09-10T10:31:32Z Cancer cell therapy: Amgen’s BCMA-era strategy expands in lung cancer https://biobriefs.com/myeloma-immunotherapy-case-report-cns BioBriefs en 2026-09-10T10:31:32Z Myeloma immunotherapy case report: CNS remission with intrathecal pairing https://biobriefs.com/biotech-financing-uk-europe-and BioBriefs en 2026-09-10T10:31:32Z Biotech financing: UK/Europe and immunology waves into late-stage readiness https://biobriefs.com/oncology-clinical-readouts-bms-car BioBriefs en 2026-09-10T10:31:32Z Oncology clinical readouts: BMS CAR T positioned for harder-to-treat myeloma https://biobriefs.com/ind-clinical-expansion-in-autoimmune BioBriefs en 2026-09-10T10:31:32Z IND/clinical expansion in autoimmune and oncology https://biobriefs.com/fda-leadership-stability BioBriefs en 2026-09-10T09:32:07Z FDA leadership stability https://biobriefs.com/clinical-setbacks-and-competitive-pressure BioBriefs en 2026-09-10T09:32:07Z Clinical setbacks and competitive pressure in oncology https://biobriefs.com/breast-cancer-regulatory-win-for BioBriefs en 2026-09-10T09:32:07Z Breast cancer regulatory win for a next-gen SERD https://biobriefs.com/car-t-efficacy-signal-in BioBriefs en 2026-09-10T09:32:07Z CAR-T efficacy signal in relapsed/refractory myeloma https://biobriefs.com/rnai-and-obesity-funding-rounds BioBriefs en 2026-09-10T09:32:07Z RNAi and obesity funding rounds https://biobriefs.com/diabetes-biotech-spinout-from-kura BioBriefs en 2026-09-10T09:32:07Z Diabetes biotech spinout from Kura oncology https://biobriefs.com/new-capital-for-genetic-medicine BioBriefs en 2026-09-10T09:32:07Z New capital for genetic medicine in rare disease https://biobriefs.com/arpa-h-funding-for-heart BioBriefs en 2026-09-10T09:32:07Z ARPA-H funding for heart disease AI tools https://biobriefs.com/immuno-oncology-funding-for-a BioBriefs en 2026-09-10T09:32:07Z Immuno-oncology funding for a next-gen CTLA-4 strategy https://biobriefs.com/diabetes-drug-development-via-nmpa BioBriefs en 2026-09-10T09:32:07Z Diabetes drug development via NMPA approvals in China https://biobriefs.com/fda-leadership-stability-signals-continuity BioBriefs en 2026-09-10T04:32:10Z FDA leadership stability signals continuity for regulators and sponsors https://biobriefs.com/encoded-and-partners-raise-to BioBriefs en 2026-09-10T04:32:10Z Encoded and partners raise to scale genetic medicine manufacturing for Dravet https://biobriefs.com/arpa-h-expands-heart-disease BioBriefs en 2026-09-10T04:32:10Z ARPA-H expands heart-disease AI tooling with industry and real-world partners https://biobriefs.com/car-t-front-bms-narrows BioBriefs en 2026-09-10T04:32:10Z CAR-T front: BMS narrows relapsed multiple myeloma risk with QUINTESSENTIAL outcome https://biobriefs.com/pharvaris-prepares-for-hae-fda BioBriefs en 2026-09-10T04:32:10Z Pharvaris prepares for HAE FDA decision after second phase 3 success https://biobriefs.com/tyras-fgfr3-bladder-cancer-update BioBriefs en 2026-09-10T04:32:10Z Tyra’s FGFR3 bladder cancer update disappoints on Phase 2 outcomes https://biobriefs.com/novartis-car-t-and-lp BioBriefs en 2026-09-10T04:32:10Z Novartis CAR T and Lp(a) setbacks add pressure after Avidity and pelacarsen failures https://biobriefs.com/moonwalk-raises-70m-series-b BioBriefs en 2026-09-10T04:32:10Z Moonwalk raises $70M Series B to push adipose-targeted RNAi obesity candidate into clinic https://biobriefs.com/gene-therapy-step-forward-in BioBriefs en 2026-09-10T04:32:10Z Gene therapy step forward in Sandhoff disease model with intravenous AAV https://biobriefs.com/biotech-manufacturing-and-quality-microscale BioBriefs en 2026-09-10T04:32:10Z Biotech manufacturing and quality: microscale chromatography shows manufacturing-aligned process signals https://biobriefs.com/capital-raises-for-precision-genetics BioBriefs en 2026-09-09T21:32:51Z Capital raises for precision genetics in epilepsy https://biobriefs.com/arpa-h-grants-to-build BioBriefs en 2026-09-09T21:32:51Z ARPA-H grants to build FDA-authorized heart AI agents https://biobriefs.com/fda-leadership-stability-in-drugs BioBriefs en 2026-09-09T21:32:51Z FDA leadership stability in drugs and biologics https://biobriefs.com/rna-drug-development-moves-from BioBriefs en 2026-09-09T21:32:51Z RNA drug development moves from target discovery to funding and IND pathways https://biobriefs.com/cell-therapy-momentum-in-multiple BioBriefs en 2026-09-09T21:32:51Z Cell therapy momentum in multiple myeloma https://biobriefs.com/ai-designed-drug-signals-biological BioBriefs en 2026-09-09T21:32:51Z AI-designed drug signals biological age shifts in early IPF trial workups https://biobriefs.com/precision-oncology-funding-solstice-bets BioBriefs en 2026-09-09T21:32:51Z Precision oncology funding—Solstice bets on next-gen CTLA-4 immunotherapy https://biobriefs.com/diabetes-r-d-spinout-tied BioBriefs en 2026-09-09T21:32:51Z Diabetes R&D spinout tied to Lilly-backed menin inhibition https://biobriefs.com/obesity-pipeline-financing-for-adipose BioBriefs en 2026-09-09T21:32:51Z Obesity pipeline financing for adipose-targeted RNAi https://biobriefs.com/clinical-trial-signal-setbacks-in BioBriefs en 2026-09-09T21:32:51Z Clinical trial signal setbacks in bladder cancer https://biobriefs.com/fda-leadership-stability-and-regulatory BioBriefs en 2026-09-09T16:31:22Z FDA leadership stability and regulatory continuity https://biobriefs.com/multiple-myeloma-car-t-expands BioBriefs en 2026-09-09T16:31:22Z Multiple myeloma CAR T expands as BMS posts Phase 2 win https://biobriefs.com/obesity-pharma-wegovy-phase-3 BioBriefs en 2026-09-09T16:31:22Z Obesity pharma: Wegovy Phase 3 data for kids and new traction https://biobriefs.com/biotech-funding-and-platform-momentum BioBriefs en 2026-09-09T16:31:22Z Biotech funding and platform momentum: Moonwalk advances adipose-targeted RNAi https://biobriefs.com/ai-designed-drug-signals-biological BioBriefs en 2026-09-09T16:31:22Z AI-designed drug signals biological-age reversal in small IPF study https://biobriefs.com/diabetes-pipeline-spinout-from-kura BioBriefs en 2026-09-09T16:31:22Z Diabetes pipeline spinout from Kura: Lilly-backed Caspian Therapeutics https://biobriefs.com/regulatory-action-in-oncology-fda BioBriefs en 2026-09-09T16:31:22Z Regulatory action in oncology: FDA clears AstraZeneca’s oral SERD for first-line breast cancer https://biobriefs.com/cell-therapy-trial-success-in BioBriefs en 2026-09-09T16:31:22Z Cell therapy trial success in bladder cancer: Tyra advances to pivotal work https://biobriefs.com/biosafety-and-quality-spotlight-antibody BioBriefs en 2026-09-09T16:31:22Z Biosafety and quality spotlight: antibody image manipulation investigation https://biobriefs.com/biopharma-development-disulfidptosis-links-to BioBriefs en 2026-09-09T16:31:22Z Biopharma development: disulfidptosis links to targets for cancer cell death https://biobriefs.com/fda-leadership-stability BioBriefs en 2026-09-09T14:32:10Z FDA leadership stability https://biobriefs.com/myeloma-car-t-differentiation BioBriefs en 2026-09-09T14:32:10Z Myeloma CAR T differentiation https://biobriefs.com/astrazeneca-breast-cancer-serd-cleared BioBriefs en 2026-09-09T14:32:10Z AstraZeneca breast cancer SERD cleared after advisory setback https://biobriefs.com/moonwalk-raises-for-adipose-targeted BioBriefs en 2026-09-09T14:32:10Z Moonwalk raises for adipose-targeted RNAi obesity therapy https://biobriefs.com/solstice-raises-for-next-gen BioBriefs en 2026-09-09T14:32:10Z Solstice raises for next-gen CTLA-4 immunotherapy https://biobriefs.com/gprc5d-directed-car-t-momentum BioBriefs en 2026-09-09T14:32:10Z GPRC5D-directed CAR T momentum for broader myeloma competition https://biobriefs.com/roivant-pulmonary-hypertension-phase-2 BioBriefs en 2026-09-09T14:32:10Z Roivant pulmonary hypertension Phase 2 wins https://biobriefs.com/kras-antibody-conjugate-dealmaking BioBriefs en 2026-09-09T14:32:10Z KRAS antibody-conjugate dealmaking https://biobriefs.com/nlrp3-inflammation-platform-heads-toward BioBriefs en 2026-09-09T14:32:10Z NLRP3 inflammation platform heads toward Phase 3 and rebrand https://biobriefs.com/us-fda-ide-for-glaucoma BioBriefs en 2026-09-09T14:32:10Z US FDA IDE for glaucoma implant feasibility https://biobriefs.com/phase-3-setbacks-and-clinical BioBriefs en 2026-09-09T10:32:06Z Phase 3 setbacks and clinical pipeline disruptions at Novartis https://biobriefs.com/fda-accelerated-approval-for-astrazenecas BioBriefs en 2026-09-09T10:32:06Z FDA accelerated approval for AstraZeneca’s camizestrant after negative adcomm vote https://biobriefs.com/gsk-expands-hutchmed-rights-for BioBriefs en 2026-09-09T10:32:06Z GSK expands Hutchmed rights for KRAS-antibody conjugate in large ex-China deal https://biobriefs.com/cro-consolidation-fortrea-buys-worldwides BioBriefs en 2026-09-09T10:32:06Z CRO consolidation: Fortrea buys Worldwide’s early phase unit for $45M https://biobriefs.com/ciliatech-secures-fda-ide-for BioBriefs en 2026-09-09T10:32:06Z Ciliatech secures FDA IDE for glaucoma implant feasibility study https://biobriefs.com/moonwalk-raises-70m-series-b BioBriefs en 2026-09-09T10:32:06Z Moonwalk raises $70M Series B for adipose-targeted RNAi obesity program https://biobriefs.com/inhibrx-claims-first-clinical-win BioBriefs en 2026-09-09T10:32:06Z Inhibrx claims first clinical win for OX40 agonist in head and neck cancer subset https://biobriefs.com/brainchild-bio-raises-116m-for BioBriefs en 2026-09-09T10:32:06Z BrainChild Bio raises $116M for pediatric CAR-T pivotal trial in DIPG https://biobriefs.com/fortifying-antitumor-immunity-lag-3 BioBriefs en 2026-09-09T10:32:06Z Fortifying antitumor immunity: LAG-3 blockade paired with microwave ablation https://biobriefs.com/rnav8-bio-chosen-for-arpa BioBriefs en 2026-09-09T10:32:06Z RNAV8 Bio chosen for ARPA-H pilot to build programmable RNA medicines https://biobriefs.com/novartis-clinical-setbacks-in-cardiology BioBriefs en 2026-09-09T09:31:55Z Novartis clinical setbacks in cardiology and neuromuscular disease https://biobriefs.com/fda-approval-for-astrazeneca-oral BioBriefs en 2026-09-09T09:31:55Z FDA approval for AstraZeneca oral SERD in ESR1-mutant advanced breast cancer https://biobriefs.com/roivant-advances-pulmonary-hypertension-program BioBriefs en 2026-09-09T09:31:55Z Roivant advances pulmonary hypertension program after Phase 2 win https://biobriefs.com/gsk-expands-antibody-conjugate-portfolio BioBriefs en 2026-09-09T09:31:55Z GSK expands antibody conjugate portfolio through Hutchmed KRAS/EGFR asset deal https://biobriefs.com/fortrea-acquires-worldwide-clinical-trials BioBriefs en 2026-09-09T09:31:55Z Fortrea acquires Worldwide Clinical Trials’ early phase unit for $45M https://biobriefs.com/moonwalk-pulls-in-70m-series BioBriefs en 2026-09-09T09:31:55Z Moonwalk pulls in $70M Series B for adipose-targeted RNAi obesity therapy https://biobriefs.com/fda-ide-clearance-enables-ciliatech BioBriefs en 2026-09-09T09:31:55Z FDA IDE clearance enables Ciliatech glaucoma implant feasibility study https://biobriefs.com/new-venture-funding-for-pediatric BioBriefs en 2026-09-09T09:31:55Z New venture funding for pediatric brain cancer CAR-T from BrainChild Bio https://biobriefs.com/gsk-and-alteogen-delivery-tech BioBriefs en 2026-09-09T09:31:55Z GSK and Alteogen delivery tech deal expands subcutaneous biologics push https://biobriefs.com/arpa-h-funds-rnav8-bio BioBriefs en 2026-09-09T09:31:55Z ARPA-H funds RNAV8 Bio to develop programmable RNA medicines https://biobriefs.com/us-regulators-lock-in-fda BioBriefs en 2026-09-09T04:32:03Z US regulators lock in FDA leadership for drug and biologics oversight https://biobriefs.com/fda-accelerated-approval-returns-astrazenecas BioBriefs en 2026-09-09T04:32:03Z FDA accelerated approval returns AstraZeneca’s oral SERD to first-line use https://biobriefs.com/roivants-mosliciguat-posts-phase-2 BioBriefs en 2026-09-09T04:32:03Z Roivant’s mosliciguat posts Phase 2 win in interstitial lung disease https://biobriefs.com/novartis-stumbles-as-pelacarsen-fails BioBriefs en 2026-09-09T04:32:03Z Novartis stumbles as pelacarsen fails cardiovascular Phase 3 outcomes https://biobriefs.com/moonwalk-wins-series-b-funding BioBriefs en 2026-09-09T04:32:03Z Moonwalk wins Series B funding to take adipose-targeted RNAi obesity program to humans https://biobriefs.com/brainchild-bio-lands-116m-series BioBriefs en 2026-09-09T04:32:03Z BrainChild Bio lands $116M Series A to run pivotal pediatric brainstem CAR-T https://biobriefs.com/fda-ide-clears-ciliatech-uveal BioBriefs en 2026-09-09T04:32:03Z FDA IDE clears Ciliatech uveal spacer implant study for glaucoma https://biobriefs.com/fortrea-buys-worldwide-clinical-trials BioBriefs en 2026-09-09T04:32:03Z Fortrea buys Worldwide Clinical Trials’ early-phase unit for $45M to expand pharmacology capacity https://biobriefs.com/gsk-secures-ex-china-rights BioBriefs en 2026-09-09T04:32:03Z GSK secures ex-China rights to Hutchmed’s KRAS/EGFR dual-mode ADC payload https://biobriefs.com/clean-cells-adds-ngs-viral BioBriefs en 2026-09-09T04:32:03Z Clean Cells adds NGS viral safety testing and acquires bioinformatics CRO Xegen https://biobriefs.com/fda-leadership-and-technology-push BioBriefs en 2026-09-08T21:31:55Z FDA leadership and technology push https://biobriefs.com/fda-accelerated-approval-for-astrazeneca BioBriefs en 2026-09-08T21:31:55Z FDA accelerated approval for AstraZeneca oral SERD https://biobriefs.com/roivant-pulmonary-hypertension-readout-and BioBriefs en 2026-09-08T21:31:55Z Roivant pulmonary hypertension readout and deal momentum https://biobriefs.com/bristol-myers-phase-2-car BioBriefs en 2026-09-08T21:31:55Z Bristol Myers Phase 2 CAR-T win in multiple myeloma https://biobriefs.com/inhibrx-ox40-agonist-data-in BioBriefs en 2026-09-08T21:31:55Z Inhibrx OX40 agonist data in head and neck cancer https://biobriefs.com/moonwalk-raises-series-b-to BioBriefs en 2026-09-08T21:31:55Z Moonwalk raises Series B to advance adipose-targeted RNAi obesity drug https://biobriefs.com/brainchild-bio-secures-116m-for BioBriefs en 2026-09-08T21:31:55Z BrainChild Bio secures $116M for pediatric brain tumor CAR-T https://biobriefs.com/fortrea-buys-worldwides-early-phase BioBriefs en 2026-09-08T21:31:55Z Fortrea buys Worldwide’s early phase clinical unit for $45M https://biobriefs.com/roche-deals-for-preclinical-trispecific BioBriefs en 2026-09-08T21:31:55Z Roche deals for preclinical trispecific TCE asset https://biobriefs.com/superluminal-raises-60m-for-rare BioBriefs en 2026-09-08T21:31:55Z Superluminal raises $60M for rare genetic obesity MC4R agonist https://biobriefs.com/roche-simcere-deal-in-b BioBriefs en 2026-09-08T16:32:25Z Roche–Simcere deal in B-cell tri-specific TCEs https://biobriefs.com/gsk-takes-hutchmeds-egfr-targeted BioBriefs en 2026-09-08T16:32:25Z GSK takes Hutchmed’s EGFR-targeted KRAS payload ADC https://biobriefs.com/novartis-alteogen-sc-drug-delivery BioBriefs en 2026-09-08T16:32:25Z Novartis–Alteogen SC drug delivery platform expansion https://biobriefs.com/china-approves-differentiated-therapies-everest BioBriefs en 2026-09-08T16:32:25Z China approves differentiated therapies: Everest heart spray and Simcere RSV antibody https://biobriefs.com/fda-grants-astrazeneca-camizestrant-approval BioBriefs en 2026-09-08T16:32:25Z FDA grants AstraZeneca camizestrant approval after negative adcomm vote https://biobriefs.com/novartis-pelacarsen-phase-3-failure BioBriefs en 2026-09-08T16:32:25Z Novartis pelacarsen Phase 3 failure dents Lp(a) clinical outcomes push https://biobriefs.com/roivant-mosliciguat-posts-phase-2 BioBriefs en 2026-09-08T16:32:25Z Roivant mosliciguat posts Phase 2 win in pulmonary hypertension https://biobriefs.com/moonwalk-raises-70m-to-advance BioBriefs en 2026-09-08T16:32:25Z Moonwalk raises $70M to advance adipose-targeted RNAi obesity program https://biobriefs.com/clean-cells-expands-viral-safety BioBriefs en 2026-09-08T16:32:25Z Clean Cells expands viral safety testing with NGS and Xegen acquisition https://biobriefs.com/brainchild-raises-116m-for-pediatric BioBriefs en 2026-09-08T16:32:25Z BrainChild raises $116M for pediatric brain tumor CAR-T pivotal trial https://biobriefs.com/regulatory-approvals-oncology BioBriefs en 2026-09-08T14:32:18Z Regulatory approvals — oncology https://biobriefs.com/clinical-trial-readouts-cardiopulmonary BioBriefs en 2026-09-08T14:32:18Z Clinical trial readouts — cardiopulmonary https://biobriefs.com/car-t-multiple-myeloma-efficacy BioBriefs en 2026-09-08T14:32:18Z CAR-T — multiple myeloma efficacy signal https://biobriefs.com/phase-3-failure-cardiovascular-lp BioBriefs en 2026-09-08T14:32:18Z Phase 3 failure — cardiovascular Lp(a) therapies https://biobriefs.com/immunotherapy-ox40-agonist-responses-in BioBriefs en 2026-09-08T14:32:18Z Immunotherapy — OX40 agonist responses in head and neck cancer https://biobriefs.com/rare-disease-cell-therapy-pediatric BioBriefs en 2026-09-08T14:32:18Z Rare disease cell therapy — pediatric CAR-T funding and trial push https://biobriefs.com/obesity-therapeutics-adipose-targeted-rnai BioBriefs en 2026-09-08T14:32:18Z Obesity therapeutics — adipose-targeted RNAi heads to the clinic https://biobriefs.com/corporate-strategy-biosimilars-manufacturing-investment BioBriefs en 2026-09-08T14:32:18Z Corporate strategy — biosimilars manufacturing investment https://biobriefs.com/biologics-innovation-regulatory-ready-growth BioBriefs en 2026-09-08T14:32:18Z Biologics innovation — regulatory-ready growth factor pathway bet https://biobriefs.com/funding-rare-genetic-obesity-platform BioBriefs en 2026-09-08T14:32:18Z Funding — rare genetic obesity platform moves toward clinic https://biobriefs.com/ai-designed-mrna-therapy-posts BioBriefs en 2026-09-08T10:32:16Z AI-designed mRNA therapy posts Phase 3 win in melanoma https://biobriefs.com/novo-nordisk-halts-inflammation-linked BioBriefs en 2026-09-08T10:32:16Z Novo Nordisk halts inflammation-linked cardiovascular trials after futility signals https://biobriefs.com/fda-accelerates-approval-of-astrazeneca BioBriefs en 2026-09-08T10:32:16Z FDA accelerates approval of AstraZeneca oral SERD despite advisory committee opposition https://biobriefs.com/beam-therapeutics-updates-1-year BioBriefs en 2026-09-08T10:32:16Z Beam Therapeutics updates 1-year durability data for AATD base editing https://biobriefs.com/roivants-mosliciguat-hits-mid-stage BioBriefs en 2026-09-08T10:32:16Z Roivant’s mosliciguat hits mid-stage endpoints in lung disease programs https://biobriefs.com/gsk-pays-110m-for-hutchmed BioBriefs en 2026-09-08T10:32:16Z GSK pays $110M for Hutchmed ATTC asset – Phase 1-ready cancer conjugate https://biobriefs.com/funding-superluminal-raises-oversubscribed-series BioBriefs en 2026-09-08T10:32:16Z Funding: Superluminal raises oversubscribed Series B to advance AI GPCR obesity therapy https://biobriefs.com/regulatory-acepodia-gets-fda-ind BioBriefs en 2026-09-08T10:32:16Z Regulatory: Acepodia gets FDA IND for GPC3-targeted ACE-723 in HCC https://biobriefs.com/rezubio-advances-rz-520-after BioBriefs en 2026-09-08T10:32:16Z Rezubio advances RZ-520 after IND clearances in respiratory diseases https://biobriefs.com/novartis-setback-deepens-after-avidity BioBriefs en 2026-09-08T10:32:16Z Novartis setback deepens after Avidity-acquired drug misses Phase 3 https://biobriefs.com/personalized-cancer-mrna-therapy-clears BioBriefs en 2026-09-08T09:31:59Z Personalized cancer mRNA therapy clears Phase 3 hurdle in melanoma https://biobriefs.com/astrazeneca-wins-fda-approval-for BioBriefs en 2026-09-08T09:31:59Z AstraZeneca wins FDA approval for camizestrant despite advisory vote setback https://biobriefs.com/novel-ind-clearances-advance-lung BioBriefs en 2026-09-08T09:31:59Z Novel IND clearances advance lung and liver oncology programs https://biobriefs.com/beam-posts-one-year-check BioBriefs en 2026-09-08T09:31:59Z Beam posts one-year check on AATD base-editing in early trial https://biobriefs.com/superluminal-raises-to-push-ai BioBriefs en 2026-09-08T09:31:59Z Superluminal raises to push AI-powered GPCR obesity program toward Phase I https://biobriefs.com/novo-nordisk-keeps-trimming-il BioBriefs en 2026-09-08T09:31:59Z Novo Nordisk keeps trimming IL-6 heart outcomes bets after futility signals https://biobriefs.com/ai-mrna-meets-clinical-design BioBriefs en 2026-09-08T09:31:59Z AI mRNA meets clinical design—researchers report recurrence and death improvements https://biobriefs.com/novartis-del-desiran-phase-3 BioBriefs en 2026-09-08T09:31:59Z Novartis’ del-desiran Phase 3 failure deepens post-Avidity setback https://biobriefs.com/cladribine-plus-rituximab-moves-hairy BioBriefs en 2026-09-08T09:31:59Z Cladribine plus rituximab moves hairy cell leukemia toward improved weekly regimen https://biobriefs.com/new-ind-start-signals-for BioBriefs en 2026-09-08T09:31:59Z New IND start signals for hepatitis C and liver oncology do not apply—focus shifts to ADC/oncology INDs https://biobriefs.com/regulatory-approval-astrazeneca-serd BioBriefs en 2026-09-08T04:32:07Z Regulatory approval: AstraZeneca SERD https://biobriefs.com/regulatory-failure-novo-nordisk-halts BioBriefs en 2026-09-08T04:32:07Z Regulatory failure: Novo Nordisk halts ziltivekimab cardiovascular trials https://biobriefs.com/phase-3-readout-merck-moderna BioBriefs en 2026-09-08T04:32:07Z Phase 3 readout: Merck/Moderna bespoke mRNA plus Keytruda in melanoma https://biobriefs.com/late-stage-failure-novartis-pelacarsen BioBriefs en 2026-09-08T04:32:07Z Late-stage failure: Novartis pelacarsen Phase 3 miss https://biobriefs.com/financing-superluminal-raises-for-rare BioBriefs en 2026-09-08T04:32:07Z Financing: Superluminal raises for rare genetic obesity program https://biobriefs.com/ind-approvals-rezubio-rz-520 BioBriefs en 2026-09-08T04:32:07Z IND approvals: Rezubio RZ-520 for respiratory diseases https://biobriefs.com/ind-approvals-acepodia-ace-723 BioBriefs en 2026-09-08T04:32:07Z IND approvals: Acepodia ACE-723 in hepatocellular carcinoma https://biobriefs.com/platform-and-partnerships-gsk-pays BioBriefs en 2026-09-08T04:32:07Z Platform and partnerships: GSK pays $110M for Hutchmed ATTC asset https://biobriefs.com/cell-therapy-research-gpnmb-targeting BioBriefs en 2026-09-08T04:32:07Z Cell therapy research: GPNMB-targeting CAR T for solid tumors https://biobriefs.com/preclinical-translational-oncology-dendritic-cell BioBriefs en 2026-09-08T04:32:07Z Preclinical translational oncology: dendritic cell SHP1 brake on memory CD8 T cells https://biobriefs.com/fda-accelerated-approval-for-astrazenecas BioBriefs en 2026-09-07T21:31:44Z FDA accelerated approval for AstraZeneca’s oral SERD https://biobriefs.com/astrazeneca-bets-on-nrf2-activation BioBriefs en 2026-09-07T21:31:44Z AstraZeneca bets on NRF2 activation milestone with C4X Discovery https://biobriefs.com/ind-approvals-expand-early-clinical BioBriefs en 2026-09-07T21:31:44Z IND approvals expand early clinical pipelines: Rezubio and Acepodia https://biobriefs.com/funding-spotlights-obesity-drug-development BioBriefs en 2026-09-07T21:31:44Z Funding spotlights obesity drug development: Superluminal raises to start Phase I https://biobriefs.com/cancer-immunotherapy-in-phase-iii BioBriefs en 2026-09-07T21:31:44Z Cancer immunotherapy in Phase III: Merck and Moderna’s bespoke mRNA therapy shows positive signal https://biobriefs.com/trial-failures-hit-cardiovascular-inflammation BioBriefs en 2026-09-07T21:31:44Z Trial failures hit cardiovascular inflammation: Novo Nordisk pauses and drops programs https://biobriefs.com/big-pharma-pipeline-setback-novartis BioBriefs en 2026-09-07T21:31:44Z Big pharma pipeline setback: Novartis pelacarsen Phase 3 miss raises pressure https://biobriefs.com/gene-therapy-progress-in-methylmalonic BioBriefs en 2026-09-07T21:31:44Z Gene therapy progress in methylmalonic acidemia: durable liver-directed results https://biobriefs.com/immuno-oncology-mechanism-advance-nk BioBriefs en 2026-09-07T21:31:44Z Immuno-oncology mechanism advance: NK cell lncRNA dysregulation and GITR antibody engineering https://biobriefs.com/digital-twins-and-ventilation-protocol BioBriefs en 2026-09-07T21:31:44Z Digital twins and ventilation protocol evaluation in ARDS https://biobriefs.com/cardiovascular-drug-development-setbacks BioBriefs en 2026-09-07T16:32:22Z Cardiovascular drug development setbacks https://biobriefs.com/cardiovascular-outcomes-failure-deepens-lp BioBriefs en 2026-09-07T16:32:22Z Cardiovascular outcomes failure deepens Lp(a) bet reassessment https://biobriefs.com/mrna-cancer-immunotherapy-reaches-phase BioBriefs en 2026-09-07T16:32:22Z mRNA cancer immunotherapy reaches Phase 3 milestone https://biobriefs.com/rare-genetic-obesity-funding-push BioBriefs en 2026-09-07T16:32:22Z Rare genetic obesity funding push https://biobriefs.com/regenerative-and-immune-co-culture BioBriefs en 2026-09-07T16:32:22Z Regenerative and immune co-culture models for obesity https://biobriefs.com/lung-cancer-resistance-shaped-by BioBriefs en 2026-09-07T16:32:22Z Lung cancer resistance shaped by the tumor microenvironment https://biobriefs.com/ind-clearances-for-next-generation BioBriefs en 2026-09-07T16:32:22Z IND clearances for next-generation oncology ADCs https://biobriefs.com/ai-enabled-clinical-therapy-development BioBriefs en 2026-09-07T16:32:22Z AI-enabled clinical therapy development signal in oncology https://biobriefs.com/microbiome-driven-drug-resistance-in BioBriefs en 2026-09-07T16:32:22Z Microbiome-driven drug resistance in CAR T therapy https://biobriefs.com/oncology-target-innovation-via-il BioBriefs en 2026-09-07T16:32:22Z Oncology target innovation via IL-11 pathway for reproductive aging https://biobriefs.com/phase-3-results-reshape-mrna BioBriefs en 2026-09-07T14:31:57Z Phase 3 results reshape mRNA cancer immunotherapy https://biobriefs.com/novo-nordisk-retreats-on-late BioBriefs en 2026-09-07T14:31:57Z Novo Nordisk retreats on late-stage ziltivekimab futility https://biobriefs.com/funding-superluminal-drives-rare-obesity BioBriefs en 2026-09-07T14:31:57Z Funding: Superluminal drives rare obesity program into the clinic https://biobriefs.com/regulatory-rezubio-starts-phase-i BioBriefs en 2026-09-07T14:31:57Z Regulatory: Rezubio starts Phase I dosing after IND clearances https://biobriefs.com/regulatory-acepodias-gpc3-targeted-adc BioBriefs en 2026-09-07T14:31:57Z Regulatory: Acepodia’s GPC3-targeted ADC enters clinical testing https://biobriefs.com/immuno-oncology-preclinical-tumor-bisdirected BioBriefs en 2026-09-07T14:31:57Z Immuno-oncology preclinical: tumor-bisdirected dendritic cell vaccine strategy https://biobriefs.com/breast-cancer-immunology-bispecific-nanobody BioBriefs en 2026-09-07T14:31:57Z Breast cancer immunology: bispecific nanobody boosts TNBC control https://biobriefs.com/therapeutic-target-discovery-prmt5-protacs BioBriefs en 2026-09-07T14:31:57Z Therapeutic target discovery: PRMT5 PROTACs move to patent stage https://biobriefs.com/gene-therapy-translational-signal-durability BioBriefs en 2026-09-07T14:31:57Z Gene therapy translational signal: durability in methylmalonic acidemia model https://biobriefs.com/vaccine-diagnostic-strategy-digital-genetic BioBriefs en 2026-09-07T14:31:57Z Vaccine/diagnostic strategy: digital genetic counseling improves access for high-risk patients https://biobriefs.com/gene-therapy-manufacturing-partnerships BioBriefs en 2026-09-07T10:32:25Z Gene therapy manufacturing partnerships https://biobriefs.com/heart-disease-drug-trial-terminations BioBriefs en 2026-09-07T10:32:25Z Heart disease drug trial terminations https://biobriefs.com/immuno-oncology-cell-therapy-resilience BioBriefs en 2026-09-07T10:32:25Z Immuno-oncology cell therapy resilience https://biobriefs.com/atherosclerosis-multi-omics-and-microbiota BioBriefs en 2026-09-07T10:32:25Z Atherosclerosis multi-omics and microbiota targeting https://biobriefs.com/car-t-manufacturing-acceleration BioBriefs en 2026-09-07T10:32:25Z CAR-T manufacturing acceleration https://biobriefs.com/cardiac-genomics-and-diagnostics BioBriefs en 2026-09-07T10:32:25Z Cardiac genomics and diagnostics https://biobriefs.com/diagnostics-for-alzheimers-biomarkers BioBriefs en 2026-09-07T10:32:25Z Diagnostics for Alzheimer’s biomarkers https://biobriefs.com/oncology-translational-imaging-prediction BioBriefs en 2026-09-07T10:32:25Z Oncology translational imaging prediction https://biobriefs.com/cancer-immunotherapy-with-exosome-delivery BioBriefs en 2026-09-07T10:32:25Z Cancer immunotherapy with exosome delivery https://biobriefs.com/cellular-aging-biology-via-proteomic BioBriefs en 2026-09-07T10:32:25Z Cellular aging biology via proteomic clocks https://biobriefs.com/trial-halt-in-il-6 BioBriefs en 2026-09-07T09:32:22Z Trial halt in IL-6 blockade for heart disease https://biobriefs.com/funding-and-capacity-build-for BioBriefs en 2026-09-07T09:32:22Z Funding and capacity build for clinical-stage siRNA https://biobriefs.com/gene-therapy-manufacturing-partnership BioBriefs en 2026-09-07T09:32:22Z Gene therapy manufacturing partnership https://biobriefs.com/roche-style-car-t-safety BioBriefs en 2026-09-07T09:32:22Z Roche-style CAR-T safety shock surfaces externally https://biobriefs.com/car-t-resistance-tied-to BioBriefs en 2026-09-07T09:32:22Z CAR-T resistance tied to resistant gut microbiome metabolite https://biobriefs.com/space-for-future-car-t BioBriefs en 2026-09-07T09:32:22Z Space for future CAR-T readiness: optimization of transduction at low viral doses https://biobriefs.com/cancer-immunotherapy-engineering-advances BioBriefs en 2026-09-07T09:32:22Z Cancer immunotherapy engineering advances https://biobriefs.com/diagnostics-rapid-imaging-biomarkers-for BioBriefs en 2026-09-07T09:32:22Z Diagnostics: rapid imaging biomarkers for Alzheimer’s https://biobriefs.com/regulatory-free-observational-evidence-in BioBriefs en 2026-09-07T09:32:22Z Regulatory-free observational evidence in diabetes tech outcomes https://biobriefs.com/clinical-guidance-ms-treatment-after BioBriefs en 2026-09-07T09:32:22Z Clinical guidance: MS treatment after extended cladribine use https://biobriefs.com/immunotherapy-setback-in-cardiovascular-rna BioBriefs en 2026-09-07T04:32:14Z Immunotherapy setback in cardiovascular RNA target https://biobriefs.com/gene-therapy-manufacturing-scale-up BioBriefs en 2026-09-07T04:32:14Z Gene therapy manufacturing scale-up for Duchenne rAAV https://biobriefs.com/car-t-therapy-durability-concerns BioBriefs en 2026-09-07T04:32:14Z CAR-T therapy durability concerns tied to gut metabolites https://biobriefs.com/cancer-imaging-ai-moves-toward BioBriefs en 2026-09-07T04:32:14Z Cancer imaging AI moves toward bedside risk stratification https://biobriefs.com/radiomics-for-glioma-progression-timing BioBriefs en 2026-09-07T04:32:14Z Radiomics for glioma progression timing https://biobriefs.com/r-d-machine-learning-radiomics BioBriefs en 2026-09-07T04:32:14Z R&D: machine learning radiomics for lung cancer invasiveness https://biobriefs.com/novel-vaginal-microbiome-modeling-for BioBriefs en 2026-09-07T04:32:14Z Novel vaginal microbiome modeling for BV prediction https://biobriefs.com/antibiotics-pipeline-new-computational-tuberculosis BioBriefs en 2026-09-07T04:32:14Z Antibiotics pipeline: new computational tuberculosis inhibitor targets KasA https://biobriefs.com/diabetes-tech-real-world-cgm BioBriefs en 2026-09-07T04:32:14Z Diabetes tech: real-world CGM linked to hypoglycemia burden and quality of life https://biobriefs.com/manufacturing-biotech-operations-stable-car BioBriefs en 2026-09-07T04:32:14Z Manufacturing/biotech operations: stable CAR-T production via microfluidics https://biobriefs.com/gene-therapy-manufacturing-scale-up BioBriefs en 2026-09-06T21:32:18Z Gene therapy manufacturing scale-up https://biobriefs.com/cardiovascular-drug-risk-after-lp BioBriefs en 2026-09-06T21:32:18Z Cardiovascular drug risk after Lp(a) trial failure https://biobriefs.com/alzheimers-blood-biomarker-limitations BioBriefs en 2026-09-06T21:32:18Z Alzheimer’s blood biomarker limitations https://biobriefs.com/oncology-immunotherapy-in-car-t BioBriefs en 2026-09-06T21:32:18Z Oncology immunotherapy in CAR-T: gut metabolite inhibition https://biobriefs.com/cancer-vaccine-platform-multivalent-mrna BioBriefs en 2026-09-06T21:32:18Z Cancer vaccine platform: multivalent mRNA exosome approach https://biobriefs.com/immuno-oncology-target-bispecific-tcr BioBriefs en 2026-09-06T21:32:18Z Immuno-oncology target: bispecific TCR-like antibody against PRAME complex https://biobriefs.com/infectious-disease-diagnostics-and-sequencing BioBriefs en 2026-09-06T21:32:18Z Infectious disease diagnostics and sequencing for MDR TB https://biobriefs.com/diabetes-technology-outcomes-real-world BioBriefs en 2026-09-06T21:32:18Z Diabetes technology outcomes: real-world CGM quality-of-life impact https://biobriefs.com/digital-health-ai-in-icu BioBriefs en 2026-09-06T21:32:18Z Digital health: AI in ICU lung ventilation transition using digital twins https://biobriefs.com/regenerative-antifibrotic-rna-therapy-in BioBriefs en 2026-09-06T21:32:18Z Regenerative/antifibrotic RNA therapy in pulmonary hypertension https://biobriefs.com/alexander-disease-approval BioBriefs en 2026-09-06T16:32:29Z Alexander disease approval https://biobriefs.com/cardiovascular-risk-drug-failure BioBriefs en 2026-09-06T16:32:29Z Cardiovascular risk drug failure https://biobriefs.com/gene-therapy-manufacturing-partnership BioBriefs en 2026-09-06T16:32:29Z Gene therapy manufacturing partnership https://biobriefs.com/adarx-ipo-plans BioBriefs en 2026-09-06T16:32:29Z ADARx IPO plans https://biobriefs.com/late-breaking-car-t-safety BioBriefs en 2026-09-06T16:32:29Z Late-breaking CAR-T safety signal and program pause https://biobriefs.com/biotech-funding-for-first-in BioBriefs en 2026-09-06T16:32:29Z Biotech funding for first-in-clinic strategy https://biobriefs.com/immunotherapy-mechanism-exosome-mrna-vaccine BioBriefs en 2026-09-06T16:32:29Z Immunotherapy mechanism—exosome-mRNA vaccine https://biobriefs.com/pharma-dealmaking-menarini-obesity-push BioBriefs en 2026-09-06T16:32:29Z Pharma dealmaking—Menarini obesity push https://biobriefs.com/regulatory-landscape-for-pipeline-approvals BioBriefs en 2026-09-06T16:32:29Z Regulatory landscape for pipeline approvals https://biobriefs.com/car-t-manufacturing-optimization BioBriefs en 2026-09-06T16:32:29Z CAR-T manufacturing optimization https://biobriefs.com/regulatory-approvals-in-rare-neurology BioBriefs en 2026-09-06T14:32:03Z Regulatory approvals in rare neurology https://biobriefs.com/clinical-trial-failure-challenges-cardiovascular BioBriefs en 2026-09-06T14:32:03Z Clinical trial failure challenges cardiovascular target validation https://biobriefs.com/biologics-engagement-upgrades-for-multiple BioBriefs en 2026-09-06T14:32:03Z Biologics/engagement upgrades for multiple myeloma https://biobriefs.com/immuno-oncology-engineered-antibody-boosts BioBriefs en 2026-09-06T14:32:03Z Immuno-oncology: engineered antibody boosts CD4 T cell–dendritic cell cooperation https://biobriefs.com/cancer-metabolism-vulnerability-in-triple BioBriefs en 2026-09-06T14:32:03Z Cancer metabolism vulnerability in triple-negative breast cancer https://biobriefs.com/early-diagnostics-ai-radiomics-for BioBriefs en 2026-09-06T14:32:03Z Early diagnostics: AI radiomics for lung cancer invasiveness https://biobriefs.com/therapeutic-manufacturing-stable-raav-producer BioBriefs en 2026-09-06T14:32:03Z Therapeutic manufacturing: stable rAAV producer cell line collaboration https://biobriefs.com/biotech-finance-series-b-funding BioBriefs en 2026-09-06T14:32:03Z Biotech finance: Series B funding to move brain-health drugs into clinics https://biobriefs.com/public-private-health-uk-end BioBriefs en 2026-09-06T14:32:03Z Public-private health: UK end-of-life benefit access shift re-scored https://biobriefs.com/institutional-review-digital-twins-guide BioBriefs en 2026-09-06T14:32:03Z Institutional review: digital twins guide ventilation protocol transitions https://biobriefs.com/alexander-disease-therapy-approval-expands BioBriefs en 2026-09-06T10:32:11Z Alexander disease therapy approval expands Ionis’s CNS franchise https://biobriefs.com/lp-a-targeting-stumbles-pelacarsen BioBriefs en 2026-09-06T10:32:11Z Lp(a) targeting stumbles – pelacarsen fails Phase 3 https://biobriefs.com/genai-and-clinical-deployment-risk BioBriefs en 2026-09-06T10:32:11Z GenAI and clinical deployment risk – guidance on trustworthy readiness claims https://biobriefs.com/direct-to-clinic-manufacturing-shift BioBriefs en 2026-09-06T10:32:11Z Direct-to-clinic manufacturing shift – microfluidic CAR-T boosts transduction at low viral doses https://biobriefs.com/raav-manufacturing-partnership-for-duchenne BioBriefs en 2026-09-06T10:32:11Z rAAV manufacturing partnership for Duchenne program scale-up https://biobriefs.com/biotech-funding-neushen-lands-series BioBriefs en 2026-09-06T10:32:11Z Biotech funding – NeuShen lands Series B to advance brain-health drugs https://biobriefs.com/immuno-oncology-direction-multivalent-mrna BioBriefs en 2026-09-06T10:32:11Z Immuno-oncology direction – multivalent mRNA-exosome vaccines seek to turn cold tumors hot https://biobriefs.com/autoimmune-and-inflammatory-t-cell BioBriefs en 2026-09-06T10:32:11Z Autoimmune and inflammatory T-cell reprogramming gets U.K. translational backing https://biobriefs.com/m-a-and-capital-markets BioBriefs en 2026-09-06T10:32:11Z M&A and capital markets – Lonza-style momentum returns as deals pick up https://biobriefs.com/diagnostics-and-public-health-products BioBriefs en 2026-09-06T10:32:11Z Diagnostics and public health products – China clears at-home treatments and RSV prevention https://biobriefs.com/regulatory-approvals BioBriefs en 2026-09-06T09:32:20Z Regulatory approvals https://biobriefs.com/cardiovascular-drug-development-setback BioBriefs en 2026-09-06T09:32:20Z Cardiovascular drug development setback https://biobriefs.com/oncology-immunotherapy-platform BioBriefs en 2026-09-06T09:32:20Z Oncology immunotherapy platform https://biobriefs.com/cancer-biology-and-microenvironment BioBriefs en 2026-09-06T09:32:20Z Cancer biology and microenvironment https://biobriefs.com/alzheimers-diagnostics-under-scrutiny BioBriefs en 2026-09-06T09:32:20Z Alzheimer’s diagnostics under scrutiny https://biobriefs.com/gene-therapy-manufacturing-partnership BioBriefs en 2026-09-06T09:32:20Z Gene therapy manufacturing partnership https://biobriefs.com/car-t-and-cell-therapy BioBriefs en 2026-09-06T09:32:20Z CAR T and cell therapy manufacturing innovation https://biobriefs.com/public-health-diagnostics-and-infectious BioBriefs en 2026-09-06T09:32:20Z Public health diagnostics and infectious disease surveillance https://biobriefs.com/biotech-financing-and-corporate-moves BioBriefs en 2026-09-06T09:32:20Z Biotech financing and corporate moves https://biobriefs.com/cancer-risk-biology-and-inherited BioBriefs en 2026-09-06T09:32:20Z Cancer risk biology and inherited predisposition https://biobriefs.com/fda-greenlights-first-disease-modifying BioBriefs en 2026-09-06T04:32:20Z FDA greenlights first disease-modifying therapy for Alexander disease https://biobriefs.com/novartis-ionis-lp-a-therapy BioBriefs en 2026-09-06T04:32:20Z Novartis/ Ionis Lp(a) therapy fails pivotal Phase 3 https://biobriefs.com/car-t-safety-signals-drive BioBriefs en 2026-09-06T04:32:20Z CAR-T safety signals drive Novartis trial pause https://biobriefs.com/gene-therapy-manufacturing-deal-for BioBriefs en 2026-09-06T04:32:20Z Gene therapy manufacturing deal for Duchenne rAAV production https://biobriefs.com/advancing-car-t-manufacturing-throughput BioBriefs en 2026-09-06T04:32:20Z Advancing CAR-T manufacturing throughput via low-dose microfluidics https://biobriefs.com/clinical-imaging-path-for-preserflo BioBriefs en 2026-09-06T04:32:20Z Clinical imaging path for PreserFlo MicroShunt success prediction https://biobriefs.com/new-fda-driven-rare-disease BioBriefs en 2026-09-06T04:32:20Z New FDA-driven rare-disease pipeline milestone in oncology and beyond https://biobriefs.com/abbvies-dual-acting-myeloma-drug BioBriefs en 2026-09-06T04:32:20Z AbbVie’s dual-acting myeloma drug posts Phase 3 win https://biobriefs.com/fda-and-regulatory-shift-for BioBriefs en 2026-09-06T04:32:20Z FDA and regulatory shift for botanical drugs via RFI https://biobriefs.com/raav-and-cell-therapy-startup BioBriefs en 2026-09-06T04:32:20Z rAAV and cell therapy startup financing to propel first clinical study https://biobriefs.com/fda-approval-rare-neurodegeneration BioBriefs en 2026-09-05T21:32:21Z FDA approval—rare neurodegeneration https://biobriefs.com/cardiovascular-failed-late-stage-lp BioBriefs en 2026-09-05T21:32:21Z Cardiovascular—failed late-stage Lp(a) strategy https://biobriefs.com/oncology-abbvie-myeloma-bispecific-hits BioBriefs en 2026-09-05T21:32:21Z Oncology—AbbVie myeloma bispecific hits Phase 3 goals https://biobriefs.com/gene-therapy-manufacturing-stable-raav BioBriefs en 2026-09-05T21:32:21Z Gene therapy manufacturing—stable rAAV producer cell lines https://biobriefs.com/biotech-finance-60m-series-b BioBriefs en 2026-09-05T21:32:21Z Biotech finance—$60M series B for first clinical study https://biobriefs.com/us-biotech-neushen-brain-health BioBriefs en 2026-09-05T21:32:21Z US biotech—NeuShen brain-health drug funding https://biobriefs.com/drug-delivery-rna-therapeutics-milk BioBriefs en 2026-09-05T21:32:21Z Drug delivery / RNA therapeutics—milk-derived vesicles for Alzheimer’s biology https://biobriefs.com/oncology-platform-bispecific-tcr-like BioBriefs en 2026-09-05T21:32:21Z Oncology platform—bispecific TCR-like antibody targeting PRAME complex https://biobriefs.com/cardiology-new-regimen-approvals-in BioBriefs en 2026-09-05T21:32:21Z Cardiology—new regimen approvals in China https://biobriefs.com/biomarker-imaging-radiology-ai-predicts BioBriefs en 2026-09-05T21:32:21Z Biomarker / imaging—radiology AI predicts lung adenocarcinoma invasiveness https://biobriefs.com/fda-approval-rare-neurology BioBriefs en 2026-09-05T16:31:45Z FDA approval – rare neurology https://biobriefs.com/late-stage-trial-failure-cardiovascular BioBriefs en 2026-09-05T16:31:45Z Late-stage trial failure – cardiovascular risk https://biobriefs.com/biotech-financing-series-b BioBriefs en 2026-09-05T16:31:45Z Biotech financing – Series B https://biobriefs.com/gene-therapy-manufacturing-raav-cell BioBriefs en 2026-09-05T16:31:45Z Gene therapy manufacturing – rAAV cell banks https://biobriefs.com/immunotherapy-prame-tcr-like-bispecific BioBriefs en 2026-09-05T16:31:45Z Immunotherapy – PRAME TCR-like bispecific https://biobriefs.com/rare-disease-fda-approval-and BioBriefs en 2026-09-05T16:31:45Z Rare disease – FDA approval and pipeline positioning https://biobriefs.com/oncology-phase-3-readout BioBriefs en 2026-09-05T16:31:45Z Oncology – Phase 3 readout https://biobriefs.com/dealmaking-european-glp-1-rights BioBriefs en 2026-09-05T16:31:45Z Dealmaking – European GLP-1 rights https://biobriefs.com/biotech-expansion-manufacturing-capacity BioBriefs en 2026-09-05T16:31:45Z Biotech expansion – manufacturing capacity https://biobriefs.com/preclinical-therapeutics-oncology-supportive-care BioBriefs en 2026-09-05T16:31:45Z Preclinical therapeutics – oncology supportive care https://biobriefs.com/regulatory-approvals BioBriefs en 2026-09-05T14:32:01Z Regulatory approvals https://biobriefs.com/clinical-trial-outcomes-in-rare BioBriefs en 2026-09-05T14:32:01Z Clinical trial outcomes in rare neurology https://biobriefs.com/cardiovascular-risk-therapeutics-in-late BioBriefs en 2026-09-05T14:32:01Z Cardiovascular risk therapeutics in late-stage testing https://biobriefs.com/oncology-drug-development-and-manufacturing BioBriefs en 2026-09-05T14:32:01Z Oncology drug development and manufacturing tactics https://biobriefs.com/biopharma-funding-and-early-clinical BioBriefs en 2026-09-05T14:32:01Z Biopharma funding and early clinical push https://biobriefs.com/sector-funding-and-ipo-planning BioBriefs en 2026-09-05T14:32:01Z Sector funding and IPO planning https://biobriefs.com/big-pharma-licensing-and-oncology BioBriefs en 2026-09-05T14:32:01Z Big pharma licensing and oncology ADC expansion https://biobriefs.com/immunotherapy-and-engineered-t-cell BioBriefs en 2026-09-05T14:32:01Z Immunotherapy and engineered T-cell access https://biobriefs.com/cellular-imaging-and-disease-monitoring BioBriefs en 2026-09-05T14:32:01Z Cellular imaging and disease monitoring https://biobriefs.com/bioinformatics-infrastructure-for-regulated-drug BioBriefs en 2026-09-05T14:32:01Z Bioinformatics infrastructure for regulated drug discovery https://biobriefs.com/regulatory-approvals-first-in-class BioBriefs en 2026-09-05T10:32:19Z Regulatory approvals – first-in-class rare disease https://biobriefs.com/cardiovascular-drug-failure-lp-a BioBriefs en 2026-09-05T10:32:19Z Cardiovascular drug failure – Lp(a) target reset at Phase 3 https://biobriefs.com/multiple-myeloma-phase-3-success BioBriefs en 2026-09-05T10:32:19Z Multiple myeloma – Phase 3 success for dual-acting T-cell engager https://biobriefs.com/oncology-licensing-and-partnership-gsk BioBriefs en 2026-09-05T10:32:19Z Oncology licensing and partnership – GSK buys ex-China rights for KRAS/EGFR dual payload https://biobriefs.com/immuno-oncology-new-bispecific-tcr BioBriefs en 2026-09-05T10:32:19Z Immuno-oncology – new bispecific TCR-like antibody targets PRAME complex https://biobriefs.com/cell-and-gene-therapy-company BioBriefs en 2026-09-05T10:32:19Z Cell and gene therapy – company launch and in vivo CAR T focus https://biobriefs.com/diagnostics-and-clinical-trials-fda BioBriefs en 2026-09-05T10:32:19Z Diagnostics and clinical trials – FDA IND clearance for mucolipidosis IV gene therapy https://biobriefs.com/biomarkers-and-therapeutic-modulation-fecal BioBriefs en 2026-09-05T10:32:19Z Biomarkers and therapeutic modulation – fecal markers for C. difficile severity https://biobriefs.com/financing-us-china-brain-health BioBriefs en 2026-09-05T10:32:19Z Financing – US-China brain-health startup secures Series B for clinical-stage pipeline https://biobriefs.com/deal-activity-and-platform-bets BioBriefs en 2026-09-05T10:32:19Z Deal activity and platform bets – Superluminal locks $60M Series B for first clinical study https://biobriefs.com/fda-approvals-for-rare-neurology BioBriefs en 2026-09-05T09:32:16Z FDA approvals for rare neurology therapies https://biobriefs.com/multiple-myeloma-trial-readout-boosts BioBriefs en 2026-09-05T09:32:16Z Multiple myeloma trial readout boosts AbbVie’s bispecific bid https://biobriefs.com/angelman-syndrome-setbacks-reshape-the BioBriefs en 2026-09-05T09:32:16Z Angelman syndrome setbacks reshape the rare neuro pipeline https://biobriefs.com/cardiovascular-risk-targeting-misses-in BioBriefs en 2026-09-05T09:32:16Z Cardiovascular risk-targeting misses in pivotal trial https://biobriefs.com/obesity-glp-1-expansion-via BioBriefs en 2026-09-05T09:32:16Z Obesity GLP-1 expansion via Menarini and Gan & Lee licensing https://biobriefs.com/neurology-and-specialty-ophthalmology-pipeline BioBriefs en 2026-09-05T09:32:16Z Neurology and specialty ophthalmology pipeline: gene therapy and dosing momentum https://biobriefs.com/oncology-m-a-and-platform BioBriefs en 2026-09-05T09:32:16Z Oncology M&A and platform-building around antibody-targeted therapy conjugates https://biobriefs.com/clinical-stage-biotech-financing-and BioBriefs en 2026-09-05T09:32:16Z Clinical-stage biotech financing and early clinical push in obesity https://biobriefs.com/drug-discovery-company-adds-uk BioBriefs en 2026-09-05T09:32:16Z Drug discovery company adds UK funding for chronic autoimmune programs https://biobriefs.com/regulatory-and-platform-signals-in BioBriefs en 2026-09-05T09:32:16Z Regulatory and platform signals in CNS therapy pipelines https://biobriefs.com/fda-approval-first-disease-modifying BioBriefs en 2026-09-05T04:32:16Z FDA approval: first disease-modifying Alexander disease therapy https://biobriefs.com/phase-3-readouts-multiple-myeloma BioBriefs en 2026-09-05T04:32:16Z Phase 3 readouts: multiple myeloma T-cell engager etentamig posts survival benefit https://biobriefs.com/phase-3-setback-novartis-pelacarsen BioBriefs en 2026-09-05T04:32:16Z Phase 3 setback: Novartis pelacarsen misses cardiovascular outcomes in HORIZON https://biobriefs.com/clinical-pipeline-funding-neushen-lands BioBriefs en 2026-09-05T04:32:16Z Clinical pipeline funding: NeuShen lands $80M Series B for brain-health drugs https://biobriefs.com/regulatory-approvals-china-clears-everest BioBriefs en 2026-09-05T04:32:16Z Regulatory approvals: China clears Everest heart spray and Simcere RSV antibody https://biobriefs.com/drug-development-pivots-ultragenyx-angelman BioBriefs en 2026-09-05T04:32:16Z Drug development pivots: Ultragenyx Angelman Phase 3 fails, prompting cost review https://biobriefs.com/big-pharma-deal-gsk-licenses BioBriefs en 2026-09-05T04:32:16Z Big Pharma deal: GSK licenses Hutchmed’s KRAS/EGFR antibody-targeted therapy conjugate https://biobriefs.com/big-pharma-technology-deal-novartis BioBriefs en 2026-09-05T04:32:16Z Big Pharma technology deal: Novartis expands access to Alteogen’s subcutaneous delivery platform https://biobriefs.com/recommender-systems-graph-attention-model BioBriefs en 2026-09-05T04:32:16Z Recommender systems: graph-attention model improves personalization by modeling interaction history https://biobriefs.com/gene-therapy-pipeline-fda-ind BioBriefs en 2026-09-05T04:32:16Z Gene therapy pipeline: FDA IND clearance for first U.S. clinical trial in mucolipidosis type IV https://biobriefs.com/cardiometabolic-glp-1-partnerships-and BioBriefs en 2026-09-04T21:32:08Z Cardiometabolic / GLP-1 partnerships and regional expansion https://biobriefs.com/regulatory-approval-first-in-class BioBriefs en 2026-09-04T21:32:08Z Regulatory approval – first-in-class for ultra-rare Alexander disease https://biobriefs.com/cardiovascular-late-stage-failure-pelacarsen BioBriefs en 2026-09-04T21:32:08Z Cardiovascular late-stage failure – pelacarsen https://biobriefs.com/oncology-phase-3-readouts-reshape BioBriefs en 2026-09-04T21:32:08Z Oncology – Phase 3 readouts reshape treatment risk-benefit https://biobriefs.com/oncology-partnering-gsk-licenses-kras BioBriefs en 2026-09-04T21:32:08Z Oncology partnering – GSK licenses KRAS–EGFR antibody-targeted conjugate from Hutchmed https://biobriefs.com/trial-failure-reshapes-rare-neurodevelopment BioBriefs en 2026-09-04T21:32:08Z Trial failure reshapes rare neurodevelopment pipeline – Angelman syndrome https://biobriefs.com/cell-and-gene-therapy-safety BioBriefs en 2026-09-04T21:32:08Z Cell and gene therapy safety – CAR-T trial pauses https://biobriefs.com/funding-neushen-series-b-to BioBriefs en 2026-09-04T21:32:08Z Funding – NeuShen Series B to advance brain-health drugs https://biobriefs.com/btk-inhibitors-remibrutinib-enters-multiple BioBriefs en 2026-09-04T21:32:08Z BTK inhibitors – remibrutinib enters multiple sclerosis regulatory race https://biobriefs.com/antimicrobial-strategy-phage-therapy-in BioBriefs en 2026-09-04T21:32:08Z Antimicrobial strategy – phage therapy in a human micro-bladder model https://biobriefs.com/regulatory-approvals-rare-pediatric-neurology BioBriefs en 2026-09-04T16:33:10Z Regulatory approvals – rare pediatric neurology https://biobriefs.com/phase-3-multiple-myeloma-bispecific BioBriefs en 2026-09-04T16:33:10Z Phase 3 – multiple myeloma bispecific win https://biobriefs.com/phase-3-rare-neuro-disorder BioBriefs en 2026-09-04T16:33:10Z Phase 3 – rare neuro disorder setback https://biobriefs.com/oncology-partnerships-and-licensing-gsk BioBriefs en 2026-09-04T16:33:10Z Oncology partnerships and licensing – GSK adds KRAS/EGFR conjugate https://biobriefs.com/regulatory-supply-chain-estrogen-patch BioBriefs en 2026-09-04T16:33:10Z Regulatory supply chain – estrogen patch market pressure https://biobriefs.com/financing-neushen-raises-to-advance BioBriefs en 2026-09-04T16:33:10Z Financing – NeuShen raises to advance brain-health programs https://biobriefs.com/financing-superluminal-obesity-drug-program BioBriefs en 2026-09-04T16:33:10Z Financing – Superluminal obesity drug program https://biobriefs.com/cell-gene-therapy-car-t BioBriefs en 2026-09-04T16:33:10Z Cell & gene therapy – CAR-T trial holds after fatalities https://biobriefs.com/late-stage-neuro-psychiatry-preclinical BioBriefs en 2026-09-04T16:33:10Z Late-stage neuro-psychiatry preclinical translation – psilocybin to prevent CIPN https://biobriefs.com/clinical-trial-evidence-pulmonary-infection BioBriefs en 2026-09-04T16:33:10Z Clinical trial evidence – pulmonary infection origin changes outcomes https://biobriefs.com/regulatory-approval-rare-neurodevelopmental-disease BioBriefs en 2026-09-04T14:32:32Z Regulatory approval: rare neurodevelopmental disease https://biobriefs.com/clinical-failure-angelman-syndrome-setbacks BioBriefs en 2026-09-04T14:32:32Z Clinical failure: Angelman syndrome setbacks https://biobriefs.com/oncology-licensing-deal-kras-egfr BioBriefs en 2026-09-04T14:32:32Z Oncology licensing deal: KRAS/EGFR targeted conjugate moves into GSK https://biobriefs.com/clinical-readout-in-lung-cancer BioBriefs en 2026-09-04T14:32:32Z Clinical readout in lung cancer: ivonescimab shows survival benefit https://biobriefs.com/biotech-m-a-and-platform BioBriefs en 2026-09-04T14:32:32Z Biotech M&A and platform bets: company pivots CRO-to-drug development https://biobriefs.com/cell-therapy-safety-car-t BioBriefs en 2026-09-04T14:32:32Z Cell therapy safety: CAR-T trial pauses after fatalities https://biobriefs.com/dealmaking-antibody-drug-conjugate-rights BioBriefs en 2026-09-04T14:32:32Z Dealmaking: antibody-drug conjugate rights reshuffle https://biobriefs.com/clinical-development-gene-therapy-ind BioBriefs en 2026-09-04T14:32:32Z Clinical development: gene therapy IND cleared in the U.S. https://biobriefs.com/platform-genomics-manufacturing-expansion-to BioBriefs en 2026-09-04T14:32:32Z Platform: genomics manufacturing expansion to support molecular diagnostics scale https://biobriefs.com/biotech-funding-new-series-a BioBriefs en 2026-09-04T14:32:32Z Biotech funding: new series A for in vivo CAR-T strategy https://biobriefs.com/gsk-bets-1-3b-on BioBriefs en 2026-09-04T10:32:39Z GSK bets $1.3B on KRAS/EGFR ATTC from Hutchmed https://biobriefs.com/hutchmeds-kras-egfr-rights-deal BioBriefs en 2026-09-04T10:32:39Z Hutchmed’s KRAS/EGFR rights deal is echoed in separate coverage https://biobriefs.com/ionis-wins-fda-approval-for BioBriefs en 2026-09-04T10:32:39Z Ionis wins FDA approval for Alexander disease treatment https://biobriefs.com/ultragenyx-phase-3-failure-in BioBriefs en 2026-09-04T10:32:39Z Ultragenyx Phase 3 failure in Angelman syndrome https://biobriefs.com/novartis-pushes-into-relapsing-ms BioBriefs en 2026-09-04T10:32:39Z Novartis pushes into relapsing MS race with second BTK inhibitor https://biobriefs.com/roche-brings-sim-0600-trispecific BioBriefs en 2026-09-04T10:32:39Z Roche brings SIM-0600 trispecific TCE into a potential $1.53B deal https://biobriefs.com/novartis-licenses-alteogen-alt-b4 BioBriefs en 2026-09-04T10:32:39Z Novartis licenses Alteogen ALT-B4 subcutaneous delivery platform in up to $3.2B https://biobriefs.com/patient-safety-halts-novartis-and BioBriefs en 2026-09-04T10:32:39Z Patient safety halts: Novartis and BMS suspend CAR-T programs https://biobriefs.com/uniqure-seeks-fda-and-mhra BioBriefs en 2026-09-04T10:32:39Z UniQure seeks FDA and MHRA approval for Huntington’s gene therapy https://biobriefs.com/watchmaker-genomics-expands-manufacturing-footprint BioBriefs en 2026-09-04T10:32:39Z Watchmaker Genomics expands manufacturing footprint in Boulder https://biobriefs.com/oncology-bd-gsk-licensing-kras BioBriefs en 2026-09-04T09:32:43Z Oncology BD: GSK licensing KRAS-EGFR ATTC https://biobriefs.com/cell-therapy-safety-car-t BioBriefs en 2026-09-04T09:32:43Z Cell therapy safety: CAR-T trial pauses after fatalities https://biobriefs.com/rare-disease-fda-approval-of BioBriefs en 2026-09-04T09:32:43Z Rare disease: FDA approval of first therapy for Alexander disease https://biobriefs.com/rare-neurodevelopment-ultragenyxs-phase-3 BioBriefs en 2026-09-04T09:32:43Z Rare neurodevelopment: Ultragenyx’s Phase 3 Angelman failure https://biobriefs.com/immuno-oncology-abbvies-etentamig-phase BioBriefs en 2026-09-04T09:32:43Z Immuno-oncology: AbbVie’s etentamig Phase 3 win in myeloma https://biobriefs.com/cns-immunology-epicardial-nrg1-erbb4 BioBriefs en 2026-09-04T09:32:43Z CNS immunology: epicardial NRG1–ERBB4 pathway stimulates heart regeneration https://biobriefs.com/virology-hiv-cure-research-venetoclax BioBriefs en 2026-09-04T09:32:43Z Virology–HIV cure research: venetoclax reduces intact SIV reservoir in macaques https://biobriefs.com/celiac-disease-tevas-gluten-challenge BioBriefs en 2026-09-04T09:32:43Z Celiac disease: Teva’s gluten challenge positive in antibody trial https://biobriefs.com/medtech-devices-selio-hydrogel-device BioBriefs en 2026-09-04T09:32:43Z Medtech/devices: Selio hydrogel device to prevent pneumothorax in CT-guided lung biopsy https://biobriefs.com/metformin-and-down-syndrome-restores BioBriefs en 2026-09-04T09:32:43Z Metformin and Down syndrome: restores mitochondrial quality control https://biobriefs.com/fda-approvals-accelerated-approval BioBriefs en 2026-09-04T04:33:10Z FDA approvals / accelerated approval https://biobriefs.com/late-stage-failures-and-pipeline BioBriefs en 2026-09-04T04:33:10Z Late-stage failures and pipeline reset https://biobriefs.com/gene-therapy-regulatory-push BioBriefs en 2026-09-04T04:33:10Z Gene therapy regulatory push https://biobriefs.com/next-gen-drug-delivery-licensing BioBriefs en 2026-09-04T04:33:10Z Next-gen drug delivery licensing https://biobriefs.com/cancer-clinical-development-bispecific-pd BioBriefs en 2026-09-04T04:33:10Z Cancer clinical development: bispecific / PD-1xVEGF https://biobriefs.com/immuno-oncology-dealmaking-and-preclinical BioBriefs en 2026-09-04T04:33:10Z Immuno-oncology dealmaking and preclinical pipeline https://biobriefs.com/virology-hiv-cure-strategies-using BioBriefs en 2026-09-04T04:33:10Z Virology / HIV cure strategies using approved oncology drugs https://biobriefs.com/psychedelic-neuroprotection-in-oncology BioBriefs en 2026-09-04T04:33:10Z Psychedelic neuroprotection in oncology https://biobriefs.com/cardiovascular-risk-imaging-with-ai BioBriefs en 2026-09-04T04:33:10Z Cardiovascular risk imaging with AI https://biobriefs.com/biopharma-trial-regulatory-operations-tooling BioBriefs en 2026-09-04T04:33:10Z Biopharma trial/regulatory operations tooling https://biobriefs.com/fda-approval-rare-disease-first BioBriefs en 2026-09-03T21:32:32Z FDA approval — rare disease first-in-class antisense therapy https://biobriefs.com/phase-3-setback-angelman-syndrome BioBriefs en 2026-09-03T21:32:32Z Phase 3 setback — Angelman syndrome antisense program fails https://biobriefs.com/big-pharma-licensing-deal-gsk BioBriefs en 2026-09-03T21:32:32Z Big pharma licensing deal — GSK steps further into ADCs https://biobriefs.com/phase-3-readout-novartis-remibrutinib BioBriefs en 2026-09-03T21:32:32Z Phase 3 readout — Novartis remibrutinib enters relapsing MS race https://biobriefs.com/big-pharma-delivery-deal-novartis BioBriefs en 2026-09-03T21:32:32Z Big pharma delivery deal — Novartis licenses Alteogen’s ALT-B4 https://biobriefs.com/adc-deal-pfizer-sells-discontinued BioBriefs en 2026-09-03T21:32:32Z ADC deal — Pfizer sells discontinued Seagen asset to Medicus https://biobriefs.com/fda-regulation-and-enforcement-cber BioBriefs en 2026-09-03T21:32:32Z FDA regulation and enforcement — CBER overrules rejection for Replimune melanoma drug https://biobriefs.com/cell-therapy-risk-car-t BioBriefs en 2026-09-03T21:32:32Z Cell therapy risk — CAR-T safety pause after Novartis and Bristol Myers study https://biobriefs.com/platform-funding-typewriter-raises-series BioBriefs en 2026-09-03T21:32:32Z Platform funding — Typewriter raises Series A for in vivo RNA CAR-T https://biobriefs.com/preclinical-neuroscience-psilocybin-prevents-chemotherapy BioBriefs en 2026-09-03T21:32:32Z Preclinical neuroscience — psilocybin prevents chemotherapy-induced peripheral neuropathy in mice https://biobriefs.com/huntingtons-gene-therapy-regulatory-path BioBriefs en 2026-09-03T16:32:19Z Huntington’s gene therapy regulatory path https://biobriefs.com/cancer-drug-partnering-roche-expands BioBriefs en 2026-09-03T16:32:19Z Cancer drug partnering: Roche expands TCE pipeline https://biobriefs.com/gsk-doubles-down-on-kras BioBriefs en 2026-09-03T16:32:19Z GSK doubles down on KRAS/EGFR targeted oncology https://biobriefs.com/drug-delivery-platform-deals-novartis BioBriefs en 2026-09-03T16:32:19Z Drug delivery platform deals: Novartis and Alteogen for subcutaneous formulations https://biobriefs.com/clinical-failure-forces-cost-resets BioBriefs en 2026-09-03T16:32:19Z Clinical failure forces cost resets at Ultragenyx https://biobriefs.com/ai-biology-funding-arpa-h BioBriefs en 2026-09-03T16:32:19Z AI biology funding: ARPA-H pushes on-demand RNA manufacturing https://biobriefs.com/ai-assisted-oncology-platform-drug BioBriefs en 2026-09-03T16:32:19Z AI-assisted oncology platform: drug discovery speed at large scale https://biobriefs.com/liquid-biopsy-startup-raises-seed BioBriefs en 2026-09-03T16:32:19Z Liquid biopsy startup raises seed for RBC-bound nucleic acids https://biobriefs.com/gene-therapy-manufacturing-partnerships-andelyn BioBriefs en 2026-09-03T16:32:19Z Gene therapy manufacturing partnerships: Andelyn scales Genprex AAV diabetes program https://biobriefs.com/clinical-translational-ai-mechanistic-mapping BioBriefs en 2026-09-03T16:32:19Z Clinical translational AI: mechanistic mapping for drug discovery https://biobriefs.com/fda-accelerated-approval-override-for BioBriefs en 2026-09-03T14:32:20Z FDA accelerated approval override for melanoma drug https://biobriefs.com/huntington-gene-therapy-heads-to BioBriefs en 2026-09-03T14:32:20Z Huntington gene therapy heads to FDA and seeks priority review https://biobriefs.com/phase-3-efficacy-readout-lifts BioBriefs en 2026-09-03T14:32:20Z Phase 3 efficacy readout lifts Akeso’s lung cancer bispecific https://biobriefs.com/abbvies-multiple-myeloma-bispecific-posts BioBriefs en 2026-09-03T14:32:20Z ABBVIE’s multiple myeloma bispecific posts positive Phase 3 https://biobriefs.com/ultragenyx-phase-3-failure-in BioBriefs en 2026-09-03T14:32:20Z Ultragenyx Phase 3 failure in Angelman syndrome https://biobriefs.com/teva-delivers-positive-celiac-gluten BioBriefs en 2026-09-03T14:32:20Z Teva delivers positive celiac gluten-challenge toplines https://biobriefs.com/roche-lands-simcere-trispecific-tce BioBriefs en 2026-09-03T14:32:20Z Roche lands Simcere trispecific TCE in large B-cell deal https://biobriefs.com/novartis-expands-subcutaneous-delivery-tech BioBriefs en 2026-09-03T14:32:20Z Novartis expands subcutaneous delivery tech with Alteogen https://biobriefs.com/arpa-h-funds-automated-custom BioBriefs en 2026-09-03T14:32:20Z ARPA-H funds automated custom RNA manufacturing network https://biobriefs.com/car-t-manufacturing-scale-out BioBriefs en 2026-09-03T14:32:20Z CAR-T manufacturing ‘scale-out’ bottleneck https://biobriefs.com/funding-for-genetic-obesity-and BioBriefs en 2026-09-03T10:32:26Z Funding for genetic obesity and early clinical testing https://biobriefs.com/big-pharma-licensing-bets-on BioBriefs en 2026-09-03T10:32:26Z Big Pharma licensing bets on KRAS-EGFR antibody conjugates https://biobriefs.com/ultragenyxs-angelman-program-stumbles-in BioBriefs en 2026-09-03T10:32:26Z Ultragenyx’s Angelman program stumbles in Phase 3 https://biobriefs.com/fda-accelerated-approval-overturned-replimunes BioBriefs en 2026-09-03T10:32:26Z FDA accelerated approval overturned—Replimune’s Tudriqev wins internal rebuke https://biobriefs.com/gene-therapy-regulatory-push-uniqure BioBriefs en 2026-09-03T10:32:26Z Gene therapy regulatory push—UniQure seeks FDA approval for Huntington’s AMT-130 https://biobriefs.com/large-scale-delivery-platform-deal BioBriefs en 2026-09-03T10:32:26Z Large-scale delivery platform deal—Novartis taps Alteogen ALT-B4 for subcutaneous formulations https://biobriefs.com/roche-partnership-in-b-cell BioBriefs en 2026-09-03T10:32:26Z Roche partnership in B-cell immunology—SIM-0600 trispecific TCE deal https://biobriefs.com/arpa-h-funding-for-on BioBriefs en 2026-09-03T10:32:26Z ARPA-H funding for on-demand automated RNA genetic medicines https://biobriefs.com/tevas-celiac-antibody-shows-success BioBriefs en 2026-09-03T10:32:26Z Teva’s celiac antibody shows success in gluten-challenge mid-stage study https://biobriefs.com/exelixis-secures-cabometyx-exclusivity-after BioBriefs en 2026-09-03T10:32:26Z Exelixis secures Cabometyx exclusivity after Federal Circuit patent win https://biobriefs.com/gene-therapy-regulatory-path BioBriefs en 2026-09-03T09:32:25Z Gene therapy regulatory path https://biobriefs.com/clinical-setback-in-cns-rare BioBriefs en 2026-09-03T09:32:25Z Clinical setback in CNS rare disease https://biobriefs.com/immunology-car-t-safety-spotlight BioBriefs en 2026-09-03T09:32:25Z Immunology: CAR-T safety spotlight https://biobriefs.com/oncology-molecular-imaging-premetastatic-detection BioBriefs en 2026-09-03T09:32:25Z Oncology & molecular imaging premetastatic detection https://biobriefs.com/immunotherapy-deals-roche-simcere-trispecific BioBriefs en 2026-09-03T09:32:25Z Immunotherapy deals: Roche Simcere trispecific licensing https://biobriefs.com/manufacturing-and-regulatory-science-eu BioBriefs en 2026-09-03T09:32:25Z Manufacturing and regulatory science: EU animal-test replacement pilot https://biobriefs.com/biopharma-policy-fda-scrutiny-of BioBriefs en 2026-09-03T09:32:25Z Biopharma policy: FDA scrutiny of foreign data https://biobriefs.com/diagnostics-coverage-expansion BioBriefs en 2026-09-03T09:32:25Z Diagnostics coverage expansion https://biobriefs.com/regulatory-action-tavneos-withdrawn-by BioBriefs en 2026-09-03T09:32:25Z Regulatory action: Tavneos withdrawn by UK and EU https://biobriefs.com/arpa-h-funding-automated-custom BioBriefs en 2026-09-03T09:32:25Z ARPA-H funding: automated custom RNA medicines https://biobriefs.com/angelman-syndrome-clinical-failure BioBriefs en 2026-09-03T04:32:17Z Angelman syndrome clinical failure https://biobriefs.com/huntington-gene-therapy-seeks-fda BioBriefs en 2026-09-03T04:32:17Z Huntington gene therapy seeks FDA priority review https://biobriefs.com/tevas-celiac-disease-gluten-challenge BioBriefs en 2026-09-03T04:32:17Z Teva’s celiac disease gluten challenge results https://biobriefs.com/roche-expands-b-cell-franchise BioBriefs en 2026-09-03T04:32:17Z Roche expands B-cell franchise with Simcere trispecific TCE deal https://biobriefs.com/novartis-pushes-remibrutinib-into-ms BioBriefs en 2026-09-03T04:32:17Z Novartis pushes remibrutinib into MS Phase 3 wins https://biobriefs.com/car-t-safety-sparks-new BioBriefs en 2026-09-03T04:32:17Z CAR-T safety sparks new debate after Novartis deaths https://biobriefs.com/arpa-h-funding-for-automated BioBriefs en 2026-09-03T04:32:17Z ARPA-H funding for automated custom RNA manufacturing https://biobriefs.com/fda-and-mhra-move-against BioBriefs en 2026-09-03T04:32:17Z FDA and MHRA move against Amgen’s Tavneos https://biobriefs.com/clinical-trial-operations-new-benchmarking BioBriefs en 2026-09-03T04:32:17Z Clinical trial operations: new benchmarking for trial sites https://biobriefs.com/planned-recombinant-manufacturing-optimization-for BioBriefs en 2026-09-03T04:32:17Z Planned recombinant manufacturing optimization for antibody cell lines https://biobriefs.com/clinical-failure-in-rare-disease BioBriefs en 2026-09-02T21:32:50Z Clinical failure in rare disease https://biobriefs.com/car-t-safety-prompts-trial BioBriefs en 2026-09-02T21:32:50Z CAR-T safety prompts trial pauses https://biobriefs.com/fda-scrutiny-of-foreign-clinical BioBriefs en 2026-09-02T21:32:50Z FDA scrutiny of foreign clinical data https://biobriefs.com/u-k-and-eu-market BioBriefs en 2026-09-02T21:32:50Z U.K. and EU market withdrawal for Tavneos https://biobriefs.com/car-t-autoimmune-risk-debate BioBriefs en 2026-09-02T21:32:50Z CAR-T autoimmune risk debate continues after additional study stoppage https://biobriefs.com/precision-degradation-expands-with-lillys BioBriefs en 2026-09-02T21:32:50Z Precision degradation expands with Lilly’s Merida acquisition https://biobriefs.com/roche-adds-preclinical-trispecific-tce BioBriefs en 2026-09-02T21:32:50Z Roche adds preclinical trispecific TCE for B-cell diseases https://biobriefs.com/fda-accelerated-approval-overruled-in BioBriefs en 2026-09-02T21:32:50Z FDA accelerated approval overruled in melanoma https://biobriefs.com/process-innovation-and-regulation-continuous BioBriefs en 2026-09-02T21:32:50Z Process innovation and regulation: continuous manufacturing controls https://biobriefs.com/next-gen-rna-manufacturing-funding BioBriefs en 2026-09-02T21:32:50Z Next-gen RNA manufacturing funding via ARPA-H https://biobriefs.com/fda-accelerated-approval-dispute-inside BioBriefs en 2026-09-02T16:32:10Z FDA accelerated approval dispute inside Replimune https://biobriefs.com/uniqure-heads-back-to-regulators BioBriefs en 2026-09-02T16:32:10Z UniQure heads back to regulators for Huntington’s gene therapy https://biobriefs.com/uk-regulator-blocks-tavneos-sales BioBriefs en 2026-09-02T16:32:10Z UK regulator blocks Tavneos sales amid UniQure filing https://biobriefs.com/roche-expands-b-cell-oncology BioBriefs en 2026-09-02T16:32:10Z Roche expands B-cell oncology/immunology with trispecific TCE licensing https://biobriefs.com/arpa-h-funds-on-demand BioBriefs en 2026-09-02T16:32:10Z ARPA-H funds on-demand automated manufacturing for personalized RNA medicines https://biobriefs.com/teva-posts-celiac-disease-win BioBriefs en 2026-09-02T16:32:10Z Teva posts celiac disease win for experimental antibody https://biobriefs.com/glp-1-expands-beyond-weight BioBriefs en 2026-09-02T16:32:10Z GLP-1 expands beyond weight loss toward potential anti-aging biology https://biobriefs.com/multiple-sclerosis-novartis-posts-phase BioBriefs en 2026-09-02T16:32:10Z Multiple sclerosis: Novartis posts Phase 3 win for remibrutinib https://biobriefs.com/lilly-buys-merida-to-broaden BioBriefs en 2026-09-02T16:32:10Z Lilly buys Merida to broaden autoimmune portfolio https://biobriefs.com/diagnostics-coverage-guardant-shield-test BioBriefs en 2026-09-02T16:32:10Z Diagnostics coverage: Guardant Shield test approved for Canadian reimbursement https://biobriefs.com/autoimmune-pipeline-successes-and-failures BioBriefs en 2026-09-02T14:32:15Z Autoimmune pipeline successes and failures (TYK2 and BTK) https://biobriefs.com/m-a-moves-reshaping-autoimmune BioBriefs en 2026-09-02T14:32:15Z M&A moves reshaping autoimmune strategy at Eli Lilly https://biobriefs.com/federal-funding-for-custom-rna BioBriefs en 2026-09-02T14:32:15Z Federal funding for custom RNA medicines on demand (ARPA-H GIVE) https://biobriefs.com/biopharma-pricing-and-access-policy BioBriefs en 2026-09-02T14:32:15Z Biopharma pricing and access policy expands under MFN deals https://biobriefs.com/clinical-trial-safety-stops-in BioBriefs en 2026-09-02T14:32:15Z Clinical-trial safety stops in autoimmune CAR-T (Novartis and BMS) https://biobriefs.com/gene-therapy-manufacturing-scale-up BioBriefs en 2026-09-02T14:32:15Z Gene therapy manufacturing scale-up for AAV diabetes program https://biobriefs.com/late-stage-regulators-align-on BioBriefs en 2026-09-02T14:32:15Z Late-stage regulators align on DLL3 ADC Phase 3 (Ideaya) https://biobriefs.com/cancer-precision-diagnostics-score-insurance BioBriefs en 2026-09-02T14:32:15Z Cancer precision diagnostics score insurance coverage milestone (Guardant Shield CRC) https://biobriefs.com/r-d-infrastructure-for-faster BioBriefs en 2026-09-02T14:32:15Z R&D infrastructure for faster drug discovery via large-scale virtual screening (AdaptiveFlow) https://biobriefs.com/liquid-biopsy-financing-boosts-rbc BioBriefs en 2026-09-02T14:32:15Z Liquid biopsy financing boosts RBC-bound nucleic acids platform (Senticell) https://biobriefs.com/biotech-funding-and-stealth-launches BioBriefs en 2026-09-02T10:31:39Z Biotech funding and stealth launches https://biobriefs.com/clinical-success-and-pivotal-trial BioBriefs en 2026-09-02T10:31:39Z Clinical success and pivotal trial readouts https://biobriefs.com/clinical-setbacks-in-autoimmune-drug BioBriefs en 2026-09-02T10:31:39Z Clinical setbacks in autoimmune drug development https://biobriefs.com/autoimmune-car-t-pauses-and BioBriefs en 2026-09-02T10:31:39Z Autoimmune CAR-T pauses and safety signals https://biobriefs.com/biopharma-policy-and-drug-pricing BioBriefs en 2026-09-02T10:31:39Z Biopharma policy and drug pricing initiatives https://biobriefs.com/manufacturing-scale-up-for-gene BioBriefs en 2026-09-02T10:31:39Z Manufacturing scale-up for gene therapy https://biobriefs.com/r-d-platform-leap-for BioBriefs en 2026-09-02T10:31:39Z R&D platform leap for automated genetic medicines https://biobriefs.com/strategic-partnerships-in-adcs-and BioBriefs en 2026-09-02T10:31:39Z Strategic partnerships in ADCs and oncology targets https://biobriefs.com/big-pharma-m-a-in BioBriefs en 2026-09-02T10:31:39Z Big pharma M&A in immunology https://biobriefs.com/regulatory-and-reimbursement-expanding-diagnostic BioBriefs en 2026-09-02T10:31:39Z Regulatory and reimbursement: expanding diagnostic access https://biobriefs.com/immunology-clinical-outcomes-and-trial BioBriefs en 2026-09-02T09:31:40Z Immunology clinical outcomes and trial pauses https://biobriefs.com/lupus-tyk2-inhibitor-stumbles-but BioBriefs en 2026-09-02T09:31:40Z Lupus TYK2 inhibitor stumbles but pivots to a subgroup strategy https://biobriefs.com/ms-efficacy-signal-for-btk BioBriefs en 2026-09-02T09:31:40Z MS efficacy signal for BTK inhibitor remibrutinib https://biobriefs.com/hhs-arpa-h-pushes-domestic BioBriefs en 2026-09-02T09:31:40Z HHS/ARPA-H pushes domestic, automated personalized RNA manufacturing https://biobriefs.com/gene-therapy-manufacturing-scale-up BioBriefs en 2026-09-02T09:31:40Z Gene therapy manufacturing scale-up for AAV diabetes program https://biobriefs.com/lilly-doubles-down-on-immunology BioBriefs en 2026-09-02T09:31:40Z Lilly doubles down on immunology via Merida acquisition https://biobriefs.com/diagnostics-guardant-shield-colorectal-test BioBriefs en 2026-09-02T09:31:40Z Diagnostics: Guardant Shield colorectal test expands coverage https://biobriefs.com/diagnostics-fujirebio-neurological-blood-tests BioBriefs en 2026-09-02T09:31:40Z Diagnostics: Fujirebio neurological blood tests cleared in Canada https://biobriefs.com/drug-pricing-policy-mfn-deals BioBriefs en 2026-09-02T09:31:40Z Drug pricing policy: MFN deals expand to midsized drugmakers https://biobriefs.com/ai-enabled-virtual-screening-scales BioBriefs en 2026-09-02T09:31:40Z AI-enabled virtual screening scales drug discovery compute https://biobriefs.com/lilly-merida-autoimmunity-m-a BioBriefs en 2026-09-02T04:31:41Z Lilly-Merida autoimmunity M&A https://biobriefs.com/arpa-h-funding-for-automated BioBriefs en 2026-09-02T04:31:41Z ARPA-H funding for automated RNA manufacturing https://biobriefs.com/gsk-mrna-flu-trial-move BioBriefs en 2026-09-02T04:31:41Z GSK mRNA flu trial move to pivotal study https://biobriefs.com/novartis-and-bms-pause-autoimmune BioBriefs en 2026-09-02T04:31:41Z Novartis and BMS pause autoimmune CAR-T trials https://biobriefs.com/genentech-fenebrutinib-ms-readouts BioBriefs en 2026-09-02T04:31:41Z Genentech fenebrutinib MS readouts https://biobriefs.com/alumis-tyk2-inhibitor-lupus-setback BioBriefs en 2026-09-02T04:31:41Z Alumis TYK2 inhibitor lupus setback https://biobriefs.com/ideaya-dll3-adc-phase-iii BioBriefs en 2026-09-02T04:31:41Z Ideaya DLL3 ADC phase III alignment https://biobriefs.com/dualitybio-roche-1b-scale-adc BioBriefs en 2026-09-02T04:31:41Z Dualitybio Roche $1B-scale ADC collaboration https://biobriefs.com/exelixis-cabometyx-exclusivity-after-patent BioBriefs en 2026-09-02T04:31:41Z Exelixis Cabometyx exclusivity after patent win https://biobriefs.com/mfn-pricing-expands-to-midsized BioBriefs en 2026-09-02T04:31:41Z MFN pricing expands to midsized biopharmas https://biobriefs.com/ai-enabled-chemical-discovery-infrastructure BioBriefs en 2026-09-01T21:32:24Z AI-enabled chemical discovery infrastructure https://biobriefs.com/federal-push-for-on-demand BioBriefs en 2026-09-01T21:32:24Z Federal push for on-demand RNA manufacturing https://biobriefs.com/regulatory-and-safety-actions-in BioBriefs en 2026-09-01T21:32:24Z Regulatory and safety actions in cellular therapy https://biobriefs.com/clinical-efficacy-signal-in-multiple BioBriefs en 2026-09-01T21:32:24Z Clinical efficacy signal in multiple sclerosis https://biobriefs.com/biopharma-licensing-and-anticancer-innovation BioBriefs en 2026-09-01T21:32:24Z Biopharma licensing and anticancer innovation https://biobriefs.com/pricing-policy-and-expansion-of BioBriefs en 2026-09-01T21:32:24Z Pricing policy and expansion of MFN agreements https://biobriefs.com/liquid-biopsy-expansion-with-rbc BioBriefs en 2026-09-01T21:32:24Z Liquid biopsy expansion with RBC-bound signals https://biobriefs.com/immunology-dealmaking-lilly-acquires-merida BioBriefs en 2026-09-01T21:32:24Z Immunology dealmaking: Lilly acquires Merida https://biobriefs.com/diagnostics-and-reimbursement-coverage-for BioBriefs en 2026-09-01T21:32:24Z Diagnostics and reimbursement coverage for colorectal cancer screening https://biobriefs.com/immunology-trial-setback-in-lupus BioBriefs en 2026-09-01T21:32:24Z Immunology trial setback in lupus https://biobriefs.com/drug-pricing-policy-and-medicaid BioBriefs en 2026-09-01T16:32:13Z Drug pricing policy and Medicaid access https://biobriefs.com/ms-prospects-revive-for-novartis BioBriefs en 2026-09-01T16:32:13Z MS prospects revive for Novartis’ brain-penetrant BTK inhibitor https://biobriefs.com/lupus-setback-deepens-for-tyk2 BioBriefs en 2026-09-01T16:32:13Z Lupus setback deepens for TYK2 blockers at Alumis https://biobriefs.com/eli-lilly-expands-immunology-with BioBriefs en 2026-09-01T16:32:13Z Eli Lilly expands immunology with Merida acquisition https://biobriefs.com/roche-deepens-antibody-pipeline-via BioBriefs en 2026-09-01T16:32:13Z Roche deepens antibody pipeline via Simcere trispecific pact https://biobriefs.com/car-t-safety-prompts-trial BioBriefs en 2026-09-01T16:32:13Z CAR-T safety prompts trial pauses at Novartis and Bristol Myers https://biobriefs.com/clinical-validation-in-acute-stroke BioBriefs en 2026-09-01T16:32:13Z Clinical validation in acute stroke: Micot TrkB agonist hits Phase 2 endpoints https://biobriefs.com/newco-buildout-for-oral-therapies BioBriefs en 2026-09-01T16:32:13Z Newco buildout for oral therapies in type 2 inflammatory diseases https://biobriefs.com/oral-mrna-flu-pivot-gsk BioBriefs en 2026-09-01T16:32:13Z Oral mRNA flu pivot: GSK moves to Phase 3 after higher Phase 2 immune responses https://biobriefs.com/diagnostics-commercialization-guardant-shield-colorectal BioBriefs en 2026-09-01T16:32:13Z Diagnostics commercialization: Guardant Shield colorectal screening covered by Carelon https://biobriefs.com/commercial-coverage-expansion-for-colorectal BioBriefs en 2026-09-01T14:32:39Z Commercial coverage expansion for colorectal screening https://biobriefs.com/autoimmunity-pipeline-setback-in-tyk2 BioBriefs en 2026-09-01T14:32:39Z Autoimmunity pipeline setback in TYK2 lupus program https://biobriefs.com/nhs-adoption-of-epigenetic-tumor BioBriefs en 2026-09-01T14:32:39Z NHS adoption of epigenetic tumor classification https://biobriefs.com/ai-enabled-rare-disease-initiatives BioBriefs en 2026-09-01T14:32:39Z AI-enabled rare disease initiatives funded by ARPA-H https://biobriefs.com/lilly-merida-acquisition-to-target BioBriefs en 2026-09-01T14:32:39Z Lilly-Merida acquisition to target pathogenic autoantibodies https://biobriefs.com/canada-regulatory-approval-for-fujirebio BioBriefs en 2026-09-01T14:32:39Z Canada regulatory approval for Fujirebio neurological blood biomarkers https://biobriefs.com/car-t-safety-pauses-in BioBriefs en 2026-09-01T14:32:39Z CAR-T safety pauses in autoimmune programs https://biobriefs.com/takeda-fda-approval-for-protagonist BioBriefs en 2026-09-01T14:32:39Z Takeda FDA approval for Protagonist rare blood cancer therapy https://biobriefs.com/widespread-execution-issues-in-clinical BioBriefs en 2026-09-01T14:32:39Z Widespread execution issues in clinical trials flagged by Tufts study https://biobriefs.com/laboratory-and-diagnostic-devices-next BioBriefs en 2026-09-01T14:32:39Z Laboratory and diagnostic devices: next-generation CRISPR for at-home nucleic acid testing https://biobriefs.com/car-t-safety-pauses BioBriefs en 2026-09-01T10:32:17Z CAR-T safety pauses https://biobriefs.com/fda-approval-for-first-in BioBriefs en 2026-09-01T10:32:17Z FDA approval for first-in-class rare disease drug https://biobriefs.com/lillys-continued-immunology-m-a BioBriefs en 2026-09-01T10:32:17Z Lilly’s continued immunology M&A push https://biobriefs.com/fda-disclosure-shift-on-crls BioBriefs en 2026-09-01T10:32:17Z FDA disclosure shift on CRLs https://biobriefs.com/car-t-autoimmune-pause-second BioBriefs en 2026-09-01T10:32:17Z CAR-T autoimmune pause – second confirmation https://biobriefs.com/deal-merida-takeout-coverage-duplicate BioBriefs en 2026-09-01T10:32:17Z Deal: Merida takeout coverage (duplicate event, retained distinct ID) https://biobriefs.com/venture-financing-arch-targets-3b BioBriefs en 2026-09-01T10:32:17Z Venture financing: ARCH targets $3B raise https://biobriefs.com/clinical-trial-execution-risk-and BioBriefs en 2026-09-01T10:32:17Z Clinical trial execution risk and CRO oversight https://biobriefs.com/biotech-ipo-electra-therapeutics-files BioBriefs en 2026-09-01T10:32:17Z Biotech IPO: Electra Therapeutics files https://biobriefs.com/takeda-pivotal-performance-heart-failure BioBriefs en 2026-09-01T10:32:17Z Takeda/Pivotal performance: heart failure phase 2b results https://biobriefs.com/regulatory-approval BioBriefs en 2026-09-01T09:32:21Z Regulatory approval https://biobriefs.com/biopharma-m-a BioBriefs en 2026-09-01T09:32:21Z Biopharma M&A https://biobriefs.com/clinical-safety-car-t-holds BioBriefs en 2026-09-01T09:32:21Z Clinical safety – CAR-T holds https://biobriefs.com/biotech-funding-ipo-filing BioBriefs en 2026-09-01T09:32:21Z Biotech funding – IPO filing https://biobriefs.com/clinical-trial-execution-cro-sponsor BioBriefs en 2026-09-01T09:32:21Z Clinical trial execution – CRO/sponsor performance gap https://biobriefs.com/drug-pricing-mfn-expansions BioBriefs en 2026-09-01T09:32:21Z Drug pricing – MFN expansions https://biobriefs.com/platform-tech-multiplex-microscopy-reagent BioBriefs en 2026-09-01T09:32:21Z Platform tech – multiplex microscopy reagent workflow https://biobriefs.com/cancer-biology-resistance-reversal-concept BioBriefs en 2026-09-01T09:32:21Z Cancer biology – resistance reversal concept https://biobriefs.com/diagnostics-innovation-at-home-crispr BioBriefs en 2026-09-01T09:32:21Z Diagnostics innovation – at-home CRISPR-style testing workflow https://biobriefs.com/ai-genomics-multimodal-foundation-modeling BioBriefs en 2026-09-01T09:32:21Z AI + genomics – multimodal foundation modeling in healthcare https://biobriefs.com/car-t-safety-pauses BioBriefs en 2026-09-01T04:32:13Z CAR-T safety pauses https://biobriefs.com/fda-approval-in-rare-blood BioBriefs en 2026-09-01T04:32:13Z FDA approval in rare blood cancer https://biobriefs.com/lilly-acquires-merida-for-selective BioBriefs en 2026-09-01T04:32:13Z Lilly acquires Merida for selective autoantibody degradation https://biobriefs.com/venture-funding-outlook BioBriefs en 2026-09-01T04:32:13Z Venture funding outlook https://biobriefs.com/mfn-drug-pricing-expansion-under BioBriefs en 2026-09-01T04:32:13Z MFN drug pricing expansion under Trump https://biobriefs.com/patient-access-after-medicare-price BioBriefs en 2026-09-01T04:32:13Z Patient access after Medicare price negotiation https://biobriefs.com/clinical-execution-risk-in-trials BioBriefs en 2026-09-01T04:32:13Z Clinical execution risk in trials https://biobriefs.com/new-gene-activation-tool-for BioBriefs en 2026-09-01T04:32:13Z New gene-activation tool for in-body editing https://biobriefs.com/biotech-ipo-filing-for-immunology BioBriefs en 2026-09-01T04:32:13Z Biotech IPO filing for immunology and cancer pipeline https://biobriefs.com/rare-blood-cancer-therapy-market BioBriefs en 2026-09-01T04:32:13Z Rare blood-cancer therapy market impact tracking https://biobriefs.com/fda-approvals-in-rare-blood BioBriefs en 2026-08-31T21:32:12Z FDA approvals in rare blood disorders https://biobriefs.com/dealmaking-and-corporate-strategy-lilly BioBriefs en 2026-08-31T21:32:12Z Dealmaking and corporate strategy—Lilly acquires Merida Biosciences https://biobriefs.com/regulatory-litigation-over-glp-1 BioBriefs en 2026-08-31T21:32:12Z Regulatory litigation over GLP-1 drug shortages https://biobriefs.com/government-drug-pricing-commitments-with BioBriefs en 2026-08-31T21:32:12Z Government drug pricing commitments with MFN-style offers https://biobriefs.com/clinical-access-impact-after-medicare BioBriefs en 2026-08-31T21:32:12Z Clinical access impact after Medicare negotiated-price rollout https://biobriefs.com/oncology-research-two-drug-strategy BioBriefs en 2026-08-31T21:32:12Z Oncology research—two-drug strategy against chemoresistant TNBC https://biobriefs.com/new-platform-technology-targeted-protein BioBriefs en 2026-08-31T21:32:12Z New platform technology—targeted protein assays reoriented after reagent issues https://biobriefs.com/biotech-financing-electra-therapeutics-files BioBriefs en 2026-08-31T21:32:12Z Biotech financing—Electra Therapeutics files for IPO to fund late-stage immunology https://biobriefs.com/red-blood-cell-engineering-darpa BioBriefs en 2026-08-31T21:32:12Z Red blood cell engineering—DARPA contract for ‘smart’ cells https://biobriefs.com/clinical-operations-tufts-flags-a BioBriefs en 2026-08-31T21:32:12Z Clinical operations—Tufts flags a growing ‘execution translation gap’ https://biobriefs.com/regulatory-approval-rare-blood-cancer BioBriefs en 2026-08-31T16:31:49Z Regulatory approval – rare blood cancer https://biobriefs.com/m-a-immunology-platform-buyout BioBriefs en 2026-08-31T16:31:49Z M&A – immunology platform buyout https://biobriefs.com/clinical-science-innate-immune-cells BioBriefs en 2026-08-31T16:31:49Z Clinical science – innate immune cells for better flu vaccines https://biobriefs.com/drug-development-next-gen-gene BioBriefs en 2026-08-31T16:31:49Z Drug development – next-gen gene activation tool https://biobriefs.com/oncology-pipeline-translational-evidence-execution BioBriefs en 2026-08-31T16:31:49Z Oncology pipeline & translational evidence – execution in trials https://biobriefs.com/company-ipo-filing-immunology-drug BioBriefs en 2026-08-31T16:31:49Z Company IPO filing – immunology drug development https://biobriefs.com/molecular-tools-targeted-protein-degradation BioBriefs en 2026-08-31T16:31:49Z Molecular tools – targeted protein degradation via DUPAC ADCs https://biobriefs.com/preclinical-data-immune-oncology-translational BioBriefs en 2026-08-31T16:31:49Z Preclinical data – immune-oncology translational signals https://biobriefs.com/regulatory-and-deal-watch-anti BioBriefs en 2026-08-31T16:31:49Z Regulatory and deal watch – anti-drug uncertainties in RNAi space https://biobriefs.com/access-funding-patient-centered-rare BioBriefs en 2026-08-31T16:31:49Z Access & funding – patient-centered rare disease pathway in China https://biobriefs.com/dealmaking-lilly-buys-immunology-asset BioBriefs en 2026-08-31T14:31:17Z Dealmaking: Lilly buys immunology asset https://biobriefs.com/regulatory-approval-first-in-class BioBriefs en 2026-08-31T14:31:17Z Regulatory approval: first-in-class hepcidin mimetic for PV https://biobriefs.com/oncology-oral-ras-inhibitor-wins BioBriefs en 2026-08-31T14:31:17Z Oncology: oral RAS inhibitor wins FDA approval for metastatic PDAC https://biobriefs.com/clinical-pipeline-early-oncology-signal BioBriefs en 2026-08-31T14:31:17Z Clinical pipeline (early oncology signal): BEGONIA platform combination https://biobriefs.com/immunology-platform-innovation-recyclable-lytacs BioBriefs en 2026-08-31T14:31:17Z Immunology platform innovation: recyclable LYTACs https://biobriefs.com/targeted-degradation-aocs-and-selective BioBriefs en 2026-08-31T14:31:17Z Targeted degradation: AOCs and selective immunology therapeutics https://biobriefs.com/biopharma-policy-and-compliance-lobbying BioBriefs en 2026-08-31T14:31:17Z Biopharma policy and compliance: lobbying spend in Washington https://biobriefs.com/ai-in-clinical-operations-oversight BioBriefs en 2026-08-31T14:31:17Z AI in clinical operations: oversight and validation gaps https://biobriefs.com/biopharma-licensing-and-late-stage BioBriefs en 2026-08-31T14:31:17Z Biopharma licensing and late-stage epilepsy asset https://biobriefs.com/research-funding-nih-grant-targets BioBriefs en 2026-08-31T14:31:17Z Research funding: NIH grant targets virus-infected cell death biology https://biobriefs.com/fda-approval-new-targeted-oral BioBriefs en 2026-08-31T10:32:05Z FDA approval – new targeted oral therapy in pancreatic cancer https://biobriefs.com/fda-approval-pv-treatment-license BioBriefs en 2026-08-31T10:32:05Z FDA approval – PV treatment license/branding https://biobriefs.com/clinical-regulatory-development-silencing-vs BioBriefs en 2026-08-31T10:32:05Z Clinical/Regulatory development – silencing vs stabilizers in ATTR-CM https://biobriefs.com/oncology-discovery-immune-oncology-target BioBriefs en 2026-08-31T10:32:05Z Oncology discovery – immune-oncology target with sex-biased macrophage crosstalk https://biobriefs.com/clinical-signal-durvalumab-plus-t BioBriefs en 2026-08-31T10:32:05Z Clinical signal – durvalumab plus T-DXd for HER2-low metastatic breast cancer https://biobriefs.com/ai-for-precision-medicine-multimodal BioBriefs en 2026-08-31T10:32:05Z AI for precision medicine – multimodal foundation model using EHR plus genomics https://biobriefs.com/ai-in-diagnostics-explainable-modeling BioBriefs en 2026-08-31T10:32:05Z AI in diagnostics – explainable modeling for disability trajectories in hospitalized older adults https://biobriefs.com/radiopharmaceuticals-expert-push-for-more BioBriefs en 2026-08-31T10:32:05Z Radiopharmaceuticals – expert push for more frequent dosing https://biobriefs.com/diabetes-prevention-glp-1-class BioBriefs en 2026-08-31T10:32:05Z Diabetes prevention – GLP-1 class review in prediabetes https://biobriefs.com/company-licensing-partnership-late-stage BioBriefs en 2026-08-31T10:32:05Z Company licensing/partnership – late-stage epilepsy asset moves to SK Bio https://biobriefs.com/regulatory-approval-prostate-adult-pv BioBriefs en 2026-08-31T09:32:09Z Regulatory approval: prostate/adult PV https://biobriefs.com/fda-approval-oral-ras-on BioBriefs en 2026-08-31T09:32:09Z FDA approval: oral RAS(ON) inhibitor for metastatic pancreatic cancer https://biobriefs.com/clinical-stage-oncology-durvalumab-plus BioBriefs en 2026-08-31T09:32:09Z Clinical-stage oncology: durvalumab plus trastuzumab deruxtecan in HER2-low breast cancer https://biobriefs.com/late-stage-competition-in-cardiometabolic BioBriefs en 2026-08-31T09:32:09Z Late-stage competition in cardiometabolic RNA therapy https://biobriefs.com/post-trial-response-alnylam-defends BioBriefs en 2026-08-31T09:32:09Z Post-trial response: Alnylam defends RNAi heart disease strategy after AstraZeneca failure https://biobriefs.com/clinical-trial-strategy-rna-guided BioBriefs en 2026-08-31T09:32:09Z Clinical trial strategy: RNA-guided CAR-T accessibility via tumor vessel normalization https://biobriefs.com/hospital-care-delivery-digital-outpatient BioBriefs en 2026-08-31T09:32:09Z Hospital care delivery: digital outpatient support with an auditable hemocompatibility dashboard https://biobriefs.com/precision-oncology-immunotherapy-signals-sex BioBriefs en 2026-08-31T09:32:09Z Precision oncology immunotherapy signals: sex-biased macrophage crosstalk https://biobriefs.com/regulatory-and-pipeline-data-feed BioBriefs en 2026-08-31T09:32:09Z Regulatory and pipeline data feed: FDA Rasonque approval market reaction https://biobriefs.com/biotech-partnerships-and-licensing-sk BioBriefs en 2026-08-31T09:32:09Z Biotech partnerships and licensing: SK Bio acquires US rights to opakalim https://biobriefs.com/regulatory-approvals-and-launches BioBriefs en 2026-08-31T04:31:37Z Regulatory approvals and launches https://biobriefs.com/oncology-therapeutics-pancreatic-cancer-targeted BioBriefs en 2026-08-31T04:31:37Z Oncology therapeutics—pancreatic cancer targeted therapy https://biobriefs.com/heart-disease-attr-cm-trial BioBriefs en 2026-08-31T04:31:37Z Heart disease—ATTR-CM trial outcome pressures RNA interference strategy https://biobriefs.com/pipeline-strategy-and-licensing-epilepsy BioBriefs en 2026-08-31T04:31:37Z Pipeline strategy and licensing—epilepsy small molecule rights move https://biobriefs.com/cardiovascular-innovation-near-field-hemodynamic BioBriefs en 2026-08-31T04:31:37Z Cardiovascular innovation—near-field hemodynamic imaging and functional assessment https://biobriefs.com/immunotherapy-and-oncology-trials-her2 BioBriefs en 2026-08-31T04:31:37Z Immunotherapy and oncology trials—HER2-low breast cancer platform https://biobriefs.com/hepatitis-b-host-directed-antiviral BioBriefs en 2026-08-31T04:31:37Z Hepatitis B—host-directed antiviral mechanism https://biobriefs.com/ai-in-clinical-decision-support BioBriefs en 2026-08-31T04:31:37Z AI in clinical decision support—risk prediction from routine imaging https://biobriefs.com/companion-diagnostics-and-oncology-imaging BioBriefs en 2026-08-31T04:31:37Z Companion diagnostics and oncology imaging—new PET/CT tracer for recurrence detection https://biobriefs.com/ai-oversight-and-hospital-adoption BioBriefs en 2026-08-31T04:31:37Z AI oversight and hospital adoption—testing gaps for third-party tools https://biobriefs.com/regulatory-approvals BioBriefs en 2026-08-30T21:32:14Z Regulatory approvals https://biobriefs.com/oncology-pipeline-and-trial-readouts BioBriefs en 2026-08-30T21:32:14Z Oncology pipeline and trial readouts https://biobriefs.com/oncology-approvals-and-market-reaction BioBriefs en 2026-08-30T21:32:14Z Oncology approvals and market reaction https://biobriefs.com/cardiometabolic-drug-development-and-clinical BioBriefs en 2026-08-30T21:32:14Z Cardiometabolic drug development and clinical economics https://biobriefs.com/cardiology-imaging-and-device-based BioBriefs en 2026-08-30T21:32:14Z Cardiology imaging and device-based trials https://biobriefs.com/ai-for-medical-imaging-and BioBriefs en 2026-08-30T21:32:14Z AI for medical imaging and diagnostics https://biobriefs.com/immunotherapy-biology-and-response-modifiers BioBriefs en 2026-08-30T21:32:14Z Immunotherapy biology and response modifiers https://biobriefs.com/rna-targeted-and-hepatology-therapeutics BioBriefs en 2026-08-30T21:32:14Z RNA-targeted and hepatology therapeutics funding https://biobriefs.com/alzheimers-and-neurotherapeutics-platform BioBriefs en 2026-08-30T21:32:14Z Alzheimer’s and neurotherapeutics platform https://biobriefs.com/healthcare-technology-regulation-and-operational BioBriefs en 2026-08-30T21:32:14Z Healthcare technology regulation and operational readiness https://biobriefs.com/fda-clears-hepcidin-mimetic-for BioBriefs en 2026-08-30T16:32:05Z FDA clears hepcidin mimetic for polycythemia vera https://biobriefs.com/fda-grants-fast-track-to BioBriefs en 2026-08-30T16:32:05Z FDA grants fast-track to EpCAM-directed Probody ADC in metastatic colorectal cancer https://biobriefs.com/late-stage-epilepsy-deal-expands BioBriefs en 2026-08-30T16:32:05Z Late-stage epilepsy deal expands U.S. commercialization options https://biobriefs.com/astrazenecas-oral-relaxin-agonist-posts BioBriefs en 2026-08-30T16:32:05Z AstraZeneca’s oral relaxin agonist posts mixed signal in mid-stage heart failure trial https://biobriefs.com/arrowhead-reports-redemplo-safety-edge BioBriefs en 2026-08-30T16:32:05Z Arrowhead reports Redemplo safety edge over Ionis in triglyceride race https://biobriefs.com/ipsc-derived-cd4-helper-t BioBriefs en 2026-08-30T16:32:05Z iPSC-derived CD4 helper T-cell generation supports next-gen off-the-shelf CAR T https://biobriefs.com/first-clinical-car-t-remission BioBriefs en 2026-08-30T16:32:05Z First clinical CAR T remission signal in refractory rheumatoid arthritis https://biobriefs.com/cancer-imaging-fapi-04-pet BioBriefs en 2026-08-30T16:32:05Z Cancer imaging: FAPI-04 PET/CT outperforms FDG for post-surgical breast cancer recurrence detection https://biobriefs.com/biotech-ip-10x-says-jury BioBriefs en 2026-08-30T16:32:05Z Biotech IP: 10x says jury found willful infringement by Parse Biosciences on Evercode WTA patents https://biobriefs.com/public-health-surveillance-meets-mrna BioBriefs en 2026-08-30T16:32:05Z Public-health surveillance meets mRNA-era accountability: hepatitis A vaccination meta-analysis https://biobriefs.com/fda-approvals-in-cardiometabolic-disease BioBriefs en 2026-08-30T14:31:45Z FDA approvals in cardiometabolic disease https://biobriefs.com/fda-clears-oral-relaxin-agonist BioBriefs en 2026-08-30T14:31:45Z FDA clears oral relaxin agonist in heart failure https://biobriefs.com/fda-expands-immune-oncology-options BioBriefs en 2026-08-30T14:31:45Z FDA expands immune-oncology options via oncology designations https://biobriefs.com/us-patent-litigation-targets-single BioBriefs en 2026-08-30T14:31:45Z US patent litigation targets single-cell sequencing IP https://biobriefs.com/company-shutdowns-and-restructuring-in BioBriefs en 2026-08-30T14:31:45Z Company shutdowns and restructuring in biopharma https://biobriefs.com/takeda-earns-rare-blood-disorder BioBriefs en 2026-08-30T14:31:45Z Takeda earns rare blood disorder approval https://biobriefs.com/precision-oncology-adc-development-accelerates BioBriefs en 2026-08-30T14:31:45Z Precision oncology: ADC development accelerates https://biobriefs.com/immunotherapy-innovation-car-t-reaches BioBriefs en 2026-08-30T14:31:45Z Immunotherapy innovation: CAR T reaches first-in-human autoimmune remission signals https://biobriefs.com/immunology-virology-hbv-replication-linked BioBriefs en 2026-08-30T14:31:45Z Immunology & virology: HBV replication linked to innate immune switches https://biobriefs.com/genomics-ai-for-drug-discovery BioBriefs en 2026-08-30T14:31:45Z Genomics & AI for drug discovery: new prime-editing strategy https://biobriefs.com/regulatory-approvals-diabetes-cardiovascular-benefit BioBriefs en 2026-08-30T10:32:26Z Regulatory approvals – diabetes cardiovascular benefit https://biobriefs.com/regulatory-approvals-hematology-rare-disease BioBriefs en 2026-08-30T10:32:26Z Regulatory approvals – hematology rare disease https://biobriefs.com/regulatory-approvals-rare-inflammatory-disease BioBriefs en 2026-08-30T10:32:26Z Regulatory approvals – rare inflammatory disease https://biobriefs.com/clinical-development-ulcerative-colitis-animal BioBriefs en 2026-08-30T10:32:26Z Clinical development – ulcerative colitis animal data https://biobriefs.com/biotech-financing-and-strategy-large BioBriefs en 2026-08-30T10:32:26Z Biotech financing and strategy – large growth equity https://biobriefs.com/biopharma-partnerships-roche-taps-next BioBriefs en 2026-08-30T10:32:26Z Biopharma partnerships – Roche taps next-gen ADC payload platform https://biobriefs.com/regulatory-pathway-fda-clearance-for BioBriefs en 2026-08-30T10:32:26Z Regulatory pathway – FDA clearance for new gene editing IND https://biobriefs.com/regulatory-ce-mark-for-next BioBriefs en 2026-08-30T10:32:26Z Regulatory – CE mark for next-gen stroke prevention device https://biobriefs.com/m-a-and-capital-allocation BioBriefs en 2026-08-30T10:32:26Z M&A and capital allocation – biopharma deal volume signal https://biobriefs.com/bankruptcy-and-restructuring-agitation-treatment BioBriefs en 2026-08-30T10:32:26Z Bankruptcy and restructuring – agitation-treatment company https://biobriefs.com/regulatory-approvals-cardiometabolic BioBriefs en 2026-08-30T09:32:12Z Regulatory approvals – cardiometabolic https://biobriefs.com/regulatory-approvals-rare-inflammatory-disease BioBriefs en 2026-08-30T09:32:12Z Regulatory approvals – rare inflammatory disease https://biobriefs.com/regulatory-setbacks-personalized-cancer-vaccines BioBriefs en 2026-08-30T09:32:12Z Regulatory setbacks – personalized cancer vaccines https://biobriefs.com/company-financing-and-funding-expansion BioBriefs en 2026-08-30T09:32:12Z Company financing and funding – expansion of oncology R&D https://biobriefs.com/drug-approvals-rare-blood-disorders BioBriefs en 2026-08-30T09:32:12Z Drug approvals – rare blood disorders https://biobriefs.com/dealmaking-oncology-adc-collaboration BioBriefs en 2026-08-30T09:32:12Z Dealmaking – oncology ADC collaboration https://biobriefs.com/m-a-and-litigation-single BioBriefs en 2026-08-30T09:32:12Z M&A and litigation – single-cell genomics patents https://biobriefs.com/clinical-updates-autoimmune-and-immunotherapy BioBriefs en 2026-08-30T09:32:12Z Clinical updates – autoimmune and immunotherapy https://biobriefs.com/biotech-investing-and-funding-womens BioBriefs en 2026-08-30T09:32:12Z Biotech investing and funding – women’s health biopharma https://biobriefs.com/clinical-development-hepatology-and-precision BioBriefs en 2026-08-30T09:32:12Z Clinical development – hepatology and precision risk signals https://biobriefs.com/fda-approvals-and-trial-readouts BioBriefs en 2026-08-30T04:31:42Z FDA approvals and trial readouts in cardiometabolic disease https://biobriefs.com/fda-clearance-and-rapid-development BioBriefs en 2026-08-30T04:31:42Z FDA clearance and rapid development for rare inflammatory disorders https://biobriefs.com/immunotherapy-pipeline-expansion-via-adc BioBriefs en 2026-08-30T04:31:42Z Immunotherapy pipeline expansion via ADC deals https://biobriefs.com/regulatory-fast-track-for-an BioBriefs en 2026-08-30T04:31:42Z Regulatory fast-track for an EpCAM-directed conditional ADC in colorectal cancer https://biobriefs.com/fundraising-to-advance-aso-therapy BioBriefs en 2026-08-30T04:31:42Z Fundraising to advance ASO therapy for chronic hepatitis B https://biobriefs.com/mechanistic-antiviral-immunity-hbv-replication BioBriefs en 2026-08-30T04:31:42Z Mechanistic antiviral immunity: HBV replication blocked via IFI35 and TRIM22 https://biobriefs.com/biotech-legal-ip-dispute-in BioBriefs en 2026-08-30T04:31:42Z Biotech legal/IP dispute in single-cell genomics https://biobriefs.com/first-in-field-ipsc-derived BioBriefs en 2026-08-30T04:31:42Z First-in-field iPSC-derived helper T cells for off-the-shelf CAR T https://biobriefs.com/clinical-trial-signal-in-advanced BioBriefs en 2026-08-30T04:31:42Z Clinical trial signal in advanced inflammatory cardiovascular edge cases https://biobriefs.com/biopharma-funding-and-market-activity BioBriefs en 2026-08-30T04:31:42Z Biopharma funding and market activity snapshot https://biobriefs.com/regulatory-approvals-type-2-diabetes BioBriefs en 2026-08-29T21:32:05Z Regulatory approvals: type 2 diabetes heart-risk reduction https://biobriefs.com/fda-approval-for-rare-inflammatory BioBriefs en 2026-08-29T21:32:05Z FDA approval for rare inflammatory disease targeting JAK/TYK https://biobriefs.com/phase-2-setback-biontech-genentech BioBriefs en 2026-08-29T21:32:05Z Phase 2 setback: BioNTech-Genentech personalized mRNA vaccine halted https://biobriefs.com/funding-moderna-upsized-raise-tied BioBriefs en 2026-08-29T21:32:05Z Funding: Moderna upsized raise tied to oncology push https://biobriefs.com/partnerships-genentech-bets-1b-on BioBriefs en 2026-08-29T21:32:05Z Partnerships: Genentech bets $1B+ on next-gen ADC payload platform https://biobriefs.com/m-a-and-bankruptcy-teva BioBriefs en 2026-08-29T21:32:05Z M&A and bankruptcy: Teva to buy BioXcel assets after Chapter 11 https://biobriefs.com/clinical-and-translational-immunotherapy-helper BioBriefs en 2026-08-29T21:32:05Z Clinical and translational immunotherapy: helper CD4 CAR-T via iPSC Notch programming https://biobriefs.com/oncology-pipeline-cytomx-gets-fast BioBriefs en 2026-08-29T21:32:05Z Oncology pipeline: CytomX gets Fast Track for EpCAM-directed masked ADC in mCRC https://biobriefs.com/virology-therapeutics-fda-ind-clearance BioBriefs en 2026-08-29T21:32:05Z Virology therapeutics: FDA IND clearance for Adicet’s ADI-212 in mCRPC https://biobriefs.com/regulatory-shift-in-oncology-crispr BioBriefs en 2026-08-29T21:32:05Z Regulatory shift in oncology: CRISPR Therapeutics plans highest dose follow-on after mixed durability https://biobriefs.com/fda-approvals-and-label-expansions BioBriefs en 2026-08-29T16:31:54Z FDA approvals and label expansions https://biobriefs.com/rare-disease-approvals-for-immunology BioBriefs en 2026-08-29T16:31:54Z Rare-disease approvals for immunology and inflammation drugs https://biobriefs.com/phase-3-readouts-in-immunology BioBriefs en 2026-08-29T16:31:54Z Phase 3 readouts in immunology and inflammation https://biobriefs.com/chronic-hepatitis-b-and-next BioBriefs en 2026-08-29T16:31:54Z Chronic hepatitis B and next-generation HBV RNA therapies https://biobriefs.com/oncology-pipeline-and-regulatory-flags BioBriefs en 2026-08-29T16:31:54Z Oncology pipeline and regulatory flags in solid tumors https://biobriefs.com/adc-deals-and-big-pharma BioBriefs en 2026-08-29T16:31:54Z ADC deals and big pharma partnering on next-gen payload platforms https://biobriefs.com/biopharma-financing-and-dealmaking-momentum BioBriefs en 2026-08-29T16:31:54Z Biopharma financing and dealmaking momentum https://biobriefs.com/gene-editing-and-rna-therapeutics BioBriefs en 2026-08-29T16:31:54Z Gene editing and RNA therapeutics R&D momentum https://biobriefs.com/clinical-trial-and-development-actions BioBriefs en 2026-08-29T16:31:54Z Clinical trial and development actions in cardiovascular care devices https://biobriefs.com/immunotherapy-approach-updates-and-mechanistic BioBriefs en 2026-08-29T16:31:54Z Immunotherapy approach updates and mechanistic cancer immunology https://biobriefs.com/regulatory-approvals-immunology-and-oncology BioBriefs en 2026-08-29T14:31:47Z Regulatory approvals – immunology and oncology https://biobriefs.com/regulatory-approvals-cardiometabolic-disease BioBriefs en 2026-08-29T14:31:47Z Regulatory approvals – cardiometabolic disease https://biobriefs.com/oncology-immune-evasion-and-next BioBriefs en 2026-08-29T14:31:47Z Oncology – immune evasion and next-gen CAR-T/ADC approaches https://biobriefs.com/precision-oncology-tools-imaging-and BioBriefs en 2026-08-29T14:31:47Z Precision oncology tools – imaging and diagnostics for target selection https://biobriefs.com/biotech-funding-platform-bets-and BioBriefs en 2026-08-29T14:31:47Z Biotech funding – platform bets and large strategic collaborations https://biobriefs.com/mid-sized-biotech-economics-and BioBriefs en 2026-08-29T14:31:47Z Mid-sized biotech economics and policy pressures https://biobriefs.com/cardiovascular-device-safety-regulator-actions BioBriefs en 2026-08-29T14:31:47Z Cardiovascular device safety – regulator actions https://biobriefs.com/clinical-development-trial-readouts-and BioBriefs en 2026-08-29T14:31:47Z Clinical development – trial readouts and FDA interaction updates https://biobriefs.com/drug-resistance-and-proteomics-driven BioBriefs en 2026-08-29T14:31:47Z Drug resistance and proteomics-driven discovery https://biobriefs.com/cybersecurity-and-clinical-operations-healthcare BioBriefs en 2026-08-29T14:31:47Z Cybersecurity and clinical operations – healthcare and platform risk https://biobriefs.com/fda-approvals-diabetes-cardiovascular-risk BioBriefs en 2026-08-29T10:32:15Z FDA approvals—diabetes cardiovascular risk https://biobriefs.com/regulatory-rare-blood-disorder-therapy BioBriefs en 2026-08-29T10:32:15Z Regulatory—rare blood disorder therapy https://biobriefs.com/fda-approvals-autoimmune-inflammation-drug BioBriefs en 2026-08-29T10:32:15Z FDA approvals—autoimmune inflammation drug https://biobriefs.com/fda-fast-track-adc-for BioBriefs en 2026-08-29T10:32:15Z FDA fast-track—ADC for metastatic colorectal cancer https://biobriefs.com/phase-3-readout-immune-disease BioBriefs en 2026-08-29T10:32:15Z Phase 3 readout—immune disease expansion path for tezepelumab https://biobriefs.com/deal-roche-bets-on-next BioBriefs en 2026-08-29T10:32:15Z Deal—Roche bets on next-gen ADC payload platform https://biobriefs.com/anticipated-biotech-money-large-financing BioBriefs en 2026-08-29T10:32:15Z Anticipated biotech money—large financing and market activity https://biobriefs.com/m-a-healthcare-services-deal BioBriefs en 2026-08-29T10:32:15Z M&A—healthcare services deal for oncology commercialization and trial ops https://biobriefs.com/patent-litigation-single-cell-multi BioBriefs en 2026-08-29T10:32:15Z Patent litigation—single-cell multi-epitope IP dispute https://biobriefs.com/clinical-innovation-failure-biontech-scraps BioBriefs en 2026-08-29T10:32:15Z Clinical innovation failure—BioNTech scraps personalized mRNA cancer vaccine phase 2 https://biobriefs.com/regulatory-approvals-metabolic-and-cardiovascular BioBriefs en 2026-08-29T09:31:23Z Regulatory approvals – metabolic and cardiovascular benefit https://biobriefs.com/regulatory-approvals-rare-autoimmune-inflammatory BioBriefs en 2026-08-29T09:31:23Z Regulatory approvals – rare autoimmune inflammatory disease https://biobriefs.com/cardiovascular-attr-cm-silencers-hit BioBriefs en 2026-08-29T09:31:23Z Cardiovascular – ATTR-CM “silencers” hit headwinds after phase 3 failure debate https://biobriefs.com/oncology-adc-pipeline-advances-with BioBriefs en 2026-08-29T09:31:23Z Oncology – ADC pipeline advances with fast-track interest and novel payload strategy https://biobriefs.com/oncology-major-partnership-for-next BioBriefs en 2026-08-29T09:31:23Z Oncology – major partnership for next-generation ADC payloads https://biobriefs.com/rare-disease-fda-approval-for BioBriefs en 2026-08-29T09:31:23Z Rare disease – FDA approval for protein engineering in polycythemia vera https://biobriefs.com/regulatory-and-reimbursement-companion-diagnostics BioBriefs en 2026-08-29T09:31:23Z Regulatory and reimbursement – companion diagnostics expand access to targeted oncology https://biobriefs.com/clinical-development-aprea-expands-phase BioBriefs en 2026-08-29T09:31:23Z Clinical development – Aprea expands Phase 1 WEE1 inhibitor program after early activity signals https://biobriefs.com/cell-therapy-car-t-meets BioBriefs en 2026-08-29T09:31:23Z Cell therapy – CAR-T meets manufacturing disruption as BMS ends CDMO collaboration https://biobriefs.com/diagnostics-reimbursement-and-platform-expansion BioBriefs en 2026-08-29T09:31:23Z Diagnostics reimbursement and platform expansion – MRD testing gains CMS coverage for immunotherapy monitoring https://biobriefs.com/regulatory-approvals-glp-1-gip BioBriefs en 2026-08-29T04:31:53Z Regulatory approvals - GLP-1/GIP cardiovascular outcomes https://biobriefs.com/regulatory-approvals-rare-inflammatory-disease BioBriefs en 2026-08-29T04:31:53Z Regulatory approvals - rare inflammatory disease drug https://biobriefs.com/oncology-regulation-and-pipeline-adc BioBriefs en 2026-08-29T04:31:53Z Oncology regulation and pipeline - ADC fast-track https://biobriefs.com/biopharma-funding-and-capital-markets BioBriefs en 2026-08-29T04:31:53Z Biopharma funding and capital markets - Moderna raises for oncology https://biobriefs.com/biopharma-funding-gates-foundation-invests BioBriefs en 2026-08-29T04:31:53Z Biopharma funding - Gates Foundation invests in maternal health protein target discovery https://biobriefs.com/partnerships-and-licensing-dualitybio-and BioBriefs en 2026-08-29T04:31:53Z Partnerships and licensing - DualityBio and Genentech in ADC pact https://biobriefs.com/molecular-diagnostics-reimbursement-mrd-assay BioBriefs en 2026-08-29T04:31:53Z Molecular diagnostics reimbursement - MRD assay gains Medicare coverage https://biobriefs.com/biotech-ip-and-legal-parse BioBriefs en 2026-08-29T04:31:53Z Biotech IP and legal - Parse and Scale/10x single-cell patents https://biobriefs.com/corporate-finance-and-restructuring-bankruptcy BioBriefs en 2026-08-29T04:31:53Z Corporate finance and restructuring - bankruptcy filing https://biobriefs.com/clinical-immunotherapy-car-t-in BioBriefs en 2026-08-29T04:31:53Z Clinical immunotherapy - CAR T in rheumatoid arthritis remission signal https://biobriefs.com/fda-approvals-rare-inflammatory-disease BioBriefs en 2026-08-28T21:31:51Z FDA approvals – rare inflammatory disease https://biobriefs.com/oncology-adc-development-accelerates-at BioBriefs en 2026-08-28T21:31:51Z Oncology – ADC development accelerates at FDA https://biobriefs.com/immuno-oncology-checkpoint-blockade-without BioBriefs en 2026-08-28T21:31:51Z Immuno-oncology – checkpoint blockade without key dendritic cells https://biobriefs.com/oncology-functional-genomics-maps-asciminib BioBriefs en 2026-08-28T21:31:51Z Oncology – functional genomics maps asciminib resistance https://biobriefs.com/platform-and-pipeline-rna-dna BioBriefs en 2026-08-28T21:31:51Z Platform and pipeline – RNA/DNA sequencing dispute in single-cell tech https://biobriefs.com/m-a-and-deals-roche BioBriefs en 2026-08-28T21:31:51Z M&A and deals – Roche taps DualityBio for next-gen ADC payloads https://biobriefs.com/biopharma-financing-moderna-raises-for BioBriefs en 2026-08-28T21:31:51Z Biopharma financing – Moderna raises for cancer push https://biobriefs.com/regulatory-and-clinical-astrazeneca-amgen BioBriefs en 2026-08-28T21:31:51Z Regulatory and clinical – AstraZeneca/Amgen Tezspire nears new indication in EoE https://biobriefs.com/clinical-development-and-trial-execution BioBriefs en 2026-08-28T21:31:51Z Clinical development and trial execution – expanding Phase 1 WEE1 inhibitor program https://biobriefs.com/biotech-startup-and-diagnostics-mrd BioBriefs en 2026-08-28T21:31:51Z Biotech startup and diagnostics – MRD test gains CMS coverage https://biobriefs.com/regulatory-wins-rare-disease-approvals BioBriefs en 2026-08-28T16:31:52Z Regulatory wins: rare disease approvals and updates https://biobriefs.com/fda-approval-reshapes-cardiovascular-risk BioBriefs en 2026-08-28T16:31:52Z FDA approval reshapes cardiovascular risk and epilepsy portfolios https://biobriefs.com/astrazeneca-heart-gene-silencer-setback BioBriefs en 2026-08-28T16:31:52Z AstraZeneca heart gene-silencer setback at ESC https://biobriefs.com/oncology-breakthrough-fda-approval-in BioBriefs en 2026-08-28T16:31:52Z Oncology: breakthrough FDA approval in pancreatic cancer and label expansion via diagnostics https://biobriefs.com/dealmaking-genentech-bets-on-dualitybios BioBriefs en 2026-08-28T16:31:52Z Dealmaking: Genentech bets on DualityBio’s ADC payload platform https://biobriefs.com/early-stage-portfolio-gene-editing BioBriefs en 2026-08-28T16:31:52Z Early-stage portfolio: gene editing push at ESC and durable expansion plans https://biobriefs.com/biomarkers-and-real-world-diagnostics BioBriefs en 2026-08-28T16:31:52Z Biomarkers and real-world diagnostics: MRD coverage and workflows https://biobriefs.com/manufacturing-and-precision-services-consolidation BioBriefs en 2026-08-28T16:31:52Z Manufacturing and precision services consolidation https://biobriefs.com/hospital-and-ecosystem-new-deals BioBriefs en 2026-08-28T16:31:52Z Hospital and ecosystem: new deals to operationalize pharmacogenomics and infection control https://biobriefs.com/immunotherapy-risk-signal-fatal-tumor BioBriefs en 2026-08-28T16:31:52Z Immunotherapy risk signal: Fatal tumor lysis syndrome after starter dose https://biobriefs.com/pancreatic-cancer-breakthrough-approval BioBriefs en 2026-08-28T14:33:03Z Pancreatic cancer breakthrough approval https://biobriefs.com/antibody-drug-conjugate-licensing-stakes BioBriefs en 2026-08-28T14:33:03Z Antibody-drug conjugate licensing stakes rise https://biobriefs.com/regulatory-roivant-dermatomyositis-drug-clears BioBriefs en 2026-08-28T14:33:03Z Regulatory: Roivant dermatomyositis drug clears FDA https://biobriefs.com/astrazeneca-ionis-heart-drug-fails BioBriefs en 2026-08-28T14:33:03Z AstraZeneca–Ionis heart drug fails after surprise setback https://biobriefs.com/cell-therapy-manufacturing-dispute-erupts BioBriefs en 2026-08-28T14:33:03Z Cell therapy manufacturing dispute erupts at Cellares https://biobriefs.com/epilepsy-deals-biohavens-kv7-asset BioBriefs en 2026-08-28T14:33:03Z Epilepsy deals: Biohaven’s Kv7 asset gets commercial partner https://biobriefs.com/diverse-regulatory-and-diagnostic-progress BioBriefs en 2026-08-28T14:33:03Z Diverse regulatory and diagnostic progress in companion testing https://biobriefs.com/biomanufacturing-services-deal-mckesson-to BioBriefs en 2026-08-28T14:33:03Z Biomanufacturing services deal: McKesson to acquire Precision Medicine Group https://biobriefs.com/fda-rare-disease-priovants-lisraya BioBriefs en 2026-08-28T14:33:03Z FDA / rare disease: Priovant’s Lisraya approval plus Roivant’s pipeline relevance https://biobriefs.com/clinical-trial-setback-severe-malnutrition BioBriefs en 2026-08-28T14:33:03Z Clinical trial setback: Severe malnutrition therapies miss endpoints https://biobriefs.com/cardiovascular-drug-development-cytokinetics-nhcm BioBriefs en 2026-08-28T10:32:15Z Cardiovascular drug development: Cytokinetics’ nHCM pivotal data and regulatory pathway https://biobriefs.com/regulatory-fda-clears-roivants-oral BioBriefs en 2026-08-28T10:32:15Z Regulatory: FDA clears Roivant’s oral brepocitinib for dermatomyositis https://biobriefs.com/oncology-regulation-revolution-medicines-rasonque BioBriefs en 2026-08-28T10:32:15Z Oncology regulation: Revolution Medicines’ Rasonque approved for pancreatic cancer https://biobriefs.com/immuno-oncology-safety-signal-tarlatamab BioBriefs en 2026-08-28T10:32:15Z Immuno-oncology safety signal: Tarlatamab case report flags tumor lysis risk https://biobriefs.com/dealmaking-genentech-expands-into-adc BioBriefs en 2026-08-28T10:32:15Z Dealmaking: Genentech expands into ADC-resistant cancers with DualityBio https://biobriefs.com/diagnostics-expansion-roche-wins-expanded BioBriefs en 2026-08-28T10:32:15Z Diagnostics expansion: Roche wins expanded FDA clearance for tests tied to Jazz’s Ziihera https://biobriefs.com/regulatory-and-trial-updates-astrazeneca BioBriefs en 2026-08-28T10:32:15Z Regulatory and trial updates: AstraZeneca/Amgen Tezspire expands toward EoE label https://biobriefs.com/funding-gates-foundation-commits-to BioBriefs en 2026-08-28T10:32:15Z Funding: Gates Foundation commits to ProFound Therapeutics for preeclampsia/eclampsia target discovery https://biobriefs.com/clinical-trial-setbacks-spyres-anti BioBriefs en 2026-08-28T10:32:15Z Clinical trial setbacks: Spyre’s anti-TL1A rheumatoid arthritis program is deprioritized https://biobriefs.com/cdmo-cell-therapy-services-bristol BioBriefs en 2026-08-28T10:32:15Z CDMO/Cell therapy services: Bristol Myers ends Cellares collaboration over Breyanzi manufacturing requirements https://biobriefs.com/fda-approvals-pancreatic-cancer-and BioBriefs en 2026-08-28T09:31:47Z FDA approvals – pancreatic cancer and immunology indication expansion https://biobriefs.com/adc-partnerships-and-next-gen BioBriefs en 2026-08-28T09:31:47Z ADC partnerships and next-gen pipeline deals https://biobriefs.com/late-stage-setbacks-astrazeneca-ionis BioBriefs en 2026-08-28T09:31:47Z Late-stage setbacks – AstraZeneca/ Ionis heart disease gene silencer stumble https://biobriefs.com/cell-and-gene-therapy-business BioBriefs en 2026-08-28T09:31:47Z Cell and gene therapy business moves – outsourcing and MRD partnerships https://biobriefs.com/gene-therapy-platform-and-diagnostic BioBriefs en 2026-08-28T09:31:47Z Gene therapy platform and diagnostic expansion – Roche expanded clearance and FDA orphan docket https://biobriefs.com/new-approvals-in-rare-autoimmune BioBriefs en 2026-08-28T09:31:47Z New approvals in rare autoimmune disease – Roivant’s Lisraya for dermatomyositis https://biobriefs.com/clinical-pipeline-execution-aprea-accelerates BioBriefs en 2026-08-28T09:31:47Z Clinical pipeline execution – Aprea accelerates Phase 1 WEE1 inhibitor development https://biobriefs.com/startup-funding-and-diagnostic-innovation BioBriefs en 2026-08-28T09:31:47Z Startup funding and diagnostic innovation – STI testing grant and MRD plus retrieval workflow https://biobriefs.com/ai-biotech-translational-infrastructure-kite BioBriefs en 2026-08-28T09:31:47Z AI+biotech translational infrastructure – KITE vector analytics and NSF genome-geometry center https://biobriefs.com/m-a-and-market-infrastructure BioBriefs en 2026-08-28T09:31:47Z M&A and market infrastructure – McKesson to acquire Precision Medicine Group https://biobriefs.com/pancreatic-cancer-first-in-class BioBriefs en 2026-08-28T04:32:09Z Pancreatic cancer—first-in-class RAS inhibition gets FDA approval https://biobriefs.com/dermatomyositis-roivants-brepocitinib-becomes-the BioBriefs en 2026-08-28T04:32:09Z Dermatomyositis—Roivant’s brepocitinib becomes the first oral option https://biobriefs.com/immunotherapy-safety-first-dose-tumor BioBriefs en 2026-08-28T04:32:09Z Immunotherapy safety—first-dose tumor lysis syndrome reported with tarlatamab https://biobriefs.com/regulatory-and-diagnostics-roche-expands BioBriefs en 2026-08-28T04:32:09Z Regulatory and diagnostics—Roche expands FDA-cleared HER2 companion testing for Ziihera access https://biobriefs.com/deals-mckesson-to-buy-precision BioBriefs en 2026-08-28T04:32:09Z Deals—McKesson to buy Precision Medicine Group to strengthen oncology services https://biobriefs.com/oncology-diagnostics-commercialization-neogenomics-radar BioBriefs en 2026-08-28T04:32:09Z Oncology diagnostics commercialization—neoGenomics’ RaDar ST gains expanded MolDX coverage https://biobriefs.com/oncology-companion-biomarker-testing-in BioBriefs en 2026-08-28T04:32:09Z Oncology companion biomarker testing in ADC trials—Natera and Angiex adopt Signatera MRD https://biobriefs.com/neuro-micots-trkb-agonist-hits BioBriefs en 2026-08-28T04:32:09Z Neuro—Micot’s TrkB agonist hits Phase 2 endpoints in acute ischemic stroke https://biobriefs.com/maternal-health-r-d-gates BioBriefs en 2026-08-28T04:32:09Z Maternal health R&D—Gates Foundation funds ProFound to discover preeclampsia biomarkers and targets https://biobriefs.com/epilepsy-sk-biopharmaceuticals-buys-biohavens BioBriefs en 2026-08-28T04:32:09Z Epilepsy—SK Biopharmaceuticals buys Biohaven’s opakalim (BHV-7000) in $795M deal https://biobriefs.com/regulatory-approvals-in-rare-autoimmune BioBriefs en 2026-08-27T21:32:17Z Regulatory approvals in rare autoimmune disease https://biobriefs.com/fda-approval-for-ras-driven BioBriefs en 2026-08-27T21:32:17Z FDA approval for RAS-driven pancreatic cancer https://biobriefs.com/phase-3-progress-for-eoe BioBriefs en 2026-08-27T21:32:17Z Phase 3 progress for EoE immune therapy to challenge Dupixent https://biobriefs.com/diagnostic-coverage-expansion-for-immunotherapy BioBriefs en 2026-08-27T21:32:17Z Diagnostic coverage expansion for immunotherapy monitoring via MRD https://biobriefs.com/oncology-diagnostics-roche-expands-fda BioBriefs en 2026-08-27T21:32:17Z Oncology diagnostics: Roche expands FDA authorization tied to Jazz’s Ziihera https://biobriefs.com/ai-enabled-clinical-trial-support BioBriefs en 2026-08-27T21:32:17Z AI-enabled clinical trial support and site governance https://biobriefs.com/gates-foundation-funding-accelerates-biomarker BioBriefs en 2026-08-27T21:32:17Z Gates Foundation funding accelerates biomarker target discovery for preeclampsia https://biobriefs.com/biopharma-dealmaking-mckesson-to-acquire BioBriefs en 2026-08-27T21:32:17Z Biopharma dealmaking: McKesson to acquire Precision Medicine Group for $2.25B https://biobriefs.com/clinical-stage-innovation-platform-ngs BioBriefs en 2026-08-27T21:32:17Z Clinical-stage innovation platform: NGS MRD test adopted into ADC trial monitoring https://biobriefs.com/med-tech-safety-and-fda BioBriefs en 2026-08-27T21:32:17Z Med-tech safety and FDA action: Abiomed removes Impella device over reported deaths and injuries https://biobriefs.com/fda-approval-for-ras-inhibitor BioBriefs en 2026-08-27T16:32:07Z FDA approval for RAS-inhibitor in pancreatic cancer https://biobriefs.com/cybersecurity-disruptions-hit-medical-technology BioBriefs en 2026-08-27T16:32:07Z Cybersecurity disruptions hit medical technology operations https://biobriefs.com/precision-oncology-services-deal-boosts BioBriefs en 2026-08-27T16:32:07Z Precision oncology services deal boosts McKesson’s clinical trial execution https://biobriefs.com/biomarker-reimbursement-expands-for-immunotherapy BioBriefs en 2026-08-27T16:32:07Z Biomarker reimbursement expands for immunotherapy monitoring MRD test https://biobriefs.com/liquid-biopsy-platform-meets-adc BioBriefs en 2026-08-27T16:32:07Z Liquid-biopsy platform meets ADC trial monitoring https://biobriefs.com/fda-trialblazer-style-ind-efficiency BioBriefs en 2026-08-27T16:32:07Z FDA Trialblazer-style IND efficiency prompts BIO pushback https://biobriefs.com/company-deal-sk-biopharmaceuticals-buys BioBriefs en 2026-08-27T16:32:07Z Company deal: SK Biopharmaceuticals buys Biohaven’s epilepsy asset https://biobriefs.com/aging-and-immunology-persistent-tumor BioBriefs en 2026-08-27T16:32:07Z Aging and immunology: persistent tumor/immune signals may link bone marrow and heart dysfunction https://biobriefs.com/scientific-platform-ai-designed-antibodies BioBriefs en 2026-08-27T16:32:07Z Scientific platform: AI-designed antibodies land among top performers in blinded benchmark https://biobriefs.com/company-funding-faro-raises-series BioBriefs en 2026-08-27T16:32:07Z Company funding: Faro raises Series B to speed AI-enabled clinical trials https://biobriefs.com/fda-approvals-and-regulatory-action BioBriefs en 2026-08-27T14:32:17Z FDA approvals and regulatory action in oncology https://biobriefs.com/phase-trial-and-label-updates BioBriefs en 2026-08-27T14:32:17Z Phase trial and label updates for cardio-metabolic drugs https://biobriefs.com/venture-and-funding-for-digital BioBriefs en 2026-08-27T14:32:17Z Venture and funding for digital health and clinical infrastructure https://biobriefs.com/partnerships-to-expand-mrd-testing BioBriefs en 2026-08-27T14:32:17Z Partnerships to expand MRD testing into new modalities and indications https://biobriefs.com/reimbursement-wins-for-molecular-diagnostics BioBriefs en 2026-08-27T14:32:17Z Reimbursement wins for molecular diagnostics tied to immunotherapy https://biobriefs.com/biomanufacturing-and-workforce-capacity-investments BioBriefs en 2026-08-27T14:32:17Z Biomanufacturing and workforce capacity investments https://biobriefs.com/clinical-development-setbacks-and-trial BioBriefs en 2026-08-27T14:32:17Z Clinical development setbacks and trial terminations https://biobriefs.com/cell-therapy-manufacturing-deal-breaks BioBriefs en 2026-08-27T14:32:17Z Cell therapy manufacturing deal breaks and dispute risk https://biobriefs.com/dealmaking-to-build-commercial-and BioBriefs en 2026-08-27T14:32:17Z Dealmaking to build commercial and late-stage epilepsy franchises https://biobriefs.com/public-markets-compliance-and-reverse BioBriefs en 2026-08-27T14:32:17Z Public markets compliance and reverse split execution https://biobriefs.com/fda-approval-ras-inhibitor-in BioBriefs en 2026-08-27T10:31:53Z FDA Approval: RAS inhibitor in pancreatic cancer https://biobriefs.com/dealmaking-bms-ends-cellares-cell BioBriefs en 2026-08-27T10:31:53Z Dealmaking: BMS ends Cellares cell-therapy manufacturing collaboration https://biobriefs.com/commercial-partnership-sk-biopharmaceuticals-buys BioBriefs en 2026-08-27T10:31:53Z Commercial partnership: SK Biopharmaceuticals buys Biohaven epilepsy drug https://biobriefs.com/biotech-m-a-services-mckesson BioBriefs en 2026-08-27T10:31:53Z Biotech M&A/Services: McKesson to acquire Precision Medicine Group https://biobriefs.com/obesity-drug-economics-zepbound-associated BioBriefs en 2026-08-27T10:31:53Z Obesity drug economics: Zepbound associated with lower healthcare costs https://biobriefs.com/clinical-ai-diagnostics-guardant-multi BioBriefs en 2026-08-27T10:31:53Z Clinical AI/Diagnostics: Guardant multi-cancer detection data build-out https://biobriefs.com/clinical-trial-readout-strategy-survodutide BioBriefs en 2026-08-27T10:31:53Z Clinical trial readout/strategy: Survodutide phase 3 in obesity without diabetes https://biobriefs.com/regulatory-surveillance-and-governance-ftc BioBriefs en 2026-08-27T10:31:53Z Regulatory surveillance and governance: FTC warns on licensing pending patents https://biobriefs.com/biopharma-manufacturing-analytics-kite-introduces BioBriefs en 2026-08-27T10:31:53Z Biopharma manufacturing analytics: Kite introduces single-particle lentiviral vector characterization https://biobriefs.com/company-funding-onos-health-raises BioBriefs en 2026-08-27T10:31:53Z Company funding: Onos Health raises $17M Series A for AI behavioral health https://biobriefs.com/fda-approval-pan-ras-inhibition BioBriefs en 2026-08-27T09:32:15Z FDA approval—pan-RAS inhibition enters pancreatic cancer frontline https://biobriefs.com/commercial-partnership-sk-biopharmaceuticals-takes BioBriefs en 2026-08-27T09:32:15Z Commercial partnership—SK Biopharmaceuticals takes up Biohaven’s epilepsy asset https://biobriefs.com/phase-3-obesity-survodutide-posts BioBriefs en 2026-08-27T09:32:15Z Phase 3 obesity—survodutide posts strong 76-week weight loss versus placebo https://biobriefs.com/aseptic-biomanufacturing-sterilization-emerges-as BioBriefs en 2026-08-27T09:32:15Z Aseptic biomanufacturing—sterilization emerges as next scaling constraint https://biobriefs.com/clinical-trial-shift-early-mobilization BioBriefs en 2026-08-27T09:32:15Z Clinical trial shift—early mobilization fails to improve 12-month outcomes in ICU https://biobriefs.com/t-cell-engager-breakthrough-teclistamab BioBriefs en 2026-08-27T09:32:15Z T-cell engager breakthrough—teclistamab shows major wins in refractory multiple myeloma https://biobriefs.com/diagnostic-innovation-roche-and-eli BioBriefs en 2026-08-27T09:32:15Z Diagnostic innovation—Roche and Eli Lilly win FDA clearance for blood Alzheimer’s test https://biobriefs.com/ai-bioprocessing-noaa-kite-develops BioBriefs en 2026-08-27T09:32:15Z AI bioprocessing—NOAA? Kite develops viral vector single-particle characterization https://biobriefs.com/neuroinflammation-biology-cgas-driven-premature BioBriefs en 2026-08-27T09:32:15Z Neuroinflammation biology—cGAS-driven premature aging links LINE1 derepression https://biobriefs.com/ecosystem-oncology-signal-thymus-radiation BioBriefs en 2026-08-27T09:32:15Z Ecosystem oncology signal—thymus radiation exposure worsens NSCLC outcomes https://biobriefs.com/pancreatic-cancer-regulatory-milestone BioBriefs en 2026-08-27T04:31:54Z Pancreatic cancer regulatory milestone https://biobriefs.com/obesity-drugs-show-real-world BioBriefs en 2026-08-27T04:31:54Z Obesity drugs show real-world cost effects https://biobriefs.com/obesity-pipeline-trial-readout-for BioBriefs en 2026-08-27T04:31:54Z Obesity pipeline trial readout for survodutide https://biobriefs.com/cell-therapy-manufacturing-dispute-and BioBriefs en 2026-08-27T04:31:54Z Cell therapy—manufacturing dispute and contract termination https://biobriefs.com/cybersecurity-medtech-systems-disrupted BioBriefs en 2026-08-27T04:31:54Z Cybersecurity—medtech systems disrupted https://biobriefs.com/cell-therapy-innovation-car-macrophage BioBriefs en 2026-08-27T04:31:54Z Cell therapy innovation—CAR macrophage approach https://biobriefs.com/rare-disease-trial-funding-and BioBriefs en 2026-08-27T04:31:54Z Rare disease trial funding and expansion https://biobriefs.com/immunology-biotech-licensing-deal-in BioBriefs en 2026-08-27T04:31:54Z Immunology biotech licensing deal in China-US https://biobriefs.com/alzheimers-diagnostics-expand-with-new BioBriefs en 2026-08-27T04:31:54Z Alzheimer’s diagnostics expand with new blood test clearance https://biobriefs.com/immunotherapy-trial-failure-rheumatoid-arthritis BioBriefs en 2026-08-27T04:31:54Z Immunotherapy trial failure—Rheumatoid arthritis TL1A program ends https://biobriefs.com/fda-approvals BioBriefs en 2026-08-26T21:31:56Z FDA approvals https://biobriefs.com/biotech-deals-and-partnerships BioBriefs en 2026-08-26T21:31:56Z Biotech deals and partnerships https://biobriefs.com/corporate-risk-and-compliance BioBriefs en 2026-08-26T21:31:56Z Corporate risk and compliance https://biobriefs.com/rare-disease-and-pediatric-trials BioBriefs en 2026-08-26T21:31:56Z Rare disease and pediatric trials https://biobriefs.com/epilepsy-monetization-deals BioBriefs en 2026-08-26T21:31:56Z Epilepsy monetization deals https://biobriefs.com/new-biotech-strategy-and-financing BioBriefs en 2026-08-26T21:31:56Z New biotech strategy and financing https://biobriefs.com/cell-therapy-manufacturing-and-partner BioBriefs en 2026-08-26T21:31:56Z Cell therapy manufacturing and partner disputes https://biobriefs.com/antibody-and-trial-pipeline-updates BioBriefs en 2026-08-26T21:31:56Z Antibody and trial pipeline updates https://biobriefs.com/gene-therapy-and-platform-development BioBriefs en 2026-08-26T21:31:56Z Gene therapy and platform development https://biobriefs.com/biopharma-regulatory-and-legal-environment BioBriefs en 2026-08-26T21:31:56Z Biopharma regulatory and legal environment https://biobriefs.com/regulatory-approvals-pancreatic-cancer-first BioBriefs en 2026-08-26T16:31:49Z Regulatory approvals: pancreatic cancer first- and second-line targeted therapy https://biobriefs.com/cardiovascular-alzheimers-diagnostic-expansion-and BioBriefs en 2026-08-26T16:31:49Z Cardiovascular: Alzheimer’s, diagnostic expansion and blood biomarker adoption https://biobriefs.com/biotech-deals-big-licensing-and BioBriefs en 2026-08-26T16:31:49Z Biotech deals: big licensing and platform expansion in cell and protein tools https://biobriefs.com/clinical-trial-readouts-and-pipeline BioBriefs en 2026-08-26T16:31:49Z Clinical trial readouts and pipeline pivots: rheumatoid arthritis TL1A antibody setback and course changes https://biobriefs.com/clinical-development-risk-regeneron-ends BioBriefs en 2026-08-26T16:31:49Z Clinical development risk: Regeneron ends CD3 antibody eye therapy trial after safety event https://biobriefs.com/biomanufacturing-scale-up-sterilization-constraints BioBriefs en 2026-08-26T16:31:49Z Biomanufacturing scale-up: sterilization constraints and alternatives gaining attention https://biobriefs.com/viral-vector-characterization-flow-virometry BioBriefs en 2026-08-26T16:31:49Z Viral vector characterization: flow virometry tool targets lentiviral analytics for in vivo CAR-T https://biobriefs.com/workforce-and-capacity-building-canada BioBriefs en 2026-08-26T16:31:49Z Workforce and capacity building: Canada funds life sciences biomanufacturing training https://biobriefs.com/genomics-diagnostics-and-implementation-citywide BioBriefs en 2026-08-26T16:31:49Z Genomics diagnostics and implementation: citywide rapid WGS in Dubai for critically ill children https://biobriefs.com/biotech-restructuring-and-funding-signals BioBriefs en 2026-08-26T16:31:49Z Biotech restructuring and funding signals: Aurora Therapeutics pauses bespoke CRISPR program https://biobriefs.com/fda-approvals-and-label-expansions BioBriefs en 2026-08-26T14:31:40Z FDA approvals and label expansions for next-wave oncology and diagnostics https://biobriefs.com/company-deals-large-licensing-and BioBriefs en 2026-08-26T14:31:40Z Company deals: large licensing and M&A that move clinical-stage assets https://biobriefs.com/clinical-setbacks-and-regulatory-holds BioBriefs en 2026-08-26T14:31:40Z Clinical setbacks and regulatory holds that reshape development plans https://biobriefs.com/immunotherapy-effectiveness-and-trial-readouts BioBriefs en 2026-08-26T14:31:40Z Immunotherapy effectiveness and trial readouts in blood cancers https://biobriefs.com/viral-vector-and-synthetic-dna BioBriefs en 2026-08-26T14:31:40Z Viral vector and synthetic DNA manufacturing partnerships https://biobriefs.com/clinical-evidence-for-prostate-cancer BioBriefs en 2026-08-26T14:31:40Z Clinical evidence for prostate cancer radiotherapy strategy https://biobriefs.com/immune-mechanism-research-cd8-t BioBriefs en 2026-08-26T14:31:40Z Immune mechanism research: CD8+ T cells and T-cell mediated protection in Zika vaccines https://biobriefs.com/data-infrastructure-and-real-world BioBriefs en 2026-08-26T14:31:40Z Data infrastructure and real-world evidence pipelines for oncology testing https://biobriefs.com/rna-and-whole-genome-clinical BioBriefs en 2026-08-26T14:31:40Z RNA and whole-genome clinical implementation: scaling rWGS in pediatrics https://biobriefs.com/biomanufacturing-and-platform-enablement-synthetic BioBriefs en 2026-08-26T14:31:40Z Biomanufacturing and platform enablement: synthetic biology tools for CHO production https://biobriefs.com/fda-clears-alzheimers-blood-testing BioBriefs en 2026-08-26T10:31:14Z FDA clears Alzheimer’s blood testing – market ramps up https://biobriefs.com/cancer-drug-approval-expands-jazzs BioBriefs en 2026-08-26T10:31:14Z Cancer drug approval expands Jazz’s Ziihera to frontline gastric cancer https://biobriefs.com/j-js-imaavy-earns-first BioBriefs en 2026-08-26T10:31:14Z J&J’s Imaavy earns first FDA label expansion for warm autoimmune hemolytic anemia https://biobriefs.com/jv-deal-genentech-and-hanmi BioBriefs en 2026-08-26T10:31:14Z JV/Deal: Genentech and Hanmi sign $2.3B obesity pact to license HM-17321 https://biobriefs.com/cell-therapy-risk-chimeric-halts BioBriefs en 2026-08-26T10:31:14Z Cell therapy risk: Chimeric halts cadherin-17 CAR T after dose-limiting toxicity https://biobriefs.com/gene-therapy-setback-regenxbios-hunter BioBriefs en 2026-08-26T10:31:14Z Gene therapy setback: Regenxbio’s Hunter syndrome program hits second clinical hold https://biobriefs.com/biotech-and-immunology-progenitor-t BioBriefs en 2026-08-26T10:31:14Z Biotech and immunology: Progenitor T cells sustain chronic type 2 lung inflammation https://biobriefs.com/biopharma-intelligence-massachusetts-biopharma-rebounds BioBriefs en 2026-08-26T10:31:14Z Biopharma intelligence: Massachusetts biopharma rebounds on fundraising, but NIH awards slide https://biobriefs.com/fda-platform-regulation-hde-approval BioBriefs en 2026-08-26T10:31:14Z FDA platform regulation: HDE approval for Oncosil brachytherapy in distal cholangiocarcinoma https://biobriefs.com/trial-disruption-regenxbio-fda-pause BioBriefs en 2026-08-26T10:31:14Z Trial disruption: Regenxbio FDA pause adds to gene-therapy safety scrutiny https://biobriefs.com/platform-accuracy-and-diagnostics-guardant BioBriefs en 2026-08-26T10:31:14Z Platform accuracy and diagnostics: Guardant gathers real-world data for multi-cancer blood test https://biobriefs.com/fda-approvals-and-label-expansions BioBriefs en 2026-08-26T09:32:12Z FDA approvals and label expansions in oncology and diagnostics https://biobriefs.com/clinical-trial-readouts-and-safety BioBriefs en 2026-08-26T09:32:12Z Clinical trial readouts and safety-related holds https://biobriefs.com/big-deals-and-licensing-agreements BioBriefs en 2026-08-26T09:32:12Z Big deals and licensing agreements reshaping drug portfolios https://biobriefs.com/cancer-immunotherapy-advances-including-t BioBriefs en 2026-08-26T09:32:12Z Cancer immunotherapy advances, including T-cell engagers and targeted immune modulation https://biobriefs.com/genomic-and-spatial-biology-tooling BioBriefs en 2026-08-26T09:32:12Z Genomic and spatial biology tooling for biomedical research https://biobriefs.com/alzheimers-diagnostics-and-biomarker-platform BioBriefs en 2026-08-26T09:32:12Z Alzheimer’s diagnostics and biomarker platform competition accelerates https://biobriefs.com/gene-and-cell-therapy-development BioBriefs en 2026-08-26T09:32:12Z Gene and cell therapy development faces repeated regulatory scrutiny https://biobriefs.com/biomanufacturing-innovation-and-process-standardization BioBriefs en 2026-08-26T09:32:12Z Biomanufacturing innovation and process standardization https://biobriefs.com/real-world-evidence-and-diagnostics BioBriefs en 2026-08-26T09:32:12Z Real-world evidence and diagnostics expansion in oncology screening https://biobriefs.com/preclinical-and-translational-immunology-tied BioBriefs en 2026-08-26T09:32:12Z Preclinical and translational immunology tied to innate sensors https://biobriefs.com/alzheimers-diagnostics-expand-with-new BioBriefs en 2026-08-26T04:32:03Z Alzheimer’s diagnostics expand with new Roche-Lilly FDA clearance and competitive landscape https://biobriefs.com/fda-approvals-broaden-jazzs-ziihera BioBriefs en 2026-08-26T04:32:03Z FDA approvals broaden Jazz’s Ziihera into frontline gastric cancer and expand market access https://biobriefs.com/j-js-imaavy-becomes-first BioBriefs en 2026-08-26T04:32:03Z J&J’s Imaavy becomes first approved therapy for warm autoimmune hemolytic anemia in label expansion moves https://biobriefs.com/roche-eli-lilly-and-broader BioBriefs en 2026-08-26T04:32:03Z Roche, Eli Lilly and broader blood-based biomarker momentum intensifies Alzheimer’s diagnostics competition https://biobriefs.com/multiple-myeloma-teclistamab-t-cell BioBriefs en 2026-08-26T04:32:03Z Multiple myeloma: teclistamab T-cell engager delivers major progression and survival benefit in MajesTEC-9 https://biobriefs.com/cardiovascular-devices-correction-to-early BioBriefs en 2026-08-26T04:32:03Z Cardiovascular devices: correction to early-discharge safety data in ACURATE Neo TAVI study https://biobriefs.com/gene-therapy-setbacks-regenxbios-hunter BioBriefs en 2026-08-26T04:32:03Z Gene therapy setbacks: Regenxbio’s Hunter syndrome trial again paused under FDA clinical hold https://biobriefs.com/oncology-devices-fda-grants-humanitarian BioBriefs en 2026-08-26T04:32:03Z Oncology devices: FDA grants humanitarian device exemption for Oncosil brachytherapy in distal cholangiocarcinoma https://biobriefs.com/deals-and-collaborations-roche-and BioBriefs en 2026-08-26T04:32:03Z Deals and collaborations: Roche and Genentech license Hanmi obesity therapy with muscle-preserving target https://biobriefs.com/digital-health-and-compliance-fda BioBriefs en 2026-08-26T04:32:03Z Digital health and compliance: FDA pilot and AI governance pressures for early trials and clinical site selection https://biobriefs.com/alzheimers-blood-based-diagnostics-gain BioBriefs en 2026-08-25T21:32:12Z Alzheimer’s blood-based diagnostics gain FDA validation https://biobriefs.com/johnson-johnson-expands-imaavy-to BioBriefs en 2026-08-25T21:32:12Z Johnson & Johnson expands Imaavy to warm autoimmune hemolytic anemia https://biobriefs.com/fda-grants-humanitarian-device-exemption BioBriefs en 2026-08-25T21:32:12Z FDA grants humanitarian device exemption for bile duct cancer https://biobriefs.com/jazz-and-actio-strike-1 BioBriefs en 2026-08-25T21:32:12Z Jazz and Actio strike $1.32B epilepsy acquisition https://biobriefs.com/genentech-and-hanmi-expand-obesity BioBriefs en 2026-08-25T21:32:12Z Genentech and Hanmi expand obesity efforts with $190M upfront https://biobriefs.com/chimeric-therapeutics-shifts-after-cadherin BioBriefs en 2026-08-25T21:32:12Z Chimeric Therapeutics shifts after cadherin-17 CAR T toxicity https://biobriefs.com/capricors-deramiocel-faces-fda-schedule BioBriefs en 2026-08-25T21:32:12Z Capricor’s deramiocel faces FDA schedule changes and review extensions https://biobriefs.com/regenxbio-gene-therapy-hit-with BioBriefs en 2026-08-25T21:32:12Z Regenxbio gene therapy hit with another clinical hold for Hunter syndrome https://biobriefs.com/guardant-builds-real-world-dataset BioBriefs en 2026-08-25T21:32:12Z Guardant builds real-world dataset for Shield multi-cancer early detection https://biobriefs.com/massachusetts-biopharma-rebound-faces-early BioBriefs en 2026-08-25T21:32:12Z Massachusetts biopharma rebound faces early funding headwinds https://biobriefs.com/regulatory-and-label-expansion BioBriefs en 2026-08-25T16:31:46Z Regulatory and label expansion https://biobriefs.com/fda-decision-timeline-and-safety BioBriefs en 2026-08-25T16:31:46Z FDA decision timeline and safety actions in gene therapy https://biobriefs.com/obesity-partnerships-and-licensing-deals BioBriefs en 2026-08-25T16:31:46Z Obesity partnerships and licensing deals https://biobriefs.com/late-stage-cancer-immunotherapy-mrna BioBriefs en 2026-08-25T16:31:46Z Late-stage cancer immunotherapy: mRNA neoantigen vaccine https://biobriefs.com/clinical-trial-readout-t-cell BioBriefs en 2026-08-25T16:31:46Z Clinical trial readout: T-cell engager in multiple myeloma https://biobriefs.com/cancer-diagnostics-and-biomarkers-fda BioBriefs en 2026-08-25T16:31:46Z Cancer diagnostics and biomarkers: FDA clearance of blood test https://biobriefs.com/diagnostics-supply-chain-integrity-antibody BioBriefs en 2026-08-25T16:31:46Z Diagnostics supply chain integrity: antibody validation image manipulation https://biobriefs.com/prequalification-and-global-diagnostics-access BioBriefs en 2026-08-25T16:31:46Z Prequalification and global diagnostics access: WHO TB test pathway https://biobriefs.com/ai-and-contract-device-regulation BioBriefs en 2026-08-25T16:31:46Z AI and contract/device regulation oversight https://biobriefs.com/funding-for-rna-immune-inflammation BioBriefs en 2026-08-25T16:31:46Z Funding for RNA/immune inflammation platform https://biobriefs.com/obesity-deals-and-licensing BioBriefs en 2026-08-25T14:32:06Z Obesity deals and licensing https://biobriefs.com/alzheimers-diagnostics-and-biomarker-testing BioBriefs en 2026-08-25T14:32:06Z Alzheimer’s diagnostics and biomarker testing https://biobriefs.com/us-gene-therapy-safety-holds BioBriefs en 2026-08-25T14:32:06Z US gene therapy safety holds and clinical program disruption https://biobriefs.com/car-t-toxicity-and-mechanism BioBriefs en 2026-08-25T14:32:06Z CAR-T toxicity and mechanism concerns https://biobriefs.com/cancer-immunotherapy-and-checkpoint-regulation BioBriefs en 2026-08-25T14:32:06Z Cancer immunotherapy and checkpoint regulation in lymphoma https://biobriefs.com/hepatocellular-carcinoma-treatment-combinations BioBriefs en 2026-08-25T14:32:06Z Hepatocellular carcinoma treatment combinations https://biobriefs.com/nfl-testing-harmonization-across-platforms BioBriefs en 2026-08-25T14:32:06Z NfL testing harmonization across platforms https://biobriefs.com/biotech-startups-and-data-infrastructure BioBriefs en 2026-08-25T14:32:06Z Biotech startups and data infrastructure funding https://biobriefs.com/fda-regulatory-operations-and-oversight BioBriefs en 2026-08-25T14:32:06Z FDA regulatory operations and oversight for gene and device therapies https://biobriefs.com/biotech-venture-and-regional-ecosystem BioBriefs en 2026-08-25T14:32:06Z Biotech venture and regional ecosystem signals in Massachusetts https://biobriefs.com/oncology-immunotherapy BioBriefs en 2026-08-25T10:32:47Z Oncology / Immunotherapy https://biobriefs.com/regulation-fda-actions BioBriefs en 2026-08-25T10:32:47Z Regulation / FDA actions https://biobriefs.com/gene-therapy-safety-and-holds BioBriefs en 2026-08-25T10:32:47Z Gene therapy / Safety and holds https://biobriefs.com/dealmaking-m-a BioBriefs en 2026-08-25T10:32:47Z Dealmaking / M&A https://biobriefs.com/diagnostics-biomarkers BioBriefs en 2026-08-25T10:32:47Z Diagnostics / Biomarkers https://biobriefs.com/immuno-oncology-cellular-biology BioBriefs en 2026-08-25T10:32:47Z Immuno-oncology / Cellular biology https://biobriefs.com/cell-therapy-car-t-mechanisms BioBriefs en 2026-08-25T10:32:47Z Cell therapy / CAR-T mechanisms https://biobriefs.com/biotech-funding-market-structure BioBriefs en 2026-08-25T10:32:47Z Biotech funding / Market structure https://biobriefs.com/rare-disease-gene-therapy-business BioBriefs en 2026-08-25T10:32:47Z Rare disease / Gene therapy business risk https://biobriefs.com/diagnostics-global-regulatory-pathway BioBriefs en 2026-08-25T10:32:47Z Diagnostics / Global regulatory pathway https://biobriefs.com/us-regulatory-pathway-for-biotech BioBriefs en 2026-08-25T09:32:11Z US regulatory pathway for biotech drug reviews https://biobriefs.com/gene-therapy-setback-in-hunter BioBriefs en 2026-08-25T09:32:11Z Gene therapy setback in Hunter syndrome https://biobriefs.com/duchenne-muscular-dystrophy-review-delays BioBriefs en 2026-08-25T09:32:11Z Duchenne muscular dystrophy review delays at FDA https://biobriefs.com/cell-therapy-funding-and-manufacturing BioBriefs en 2026-08-25T09:32:11Z Cell therapy funding and manufacturing restructuring https://biobriefs.com/obesity-m-a-and-licensing BioBriefs en 2026-08-25T09:32:11Z Obesity M&A and licensing: Roche expands Hanmi rights https://biobriefs.com/clinical-signal-in-liver-cancer BioBriefs en 2026-08-25T09:32:11Z Clinical signal in liver cancer using immunotherapy and local therapy https://biobriefs.com/car-t-pipeline-dominance-in BioBriefs en 2026-08-25T09:32:11Z CAR-T pipeline dominance in multiple myeloma https://biobriefs.com/fda-clears-new-alzheimers-blood BioBriefs en 2026-08-25T09:32:11Z FDA clears new Alzheimer’s blood biomarker https://biobriefs.com/regulatory-and-legal-duplex-sequencing BioBriefs en 2026-08-25T09:32:11Z Regulatory and legal: duplex sequencing patent damages https://biobriefs.com/who-prequalification-pathway-for-tb BioBriefs en 2026-08-25T09:32:11Z WHO prequalification pathway for TB diagnostics using IGRA and targeted NGS https://biobriefs.com/alzheimers-blood-biomarker-clearance BioBriefs en 2026-08-25T04:32:05Z Alzheimer’s blood biomarker clearance https://biobriefs.com/gene-therapy-safety-holds-for BioBriefs en 2026-08-25T04:32:05Z Gene therapy safety holds for Hunter syndrome https://biobriefs.com/cdk4-6-benefit-depends-on BioBriefs en 2026-08-25T04:32:05Z CDK4/6 benefit depends on menopause status https://biobriefs.com/moderna-and-merck-melanoma-vaccine BioBriefs en 2026-08-25T04:32:05Z Moderna and Merck melanoma vaccine delivers positive Phase 3 readout https://biobriefs.com/roche-licensing-a-hanmi-obesity BioBriefs en 2026-08-25T04:32:05Z Roche licensing a Hanmi obesity drug that aims to preserve lean mass https://biobriefs.com/r-d-and-platform-mrna BioBriefs en 2026-08-25T04:32:05Z R&D and platform: mRNA delivery for in-body CAR T generation https://biobriefs.com/cell-therapy-fda-extends-review BioBriefs en 2026-08-25T04:32:05Z Cell therapy: FDA extends review for Capricor deramiocel https://biobriefs.com/diagnostics-access-who-prequalification-pathway BioBriefs en 2026-08-25T04:32:05Z Diagnostics access: WHO prequalification pathway for TB targeted NGS and IGRA https://biobriefs.com/immuno-oncology-pipeline-shift-car BioBriefs en 2026-08-25T04:32:05Z Immuno-oncology pipeline shift: CAR-T dominates multiple myeloma trials https://biobriefs.com/clinical-trial-tech-multiplex-pcr BioBriefs en 2026-08-25T04:32:05Z Clinical trial tech: multiplex PCR-guided antibiotics in hospital-acquired pneumonia https://biobriefs.com/gene-therapy-safety-fda-pauses BioBriefs en 2026-08-24T21:32:51Z Gene therapy safety—FDA pauses Regenxbio Hunter syndrome program https://biobriefs.com/obesity-deals-roche-locks-in BioBriefs en 2026-08-24T21:32:51Z Obesity deals—Roche locks in Hanmi muscle-sparing asset https://biobriefs.com/alzheimers-diagnostics-fda-clears-roche BioBriefs en 2026-08-24T21:32:51Z Alzheimer’s diagnostics—FDA clears Roche/Lilly blood-based biomarker test https://biobriefs.com/device-approval-fda-grants-humanitarian BioBriefs en 2026-08-24T21:32:51Z Device approval—FDA grants humanitarian approval to Oncosil brachytherapy https://biobriefs.com/cell-therapy-regulatory-clock-fda BioBriefs en 2026-08-24T21:32:51Z Cell therapy regulatory clock—FDA extends review for Capricor deramiocel https://biobriefs.com/gene-sequencing-ip-twinstrand-victory BioBriefs en 2026-08-24T21:32:51Z Gene sequencing IP—TwinStrand victory forces payouts from Guardant https://biobriefs.com/diagnostic-qa-access-who-prequalification BioBriefs en 2026-08-24T21:32:51Z Diagnostic QA & access—WHO prequalification opens for TB IGRA and targeted NGS tests https://biobriefs.com/corporate-clinical-stage-expansion-ambros BioBriefs en 2026-08-24T21:32:51Z Corporate/clinical-stage expansion—Ambros merger with Werewolf advances CRPS asset https://biobriefs.com/biopharma-pipeline-ops-rznomics-joins BioBriefs en 2026-08-24T21:32:51Z Biopharma pipeline ops—Rznomics joins Lilly Gateway Labs for RNA therapeutics buildout https://biobriefs.com/genai-regulation-fdas-cdrh-solicits BioBriefs en 2026-08-24T21:32:51Z GenAI regulation—FDA’s CDRH solicits input on regulating generative AI medical devices https://biobriefs.com/regenxbios-hunter-gene-therapy-faces BioBriefs en 2026-08-24T16:32:18Z Regenxbio’s Hunter gene therapy faces renewed FDA action https://biobriefs.com/capricor-deramiocel-reviews-extended-as BioBriefs en 2026-08-24T16:32:18Z Capricor deramiocel reviews extended as agency requests more data https://biobriefs.com/ambros-completes-werewolf-merger-to BioBriefs en 2026-08-24T16:32:18Z Ambros completes Werewolf merger to fund pivotal CRPS-1 path https://biobriefs.com/who-opens-prequalification-pathway-for BioBriefs en 2026-08-24T16:32:18Z WHO opens prequalification pathway for targeted NGS and TB IGRAs https://biobriefs.com/twinstrand-wins-major-duplex-sequencing BioBriefs en 2026-08-24T16:32:18Z TwinStrand wins major duplex sequencing patent damages vs Guardant https://biobriefs.com/moderna-and-mercks-intismeran-autogene BioBriefs en 2026-08-24T16:32:18Z Moderna and Merck’s intismeran autogene posts positive Phase III melanoma readout https://biobriefs.com/roche-expands-obesity-portfolio-with BioBriefs en 2026-08-24T16:32:18Z Roche expands obesity portfolio with Hanmi urocortin-2 analog deal https://biobriefs.com/orum-gets-fda-clearance-for BioBriefs en 2026-08-24T16:32:18Z Orum gets FDA clearance for IND on CD123-targeted GSPT1 degrader-antibody conjugate https://biobriefs.com/cell-free-diagnostic-pathway-expands BioBriefs en 2026-08-24T16:32:18Z Cell-free diagnostic pathway expands as WHO moves toward TB diagnostics prequalification https://biobriefs.com/tech-and-automation-investment-signals BioBriefs en 2026-08-24T16:32:18Z Tech and automation investment signals momentum in sequencing and labs https://biobriefs.com/gene-therapy-safety-and-fda BioBriefs en 2026-08-24T14:32:08Z Gene therapy safety and FDA holds https://biobriefs.com/melanoma-cancer-vaccine-phase-3 BioBriefs en 2026-08-24T14:32:08Z Melanoma cancer vaccine Phase 3 readout https://biobriefs.com/roche-licensing-and-obesity-drug BioBriefs en 2026-08-24T14:32:08Z Roche licensing and obesity drug pipeline expansion https://biobriefs.com/obstetrics-surgery-recovery-pathways-for BioBriefs en 2026-08-24T14:32:08Z Obstetrics surgery recovery pathways for newborns and infants https://biobriefs.com/rare-inflammatory-disease-funding-and BioBriefs en 2026-08-24T14:32:08Z Rare inflammatory disease funding and next-phase clinical strategy https://biobriefs.com/digital-health-and-value-based BioBriefs en 2026-08-24T14:32:08Z Digital health and value-based care consolidation https://biobriefs.com/ai-readthrough-of-personalized-cancer BioBriefs en 2026-08-24T14:32:08Z AI readthrough of personalized cancer vaccine market implications https://biobriefs.com/universal-flu-vaccine-platform-preclinical BioBriefs en 2026-08-24T14:32:08Z Universal flu vaccine platform preclinical evidence https://biobriefs.com/hcv-free-no-genomic-trigger BioBriefs en 2026-08-24T14:32:08Z HCV-free? No—genomic trigger discovery for gene activation https://biobriefs.com/on-the-ground-policy-and BioBriefs en 2026-08-24T14:32:08Z On-the-ground policy and implementation risk for immunization scheduling https://biobriefs.com/oncology-mrna-cancer-vaccines BioBriefs en 2026-08-24T10:32:19Z Oncology / mRNA cancer vaccines https://biobriefs.com/m-a-financing-in-obesity BioBriefs en 2026-08-24T10:32:19Z M&A / financing in obesity drug development https://biobriefs.com/rare-inflammatory-disease-turnaround-funding BioBriefs en 2026-08-24T10:32:19Z Rare inflammatory disease turnaround funding https://biobriefs.com/digital-health-value-based-care BioBriefs en 2026-08-24T10:32:19Z Digital health / value-based care consolidation https://biobriefs.com/clinical-ai-drug-discovery-and BioBriefs en 2026-08-24T10:32:19Z Clinical AI / drug discovery and pipeline operations (opportunity framing) https://biobriefs.com/ai-in-biotech-workflow-strategy BioBriefs en 2026-08-24T10:32:19Z AI in biotech workflow strategy (paid media / answer engines) https://biobriefs.com/computational-biology-genetic-on-switch BioBriefs en 2026-08-24T10:32:19Z Computational biology / genetic “on switch” decoding https://biobriefs.com/translational-oncology-ai-ml-in BioBriefs en 2026-08-24T10:32:19Z Translational oncology AI/ML in neurodegeneration (method update) https://biobriefs.com/virology-platform-vaccination-concept BioBriefs en 2026-08-24T10:32:19Z Virology / platform vaccination concept https://biobriefs.com/clinical-operations-rare-pediatric-trial BioBriefs en 2026-08-24T10:32:19Z Clinical operations / rare pediatric trial planning https://biobriefs.com/personalized-cancer-vaccine-in-phase BioBriefs en 2026-08-24T09:32:00Z Personalized cancer vaccine in Phase 3 https://biobriefs.com/r-d-restart-for-rare BioBriefs en 2026-08-24T09:32:00Z R&D restart for rare inflammatory myositis https://biobriefs.com/value-based-rural-care-expansion BioBriefs en 2026-08-24T09:32:00Z Value-based rural care expansion via acquisition and new financing https://biobriefs.com/clinical-evidence-strategy-for-ai BioBriefs en 2026-08-24T09:32:00Z Clinical evidence strategy for AI-driven pharma marketing https://biobriefs.com/ai-scribe-deployment-outcomes-in BioBriefs en 2026-08-24T09:32:00Z AI scribe deployment outcomes in clinician retention https://biobriefs.com/consensus-planning-to-enable-trials BioBriefs en 2026-08-24T09:32:00Z Consensus planning to enable trials in rare childhood CNS tumors https://biobriefs.com/cancer-biology-lysosomal-disruption-from BioBriefs en 2026-08-24T09:32:00Z Cancer biology: lysosomal disruption from blocking glucosylceramide synthesis https://biobriefs.com/molecular-discovery-dna-initiator-sequence BioBriefs en 2026-08-24T09:32:00Z Molecular discovery: DNA initiator sequence decoding with AI https://biobriefs.com/biomarkers-for-early-cardiometabolic-risk BioBriefs en 2026-08-24T09:32:00Z Biomarkers for early cardiometabolic risk in teens https://biobriefs.com/diagnostic-potential-oral-microbiome-signals BioBriefs en 2026-08-24T09:32:00Z Diagnostic potential: oral microbiome signals in gastric cancer https://biobriefs.com/merck-and-modernas-personalized-mrna BioBriefs en 2026-08-24T04:32:37Z Merck and Moderna’s personalized mRNA cancer vaccine posts positive Phase 3 readout https://biobriefs.com/abcuro-raises-66m-to-restart BioBriefs en 2026-08-24T04:32:37Z Abcuro raises $66M to restart development in inclusion body myositis https://biobriefs.com/cityblock-to-acquire-homeward-health BioBriefs en 2026-08-24T04:32:37Z Cityblock to acquire Homeward Health and expand rural value-based care https://biobriefs.com/real-world-psilocybin-program-in BioBriefs en 2026-08-24T04:32:37Z Real-world psilocybin program in Oregon shows generally favorable safety and participant experiences https://biobriefs.com/diet-microbes-and-gastric-cancer BioBriefs en 2026-08-24T04:32:37Z Diet, microbes, and gastric cancer diagnostics – mouth-to-gut bacterial migration signal https://biobriefs.com/targeting-lysosomal-lipid-production-exposes BioBriefs en 2026-08-24T04:32:37Z Targeting lysosomal lipid production exposes a cancer vulnerability https://biobriefs.com/consensus-roadmap-aims-to-make BioBriefs en 2026-08-24T04:32:37Z Consensus roadmap aims to make rare childhood CNS tumor trials more workable https://biobriefs.com/kaist-ai-driven-insights-into BioBriefs en 2026-08-24T04:32:37Z KAIST AI-driven insights into lithium plating risk could accelerate battery design https://biobriefs.com/new-ai-model-decodes-a BioBriefs en 2026-08-24T04:32:37Z New AI model decodes a DNA initiator sequence present in most human genes https://biobriefs.com/cochrane-gap-map-flags-major BioBriefs en 2026-08-24T04:32:37Z Cochrane gap map flags major evidence shortfalls in dengue prevention https://biobriefs.com/personalized-mrna-cancer-vaccine-delivers BioBriefs en 2026-08-23T21:32:16Z Personalized mRNA cancer vaccine delivers positive Phase 3 readout https://biobriefs.com/abcuro-raises-fresh-capital-to BioBriefs en 2026-08-23T21:32:16Z Abcuro raises fresh capital to restart rare inflammatory disorder program https://biobriefs.com/cityblock-expands-value-based-care BioBriefs en 2026-08-23T21:32:16Z Cityblock expands value-based care footprint via Homeward Health deal and Series E https://biobriefs.com/fda-clears-blood-test-to BioBriefs en 2026-08-23T21:32:16Z FDA clears blood test to evaluate Alzheimer’s amyloid pathology https://biobriefs.com/psychedelics-regulation-real-world-psilocybin BioBriefs en 2026-08-23T21:32:16Z Psychedelics regulation: real-world psilocybin program shows safety signal https://biobriefs.com/rare-disease-trial-revival-consensus BioBriefs en 2026-08-23T21:32:16Z Rare disease trial revival: consensus roadmap for rare childhood CNS tumors https://biobriefs.com/healthcare-workforce-cleveland-clinic-ai BioBriefs en 2026-08-23T21:32:16Z Healthcare workforce: Cleveland Clinic AI scribe rollout tied to clinician retention https://biobriefs.com/oncology-translational-science-blood-test BioBriefs en 2026-08-23T21:32:16Z Oncology translational science: blood test identifies vulnerability in triple-negative spread https://biobriefs.com/mechanistic-cell-biology-for-cancer BioBriefs en 2026-08-23T21:32:16Z Mechanistic cell biology for cancer: lysosomal dysfunction instead of ceramide buildup https://biobriefs.com/early-clinical-pipeline-zanidatamab-shows BioBriefs en 2026-08-23T21:32:16Z Early clinical pipeline: zanidatamab shows signal in NeoZanHER phase 2 for HER2-positive breast cancer https://biobriefs.com/company-moves-in-value-based BioBriefs en 2026-08-23T16:32:17Z Company moves in value-based care via acquisition and fresh capital https://biobriefs.com/regulatory-clearance-for-alzheimers-diagnostics BioBriefs en 2026-08-23T16:32:17Z Regulatory clearance for Alzheimer’s diagnostics https://biobriefs.com/immuno-oncology-regulatory-milestone-in BioBriefs en 2026-08-23T16:32:17Z Immuno-oncology regulatory milestone in China https://biobriefs.com/clinical-evidence-for-early-stage BioBriefs en 2026-08-23T16:32:17Z Clinical evidence for early-stage HER2-directed treatment https://biobriefs.com/advances-in-molecular-targeting-of BioBriefs en 2026-08-23T16:32:17Z Advances in molecular targeting of hard-to-treat cancer https://biobriefs.com/early-clinical-and-preclinical-work BioBriefs en 2026-08-23T16:32:17Z Early clinical and preclinical work on antibody-based cancer therapy targeting persistence https://biobriefs.com/biomarker-and-risk-prediction-for BioBriefs en 2026-08-23T16:32:17Z Biomarker and risk prediction for cancer immunotherapy response https://biobriefs.com/neuroscience-and-neuro-oncology-mechanistic BioBriefs en 2026-08-23T16:32:17Z Neuroscience and neuro-oncology mechanistic discovery tied to immune evasion https://biobriefs.com/ai-enabled-genomic-regulation-mapping BioBriefs en 2026-08-23T16:32:17Z AI-enabled genomic regulation mapping relevant to gene-activation biology https://biobriefs.com/alzheimers-and-clinical-trial-readiness BioBriefs en 2026-08-23T16:32:17Z Alzheimer’s and clinical trial-readiness policy debate affecting early-career trialists https://biobriefs.com/hospital-value-based-care-expands BioBriefs en 2026-08-23T14:32:19Z Hospital value-based care expands into rural Medicare populations https://biobriefs.com/fda-clearance-advances-blood-based BioBriefs en 2026-08-23T14:32:19Z FDA clearance advances blood-based Alzheimer’s evaluation https://biobriefs.com/european-regulators-unwind-amgens-marketing BioBriefs en 2026-08-23T14:32:19Z European regulators unwind Amgen’s marketing authorization for Tavneos https://biobriefs.com/new-therapy-delivery-uses-non BioBriefs en 2026-08-23T14:32:19Z New therapy delivery uses non-viral targeted lipid nanoparticles https://biobriefs.com/clinical-stage-immuno-oncology-advances BioBriefs en 2026-08-23T14:32:19Z Clinical-stage immuno-oncology advances in China with 4-1BB bispecific https://biobriefs.com/discovery-biology-targets-replication-histone BioBriefs en 2026-08-23T14:32:19Z Discovery biology targets replication histone mRNA translation https://biobriefs.com/alzheimers-and-cancer-imaging-intersects BioBriefs en 2026-08-23T14:32:19Z Alzheimer’s and cancer imaging intersects with digital pathology forecasting https://biobriefs.com/parkinsons-targeted-degradation-blocks-alpha BioBriefs en 2026-08-23T14:32:19Z Parkinson’s targeted degradation blocks alpha-synuclein aggregation triggered by PFF https://biobriefs.com/rare-neuroimmunology-roadmap-guides-how BioBriefs en 2026-08-23T14:32:19Z Rare neuroimmunology roadmap guides how trials should be designed https://biobriefs.com/ai-commercial-platform-adds-medical BioBriefs en 2026-08-23T14:32:19Z AI commercial platform adds medical affairs and market research functions https://biobriefs.com/regulatory-approval-and-withdrawal-in BioBriefs en 2026-08-23T10:32:08Z Regulatory approval and withdrawal in rare disease https://biobriefs.com/china-nmpa-acceptance-for-4 BioBriefs en 2026-08-23T10:32:08Z China NMPA acceptance for 4-1BB targeting bispecific in EP-NEC https://biobriefs.com/clinical-development-momentum-for-pre BioBriefs en 2026-08-23T10:32:08Z Clinical development momentum for pre-surgery HER2 antibody in early breast cancer https://biobriefs.com/oncology-trial-execution-and-strategic BioBriefs en 2026-08-23T10:32:08Z Oncology trial execution and strategic timing ahead of a major readout https://biobriefs.com/biotech-funding-and-reverse-merger BioBriefs en 2026-08-23T10:32:08Z Biotech funding and reverse merger cash runway https://biobriefs.com/reverse-merger-for-chronic-pain BioBriefs en 2026-08-23T10:32:08Z Reverse merger for chronic pain drug into U.S. public markets https://biobriefs.com/capital-light-ai-commercialization-expansion BioBriefs en 2026-08-23T10:32:08Z Capital-light AI commercialization expansion for life sciences workflows https://biobriefs.com/data-platform-launch-for-single BioBriefs en 2026-08-23T10:32:08Z Data platform launch for single-cell drug toxicity mechanism prediction https://biobriefs.com/clinical-trial-infrastructure-and-study BioBriefs en 2026-08-23T10:32:08Z Clinical trial infrastructure and study start mechanics https://biobriefs.com/workforce-pressure-and-clinical-trial BioBriefs en 2026-08-23T10:32:08Z Workforce pressure and clinical trial training pipeline uncertainty at NIH https://biobriefs.com/regulatory-action-on-late-stage BioBriefs en 2026-08-23T09:32:01Z Regulatory action on late-stage assets https://biobriefs.com/us-fda-clearance-for-alzheimers BioBriefs en 2026-08-23T09:32:01Z US FDA clearance for Alzheimer’s blood testing https://biobriefs.com/china-nmpa-advances-first-in BioBriefs en 2026-08-23T09:32:01Z China NMPA advances first-in-class immuno-oncology strategy https://biobriefs.com/phase-2-early-clinical-readouts BioBriefs en 2026-08-23T09:32:01Z Phase 2/early clinical readouts in solid tumors https://biobriefs.com/new-clinical-evidence-on-glp BioBriefs en 2026-08-23T09:32:01Z New clinical evidence on GLP-1s and infection risk https://biobriefs.com/ai-and-deep-learning-tools BioBriefs en 2026-08-23T09:32:01Z AI and deep-learning tools move toward oncology decision support https://biobriefs.com/drug-development-finance-amylyx-funds BioBriefs en 2026-08-23T09:32:01Z Drug development finance: Amylyx funds ahead of filing https://biobriefs.com/clinical-development-momentum-via-nmpa BioBriefs en 2026-08-23T09:32:01Z Clinical development momentum via NMPA clearances in solid tumors and retina https://biobriefs.com/biotech-business-operations-ai-platform BioBriefs en 2026-08-23T09:32:01Z Biotech business operations: AI platform expansion at EVERSANA https://biobriefs.com/preclinical-mechanistic-research-in-cancer BioBriefs en 2026-08-23T09:32:01Z Preclinical mechanistic research in cancer immunology and targeted protein control https://biobriefs.com/regulatory-action-and-recall-in BioBriefs en 2026-08-23T04:32:07Z Regulatory action and recall in Europe https://biobriefs.com/china-nmpa-review-moves-immunotherapy BioBriefs en 2026-08-23T04:32:07Z China NMPA review moves immunotherapy target forward https://biobriefs.com/us-fda-clears-a-blood BioBriefs en 2026-08-23T04:32:07Z US FDA clears a blood test for Alzheimer’s evaluation https://biobriefs.com/high-impact-trial-and-pipeline BioBriefs en 2026-08-23T04:32:07Z High-impact trial and pipeline finance signals https://biobriefs.com/stem-cell-platform-funding-for BioBriefs en 2026-08-23T04:32:07Z Stem-cell platform funding for Type 1 diabetes research https://biobriefs.com/cancer-biology-precision-immune-organoid BioBriefs en 2026-08-23T04:32:07Z Cancer biology: precision immune-organoid modeling https://biobriefs.com/immunotherapy-prediction-using-deep-learning BioBriefs en 2026-08-23T04:32:07Z Immunotherapy prediction using deep-learning pathology https://biobriefs.com/oncology-drug-development-novel-targeting BioBriefs en 2026-08-23T04:32:07Z Oncology drug development: novel targeting strategy in breast cancer https://biobriefs.com/biotech-ai-tooling-commercialization-and BioBriefs en 2026-08-23T04:32:07Z Biotech AI tooling: commercialization and toxicology atlas launch https://biobriefs.com/med-tech-and-care-delivery BioBriefs en 2026-08-23T04:32:07Z Med-tech and care delivery innovation in breast cancer https://biobriefs.com/immuno-oncology-china-regulatory-filing BioBriefs en 2026-08-22T21:32:51Z Immuno-oncology – China regulatory filing for a novel 4-1BB bispecific https://biobriefs.com/oncology-early-stage-antibody-signal BioBriefs en 2026-08-22T21:32:51Z Oncology – early-stage antibody signal in pre-surgery HER2-positive breast cancer https://biobriefs.com/rare-disease-rna-interference-phase BioBriefs en 2026-08-22T21:32:51Z Rare disease & RNA interference – Phase II efficacy for divesiran in polycythemia vera https://biobriefs.com/drug-safety-real-world-psychosis BioBriefs en 2026-08-22T21:32:51Z Drug safety – real-world psychosis signal for subcutaneous foslevodopa/foscarbidopa https://biobriefs.com/neurodegeneration-targeted-alpha-synuclein-degradation BioBriefs en 2026-08-22T21:32:51Z Neurodegeneration – targeted alpha-synuclein degradation blocks PFF aggregation https://biobriefs.com/central-nervous-system-tumors-roadmap BioBriefs en 2026-08-22T21:32:51Z Central nervous system tumors – roadmap aims to accelerate trials in rare childhood CNS cancers https://biobriefs.com/regulatory-europe-recalls-amgens-tavneos BioBriefs en 2026-08-22T21:32:51Z Regulatory – Europe recalls Amgen’s Tavneos after marketing authorization cancellation https://biobriefs.com/finance-pipeline-operations-amylyx-books BioBriefs en 2026-08-22T21:32:51Z Finance & pipeline operations – Amylyx books $500M ahead of submission after readout https://biobriefs.com/platform-manufacturing-genentech-invests-750m BioBriefs en 2026-08-22T21:32:51Z Platform & manufacturing – Genentech invests $750M for drug delivery device facility https://biobriefs.com/ai-commercialization-eversana-expands-ai BioBriefs en 2026-08-22T21:32:51Z AI commercialization – EVERSANA expands AI platform with medical affairs and commercial functions https://biobriefs.com/regulatory-action-in-alzheimers-diagnostics BioBriefs en 2026-08-22T16:32:06Z Regulatory action in Alzheimer’s diagnostics https://biobriefs.com/immuno-oncology-in-china-next BioBriefs en 2026-08-22T16:32:06Z Immuno-oncology in China: next-generation 4-1BB agonism https://biobriefs.com/oncology-drug-development-her2-therapy BioBriefs en 2026-08-22T16:32:06Z Oncology drug development: HER2 therapy earlier in the care pathway https://biobriefs.com/rare-disease-sirna-shows-strong BioBriefs en 2026-08-22T16:32:06Z Rare disease: siRNA shows strong Phase II signal in polycythemia vera https://biobriefs.com/oncology-trial-signal-driving-financing BioBriefs en 2026-08-22T16:32:06Z Oncology trial signal driving financing: Amylyx banks $500M ahead of submission https://biobriefs.com/biotech-financing-66-million-for BioBriefs en 2026-08-22T16:32:06Z Biotech financing: $66 million for inclusion body myositis program https://biobriefs.com/ai-commercialization-eversana-expands-an BioBriefs en 2026-08-22T16:32:06Z AI commercialization: EVERSANA expands an enterprise platform https://biobriefs.com/regulatory-or-clinical-safety-europe BioBriefs en 2026-08-22T16:32:06Z Regulatory or clinical safety: Europe recalls Amgen’s Tavneos after marketing authorization cancellation https://biobriefs.com/china-clinical-pipeline-start-akeso BioBriefs en 2026-08-22T16:32:06Z China clinical pipeline start: Akeso gets clearance for AK-157D1 Phase I https://biobriefs.com/biopharma-workforce-and-operational-policy BioBriefs en 2026-08-22T16:32:06Z Biopharma workforce and operational policy: return-to-office pressures R&D roles https://biobriefs.com/regulatory-approvals-and-withdrawals BioBriefs en 2026-08-22T14:32:16Z Regulatory approvals and withdrawals https://biobriefs.com/oncology-drug-pipeline-early-clinical BioBriefs en 2026-08-22T14:32:16Z Oncology drug pipeline: early clinical progress and new study signals https://biobriefs.com/immuno-oncology-and-bispecific-antibodies BioBriefs en 2026-08-22T14:32:16Z Immuno-oncology and bispecific antibodies https://biobriefs.com/clinical-outcomes-diagnostics-digital-health BioBriefs en 2026-08-22T14:32:16Z Clinical outcomes: diagnostics, digital health, and trial readouts https://biobriefs.com/trial-and-regulation-scrutiny-clinical BioBriefs en 2026-08-22T14:32:16Z Trial and regulation scrutiny: clinical trial workforce and study-start pressure https://biobriefs.com/company-financing-and-reverse-mergers BioBriefs en 2026-08-22T14:32:16Z Company financing and reverse mergers https://biobriefs.com/diabetes-and-glp-1-safety BioBriefs en 2026-08-22T14:32:16Z Diabetes and GLP-1 safety: tuberculosis risk signal https://biobriefs.com/cutting-edge-platform-tech-ai BioBriefs en 2026-08-22T14:32:16Z Cutting-edge platform tech: AI + single-cell and bioprocessing tools https://biobriefs.com/oncology-discovery-and-targeted-mechanisms BioBriefs en 2026-08-22T14:32:16Z Oncology discovery and targeted mechanisms https://biobriefs.com/biotech-innovation-in-rare-disease BioBriefs en 2026-08-22T14:32:16Z Biotech innovation in rare disease and advanced therapeutics https://biobriefs.com/regulatory-fallout-and-accelerated-clinical BioBriefs en 2026-08-22T10:32:45Z Regulatory fallout and accelerated clinical trial scrutiny in China https://biobriefs.com/fda-approves-first-in-class BioBriefs en 2026-08-22T10:32:45Z FDA approves first-in-class gene therapy for ultra-rare glycogen storage disease type Ia https://biobriefs.com/china-nmpa-accepts-nda-for BioBriefs en 2026-08-22T10:32:45Z China NMPA accepts NDA for 4-1BB PD-L1 bispecific opamtistomig in advanced extrapulmonary neuroendocrine carcinoma https://biobriefs.com/modernas-personalized-cancer-vaccine-posts BioBriefs en 2026-08-22T10:32:45Z Moderna’s personalized cancer vaccine posts topline results as investors react https://biobriefs.com/breakthrough-therapy-designation-in-oncology BioBriefs en 2026-08-22T10:32:45Z Breakthrough therapy designation in oncology pipeline: NeoZanHER phase 2 data for neoadjuvant zanidatamab https://biobriefs.com/silence-therapeutics-advances-sirna-divesiran BioBriefs en 2026-08-22T10:32:45Z Silence Therapeutics advances siRNA divesiran in polycythemia vera with positive Phase II https://biobriefs.com/genentech-commits-750m-to-expand BioBriefs en 2026-08-22T10:32:45Z Genentech commits $750M to expand drug-delivery device manufacturing https://biobriefs.com/regeneron-scores-fda-clearance-for BioBriefs en 2026-08-22T10:32:45Z Regeneron scores FDA clearance for Pasatru in fibrodysplasia ossificans progressiva https://biobriefs.com/next-wave-diagnostics-and-real BioBriefs en 2026-08-22T10:32:45Z Next wave diagnostics and real-world testing: FDA clears blood test to assess Alzheimer’s amyloid pathology https://biobriefs.com/deepcyte-launches-deetox-atlas-to BioBriefs en 2026-08-22T10:32:45Z DeepCyte launches DeeTox Atlas to model drug toxicity mechanisms at single-cell resolution https://biobriefs.com/fda-clears-first-in-class BioBriefs en 2026-08-22T09:32:18Z FDA clears first-in-class gene therapy for ultra-rare glycogen storage disease https://biobriefs.com/european-regulators-pull-marketing-authorization BioBriefs en 2026-08-22T09:32:18Z European regulators pull marketing authorization for Amgen’s Tavneos https://biobriefs.com/chinas-nmpa-accepts-nda-for BioBriefs en 2026-08-22T09:32:18Z China’s NMPA accepts NDA for PD-L1/4-1BB bispecific opamtistomig https://biobriefs.com/deepcyte-launches-deetox-atlas-for BioBriefs en 2026-08-22T09:32:18Z DeepCyte launches DeeTox Atlas for single-cell toxicity mechanism modeling https://biobriefs.com/silence-therapeutics-reports-positive-phase BioBriefs en 2026-08-22T09:32:18Z Silence Therapeutics reports positive Phase II results for divesiran in polycythemia vera https://biobriefs.com/ongoing-clinical-trial-updates-ambros BioBriefs en 2026-08-22T09:32:18Z Ongoing clinical trial updates: Ambros reverse merger to advance phase 3 pain therapy https://biobriefs.com/amid-questions-ngs-testing-adoption BioBriefs en 2026-08-22T09:32:18Z Amid questions, NGS testing adoption remains uneven even after Medicare coverage https://biobriefs.com/fda-clears-first-standalone-robotic BioBriefs en 2026-08-22T09:32:18Z FDA clears first standalone robotic blood draw device in the US https://biobriefs.com/silicon-and-ai-meet-cell BioBriefs en 2026-08-22T09:32:18Z Silicon and AI meet cell line development: Deepcell and Gilead co-develop morphology foundation model https://biobriefs.com/car-t-engineering-approach-localized BioBriefs en 2026-08-22T09:32:18Z CAR T engineering approach: localized secretion of EpCAM bispecific engagers https://biobriefs.com/regulatory-approval-rare-genetic-disease BioBriefs en 2026-08-22T04:32:12Z Regulatory approval – rare genetic disease gene therapy https://biobriefs.com/oncology-fda-approval-for-bone BioBriefs en 2026-08-22T04:32:12Z Oncology – FDA approval for bone disease drug https://biobriefs.com/company-market-chronic-pain-biopharma BioBriefs en 2026-08-22T04:32:12Z Company/market – chronic pain biopharma advances via reverse merger https://biobriefs.com/clinical-trial-home-based-breast BioBriefs en 2026-08-22T04:32:12Z Clinical trial – home-based breast cancer injections supported by telemedicine https://biobriefs.com/immunotherapy-discovery-engineered-drug-molecular BioBriefs en 2026-08-22T04:32:12Z Immunotherapy discovery – engineered drug “molecular glue” flips cancer drivers https://biobriefs.com/rare-disease-pipeline-sirna-phase BioBriefs en 2026-08-22T04:32:12Z Rare disease pipeline – siRNA Phase II shows strong PV response https://biobriefs.com/cell-and-gene-therapy-platform BioBriefs en 2026-08-22T04:32:12Z Cell and gene therapy platform – targeted lipid nanoparticles for in vivo editing https://biobriefs.com/diagnostics-ai-governance-pathology-models BioBriefs en 2026-08-22T04:32:12Z Diagnostics/AI governance – pathology models need uncertainty signals and human review https://biobriefs.com/oncology-nmpa-accepts-nda-for BioBriefs en 2026-08-22T04:32:12Z Oncology – NMPA accepts NDA for 4-1BB bispecific in extrapulmonary NEC https://biobriefs.com/biotech-innovation-open-access-human BioBriefs en 2026-08-22T04:32:12Z Biotech innovation – Open-access human cell surface atlas for drug delivery https://biobriefs.com/regulatory-approvals-genes-and-rare BioBriefs en 2026-08-21T21:32:17Z Regulatory approvals—genes and rare disease https://biobriefs.com/immuno-oncology-targeted-immune-activation BioBriefs en 2026-08-21T21:32:17Z Immuno-oncology—targeted immune activation and T-cell engineering https://biobriefs.com/clinical-trial-readouts-oncology-precision BioBriefs en 2026-08-21T21:32:17Z Clinical trial readouts—oncology precision and patient selection https://biobriefs.com/platform-and-translational-ai-in BioBriefs en 2026-08-21T21:32:17Z Platform and translational AI in drug safety—single-cell toxicology foundations https://biobriefs.com/m-a-and-market-restructuring BioBriefs en 2026-08-21T21:32:17Z M&A and market restructuring—reverse mergers and rare disease pipelines https://biobriefs.com/device-and-workflow-innovation-next BioBriefs en 2026-08-21T21:32:17Z Device and workflow innovation—next-generation blood draw automation https://biobriefs.com/biotech-research-funding-type-1 BioBriefs en 2026-08-21T21:32:17Z Biotech research funding—Type 1 diabetes stem cell discovery https://biobriefs.com/cell-platforms-and-gene-delivery BioBriefs en 2026-08-21T21:32:17Z Cell platforms and gene delivery—non-viral in vivo editing https://biobriefs.com/translational-ai-in-commercialization-medical BioBriefs en 2026-08-21T21:32:17Z Translational AI in commercialization—medical affairs automation https://biobriefs.com/regulatory-oversight-and-trial-integrity BioBriefs en 2026-08-21T21:32:17Z Regulatory oversight and trial integrity—FDA focus on China clinical data https://biobriefs.com/personalized-cancer-mrna-therapy BioBriefs en 2026-08-21T16:32:25Z Personalized cancer mRNA therapy https://biobriefs.com/fda-approvals-gene-therapy-and BioBriefs en 2026-08-21T16:32:25Z FDA approvals – gene therapy and bone disease antibody https://biobriefs.com/fda-clearance-rare-blood-cancer BioBriefs en 2026-08-21T16:32:25Z FDA clearance – rare blood cancer siRNA https://biobriefs.com/m-a-and-reverse-mergers BioBriefs en 2026-08-21T16:32:25Z M&A and reverse mergers – market access moves https://biobriefs.com/clinical-strategy-first-line-egfr BioBriefs en 2026-08-21T16:32:25Z Clinical strategy – first-line EGFR exon 20 targeted therapy https://biobriefs.com/new-factory-and-trial-timing BioBriefs en 2026-08-21T16:32:25Z New factory and trial timing – manufacturing and program signals https://biobriefs.com/biotech-funding-late-stage-clinical BioBriefs en 2026-08-21T16:32:25Z Biotech funding – late-stage clinical push in inclusion body myositis https://biobriefs.com/ai-in-diagnostics-and-health BioBriefs en 2026-08-21T16:32:25Z AI in diagnostics and health systems – trust, reliability, and foundations https://biobriefs.com/targeted-delivery-for-gene-editing BioBriefs en 2026-08-21T16:32:25Z Targeted delivery for gene editing in vivo https://biobriefs.com/hematology-transplant-access-broader-donor BioBriefs en 2026-08-21T16:32:25Z Hematology transplant access – broader donor selection https://biobriefs.com/fda-approvals-gene-therapy-for BioBriefs en 2026-08-21T14:32:22Z FDA approvals – gene therapy for ultra-rare glycogen storage disease https://biobriefs.com/fda-approvals-bone-disorder-antibody BioBriefs en 2026-08-21T14:32:22Z FDA approvals – bone disorder antibody moves into clinic competition https://biobriefs.com/phase-3-oncology-personalized-mrna BioBriefs en 2026-08-21T14:32:22Z Phase 3 oncology – personalized mRNA neoantigen vaccine shows recurrence benefit in melanoma https://biobriefs.com/phase-2-rare-blood-cancer BioBriefs en 2026-08-21T14:32:22Z Phase 2 rare blood cancer – siRNA therapy delivers large hematocrit response vs placebo https://biobriefs.com/m-a-reshapes-industry-teams BioBriefs en 2026-08-21T14:32:22Z M&A reshapes industry teams – workforce cuts follow integrated deals https://biobriefs.com/clinical-trial-update-sunvozertinib-extends BioBriefs en 2026-08-21T14:32:22Z Clinical trial update – Sunvozertinib extends progression-free survival in EGFR exon 20 NSCLC https://biobriefs.com/trial-and-access-stem-cell BioBriefs en 2026-08-21T14:32:22Z Trial and access – stem cell donor options broaden using mismatched donors https://biobriefs.com/diagnostics-and-reimbursement-ngs-adoption BioBriefs en 2026-08-21T14:32:22Z Diagnostics and reimbursement – NGS adoption lags despite Medicare national coverage https://biobriefs.com/biotech-growth-capital-abcuro-raises BioBriefs en 2026-08-21T14:32:22Z Biotech growth capital – Abcuro raises Series D to advance inclusion body myositis candidate https://biobriefs.com/enterprise-ai-in-drugmaking-deepcell BioBriefs en 2026-08-21T14:32:22Z Enterprise AI in drugmaking – Deepcell and Gilead collaborate on CHO cell morphology foundation model https://biobriefs.com/personalized-mrna-cancer-vaccine-delivers BioBriefs en 2026-08-21T10:32:53Z Personalized mRNA cancer vaccine delivers Phase 3 success https://biobriefs.com/fda-approvals-expand-rare-bone BioBriefs en 2026-08-21T10:32:53Z FDA approvals expand rare bone disease options https://biobriefs.com/ultragenyx-secures-first-gene-therapy BioBriefs en 2026-08-21T10:32:53Z Ultragenyx secures first gene therapy approval for ultra-rare GSDIa https://biobriefs.com/silence-therapeutics-advances-sirna-drug BioBriefs en 2026-08-21T10:32:53Z Silence Therapeutics advances siRNA drug for polycythemia vera https://biobriefs.com/abcuro-funds-registrational-study-for BioBriefs en 2026-08-21T10:32:53Z Abcuro funds registrational study for inclusion body myositis antibody https://biobriefs.com/biomarin-buys-alesta-for-oral BioBriefs en 2026-08-21T10:32:53Z BioMarin buys Alesta for oral bone disease therapy https://biobriefs.com/network-bio-launches-with-50m BioBriefs en 2026-08-21T10:32:53Z Network Bio launches with $50M and Nvidia partnership for cfRNA foundation models https://biobriefs.com/deepcell-and-gilead-co-develop BioBriefs en 2026-08-21T10:32:53Z Deepcell and Gilead co-develop CHO cell morphology AI foundation model https://biobriefs.com/fda-diagnostic-and-oncology-systems BioBriefs en 2026-08-21T10:32:53Z FDA, diagnostic and oncology systems: benchmarking and coverage issues https://biobriefs.com/phase-i-safety-pause-in BioBriefs en 2026-08-21T10:32:53Z Phase I safety pause in Boehringer program https://biobriefs.com/personalized-cancer-mrna-immunotherapy-scores BioBriefs en 2026-08-21T09:32:08Z Personalized cancer mRNA immunotherapy scores Phase 3 win https://biobriefs.com/fda-clears-ultragenyxs-first-marketed BioBriefs en 2026-08-21T09:32:08Z FDA clears Ultragenyx’s first marketed gene therapy https://biobriefs.com/regenerons-activin-a-antibody-wins BioBriefs en 2026-08-21T09:32:08Z Regeneron’s activin A antibody wins FDA approval for FOP https://biobriefs.com/rare-bone-disease-m-a BioBriefs en 2026-08-21T09:32:08Z Rare bone disease M&A—BioMarin buys Alesta’s oral HPP candidate https://biobriefs.com/immuno-oncology-ai-tooling-gets BioBriefs en 2026-08-21T09:32:08Z Immuno-oncology AI tooling gets new industry backing https://biobriefs.com/cell-free-rna-ai-and BioBriefs en 2026-08-21T09:32:08Z Cell-free RNA AI and Nvidia collaboration https://biobriefs.com/rare-blood-cancer-sirna-hits BioBriefs en 2026-08-21T09:32:08Z Rare blood cancer siRNA hits Phase 2 primary endpoint https://biobriefs.com/startup-funding-abcuro-raises-66m BioBriefs en 2026-08-21T09:32:08Z Startup funding—Abcuro raises $66m to expand inclusion body myositis study https://biobriefs.com/ai-for-diagnostics-quality-truecam BioBriefs en 2026-08-21T09:32:08Z AI for diagnostics quality—TRUECAM aims to flag uncertainty https://biobriefs.com/innovation-in-genomic-medicine-manufacturing BioBriefs en 2026-08-21T09:32:08Z Innovation in genomic medicine manufacturing—Fulcrum reverse merger closes public-market path https://biobriefs.com/regulatory-approvals-rare-disease-gene BioBriefs en 2026-08-21T04:31:57Z Regulatory approvals: rare disease gene and biologic milestones https://biobriefs.com/oncology-personalized-mrna-neoantigen-vaccine BioBriefs en 2026-08-21T04:31:57Z Oncology: personalized mRNA neoantigen vaccine clears late-stage melanoma hurdle https://biobriefs.com/rare-bone-disease-m-a BioBriefs en 2026-08-21T04:31:57Z Rare bone disease M&A: BioMarin expands mineralization pipeline with Alesta buy https://biobriefs.com/cell-therapy-chimeric-pushes-in BioBriefs en 2026-08-21T04:31:57Z Cell therapy: Chimeric pushes in vivo pivot after CAR T toxicities https://biobriefs.com/oncology-therapeutics-sunvozertinib-beats-chemotherapy BioBriefs en 2026-08-21T04:31:57Z Oncology therapeutics: sunvozertinib beats chemotherapy in phase 3 first-line EGFR exon 20 insertion NSCLC https://biobriefs.com/healthcare-policy-and-reimbursement-teva BioBriefs en 2026-08-21T04:31:57Z Healthcare policy and reimbursement: Teva IRA litigation revived by US appeals court https://biobriefs.com/precision-diagnostics-and-platform-validation BioBriefs en 2026-08-21T04:31:57Z Precision diagnostics and platform validation: benchmarking NGS assay concordance https://biobriefs.com/genetic-testing-access-medicare-ngs BioBriefs en 2026-08-21T04:31:57Z Genetic testing access: Medicare NGS coverage still leaves practical gaps https://biobriefs.com/ai-in-bioprocessing-deepcell-and BioBriefs en 2026-08-21T04:31:57Z AI in bioprocessing: Deepcell and Gilead co-develop a CHO cell morphology foundation model https://biobriefs.com/cell-and-gene-therapy-manufacturing BioBriefs en 2026-08-21T04:31:57Z Cell and gene therapy manufacturing: AAV vector supply constraints spur purification focus https://biobriefs.com/personalized-melanoma-mrna-vaccine-clears BioBriefs en 2026-08-20T21:32:18Z Personalized melanoma mRNA vaccine clears Phase 3 milestone https://biobriefs.com/fda-clears-regenerons-garetosmab-pasatru BioBriefs en 2026-08-20T21:32:18Z FDA clears Regeneron’s garetosmab (Pasatru) for ultra-rare FOP https://biobriefs.com/fda-accelerates-ultragenyxs-first-gene BioBriefs en 2026-08-20T21:32:18Z FDA accelerates Ultragenyx’s first gene therapy for GSDIa https://biobriefs.com/regulatory-oversight-gaps-for-digital BioBriefs en 2026-08-20T21:32:18Z Regulatory oversight gaps for digital health AI devices https://biobriefs.com/gene-therapy-and-trial-risk BioBriefs en 2026-08-20T21:32:18Z Gene therapy and trial risk in China’s fast investigator-initiated model https://biobriefs.com/diagnostics-and-reimbursement-access-gaps BioBriefs en 2026-08-20T21:32:18Z Diagnostics and reimbursement: access gaps persist for NGS cancer testing https://biobriefs.com/rare-disease-dealmaking-biomarin-acquires BioBriefs en 2026-08-20T21:32:18Z Rare-disease dealmaking: BioMarin acquires Alesta to expand oral PPi-pathway therapy focus https://biobriefs.com/deep-tech-meets-drug-development BioBriefs en 2026-08-20T21:32:18Z Deep-tech meets drug development: Deepcell and Gilead build CHO morphology foundation model https://biobriefs.com/car-t-program-setback-drives BioBriefs en 2026-08-20T21:32:18Z CAR T program setback drives pivot toward in vivo platform https://biobriefs.com/space-and-life-sciences-nasa BioBriefs en 2026-08-20T21:32:18Z Space and life sciences: NASA flags possible microbial survival on the Moon https://biobriefs.com/fda-approvals-rare-disease-therapeutics BioBriefs en 2026-08-20T16:32:29Z FDA approvals—rare disease therapeutics https://biobriefs.com/gene-therapy-first-approvals-and BioBriefs en 2026-08-20T16:32:29Z Gene therapy—first approvals and commercialization path https://biobriefs.com/cancer-vaccines-personalized-neoantigen-mrna BioBriefs en 2026-08-20T16:32:29Z Cancer vaccines—personalized neoantigen mRNA moves toward approval https://biobriefs.com/phase-3-oncology-head-to BioBriefs en 2026-08-20T16:32:29Z Phase 3 oncology—head-to-head competitiveness in targeted NSCLC https://biobriefs.com/biotech-dealmaking-reverse-merger-puts BioBriefs en 2026-08-20T16:32:29Z Biotech dealmaking—reverse merger puts migraine antibody into public markets https://biobriefs.com/diagnostics-ngs-adoption-uneven-despite BioBriefs en 2026-08-20T16:32:29Z Diagnostics—NGS adoption uneven despite Medicare national coverage https://biobriefs.com/digital-health-regulation-fdas-tempo BioBriefs en 2026-08-20T16:32:29Z Digital health regulation—FDA’s TEMPO pilot advances for remote monitoring https://biobriefs.com/biopharma-partnerships-deepcell-and-gilead BioBriefs en 2026-08-20T16:32:29Z Biopharma partnerships—Deepcell and Gilead co-develop CHO cell-line morphology foundation model https://biobriefs.com/funding-network-bio-launches-with BioBriefs en 2026-08-20T16:32:29Z Funding—Network Bio launches with $50M and Nvidia partnership https://biobriefs.com/regulatory-and-litigation-parse-biosciences BioBriefs en 2026-08-20T16:32:29Z Regulatory and litigation—Parse Biosciences wins appeals over 10x patents https://biobriefs.com/personalized-neoantigen-mrna-vaccines-deliver BioBriefs en 2026-08-20T14:31:52Z Personalized neoantigen mRNA vaccines deliver randomized Phase 3 signal in melanoma https://biobriefs.com/fda-clears-regenerons-activin-a BioBriefs en 2026-08-20T14:31:52Z FDA clears Regeneron’s activin A antibody for fibrodysplasia ossificans progressiva https://biobriefs.com/new-phase-3-win-extends BioBriefs en 2026-08-20T14:31:52Z New Phase 3 win extends first-line benefit of EGFR exon 20 insertions drug https://biobriefs.com/biotech-dealmaking-biomarin-buys-alestas BioBriefs en 2026-08-20T14:31:52Z Biotech dealmaking: BioMarin buys Alesta’s oral ALE1 for hypophosphatasia https://biobriefs.com/cell-and-gene-therapy-operations BioBriefs en 2026-08-20T14:31:52Z Cell and gene therapy operations: analytics automation targets cell therapy auditing at scale https://biobriefs.com/ai-and-data-infrastructure-network BioBriefs en 2026-08-20T14:31:52Z AI and data infrastructure: Network Bio launches with $50M and partners with NVIDIA https://biobriefs.com/liquid-biopsy-expansion-pillar-biosciences BioBriefs en 2026-08-20T14:31:52Z Liquid biopsy expansion: Pillar Biosciences brings sequencing assay into Japan cfDNA/cfRNA screening https://biobriefs.com/diagnostics-evidence-standardization-diaceutics-and BioBriefs en 2026-08-20T14:31:52Z Diagnostics evidence standardization: Diaceutics and PCC launch NGS concordance study https://biobriefs.com/regulatory-and-compliance-scrutiny-of BioBriefs en 2026-08-20T14:31:52Z Regulatory and compliance scrutiny of AI medical devices https://biobriefs.com/epigenetic-mechanism-study-kdm2a-loss BioBriefs en 2026-08-20T14:31:52Z Epigenetic mechanism study: KDM2A loss restores antitumor immunity in liver cancer https://biobriefs.com/acquisitions-pipeline-expansion-in-rare BioBriefs en 2026-08-20T10:31:51Z Acquisitions & pipeline expansion in rare bone disease https://biobriefs.com/fda-approvals-for-ultra-rare BioBriefs en 2026-08-20T10:31:51Z FDA approvals for ultra-rare conditions targeting activin A https://biobriefs.com/late-stage-win-for-personalized BioBriefs en 2026-08-20T10:31:51Z Late-stage win for personalized mRNA neoantigen vaccines https://biobriefs.com/phase-3-confirmation-in-egfr BioBriefs en 2026-08-20T10:31:51Z Phase 3 confirmation in EGFR exon 20 insertion NSCLC https://biobriefs.com/antibody-engineering-diagnostics-liquid-biopsy BioBriefs en 2026-08-20T10:31:51Z Antibody engineering & diagnostics: liquid biopsy genomics in Japan https://biobriefs.com/fda-policy-regulatory-oversight-appointment BioBriefs en 2026-08-20T10:31:51Z FDA policy & regulatory oversight: appointment path for FDA commissioner https://biobriefs.com/gene-therapy-patent-litigation-victory BioBriefs en 2026-08-20T10:31:51Z Gene therapy patent litigation victory in single-cell genomics https://biobriefs.com/regulatory-risk-ai-devices-cleared BioBriefs en 2026-08-20T10:31:51Z Regulatory risk: AI devices cleared without patient-outcome evidence https://biobriefs.com/cell-therapy-manufacturing-scaling-analytics BioBriefs en 2026-08-20T10:31:51Z Cell therapy manufacturing: scaling analytics automation for small-batch workflows https://biobriefs.com/biotech-investing-network-bio-launches BioBriefs en 2026-08-20T10:31:51Z Biotech investing: Network Bio launches with $50M and Nvidia partnership https://biobriefs.com/regulatory-approvals-in-rare-bone BioBriefs en 2026-08-20T09:32:19Z Regulatory approvals in rare bone disease https://biobriefs.com/personalized-mrna-cancer-vaccines-gain BioBriefs en 2026-08-20T09:32:19Z Personalized mRNA cancer vaccines gain Phase 3 milestone https://biobriefs.com/first-line-targeted-therapy-for BioBriefs en 2026-08-20T09:32:19Z First-line targeted therapy for EGFR exon 20 insertions clears Phase 3 hurdle https://biobriefs.com/big-deal-in-rare-bone BioBriefs en 2026-08-20T09:32:19Z Big deal in rare bone disease – BioMarin buys Alesta’s ALE-1 https://biobriefs.com/car-t-development-pivot-after BioBriefs en 2026-08-20T09:32:19Z Car T development pivot after toxicity in solid-tumor program https://biobriefs.com/ai-in-clinical-devices-fda BioBriefs en 2026-08-20T09:32:19Z AI in clinical devices – FDA-cleared products lacked outcome testing https://biobriefs.com/fda-oversight-for-generative-ai BioBriefs en 2026-08-20T09:32:19Z FDA oversight for generative AI-enabled medical devices https://biobriefs.com/business-and-litigation-parse-wins BioBriefs en 2026-08-20T09:32:19Z Business and litigation: Parse wins appellate IP dispute vs 10x Genomics https://biobriefs.com/startup-launch-with-large-scale BioBriefs en 2026-08-20T09:32:19Z Startup launch with large-scale cfRNA model ambitions https://biobriefs.com/clinical-tradeoffs-and-cost-pressures BioBriefs en 2026-08-20T09:32:19Z Clinical tradeoffs and cost pressures in CAR T manufacturing https://biobriefs.com/personalized-mrna-vaccines-score-phase BioBriefs en 2026-08-20T04:31:51Z Personalized mRNA vaccines score Phase 3 win in melanoma https://biobriefs.com/fda-approves-first-activin-a BioBriefs en 2026-08-20T04:31:51Z FDA approves first activin A antibody for fibrodysplasia ossificans progressiva https://biobriefs.com/phase-3-evidence-reshapes-first BioBriefs en 2026-08-20T04:31:51Z Phase 3 evidence reshapes first-line EGFR exon 20 insertion treatment https://biobriefs.com/biotech-deals-and-approvals-expand BioBriefs en 2026-08-20T04:31:51Z Biotech deals and approvals expand rare disease bone pipeline https://biobriefs.com/diagnostic-innovation-liquid-biopsy-and BioBriefs en 2026-08-20T04:31:51Z Diagnostic innovation: liquid biopsy and urine testing move toward clinical scale https://biobriefs.com/car-t-manufacturing-and-gene BioBriefs en 2026-08-20T04:31:51Z CAR T manufacturing and gene therapy throughput: analytics automation and vector bottlenecks https://biobriefs.com/oncology-research-new-models-target BioBriefs en 2026-08-20T04:31:51Z Oncology research: new models target metastasis biology https://biobriefs.com/immunology-and-inflammation-reprogramming-paths BioBriefs en 2026-08-20T04:31:51Z Immunology and inflammation: reprogramming paths in colorectal cancer and T cell exhaustion escape https://biobriefs.com/neuroimmunology-and-cns-drug-delivery BioBriefs en 2026-08-20T04:31:51Z Neuroimmunology and CNS drug delivery: BBB shuttles and new mRNA STING activation approach https://biobriefs.com/platform-and-funding-network-bio BioBriefs en 2026-08-20T04:31:51Z Platform and funding: Network Bio raises $50M to build cfRNA foundation model with Nvidia https://biobriefs.com/personalized-mrna-oncology-delivers-first BioBriefs en 2026-08-19T21:32:08Z Personalized mRNA oncology delivers first randomized Phase 3 signal https://biobriefs.com/regeneron-secures-fda-nod-for BioBriefs en 2026-08-19T21:32:08Z Regeneron secures FDA nod for ultra-rare fibrodysplasia ossificans progressiva https://biobriefs.com/gene-therapy-manufacturing-bottleneck-spotlights BioBriefs en 2026-08-19T21:32:08Z Gene therapy manufacturing bottleneck spotlights need to separate full and empty AAV https://biobriefs.com/new-cell-therapy-analytics-automation BioBriefs en 2026-08-19T21:32:08Z New cell-therapy analytics automation targets high-throughput auditing at small volumes https://biobriefs.com/court-ruling-upholds-parse-biosciences BioBriefs en 2026-08-19T21:32:08Z Court ruling upholds Parse Biosciences win in patent dispute over 10x Genomics https://biobriefs.com/new-fda-pick-signals-next BioBriefs en 2026-08-19T21:32:08Z New FDA pick signals next chapter for agency leadership https://biobriefs.com/network-bio-launches-cfrna-foundation BioBriefs en 2026-08-19T21:32:08Z Network Bio launches cfRNA foundation model program with Nvidia https://biobriefs.com/biomarin-expands-rare-bone-pipeline BioBriefs en 2026-08-19T21:32:08Z BioMarin expands rare bone pipeline by acquiring Alesta’s ALE-1 https://biobriefs.com/craif-scales-us-push-for BioBriefs en 2026-08-19T21:32:08Z Craif scales US push for urine-based pancreatic cancer screening test https://biobriefs.com/startup-snipr-reports-first-positive BioBriefs en 2026-08-19T21:32:08Z Startup Snipr reports first positive patient signal for CRISPR-modified phage SNIPR-001 https://biobriefs.com/personalized-mrna-vaccines-in-late BioBriefs en 2026-08-19T16:32:04Z personalized mRNA vaccines in late-stage oncology https://biobriefs.com/fda-leadership-shakeup-and-regulatory BioBriefs en 2026-08-19T16:32:04Z FDA leadership shakeup and regulatory outlook https://biobriefs.com/post-bariatric-hypoglycemia-enters-late BioBriefs en 2026-08-19T16:32:04Z post-bariatric hypoglycemia enters late-stage GLP-1 antagonist era https://biobriefs.com/liquid-biopsy-scaling-in-japan BioBriefs en 2026-08-19T16:32:04Z liquid biopsy scaling in Japan for lung cancer screening https://biobriefs.com/urine-based-pancreatic-cancer-screening BioBriefs en 2026-08-19T16:32:04Z urine-based pancreatic cancer screening moves toward US trial buildout https://biobriefs.com/ai-infrastructure-for-cell-free BioBriefs en 2026-08-19T16:32:04Z AI infrastructure for cell-free RNA foundations https://biobriefs.com/sting-adjuvanted-mrna-vaccines-sharpen BioBriefs en 2026-08-19T16:32:04Z STING-adjuvanted mRNA vaccines sharpen antitumor immunity https://biobriefs.com/sequencing-platform-and-ai-diagnostics BioBriefs en 2026-08-19T16:32:04Z sequencing platform and AI diagnostics expansion in biopharma workflows https://biobriefs.com/amylin-analog-glp-1-race BioBriefs en 2026-08-19T16:32:04Z amylin analog/GLP-1 race focuses on design differentiation https://biobriefs.com/cd4-cytotoxic-t-lymphocytes-and BioBriefs en 2026-08-19T16:32:04Z CD4 cytotoxic T lymphocytes and immune adaptations in extreme longevity https://biobriefs.com/personalized-mrna-cancer-vaccines-in BioBriefs en 2026-08-19T14:31:53Z Personalized mRNA cancer vaccines in late-stage readouts https://biobriefs.com/glp-1-receptor-antagonist-moves BioBriefs en 2026-08-19T14:31:53Z GLP-1 receptor antagonist moves toward approval for post-bariatric hypoglycemia https://biobriefs.com/china-regulatory-progress-harbour-biomeds BioBriefs en 2026-08-19T14:31:53Z China regulatory progress: Harbour Biomed’s HBM-7004 reaches the clinic https://biobriefs.com/rare-disease-dealmaking-biomarin-acquires BioBriefs en 2026-08-19T14:31:53Z Rare disease dealmaking: BioMarin acquires Alesta program for skeletal pipeline https://biobriefs.com/oncology-trial-updates-in-china BioBriefs en 2026-08-19T14:31:53Z Oncology trial updates in China: Akeso and Summit face shrinking benefit for ivonescimab https://biobriefs.com/partnered-drug-discovery-platform-omniab BioBriefs en 2026-08-19T14:31:53Z Partnered drug discovery platform: OmniAb inks up to $370M Lilly ion-channel collaboration https://biobriefs.com/diagnostics-expansion-craif-pushes-urine BioBriefs en 2026-08-19T14:31:53Z Diagnostics expansion: Craif pushes urine-based pancreatic cancer test toward U.S. trial https://biobriefs.com/neuroscience-technology-live-cell-ras BioBriefs en 2026-08-19T14:31:53Z Neuroscience technology: live-cell Ras activity biosensor enters drug research workflows https://biobriefs.com/fda-policy-on-generative-ai BioBriefs en 2026-08-19T14:31:53Z FDA policy on generative AI devices: agency solicits input on regulating medical tools https://biobriefs.com/biotech-startup-funding-and-compute BioBriefs en 2026-08-19T14:31:53Z Biotech startup funding and compute partnerships: Network Bio launches with Nvidia-backed cfRNA foundation model https://biobriefs.com/post-bariatric-hypoglycemia-drug-readouts BioBriefs en 2026-08-19T10:32:42Z Post-bariatric hypoglycemia drug readouts https://biobriefs.com/u-s-fda-moves-on BioBriefs en 2026-08-19T10:32:42Z U.S. FDA moves on generative AI medical device oversight https://biobriefs.com/protein-biomarkers-and-trial-endpoints BioBriefs en 2026-08-19T10:32:42Z Protein biomarkers and trial endpoints in autoimmune myositis https://biobriefs.com/gene-editing-safety-scrutiny-tied BioBriefs en 2026-08-19T10:32:42Z Gene editing safety scrutiny tied to Huidagene trial decisions https://biobriefs.com/car-t-portfolio-reshuffling-at BioBriefs en 2026-08-19T10:32:42Z CAR T portfolio reshuffling at Janssen https://biobriefs.com/deal-biomarin-expands-rare-bone BioBriefs en 2026-08-19T10:32:42Z Deal: BioMarin expands rare bone pipeline with Alesta buyout https://biobriefs.com/leo-pharma-licensing-for-oral BioBriefs en 2026-08-19T10:32:42Z Leo Pharma licensing for oral rare photosensitivity drug https://biobriefs.com/precision-oncology-infrastructure-navinci-and BioBriefs en 2026-08-19T10:32:42Z Precision oncology infrastructure: NAVINCI and BrainZell spatial proteomics https://biobriefs.com/cancer-immunotherapy-platform-delayed-sting BioBriefs en 2026-08-19T10:32:42Z Cancer immunotherapy platform: delayed STING activation with mRNA vaccines https://biobriefs.com/liquid-biopsy-coverage-push-for BioBriefs en 2026-08-19T10:32:42Z Liquid biopsy coverage push for Freenome https://biobriefs.com/endocrine-rare-disease-drug-progress BioBriefs en 2026-08-19T09:32:09Z Endocrine rare disease drug progress https://biobriefs.com/fda-regulated-gene-editing-scrutiny BioBriefs en 2026-08-19T09:32:09Z FDA-regulated gene editing scrutiny in China https://biobriefs.com/regulatory-pathway-for-ai-enabled BioBriefs en 2026-08-19T09:32:09Z Regulatory pathway for AI-enabled medical devices https://biobriefs.com/fda-commissioner-nomination BioBriefs en 2026-08-19T09:32:09Z FDA commissioner nomination https://biobriefs.com/oncology-franchise-deals-and-pipeline BioBriefs en 2026-08-19T09:32:09Z Oncology franchise deals and pipeline readouts https://biobriefs.com/next-generation-immunotherapy-outcomes-in BioBriefs en 2026-08-19T09:32:09Z Next-generation immunotherapy outcomes in solid tumors https://biobriefs.com/big-pharma-dealmaking-dermatology-acquisition BioBriefs en 2026-08-19T09:32:09Z Big pharma dealmaking—dermatology acquisition and pipeline expansion https://biobriefs.com/biopharma-financing-and-u-s BioBriefs en 2026-08-19T09:32:09Z Biopharma financing and U.S. scale-up for diagnostics https://biobriefs.com/car-t-program-discontinuation-and BioBriefs en 2026-08-19T09:32:09Z CAR T program discontinuation and asset reversion https://biobriefs.com/venture-and-public-market-momentum BioBriefs en 2026-08-19T09:32:09Z Venture and public-market momentum for AI-driven drug discovery https://biobriefs.com/amylyx-pivots-to-glp-1 BioBriefs en 2026-08-19T04:32:07Z Amylyx pivots to GLP-1 blockade and posts a Phase 3 win in PBH https://biobriefs.com/fda-ind-goes-live-for BioBriefs en 2026-08-19T04:32:07Z FDA IND goes live for Amygdala Neurosciences’ ALDH2 inhibitor https://biobriefs.com/leo-pharma-buys-tanabes-late BioBriefs en 2026-08-19T04:32:07Z Leo Pharma buys Tanabe’s late-stage oral rare-skin drug https://biobriefs.com/argenx-wins-phase-3-endpoint BioBriefs en 2026-08-19T04:32:07Z Argenx wins Phase 3 endpoint for subcutaneous Vyvgart Hytrulo in myositis subtype https://biobriefs.com/gsk-backs-out-of-its BioBriefs en 2026-08-19T04:32:07Z GSK backs out of its Verzenio? No—AstraZeneca halts a Phase 3 lung cancer trial https://biobriefs.com/crispr-off-target-nomination-service BioBriefs en 2026-08-19T04:32:07Z CRISPR off-target nomination service expands at IDT https://biobriefs.com/biotech-innovation-funding-freenome-lands BioBriefs en 2026-08-19T04:32:07Z Biotech innovation funding: Freenome lands fresh Wall Street coverage https://biobriefs.com/translational-execution-chilled-platelets-extend BioBriefs en 2026-08-19T04:32:07Z Translational execution: Chilled platelets extend storage window https://biobriefs.com/biotech-governance-and-data-quality BioBriefs en 2026-08-19T04:32:07Z Biotech governance and data quality: standardized subject IDs for CRO portfolios https://biobriefs.com/car-t-portfolio-reset-janssen BioBriefs en 2026-08-19T04:32:07Z CAR-T portfolio reset: Janssen exits CD20/CD19 CAR T program https://biobriefs.com/glp-1-antagonist-avexitide-claims BioBriefs en 2026-08-18T21:32:26Z GLP-1 antagonist avexitide claims Phase 3 win in post-bariatric hypoglycemia (PBH) https://biobriefs.com/fda-policy-on-generative-ai BioBriefs en 2026-08-18T21:32:26Z FDA policy on generative AI medical devices https://biobriefs.com/carcinoma-immunotherapy-pipeline-sees-china BioBriefs en 2026-08-18T21:32:26Z Carcinoma immunotherapy pipeline sees China follow-up pressure on ivonescimab https://biobriefs.com/argenx-pushes-vyvgart-hytrulo-phase BioBriefs en 2026-08-18T21:32:26Z Argenx pushes Vyvgart Hytrulo Phase 3 success in autoimmune myositis subtype https://biobriefs.com/biotech-deals-leo-pharma-acquires BioBriefs en 2026-08-18T21:32:26Z Biotech deals: Leo Pharma acquires dersimelagon from Tanabe for rare photosensitivity skin diseases https://biobriefs.com/genomics-diagnostics-craif-funds-u BioBriefs en 2026-08-18T21:32:26Z Genomics diagnostics: Craif funds U.S. clinical work on urine-based pancreatic cancer test https://biobriefs.com/organ-preservation-bridge-to-life BioBriefs en 2026-08-18T21:32:26Z Organ preservation: Bridge to Life secures $110M for HOPE system expansion https://biobriefs.com/ai-powered-liquid-biopsy-coverage BioBriefs en 2026-08-18T21:32:26Z AI-powered liquid biopsy coverage: Freenome initiates research-backed investor interest https://biobriefs.com/car-t-rights-reshuffle-janssen BioBriefs en 2026-08-18T21:32:26Z CAR T rights reshuffle: Janssen exits CD20/CD19 CAR T development; Abelzeta regains rights https://biobriefs.com/clinical-trial-setbacks-in-wet BioBriefs en 2026-08-18T21:32:26Z Clinical trial setbacks in wet AMD: EyePoint Duravyu Phase 3 fails non-inferiority https://biobriefs.com/endocrine-breakthrough-for-post-bariatric BioBriefs en 2026-08-18T16:32:11Z Endocrine breakthrough for post-bariatric hypoglycemia https://biobriefs.com/regulatory-expansion-for-fcrn-antagonist BioBriefs en 2026-08-18T16:32:11Z Regulatory expansion for FcRn antagonist Vyvgart Hytrulo in myositis https://biobriefs.com/large-oncology-deal-biomarin-acquires BioBriefs en 2026-08-18T16:32:11Z Large oncology deal: BioMarin acquires Alesta to replenish bone pipeline https://biobriefs.com/car-t-rights-shuffle-janssen BioBriefs en 2026-08-18T16:32:11Z CAR T rights shuffle: Janssen exits CD20/CD19 program https://biobriefs.com/fda-action-ind-clearance-for BioBriefs en 2026-08-18T16:32:11Z FDA action: IND clearance for ALDH2 inhibitor ANS-858 https://biobriefs.com/oncology-imaging-collaboration-navinci-and BioBriefs en 2026-08-18T16:32:11Z Oncology imaging collaboration: Navinci and BrainZell expand spatial proteomics https://biobriefs.com/adc-early-clinical-signal-boans BioBriefs en 2026-08-18T16:32:11Z ADC early clinical signal: Boan’s CD228-targeted BA-1302 https://biobriefs.com/platform-and-funding-craif-raises BioBriefs en 2026-08-18T16:32:11Z Platform and funding: Craif raises $33M to advance urine pancreatic cancer test to US trial https://biobriefs.com/corporate-strategy-fresenius-launches-eur200m BioBriefs en 2026-08-18T16:32:11Z Corporate strategy: Fresenius launches €200M fund for emerging biotech talent https://biobriefs.com/regulatory-and-clinical-setback-eyepoints BioBriefs en 2026-08-18T16:32:11Z Regulatory and clinical setback: Eyepoint’s Duravyu Phase 3 fails primary endpoint https://biobriefs.com/leo-pharma-buys-late-stage BioBriefs en 2026-08-18T14:32:14Z LEO Pharma buys late-stage rare-disease oral asset from Tanabe https://biobriefs.com/amylyx-posts-phase-3-win BioBriefs en 2026-08-18T14:32:14Z Amylyx posts Phase 3 win for GLP-1 antagonist avexitide after bariatric surgery https://biobriefs.com/argenxs-vyvgart-hytrulo-hits-phase BioBriefs en 2026-08-18T14:32:14Z Argenx’s Vyvgart Hytrulo hits Phase 3 signal in autoimmune myositis https://biobriefs.com/biomarin-buys-alesta-therapeutics-in BioBriefs en 2026-08-18T14:32:14Z BioMarin buys Alesta Therapeutics in $275M push toward rare bone disease https://biobriefs.com/bristol-myers-loses-courtroom-shield BioBriefs en 2026-08-18T14:32:14Z Bristol Myers loses courtroom shield in Breyanzi delayed-approval suit https://biobriefs.com/eyepoints-wet-amd-phase-3 BioBriefs en 2026-08-18T14:32:14Z EyePoint’s wet AMD Phase 3 insert fails primary goal vs Eylea https://biobriefs.com/reverse-merger-surge-slate-and BioBriefs en 2026-08-18T14:32:14Z Reverse-merger surge: Slate and Fulcrum combine to fund migraine pipeline https://biobriefs.com/regulatory-timing-reform-push-for BioBriefs en 2026-08-18T14:32:14Z Regulatory timing reform push for US first-in-human trials https://biobriefs.com/precision-oncology-collaboration-thermo-fisher BioBriefs en 2026-08-18T14:32:14Z Precision oncology collaboration: Thermo Fisher and KYAN partner on tumoroid-based drug response testing https://biobriefs.com/microbiome-culturing-startup-bac-3 BioBriefs en 2026-08-18T14:32:14Z Microbiome culturing startup Bac 3 Gel aims to boost species recovery from complex samples https://biobriefs.com/obesity-drug-concept-with-potential BioBriefs en 2026-08-18T10:32:11Z Obesity drug concept with potential muscle-preservation angle https://biobriefs.com/myositis-fcrn-antagonist-expands-with BioBriefs en 2026-08-18T10:32:11Z Myositis: FcRn antagonist expands with subcutaneous Vyvgart Hytrulo Phase 3 signal https://biobriefs.com/eye-care-eyepoints-duravyu-phase BioBriefs en 2026-08-18T10:32:11Z Eye care: Eyepoint’s Duravyu Phase 3 strategy hits primary endpoint miss https://biobriefs.com/fda-pathway-timing-pressure-us BioBriefs en 2026-08-18T10:32:11Z FDA pathway timing pressure: US moves to cut pre-IND timelines https://biobriefs.com/cro-operations-new-subject-id BioBriefs en 2026-08-18T10:32:11Z CRO operations: new subject-ID schema aims to fix tracking fragmentation https://biobriefs.com/biotech-licensing-leo-pharma-pays BioBriefs en 2026-08-18T10:32:11Z Biotech licensing: Leo Pharma pays up to $435M for Tanabe rare skin disease drug https://biobriefs.com/clinical-development-astrazeneca-drops-phase BioBriefs en 2026-08-18T10:32:11Z Clinical development: AstraZeneca drops Phase 3 volrustomig lung cancer study https://biobriefs.com/gene-editing-tools-idt-expands BioBriefs en 2026-08-18T10:32:11Z Gene editing tools: IDT expands CRISPR off-target nomination with UNCOVERseq https://biobriefs.com/oncology-genomics-operations-centralized-processing BioBriefs en 2026-08-18T10:32:11Z Oncology genomics operations: centralized processing for whole-genome data from frozen tumors https://biobriefs.com/platelet-storage-chilled-platelets-can BioBriefs en 2026-08-18T10:32:11Z Platelet storage: chilled platelets can safely extend supplies up to 21 days https://biobriefs.com/clinical-wins-and-setbacks-in BioBriefs en 2026-08-18T09:32:35Z Clinical wins and setbacks in late-stage ophthalmology and immunology https://biobriefs.com/regulatory-and-legal-pressure-on BioBriefs en 2026-08-18T09:32:35Z Regulatory and legal pressure on drug approvals https://biobriefs.com/drug-pipeline-updates-and-platform BioBriefs en 2026-08-18T09:32:35Z Drug pipeline updates and platform pivots in immuno-oncology https://biobriefs.com/funding-and-public-market-access BioBriefs en 2026-08-18T09:32:35Z Funding and public-market access via reverse mergers and private placements https://biobriefs.com/big-pharma-dealmaking-in-rare BioBriefs en 2026-08-18T09:32:35Z Big pharma dealmaking in rare disease and platform partnerships https://biobriefs.com/ai-enabled-platforms-ramp-in BioBriefs en 2026-08-18T09:32:35Z AI-enabled platforms ramp in drug discovery and healthcare workflows https://biobriefs.com/precision-immunology-and-next-gen BioBriefs en 2026-08-18T09:32:35Z Precision immunology and next-gen therapeutics design https://biobriefs.com/oncology-biomarker-and-trial-adjacent BioBriefs en 2026-08-18T09:32:35Z Oncology biomarker and trial-adjacent measurement advances https://biobriefs.com/clinical-and-operational-system-changes BioBriefs en 2026-08-18T09:32:35Z Clinical and operational system changes in early-stage drug development https://biobriefs.com/platform-and-methodology-innovation-monitoring BioBriefs en 2026-08-18T09:32:35Z Platform and methodology innovation: monitoring, delivery, and trial execution https://biobriefs.com/ocular-drug-setback-in-wet BioBriefs en 2026-08-18T04:32:03Z Ocular drug setback in wet AMD trial https://biobriefs.com/vyvgart-expands-in-myositis-with BioBriefs en 2026-08-18T04:32:03Z Vyvgart expands in myositis with Phase 3 win https://biobriefs.com/astrazeneca-halts-lung-cancer-phase BioBriefs en 2026-08-18T04:32:03Z AstraZeneca halts lung cancer Phase 3 volrustomig https://biobriefs.com/bristol-myers-faces-legal-challenge BioBriefs en 2026-08-18T04:32:03Z Bristol Myers faces legal challenge over Breyanzi approval delays https://biobriefs.com/fda-adjacent-r-d-turmoil BioBriefs en 2026-08-18T04:32:03Z FDA-adjacent R&D turmoil: proposed US research funding rule changes https://biobriefs.com/carbohydrate-free-platelet-supply-extension BioBriefs en 2026-08-18T04:32:03Z Carbohydrate-free platelet supply extension with chilled storage https://biobriefs.com/gene-editing-safety-and-off BioBriefs en 2026-08-18T04:32:03Z Gene editing safety and off-target nomination improvements https://biobriefs.com/migraine-biotech-reverse-merger-and BioBriefs en 2026-08-18T04:32:03Z Migraine biotech reverse merger and financing https://biobriefs.com/car-t-rights-shift-after BioBriefs en 2026-08-18T04:32:03Z CAR-T rights shift after Janssen termination https://biobriefs.com/radiopharmaceutical-trial-in-kidney-cancer BioBriefs en 2026-08-18T04:32:03Z Radiopharmaceutical trial in kidney cancer shows no bone-complication reduction https://biobriefs.com/migraine-monetization-and-pipeline-reshuffling BioBriefs en 2026-08-17T21:32:05Z Migraine monetization and pipeline reshuffling https://biobriefs.com/wet-amd-setbacks-and-competitive BioBriefs en 2026-08-17T21:32:05Z Wet AMD setbacks and competitive pressure https://biobriefs.com/autoimmune-myositis-expansion-for-vyvgart BioBriefs en 2026-08-17T21:32:05Z Autoimmune myositis expansion for Vyvgart Hytrulo https://biobriefs.com/cold-stored-platelets-approach-durable BioBriefs en 2026-08-17T21:32:05Z Cold-stored platelets approach durable storage window https://biobriefs.com/big-pharma-trial-failures-in BioBriefs en 2026-08-17T21:32:05Z Big Pharma trial failures in lung cancer https://biobriefs.com/gene-therapy-litigation-over-fda BioBriefs en 2026-08-17T21:32:05Z Gene therapy litigation over FDA timing https://biobriefs.com/precision-gene-editing-services-improving BioBriefs en 2026-08-17T21:32:05Z Precision gene editing services: improving CRISPR off-target nomination https://biobriefs.com/cell-free-dna-toxicity-monitoring BioBriefs en 2026-08-17T21:32:05Z Cell-free DNA toxicity monitoring https://biobriefs.com/gene-edited-pets-and-allergy BioBriefs en 2026-08-17T21:32:05Z Gene-edited pets and allergy risk https://biobriefs.com/autoimmunity-and-immunotherapy-platform-economics BioBriefs en 2026-08-17T21:32:05Z Autoimmunity and immunotherapy platform economics https://biobriefs.com/argenx-expands-vyvgart-reach-in BioBriefs en 2026-08-17T16:32:01Z Argenx expands Vyvgart reach in autoimmune myositis with new Phase 3 readout https://biobriefs.com/astrazeneca-pulls-lung-cancer-bispecific BioBriefs en 2026-08-17T16:32:01Z AstraZeneca pulls lung cancer bispecific trial after interim survival check https://biobriefs.com/eyepoint-fails-pivotal-phase-3 BioBriefs en 2026-08-17T16:32:01Z EyePoint fails pivotal Phase 3 in wet AMD – stock reels https://biobriefs.com/caris-cro-data-infrastructure-new BioBriefs en 2026-08-17T16:32:01Z Caris/CRO data infrastructure: new standardized subject ID schema aims to reduce duplication across portfolios https://biobriefs.com/systems-medicine-for-cancer-models BioBriefs en 2026-08-17T16:32:01Z Systems medicine for cancer models: Jackson Laboratory promotes improved humanized platforms https://biobriefs.com/precision-oncology-resources-tumor-derived BioBriefs en 2026-08-17T16:32:01Z Precision oncology resources: tumor-derived organoid biobank maps gene dependencies across cancer types https://biobriefs.com/oncology-innovation-virus-like-particles BioBriefs en 2026-08-17T16:32:01Z Oncology innovation: virus-like particles expand gene engineering and pooled CRISPR screening in primary myeloid cells https://biobriefs.com/regulatory-and-commercialization-planning-celcuity BioBriefs en 2026-08-17T16:32:01Z Regulatory and commercialization planning: Celcuity waits for FDA review on second factory for approved cancer drug https://biobriefs.com/biopharma-funding-and-market-access BioBriefs en 2026-08-17T16:32:01Z Biopharma funding and market access: reverse merger wave targets public listings and trial capital https://biobriefs.com/bank-coverage-and-commercialization-momentum BioBriefs en 2026-08-17T16:32:01Z Bank coverage and commercialization momentum: Freenome initiates coverage with buy ratings as Abbott and Roche deals underpin cancer screening push https://biobriefs.com/regulatory-approvals-label-expansions-in BioBriefs en 2026-08-17T14:32:45Z Regulatory approvals & label expansions in oncology diagnostics https://biobriefs.com/astrazenecas-lung-cancer-pipeline-setbacks BioBriefs en 2026-08-17T14:32:45Z AstraZeneca’s lung cancer pipeline setbacks https://biobriefs.com/late-stage-autoimmune-drug-efficacy BioBriefs en 2026-08-17T14:32:45Z Late-stage autoimmune drug efficacy signal with a subgroup miss https://biobriefs.com/portfolio-shift-in-next-gen BioBriefs en 2026-08-17T14:32:45Z Portfolio shift in next-gen cancer vaccines https://biobriefs.com/trial-outcomes-in-bladder-cancer BioBriefs en 2026-08-17T14:32:45Z Trial outcomes in bladder cancer immunotherapy https://biobriefs.com/drug-resistance-surveillance-in-malaria BioBriefs en 2026-08-17T14:32:45Z Drug resistance surveillance in malaria https://biobriefs.com/clinical-evidence-critique-in-maternal BioBriefs en 2026-08-17T14:32:45Z Clinical evidence critique in maternal-neonatal nutrition trial https://biobriefs.com/gene-engineering-enabling-pooled-crispr BioBriefs en 2026-08-17T14:32:45Z Gene engineering enabling pooled CRISPR screens in myeloid cells https://biobriefs.com/health-care-ai-operations-still BioBriefs en 2026-08-17T14:32:45Z Health-care AI operations still ahead of governance https://biobriefs.com/mechanistic-cancer-biology-metabolic-and BioBriefs en 2026-08-17T14:32:45Z Mechanistic cancer biology: metabolic and DNA-damage linked ferroptosis pathways https://biobriefs.com/astrazeneca-clinical-setback BioBriefs en 2026-08-17T10:32:07Z AstraZeneca clinical setback https://biobriefs.com/astrazeneca-earlier-lung-cancer-hold BioBriefs en 2026-08-17T10:32:07Z AstraZeneca earlier lung-cancer hold https://biobriefs.com/oncolytic-immunotherapy-in-bladder-cancer BioBriefs en 2026-08-17T10:32:07Z Oncolytic immunotherapy in bladder cancer https://biobriefs.com/contract-development-manufacturing-expansion BioBriefs en 2026-08-17T10:32:07Z Contract development & manufacturing expansion https://biobriefs.com/digital-tools-for-genome-editing BioBriefs en 2026-08-17T10:32:07Z Digital tools for genome editing in primary cells https://biobriefs.com/aging-biology-via-glp-1 BioBriefs en 2026-08-17T10:32:07Z Aging biology via GLP-1 signaling https://biobriefs.com/parkinsons-diagnostic-biomarker-panel BioBriefs en 2026-08-17T10:32:07Z Parkinson’s diagnostic biomarker panel https://biobriefs.com/targeting-metabolic-resistance-in-thyroid BioBriefs en 2026-08-17T10:32:07Z Targeting metabolic resistance in thyroid cancer https://biobriefs.com/malaria-drug-resistance-mutations-in BioBriefs en 2026-08-17T10:32:07Z Malaria drug resistance mutations in Uganda https://biobriefs.com/genome-scale-organoid-dependency-mapping BioBriefs en 2026-08-17T10:32:07Z Genome-scale organoid dependency mapping resource https://biobriefs.com/astrazeneca-pauses-volrustomig-phase-3 BioBriefs en 2026-08-17T09:31:56Z AstraZeneca pauses volrustomig Phase 3 in lung cancer https://biobriefs.com/astrazeneca-halts-additional-late-stage BioBriefs en 2026-08-17T09:31:56Z AstraZeneca halts additional late-stage lung cancer study https://biobriefs.com/cretostimogene-grenadenorepvec-posts-strong-phase BioBriefs en 2026-08-17T09:31:56Z Cretostimogene grenadenorepvec posts strong Phase 3 complete response in BCG-unresponsive NMIBC https://biobriefs.com/new-tumor-organoid-biobank-maps BioBriefs en 2026-08-17T09:31:56Z New tumor-organoid biobank maps drug and gene vulnerabilities https://biobriefs.com/pd-1-pathway-coordinates-brain BioBriefs en 2026-08-17T09:31:56Z PD-1 pathway coordinates brain antiviral immunity while limiting neuroinflammation https://biobriefs.com/long-term-glp-1-exposure BioBriefs en 2026-08-17T09:31:56Z Long-term GLP-1 exposure remodels pancreatic beta-cell gene expression https://biobriefs.com/blocking-phgdh-reverses-dabrafenib-resistance BioBriefs en 2026-08-17T09:31:56Z Blocking PHGDH reverses dabrafenib resistance in BRAF V600E anaplastic thyroid cancer https://biobriefs.com/dusp4-boosts-antitumor-cd8-t BioBriefs en 2026-08-17T09:31:56Z DUSP4 boosts antitumor CD8 T-cell function and CAR-T efficacy in colorectal cancer models https://biobriefs.com/fujifilm-biotechnologies-expands-in-fda BioBriefs en 2026-08-17T09:31:56Z Fujifilm Biotechnologies expands in FDA PreCheck Pilot with new commercial facility selection https://biobriefs.com/vogenx-raises-81m-in-ipo BioBriefs en 2026-08-17T09:31:56Z Vogenx raises $81M in IPO to advance mizagliflozin into Phase 2b for PBH https://biobriefs.com/bladder-cancer-immunotherapy-efficacy-in BioBriefs en 2026-08-17T04:31:52Z Bladder cancer immunotherapy efficacy in BCG-unresponsive disease https://biobriefs.com/drug-pricing-and-reimbursement-pressure BioBriefs en 2026-08-17T04:31:52Z Drug pricing and reimbursement pressure on women’s health companies https://biobriefs.com/glp-1-biology-with-long BioBriefs en 2026-08-17T04:31:52Z GLP-1 biology with long-term exposure effects on beta cells https://biobriefs.com/new-organoid-biobank-mapping-tumor BioBriefs en 2026-08-17T04:31:52Z New organoid biobank mapping tumor dependencies for precision oncology https://biobriefs.com/thyroid-cancer-resistance-reversal-via BioBriefs en 2026-08-17T04:31:52Z Thyroid cancer resistance reversal via metabolic target PHGDH https://biobriefs.com/colorectal-cancer-immunotherapy-biology-dusp4 BioBriefs en 2026-08-17T04:31:52Z Colorectal cancer immunotherapy biology: DUSP4 boosts CD8+ T cells and CAR-T https://biobriefs.com/post-surgery-neuropathic-pain-mechanism BioBriefs en 2026-08-17T04:31:52Z Post-surgery neuropathic pain mechanism via PARP1 and ferroptosis https://biobriefs.com/cognition-in-parkinsons-theta-rhythm BioBriefs en 2026-08-17T04:31:52Z Cognition in Parkinson’s: theta-rhythm stimulation improves performance https://biobriefs.com/disease-monitoring-hardware-epoxy-engineered BioBriefs en 2026-08-17T04:31:52Z Disease monitoring hardware: epoxy-engineered PZT sensors for swallowing and health signals https://biobriefs.com/ai-deployment-in-healthcare-administration BioBriefs en 2026-08-17T04:31:52Z AI deployment in healthcare administration: Commure referral compensation scrutiny https://biobriefs.com/oncolytic-immunotherapy BioBriefs en 2026-08-16T21:32:15Z Oncolytic immunotherapy https://biobriefs.com/gene-editing-allergy-mitigation BioBriefs en 2026-08-16T21:32:15Z Gene-editing allergy mitigation https://biobriefs.com/regulatory-fallout-and-vaccine-safety BioBriefs en 2026-08-16T21:32:15Z Regulatory fallout and vaccine safety https://biobriefs.com/cdmo-capacity-and-fda-readiness BioBriefs en 2026-08-16T21:32:15Z CDMO capacity and FDA readiness https://biobriefs.com/fda-decision-path-for-duchenne BioBriefs en 2026-08-16T21:32:15Z FDA decision path for Duchenne cell therapy https://biobriefs.com/immunotherapy-biosimilar-backbone-in-gastric BioBriefs en 2026-08-16T21:32:15Z Immunotherapy + biosimilar backbone in gastric cancer https://biobriefs.com/tumor-model-resource-for-precision BioBriefs en 2026-08-16T21:32:15Z Tumor model resource for precision oncology https://biobriefs.com/metabolic-targeting-to-reverse-drug BioBriefs en 2026-08-16T21:32:15Z Metabolic targeting to reverse drug resistance https://biobriefs.com/cdmo-and-manufacturing-quality-systems BioBriefs en 2026-08-16T21:32:15Z CDMO and manufacturing quality systems https://biobriefs.com/ai-and-precision-patient-monitoring BioBriefs en 2026-08-16T21:32:15Z AI and precision patient monitoring https://biobriefs.com/multiple-myeloma-regulatory-milestone BioBriefs en 2026-08-16T16:32:00Z Multiple myeloma regulatory milestone https://biobriefs.com/first-in-class-fda-approval BioBriefs en 2026-08-16T16:32:00Z First-in-class FDA approval for a new drug class https://biobriefs.com/oncology-immunotherapy-late-stage-efficacy BioBriefs en 2026-08-16T16:32:00Z Oncology immunotherapy late-stage efficacy https://biobriefs.com/regulatory-development-disruption-and-milestone BioBriefs en 2026-08-16T16:32:00Z Regulatory development disruption and milestone economics https://biobriefs.com/fda-application-amendment-after-prior BioBriefs en 2026-08-16T16:32:00Z FDA application amendment after prior complete response letter https://biobriefs.com/viral-biomarker-validation-and-pipeline BioBriefs en 2026-08-16T16:32:00Z Viral-biomarker validation and pipeline credibility https://biobriefs.com/retraction-in-breast-cancer-preclinical BioBriefs en 2026-08-16T16:32:00Z Retraction in breast cancer preclinical research https://biobriefs.com/new-oncolytic-immunotherapy-trial-result BioBriefs en 2026-08-16T16:32:00Z New oncolytic immunotherapy trial result https://biobriefs.com/biosecurity-and-regulatory-science-dispute BioBriefs en 2026-08-16T16:32:00Z Biosecurity and regulatory science dispute over clinical coding https://biobriefs.com/ai-in-life-sciences-clinical BioBriefs en 2026-08-16T16:32:00Z AI in life sciences—clinical semantics focus https://biobriefs.com/multiple-myeloma-fda-approvals-and BioBriefs en 2026-08-16T14:32:15Z Multiple myeloma FDA approvals and label expansion https://biobriefs.com/protein-degraders-and-celmods-as BioBriefs en 2026-08-16T14:32:15Z Protein degraders and CELMoDs as a new oncology modality https://biobriefs.com/oncolytic-immunotherapy-in-bcg-unresponsive BioBriefs en 2026-08-16T14:32:15Z Oncolytic immunotherapy in BCG-unresponsive bladder cancer https://biobriefs.com/duchenne-muscular-dystrophy-regulatory-pathway BioBriefs en 2026-08-16T14:32:15Z Duchenne muscular dystrophy regulatory pathway shift for deramiocel https://biobriefs.com/regulatory-clearance-withdrawn-for-ct BioBriefs en 2026-08-16T14:32:15Z Regulatory clearance withdrawn for CT/NG molecular test https://biobriefs.com/biopharma-manufacturing-capacity-and-fda BioBriefs en 2026-08-16T14:32:15Z BioPharma manufacturing capacity and FDA readiness programs https://biobriefs.com/contracting-investment-into-clinical-stage BioBriefs en 2026-08-16T14:32:15Z Contracting investment into clinical-stage AI-driven primary care https://biobriefs.com/stealth-to-clinic-launch-for BioBriefs en 2026-08-16T14:32:15Z Stealth-to-clinic launch for B cell–targeted autoimmune biopharma https://biobriefs.com/private-biotech-funding-for-next BioBriefs en 2026-08-16T14:32:15Z Private biotech funding for next-stage schizophrenia tools https://biobriefs.com/biotech-quality-and-scientific-validity BioBriefs en 2026-08-16T14:32:15Z Biotech quality and scientific validity via journal retractions https://biobriefs.com/fda-approval-first-in-class BioBriefs en 2026-08-16T10:31:46Z FDA approval – first-in-class CELMoDs expansion in multiple myeloma https://biobriefs.com/oncology-trial-oncolytic-immunotherapy-achieves BioBriefs en 2026-08-16T10:31:46Z Oncology trial – oncolytic immunotherapy achieves high complete response in BCG-unresponsive NMIBC https://biobriefs.com/biotech-funding-new-stealth-launch BioBriefs en 2026-08-16T10:31:46Z Biotech funding – new stealth launch for autoimmune platform-backed by Deerfield https://biobriefs.com/regulatory-commercial-orasure-withdraws-fda BioBriefs en 2026-08-16T10:31:46Z Regulatory & commercial – OraSure withdraws FDA submission for CT/NG test, rewires milestone economics https://biobriefs.com/biotech-pipeline-capricor-seeks-fda BioBriefs en 2026-08-16T10:31:46Z Biotech pipeline – Capricor seeks FDA review after advisory vote for deramiocel in Duchenne https://biobriefs.com/cdmo-manufacturing-fujifilm-biotechnologies-expands BioBriefs en 2026-08-16T10:31:46Z CDMO / manufacturing – Fujifilm Biotechnologies expands cell culture capacity under FDA PreCheck https://biobriefs.com/genomics-platform-freenome-gets-analyst BioBriefs en 2026-08-16T10:31:46Z Genomics platform – Freenome gets analyst initiation after SimpleScreen CRC FDA approval https://biobriefs.com/acquisition-rare-disease-gene-therapy BioBriefs en 2026-08-16T10:31:46Z Acquisition & rare disease gene therapy – PTC buys Sangamo’s ST-920 in auction https://biobriefs.com/company-financing-illumina-secures-1b BioBriefs en 2026-08-16T10:31:46Z Company financing – Illumina secures $1B credit facility and launches note offering https://biobriefs.com/preclinical-translational-biology-organoid-biobank BioBriefs en 2026-08-16T10:31:46Z Preclinical translational biology – organoid biobank maps colorectal and other cancer dependencies https://biobriefs.com/first-in-class-celmod-myeloma BioBriefs en 2026-08-16T09:31:41Z First-in-class CELMoD myeloma approval in the US https://biobriefs.com/capricor-looks-for-fda-reconsideration BioBriefs en 2026-08-16T09:31:41Z Capricor looks for FDA reconsideration after DMD setback https://biobriefs.com/m-a-and-licensing-ptc BioBriefs en 2026-08-16T09:31:41Z M&A and licensing: PTC wins Sangamo’s Fabry gene therapy https://biobriefs.com/manufacturing-scale-up-and-capacity BioBriefs en 2026-08-16T09:31:41Z Manufacturing scale-up and capacity commitments in biopharma https://biobriefs.com/multiple-myeloma-manufacturing-and-platform BioBriefs en 2026-08-16T09:31:41Z Multiple myeloma manufacturing and platform collaboration push https://biobriefs.com/regulatory-pathway-clarity-for-rare BioBriefs en 2026-08-16T09:31:41Z Regulatory pathway clarity for rare disease: Polaryx Q&A https://biobriefs.com/contract-research-and-manufacturing-fda BioBriefs en 2026-08-16T09:31:41Z Contract research and manufacturing: FDA withdrawal delays OraSure CT/NG test https://biobriefs.com/oncology-translational-platform-open-organoid BioBriefs en 2026-08-16T09:31:41Z Oncology translational platform: open organoid dependency biobank https://biobriefs.com/anticancer-approach-dusp4-boosts-cd8 BioBriefs en 2026-08-16T09:31:41Z Anticancer approach: DUSP4 boosts CD8 CAR-T activity in vivo https://biobriefs.com/diagnostics-and-commercialization-proteotype-prepares BioBriefs en 2026-08-16T09:31:41Z Diagnostics and commercialization: Proteotype prepares new CE-IVDR support study https://biobriefs.com/multiple-myeloma-regulatory-approval BioBriefs en 2026-08-16T04:32:08Z Multiple myeloma regulatory approval https://biobriefs.com/duchenne-muscular-dystrophy-regulatory-path BioBriefs en 2026-08-16T04:32:08Z Duchenne muscular dystrophy regulatory path https://biobriefs.com/cell-therapy-resurgence-via-open BioBriefs en 2026-08-16T04:32:08Z Cell therapy resurgence via open-label FDA-cleared data https://biobriefs.com/multiple-myeloma-manufacturing-and-ai BioBriefs en 2026-08-16T04:32:08Z Multiple myeloma: manufacturing and AI discovery collaboration https://biobriefs.com/gene-therapy-deal-sangamo-fabry BioBriefs en 2026-08-16T04:32:08Z Gene therapy deal: Sangamo Fabry asset sold via auction https://biobriefs.com/diagnostics-regulation-orasure-withdraws-fda BioBriefs en 2026-08-16T04:32:08Z Diagnostics regulation: OraSure withdraws FDA submission https://biobriefs.com/early-cancer-detection-proteotype-study BioBriefs en 2026-08-16T04:32:08Z Early cancer detection: Proteotype study to support CE-IVDR filing https://biobriefs.com/company-funding-and-pipeline-build BioBriefs en 2026-08-16T04:32:08Z Company funding and pipeline build: Boulevard emerges from stealth https://biobriefs.com/biotech-reorganization-biocryst-shifts-to BioBriefs en 2026-08-16T04:32:08Z Biotech reorganization: BioCryst shifts to external innovation https://biobriefs.com/oncology-translational-model-tumor-organoid BioBriefs en 2026-08-16T04:32:08Z Oncology translational model: tumor organoid dependency biobank https://biobriefs.com/regulatory-approvals-and-fda-decisions BioBriefs en 2026-08-15T21:31:23Z Regulatory approvals and FDA decisions https://biobriefs.com/late-stage-bladder-cancer-immunotherapy BioBriefs en 2026-08-15T21:31:23Z Late-stage bladder cancer immunotherapy https://biobriefs.com/rare-disease-cell-therapy-regulatory BioBriefs en 2026-08-15T21:31:23Z Rare disease cell therapy regulatory pathway shifts https://biobriefs.com/myeloma-drug-economics-and-payer BioBriefs en 2026-08-15T21:31:23Z Myeloma drug economics and payer coverage behavior https://biobriefs.com/healthcare-market-signals-and-platform BioBriefs en 2026-08-15T21:31:23Z Healthcare market signals and platform monetization https://biobriefs.com/liquid-biopsy-investments-and-market BioBriefs en 2026-08-15T21:31:23Z Liquid biopsy investments and market positioning https://biobriefs.com/biotech-manufacturing-capacity-and-fda BioBriefs en 2026-08-15T21:31:23Z Biotech manufacturing capacity and FDA-facing quality programs https://biobriefs.com/funding-and-financing-for-innovation BioBriefs en 2026-08-15T21:31:23Z Funding and financing for innovation-driven healthcare startups https://biobriefs.com/aging-and-neurobiologic-biotech-platform BioBriefs en 2026-08-15T21:31:23Z Aging and neurobiologic biotech platform funding https://biobriefs.com/protein-sequencing-platform-timeline-adjustment BioBriefs en 2026-08-15T21:31:23Z Protein sequencing platform timeline adjustment https://biobriefs.com/multiple-myeloma-regulatory-approval BioBriefs en 2026-08-15T16:31:23Z Multiple myeloma regulatory approval https://biobriefs.com/capricor-duchenne-regulatory-strategy-shift BioBriefs en 2026-08-15T16:31:23Z Capricor Duchenne regulatory strategy shift https://biobriefs.com/sangamo-gene-therapy-sold-via BioBriefs en 2026-08-15T16:31:23Z Sangamo gene therapy sold via bankruptcy auction https://biobriefs.com/oral-immune-tolerance-therapy-enters BioBriefs en 2026-08-15T16:31:23Z Oral immune tolerance therapy enters clinical stage for type 1 diabetes https://biobriefs.com/protein-cross-section-diagnostics-push BioBriefs en 2026-08-15T16:31:23Z Protein cross-section diagnostics push for CE-IVDR and new clinical study https://biobriefs.com/biotech-funding-and-company-launches BioBriefs en 2026-08-15T16:31:23Z Biotech funding and company launches: Boulevard emerges from stealth https://biobriefs.com/advance-in-proteomics-for-parkinsons BioBriefs en 2026-08-15T16:31:23Z Advance in proteomics for Parkinson’s precision medicine resources https://biobriefs.com/capital-markets-illumina-raises-debt BioBriefs en 2026-08-15T16:31:23Z Capital markets: Illumina raises debt and issues notes https://biobriefs.com/funding-and-financing-quantum-si BioBriefs en 2026-08-15T16:31:23Z Funding and financing: Quantum-Si delays Proteus and reduces workforce https://biobriefs.com/diagnostics-orasure-withdraws-fda-submission BioBriefs en 2026-08-15T16:31:23Z Diagnostics: OraSure withdraws FDA submission for CT/NG test https://biobriefs.com/fda-approvals-multiple-myeloma-protein BioBriefs en 2026-08-15T14:32:03Z FDA approvals – multiple myeloma protein degrader debut https://biobriefs.com/capricor-duchenne-cell-therapy-bla BioBriefs en 2026-08-15T14:32:03Z Capricor – Duchenne cell therapy BLA pathway shifts after FDA open-label results https://biobriefs.com/biogen-first-china-approval-for BioBriefs en 2026-08-15T14:32:03Z Biogen – first China approval for multiple myeloma monoclonal antibody https://biobriefs.com/fda-submission-setback-orasure-pulls BioBriefs en 2026-08-15T14:32:03Z FDA submission setback – OraSure pulls CT/NG submission tied to Sherlock milestone payments https://biobriefs.com/corporate-finance-silence-therapeutics-upsized BioBriefs en 2026-08-15T14:32:03Z Corporate finance – silence therapeutics upsized funding for siRNA pipeline after Phase 2 win https://biobriefs.com/company-funding-launch-boulevard-emerges BioBriefs en 2026-08-15T14:32:03Z Company funding/launch – Boulevard emerges from stealth with $65M for quarterly autoimmune antibodies https://biobriefs.com/clinical-research-theta-rhythm-stimulation BioBriefs en 2026-08-15T14:32:03Z Clinical research – Theta-rhythm stimulation shows cognitive benefit in Parkinson’s impairment https://biobriefs.com/cancer-immunology-phgdh-blockade-reverses BioBriefs en 2026-08-15T14:32:03Z Cancer immunology – PHGDH blockade reverses dabrafenib resistance in BRAF V600E anaplastic thyroid cancer https://biobriefs.com/genomics-dx-proteotype-launches-clinical BioBriefs en 2026-08-15T14:32:03Z Genomics/dx – Proteotype launches clinical studies to support CE-IVDR filing for Enlighten MCED test https://biobriefs.com/bio-manufacturing-tech-shift-merger BioBriefs en 2026-08-15T14:32:03Z Bio manufacturing/tech shift – Merger-backed public platform moves into fibrosis pipeline with $125M https://biobriefs.com/regulatory-approvals-in-oncology BioBriefs en 2026-08-15T10:31:51Z Regulatory approvals in oncology https://biobriefs.com/china-regulatory-greenlights-for-oncology BioBriefs en 2026-08-15T10:31:51Z China regulatory greenlights for oncology and diagnostics https://biobriefs.com/carve-outs-licensing-and-deals BioBriefs en 2026-08-15T10:31:51Z Carve-outs, licensing, and deals reshaping rare-disease gene therapy portfolios https://biobriefs.com/car-t-and-advanced-cell BioBriefs en 2026-08-15T10:31:51Z CAR-T and advanced cell therapy evolution in oncology https://biobriefs.com/duchenne-muscular-dystrophy-fda-pathway BioBriefs en 2026-08-15T10:31:51Z Duchenne muscular dystrophy: FDA pathway maneuver for deramiocel https://biobriefs.com/late-stage-diabetes-and-obesity BioBriefs en 2026-08-15T10:31:51Z Late-stage diabetes and obesity therapeutics: market access and policy pressure https://biobriefs.com/biotech-funding-and-launch-financing BioBriefs en 2026-08-15T10:31:51Z Biotech funding and launch financing https://biobriefs.com/capital-markets-and-corporate-finance BioBriefs en 2026-08-15T10:31:51Z Capital markets and corporate finance for life science tools https://biobriefs.com/clinical-development-setbacks-and-adjustments BioBriefs en 2026-08-15T10:31:51Z Clinical development setbacks and adjustments in respiratory oncology https://biobriefs.com/next-generation-analytics-liquid-biopsy BioBriefs en 2026-08-15T10:31:51Z Next-generation analytics: liquid biopsy and companion diagnostics platform progress https://biobriefs.com/multiple-myeloma-fda-accelerated-approval BioBriefs en 2026-08-15T09:32:07Z Multiple myeloma – FDA accelerated approval and next-gen CELMoDs https://biobriefs.com/multiple-myeloma-china-market-entry BioBriefs en 2026-08-15T09:32:07Z Multiple myeloma – China market entry for felzartamab https://biobriefs.com/duchenne-muscular-dystrophy-capricor-shifts BioBriefs en 2026-08-15T09:32:07Z Duchenne muscular dystrophy – Capricor shifts BLA after FDA adcomm setback https://biobriefs.com/fabry-gene-therapy-ptc-wins BioBriefs en 2026-08-15T09:32:07Z Fabry gene therapy – PTC wins Sangamo assets in bankruptcy auction https://biobriefs.com/hematology-funding-silence-raises-for BioBriefs en 2026-08-15T09:32:07Z Hematology funding – Silence raises for siRNA divesiran after Phase 2 win https://biobriefs.com/diagnostic-regulation-orasure-withdraws-fda BioBriefs en 2026-08-15T09:32:07Z Diagnostic regulation – OraSure withdraws FDA submission for CT/NG test https://biobriefs.com/diagnostics-proteotype-starts-clinical-studies BioBriefs en 2026-08-15T09:32:07Z Diagnostics – Proteotype starts clinical studies for MCED CE-IVDR pathway https://biobriefs.com/financing-and-workforce-illumina-raises BioBriefs en 2026-08-15T09:32:07Z Financing and workforce – Illumina raises debt and issues notes https://biobriefs.com/clinical-development-ardd-expands-longevity BioBriefs en 2026-08-15T09:32:07Z Clinical development – ARDD expands longevity leadership lineup https://biobriefs.com/biotech-corporate-funding-abcellera-launches BioBriefs en 2026-08-15T09:32:07Z Biotech corporate funding – AbCellera launches $200 million public offering https://biobriefs.com/fda-accelerated-approval-for-zenbexus BioBriefs en 2026-08-15T04:32:03Z FDA accelerated approval for Zenbexus expands CELMoDs in multiple myeloma https://biobriefs.com/zenbexus-approval-as-first-in BioBriefs en 2026-08-15T04:32:03Z Zenbexus approval as first-in-class CELMoDs franchise cornerstone https://biobriefs.com/industry-supply-chain-us-manufacturing BioBriefs en 2026-08-15T04:32:03Z Industry supply chain: US manufacturing expansion in biologics and drugs https://biobriefs.com/cell-therapy-funding-and-update BioBriefs en 2026-08-15T04:32:03Z Cell therapy funding and update: Capricor seeks FDA review after DMD setbacks https://biobriefs.com/ai-biotech-finance-precision-immunology BioBriefs en 2026-08-15T04:32:03Z AI+biotech finance: Precision immunology startup Boulevard emerges from stealth with $65M https://biobriefs.com/protein-sequencing-systems-quantum-si BioBriefs en 2026-08-15T04:32:03Z Protein sequencing systems: Quantum-Si pushes Proteus launch to 2Q 2027 and cuts 20% staff https://biobriefs.com/rare-disease-gene-therapy-m BioBriefs en 2026-08-15T04:32:03Z Rare disease gene therapy M&A: PTC outbids rivals for Sangamo’s Fabry asset https://biobriefs.com/regulatory-quality-in-oncology-eu BioBriefs en 2026-08-15T04:32:03Z Regulatory/quality in oncology: EU regulators detail why Tavneos was pulled https://biobriefs.com/diagnostic-regulation-orasure-withdraws-fda BioBriefs en 2026-08-15T04:32:03Z Diagnostic regulation: OraSure withdraws FDA submission for CT/NG point-of-care test https://biobriefs.com/clinical-stage-financing-silence-therapeutics BioBriefs en 2026-08-15T04:32:03Z Clinical-stage financing: Silence Therapeutics upsizes $175M offering after Phase 2 “best-case” outcome https://biobriefs.com/multiple-myeloma-zenbexus-gets-fda BioBriefs en 2026-08-14T21:32:10Z Multiple myeloma – Zenbexus gets FDA accelerated approval https://biobriefs.com/multiple-myeloma-zenbexus-approval-explained BioBriefs en 2026-08-14T21:32:10Z Multiple myeloma – Zenbexus approval explained as CELMoDs milestone https://biobriefs.com/myeloma-biogen-felzartamab-receives-first BioBriefs en 2026-08-14T21:32:10Z Myeloma – Biogen felzartamab receives first global approval in China https://biobriefs.com/regulatory-and-reimbursement-icer-says BioBriefs en 2026-08-14T21:32:10Z Regulatory and reimbursement – ICER says Baxfendy not cost-effective https://biobriefs.com/clinical-development-capricor-seeks-fda BioBriefs en 2026-08-14T21:32:10Z Clinical development – Capricor seeks FDA review after adcomm setback https://biobriefs.com/biotech-funding-boulevard-emerges-from BioBriefs en 2026-08-14T21:32:10Z Biotech funding – Boulevard emerges from stealth with $65m for autoimmune antibodies https://biobriefs.com/gene-therapy-dealmaking-ptc-wins BioBriefs en 2026-08-14T21:32:10Z Gene therapy dealmaking – PTC wins $211m bid for Sangamo Fabry program https://biobriefs.com/regulatory-submissions-orasure-withdraws-fda BioBriefs en 2026-08-14T21:32:10Z Regulatory submissions – OraSure withdraws FDA filing for CT/NG molecular test https://biobriefs.com/funding-and-scale-up-silence BioBriefs en 2026-08-14T21:32:10Z Funding and scale-up – Silence upsized $175m public offering for siRNA divesiran https://biobriefs.com/company-funding-aligned-marketplace-raises BioBriefs en 2026-08-14T21:32:10Z Company funding – Aligned Marketplace raises $20m for primary care matching https://biobriefs.com/fda-multiple-myeloma-approval-for BioBriefs en 2026-08-14T16:32:21Z FDA multiple myeloma approval for new CELMoD class https://biobriefs.com/duchenne-therapy-capricor-seeks-fda BioBriefs en 2026-08-14T16:32:21Z Duchenne therapy: Capricor seeks FDA review after advisory setback https://biobriefs.com/gene-therapy-dealmaking-ptc-wins BioBriefs en 2026-08-14T16:32:21Z Gene therapy dealmaking: PTC wins Sangamo Fabry program in bankruptcy auction https://biobriefs.com/oncology-trials-taiho-and-cullinan BioBriefs en 2026-08-14T16:32:21Z Oncology trials: Taiho and Cullinan advance zipalertinib after early unblinding https://biobriefs.com/oligonucleotide-therapeutics-silence-upsizes-public BioBriefs en 2026-08-14T16:32:21Z Oligonucleotide therapeutics: Silence upsizes public offering after Phase 2 ‘best-case’ signal https://biobriefs.com/antibody-startup-launch-boulevard-bio BioBriefs en 2026-08-14T16:32:21Z Antibody startup launch: Boulevard Bio debuts with $65M and quarterly-dosing plan https://biobriefs.com/big-data-and-financing-illumina BioBriefs en 2026-08-14T16:32:21Z Big data and financing: Illumina locks in $1B credit facility and $300M note offering https://biobriefs.com/proteomics-platform-setback-quantum-si BioBriefs en 2026-08-14T16:32:21Z Proteomics platform setback: Quantum-Si delays Proteus launch and cuts jobs https://biobriefs.com/resource-allocation-in-schizophrenia-drug BioBriefs en 2026-08-14T16:32:21Z Resource allocation in schizophrenia drug programs: MapLight dims preclinical work to advance lead asset https://biobriefs.com/liquid-biopsy-screening-coverage-freenome BioBriefs en 2026-08-14T16:32:21Z Liquid biopsy screening coverage: Freenome coverage initiated ahead of colorectal test launch https://biobriefs.com/fda-approval-spotlights-a-new BioBriefs en 2026-08-14T14:32:13Z FDA approval spotlights a new multiple myeloma drug class https://biobriefs.com/bankruptcy-auction-reshuffles-rare-disease BioBriefs en 2026-08-14T14:32:13Z Bankruptcy auction reshuffles rare-disease gene therapy assets https://biobriefs.com/fda-action-pressure-enforcement-and BioBriefs en 2026-08-14T14:32:13Z FDA action pressure: enforcement and reimbursement reviews target new drug economics https://biobriefs.com/proteomics-instrumentation-delays-force-cost BioBriefs en 2026-08-14T14:32:13Z Proteomics instrumentation delays force cost cuts and timeline resets https://biobriefs.com/sequencing-and-diagnostic-financing-illumina BioBriefs en 2026-08-14T14:32:13Z Sequencing and diagnostic financing: Illumina taps capital markets to fund operations https://biobriefs.com/decentralized-trial-operations-need-trained BioBriefs en 2026-08-14T14:32:13Z Decentralized trial operations need trained mobile clinical workforce https://biobriefs.com/ai-in-clinical-monitoring-and BioBriefs en 2026-08-14T14:32:13Z AI in clinical monitoring and site operations delivers measurable financial lift https://biobriefs.com/surgical-scene-understanding-ai-faces BioBriefs en 2026-08-14T14:32:13Z Surgical scene-understanding AI faces validation challenge in the operating room https://biobriefs.com/genome-directed-precision-for-lung BioBriefs en 2026-08-14T14:32:13Z Genome-directed precision for lung cancer: Freenome targets FDA review path https://biobriefs.com/genomic-newborn-screening-explores-inherited BioBriefs en 2026-08-14T14:32:13Z Genomic newborn screening explores inherited risk for early cancers https://biobriefs.com/fda-approvals-regulatory-action BioBriefs en 2026-08-14T10:31:16Z FDA approvals & regulatory action https://biobriefs.com/regulatory-policy-user-fees BioBriefs en 2026-08-14T10:31:16Z Regulatory policy – user fees https://biobriefs.com/bankruptcy-m-a-in-gene BioBriefs en 2026-08-14T10:31:16Z Bankruptcy M&A in gene therapy https://biobriefs.com/oncology-trial-readouts-and-phase BioBriefs en 2026-08-14T10:31:16Z Oncology trial readouts and phase transitions https://biobriefs.com/company-finance-fundraising BioBriefs en 2026-08-14T10:31:16Z Company finance & fundraising https://biobriefs.com/venture-funding-for-new-biotechs BioBriefs en 2026-08-14T10:31:16Z Venture funding for new biotechs https://biobriefs.com/digital-health-ai-in-clinical BioBriefs en 2026-08-14T10:31:16Z Digital health & AI in clinical operations https://biobriefs.com/new-diagnostics-biomarker-tools BioBriefs en 2026-08-14T10:31:16Z New diagnostics & biomarker tools https://biobriefs.com/clinical-development-in-rare-disease BioBriefs en 2026-08-14T10:31:16Z Clinical development in rare disease https://biobriefs.com/metabolic-cardiovascular-drugs-health-economics BioBriefs en 2026-08-14T10:31:16Z Metabolic & cardiovascular drugs – health economics pushback https://biobriefs.com/fda-approvals-and-removals-in BioBriefs en 2026-08-14T09:32:34Z FDA approvals and removals in oncology and immunology https://biobriefs.com/car-t-and-next-gen BioBriefs en 2026-08-14T09:32:34Z CAR-T and next-gen cell therapies expand beyond the autologous model https://biobriefs.com/radiation-oncology-guideline-update-for BioBriefs en 2026-08-14T09:32:34Z Radiation oncology guideline update for pancreatic cancer https://biobriefs.com/phase-3-readouts-reshape-lung BioBriefs en 2026-08-14T09:32:34Z Phase 3 readouts reshape lung cancer competition at EGFR exon 20 https://biobriefs.com/cyber-physical-security-finds-a BioBriefs en 2026-08-14T09:32:34Z Cyber-physical security finds a path from proximity to onboard aircraft electronics https://biobriefs.com/gene-therapy-deals-after-sangamo BioBriefs en 2026-08-14T09:32:34Z Gene therapy deals after Sangamo bankruptcy auction https://biobriefs.com/trial-results-and-trial-design BioBriefs en 2026-08-14T09:32:34Z Trial results and trial design signals in rare disease and beyond https://biobriefs.com/clinical-development-financing-and-capital BioBriefs en 2026-08-14T09:32:34Z Clinical development financing and capital markets for RNA and antibodies https://biobriefs.com/venture-funding-and-new-startups BioBriefs en 2026-08-14T09:32:34Z Venture funding and new startups targeting autoimmune and specialty indications https://biobriefs.com/regulatory-and-policy-framework-shift BioBriefs en 2026-08-14T09:32:34Z Regulatory and policy framework shift: FDA user-fee reauthorization https://biobriefs.com/fda-approvals-regulatory-actions BioBriefs en 2026-08-14T04:31:53Z FDA approvals & regulatory actions https://biobriefs.com/car-t-and-next-generation BioBriefs en 2026-08-14T04:31:53Z CAR-T and next-generation cellular immunotherapy https://biobriefs.com/gene-therapy-bankruptcy-auction-dealmaking BioBriefs en 2026-08-14T04:31:53Z Gene therapy: bankruptcy auction dealmaking and asset transfer https://biobriefs.com/oncology-drug-development-early-clinical BioBriefs en 2026-08-14T04:31:53Z Oncology drug development: early clinical signals https://biobriefs.com/oncology-trials-egfr-inhibitor-competitiveness BioBriefs en 2026-08-14T04:31:53Z Oncology trials: EGFR inhibitor competitiveness in lung cancer https://biobriefs.com/cancer-immunotherapy-platforms-car-t BioBriefs en 2026-08-14T04:31:53Z Cancer immunotherapy platforms: CAR-T strength against solid tumors https://biobriefs.com/biotech-funding-corporate-finance BioBriefs en 2026-08-14T04:31:53Z Biotech funding & corporate finance https://biobriefs.com/diagnostics-regulatory-adjacent-approvals BioBriefs en 2026-08-14T04:31:53Z Diagnostics & regulatory-adjacent approvals https://biobriefs.com/immunology-platform-startups BioBriefs en 2026-08-14T04:31:53Z Immunology & platform startups https://biobriefs.com/clinical-trial-design-and-guideline BioBriefs en 2026-08-14T04:31:53Z Clinical trial design and guideline alignment in prostate cancer https://biobriefs.com/multiple-myeloma-accelerated-approval BioBriefs en 2026-08-13T21:31:50Z Multiple myeloma accelerated approval https://biobriefs.com/cancer-drug-pricing-and-cost BioBriefs en 2026-08-13T21:31:50Z Cancer drug pricing and cost-effectiveness review https://biobriefs.com/ai-to-reduce-clinical-trial BioBriefs en 2026-08-13T21:31:50Z AI to reduce clinical trial monitoring costs https://biobriefs.com/fda-device-pathway-for-blood BioBriefs en 2026-08-13T21:31:50Z FDA device pathway for blood-based lung cancer screening https://biobriefs.com/gene-therapy-bankruptcy-auction-and BioBriefs en 2026-08-13T21:31:50Z Gene therapy bankruptcy auction and asset transfer https://biobriefs.com/car-t-company-transitions-and BioBriefs en 2026-08-13T21:31:50Z CAR-T company transitions and profitability milestone https://biobriefs.com/ai-driven-biotech-capital-raise BioBriefs en 2026-08-13T21:31:50Z AI-driven biotech capital raise for menopause antibody https://biobriefs.com/oncology-trial-set-back-and BioBriefs en 2026-08-13T21:31:50Z Oncology trial set-back and pipeline reprioritization https://biobriefs.com/new-rare-disease-therapy-enters BioBriefs en 2026-08-13T21:31:50Z New rare disease therapy enters phase III with large Series B https://biobriefs.com/fda-approved-oral-contraception-alternative BioBriefs en 2026-08-13T21:31:50Z FDA approved oral contraception alternative in device/diagnostics stream https://biobriefs.com/lung-cancer-phase-3-readout BioBriefs en 2026-08-13T16:31:57Z Lung cancer – Phase 3 readout for exon 20 EGFR inhibitor sets up major FDA race https://biobriefs.com/neurodegeneration-car-t-regimens-move BioBriefs en 2026-08-13T16:31:57Z Neurodegeneration – CAR-T regimens move toward α-synuclein targeting in Parkinson’s https://biobriefs.com/genie-therapy-sangamo-fabry-assets BioBriefs en 2026-08-13T16:31:57Z Genie therapy – Sangamo Fabry assets auction accelerates PTC and Lilly entry https://biobriefs.com/oncology-intranasal-neo100-shows-phase BioBriefs en 2026-08-13T16:31:57Z Oncology – Intranasal NEO100 shows Phase 2a endpoint hit in IDH1-mutant glioma https://biobriefs.com/rare-disease-antibodies-abcellera-raises BioBriefs en 2026-08-13T16:31:57Z Rare disease antibodies – AbCellera raises $200M to fund ABCL635 and ABCL365 programs https://biobriefs.com/regulatory-devices-fda-grants-breakthrough BioBriefs en 2026-08-13T16:31:57Z Regulatory devices – FDA grants Breakthrough Device designation to Freenome’s SimpleScreen lung test https://biobriefs.com/capital-markets-epicrispr-secures-90m BioBriefs en 2026-08-13T16:31:57Z Capital markets – Epicrispr secures $90M Series C to advance gene-silencing therapy into pivotal trials https://biobriefs.com/biotech-funding-and-innovation-khartis BioBriefs en 2026-08-13T16:31:57Z Biotech funding and innovation – Khartis Therapeutics emerges with $95M for oral TED IGF-1R inhibitor https://biobriefs.com/clinical-pipeline-and-drug-safety BioBriefs en 2026-08-13T16:31:57Z Clinical pipeline and drug safety – Neurocrine’s Vykat XR faces expert concerns tied to reported deaths and severe events https://biobriefs.com/molecular-glue-and-gene-editing BioBriefs en 2026-08-13T16:31:57Z Molecular glue and gene editing finance – Sangamo bankruptcy auction also brings Lilly purchase of technology stake https://biobriefs.com/lung-cancer-detection-assay-validation BioBriefs en 2026-08-13T14:31:51Z Lung cancer detection assay validation and regulatory pathway https://biobriefs.com/egfr-driven-lung-cancer-phase BioBriefs en 2026-08-13T14:31:51Z EGFR-driven lung cancer: Phase 3 wins and competitive positioning https://biobriefs.com/fda-regulatory-signals-for-screening BioBriefs en 2026-08-13T14:31:51Z FDA regulatory signals for screening: Freenome’s lung blood test https://biobriefs.com/gene-therapy-deal-making-ptc BioBriefs en 2026-08-13T14:31:51Z Gene therapy deal-making: PTC to buy Sangamo Fabry program https://biobriefs.com/rare-disease-financing-and-late BioBriefs en 2026-08-13T14:31:51Z Rare disease financing and late-stage execution: Vaderis HHT Phase 3 https://biobriefs.com/ai-enabled-clinical-operations-roi BioBriefs en 2026-08-13T14:31:51Z AI-enabled clinical operations ROI for oncology trials https://biobriefs.com/corporate-restructuring-and-new-metaboic BioBriefs en 2026-08-13T14:31:51Z Corporate restructuring and new metaboic pipeline funding: Vogenx IPO https://biobriefs.com/diagnostic-technology-rollout-n6-tec BioBriefs en 2026-08-13T14:31:51Z Diagnostic technology rollout: N6 Tec expands IconPCR distribution https://biobriefs.com/gene-editing-safety-and-oversight BioBriefs en 2026-08-13T14:31:51Z Gene editing safety and oversight: new report of a DMD editing death in China https://biobriefs.com/neuroendocrine-cancer-regulation-itm-isotope BioBriefs en 2026-08-13T14:31:51Z Neuroendocrine cancer regulation: ITM Isotope receives CRL for ITM-11 https://biobriefs.com/regulatory-approvals-designations BioBriefs en 2026-08-13T10:31:59Z Regulatory approvals & designations https://biobriefs.com/clinical-stage-wins-trial-readouts BioBriefs en 2026-08-13T10:31:59Z Clinical-stage wins, trial readouts & enrollment starts https://biobriefs.com/m-a-deals-partnerships-including BioBriefs en 2026-08-13T10:31:59Z M&A, deals & partnerships (including licensing) https://biobriefs.com/biotech-financing-ipos BioBriefs en 2026-08-13T10:31:59Z Biotech financing & IPOs https://biobriefs.com/drug-safety-warnings-adverse-event BioBriefs en 2026-08-13T10:31:59Z Drug safety warnings & adverse-event follow-ups https://biobriefs.com/pipeline-momentum-in-oncology-precision BioBriefs en 2026-08-13T10:31:59Z Pipeline momentum in oncology & precision medicine tools https://biobriefs.com/regulatory-policy-pricing-battles-us BioBriefs en 2026-08-13T10:31:59Z Regulatory policy & pricing battles (US healthcare) https://biobriefs.com/clinical-research-operations-decentralization BioBriefs en 2026-08-13T10:31:59Z Clinical research operations & decentralization https://biobriefs.com/biotech-innovation-ai-enabled-diagnostics BioBriefs en 2026-08-13T10:31:59Z Biotech innovation: AI-enabled diagnostics & trial productivity tools https://biobriefs.com/advanced-cell-therapy-platform-scale BioBriefs en 2026-08-13T10:31:59Z Advanced cell therapy platform scale and access https://biobriefs.com/fda-device-milestone-for-blood BioBriefs en 2026-08-13T09:32:31Z FDA device milestone for blood-based lung cancer screening https://biobriefs.com/clinical-safety-warning-and-death BioBriefs en 2026-08-13T09:32:31Z Clinical safety warning and death reports linked to Prader-Willi drug https://biobriefs.com/oncology-immunotherapy-and-trial-ready BioBriefs en 2026-08-13T09:32:31Z Oncology immunotherapy and trial-ready momentum for rare glioma target https://biobriefs.com/expansion-financing-and-phase-iii BioBriefs en 2026-08-13T09:32:31Z Expansion financing and Phase III initiation for HHT AKT-targeted therapy https://biobriefs.com/advanced-cancer-diagnostics-platform-strategy BioBriefs en 2026-08-13T09:32:31Z Advanced cancer diagnostics platform strategy at NeoGenomics https://biobriefs.com/ipo-funding-for-metabolic-pipeline BioBriefs en 2026-08-13T09:32:31Z IPO funding for metabolic pipeline lead targeting SGLT1 https://biobriefs.com/gene-therapy-innovation-and-trial BioBriefs en 2026-08-13T09:32:31Z Gene therapy innovation and trial start for deafness https://biobriefs.com/regulatory-navigation-fda-clears-ind BioBriefs en 2026-08-13T09:32:31Z Regulatory navigation: FDA clears IND for Ribox circRNA-based CAR-T https://biobriefs.com/ai-enabled-clinical-monitoring-roi BioBriefs en 2026-08-13T09:32:31Z AI-enabled clinical monitoring ROI claims for oncology trials https://biobriefs.com/broader-access-strategy-for-allogeneic BioBriefs en 2026-08-13T09:32:31Z Broader access strategy for allogeneic CAR T programs https://biobriefs.com/fda-regulatory-actions BioBriefs en 2026-08-13T04:31:54Z FDA & regulatory actions https://biobriefs.com/court-actions-and-drug-access BioBriefs en 2026-08-13T04:31:54Z Court actions and drug-access enforcement https://biobriefs.com/funding-and-ipos BioBriefs en 2026-08-13T04:31:54Z Funding and IPOs https://biobriefs.com/clinical-readouts-and-trial-progress BioBriefs en 2026-08-13T04:31:54Z Clinical readouts and trial progress https://biobriefs.com/diagnostics-mrd-and-early-detection BioBriefs en 2026-08-13T04:31:54Z Diagnostics, MRD and early detection https://biobriefs.com/immunology-platforms-and-next-gen BioBriefs en 2026-08-13T04:31:54Z Immunology platforms and next-gen cell therapy https://biobriefs.com/biopharma-deals-and-corporate-moves BioBriefs en 2026-08-13T04:31:54Z Biopharma deals and corporate moves https://biobriefs.com/drug-approvals-and-pipeline-updates BioBriefs en 2026-08-13T04:31:54Z Drug approvals and pipeline updates https://biobriefs.com/translational-platforms-and-clinical-operations BioBriefs en 2026-08-13T04:31:54Z Translational platforms and clinical operations technology https://biobriefs.com/cell-biology-and-biomarker-discovery BioBriefs en 2026-08-13T04:31:54Z Cell biology and biomarker discovery https://biobriefs.com/retatrutide-knockoffs-spark-legal-action BioBriefs en 2026-08-12T21:31:50Z Retatrutide knockoffs spark legal action https://biobriefs.com/freenomes-simplescreen-earns-fda-breakthrough BioBriefs en 2026-08-12T21:31:50Z Freenome’s SimpleScreen earns FDA breakthrough device nod https://biobriefs.com/caribou-positions-allogeneic-car-t BioBriefs en 2026-08-12T21:31:50Z Caribou positions allogeneic CAR T for Phase III expansion https://biobriefs.com/ai-monitoring-agent-delivers-outsized BioBriefs en 2026-08-12T21:31:50Z AI monitoring agent delivers outsized trial ROI in oncology modeling https://biobriefs.com/vaderis-closes-152m-series-b BioBriefs en 2026-08-12T21:31:50Z Vaderis closes $152M Series B and starts HHT pivotal Phase III https://biobriefs.com/definium-posts-another-phase-3 BioBriefs en 2026-08-12T21:31:50Z Definium posts another Phase 3 win in generalized anxiety https://biobriefs.com/neonatal-car-t-rare-immunology BioBriefs en 2026-08-12T21:31:50Z Neonatal CAR-T/rare immunology: Ribox gets IND for circRNA-based in vivo therapy https://biobriefs.com/natera-and-kupando-test-ctdna BioBriefs en 2026-08-12T21:31:50Z Natera and Kupando test ctDNA dynamics with innate-immune therapy https://biobriefs.com/neurocrine-safety-signals-prompt-expert BioBriefs en 2026-08-12T21:31:50Z Neurocrine safety signals prompt expert warnings for Vykat XR https://biobriefs.com/tufts-style-trial-ops-economics BioBriefs en 2026-08-12T21:31:50Z Tufts-style trial ops economics meet regulatory modernization momentum https://biobriefs.com/car-t-access-expansion-via BioBriefs en 2026-08-12T16:31:55Z CAR-T access expansion via allogeneic platforms https://biobriefs.com/definiums-lsd-therapy-posts-additional BioBriefs en 2026-08-12T16:31:55Z Definium’s LSD therapy posts additional Phase 3 win in anxiety https://biobriefs.com/neuro-oncology-signal-intranasal-neo100 BioBriefs en 2026-08-12T16:31:55Z Neuro-oncology signal: intranasal NEO100 reaches Phase 2a endpoint https://biobriefs.com/rare-disease-finance-vaderis-raises BioBriefs en 2026-08-12T16:31:55Z Rare disease finance: Vaderis raises to advance engasertib into pivotal testing https://biobriefs.com/fda-action-freenomes-simplescreen-lung BioBriefs en 2026-08-12T16:31:55Z FDA action: Freenome’s SimpleScreen lung test earns Breakthrough device status https://biobriefs.com/diagnostics-and-mrd-expansion-natera BioBriefs en 2026-08-12T16:31:55Z Diagnostics and MRD expansion: Natera moves deeper into early cancer detection https://biobriefs.com/immunotherapy-industry-dealmaking-innate-and BioBriefs en 2026-08-12T16:31:55Z Immunotherapy-industry dealmaking: Innate and Sobi expand toward accelerated CTCL filing https://biobriefs.com/cdmo-scale-and-manufacturing-reshoring BioBriefs en 2026-08-12T16:31:55Z CDMO scale and manufacturing reshoring: BMS commits $2.3B Houston campus https://biobriefs.com/funding-for-new-platforms-infinimmune BioBriefs en 2026-08-12T16:31:55Z Funding for new platforms: Infinimmune raises to enter atopic dermatitis clinic https://biobriefs.com/biotech-financing-and-corporate-growth BioBriefs en 2026-08-12T16:31:55Z Biotech financing and corporate growth: Epicrispr raises $90M for FSHD epigenetic therapy https://biobriefs.com/thermo-fisher-exits-microbiology BioBriefs en 2026-08-12T14:31:54Z Thermo Fisher exits microbiology https://biobriefs.com/phase-iii-funding-jump-for BioBriefs en 2026-08-12T14:31:54Z Phase III funding jump for hereditary hemorrhagic telangiectasia https://biobriefs.com/natera-expands-ctdna-monitoring-into BioBriefs en 2026-08-12T14:31:54Z Natera expands ctDNA monitoring into skin cancer https://biobriefs.com/fda-approval-clears-first-oral BioBriefs en 2026-08-12T14:31:54Z FDA approval clears first oral orexin therapy for narcolepsy type 1 https://biobriefs.com/ambitious-rare-disease-financing-and BioBriefs en 2026-08-12T14:31:54Z Ambitious rare-disease financing and Phase III start https://biobriefs.com/definiums-late-stage-anxiety-readout BioBriefs en 2026-08-12T14:31:54Z Definium’s late-stage anxiety readout draws attention https://biobriefs.com/fda-rejects-itm-isotope-radiopharma BioBriefs en 2026-08-12T14:31:54Z FDA rejects ITM Isotope radiopharma manufacturing https://biobriefs.com/moderna-becomes-first-to-win BioBriefs en 2026-08-12T14:31:54Z Moderna becomes first to win FDA approval for an mRNA flu shot https://biobriefs.com/lundgren-style-innovation-new-microbiology BioBriefs en 2026-08-12T14:31:54Z Lundgren-style innovation: new microbiology distribution expansion https://biobriefs.com/next-generation-oncology-automation-and BioBriefs en 2026-08-12T14:31:54Z Next-generation oncology automation and expanded trial access funding https://biobriefs.com/fda-approval-and-post-market BioBriefs en 2026-08-12T10:32:08Z FDA approval and post-market safety signals for rare disease drugs https://biobriefs.com/clinical-setbacks-and-market-impact BioBriefs en 2026-08-12T10:32:08Z Clinical setbacks and market impact in cystic fibrosis https://biobriefs.com/biopharma-financing-and-clinical-pipeline BioBriefs en 2026-08-12T10:32:08Z Biopharma financing and clinical pipeline funding https://biobriefs.com/regulatory-approvals-for-novel-therapeutics BioBriefs en 2026-08-12T10:32:08Z Regulatory approvals for novel therapeutics https://biobriefs.com/hot-flash-drug-development-and BioBriefs en 2026-08-12T10:32:08Z Hot flash drug development and Phase 2 efficacy benchmark https://biobriefs.com/biotech-deals-and-corporate-transactions BioBriefs en 2026-08-12T10:32:08Z Biotech deals and corporate transactions in oncology/neuroscience https://biobriefs.com/regulatory-manufacturing-failures-halting-radiopharma BioBriefs en 2026-08-12T10:32:08Z Regulatory manufacturing failures halting radiopharma competition https://biobriefs.com/clinical-stage-transformation-in-rare BioBriefs en 2026-08-12T10:32:08Z Clinical-stage transformation in rare disease immunology https://biobriefs.com/ai-based-regulation-and-compliance BioBriefs en 2026-08-12T10:32:08Z AI-based regulation and compliance constraints for clinical trials https://biobriefs.com/diagnostics-reimbursement-and-policy-pressure BioBriefs en 2026-08-12T10:32:08Z Diagnostics reimbursement and policy pressure around 340B drug pricing https://biobriefs.com/regulatory-safety-signal-for-vykat BioBriefs en 2026-08-12T09:31:25Z Regulatory safety signal for Vykat XR in Prader-Willi syndrome https://biobriefs.com/fda-approvals-expand-biotech-product BioBriefs en 2026-08-12T09:31:25Z FDA approvals expand biotech product launches across immunology and oncology https://biobriefs.com/fda-rejects-radiopharma-competitor-due BioBriefs en 2026-08-12T09:31:25Z FDA rejects radiopharma competitor due to manufacturing issues https://biobriefs.com/phase-2-success-lifts-abcelleras BioBriefs en 2026-08-12T09:31:25Z Phase 2 success lifts Abcellera’s hot-flashes program https://biobriefs.com/phase-2-failure-douses-sionnas BioBriefs en 2026-08-12T09:31:25Z Phase 2 failure douses Sionna’s cystic fibrosis add-on strategy https://biobriefs.com/biotech-fundraising-and-vc-expansion BioBriefs en 2026-08-12T09:31:25Z Biotech fundraising and VC expansion in the UK https://biobriefs.com/major-rare-disease-financing-to BioBriefs en 2026-08-12T09:31:25Z Major rare-disease financing to advance HEREDITARY hemorrhagic telangiectasia (HHT) https://biobriefs.com/new-biotech-deals-for-il BioBriefs en 2026-08-12T09:31:25Z New biotech deals for IL-22 and IL-13 in atopic dermatitis via Infinimmune’s Series A https://biobriefs.com/corporate-leadership-shift-at-k2 BioBriefs en 2026-08-12T09:31:25Z Corporate leadership shift at K2 Therapeutics after Legend exit https://biobriefs.com/fda-authorization-for-a-stargardt BioBriefs en 2026-08-12T09:31:25Z FDA authorization for a Stargardt-related and oncology-adjacent move in genomics diagnostics (MRD expansion context) https://biobriefs.com/immunology-delivery-and-anticancer-immunity BioBriefs en 2026-08-12T04:31:36Z Immunology delivery and anticancer immunity via microbiome-derived signals https://biobriefs.com/regulatory-and-reimbursement-340b-payment BioBriefs en 2026-08-12T04:31:36Z Regulatory and reimbursement: 340B payment and rebate model shifts https://biobriefs.com/late-stage-pipeline-setbacks-and BioBriefs en 2026-08-12T04:31:36Z Late-stage pipeline setbacks and capital preservation after clinical failures https://biobriefs.com/clinical-expansion-in-rare-disease BioBriefs en 2026-08-12T04:31:36Z Clinical expansion in rare disease: Series B funding for Vaderis hereditary hemorrhagic telangiectasia (HHT) https://biobriefs.com/fda-approvals-first-of-its BioBriefs en 2026-08-12T04:31:36Z FDA approvals: first-of-its-kind therapies and precision diagnostics https://biobriefs.com/immunotherapy-durability-in-inflammatory-disease BioBriefs en 2026-08-12T04:31:36Z Immunotherapy durability in inflammatory disease: AbCellera hot-flash Phase 2 and downstream Phase 3 benchmark-setting https://biobriefs.com/biologics-financing-and-clinical-entry BioBriefs en 2026-08-12T04:31:36Z Biologics financing and clinical entry for eczema competitors to Dupixent https://biobriefs.com/platform-funding-remedium-bio-launches BioBriefs en 2026-08-12T04:31:36Z Platform funding: Remedium Bio launches durable protein therapeutics Series A https://biobriefs.com/oncology-immunotherapy-resistance-biology-myeloid BioBriefs en 2026-08-12T04:31:36Z Oncology immunotherapy resistance biology: myeloid networks and tumor immune failure https://biobriefs.com/disease-mechanism-and-translational-acceleration BioBriefs en 2026-08-12T04:31:36Z Disease mechanism and translational acceleration: FDA-enabled gene editing trial risk watch and cell therapy pipeline moves https://biobriefs.com/atopic-dermatitis-antibody-race-heats BioBriefs en 2026-08-11T21:32:50Z Atopic dermatitis antibody race heats up https://biobriefs.com/rare-bleeding-disorder-bankrolls-phase BioBriefs en 2026-08-11T21:32:50Z Rare bleeding disorder bankrolls Phase 3 push https://biobriefs.com/crispr-gene-edited-therapy-safety BioBriefs en 2026-08-11T21:32:50Z CRISPR gene-edited therapy safety spotlight https://biobriefs.com/fda-blocks-radiopharma-competitor-to BioBriefs en 2026-08-11T21:32:50Z FDA blocks radiopharma competitor to Lutathera https://biobriefs.com/antibody-engineering-startup-opens-clinic BioBriefs en 2026-08-11T21:32:50Z Antibody engineering startup opens clinic data run for hot flashes https://biobriefs.com/china-clearance-for-fgfr2-cholangiocarcinoma BioBriefs en 2026-08-11T21:32:50Z China clearance for FGFR2+ cholangiocarcinoma after FGFR therapy https://biobriefs.com/discovery-platform-funding-durable-protein BioBriefs en 2026-08-11T21:32:50Z Discovery platform funding: durable protein therapeutics https://biobriefs.com/heart-regeneration-funding-lands-for BioBriefs en 2026-08-11T21:32:50Z Heart regeneration funding lands for USC stem-cell trial https://biobriefs.com/venture-backed-gene-editing-competitor BioBriefs en 2026-08-11T21:32:50Z Venture-backed gene editing competitor eyes hearing restoration https://biobriefs.com/large-insurer-panel-calls-out BioBriefs en 2026-08-11T21:32:50Z Large insurer panel calls out AI adoption limits https://biobriefs.com/fda-narcolepsy-approval BioBriefs en 2026-08-11T16:31:37Z FDA narcolepsy approval https://biobriefs.com/china-approvals-in-molecular-oncology BioBriefs en 2026-08-11T16:31:37Z China approvals in molecular oncology https://biobriefs.com/regulatory-action-reshapes-drug-program BioBriefs en 2026-08-11T16:31:37Z Regulatory action reshapes drug program execution https://biobriefs.com/340b-payment-and-rebate-policy BioBriefs en 2026-08-11T16:31:37Z 340B payment and rebate policy https://biobriefs.com/liquid-biopsy-funding-for-invasive BioBriefs en 2026-08-11T16:31:37Z Liquid biopsy funding for invasive fungal disease https://biobriefs.com/oncology-corporate-development-dealmaking BioBriefs en 2026-08-11T16:31:37Z Oncology corporate development dealmaking https://biobriefs.com/biotech-financing-and-ai-driven BioBriefs en 2026-08-11T16:31:37Z Biotech financing and AI-driven platforms https://biobriefs.com/rare-disease-gene-edited-therapy BioBriefs en 2026-08-11T16:31:37Z Rare disease gene-edited therapy safety setback https://biobriefs.com/rare-disease-m-a-jazzs BioBriefs en 2026-08-11T16:31:37Z Rare disease M&A: Jazz’s Actio acquisition https://biobriefs.com/startup-leadership-fundraising-for-drug BioBriefs en 2026-08-11T16:31:37Z Startup leadership + fundraising for drug discovery search https://biobriefs.com/muscular-dystrophy-epigenetic-therapy-funding BioBriefs en 2026-08-11T14:32:29Z Muscular dystrophy epigenetic therapy funding https://biobriefs.com/eczema-antibody-race-heats-up BioBriefs en 2026-08-11T14:32:29Z Eczema antibody race heats up with new financing https://biobriefs.com/cystic-fibrosis-setback-reshapes-vertex BioBriefs en 2026-08-11T14:32:29Z Cystic fibrosis setback reshapes Vertex competition https://biobriefs.com/gene-therapy-trial-startup-launches BioBriefs en 2026-08-11T14:32:29Z Gene therapy trial startup launches in deafness https://biobriefs.com/radiopharma-manufacturing-rejection-impacts-competitive BioBriefs en 2026-08-11T14:32:29Z Radiopharma manufacturing rejection impacts competitive landscape https://biobriefs.com/venture-backed-base-editing-off BioBriefs en 2026-08-11T14:32:29Z Venture-backed base editing off-target testing platform https://biobriefs.com/oncology-companion-diagnostic-cleared-by BioBriefs en 2026-08-11T14:32:29Z Oncology companion diagnostic cleared by FDA https://biobriefs.com/regulatory-framework-for-medical-devices BioBriefs en 2026-08-11T14:32:29Z Regulatory framework for medical devices—CMS RAPID pathway advances https://biobriefs.com/china-tightens-clinical-trial-rules BioBriefs en 2026-08-11T14:32:29Z China tightens clinical trial rules affecting speed model https://biobriefs.com/ecosystem-manufacturing-bms-picks-houston BioBriefs en 2026-08-11T14:32:29Z Ecosystem manufacturing: BMS picks Houston for $2.3B campus https://biobriefs.com/regulatory-approval-mrna-flu-vaccine BioBriefs en 2026-08-11T10:32:12Z Regulatory approval – mRNA flu vaccine https://biobriefs.com/biopharma-reshoring-bms-manufacturing-campus BioBriefs en 2026-08-11T10:32:12Z Biopharma reshoring – BMS manufacturing campus https://biobriefs.com/clinical-setback-cystic-fibrosis-add BioBriefs en 2026-08-11T10:32:12Z Clinical setback – cystic fibrosis add-on failure https://biobriefs.com/rare-disease-m-a-jazz BioBriefs en 2026-08-11T10:32:12Z Rare disease M&A – Jazz acquires Actio https://biobriefs.com/rare-blood-cancer-trial-win BioBriefs en 2026-08-11T10:32:12Z Rare blood cancer trial win – Silence Phase 2 https://biobriefs.com/cell-therapy-decision-support-aml BioBriefs en 2026-08-11T10:32:12Z Cell therapy decision support – AML transplant model https://biobriefs.com/companion-diagnostics-labcorp-fda-approval BioBriefs en 2026-08-11T10:32:12Z Companion diagnostics – Labcorp FDA approval https://biobriefs.com/weight-management-access-medicare-glp BioBriefs en 2026-08-11T10:32:12Z Weight management access – Medicare GLP-1 Bridge pricing https://biobriefs.com/oncology-transplant-cancer-diagnostics-natera BioBriefs en 2026-08-11T10:32:12Z Oncology transplant/cancer diagnostics – Natera MRD and early cancer push https://biobriefs.com/drug-safety-and-clinical-trial BioBriefs en 2026-08-11T10:32:12Z Drug safety and clinical trial operations – ITTs under China tightening https://biobriefs.com/fda-approvals BioBriefs en 2026-08-11T09:32:13Z FDA approvals https://biobriefs.com/company-earnings-platform-expansion BioBriefs en 2026-08-11T09:32:13Z Company earnings & platform expansion https://biobriefs.com/clinical-trial-failures-in-competitive BioBriefs en 2026-08-11T09:32:13Z Clinical trial failures in competitive areas (cystic fibrosis) https://biobriefs.com/clinical-trial-success-driving-advancement BioBriefs en 2026-08-11T09:32:13Z Clinical trial success driving advancement (rare blood cancer) https://biobriefs.com/dealmaking-expansion-epilepsy BioBriefs en 2026-08-11T09:32:13Z Dealmaking & expansion (epilepsy) https://biobriefs.com/regulatory-action-trial-acceleration-policy BioBriefs en 2026-08-11T09:32:13Z Regulatory action & trial acceleration policy https://biobriefs.com/regulatory-pipeline-for-diagnostics-fda BioBriefs en 2026-08-11T09:32:13Z Regulatory pipeline for diagnostics (FDA clearance) https://biobriefs.com/oncology-diagnostics-companion-testing-fda BioBriefs en 2026-08-11T09:32:13Z Oncology diagnostics & companion testing (FDA approval) https://biobriefs.com/radiopharmaceuticals-safety-manufacturing-setbacks BioBriefs en 2026-08-11T09:32:13Z Radiopharmaceuticals: safety/manufacturing setbacks https://biobriefs.com/immunotherapy-trial-momentum-phase-2 BioBriefs en 2026-08-11T09:32:13Z Immunotherapy trial momentum (Phase 2 data) https://biobriefs.com/mrna-vaccine-approvals-expand-platform BioBriefs en 2026-08-11T04:32:27Z mRNA vaccine approvals expand platform scope https://biobriefs.com/medicares-glp-1-bridge-shifts BioBriefs en 2026-08-11T04:32:27Z Medicare’s GLP-1 Bridge shifts weight-loss drug pricing mechanics https://biobriefs.com/teeth-gritting-trial-failures-hit BioBriefs en 2026-08-11T04:32:27Z Teeth-gritting trial failures hit multiple CF and heart-drug programs https://biobriefs.com/bms-commits-2-3b-to BioBriefs en 2026-08-11T04:32:27Z BMS commits $2.3B to Houston multi-modality manufacturing campus https://biobriefs.com/oncology-diagnostics-labcorps-fda-ok BioBriefs en 2026-08-11T04:32:27Z Oncology diagnostics: Labcorp’s FDA OK for BRAF companion diagnostic https://biobriefs.com/cell-gene-precision-therapy-spinoff BioBriefs en 2026-08-11T04:32:27Z Cell & gene precision therapy: spinoff pipeline for off-target characterization https://biobriefs.com/mrd-and-early-cancer-detection BioBriefs en 2026-08-11T04:32:27Z MRD and early cancer detection push by Natera expands globally https://biobriefs.com/jazz-doubles-down-on-rare BioBriefs en 2026-08-11T04:32:27Z Jazz doubles down on rare epilepsy with Actio acquisition https://biobriefs.com/cyber-and-healthcare-ai-digital BioBriefs en 2026-08-11T04:32:27Z Cyber and healthcare AI: Digital Science connects AI agents to Dimensions research data https://biobriefs.com/fda-rejects-itm-radiopharma-due BioBriefs en 2026-08-11T04:32:27Z FDA rejects ITM radiopharma due to manufacturing deficiencies https://biobriefs.com/regulatory-radiopharma-manufacturing-refusal BioBriefs en 2026-08-10T21:32:22Z Regulatory: radiopharma manufacturing refusal https://biobriefs.com/clinical-failure-cf-add-on BioBriefs en 2026-08-10T21:32:22Z Clinical failure: CF add-on trial sinks Sionna https://biobriefs.com/regulatory-us-approval-for-modernas BioBriefs en 2026-08-10T21:32:22Z Regulatory: US approval for Moderna’s mRNA flu shot https://biobriefs.com/deal-jazz-buys-actio-for BioBriefs en 2026-08-10T21:32:22Z Deal: Jazz buys Actio for rare epilepsy https://biobriefs.com/oncology-labcorp-companion-diagnostic-gets BioBriefs en 2026-08-10T21:32:22Z Oncology: Labcorp companion diagnostic gets FDA nod for BRAF melanoma https://biobriefs.com/rare-disease-fibrosis-sobi-takes BioBriefs en 2026-08-10T21:32:22Z Rare disease / fibrosis: Sobi takes Innate skin cancer asset https://biobriefs.com/biometrics-and-diagnostics-broken-string BioBriefs en 2026-08-10T21:32:22Z Biometrics and diagnostics: Broken String launches BaseMap ABE https://biobriefs.com/biopharma-manufacturing-bristol-myers-expands BioBriefs en 2026-08-10T21:32:22Z Biopharma manufacturing: Bristol Myers expands in Houston https://biobriefs.com/trial-access-partnership-uchicago-medicine BioBriefs en 2026-08-10T21:32:22Z Trial access partnership: UChicago Medicine and Eli Lilly https://biobriefs.com/regulatory-policy-and-clinical-operations BioBriefs en 2026-08-10T21:32:22Z Regulatory policy and clinical operations: CMS proposes RAPID pathway https://biobriefs.com/regulatory-approval-mrna-flu-vaccine BioBriefs en 2026-08-10T16:31:17Z Regulatory approval: mRNA flu vaccine https://biobriefs.com/precision-oncology-diagnostics BioBriefs en 2026-08-10T16:31:17Z Precision oncology diagnostics https://biobriefs.com/big-biotech-m-a-jazz BioBriefs en 2026-08-10T16:31:17Z Big biotech M&A: Jazz and Actio https://biobriefs.com/cystic-fibrosis-pipeline-setback BioBriefs en 2026-08-10T16:31:17Z Cystic fibrosis pipeline setback https://biobriefs.com/hot-flashes-vasomotor-symptoms-phase BioBriefs en 2026-08-10T16:31:17Z Hot flashes / vasomotor symptoms Phase 2 https://biobriefs.com/blood-cancer-gene-silencing-progress BioBriefs en 2026-08-10T16:31:17Z Blood cancer gene silencing progress https://biobriefs.com/cardiometabolic-oral-glp-1-advance BioBriefs en 2026-08-10T16:31:17Z Cardiometabolic oral GLP-1 advance https://biobriefs.com/radiopharmaceuticals-fda-rejection-and-safety BioBriefs en 2026-08-10T16:31:17Z Radiopharmaceuticals: FDA rejection and safety scrutiny https://biobriefs.com/therapeutics-platform-base-editing-off BioBriefs en 2026-08-10T16:31:17Z Therapeutics platform: base editing off-target characterization https://biobriefs.com/china-clinical-trials-oversight-shift BioBriefs en 2026-08-10T16:31:17Z China clinical trials oversight shift https://biobriefs.com/late-stage-heart-failure-setback BioBriefs en 2026-08-10T14:32:04Z Late-stage heart failure setback https://biobriefs.com/cystic-fibrosis-add-on-trial BioBriefs en 2026-08-10T14:32:04Z Cystic fibrosis add-on trial disappointment https://biobriefs.com/gene-silencing-path-to-late BioBriefs en 2026-08-10T14:32:04Z Gene-silencing path to late-stage in polycythemia vera https://biobriefs.com/silence-data-to-challenge-takeda BioBriefs en 2026-08-10T14:32:04Z Silence data to challenge Takeda https://biobriefs.com/jazz-expands-epilepsy-portfolio-via BioBriefs en 2026-08-10T14:32:04Z Jazz expands epilepsy portfolio via acquisition https://biobriefs.com/sobi-steps-into-late-skin BioBriefs en 2026-08-10T14:32:04Z Sobi steps into late skin cancer with Innate’s KIR3DL2 antibody https://biobriefs.com/fda-ind-clears-mpox-mrna BioBriefs en 2026-08-10T14:32:04Z FDA IND clears mpox mRNA vaccine candidate https://biobriefs.com/wuxi-apptec-challenged-and-partially BioBriefs en 2026-08-10T14:32:04Z WUXi AppTec challenged and partially protected in DoD-related case https://biobriefs.com/biontech-former-executive-backs-virtual BioBriefs en 2026-08-10T14:32:04Z BioNTech former executive backs virtual cancer surveillance startup https://biobriefs.com/novo-nordisk-and-aws-expand BioBriefs en 2026-08-10T14:32:04Z Novo Nordisk and AWS expand AI partnership with London hub https://biobriefs.com/clinical-testing-is-tightening-as BioBriefs en 2026-08-10T10:31:19Z Clinical testing is tightening as China scrutinizes faster trial pathways https://biobriefs.com/radiopharmaceuticals-confront-safety-signals-as BioBriefs en 2026-08-10T10:31:19Z Radiopharmaceuticals confront safety signals as developers scale candidates https://biobriefs.com/egfr-lung-cancer-surgery-follow BioBriefs en 2026-08-10T10:31:19Z EGFR lung cancer surgery follow-up gets guidance from molecular residual disease testing https://biobriefs.com/targeting-nrf2-hits-a-wall BioBriefs en 2026-08-10T10:31:19Z Targeting Nrf2 hits a wall as Arpeggio Biosciences winds down https://biobriefs.com/corporate-finance-lifts-lilly-as BioBriefs en 2026-08-10T10:31:19Z Corporate finance lifts Lilly as tirzepatide revenue momentum fuels guidance https://biobriefs.com/atyr-cuts-headcount-to-preserve BioBriefs en 2026-08-10T10:31:19Z aTyr cuts headcount to preserve cash for a second Phase 3 attempt https://biobriefs.com/new-ipo-funding-targets-non BioBriefs en 2026-08-10T10:31:19Z New IPO funding targets non-opioid pain and precision cancer drug development https://biobriefs.com/braveheart-bio-raises-heavily-for BioBriefs en 2026-08-10T10:31:19Z Braveheart Bio raises heavily for a heart drug program https://biobriefs.com/regulatory-compliance-operations-get-a BioBriefs en 2026-08-10T10:31:19Z Regulatory compliance operations get a spotlight as dossiers move from strategy to execution https://biobriefs.com/oncology-biomarkers-psa-threshold-links BioBriefs en 2026-08-10T10:31:19Z Oncology biomarkers: PSA threshold links to survival signals in real-world prostate cancer care https://biobriefs.com/regulatory-operations-and-ectd-submission BioBriefs en 2026-08-10T09:32:18Z Regulatory operations and eCTD submission readiness https://biobriefs.com/china-tightens-clinical-trial-rules BioBriefs en 2026-08-10T09:32:18Z China tightens clinical trial rules amid scrutiny of investigator-initiated studies https://biobriefs.com/radiopharmaceutical-safety-concerns-in-early BioBriefs en 2026-08-10T09:32:18Z Radiopharmaceutical safety concerns in early clinical development https://biobriefs.com/liver-microenvironment-changes-linked-to BioBriefs en 2026-08-10T09:32:18Z Liver microenvironment changes linked to adaptive β-catenin oncogenesis https://biobriefs.com/antimicrobials-biologics-safety-via-engineered BioBriefs en 2026-08-10T09:32:18Z Antimicrobials/biologics safety via engineered conjugates against cancer https://biobriefs.com/atyr-repositions-after-phase-3 BioBriefs en 2026-08-10T09:32:18Z aTyr repositions after phase 3 setback, cutting workforce for second attempt https://biobriefs.com/oncology-biomarker-threshold-for-prostate BioBriefs en 2026-08-10T09:32:18Z Oncology biomarker threshold for prostate cancer treatment response https://biobriefs.com/ebola-vaccine-expands-toward-pan BioBriefs en 2026-08-10T09:32:18Z Ebola vaccine expands toward pan-species protection in rodents https://biobriefs.com/braveheart-bio-raises-capital-with BioBriefs en 2026-08-10T09:32:18Z Braveheart Bio raises capital with a large IPO for cardiomyopathy program https://biobriefs.com/latigo-bio-ipo-funds-next BioBriefs en 2026-08-10T09:32:18Z Latigo Bio IPO funds next-generation non-opioid pain pipeline https://biobriefs.com/cardiology-dealmaking-and-ipo-pipeline BioBriefs en 2026-08-10T04:31:49Z Cardiology dealmaking and IPO pipeline https://biobriefs.com/non-opioid-pain-and-oncology BioBriefs en 2026-08-10T04:31:49Z Non-opioid pain and oncology funding via public markets https://biobriefs.com/translational-cell-therapy-concepts-in BioBriefs en 2026-08-10T04:31:49Z Translational cell therapy concepts in brain aging https://biobriefs.com/neuroinflammation-targeting-with-epigenetic-guided BioBriefs en 2026-08-10T04:31:49Z Neuroinflammation targeting with epigenetic-guided nanomedicine https://biobriefs.com/cancer-immunotherapy-via-engineered-bacterial BioBriefs en 2026-08-10T04:31:49Z Cancer immunotherapy via engineered bacterial conjugates https://biobriefs.com/mri-ai-for-end-to BioBriefs en 2026-08-10T04:31:49Z MRI AI for end-to-end tumor assessment https://biobriefs.com/metabolism-and-synapse-formation-mechanisms BioBriefs en 2026-08-10T04:31:49Z Metabolism and synapse formation mechanisms in C. elegans https://biobriefs.com/cancer-genomics-and-metastatic-biology BioBriefs en 2026-08-10T04:31:49Z Cancer genomics and metastatic biology in 17q-linked neuroblastoma https://biobriefs.com/cns-tumor-biology-mapped-in BioBriefs en 2026-08-10T04:31:49Z CNS tumor biology mapped in living brains https://biobriefs.com/microbiome-remodeling-through-rapid-dietary BioBriefs en 2026-08-10T04:31:49Z Microbiome remodeling through rapid dietary shifts https://biobriefs.com/regulatory-and-policy-pressure-on BioBriefs en 2026-08-09T21:31:34Z Regulatory and policy pressure on drug reimbursement https://biobriefs.com/fda-accelerated-approval-turnaround-for BioBriefs en 2026-08-09T21:31:34Z FDA accelerated approval turnaround for oncolytic viral therapy https://biobriefs.com/fdas-steadying-signal-from-contentious BioBriefs en 2026-08-09T21:31:34Z FDA’s steadying signal from contentious and controversial therapy reviews https://biobriefs.com/late-stage-kidney-disease-data BioBriefs en 2026-08-09T21:31:34Z Late-stage kidney disease data: Otsuka’s anti-APRIL in IgA nephropathy https://biobriefs.com/clinical-stage-noise-canceling-imaging BioBriefs en 2026-08-09T21:31:34Z Clinical-stage noise-canceling: imaging AI to unify cancer assessment workflows https://biobriefs.com/targeted-drug-delivery-engineering-for BioBriefs en 2026-08-09T21:31:34Z Targeted drug delivery engineering for therapeutic peptides https://biobriefs.com/vaccines-and-infectious-disease-pan BioBriefs en 2026-08-09T21:31:34Z Vaccines and infectious disease: pan-Ebolavirus coverage with nanoparticle immunogens https://biobriefs.com/on-the-hunt-biomarkers-in BioBriefs en 2026-08-09T21:31:34Z On-the-hunt biomarkers in oncology: breast cancer gene interaction for metastasis and benefit https://biobriefs.com/microbiome-and-proteogenomics-rapid-diet BioBriefs en 2026-08-09T21:31:34Z Microbiome and proteogenomics: rapid diet changes reshape molecular profiles https://biobriefs.com/neuroscience-and-neuroinflammation-mettl3-targeted BioBriefs en 2026-08-09T21:31:34Z Neuroscience and neuroinflammation: METTL3-targeted engineered nanovesicles https://biobriefs.com/regulatory-moves-in-oncology-and BioBriefs en 2026-08-09T16:31:56Z Regulatory moves in oncology and vaccine-era policy signals https://biobriefs.com/kidney-care-cost-pressures-and BioBriefs en 2026-08-09T16:31:56Z Kidney care cost pressures and payment-target effectiveness https://biobriefs.com/advancing-immunotherapy-engineering-with-bacterial BioBriefs en 2026-08-09T16:31:56Z Advancing immunotherapy engineering with bacterial targeting and immune activation https://biobriefs.com/molecular-glue-discovery-expands-druggable BioBriefs en 2026-08-09T16:31:56Z Molecular glue discovery expands druggable space in cancer https://biobriefs.com/ai-assisted-imaging-for-end BioBriefs en 2026-08-09T16:31:56Z AI-assisted imaging for end-to-end tumor assessment https://biobriefs.com/diagnostics-innovation-near-home-molecular BioBriefs en 2026-08-09T16:31:56Z Diagnostics innovation: near-home molecular testing with fluorescence optics https://biobriefs.com/genomics-platform-dispute-spatial-multiomics BioBriefs en 2026-08-09T16:31:56Z Genomics platform dispute: spatial multiomics patent litigation https://biobriefs.com/biotech-finance-biotech-ipo-run BioBriefs en 2026-08-09T16:31:56Z Biotech finance: biotech IPO run pushes fresh capital into the sector https://biobriefs.com/lab-automation-and-sequencing-supply BioBriefs en 2026-08-09T16:31:56Z Lab automation and sequencing supply chain moves in China https://biobriefs.com/spatiotemporal-drug-delivery-materials-controlled BioBriefs en 2026-08-09T16:31:55Z Spatiotemporal drug delivery materials: controlled peptide release from gelatin systems https://biobriefs.com/regulatory-approvals-and-fda-action BioBriefs en 2026-08-09T14:31:53Z Regulatory approvals and FDA action for oncology https://biobriefs.com/fda-scrutiny-set-for-early BioBriefs en 2026-08-09T14:31:53Z FDA scrutiny set for early cancer detection test after failed trial https://biobriefs.com/healthcare-reimbursement-and-policy-pressure BioBriefs en 2026-08-09T14:31:53Z Healthcare reimbursement and policy pressure on hospital drug discounting https://biobriefs.com/medicaid-work-requirement-rule-faces BioBriefs en 2026-08-09T14:31:53Z Medicaid work requirement rule faces congressional pushback https://biobriefs.com/biotech-ipo-fundraising-momentum BioBriefs en 2026-08-09T14:31:53Z Biotech IPO fundraising momentum https://biobriefs.com/mass-device-approval-expansion-in BioBriefs en 2026-08-09T14:31:53Z Mass device approval expansion in electrophysiology https://biobriefs.com/ai-in-oncology-workflows BioBriefs en 2026-08-09T14:31:53Z AI in oncology workflows https://biobriefs.com/diagnostics-hardware-and-spatial-biology BioBriefs en 2026-08-09T14:31:53Z Diagnostics hardware and spatial biology platform developments https://biobriefs.com/spatial-genomics-patent-litigation-between BioBriefs en 2026-08-09T14:31:53Z Spatial genomics patent litigation between startups and major platform vendor https://biobriefs.com/new-investment-in-molecular-diagnostics BioBriefs en 2026-08-09T14:31:53Z New investment in molecular diagnostics for resource-limited settings https://biobriefs.com/fda-approvals-and-regulatory-momentum BioBriefs en 2026-08-09T10:31:22Z FDA approvals and regulatory momentum https://biobriefs.com/regulatory-decisions-and-disputes-in BioBriefs en 2026-08-09T10:31:22Z Regulatory decisions and disputes in cancer diagnostics https://biobriefs.com/china-biotech-policy-and-trade BioBriefs en 2026-08-09T10:31:22Z China biotech policy and trade access https://biobriefs.com/biotech-funding-and-capital-formation BioBriefs en 2026-08-09T10:31:22Z Biotech funding and capital formation https://biobriefs.com/oncology-pipeline-and-fast-track BioBriefs en 2026-08-09T10:31:22Z Oncology pipeline and fast-track activity https://biobriefs.com/oncology-diagnostics-and-mrd-evidence BioBriefs en 2026-08-09T10:31:22Z Oncology diagnostics and MRD evidence generation https://biobriefs.com/spatial-biology-platform-and-platform BioBriefs en 2026-08-09T10:31:22Z Spatial biology platform and platform demand https://biobriefs.com/biotech-startup-leadership-and-corporate BioBriefs en 2026-08-09T10:31:22Z Biotech startup leadership and corporate changes https://biobriefs.com/regenerative-medicine-and-gene-therapy BioBriefs en 2026-08-09T10:31:22Z Regenerative medicine and gene-therapy partnerships https://biobriefs.com/regulatory-designations-in-rare-pediatric BioBriefs en 2026-08-09T10:31:22Z Regulatory designations in rare pediatric disease https://biobriefs.com/accelerated-fda-approval-for-replimune BioBriefs en 2026-08-09T09:32:08Z Accelerated FDA approval for Replimune's oncolytic viral therapy https://biobriefs.com/fda-fast-track-activity-accelerates BioBriefs en 2026-08-09T09:32:08Z FDA fast-track activity accelerates ADC, immunotherapy, and PARP-combination programs https://biobriefs.com/otsukas-anti-april-antibody-voyxact BioBriefs en 2026-08-09T09:32:08Z Otsuka’s anti-APRIL antibody Voyxact eyes line-of-therapy shift in IgA nephropathy https://biobriefs.com/non-opioid-pain-innovation-hits BioBriefs en 2026-08-09T09:32:08Z Non-opioid pain innovation hits IPO market: Latigo launches Nav1.8 program https://biobriefs.com/blossomhill-joins-ipo-wave-to BioBriefs en 2026-08-09T09:32:08Z Blossomhill joins IPO wave to fund macrocyclic oncology drug development https://biobriefs.com/ipo-runway-strengthens-with-10x BioBriefs en 2026-08-09T09:32:08Z IPO runway strengthens with 10x Genomics Atera-driven demand—guidance raised https://biobriefs.com/molecular-glue-platform-expands-hunt BioBriefs en 2026-08-09T09:32:08Z Molecular glue platform expands hunt for degraders beyond classic E3 ligase coverage https://biobriefs.com/oncology-diagnostics-and-mrd-natera BioBriefs en 2026-08-09T09:32:08Z Oncology diagnostics and MRD: Natera expands prospective readouts for Signatera https://biobriefs.com/regulatory-review-fda-adcomm-to BioBriefs en 2026-08-09T09:32:08Z Regulatory review: FDA adcomm to revisit Grail cancer test failure in large randomized trial https://biobriefs.com/manufacturing-automation-platform-from-oak BioBriefs en 2026-08-09T09:32:08Z Manufacturing automation: platform from Oak Ridge speeds bacterial gene mapping for biotech design https://biobriefs.com/regulatory-approvals-and-high-stakes BioBriefs en 2026-08-09T04:31:47Z Regulatory approvals and high-stakes FDA actions https://biobriefs.com/oncology-therapeutics-new-biologics-biomarker BioBriefs en 2026-08-09T04:31:47Z Oncology therapeutics: new biologics, biomarker logic, and immune evasion https://biobriefs.com/clinical-development-and-long-term BioBriefs en 2026-08-09T04:31:47Z Clinical development and long-term survivorship improvements in pediatric oncology https://biobriefs.com/antimicrobials-and-translational-biosecurity-policy BioBriefs en 2026-08-09T04:31:47Z Antimicrobials and translational biosecurity policy https://biobriefs.com/new-diagnostics-and-molecular-testing BioBriefs en 2026-08-09T04:31:47Z New diagnostics and molecular testing tools https://biobriefs.com/biotech-funding-momentum-ipos-and BioBriefs en 2026-08-09T04:31:47Z Biotech funding momentum: IPOs and large capital raises https://biobriefs.com/spatial-and-single-cell-platform BioBriefs en 2026-08-09T04:31:47Z Spatial and single-cell platform competition: lawsuits and guidance demand https://biobriefs.com/protein-degradation-innovation-molecular-glue BioBriefs en 2026-08-09T04:31:47Z Protein degradation innovation: molecular glue platform from Dana-Farber https://biobriefs.com/public-private-biotech-execution-ai BioBriefs en 2026-08-09T04:31:47Z Public-private biotech execution: AI in oncology clinical workflows https://biobriefs.com/viral-and-immunotherapy-platforms-vaccine BioBriefs en 2026-08-09T04:31:47Z Viral and immunotherapy platforms: vaccine breadth and engineered delivery https://biobriefs.com/accelerated-approval-after-prior-fda BioBriefs en 2026-08-08T21:31:51Z Accelerated approval after prior FDA rejection https://biobriefs.com/phase-3-readouts-shift-expectations BioBriefs en 2026-08-08T21:31:51Z Phase 3 readouts shift expectations in IgA nephropathy https://biobriefs.com/ipo-pipeline-bright-spots-for BioBriefs en 2026-08-08T21:31:51Z IPO pipeline bright spots for biopharma https://biobriefs.com/ai-enabled-oncology-workflow-support BioBriefs en 2026-08-08T21:31:51Z AI-enabled oncology workflow support https://biobriefs.com/platform-and-regulatory-step-for BioBriefs en 2026-08-08T21:31:51Z Platform and regulatory step for novel OX2R agonist in narcolepsy https://biobriefs.com/noninvasive-diagnostics-for-portal-hypertension BioBriefs en 2026-08-08T21:31:51Z Noninvasive diagnostics for portal hypertension https://biobriefs.com/lymphoma-diagnostic-acceleration-in-low BioBriefs en 2026-08-08T21:31:51Z Lymphoma diagnostic acceleration in low-resource settings https://biobriefs.com/spatial-genomics-patent-fight-escalates BioBriefs en 2026-08-08T21:31:51Z Spatial genomics patent fight escalates https://biobriefs.com/ai-designed-phages-for-antimicrobial BioBriefs en 2026-08-08T21:31:51Z AI-designed phages for antimicrobial resistance with biosafety concerns https://biobriefs.com/rare-pediatrics-designation-for-cardiomyopathy BioBriefs en 2026-08-08T21:31:51Z Rare pediatrics designation for cardiomyopathy program https://biobriefs.com/fda-accelerated-approval-and-post BioBriefs en 2026-08-08T16:32:04Z FDA accelerated approval and post-rejection turnaround for an oncolytic virus in melanoma https://biobriefs.com/company-reshapes-rare-disease-development BioBriefs en 2026-08-08T16:32:04Z Company reshapes rare-disease development after mixed Phase 3 outcomes https://biobriefs.com/clinical-stage-mover-ox2r-agonist BioBriefs en 2026-08-08T16:32:04Z Clinical-stage mover: OX2R agonist wins FDA approval in narcolepsy type 1 https://biobriefs.com/us-fda-advisory-committee-set BioBriefs en 2026-08-08T16:32:04Z US FDA advisory committee set for Grail’s failed cancer screening test https://biobriefs.com/obesity-market-competition-survey-shows BioBriefs en 2026-08-08T16:32:04Z Obesity market competition: survey shows injectable GLP-1s still win clinician satisfaction https://biobriefs.com/biotech-platform-and-financing-momentum BioBriefs en 2026-08-08T16:32:04Z Biotech platform and financing momentum: large IPOs in pain and oncology https://biobriefs.com/molecular-tools-and-diagnostic-access BioBriefs en 2026-08-08T16:32:04Z Molecular tools and diagnostic access: Co-Diagnostics advances point-of-care respiratory multiplex testing https://biobriefs.com/bioengineering-and-therapeutics-nanovesicles-targeting BioBriefs en 2026-08-08T16:32:04Z Bioengineering and therapeutics: nanovesicles targeting METTL3 curb neuroinflammation https://biobriefs.com/new-degrader-platform-expands-molecular BioBriefs en 2026-08-08T16:32:04Z New degrader platform expands molecular glue discovery for cancer targets https://biobriefs.com/china-focused-diagnostics-and-genomics BioBriefs en 2026-08-08T16:32:04Z China-focused diagnostics and genomics industry: Illumina local MiSeq i100 launch in China https://biobriefs.com/regulatory-approval-oncolytic-virus-melanoma BioBriefs en 2026-08-08T14:32:29Z Regulatory approval – oncolytic virus melanoma (Replimune/Tudriqev) https://biobriefs.com/regulatory-approval-first-in-class BioBriefs en 2026-08-08T14:32:29Z Regulatory approval – first-in-class orexin receptor agonist for narcolepsy type 1 https://biobriefs.com/clinical-development-non-opioid-pain BioBriefs en 2026-08-08T14:32:29Z Clinical development – non-opioid pain IPO advances Nav1.8 pipeline (Latigo) https://biobriefs.com/ipo-funding-macrocyclic-oncology-platform BioBriefs en 2026-08-08T14:32:29Z IPO funding – macrocyclic oncology platform (Blossomhill) https://biobriefs.com/regulatory-pipeline-fast-track-and BioBriefs en 2026-08-08T14:32:29Z Regulatory pipeline – fast-track and priority review signals across oncology https://biobriefs.com/diagnostic-expansion-portable-at-home BioBriefs en 2026-08-08T14:32:29Z Diagnostic expansion – portable, at-home molecular testing device (VPodDuo) https://biobriefs.com/spatial-biology-10x-genomics-raises BioBriefs en 2026-08-08T14:32:29Z Spatial biology – 10x Genomics raises outlook on Atera demand https://biobriefs.com/regulatory-and-industry-policy-340b BioBriefs en 2026-08-08T14:32:29Z Regulatory and industry policy – 340B rebate push meets bipartisan resistance https://biobriefs.com/biotech-exec-movement-and-leadership BioBriefs en 2026-08-08T14:32:29Z Biotech exec movement and leadership changes – BioCentury/management track merger of information (Terremoto CEO) https://biobriefs.com/cell-and-gene-therapy-tooling BioBriefs en 2026-08-08T14:32:29Z Cell and gene therapy tooling – AAV manufacturing improvement via helper plasmid engineering https://biobriefs.com/accelerated-approval-and-setbacks-in BioBriefs en 2026-08-08T10:32:12Z Accelerated approval and setbacks in oncology https://biobriefs.com/regulatory-wins-in-vaccines-and BioBriefs en 2026-08-08T10:32:12Z Regulatory wins in vaccines and infectious disease products https://biobriefs.com/biotech-ipo-momentum-and-large BioBriefs en 2026-08-08T10:32:12Z Biotech IPO momentum and large funding raises https://biobriefs.com/molecular-diagnostics-and-mrd-demand BioBriefs en 2026-08-08T10:32:12Z Molecular diagnostics and MRD: demand signals and platform expansion https://biobriefs.com/gene-editing-and-safety-risks BioBriefs en 2026-08-08T10:32:12Z Gene editing and safety risks in China https://biobriefs.com/first-in-class-sleep-and BioBriefs en 2026-08-08T10:32:12Z First-in-class sleep and neurology approvals https://biobriefs.com/targeted-cancer-diagnostics-and-platform BioBriefs en 2026-08-08T10:32:12Z Targeted cancer diagnostics and platform competition in spatial biology https://biobriefs.com/biopharma-capital-markets-uk-vc BioBriefs en 2026-08-08T10:32:12Z Biopharma capital markets: UK VC surge https://biobriefs.com/fda-pathway-and-international-expansion BioBriefs en 2026-08-08T10:32:12Z FDA pathway and international expansion in life science tools https://biobriefs.com/biotech-innovation-protein-degradation-platform BioBriefs en 2026-08-08T10:32:12Z Biotech innovation: protein degradation platform for molecular glue discovery https://biobriefs.com/regulatory-approvals-oncology-accelerated-approval BioBriefs en 2026-08-08T09:32:30Z Regulatory approvals: oncology (accelerated approval) rebound https://biobriefs.com/regulatory-decisions-rare-disease-and BioBriefs en 2026-08-08T09:32:30Z Regulatory decisions: rare disease and pediatric designations https://biobriefs.com/fda-approvals-first-in-class BioBriefs en 2026-08-08T09:32:30Z FDA approvals: first-in-class orexin pathway sleep drug https://biobriefs.com/clinical-data-and-diagnostics-ovarian BioBriefs en 2026-08-08T09:32:30Z Clinical data and diagnostics: ovarian function under ketamine and fertility protection https://biobriefs.com/clinical-evidence-fecal-microbiome-transplant BioBriefs en 2026-08-08T09:32:30Z Clinical evidence: fecal microbiome transplant in peanut allergy tolerance https://biobriefs.com/diagnostics-and-workflows-ai-embedded BioBriefs en 2026-08-08T09:32:30Z Diagnostics and workflows: AI embedded into oncology physician practice https://biobriefs.com/regulatory-review-risk-fda-to BioBriefs en 2026-08-08T09:32:30Z Regulatory review risk: FDA to convene adcomm for Grail’s failed cancer test https://biobriefs.com/biotech-financing-blockbuster-ipos-in BioBriefs en 2026-08-08T09:32:30Z Biotech financing: blockbuster IPOs in 2026 and demand for early-stage growth https://biobriefs.com/translational-biology-tau-disrupts-mitochondrial BioBriefs en 2026-08-08T09:32:30Z Translational biology: tau disrupts mitochondrial function via reverse electron transport https://biobriefs.com/drug-development-and-early-stage BioBriefs en 2026-08-08T09:32:30Z Drug development and early-stage pipeline: ferroptosis linked to FLT3 inhibitors in AML https://biobriefs.com/fda-accelerated-approval-for-replimune BioBriefs en 2026-08-08T04:31:53Z FDA accelerated approval for Replimune melanoma therapy https://biobriefs.com/takeda-wins-fda-nod-for BioBriefs en 2026-08-08T04:31:53Z Takeda wins FDA nod for first-in-class narcolepsy type 1 therapy https://biobriefs.com/moderna-secures-fda-approval-for BioBriefs en 2026-08-08T04:31:53Z Moderna secures FDA approval for first mRNA seasonal flu vaccine https://biobriefs.com/spatial-genomics-patent-litigation-moves BioBriefs en 2026-08-08T04:31:53Z Spatial genomics patent litigation moves forward in federal court https://biobriefs.com/new-rapid-point-of-care BioBriefs en 2026-08-08T04:31:53Z New rapid point-of-care respiratory multiplex test submission https://biobriefs.com/big-biotech-fundraising-milestone-uk BioBriefs en 2026-08-08T04:31:53Z Big biotech fundraising milestone: UK biotech VC hits 5-year high https://biobriefs.com/protein-degraders-dana-farber-platform BioBriefs en 2026-08-08T04:31:53Z Protein degraders: Dana-Farber platform discovers metabolically activated molecular glue https://biobriefs.com/novel-platform-speeds-bacterial-gene BioBriefs en 2026-08-08T04:31:53Z Novel platform speeds bacterial gene mapping for biotech design https://biobriefs.com/ai-designed-phages-enter-clinic BioBriefs en 2026-08-08T04:31:53Z AI-designed phages enter clinic-adjacent conversation as biosafety risks emerge https://biobriefs.com/takeda-backed-csf1r-inhibitor-ip BioBriefs en 2026-08-08T04:31:53Z Takeda-backed CSF1R inhibitor IP enters protection cycle https://biobriefs.com/regulatory-approvals-oncology-and-rare BioBriefs en 2026-08-07T21:32:12Z Regulatory approvals: oncology and rare disease https://biobriefs.com/regulatory-review-looming-cancer-screening BioBriefs en 2026-08-07T21:32:12Z Regulatory review looming: cancer screening test https://biobriefs.com/market-and-clinical-evidence-obesity BioBriefs en 2026-08-07T21:32:12Z Market and clinical evidence: obesity treatment preferences https://biobriefs.com/ai-and-drug-discovery-operations BioBriefs en 2026-08-07T21:32:12Z AI and drug discovery operations in oncology https://biobriefs.com/non-opioid-pain-pipeline-meets BioBriefs en 2026-08-07T21:32:12Z Non-opioid pain pipeline meets the public markets https://biobriefs.com/oncology-platform-expansion-spatial-biology BioBriefs en 2026-08-07T21:32:12Z Oncology platform expansion: spatial biology demand and outlook https://biobriefs.com/genomics-and-diagnostics-spatial-patent BioBriefs en 2026-08-07T21:32:12Z Genomics and diagnostics: spatial patent dispute threatens platform traction https://biobriefs.com/clinical-trials-and-regulatory-pipeline BioBriefs en 2026-08-07T21:32:12Z Clinical trials and regulatory pipeline: targeted accelerated development https://biobriefs.com/biopharma-finance-upsized-ipos-extend BioBriefs en 2026-08-07T21:32:12Z Biopharma finance: UPSIZED IPOs extend 2026’s listing momentum https://biobriefs.com/clinical-and-platform-innovation-microbiome BioBriefs en 2026-08-07T21:32:12Z Clinical and platform innovation: microbiome therapy signals in food allergy https://biobriefs.com/regulatory-action-new-therapy-approvals BioBriefs en 2026-08-07T16:32:24Z Regulatory action: new therapy approvals and advisory review https://biobriefs.com/obesity-market-injectable-dominance-persists BioBriefs en 2026-08-07T16:32:24Z Obesity market: injectable dominance persists as oral options launch https://biobriefs.com/oncology-pipeline-fast-track-designations BioBriefs en 2026-08-07T16:32:24Z Oncology pipeline: fast-track designations expand accelerated development https://biobriefs.com/cancer-diagnostics-mrd-study-pipeline BioBriefs en 2026-08-07T16:32:24Z Cancer diagnostics: MRD study pipeline ramps at Natera https://biobriefs.com/biopharma-finance-major-ipo-fundraising BioBriefs en 2026-08-07T16:32:24Z Biopharma finance: major IPO fundraising for pain and cardiology https://biobriefs.com/ophthalmology-deal-tarsus-buys-alkeus BioBriefs en 2026-08-07T16:32:24Z Ophthalmology deal: Tarsus buys Alkeus for late-stage Stargardt therapy https://biobriefs.com/antimicrobial-policy-and-market-us BioBriefs en 2026-08-07T16:32:24Z Antimicrobial policy and market: US senators weigh AMR and biotech leadership https://biobriefs.com/clinical-research-update-robotic-cataract BioBriefs en 2026-08-07T16:32:24Z Clinical research update: robotic cataract surgery integrates into routine workflow https://biobriefs.com/diagnostics-platform-growth-co-diagnostics BioBriefs en 2026-08-07T16:32:24Z Diagnostics platform growth: Co-Diagnostics advances point-of-care multiplex respiratory test https://biobriefs.com/cell-and-gene-therapy-biomarin BioBriefs en 2026-08-07T16:32:24Z Cell and gene therapy: BioMarin discontinues ENPP1 deficiency program after mixed Phase 3 https://biobriefs.com/cancer-early-detection-regulatory-path BioBriefs en 2026-08-07T14:32:06Z Cancer early detection regulatory path https://biobriefs.com/fda-oncology-designations-accelerate-development BioBriefs en 2026-08-07T14:32:06Z FDA oncology designations accelerate development https://biobriefs.com/melanoma-approval-closes-replimunes-accelerated BioBriefs en 2026-08-07T14:32:06Z Melanoma approval closes Replimune’s accelerated approval saga https://biobriefs.com/pulmonary-fibrosis-and-cancer-biotech BioBriefs en 2026-08-07T14:32:06Z Pulmonary fibrosis and cancer biotech pipeline gets new regulatory attention via expedited pathways https://biobriefs.com/rare-disease-failure-reshapes-biomarins BioBriefs en 2026-08-07T14:32:06Z Rare disease failure reshapes BioMarin’s pipeline after ENPP1 deficiency exit https://biobriefs.com/oncology-checkpoint-era-science-tau BioBriefs en 2026-08-07T14:32:06Z Oncology checkpoint-era science: tau mechanism links mitochondria dysfunction to neurodegeneration https://biobriefs.com/alzheimers-biomarker-expansion-across-populations BioBriefs en 2026-08-07T14:32:06Z Alzheimer’s biomarker expansion across populations https://biobriefs.com/biotech-capital-markets-major-ipo BioBriefs en 2026-08-07T14:32:06Z Biotech capital markets: major IPO fundraising for new biologic franchises https://biobriefs.com/biotech-funding-and-workforce-growth BioBriefs en 2026-08-07T14:32:06Z Biotech funding and workforce growth for transplant immunosuppression https://biobriefs.com/antimicrobial-resistance-policy-and-u BioBriefs en 2026-08-07T14:32:06Z Antimicrobial resistance policy and U.S. biotech leadership https://biobriefs.com/regulatory-approvals-vaccines-and-oncology BioBriefs en 2026-08-07T10:32:27Z Regulatory approvals: vaccines and oncology clearances https://biobriefs.com/clinical-trial-and-early-efficacy BioBriefs en 2026-08-07T10:32:27Z Clinical trial and early efficacy signals: targeted immunology and cell-based approaches https://biobriefs.com/drug-development-in-ophthalmology-large BioBriefs en 2026-08-07T10:32:27Z Drug development in ophthalmology: large deals and late-stage asset moves https://biobriefs.com/biotech-ipos-new-listings-to BioBriefs en 2026-08-07T10:32:27Z Biotech IPOs: new listings to fund clinical catalysts https://biobriefs.com/oncology-drug-delivery-radiopharmaceutical-trial BioBriefs en 2026-08-07T10:32:27Z Oncology drug delivery: radiopharmaceutical trial strategy advances earlier use https://biobriefs.com/m-a-and-portfolio-reshaping BioBriefs en 2026-08-07T10:32:27Z M&A and portfolio reshaping: platform and asset acquisitions https://biobriefs.com/funding-and-venture-new-financing BioBriefs en 2026-08-07T10:32:27Z Funding and venture: new financing rounds to push clinic-ready programs https://biobriefs.com/platform-innovation-molecular-glue-degraders BioBriefs en 2026-08-07T10:32:27Z Platform innovation: molecular glue degraders and next-generation targeted degradation https://biobriefs.com/ai-enabled-clinical-operations-trial BioBriefs en 2026-08-07T10:32:27Z AI-enabled clinical operations: trial delivery automation https://biobriefs.com/transplant-and-immunology-outcome-linked BioBriefs en 2026-08-07T10:32:27Z Transplant and immunology: outcome-linked policy models for gene therapy access https://biobriefs.com/fda-approvals-oncology-and-vaccines BioBriefs en 2026-08-07T09:31:45Z FDA approvals: oncology and vaccines https://biobriefs.com/modernas-mrna-flu-vaccine-regulatory BioBriefs en 2026-08-07T09:31:45Z Moderna’s mRNA flu vaccine: regulatory turnaround https://biobriefs.com/ophthalmology-m-a-tarsus-acquires BioBriefs en 2026-08-07T09:31:45Z Ophthalmology M&A: Tarsus acquires Alkeus for Stargardt asset https://biobriefs.com/immuno-oncology-pipeline-engineered-oncolytic BioBriefs en 2026-08-07T09:31:45Z Immuno-oncology pipeline: engineered oncolytic therapy approval and viral vector immunobiology https://biobriefs.com/biotech-funding-and-ipos-cash BioBriefs en 2026-08-07T09:31:45Z Biotech funding and IPOs: cash for late-stage and platform bets https://biobriefs.com/biotech-funding-expeditions-copd-series BioBriefs en 2026-08-07T09:31:45Z Biotech funding: Expedition’s COPD Series B and platform push https://biobriefs.com/gene-editing-and-cell-therapy BioBriefs en 2026-08-07T09:31:45Z Gene editing and cell therapy risks: China DMD death and clinical transparency concerns https://biobriefs.com/diagnostics-and-mrd-new-regulatory BioBriefs en 2026-08-07T09:31:45Z Diagnostics and MRD: new regulatory submissions in bladder cancer https://biobriefs.com/alzheimers-mechanisms-and-biomarkers-tau BioBriefs en 2026-08-07T09:31:45Z Alzheimer’s mechanisms and biomarkers: tau enters mitochondria and pTau217 expands populations https://biobriefs.com/genomics-reference-and-immunology-design BioBriefs en 2026-08-07T09:31:45Z Genomics reference and immunology design: telomere-to-telomere consortium expands benchmarking https://biobriefs.com/oncology-regulatory-milestone BioBriefs en 2026-08-07T05:01:49Z Oncology regulatory milestone https://biobriefs.com/rare-disease-and-gene-editing BioBriefs en 2026-08-07T05:01:49Z Rare disease and gene-editing risk signal https://biobriefs.com/eye-care-deal-in-stargardt BioBriefs en 2026-08-07T05:01:49Z Eye-care deal in Stargardt https://biobriefs.com/pulmonary-and-immune-pipeline-funding BioBriefs en 2026-08-07T05:01:49Z Pulmonary and immune pipeline funding and trial momentum https://biobriefs.com/pricing-and-reimbursement-pressure-in BioBriefs en 2026-08-07T05:01:49Z Pricing and reimbursement pressure in oncology diagnostics https://biobriefs.com/fda-action-for-vaccine-technology BioBriefs en 2026-08-07T05:01:49Z FDA action for vaccine technology platform https://biobriefs.com/phase-1-food-allergy-microbiome BioBriefs en 2026-08-07T05:01:49Z Phase 1 food-allergy microbiome therapy signal https://biobriefs.com/platform-validation-for-point-of BioBriefs en 2026-08-07T05:01:49Z Platform validation for point-of-care diagnostics https://biobriefs.com/hcm-drug-developer-goes-public BioBriefs en 2026-08-07T05:01:49Z HCM drug developer goes public https://biobriefs.com/rare-kidney-disease-biotech-funding BioBriefs en 2026-08-07T05:01:49Z Rare kidney disease biotech funding https://biobriefs.com/fda-approvals-and-regulatory-decisions BioBriefs en 2026-08-06T21:32:07Z FDA approvals and regulatory decisions https://biobriefs.com/fda-approvals-novel-sleep-medicine BioBriefs en 2026-08-06T21:32:07Z FDA approvals: novel sleep medicine class https://biobriefs.com/mrna-flu-vaccine-regulatory-green BioBriefs en 2026-08-06T21:32:07Z mRNA flu vaccine regulatory green light https://biobriefs.com/biotech-financing-ipos-and-major BioBriefs en 2026-08-06T21:32:07Z Biotech financing: IPOs and major venture rounds https://biobriefs.com/venture-capital-growth-for-respiratory BioBriefs en 2026-08-06T21:32:07Z Venture capital: growth for respiratory and kidney pipelines https://biobriefs.com/cdmo-and-platform-partnerships-for BioBriefs en 2026-08-06T21:32:07Z CDMO and platform partnerships for gene therapy manufacturing https://biobriefs.com/liquid-biopsy-diagnostics-expand-to BioBriefs en 2026-08-06T21:32:07Z Liquid biopsy diagnostics expand to international regulators https://biobriefs.com/alkeus-acquisition-late-stage-eye BioBriefs en 2026-08-06T21:32:07Z Alkeus acquisition: late-stage eye therapy deal https://biobriefs.com/ai-driven-platform-recursion-and BioBriefs en 2026-08-06T21:32:07Z AI-driven platform: Recursion and Genentech validate a neuro target https://biobriefs.com/clinical-research-patient-reported-outcomes BioBriefs en 2026-08-06T21:32:07Z Clinical research: patient-reported outcomes monitoring in metastatic breast cancer https://biobriefs.com/fda-approval BioBriefs en 2026-08-06T16:32:27Z FDA approval https://biobriefs.com/fda-approval-vaccines BioBriefs en 2026-08-06T16:32:27Z FDA approval - vaccines https://biobriefs.com/medicare-health-policy-impact-on BioBriefs en 2026-08-06T16:32:27Z Medicare/health policy impact on biotech access https://biobriefs.com/oncology-diagnostics-mrd BioBriefs en 2026-08-06T16:32:27Z Oncology diagnostics - MRD https://biobriefs.com/gene-editing-safety-clinical-insights BioBriefs en 2026-08-06T16:32:27Z Gene editing safety/clinical insights https://biobriefs.com/rare-disease-drug-launch-pipeline BioBriefs en 2026-08-06T16:32:27Z Rare disease drug launch pipeline - pediatrics/autoimmunity https://biobriefs.com/biotech-ipos-cardiomyopathy BioBriefs en 2026-08-06T16:32:27Z Biotech IPOs - cardiomyopathy https://biobriefs.com/precision-diagnostics-liquid-biopsy-nipt BioBriefs en 2026-08-06T16:32:27Z Precision diagnostics - liquid biopsy/NIPT expansion https://biobriefs.com/cancer-diagnostics-oncology-services-growth BioBriefs en 2026-08-06T16:32:27Z Cancer diagnostics/oncology services growth https://biobriefs.com/funding-transplant-autoimmunity-immunosuppressant BioBriefs en 2026-08-06T16:32:27Z Funding - transplant/autoimmunity immunosuppressant https://biobriefs.com/regulatory-approvals-and-vaccine-platform BioBriefs en 2026-08-06T14:31:51Z Regulatory approvals and vaccine platform momentum https://biobriefs.com/clinical-and-commercial-pressure-in BioBriefs en 2026-08-06T14:31:51Z Clinical and commercial pressure in late-stage oncology and gene therapy https://biobriefs.com/capital-raises-and-dealmaking-in BioBriefs en 2026-08-06T14:31:51Z Capital raises and dealmaking in specialty biopharma https://biobriefs.com/oncology-diagnostics-expansion-and-companion BioBriefs en 2026-08-06T14:31:51Z Oncology diagnostics expansion and companion testing submissions https://biobriefs.com/fda-and-trial-pipeline-signals BioBriefs en 2026-08-06T14:31:51Z FDA and trial pipeline signals from early-to-mid stage companies https://biobriefs.com/regulatory-and-leadership-shakeups-in BioBriefs en 2026-08-06T14:31:51Z Regulatory and leadership shakeups in sequencing and genomics tools https://biobriefs.com/strategic-oncology-and-cns-corporate BioBriefs en 2026-08-06T14:31:51Z Strategic oncology and CNS corporate deals https://biobriefs.com/ai-enabled-clinical-development-operations BioBriefs en 2026-08-06T14:31:51Z AI-enabled clinical development operations https://biobriefs.com/ophthalmology-portfolio-expansion-via-phase BioBriefs en 2026-08-06T14:31:51Z Ophthalmology portfolio expansion via Phase 3 acquisition https://biobriefs.com/late-stage-regulatory-and-pipeline BioBriefs en 2026-08-06T14:31:51Z Late-stage regulatory and pipeline commentary in chronic disease https://biobriefs.com/fda-approvals-mrna-flu BioBriefs en 2026-08-06T10:31:46Z FDA approvals – mRNA flu https://biobriefs.com/m-a-cns-consolidation BioBriefs en 2026-08-06T10:31:46Z M&A – CNS consolidation https://biobriefs.com/biotech-financing-upsized-ipo BioBriefs en 2026-08-06T10:31:46Z Biotech financing – upsized IPO https://biobriefs.com/biotech-financing-attovia-ipo-spree BioBriefs en 2026-08-06T10:31:46Z Biotech financing – Attovia IPO spree https://biobriefs.com/clinical-delivery-mrd-cdx-in BioBriefs en 2026-08-06T10:31:46Z Clinical delivery – MRD CDx in bladder cancer https://biobriefs.com/clinical-trial-targeted-mrna-ai BioBriefs en 2026-08-06T10:31:46Z Clinical trial – targeted mRNA/AI in oncology delivery ops https://biobriefs.com/therapeutic-strategy-glp-1-market BioBriefs en 2026-08-06T10:31:46Z Therapeutic strategy – GLP-1 market update https://biobriefs.com/oncology-pipeline-mrd-and-next BioBriefs en 2026-08-06T10:31:46Z Oncology pipeline – MRD and next-gen models https://biobriefs.com/immunotherapy-market-prep-revenue-milestone BioBriefs en 2026-08-06T10:31:46Z Immunotherapy market – PrEP revenue milestone https://biobriefs.com/enterprise-biotech-genomics-manufacturing-and BioBriefs en 2026-08-06T10:31:46Z Enterprise biotech – genomics manufacturing and validation https://biobriefs.com/moderna-mrna-flu-shot-wins BioBriefs en 2026-08-06T09:31:43Z Moderna mRNA flu shot wins FDA approval after prior agency standoff https://biobriefs.com/braveheart-lands-nasdaq-ipo-to BioBriefs en 2026-08-06T09:31:43Z Braveheart lands Nasdaq IPO to move Hengrui cardio drug into Phase 3 https://biobriefs.com/takeda-orexin-agonist-orzeyful-gets BioBriefs en 2026-08-06T09:31:43Z Takeda orexin agonist Orzeyful gets FDA approval for narcolepsy type 1 https://biobriefs.com/natera-submits-signatera-mrd-test BioBriefs en 2026-08-06T09:31:43Z Natera submits Signatera MRD test to Japan’s PMDA for bladder cancer https://biobriefs.com/a-merger-is-off-the BioBriefs en 2026-08-06T09:31:43Z A merger is off the table: Reuters says no talks between AstraZeneca and BMS https://biobriefs.com/recursion-and-genentech-extend-ai BioBriefs en 2026-08-06T09:31:43Z Recursion and Genentech extend AI-to-clinic momentum with a validated neuroscience target https://biobriefs.com/curative-and-wondr-expand-weight BioBriefs en 2026-08-06T09:31:43Z Curative and Wondr expand weight and metabolic support access via partnership https://biobriefs.com/caris-raises-full-year-momentum BioBriefs en 2026-08-06T09:31:43Z Caris raises full-year momentum on molecular profiling growth and new MRD roadmap https://biobriefs.com/nci-linked-biobank-expands-3d BioBriefs en 2026-08-06T09:31:43Z NCI-linked biobank expands 3D patient tumor models to expose cancer vulnerabilities https://biobriefs.com/takedas-narcolepsy-approval-parallels-a BioBriefs en 2026-08-06T09:31:43Z Takeda’s narcolepsy approval parallels a market shift toward mechanism-led sleep therapeutics https://biobriefs.com/regulatory-approvals-and-fda-actions BioBriefs en 2026-08-06T04:31:50Z Regulatory approvals and FDA actions https://biobriefs.com/immunology-and-oncology-translational-breakthroughs BioBriefs en 2026-08-06T04:31:50Z Immunology and oncology translational breakthroughs https://biobriefs.com/ai-driven-drug-discovery-and BioBriefs en 2026-08-06T04:31:50Z AI-driven drug discovery and early pipeline nomination https://biobriefs.com/funding-and-ipo-momentum-for BioBriefs en 2026-08-06T04:31:50Z Funding and IPO momentum for biotech https://biobriefs.com/precision-oncology-diagnostics-and-mrd BioBriefs en 2026-08-06T04:31:50Z Precision oncology diagnostics and MRD expansion https://biobriefs.com/clinical-development-shifts-and-trial BioBriefs en 2026-08-06T04:31:50Z Clinical development shifts and trial portfolio management https://biobriefs.com/hiv-prevention-performance-and-market BioBriefs en 2026-08-06T04:31:50Z HIV prevention performance and market durability debate https://biobriefs.com/genetic-diagnostics-expansion-and-revenue BioBriefs en 2026-08-06T04:31:50Z Genetic diagnostics expansion and revenue growth https://biobriefs.com/clinical-trial-and-ind-progress BioBriefs en 2026-08-06T04:31:50Z Clinical trial and IND progress in oncology https://biobriefs.com/deal-making-and-business-combinations BioBriefs en 2026-08-06T04:31:50Z Deal making and business combinations in CNS therapeutics https://biobriefs.com/regulatory-approvals-and-labeling-decisions BioBriefs en 2026-08-05T21:31:52Z Regulatory approvals and labeling decisions https://biobriefs.com/precision-diagnostics-for-oncology BioBriefs en 2026-08-05T21:31:52Z Precision diagnostics for oncology https://biobriefs.com/cdmo-sequencing-operations-and-leadership BioBriefs en 2026-08-05T21:31:52Z CDMO, sequencing operations, and leadership transitions https://biobriefs.com/biotech-ipo-momentum-and-public BioBriefs en 2026-08-05T21:31:52Z Biotech IPO momentum and public-market fundraising https://biobriefs.com/ai-enabled-drug-discovery-moving BioBriefs en 2026-08-05T21:31:52Z AI-enabled drug discovery moving toward the clinic https://biobriefs.com/clinical-stage-trial-and-drug BioBriefs en 2026-08-05T21:31:52Z Clinical-stage trial and drug update in obesity competition https://biobriefs.com/cancer-biology-targeted-drug-resistance BioBriefs en 2026-08-05T21:31:52Z Cancer biology: targeted drug resistance reversal https://biobriefs.com/oncology-m-a-radiopharma-consolidation BioBriefs en 2026-08-05T21:31:52Z Oncology M&A: radiopharma consolidation https://biobriefs.com/biotech-funding-and-pipeline-nervous BioBriefs en 2026-08-05T21:31:52Z Biotech funding and pipeline: nervous system innovation via AI validation https://biobriefs.com/regulatory-and-ethics-controversy-in BioBriefs en 2026-08-05T21:31:52Z Regulatory and ethics controversy in gene editing transparency https://biobriefs.com/glp-1-competitive-dynamics-and BioBriefs en 2026-08-05T16:32:00Z GLP-1 competitive dynamics and pipeline pressure https://biobriefs.com/novo-pipeline-setback-and-ceo BioBriefs en 2026-08-05T16:32:00Z Novo pipeline setback and CEO response on innovation https://biobriefs.com/hiv-prevention-revenue-milestone-and BioBriefs en 2026-08-05T16:32:00Z HIV prevention revenue milestone and scrutiny of durability https://biobriefs.com/court-limits-duty-to-innovate BioBriefs en 2026-08-05T16:32:00Z Court limits ‘duty to innovate’ claims against drugmakers https://biobriefs.com/astrazeneca-bristol-myers-merger-rumors BioBriefs en 2026-08-05T16:32:00Z AstraZeneca-Bristol Myers merger rumors cooled by Reuters report https://biobriefs.com/precision-oncology-diagnostics-expand-in BioBriefs en 2026-08-05T16:32:00Z Precision oncology diagnostics expand in Japan https://biobriefs.com/china-to-us-ai-discovery BioBriefs en 2026-08-05T16:32:00Z China-to-US AI-discovery partnership milestone with Genentech https://biobriefs.com/m-a-reshaping-cns-focused BioBriefs en 2026-08-05T16:32:00Z M&A reshaping CNS-focused portfolios https://biobriefs.com/regulatory-pathway-for-gene-editing BioBriefs en 2026-08-05T16:32:00Z Regulatory pathway for gene-editing therapies highlighted by IND activity and setbacks https://biobriefs.com/biotech-funding-and-ipo-pipeline BioBriefs en 2026-08-05T16:32:00Z Biotech funding and IPO pipeline—Capital formation remains active https://biobriefs.com/recursions-pi3ka-program-advances-into BioBriefs en 2026-08-05T14:31:45Z Recursion’s PI3Kα program advances into early-stage trials https://biobriefs.com/fda-moves-pluvicto-earlier-in BioBriefs en 2026-08-05T14:31:45Z FDA moves Pluvicto earlier in prostate cancer pathway https://biobriefs.com/curium-and-lantheus-agree-radiopharma BioBriefs en 2026-08-05T14:31:45Z Curium and Lantheus agree radiopharma tie-up to form larger nuclear medicine platform https://biobriefs.com/supernus-and-indivior-set-merger BioBriefs en 2026-08-05T14:31:45Z Supernus and Indivior set merger terms for a CNS-focused company https://biobriefs.com/antibody-drug-conjugate-licensing-pathos BioBriefs en 2026-08-05T14:31:45Z Antibody-drug conjugate licensing: Pathos AI expands cancer pipeline with Alphamab deal https://biobriefs.com/fda-grants-ind-clearance-for BioBriefs en 2026-08-05T14:31:45Z FDA grants IND clearance for Brightpath multiple myeloma asset https://biobriefs.com/dna-synthesis-and-ai-demand BioBriefs en 2026-08-05T14:31:45Z DNA synthesis and AI demand lift Twist Bioscience’s results and financing https://biobriefs.com/financing-boost-for-expedition-therapeutics BioBriefs en 2026-08-05T14:31:45Z Financing boost for Expedition Therapeutics COPD program reaches phase 2 https://biobriefs.com/ipo-and-scaling-push-attovia BioBriefs en 2026-08-05T14:31:45Z IPO and scaling push: Attovia raises on anti-itch immunology pipeline https://biobriefs.com/recoding-clinical-workflows-ultrasound-guidance BioBriefs en 2026-08-05T14:31:45Z Recoding clinical workflows: ultrasound guidance reduces neonatal feeding tube misplacement and radiation https://biobriefs.com/gene-editing-safety-scrutiny-after BioBriefs en 2026-08-05T10:32:20Z Gene-editing safety scrutiny after fatal first-in-human death https://biobriefs.com/big-radiopharma-consolidates-to-expand BioBriefs en 2026-08-05T10:32:20Z Big radiopharma consolidates to expand theranostics footprint https://biobriefs.com/cns-focused-pharma-merger-of BioBriefs en 2026-08-05T10:32:20Z CNS-focused pharma merger of equals https://biobriefs.com/new-fda-label-expansion-for BioBriefs en 2026-08-05T10:32:20Z New FDA label expansion for Pluvicto in earlier prostate cancer https://biobriefs.com/obesity-pipeline-reshuffle-at-amgen BioBriefs en 2026-08-05T10:32:20Z Obesity pipeline reshuffle at Amgen https://biobriefs.com/ai-enabled-clinical-trials-and BioBriefs en 2026-08-05T10:32:20Z AI-enabled clinical trials and digital patient outcome modeling https://biobriefs.com/checkpoint-resistant-cancer-biology-identified BioBriefs en 2026-08-05T10:32:20Z Checkpoint-resistant cancer biology identified through PD-L1 nuclear trafficking https://biobriefs.com/oncology-product-development-gene-modifying BioBriefs en 2026-08-05T10:32:20Z Oncology product development: gene-modifying ADC assets change hands https://biobriefs.com/genetics-diagnostics-expansion-via-tempus BioBriefs en 2026-08-05T10:32:20Z Genetics diagnostics expansion via Tempus acquisition expectations https://biobriefs.com/antibody-drug-conjugate-interest-intensifies BioBriefs en 2026-08-05T10:32:20Z Antibody-drug conjugate interest intensifies with TROP2/HER3 licensing preview https://biobriefs.com/oncology-fda-priority-review-for BioBriefs en 2026-08-05T09:32:03Z Oncology: FDA priority review for subcutaneous amivantamab-hyaluronidase in post-platinum head and neck cancer https://biobriefs.com/radiopharmaceuticals-curium-agrees-to-buy BioBriefs en 2026-08-05T09:32:03Z Radiopharmaceuticals: Curium agrees to buy Lantheus in up-to-$8B deal https://biobriefs.com/cns-m-a-supernus-and BioBriefs en 2026-08-05T09:32:03Z CNS M&A: Supernus and Indivior sign “merger of equals” to form a CNS-focused pharma https://biobriefs.com/digital-health-clinical-operations-cu BioBriefs en 2026-08-05T09:32:03Z Digital health + clinical operations: CU Anschutz trial shows AI-controlled oxygen delivery improves time in range https://biobriefs.com/diagnostics-and-companion-testing-sophia BioBriefs en 2026-08-05T09:32:03Z Diagnostics and companion testing: Sophia Genetics expands with AstraZeneca CDx collaboration as revenue rises https://biobriefs.com/precision-oncology-biomarker-workflows-quanthealth BioBriefs en 2026-08-05T09:32:03Z Precision oncology + biomarker workflows: QuantHealth raises $45M Series B to simulate clinical trials before enrollment https://biobriefs.com/company-performance-consolidation-personalis-q2 BioBriefs en 2026-08-05T09:32:03Z Company performance + consolidation: Personalis Q2 revenue jumps as Medicare coverage expands; Tempus acquisition pending https://biobriefs.com/biopharma-portfolio-regulatory-shift-fda BioBriefs en 2026-08-05T09:32:03Z Biopharma portfolio + regulatory shift: FDA expands Pluvicto use with hormone therapy in broader metastatic prostate cancer population https://biobriefs.com/company-finance-restructuring-genedx-cuts BioBriefs en 2026-08-05T09:32:03Z Company finance + restructuring: GeneDx cuts ~75 jobs as Q2 revenue improves 11% https://biobriefs.com/rare-disease-gene-therapy-oversight BioBriefs en 2026-08-05T09:32:03Z Rare disease gene therapy oversight: Death in Shanghai gene-editing trial triggers fresh ethics scrutiny https://biobriefs.com/radiopharmaceuticals-m-a BioBriefs en 2026-08-05T04:31:49Z Radiopharmaceuticals M&A https://biobriefs.com/cns-pharma-consolidation BioBriefs en 2026-08-05T04:31:49Z CNS pharma consolidation https://biobriefs.com/ai-driven-clinical-trial-simulation BioBriefs en 2026-08-05T04:31:49Z AI-driven clinical trial simulation https://biobriefs.com/oncology-precision-diagnostics-and-reimbursement BioBriefs en 2026-08-05T04:31:49Z Oncology precision diagnostics and reimbursement tailwinds https://biobriefs.com/diagnostic-platform-partnerships BioBriefs en 2026-08-05T04:31:49Z Diagnostic platform partnerships https://biobriefs.com/regulatory-action-for-a-blockbuster BioBriefs en 2026-08-05T04:31:49Z Regulatory action for a blockbuster radioligand https://biobriefs.com/biotech-ai-adc-licensing-expansion BioBriefs en 2026-08-05T04:31:49Z Biotech AI/ADC licensing expansion https://biobriefs.com/pipeline-update-in-obesity BioBriefs en 2026-08-05T04:31:49Z Pipeline update in obesity https://biobriefs.com/clinical-drug-development-beat-in BioBriefs en 2026-08-05T04:31:49Z Clinical drug development beat in HIV prevention https://biobriefs.com/regulatory-controversy-in-gene-editing BioBriefs en 2026-08-05T04:31:49Z Regulatory controversy in gene editing oversight https://biobriefs.com/m-a-reshapes-the-cns BioBriefs en 2026-08-04T21:32:19Z M&A reshapes the CNS market https://biobriefs.com/radiopharma-consolidation-and-theranostics-scale BioBriefs en 2026-08-04T21:32:19Z Radiopharma consolidation and theranostics scale-up https://biobriefs.com/fda-moves-pluvicto-earlier-in BioBriefs en 2026-08-04T21:32:19Z FDA moves Pluvicto earlier in prostate cancer https://biobriefs.com/regulatory-approval-for-subcutaneous-head BioBriefs en 2026-08-04T21:32:19Z Regulatory approval for subcutaneous head and neck cancer regimen https://biobriefs.com/strategic-genomics-expansion-through-acquisition BioBriefs en 2026-08-04T21:32:19Z Strategic genomics expansion through acquisition https://biobriefs.com/tempus-moves-to-acquire-personalis BioBriefs en 2026-08-04T21:32:19Z Tempus moves to acquire Personalis after strong quarter https://biobriefs.com/device-regulation-ce-mark-for BioBriefs en 2026-08-04T21:32:19Z Device regulation: CE mark for aneurysm embolization system https://biobriefs.com/ai-enabled-platform-partnerships-in BioBriefs en 2026-08-04T21:32:19Z AI-enabled platform partnerships in oncology ADCs https://biobriefs.com/gene-editing-safety-and-oversight BioBriefs en 2026-08-04T21:32:19Z Gene-editing safety and oversight under scrutiny after death https://biobriefs.com/venture-backed-crispr-startup-halts BioBriefs en 2026-08-04T21:32:19Z Venture-backed CRISPR startup halts lead program https://biobriefs.com/regulatory-shift-on-gray-market BioBriefs en 2026-08-04T16:31:33Z Regulatory shift on gray-market peptides and compounding access https://biobriefs.com/r-d-measurement-and-outcome BioBriefs en 2026-08-04T16:31:33Z R&D measurement and outcome assessment gaps driving neurologic trial failures https://biobriefs.com/precision-oncology-enters-earlier-prostate BioBriefs en 2026-08-04T16:31:33Z Precision oncology enters earlier prostate-cancer setting with Pluvicto label expansion https://biobriefs.com/radiopharma-consolidation-curium-to-acquire BioBriefs en 2026-08-04T16:31:33Z Radiopharma consolidation: Curium to acquire Lantheus in up-to-$8B deal https://biobriefs.com/cns-portfolio-merger-supernus-to BioBriefs en 2026-08-04T16:31:33Z CNS portfolio merger: Supernus to combine with Indivior in all-stock deal https://biobriefs.com/diagnostics-sophia-genetics-lands-cdx BioBriefs en 2026-08-04T16:31:33Z Diagnostics: Sophia Genetics lands CDx collaboration with AstraZeneca as revenue rises https://biobriefs.com/molecule-and-platform-pipeline-satellite BioBriefs en 2026-08-04T16:31:33Z Molecule and platform pipeline: Satellite Biosciences gets IND clearance for SB-101 in urea cycle disorders https://biobriefs.com/biotech-funding-inocras-closes-additional BioBriefs en 2026-08-04T16:31:33Z Biotech funding: Inocras closes additional $31M Series B-3 for whole-genome sequencing expansion https://biobriefs.com/manufacturing-and-instrumentation-ge-healthcare BioBriefs en 2026-08-04T16:31:33Z Manufacturing and instrumentation: GE Healthcare and DNA Script receive up to $26M ARPA-H funding for FLASH enzymatic DNA synthesis https://biobriefs.com/ai-in-drug-discovery-meets BioBriefs en 2026-08-04T16:31:33Z AI in drug discovery meets capital markets: Twist reports growth and points to AI-driven therapeutics orders https://biobriefs.com/radiopharma-deal-reshapes-us-nuclear BioBriefs en 2026-08-04T14:31:47Z Radiopharma deal reshapes US nuclear medicine footprint https://biobriefs.com/fda-expands-pluvicto-earlier-in BioBriefs en 2026-08-04T14:31:47Z FDA expands Pluvicto earlier in prostate cancer care https://biobriefs.com/priority-review-for-subcutaneous-amivantamab BioBriefs en 2026-08-04T14:31:47Z Priority review for subcutaneous amivantamab in head and neck cancer https://biobriefs.com/arpa-h-backs-enzymatic-dna BioBriefs en 2026-08-04T14:31:47Z ARPA-H backs enzymatic DNA synthesis automation platform https://biobriefs.com/fda-clearance-pushes-genomics-into BioBriefs en 2026-08-04T14:31:47Z FDA clearance pushes genomics into more routine transplant monitoring https://biobriefs.com/ai-focused-startup-expands-across BioBriefs en 2026-08-04T14:31:47Z AI-focused startup expands across hospital networks for intake and diagnosis support https://biobriefs.com/ipo-funds-non-opioid-nav1 BioBriefs en 2026-08-04T14:31:47Z IPO funds non-opioid Nav1.8 pipeline to challenge Journavx https://biobriefs.com/biotech-funds-expansion-for-whole BioBriefs en 2026-08-04T14:31:47Z Biotech funds expansion for whole-genome diagnostics in US https://biobriefs.com/cns-consolidation-supernus-and-indivior BioBriefs en 2026-08-04T14:31:47Z CNS consolidation: Supernus and Indivior merger closes with CNS portfolio build https://biobriefs.com/regulatory-fda-adopts-broader-use BioBriefs en 2026-08-04T14:31:47Z Regulatory: FDA adopts broader use for Pluvicto and amivantamab while grant policy tightens https://biobriefs.com/oncology-regulatory-approvals-and-label BioBriefs en 2026-08-04T10:32:09Z Oncology regulatory approvals and label expansion https://biobriefs.com/radiopharmaceutical-dealmaking-to-broaden-theranostics BioBriefs en 2026-08-04T10:32:09Z Radiopharmaceutical dealmaking to broaden theranostics footprint https://biobriefs.com/cns-focused-pharma-consolidation BioBriefs en 2026-08-04T10:32:09Z CNS-focused pharma consolidation https://biobriefs.com/drug-safety-and-regulatory-scrutiny BioBriefs en 2026-08-04T10:32:09Z Drug safety and regulatory scrutiny around clinical effectiveness https://biobriefs.com/biotech-corporate-m-a-and BioBriefs en 2026-08-04T10:32:09Z Biotech corporate M&A and deal rumors reshaping investor positioning https://biobriefs.com/biotech-financing-and-market-expansion BioBriefs en 2026-08-04T10:32:09Z Biotech financing and market expansion signals https://biobriefs.com/clinical-translational-science-blood-based BioBriefs en 2026-08-04T10:32:09Z Clinical translational science: blood-based biomarkers and precision decision support https://biobriefs.com/immuno-oncology-and-resistance-biology BioBriefs en 2026-08-04T10:32:09Z Immuno-oncology and resistance biology https://biobriefs.com/microbiome-linked-therapeutics-and-infectious BioBriefs en 2026-08-04T10:32:09Z Microbiome-linked therapeutics and infectious disease management https://biobriefs.com/big-pharma-payer-policy-and BioBriefs en 2026-08-04T10:32:09Z Big pharma, payer policy, and federal program shifts impacting drug access https://biobriefs.com/regulatory-milestones-in-oncology-radioligand BioBriefs en 2026-08-04T09:31:34Z Regulatory milestones in oncology radioligand and targeted therapies https://biobriefs.com/experimental-oncology-tackling-drug-resistance BioBriefs en 2026-08-04T09:31:34Z Experimental oncology: tackling drug resistance and improving ADC performance https://biobriefs.com/fda-breakthrough-designation-for-kras BioBriefs en 2026-08-04T09:31:34Z FDA breakthrough designation for KRAS G12C pancreatic cancer https://biobriefs.com/corporate-deals-reshaping-pharma-and BioBriefs en 2026-08-04T09:31:34Z Corporate deals reshaping pharma and radiopharma footprints https://biobriefs.com/diagnostics-and-enabling-platforms-whole BioBriefs en 2026-08-04T09:31:34Z Diagnostics and enabling platforms: whole-genome sequencing expansion https://biobriefs.com/funding-and-market-dynamics-biotech BioBriefs en 2026-08-04T09:31:34Z Funding and market dynamics: biotech mega-round momentum https://biobriefs.com/corporate-strategy-in-genomic-tools BioBriefs en 2026-08-04T09:31:34Z Corporate strategy in genomic tools: Twist growth tied to AI-enabled discovery https://biobriefs.com/tech-to-therapy-pipeline-early BioBriefs en 2026-08-04T09:31:34Z Tech-to-therapy pipeline: early cancer drug startups raise and move into the clinic https://biobriefs.com/cloud-computing-and-clinical-operations BioBriefs en 2026-08-04T09:31:34Z Cloud computing and clinical operations: regulatory-adjacent workflow tooling https://biobriefs.com/ai-in-healthcare-delivery-precision BioBriefs en 2026-08-04T09:31:34Z AI in healthcare delivery: precision oxygen management trial https://biobriefs.com/oncology-regulatory-moves-for-radioligand BioBriefs en 2026-08-04T04:32:23Z Oncology regulatory moves for radioligand therapy and KRAS-targeted drugs https://biobriefs.com/dealmaking-reshapes-specialty-pharma-and BioBriefs en 2026-08-04T04:32:23Z Dealmaking reshapes specialty pharma and radiopharma scale https://biobriefs.com/genetic-and-translational-oncology-research BioBriefs en 2026-08-04T04:32:23Z Genetic and translational oncology research finds new combinability https://biobriefs.com/platform-and-ai-driven-life BioBriefs en 2026-08-04T04:32:23Z Platform and AI-driven life science infrastructure expands https://biobriefs.com/bioinformatics-computational-validation-and-translational BioBriefs en 2026-08-04T04:32:23Z Bioinformatics, computational validation, and translational diagnostics https://biobriefs.com/laboratory-scale-and-genomics-expansion BioBriefs en 2026-08-04T04:32:23Z Laboratory scale and genomics expansion via new financing https://biobriefs.com/regulatory-and-health-policy-pressure BioBriefs en 2026-08-04T04:32:23Z Regulatory and health-policy pressure on U.S. drug distribution and pricing programs https://biobriefs.com/clinical-pipeline-setbacks-and-next BioBriefs en 2026-08-04T04:32:23Z Clinical pipeline setbacks and next-step uncertainty in immune and cell therapies https://biobriefs.com/funding-and-ipo-pipeline-for BioBriefs en 2026-08-04T04:32:23Z Funding and IPO pipeline for emerging biotech candidates https://biobriefs.com/translational-microbiome-and-microbiology-interventions BioBriefs en 2026-08-04T04:32:23Z Translational microbiome and microbiology interventions https://biobriefs.com/kras-g12c-pancreatic-cancer-regulatory BioBriefs en 2026-08-03T21:32:25Z KRAS G12C pancreatic cancer regulatory breakthrough https://biobriefs.com/pluvicto-expands-earlier-stage-prostate BioBriefs en 2026-08-03T21:32:25Z Pluvicto expands earlier-stage prostate cancer use https://biobriefs.com/pluvicto-approval-rivals-label-expansion BioBriefs en 2026-08-03T21:32:25Z Pluvicto approval rivals label expansion reporting https://biobriefs.com/curium-to-buy-lantheus-in BioBriefs en 2026-08-03T21:32:25Z Curium to buy Lantheus in radiopharma consolidation https://biobriefs.com/supernus-and-indivior-merge-to BioBriefs en 2026-08-03T21:32:25Z Supernus and Indivior merge to form CNS-focused pharma https://biobriefs.com/sandoz-settles-us-generic-antitrust BioBriefs en 2026-08-03T21:32:25Z Sandoz settles US generic antitrust litigation https://biobriefs.com/inocras-raises-for-clinical-wgs BioBriefs en 2026-08-03T21:32:25Z Inocras raises for clinical WGS expansion in US https://biobriefs.com/twist-bioscience-momentum-tied-to BioBriefs en 2026-08-03T21:32:25Z Twist Bioscience momentum tied to AI-driven protein discovery https://biobriefs.com/caredx-analyst-upgrade-points-to BioBriefs en 2026-08-03T21:32:25Z CareDx analyst upgrade points to assay label expansion expectations https://biobriefs.com/fda-panel-skepticism-undermines-capricors BioBriefs en 2026-08-03T21:32:25Z FDA panel skepticism undermines Capricor’s Deramiocel resubmission https://biobriefs.com/regulatory-expansion-for-radioligand-prostate BioBriefs en 2026-08-03T16:32:18Z Regulatory expansion for radioligand prostate cancer therapy https://biobriefs.com/leadership-transition-at-biontech-as BioBriefs en 2026-08-03T16:32:18Z Leadership transition at BioNTech as it pivots further into oncology https://biobriefs.com/clinical-trial-setbacks-in-cardiometabolic BioBriefs en 2026-08-03T16:32:18Z Clinical trial setbacks in cardiometabolic inflammation https://biobriefs.com/fda-advisory-committee-signals-pushback BioBriefs en 2026-08-03T16:32:18Z FDA advisory committee signals pushback on Duchenne cardiomyopathy cell therapy https://biobriefs.com/radiopharma-dealmaking-curium-to-acquire BioBriefs en 2026-08-03T16:32:18Z Radiopharma dealmaking: Curium to acquire Lantheus for $8B https://biobriefs.com/generic-drug-antitrust-settlements-sandoz BioBriefs en 2026-08-03T16:32:18Z Generic drug antitrust settlements: Sandoz secures scope resolution in US https://biobriefs.com/biotech-innovation-funding-and-startup BioBriefs en 2026-08-03T16:32:18Z Biotech innovation funding and startup financing: Dash Bio raises $30M https://biobriefs.com/genomics-tools-and-earnings-twist BioBriefs en 2026-08-03T16:32:18Z Genomics tools and earnings: Twist Bioscience grows on DNA, protein and NGS demand https://biobriefs.com/corporate-consolidation-in-cns-focused BioBriefs en 2026-08-03T16:32:18Z Corporate consolidation in CNS-focused neuroscience drugs https://biobriefs.com/biopharma-corporate-risk-amgen-cloud BioBriefs en 2026-08-03T16:32:18Z Biopharma corporate risk: Amgen cloud breach affecting patient data https://biobriefs.com/regulatory-approvals-radioligand-therapy-expands BioBriefs en 2026-08-03T14:32:21Z Regulatory approvals – radioligand therapy expands in prostate cancer https://biobriefs.com/fda-decisions-and-advisory-committee BioBriefs en 2026-08-03T14:32:21Z FDA decisions and advisory committee outcomes – cell therapy effectiveness questioned https://biobriefs.com/clinical-trial-readouts-failed-il BioBriefs en 2026-08-03T14:32:21Z Clinical trial readouts – failed IL-6 strategy in ZEUS cardiovascular Phase 3 https://biobriefs.com/deal-making-potential-merger-talk BioBriefs en 2026-08-03T14:32:21Z Deal-making – potential merger talk sparks market reaction https://biobriefs.com/leadership-change-biontech-brings-in BioBriefs en 2026-08-03T14:32:21Z Leadership change – BioNTech brings in incoming CEO from Sobi https://biobriefs.com/cns-sector-supernus-and-indivior BioBriefs en 2026-08-03T14:32:21Z CNS sector – Supernus and Indivior sign all-stock merger https://biobriefs.com/oncology-odac-vote-supports-rp1 BioBriefs en 2026-08-03T14:32:21Z Oncology – ODAC vote supports RP1 with nivolumab in melanoma https://biobriefs.com/biomarkers-and-diagnostics-roche-partners BioBriefs en 2026-08-03T14:32:21Z Biomarkers and diagnostics – Roche partners with Genprex on TROP2 assay validation https://biobriefs.com/drug-distribution-policy-arkansas-act BioBriefs en 2026-08-03T14:32:21Z Drug distribution policy – Arkansas Act 630 blocked after court ruling https://biobriefs.com/funding-and-public-markets-blossomhill BioBriefs en 2026-08-03T14:32:21Z Funding and public markets – BlossomHill targets an IPO to back EGFR oncology pipeline https://biobriefs.com/regulatory-setbacks-in-cell-therapy BioBriefs en 2026-08-03T10:31:54Z Regulatory setbacks in cell therapy for DMD cardiomyopathy https://biobriefs.com/fda-approval-expands-radioligand-therapy BioBriefs en 2026-08-03T10:31:54Z FDA approval expands radioligand therapy to earlier prostate-cancer stage https://biobriefs.com/late-stage-failure-reshapes-il BioBriefs en 2026-08-03T10:31:54Z Late-stage failure reshapes IL-6 inhibitor bets in cardiometabolic disease https://biobriefs.com/oncology-regulatory-caution-over-accelerated BioBriefs en 2026-08-03T10:31:54Z Oncology regulatory caution over accelerated approval underuse https://biobriefs.com/replimune-oncolytic-virus-regains-footing BioBriefs en 2026-08-03T10:31:54Z Replimune oncolytic virus regains footing with ODAC-level recommendation https://biobriefs.com/first-oral-sleep-apnea-drug BioBriefs en 2026-08-03T10:31:54Z First oral sleep apnea drug heads to FDA decision after $192M IPO https://biobriefs.com/alzheimers-diagnosis-expands-with-blood BioBriefs en 2026-08-03T10:31:54Z Alzheimer’s diagnosis expands with blood-based amyloid testing https://biobriefs.com/massive-contamination-outbreak-linked-to BioBriefs en 2026-08-03T10:31:54Z Massive contamination outbreak linked to iceberg lettuce cluster https://biobriefs.com/ai-tool-benchmarks-for-drug BioBriefs en 2026-08-03T10:31:54Z AI tool benchmarks for drug discovery evaluation https://biobriefs.com/tao-of-large-scale-organ BioBriefs en 2026-08-03T10:31:54Z TAO of large-scale organ generation via xenophagocytosis control https://biobriefs.com/regulatory-decisions-in-oncology-and BioBriefs en 2026-08-03T09:31:49Z Regulatory decisions in oncology and advanced therapy https://biobriefs.com/fda-review-outcomes-and-effectiveness BioBriefs en 2026-08-03T09:31:49Z FDA review outcomes and effectiveness evidence in cell therapy https://biobriefs.com/fda-approval-expands-radioligand-therapy BioBriefs en 2026-08-03T09:31:49Z FDA approval expands radioligand therapy earlier in prostate cancer care https://biobriefs.com/clinical-failure-in-late-stage BioBriefs en 2026-08-03T09:31:49Z Clinical failure in late-stage cardiovascular inflammation strategy https://biobriefs.com/regulatory-pathway-use-in-cancer BioBriefs en 2026-08-03T09:31:49Z Regulatory pathway use in cancer approvals draws new scrutiny https://biobriefs.com/blood-based-biomarkers-expand-alzheimers BioBriefs en 2026-08-03T09:31:49Z Blood-based biomarkers expand Alzheimer’s diagnostic access https://biobriefs.com/oral-drug-development-in-sleep BioBriefs en 2026-08-03T09:31:49Z Oral drug development in sleep apnea backed by IPO funding https://biobriefs.com/mega-deal-talks-raise-consolidation BioBriefs en 2026-08-03T09:31:49Z Mega-deal talks raise consolidation stakes for big pharma https://biobriefs.com/artificial-intelligence-tools-for-clinical BioBriefs en 2026-08-03T09:31:49Z Artificial intelligence tools for clinical risk from wearable sleep data https://biobriefs.com/ai-benchmarking-platform-for-drug BioBriefs en 2026-08-03T09:31:49Z AI benchmarking platform for drug discovery and evaluation https://biobriefs.com/regulatory-decisions-for-oncology-cell BioBriefs en 2026-08-03T04:31:53Z Regulatory decisions for oncology cell and gene therapies https://biobriefs.com/fda-approval-expands-radioligand-therapy BioBriefs en 2026-08-03T04:31:53Z FDA approval expands radioligand therapy earlier in prostate cancer https://biobriefs.com/cell-therapy-effectiveness-questioned-by BioBriefs en 2026-08-03T04:31:53Z Cell therapy effectiveness questioned by FDA advisory committee https://biobriefs.com/cardiometabolic-drug-failure-in-phase BioBriefs en 2026-08-03T04:31:53Z Cardiometabolic drug failure in Phase 3 https://biobriefs.com/ai-in-healthcare-operations-and BioBriefs en 2026-08-03T04:31:53Z AI in healthcare operations and clinical decision workflows https://biobriefs.com/alzheimers-diagnostics-blood-test-cleared BioBriefs en 2026-08-03T04:31:53Z Alzheimer’s diagnostics: blood test cleared by FDA https://biobriefs.com/oncology-regulation-and-evidence-quality BioBriefs en 2026-08-03T04:31:53Z Oncology regulation and evidence quality: accelerated approval use under scrutiny https://biobriefs.com/biopharma-m-a-speculation BioBriefs en 2026-08-03T04:31:53Z Biopharma M&A speculation https://biobriefs.com/new-biotech-listing-capital-for BioBriefs en 2026-08-03T04:31:53Z New biotech listing capital for oral sleep apnea therapy https://biobriefs.com/drug-discovery-ai-benchmarks-in BioBriefs en 2026-08-03T04:31:53Z Drug discovery AI benchmarks in biotech R&D https://biobriefs.com/mega-merger-talks BioBriefs en 2026-08-02T21:32:06Z Mega-merger talks https://biobriefs.com/oncology-regulatory-decision-rp1-viusolimogene BioBriefs en 2026-08-02T21:32:06Z Oncology regulatory decision—RP1/viusolimogene oderparepvec https://biobriefs.com/prostate-cancer-expansion-radioligand-to BioBriefs en 2026-08-02T21:32:06Z Prostate cancer expansion—radioligand to hormone-sensitive metastatic setting https://biobriefs.com/clinical-failure-in-cardiometabolic-inflammation BioBriefs en 2026-08-02T21:32:06Z Clinical failure in cardiometabolic inflammation—ziltivekimab https://biobriefs.com/regulatory-evidence-standards-in-oncology BioBriefs en 2026-08-02T21:32:06Z Regulatory evidence standards in oncology https://biobriefs.com/drug-discovery-evaluation-ai-benchmarking BioBriefs en 2026-08-02T21:32:06Z Drug discovery evaluation—AI benchmarking platform https://biobriefs.com/biopharma-market-moves-seer-and BioBriefs en 2026-08-02T21:32:06Z Biopharma market moves—Seer and 10x Genomics deal/news https://biobriefs.com/clinical-trial-design-blood-test BioBriefs en 2026-08-02T21:32:06Z Clinical trial design—blood test for cancers of unknown primary https://biobriefs.com/trial-activation-bispecific-immunotherapy-in BioBriefs en 2026-08-02T21:32:06Z Trial activation—bispecific immunotherapy in rare leukemia https://biobriefs.com/emerging-dmd-gene-therapy-modality BioBriefs en 2026-08-02T21:32:06Z Emerging DMD gene therapy modality—non-viral delivery https://biobriefs.com/regulatory-expansion-for-prostate-radioligand BioBriefs en 2026-08-02T16:32:07Z Regulatory expansion for prostate radioligand therapy in earlier disease https://biobriefs.com/oncology-trial-setbacks-and-partial BioBriefs en 2026-08-02T16:32:07Z Oncology trial setbacks and partial recovery on FDA panel for melanoma therapy https://biobriefs.com/clinical-testing-of-repurposed-drugs BioBriefs en 2026-08-02T16:32:07Z Clinical testing of repurposed drugs for post-COVID cardiac inflammation https://biobriefs.com/immunology-and-inflammation-control-using BioBriefs en 2026-08-02T16:32:07Z Immunology and inflammation control using engineered extracellular vesicles https://biobriefs.com/precision-oncology-diagnostics-ai-augmented BioBriefs en 2026-08-02T16:32:07Z Precision oncology diagnostics: AI-augmented blood testing for liver cancer https://biobriefs.com/radiopharmaceutical-targeting-and-immunotherapy-extension BioBriefs en 2026-08-02T16:32:07Z Radiopharmaceutical targeting and immunotherapy extension for prostate cancer https://biobriefs.com/molecular-diagnostics-workflow-integrating-long BioBriefs en 2026-08-02T16:32:07Z Molecular diagnostics workflow: integrating long-read WGS into reporting https://biobriefs.com/biopharma-funding-and-market-moves BioBriefs en 2026-08-02T16:32:07Z Biopharma funding and market moves: ecosystem finance snapshots https://biobriefs.com/ai-model-evaluation-infrastructure-for BioBriefs en 2026-08-02T16:32:07Z AI model evaluation infrastructure for drug discovery https://biobriefs.com/new-cro-and-platform-execution BioBriefs en 2026-08-02T16:32:07Z New CRO and platform execution: GenomOncology and trial tooling https://biobriefs.com/regulatory-approval-radioligand-expansion-in BioBriefs en 2026-08-02T14:31:25Z Regulatory approval – radioligand expansion in prostate cancer https://biobriefs.com/fda-panel-and-clinical-path BioBriefs en 2026-08-02T14:31:25Z FDA panel and clinical-path reset – viral-vector melanoma therapy https://biobriefs.com/phase-3-cardiovascular-failure-anti BioBriefs en 2026-08-02T14:31:25Z Phase 3 cardiovascular failure – anti-inflammatory IL-6 strategy https://biobriefs.com/phase-3-oncology-failure-and BioBriefs en 2026-08-02T14:31:25Z Phase 3 oncology failure and strategic runway – cash crunch at Karyopharm https://biobriefs.com/big-biotech-deal-acquisition-to BioBriefs en 2026-08-02T14:31:25Z Big biotech deal – acquisition to move beyond wound care https://biobriefs.com/radiopharma-financing-new-capital-for BioBriefs en 2026-08-02T14:31:25Z Radiopharma financing – new capital for clinical development https://biobriefs.com/fda-pilot-policy-340b-rebate BioBriefs en 2026-08-02T14:31:25Z FDA pilot policy – 340B rebate framework changes https://biobriefs.com/regulatory-compliance-and-lab-capability BioBriefs en 2026-08-02T14:31:25Z Regulatory compliance and lab capability – EU IVD rollout for HIV and respiratory panels https://biobriefs.com/imaging-and-diagnostics-workflow-long BioBriefs en 2026-08-02T14:31:25Z Imaging and diagnostics workflow – long-read WGS integration into reporting https://biobriefs.com/biotech-market-and-deal-pressure BioBriefs en 2026-08-02T14:31:25Z Biotech market and deal pressure – takeover jockeying in proteomics https://biobriefs.com/fda-advisory-committee-and-melanoma BioBriefs en 2026-08-02T10:32:00Z FDA advisory committee and melanoma resubmission momentum https://biobriefs.com/cardiovascular-inflammation-drug-setback-in BioBriefs en 2026-08-02T10:32:00Z Cardiovascular inflammation drug setback in late-stage trial https://biobriefs.com/oncology-setbacks-and-rapid-cash BioBriefs en 2026-08-02T10:32:00Z Oncology setbacks and rapid cash pressure in endometrial cancer https://biobriefs.com/clinical-immunotherapy-bioengineering-and-cell BioBriefs en 2026-08-02T10:32:00Z Clinical immunotherapy bioengineering and cell-killing mechanisms https://biobriefs.com/in-vivo-car-t-expands BioBriefs en 2026-08-02T10:32:00Z In vivo CAR T expands toward autoimmune indications in Australia https://biobriefs.com/precision-sequencing-workflow-integration-for BioBriefs en 2026-08-02T10:32:00Z Precision sequencing workflow integration for blood cancer reporting https://biobriefs.com/ai-drug-discovery-evaluation-benchmark BioBriefs en 2026-08-02T10:32:00Z AI drug discovery evaluation benchmark launch https://biobriefs.com/radiopharma-funding-for-trials-and BioBriefs en 2026-08-02T10:32:00Z Radiopharma funding for trials and pipeline execution https://biobriefs.com/genomic-diagnostics-company-expands-with BioBriefs en 2026-08-02T10:32:00Z Genomic diagnostics company expands with CE-IVD registrations https://biobriefs.com/immunotherapy-commercialization-momentum-and-partnership BioBriefs en 2026-08-02T10:32:00Z Immunotherapy commercialization momentum and partnership push https://biobriefs.com/phase-3-failures-reshape-cardiovascular BioBriefs en 2026-08-02T09:31:43Z Phase 3 failures reshape cardiovascular and oncology outlooks https://biobriefs.com/regulators-and-approvals-fda-panel BioBriefs en 2026-08-02T09:31:43Z Regulators and approvals: FDA panel dynamics for advanced melanoma https://biobriefs.com/biotech-m-a-expands-surgical BioBriefs en 2026-08-02T09:31:43Z Biotech M&A expands surgical footprint and deals move through https://biobriefs.com/revenue-and-competitive-pressure-in BioBriefs en 2026-08-02T09:31:43Z Revenue and competitive pressure in immunology blockbuster franchises https://biobriefs.com/radiopharmaceutical-and-clinical-stage-funding BioBriefs en 2026-08-02T09:31:43Z Radiopharmaceutical and clinical-stage funding moves https://biobriefs.com/ai-for-drug-discovery-evaluation BioBriefs en 2026-08-02T09:31:43Z AI for drug discovery evaluation reaches new productization https://biobriefs.com/oncology-diagnostics-and-liquid-biopsy BioBriefs en 2026-08-02T09:31:43Z Oncology diagnostics and liquid biopsy workflow upgrades https://biobriefs.com/immunology-drug-price-policy-and BioBriefs en 2026-08-02T09:31:43Z Immunology drug price policy and market access pressure https://biobriefs.com/diagnostics-approvals-ce-ivd-registrations BioBriefs en 2026-08-02T09:31:43Z Diagnostics approvals: CE-IVD registrations expand infectious disease testing menu https://biobriefs.com/biopharma-market-financing-and-ipo BioBriefs en 2026-08-02T09:31:43Z Biopharma market financing and IPO pipeline continues to build https://biobriefs.com/novo-nordisk-il-6-heart BioBriefs en 2026-08-02T04:32:04Z Novo Nordisk IL-6 heart drug trial failure https://biobriefs.com/replimune-rp1-regains-momentum-after BioBriefs en 2026-08-02T04:32:04Z Replimune RP1 regains momentum after FDA advisory support https://biobriefs.com/karyopharm-endometrial-cancer-failure-and BioBriefs en 2026-08-02T04:32:04Z Karyopharm endometrial cancer failure and cash pressure https://biobriefs.com/seer-takeover-bids-intensify-after BioBriefs en 2026-08-02T04:32:04Z Seer takeover bids intensify after CEO raises offer https://biobriefs.com/i-spy2-preoperative-dual-immunotherapy BioBriefs en 2026-08-02T04:32:04Z I-SPY2 preoperative dual immunotherapy improves tumor eradication in HER2-negative breast cancer https://biobriefs.com/alliance-for-clinical-trials-in BioBriefs en 2026-08-02T04:32:04Z Alliance for Clinical Trials in Oncology opens QUANTUM bispecific trial for rare leukemia https://biobriefs.com/nabsys-and-indiana-university-partner BioBriefs en 2026-08-02T04:32:04Z Nabsys and Indiana University partner on electronic genome mapping https://biobriefs.com/create-medicines-crt-402-clears BioBriefs en 2026-08-02T04:32:04Z Create Medicines CRT-402 clears Australia clinic start https://biobriefs.com/tas-ab2-bio-milestone-as BioBriefs en 2026-08-02T04:32:04Z TAS: AB2 Bio milestone as Nippon Shinyaku takes U.S. rights for tadekinig alfa https://biobriefs.com/funding-ratio-therapeutics-raises-70m BioBriefs en 2026-08-02T04:32:04Z Funding: Ratio Therapeutics raises $70M for radiopharma trials; Vogenx IPO plans $67M https://biobriefs.com/fda-advisory-panel-and-biotech BioBriefs en 2026-08-01T21:31:41Z FDA advisory panel and biotech regulatory momentum https://biobriefs.com/phase-3-and-late-stage BioBriefs en 2026-08-01T21:31:41Z Phase 3 and late-stage pipeline failures reshaping cardiovascular strategies https://biobriefs.com/fda-policy-shift-for-340b BioBriefs en 2026-08-01T21:31:41Z FDA policy shift for 340B drug rebates https://biobriefs.com/clinical-cardiovascular-repurposing-after-covid BioBriefs en 2026-08-01T21:31:41Z Clinical cardiovascular repurposing after COVID-19 https://biobriefs.com/genetic-diagnostics-and-long-read BioBriefs en 2026-08-01T21:31:41Z Genetic diagnostics and long-read sequencing workflow integration https://biobriefs.com/radiopharma-funding-to-expand-clinical BioBriefs en 2026-08-01T21:31:41Z Radiopharma funding to expand clinical development capacity https://biobriefs.com/oncology-liquid-biopsy-growth-and BioBriefs en 2026-08-01T21:31:41Z Oncology liquid biopsy growth and regulatory validation https://biobriefs.com/diagnostics-companies-raising-forecasts-on BioBriefs en 2026-08-01T21:31:41Z Diagnostics companies raising forecasts on testing momentum https://biobriefs.com/biotech-dealmaking-in-in-vivo BioBriefs en 2026-08-01T21:31:41Z Biotech dealmaking in in vivo CAR T and platform expansion https://biobriefs.com/regulatory-and-clinical-progress-for BioBriefs en 2026-08-01T21:31:41Z Regulatory and clinical progress for a new obesity drug entrant via IPO https://biobriefs.com/immuno-oncology-engineering-and-macrophage BioBriefs en 2026-08-01T16:31:52Z Immuno-oncology engineering and macrophage-mediated tumor killing https://biobriefs.com/preoperative-immunotherapy-in-high-risk BioBriefs en 2026-08-01T16:31:52Z Preoperative immunotherapy in high-risk early HER2-negative breast cancer https://biobriefs.com/ai-evaluation-for-frontier-drug BioBriefs en 2026-08-01T16:31:52Z AI evaluation for frontier drug-discovery models https://biobriefs.com/fda-advisory-support-for-intratumoral BioBriefs en 2026-08-01T16:31:52Z FDA advisory support for intratumoral RP1 plus checkpoint blockade https://biobriefs.com/novanordisks-il-6-pathway-bet BioBriefs en 2026-08-01T16:31:52Z NovaNordisk’s IL-6 pathway bet derailed in Phase 3 https://biobriefs.com/public-market-momentum-apnimed-upsized BioBriefs en 2026-08-01T16:31:52Z Public-market momentum: Apnimed upsized IPO for sleep apnea drug https://biobriefs.com/diagnostics-and-companion-diagnostics-coverage BioBriefs en 2026-08-01T16:31:52Z Diagnostics and companion diagnostics coverage expands for blood-based oncology https://biobriefs.com/in-vivo-car-t-expansion BioBriefs en 2026-08-01T16:31:52Z In vivo CAR T expansion in autoimmune disease through major J&J deal https://biobriefs.com/plasma-cell-cancer-trial-activation BioBriefs en 2026-08-01T16:31:52Z Plasma-cell cancer trial activation: QUANTUM study for rare leukemia https://biobriefs.com/gene-therapy-workflow-modernization-using BioBriefs en 2026-08-01T16:31:52Z Gene therapy workflow modernization using long-read sequencing pipelines https://biobriefs.com/clinical-failure-and-pipeline-disruption BioBriefs en 2026-08-01T14:32:06Z Clinical failure and pipeline disruption at Novo Nordisk https://biobriefs.com/regulatory-headwinds-for-replimunes-melanoma BioBriefs en 2026-08-01T14:32:06Z Regulatory headwinds for Replimune’s melanoma therapy https://biobriefs.com/oncology-turnaround-attempt-at-karyopharm BioBriefs en 2026-08-01T14:32:06Z Oncology turnaround attempt at Karyopharm after endometrial cancer flop https://biobriefs.com/money-and-market-expansion-apnimed BioBriefs en 2026-08-01T14:32:06Z Money and market expansion: Apnimed prices upsized IPO https://biobriefs.com/new-trial-approvals-for-in BioBriefs en 2026-08-01T14:32:06Z New trial approvals for in vivo CAR T in Australia https://biobriefs.com/data-and-performance-tempus-ais BioBriefs en 2026-08-01T14:32:06Z Data and performance: Tempus AI’s oncology testing growth lifts guidance https://biobriefs.com/diagnostics-and-workflow-integration-genomoncology BioBriefs en 2026-08-01T14:32:06Z Diagnostics and workflow integration: GenomOncology adds PacBio HiFi WGS reporting https://biobriefs.com/autoimmune-and-immune-engineering-j BioBriefs en 2026-08-01T14:32:06Z Autoimmune and immune engineering: J&J inks Sail in vivo CAR T deal https://biobriefs.com/venture-and-public-markets-ai BioBriefs en 2026-08-01T14:32:06Z Venture and public markets: AI lab automation subsidiary from MGI Tech https://biobriefs.com/first-therapeutic-cross-over-ruxolitinib BioBriefs en 2026-08-01T14:32:06Z First therapeutic cross-over: ruxolitinib shown to prevent irreversible endocrine complications in APECED https://biobriefs.com/fda-advisory-pushes-oncology-cell BioBriefs en 2026-08-01T10:32:14Z FDA advisory pushes oncology cell therapy forward https://biobriefs.com/novo-nordisks-il-6-heart BioBriefs en 2026-08-01T10:32:14Z Novo Nordisk’s IL-6 heart inflammation bet stumbles in Phase 3 https://biobriefs.com/biotech-earnings-shakeouts-deepen-amid BioBriefs en 2026-08-01T10:32:14Z Biotech earnings shakeouts deepen amid guidance cuts https://biobriefs.com/public-market-cash-raises-for BioBriefs en 2026-08-01T10:32:14Z Public-market cash raises for drug development https://biobriefs.com/m-a-scales-up-surgical BioBriefs en 2026-08-01T10:32:14Z M&A scales up surgical and device footprint https://biobriefs.com/in-vivo-car-t-expands BioBriefs en 2026-08-01T10:32:14Z In vivo CAR T expands with major J&J pact https://biobriefs.com/gene-editing-ethics-under-pressure BioBriefs en 2026-08-01T10:32:14Z Gene-editing ethics under pressure after fatal trial https://biobriefs.com/car-t-like-immune-reset BioBriefs en 2026-08-01T10:32:14Z CAR-T-like immune reset takes shape via next-generation in vivo partnerships https://biobriefs.com/ai-valuation-and-foundation-model BioBriefs en 2026-08-01T10:32:14Z AI valuation and foundation-model momentum stays under scrutiny https://biobriefs.com/personalized-diagnostics-grow-as-oncology BioBriefs en 2026-08-01T10:32:14Z Personalized diagnostics grow as oncology testing drives revenue https://biobriefs.com/cell-therapy-dealmaking-in-vivo BioBriefs en 2026-08-01T09:31:35Z Cell therapy dealmaking in vivo CAR T https://biobriefs.com/fda-advisory-vote-swing-for BioBriefs en 2026-08-01T09:31:35Z FDA advisory vote swing for Replimune melanoma therapy https://biobriefs.com/phase-3-setbacks-and-cash BioBriefs en 2026-08-01T09:31:35Z Phase 3 setbacks and cash pressure in oncology https://biobriefs.com/novo-nordisk-il-6-heart BioBriefs en 2026-08-01T09:31:35Z Novo Nordisk IL-6 heart failure highlights cardiovascular inflammation risk https://biobriefs.com/alnylam-attr-franchise-guidance-cut BioBriefs en 2026-08-01T09:31:35Z Alnylam ATTR franchise: guidance cut triggers investor shock https://biobriefs.com/in-vivo-immunotherapy-funding-brenus BioBriefs en 2026-08-01T09:31:35Z In vivo immunotherapy funding: Brenus Series A extension https://biobriefs.com/diagnostics-and-clinical-adoption-tempus BioBriefs en 2026-08-01T09:31:35Z Diagnostics and clinical adoption: Tempus oncology testing growth and Personalis deal https://biobriefs.com/radiopharma-and-late-stage-capital BioBriefs en 2026-08-01T09:31:35Z Radiopharma and late-stage capital formation https://biobriefs.com/ai-guided-drug-discovery-platform BioBriefs en 2026-08-01T09:31:35Z AI-guided drug discovery platform deals: Relation and GSK https://biobriefs.com/cancer-diagnostics-testing-growth-and BioBriefs en 2026-08-01T09:31:35Z Cancer diagnostics testing growth and guideline-linked coverage https://biobriefs.com/il-6-inhibitor-failure-reshapes BioBriefs en 2026-08-01T04:31:54Z IL-6 inhibitor failure reshapes cardiovascular inflammation strategy https://biobriefs.com/third-party-pressure-on-drug BioBriefs en 2026-08-01T04:31:54Z Third-party pressure on drug pricing: 340B rebate pilot changes https://biobriefs.com/advisory-committee-clears-replimunes-rp BioBriefs en 2026-08-01T04:31:54Z Advisory committee clears Replimune’s RP-1 on melanoma efficacy https://biobriefs.com/in-vivo-car-t-becomes BioBriefs en 2026-08-01T04:31:54Z In vivo CAR T becomes board-level focus as J&J expands Sail option https://biobriefs.com/tempus-accelerates-oncology-diagnostics-with BioBriefs en 2026-08-01T04:31:54Z Tempus accelerates oncology diagnostics with regulatory approvals and Personalis deal https://biobriefs.com/mrd-testing-demand-lifts-adaptive BioBriefs en 2026-08-01T04:31:54Z MRD testing demand lifts Adaptive Biotechnologies revenue outlook again https://biobriefs.com/radiopharma-funding-ratio-raises-to BioBriefs en 2026-08-01T04:31:54Z Radiopharma funding: Ratio raises to build clinical pipeline https://biobriefs.com/public-markets-apnimed-upsized-ipo BioBriefs en 2026-08-01T04:31:54Z Public markets: Apnimed upsized IPO as FDA decision nears https://biobriefs.com/genomics-tooling-for-clinical-labs BioBriefs en 2026-08-01T04:31:54Z Genomics tooling for clinical labs: GenomOncology integrates PacBio HiFi into reporting https://biobriefs.com/cns-safety-and-efficacy-debate BioBriefs en 2026-08-01T04:31:54Z CNS safety and efficacy debate: Capricor deramiocel rejected by FDA adcomm https://biobriefs.com/in-vivo-car-t-partnerships BioBriefs en 2026-07-31T21:32:03Z In vivo CAR-T partnerships intensify in autoimmunity https://biobriefs.com/fda-advisory-support-lifts-replimunes BioBriefs en 2026-07-31T21:32:03Z FDA advisory support lifts Replimune’s melanoma approval odds https://biobriefs.com/novo-nordisks-il-6-strategy BioBriefs en 2026-07-31T21:32:03Z Novo Nordisk’s IL-6 strategy fails in late-stage cardiovascular outcomes https://biobriefs.com/endometrial-cancer-setback-exposes-karyopharms BioBriefs en 2026-07-31T21:32:03Z Endometrial cancer setback exposes Karyopharm’s funding pressure https://biobriefs.com/public-market-momentum-apnimed-prices BioBriefs en 2026-07-31T21:32:03Z Public-market momentum: Apnimed prices upsized $192M IPO for sleep apnea pill https://biobriefs.com/ai-enabled-clinical-trial-recruitment BioBriefs en 2026-07-31T21:32:03Z AI-enabled clinical trial recruitment starts to scale through acquisition https://biobriefs.com/diagnostics-and-lab-automation-genomoncology BioBriefs en 2026-07-31T21:32:03Z Diagnostics and lab automation: GenomOncology integrates PacBio HiFi WGS into reporting https://biobriefs.com/large-scale-ai-cellular-models BioBriefs en 2026-07-31T21:32:03Z Large-scale AI cellular models gain new pharma data pact https://biobriefs.com/clinical-biotech-funding-brenus-pharma BioBriefs en 2026-07-31T21:32:03Z Clinical biotech funding: Brenus Pharma extends Series A with €11M https://biobriefs.com/mrd-testing-growth-propels-adaptive BioBriefs en 2026-07-31T21:32:03Z MRD testing growth propels Adaptive Biotechnologies guidance lift https://biobriefs.com/in-vivo-car-t-dealmaking BioBriefs en 2026-07-31T16:32:10Z In vivo CAR T dealmaking accelerates https://biobriefs.com/regeneron-sanofi-dupixent-growth-and BioBriefs en 2026-07-31T16:32:10Z Regeneron–Sanofi Dupixent growth and partnership expansion talks https://biobriefs.com/alnylam-attr-franchise-takes-earnings BioBriefs en 2026-07-31T16:32:10Z Alnylam ATTR franchise takes earnings-driven hit https://biobriefs.com/novo-nordisk-ziltivekimab-fails-in BioBriefs en 2026-07-31T16:32:10Z Novo Nordisk ziltivekimab fails in late-stage heart-inflammation bet https://biobriefs.com/fda-advisory-panel-backs-replimunes BioBriefs en 2026-07-31T16:32:10Z FDA advisory panel backs Replimune’s RP-1 for melanoma https://biobriefs.com/capricor-dmd-therapy-rejected-by BioBriefs en 2026-07-31T16:32:10Z Capricor DMD therapy rejected by FDA adcomm https://biobriefs.com/oncology-testing-momentum-lifts-guardant BioBriefs en 2026-07-31T16:32:10Z Oncology testing momentum lifts Guardant and Tempus https://biobriefs.com/public-markets-stay-open-to BioBriefs en 2026-07-31T16:32:10Z Public markets stay open to select biotech IPOs https://biobriefs.com/diagnostics-expansion-abl-diagnostics-wins BioBriefs en 2026-07-31T16:32:10Z Diagnostics expansion: ABL Diagnostics wins CE-IVD coverage https://biobriefs.com/radiopharma-funding-ratio-therapeutics-series BioBriefs en 2026-07-31T16:32:10Z Radiopharma funding: Ratio Therapeutics series C https://biobriefs.com/fda-and-advisory-committee-outcomes BioBriefs en 2026-07-31T14:32:23Z FDA and advisory committee outcomes reshape rare-disease cell therapy prospects https://biobriefs.com/in-vivo-car-t-dealmaking BioBriefs en 2026-07-31T14:32:23Z In vivo CAR-T dealmaking accelerates as J&J buys options on next-generation platform https://biobriefs.com/melanoma-oncolytic-virus-therapy-gains BioBriefs en 2026-07-31T14:32:23Z Melanoma oncolytic virus therapy gains major FDA-adjacent momentum https://biobriefs.com/attr-franchise-weakness-rattles-alnylam BioBriefs en 2026-07-31T14:32:23Z ATTR franchise weakness rattles Alnylam as Amvuttra outlook cuts hit shares https://biobriefs.com/diagnostics-and-oncology-testing-companies BioBriefs en 2026-07-31T14:32:23Z Diagnostics and oncology testing companies raise guidance after strong quarters https://biobriefs.com/mrd-and-precision-diagnostics-businesses BioBriefs en 2026-07-31T14:32:23Z MRD and precision diagnostics businesses keep expanding as testing volumes rise https://biobriefs.com/in-vivo-sequencing-platform-adoption BioBriefs en 2026-07-31T14:32:23Z In vivo sequencing platform adoption spreads in Europe via Ultima UG200 certification https://biobriefs.com/early-stage-launch-clearance-in BioBriefs en 2026-07-31T14:32:23Z Early-stage launch clearance in Australia for in vivo CAR-T candidate CRT-402 https://biobriefs.com/funding-and-platform-expansion-function BioBriefs en 2026-07-31T14:32:23Z Funding and platform expansion: Function Health gets major growth financing from General Catalyst https://biobriefs.com/aging-biology-mitochondrial-epigenetic-crosstalk BioBriefs en 2026-07-31T14:32:23Z Aging biology: mitochondrial–epigenetic crosstalk links to senescent inflammation https://biobriefs.com/in-vivo-car-t-deals BioBriefs en 2026-07-31T10:32:03Z In vivo CAR T deals heat up https://biobriefs.com/fda-adcom-swings-on-replimune BioBriefs en 2026-07-31T10:32:03Z FDA adcom swings on Replimune melanoma therapy https://biobriefs.com/deramiocel-dmd-cell-therapy-rejected BioBriefs en 2026-07-31T10:32:03Z Deramiocel DMD cell therapy rejected by FDA panel https://biobriefs.com/apnimed-ipo-funds-fda-decision BioBriefs en 2026-07-31T10:32:03Z Apnimed IPO funds FDA decision for Oxnimbi https://biobriefs.com/guardant-oncology-revenue-growth-and BioBriefs en 2026-07-31T10:32:03Z Guardant oncology revenue growth and FDA companion diagnostic approval https://biobriefs.com/tempus-expands-oncology-diagnostics-growth BioBriefs en 2026-07-31T10:32:03Z Tempus expands oncology diagnostics growth and MRD strategy https://biobriefs.com/latigo-posts-phase-2b-non BioBriefs en 2026-07-31T10:32:03Z Latigo posts Phase 2b non-opioid pain win vs placebo https://biobriefs.com/relation-and-gsk-expand-cellular BioBriefs en 2026-07-31T10:32:03Z Relation and GSK expand cellular foundation model collaboration https://biobriefs.com/cleerly-and-allelica-launch-coronary BioBriefs en 2026-07-31T10:32:03Z Cleerly and Allelica launch coronary polygenic risk test https://biobriefs.com/genoria-ai-targets-autonomous-wet BioBriefs en 2026-07-31T10:32:03Z Genoria AI targets autonomous wet-lab research https://biobriefs.com/fda-advisory-panel-pushes-back BioBriefs en 2026-07-31T09:32:26Z FDA advisory panel pushes back on advanced melanoma gene therapy https://biobriefs.com/fda-panel-splits-over-capricor BioBriefs en 2026-07-31T09:32:26Z FDA panel splits over Capricor Duchenne cell therapy evidence https://biobriefs.com/cell-therapy-milestone-deramiocel-phase BioBriefs en 2026-07-31T09:32:26Z Cell therapy milestone: deramiocel phase 3 trial shows slowing muscle decline https://biobriefs.com/in-vivo-car-t-deal BioBriefs en 2026-07-31T09:32:26Z In vivo CAR T deal accelerates J&J push into immune reset https://biobriefs.com/revenue-momentum-guardant-health-credits BioBriefs en 2026-07-31T09:32:26Z Revenue momentum: Guardant Health credits oncology and FDA companion diagnostic approval https://biobriefs.com/diagnostics-scale-up-tempus-lifts BioBriefs en 2026-07-31T09:32:26Z Diagnostics scale-up: Tempus lifts guidance on oncology test growth and MRD acquisition plans https://biobriefs.com/advisory-panel-clears-gene-therapy BioBriefs en 2026-07-31T09:32:26Z Advisory panel clears: gene therapy evidence dispute shifts back toward approval calculus https://biobriefs.com/biotech-funding-and-market-appetite BioBriefs en 2026-07-31T09:32:26Z Biotech funding and market appetite: Apnimed upsized IPO for sleep apnea pill https://biobriefs.com/function-health-banks-large-growth BioBriefs en 2026-07-31T09:32:26Z Function Health banks large growth financing for preventive testing expansion https://biobriefs.com/ai-foundation-models-relation-and BioBriefs en 2026-07-31T09:32:26Z AI foundation models: Relation and GSK sign multiomic perturbation pact https://biobriefs.com/oncology-diagnostics-momentum-and-guidance BioBriefs en 2026-07-31T04:31:59Z Oncology diagnostics momentum and guidance updates https://biobriefs.com/fda-adcom-decision-swings-for BioBriefs en 2026-07-31T04:31:59Z FDA adcom decision swings for Replimune’s RP-1 melanoma therapy https://biobriefs.com/big-pharma-earnings-pressure-and BioBriefs en 2026-07-31T04:31:59Z Big pharma earnings pressure and strategic recalibration in RNA and diagnostics https://biobriefs.com/tempus-scales-oncology-testing-and BioBriefs en 2026-07-31T04:31:59Z Tempus scales oncology testing and advances MRD strategy via Personalis https://biobriefs.com/sequencing-tools-illumina-raises-guidance BioBriefs en 2026-07-31T04:31:59Z Sequencing tools: Illumina raises guidance on clinical application expansion https://biobriefs.com/in-vivo-car-t-dealmaking BioBriefs en 2026-07-31T04:31:59Z In vivo CAR-T dealmaking accelerates with J&J and Sail https://biobriefs.com/cell-therapy-failure-pressures-capricors BioBriefs en 2026-07-31T04:31:59Z Cell therapy failure pressures: Capricor’s deramiocel rejected again by FDA panel https://biobriefs.com/strategy-and-pipeline-reshuffling-at BioBriefs en 2026-07-31T04:31:59Z Strategy and pipeline reshuffling at major pharma: pipeline cuts and R&D cleanup https://biobriefs.com/ai-enabled-cellular-discovery-gsk BioBriefs en 2026-07-31T04:31:59Z AI-enabled cellular discovery: GSK pays for Relation foundation models https://biobriefs.com/autonomous-lab-tooling-mgi-tech BioBriefs en 2026-07-31T04:31:59Z Autonomous lab tooling: MGI Tech creates Genoria AI for self-executing experiments https://biobriefs.com/melanoma-gene-therapy-faces-a BioBriefs en 2026-07-30T21:31:46Z Melanoma gene therapy faces a critical FDA advisory decision https://biobriefs.com/alnylams-ttr-franchise-outlook-wobbles BioBriefs en 2026-07-30T21:31:46Z Alnylam’s TTR franchise outlook wobbles after earnings guidance cut https://biobriefs.com/next-gen-sequencing-tools-rebound BioBriefs en 2026-07-30T21:31:46Z Next-gen sequencing tools rebound: Illumina raises 2026 guidance on momentum https://biobriefs.com/mrd-testing-provider-turns-growth BioBriefs en 2026-07-30T21:31:46Z MRD testing provider turns growth into another revenue guidance increase https://biobriefs.com/precision-cancer-cell-diagnostics-caredx BioBriefs en 2026-07-30T21:31:46Z Precision cancer cell diagnostics: CareDx lifts 2026 revenue guidance after strong Q2 https://biobriefs.com/ai-for-drug-discovery-with BioBriefs en 2026-07-30T21:31:46Z AI for drug discovery with cellular foundation models: Relation and GSK expand the pact https://biobriefs.com/in-vivo-car-t-deal BioBriefs en 2026-07-30T21:31:46Z In vivo CAR-T deal accelerates: J&J partners with Sail Biomedicines https://biobriefs.com/immune-reset-car-t-option BioBriefs en 2026-07-30T21:31:46Z Immune reset CAR-T option pricing enters the market conversation https://biobriefs.com/gene-editing-infrastructure-openabe-base BioBriefs en 2026-07-30T21:31:46Z Gene editing infrastructure: OpenABE base editor advances toward next-generation therapy https://biobriefs.com/capricors-duchenne-cell-therapy-fails BioBriefs en 2026-07-30T21:31:46Z Capricor’s Duchenne cell therapy fails FDA adcom amid statistics dispute https://biobriefs.com/in-vivo-car-t-dealmaking BioBriefs en 2026-07-30T16:32:04Z In-vivo CAR-T dealmaking accelerates https://biobriefs.com/fda-advisory-committee-turns-down BioBriefs en 2026-07-30T16:32:04Z FDA advisory committee turns down Duchenne cell therapy https://biobriefs.com/pfizers-phase-3-win-for BioBriefs en 2026-07-30T16:32:04Z Pfizer’s Phase 3 win for Litfulo expands autoimmune skin pipeline https://biobriefs.com/adaptive-biotechnologies-raises-mrd-outlook BioBriefs en 2026-07-30T16:32:04Z Adaptive Biotechnologies raises MRD outlook as ClonoSEQ testing grows https://biobriefs.com/ai-cellular-foundation-models-get BioBriefs en 2026-07-30T16:32:04Z AI cellular foundation models get major GSK funding https://biobriefs.com/biotech-deals-and-ipo-pipeline BioBriefs en 2026-07-30T16:32:04Z Biotech deals and IPO pipeline reshuffle https://biobriefs.com/new-cellular-therapy-and-supply BioBriefs en 2026-07-30T16:32:04Z New cellular therapy and supply chain buildouts https://biobriefs.com/new-guidance-and-market-risk BioBriefs en 2026-07-30T16:32:04Z New guidance and market risk around GLP-1 generics https://biobriefs.com/ftc-cracks-down-on-telehealth BioBriefs en 2026-07-30T16:32:04Z FTC cracks down on telehealth privacy and billing practices https://biobriefs.com/infectious-disease-tools-advance-crispr BioBriefs en 2026-07-30T16:32:04Z Infectious disease tools advance: CRISPR-TB distribution and HIV side-effect research https://biobriefs.com/duchenne-cell-therapy-faces-fda BioBriefs en 2026-07-30T14:32:21Z Duchenne cell therapy faces FDA advisory blowback https://biobriefs.com/groundbreaking-phase-3-outcome-for BioBriefs en 2026-07-30T14:32:21Z Groundbreaking Phase 3 outcome for deramiocel https://biobriefs.com/j-j-doubles-down-on BioBriefs en 2026-07-30T14:32:21Z J&J doubles down on in vivo CAR-T with Sail option https://biobriefs.com/gsk-expands-ai-driven-target BioBriefs en 2026-07-30T14:32:21Z GSK expands AI-driven target discovery collaboration with Relation https://biobriefs.com/insilico-wins-fda-fast-track BioBriefs en 2026-07-30T14:32:21Z Insilico wins FDA fast track for AI-designed mesothelioma inhibitor https://biobriefs.com/alnylam-cuts-amvuttra-guidance-amid BioBriefs en 2026-07-30T14:32:21Z Alnylam cuts Amvuttra guidance amid shifting demand https://biobriefs.com/gsk-prepares-for-patent-cliff BioBriefs en 2026-07-30T14:32:21Z GSK prepares for patent cliff with multibillion cost-cutting plan https://biobriefs.com/next-gen-cell-therapy-funding BioBriefs en 2026-07-30T14:32:21Z Next-gen cell therapy funding pipeline: IPO runway for Apnimed https://biobriefs.com/revenue-and-strategy-reset-biogen BioBriefs en 2026-07-30T14:32:21Z Revenue and strategy reset: Biogen eases M&A while eyeing late-stage readouts https://biobriefs.com/commercial-infrastructure-boost-celonic-and BioBriefs en 2026-07-30T14:32:21Z Commercial infrastructure boost: Celonic and Leukocare team on complex biologics https://biobriefs.com/fda-advisory-committee-turns-against BioBriefs en 2026-07-30T10:32:02Z FDA advisory committee turns against Capricor’s deramiocel for Duchenne cardiomyopathy https://biobriefs.com/phase-3-deramiocel-data-in BioBriefs en 2026-07-30T10:32:02Z Phase 3 deramiocel data in The Lancet show slower muscle decline in advanced DMD https://biobriefs.com/fda-expert-panel-review-pressures BioBriefs en 2026-07-30T10:32:02Z FDA expert panel review pressures Replimune’s RP1 melanoma program https://biobriefs.com/j-js-sail-biomedicines-deal BioBriefs en 2026-07-30T10:32:02Z J&J’s Sail Biomedicines deal pushes deeper into in vivo CAR-T with option to acquire https://biobriefs.com/vertex-backs-abcelleras-multispecific-t BioBriefs en 2026-07-30T10:32:02Z Vertex backs AbCellera’s multispecific T-cell engager platform in autoimmune push https://biobriefs.com/new-phase-2-readout-targets BioBriefs en 2026-07-30T10:32:02Z New Phase 2 readout targets non-opioid post-surgical pain with LTG-001 https://biobriefs.com/alveo-and-utmb-advance-point BioBriefs en 2026-07-30T10:32:02Z Alveo and UTMB advance point-of-care Lassa testing for field settings https://biobriefs.com/claris-raises-118m-series-b BioBriefs en 2026-07-30T10:32:02Z Claris raises $118M Series B to push limbal stem cell deficiency eye drop into pivotal trials https://biobriefs.com/dna-script-distribution-expansion-brings BioBriefs en 2026-07-30T10:32:02Z DNA script distribution expansion brings on-demand DNA synthesis to India https://biobriefs.com/sanofi-exits-and-write-off BioBriefs en 2026-07-30T10:32:02Z Sanofi exits and write-off targets immunology pipeline after eczema asset termination https://biobriefs.com/cell-therapy-phase-3-readout BioBriefs en 2026-07-30T09:31:48Z Cell therapy Phase 3 readout in Duchenne muscular dystrophy https://biobriefs.com/fda-adcomm-fallout-over-deramiocel BioBriefs en 2026-07-30T09:31:48Z FDA adcomm fallout over deramiocel efficacy evidence https://biobriefs.com/alzheimers-interim-safety-signal-in BioBriefs en 2026-07-30T09:31:48Z Alzheimer’s: interim safety signal in amyloid-directed trial https://biobriefs.com/car-t-platform-licensing-push BioBriefs en 2026-07-30T09:31:48Z CAR-T platform licensing push: J&J options Sail in vivo CAR-T https://biobriefs.com/ai-drug-discovery-partnership-between BioBriefs en 2026-07-30T09:31:48Z AI drug discovery partnership between Elix and University of Vienna https://biobriefs.com/gene-therapy-targeting-huntingtons-in BioBriefs en 2026-07-30T09:31:48Z Gene therapy targeting Huntington’s: in vivo base editing reverses disease in mice https://biobriefs.com/regulatory-economics-ftc-sues-hims BioBriefs en 2026-07-30T09:31:48Z Regulatory economics: FTC sues Hims over privacy and deceptive billing https://biobriefs.com/biotech-m-a-and-financing BioBriefs en 2026-07-30T09:31:48Z Biotech M&A and financing: Caldera reverse merger plus PIPE funding https://biobriefs.com/diagnostics-and-infectious-disease-crispr BioBriefs en 2026-07-30T09:31:48Z Diagnostics and infectious disease: CRISPR-TB distribution expands to Taiwan and South Africa https://biobriefs.com/deal-making-in-immunology-abcellera BioBriefs en 2026-07-30T09:31:48Z Deal-making in immunology: AbCellera and Vertex for multispecific T-cell engagers https://biobriefs.com/fda-adcom-takes-aim-at BioBriefs en 2026-07-30T04:32:01Z FDA adcom takes aim at deramiocel’s statistical support https://biobriefs.com/phase-3-win-for-deramiocel BioBriefs en 2026-07-30T04:32:01Z Phase 3 win for deramiocel in The Lancet—offsets regulatory fight https://biobriefs.com/gene-therapy-base-editing-strategy BioBriefs en 2026-07-30T04:32:01Z Gene therapy—base editing strategy shows Huntington reversal in mice https://biobriefs.com/regulatory-exposure-fda-and-advisory BioBriefs en 2026-07-30T04:32:01Z Regulatory exposure—FDA and advisory scrutiny surround Replimune’s RP1 https://biobriefs.com/cell-therapy-mechanism-readout-cd19 BioBriefs en 2026-07-30T04:32:01Z Cell therapy mechanism readout—CD19 transfers between immune cells https://biobriefs.com/biotech-partnership-to-expand-cancer BioBriefs en 2026-07-30T04:32:01Z Biotech partnership to expand cancer single-cell biomarker discovery https://biobriefs.com/corporate-deal-argenx-acquires-forte BioBriefs en 2026-07-30T04:32:01Z Corporate deal—Argenx acquires Forte Biosciences to add FB102 https://biobriefs.com/funding-pipeline-claris-moves-csb BioBriefs en 2026-07-30T04:32:01Z Funding + pipeline—Claris moves CSB-001 into pivotal trials for LSCD https://biobriefs.com/rare-disease-expansion-papillon-and BioBriefs en 2026-07-30T04:32:01Z Rare disease expansion—Papillon and Cellares scale CRISPR-based FA therapy manufacturing https://biobriefs.com/ai-enabled-diagnostics-en-carta BioBriefs en 2026-07-30T04:32:01Z AI-enabled diagnostics—En Carta prepares Lyme at-home molecular test https://biobriefs.com/dmd-cell-therapy-phase-3 BioBriefs en 2026-07-29T21:31:53Z DMD cell therapy — Phase 3 results and FDA advisory risk https://biobriefs.com/schizophrenia-trial-maplights-mid-stage BioBriefs en 2026-07-29T21:31:53Z Schizophrenia trial — MapLight’s mid-stage signal reshapes investor expectations https://biobriefs.com/transatlantic-acquisitions-caldera-and-vidya BioBriefs en 2026-07-29T21:31:53Z Transatlantic acquisitions — Caldera and Vidya pursue reverse-merger paths to Nasdaq https://biobriefs.com/immunology-partnership-abcellera-teams-with BioBriefs en 2026-07-29T21:31:53Z Immunology partnership — AbCellera teams with Vertex for autoimmune T-cell engagers https://biobriefs.com/ophthalmology-claris-biotherapeutics-funds-limbal BioBriefs en 2026-07-29T21:31:53Z Ophthalmology — Claris Biotherapeutics funds limbal stem cell deficiency pivots https://biobriefs.com/tb-diagnostics-intelligenome-expands-distribution BioBriefs en 2026-07-29T21:31:53Z TB diagnostics — IntelliGenome expands distribution for CRISPR blood test https://biobriefs.com/immunology-dealmaking-abcellera-vertex-and BioBriefs en 2026-07-29T21:31:53Z Immunology dealmaking — AbCellera-Vertex and Argenx’s Forte acquisition both show portfolio-in-a-product momentum https://biobriefs.com/alzheimers-safety-signal-promis-interim BioBriefs en 2026-07-29T21:31:53Z Alzheimer’s safety signal — ProMIS interim ARIA readout improves tolerability profile https://biobriefs.com/regulatory-scrutiny-replimune-faces-renewed BioBriefs en 2026-07-29T21:31:53Z Regulatory scrutiny — Replimune faces renewed FDA advisory concerns on RP1 data https://biobriefs.com/gene-editing-in-vivo-crispr BioBriefs en 2026-07-29T21:31:53Z Gene editing — In vivo CRISPR base editing reverses Huntington’s disease phenotypes in mice https://biobriefs.com/dmd-cell-therapy-hope-3 BioBriefs en 2026-07-29T16:32:03Z DMD cell therapy: HOPE-3 phase 3 signals on function and cardiac preservation https://biobriefs.com/immunotherapy-delivery-in-bladder-cancer BioBriefs en 2026-07-29T16:32:03Z Immunotherapy delivery in bladder cancer: trial supports potential to avoid cystectomy https://biobriefs.com/autoimmune-t-cell-engagers-vertex BioBriefs en 2026-07-29T16:32:03Z Autoimmune T-cell engagers: Vertex doubles down on AbCellera’s TCE platform https://biobriefs.com/regulatory-scrutiny-in-melanoma-gene BioBriefs en 2026-07-29T16:32:03Z Regulatory scrutiny in melanoma gene therapy: Replimune faces continued FDA skepticism https://biobriefs.com/precision-microbiology-and-diagnostics-10x BioBriefs en 2026-07-29T16:32:03Z Precision microbiology and diagnostics: 10x Genomics and Lausanne Hospital target tumor biomarkers https://biobriefs.com/biotech-takeout-argenx-agrees-2 BioBriefs en 2026-07-29T16:32:03Z Biotech takeout: Argenx agrees $2.2B acquisition of Forte for FB102 autoimmunity expansion https://biobriefs.com/oncology-adc-signal-gsk-hansoh BioBriefs en 2026-07-29T16:32:03Z Oncology ADC signal: GSK/Hansoh B7-H3 therapy posts another phase 3 win in China https://biobriefs.com/alzheimers-pipeline-safety-signal-interim BioBriefs en 2026-07-29T16:32:03Z Alzheimer’s pipeline safety signal: interim ProMIS study suggests lower ARIA rates https://biobriefs.com/new-funding-for-ophthalmology-claris BioBriefs en 2026-07-29T16:32:03Z New funding for ophthalmology: Claris $118M Series B to move eye drop into pivotal LSCD testing https://biobriefs.com/gene-therapy-and-po-c BioBriefs en 2026-07-29T16:32:03Z Gene therapy and PO C manufacturing: Cellares partners with Papillon to scale CRISPR cell therapy for Friedreich’s ataxia https://biobriefs.com/autoimmune-and-multispecific-t-cell BioBriefs en 2026-07-29T14:32:30Z Autoimmune and multispecific T-cell engager collaborations https://biobriefs.com/commercial-stage-performance-and-guidance BioBriefs en 2026-07-29T14:32:30Z Commercial-stage performance and guidance momentum at Biogen https://biobriefs.com/fda-scrutiny-and-advisory-committee BioBriefs en 2026-07-29T14:32:30Z FDA scrutiny and advisory committee pressure for Duchenne cell therapy https://biobriefs.com/big-biotech-deal-expands-immunology BioBriefs en 2026-07-29T14:32:30Z Big biotech deal expands immunology pipelines https://biobriefs.com/ipo-push-in-sleep-apnea BioBriefs en 2026-07-29T14:32:30Z IPO push in sleep apnea with FDA acceptance for a neuromuscular OSA pill https://biobriefs.com/cell-therapy-manufacturing-scale-up BioBriefs en 2026-07-29T14:32:30Z Cell therapy manufacturing scale-up for AAV retinal gene therapy https://biobriefs.com/gene-editing-and-safety-benchmarking BioBriefs en 2026-07-29T14:32:30Z Gene editing and safety benchmarking for CRISPR-edited therapies https://biobriefs.com/hospital-diagnostics-expansion-blood-based BioBriefs en 2026-07-29T14:32:30Z Hospital diagnostics expansion: blood-based colorectal screening approval https://biobriefs.com/oncology-immunotherapy-trial-support-to BioBriefs en 2026-07-29T14:32:30Z Oncology immunotherapy trial support to avoid cystectomy in BCG-unresponsive bladder cancer https://biobriefs.com/ai-powered-point-of-care BioBriefs en 2026-07-29T14:32:30Z AI-powered point-of-care diagnostics funding for COPD detection https://biobriefs.com/regulatory-scrutiny-for-fda-advisory BioBriefs en 2026-07-29T10:31:16Z Regulatory scrutiny for FDA advisory committee decisions https://biobriefs.com/biotech-ipo-and-late-stage BioBriefs en 2026-07-29T10:31:16Z Biotech IPO and late-stage clinical momentum https://biobriefs.com/m-a-reshapes-immunology-pipeline BioBriefs en 2026-07-29T10:31:16Z M&A reshapes immunology pipeline portfolios https://biobriefs.com/orphan-gene-edited-cell-therapy BioBriefs en 2026-07-29T10:31:16Z Orphan gene-edited cell therapy manufacturing scaling https://biobriefs.com/cdmo-capacity-and-process-execution BioBriefs en 2026-07-29T10:31:16Z CDMO capacity and process execution for AAV retinal gene therapy https://biobriefs.com/diagnostics-and-regulatory-approval-for BioBriefs en 2026-07-29T10:31:16Z Diagnostics and regulatory approval for colorectal cancer screening https://biobriefs.com/gene-therapies-and-ai-designed BioBriefs en 2026-07-29T10:31:16Z Gene therapies and AI-designed oncology candidates move toward clinical readouts https://biobriefs.com/clinical-trial-signal-for-metabolic BioBriefs en 2026-07-29T10:31:16Z Clinical trial signal for metabolic overlap in alcohol use disorder https://biobriefs.com/protein-and-genome-editing-ai BioBriefs en 2026-07-29T10:31:16Z Protein and genome editing AI tooling expands for next-gen therapeutics https://biobriefs.com/platform-investment-expanded-access-to BioBriefs en 2026-07-29T10:31:16Z Platform investment: expanded access to precision DNA synthesis https://biobriefs.com/product-launches-and-clinical-validation BioBriefs en 2026-07-29T09:32:07Z Product launches and clinical validation in immuno-oncology https://biobriefs.com/fda-and-regulatory-review-turbulence BioBriefs en 2026-07-29T09:32:07Z FDA and regulatory review turbulence for cell therapies https://biobriefs.com/clinical-stage-turnaround-bets-in BioBriefs en 2026-07-29T09:32:07Z Clinical-stage turnaround bets in the Alzheimer’s pipeline https://biobriefs.com/late-stage-and-pivotal-development BioBriefs en 2026-07-29T09:32:07Z Late-stage and pivotal development commitments for oncology drug conjugates https://biobriefs.com/ipo-pipeline-momentum-in-sleep BioBriefs en 2026-07-29T09:32:07Z IPO pipeline momentum in sleep apnea pharmacotherapy https://biobriefs.com/cell-therapy-manufacturing-scale-up BioBriefs en 2026-07-29T09:32:07Z Cell therapy manufacturing scale-up via CDMO partnerships https://biobriefs.com/precision-diagnostics-expansion-in-colorectal BioBriefs en 2026-07-29T09:32:07Z Precision diagnostics expansion in colorectal cancer screening https://biobriefs.com/digital-and-sensor-based-monitoring BioBriefs en 2026-07-29T09:32:07Z Digital and sensor-based monitoring moving into clinical care workflows https://biobriefs.com/regenerative-ophthalmology-gets-late-stage BioBriefs en 2026-07-29T09:32:07Z Regenerative ophthalmology gets late-stage funding push https://biobriefs.com/fda-policy-and-governance-shifts BioBriefs en 2026-07-29T09:32:07Z FDA policy and governance shifts around advisory panels and trial evidence https://biobriefs.com/regulatory-safety-review-for-next BioBriefs en 2026-07-29T04:31:59Z Regulatory / Safety review for next-gen immunotherapies https://biobriefs.com/strategic-m-a-in-immunology BioBriefs en 2026-07-29T04:31:59Z Strategic M&A in immunology https://biobriefs.com/expanding-molecular-diagnostics-with-fda BioBriefs en 2026-07-29T04:31:59Z Expanding molecular diagnostics with FDA-backed screening https://biobriefs.com/novel-drug-development-in-late BioBriefs en 2026-07-29T04:31:59Z Novel drug development in late-stage trials https://biobriefs.com/company-acquisition-and-lab-automation BioBriefs en 2026-07-29T04:31:59Z Company acquisition and lab automation for next-gen sequencing workflows https://biobriefs.com/medical-device-and-ai-monitoring BioBriefs en 2026-07-29T04:31:59Z Medical device and AI monitoring investments https://biobriefs.com/diagnostics-innovation-in-oncology-screening BioBriefs en 2026-07-29T04:31:59Z Diagnostics innovation in oncology screening https://biobriefs.com/regulatory-and-precision-medicine-infrastructure BioBriefs en 2026-07-29T04:31:59Z Regulatory and precision-medicine infrastructure https://biobriefs.com/r-d-funding-for-platform BioBriefs en 2026-07-29T04:31:59Z R&D funding for platform expansion in genetic testing tools https://biobriefs.com/corporate-biotech-leadership-and-governance BioBriefs en 2026-07-29T04:31:59Z Corporate biotech leadership and governance shifts https://biobriefs.com/immunology-m-a-argenx-buys BioBriefs en 2026-07-28T21:31:34Z Immunology M&A: Argenx buys Forte Biosciences to add anti-CD122 antibody FB102 https://biobriefs.com/fda-oncology-oversight-replimunes-rp BioBriefs en 2026-07-28T21:31:34Z FDA oncology oversight: Replimune’s RP-1 faces renewed efficacy concerns ahead of adcom https://biobriefs.com/regulatory-change-fda-expands-simtriyo BioBriefs en 2026-07-28T21:31:34Z Regulatory change: FDA expands Simtriyo label in adult and pediatric ADHD https://biobriefs.com/clinical-trial-mayo-led-phase BioBriefs en 2026-07-28T21:31:34Z Clinical trial: Mayo-led Phase 3 suggests intravesical cretostimogene grenadenorepvec may delay cystectomy https://biobriefs.com/fda-diagnostics-approval-freenomes-simplescreen BioBriefs en 2026-07-28T21:31:34Z FDA diagnostics approval: Freenome’s SimpleScreen CRC gets U.S. green light; Abbott to commercialize https://biobriefs.com/oncology-drug-development-casdatifan-shows BioBriefs en 2026-07-28T21:31:34Z Oncology drug development: casdatifan shows durable tumor responses in Phase 1 ccRCC trial https://biobriefs.com/cell-therapy-regulatory-pressure-capricors BioBriefs en 2026-07-28T21:31:34Z Cell therapy regulatory pressure: Capricor’s deramiocel faces FDA skepticism ahead of DMD adcom https://biobriefs.com/ai-biosensing-startup-epitel-raises BioBriefs en 2026-07-28T21:31:34Z AI + biosensing startup: Epitel raises $26M for wireless EEG seizure monitoring https://biobriefs.com/diagnostics-genomics-infrastructure-ema-selects BioBriefs en 2026-07-28T21:31:34Z Diagnostics & genomics infrastructure: EMA selects TrialAssure tool to anonymize public clinical trial documents https://biobriefs.com/platform-finance-nova-biomedical-acquires BioBriefs en 2026-07-28T21:31:34Z Platform finance: Nova Biomedical acquires NanoCellect assets to broaden cell line development workflow https://biobriefs.com/cancer-diagnostics-approval-and-commercialization BioBriefs en 2026-07-28T16:32:02Z Cancer diagnostics approval and commercialization rights https://biobriefs.com/immunology-m-a-reshapes-autoimmune BioBriefs en 2026-07-28T16:32:02Z Immunology M&A reshapes autoimmune pipeline https://biobriefs.com/fda-cautions-on-cell-therapy BioBriefs en 2026-07-28T16:32:02Z FDA cautions on cell therapy efficacy ahead of advisory vote https://biobriefs.com/fda-challenges-on-melanoma-gene BioBriefs en 2026-07-28T16:32:02Z FDA challenges on melanoma gene therapy for systemic benefit https://biobriefs.com/company-funding-for-pivoting-clinical BioBriefs en 2026-07-28T16:32:02Z Company funding for pivoting clinical-stage ophthalmology asset https://biobriefs.com/us-trial-network-push-uses BioBriefs en 2026-07-28T16:32:02Z US trial network push uses regulatory quality signals https://biobriefs.com/ai-enabled-diagnostic-platform-funding BioBriefs en 2026-07-28T16:32:02Z AI-enabled diagnostic platform funding for COPD https://biobriefs.com/late-stage-decision-reshuffles-oncology BioBriefs en 2026-07-28T16:32:02Z Late-stage decision reshuffles oncology pipeline at Incyte https://biobriefs.com/regulatory-operations-ema-selects-ai BioBriefs en 2026-07-28T16:32:02Z Regulatory operations: EMA selects AI anonymization tool https://biobriefs.com/ongoing-clinical-program-restart-via BioBriefs en 2026-07-28T16:32:02Z Ongoing clinical program restart via gene therapy with dietary drug synergy https://biobriefs.com/fda-review-and-trial-evidence BioBriefs en 2026-07-28T14:32:50Z FDA review and trial evidence for skin cancer therapy https://biobriefs.com/biotech-financing-to-advance-rare BioBriefs en 2026-07-28T14:32:50Z Biotech financing to advance rare eye disease drug into pivotal testing https://biobriefs.com/argenx-acquisition-expands-immunology-pipeline BioBriefs en 2026-07-28T14:32:50Z Argenx acquisition expands immunology pipeline with Forte’s anti-CD122 https://biobriefs.com/fda-approval-for-blood-based BioBriefs en 2026-07-28T14:32:50Z FDA approval for blood-based colorectal cancer screening with Abbott commercialization https://biobriefs.com/altimmune-mid-stage-alcohol-use BioBriefs en 2026-07-28T14:32:50Z Altimmune mid-stage alcohol-use disorder data for GLP-1/glucagon agonist https://biobriefs.com/capricor-faces-fda-questions-on BioBriefs en 2026-07-28T14:32:50Z Capricor faces FDA questions on DMD cell therapy efficacy ahead of adcom https://biobriefs.com/maplights-schizophrenia-program-stumbles-on BioBriefs en 2026-07-28T14:32:50Z Maplight’s schizophrenia program stumbles on once-daily regimen https://biobriefs.com/hospital-and-device-trial-evidence BioBriefs en 2026-07-28T14:32:50Z Hospital and device trial evidence for Claris-like innovation in neonatal care workflows (neonatal POCUS standardization) https://biobriefs.com/germany-scales-genomics-guided-precision BioBriefs en 2026-07-28T14:32:50Z Germany scales genomics-guided precision medicine pilot toward large enrollment https://biobriefs.com/ai-and-trial-execution-risk BioBriefs en 2026-07-28T14:32:50Z AI and trial-execution risk signals for first-in-human studies https://biobriefs.com/immunology-m-a BioBriefs en 2026-07-28T10:31:54Z Immunology M&A https://biobriefs.com/oncology-clinical-development BioBriefs en 2026-07-28T10:31:54Z Oncology clinical development https://biobriefs.com/fda-regulatory-scrutiny-and-advisory BioBriefs en 2026-07-28T10:31:54Z FDA regulatory scrutiny and advisory committee https://biobriefs.com/regulatory-approval-for-cancer-screening BioBriefs en 2026-07-28T10:31:54Z Regulatory approval for cancer screening https://biobriefs.com/ai-enabled-diagnostics-for-respiratory BioBriefs en 2026-07-28T10:31:54Z AI-enabled diagnostics for respiratory disease https://biobriefs.com/ai-driven-drug-safety-in BioBriefs en 2026-07-28T10:31:54Z AI-driven drug safety in Alzheimer’s trials https://biobriefs.com/cancer-precision-diagnostics-startup-funding BioBriefs en 2026-07-28T10:31:54Z Cancer precision diagnostics startup funding https://biobriefs.com/biopharma-leadership-and-market-impact BioBriefs en 2026-07-28T10:31:54Z Biopharma leadership and market impact https://biobriefs.com/antiviral-immune-engineering-in-oncology BioBriefs en 2026-07-28T10:31:54Z Antiviral/immune engineering in oncology https://biobriefs.com/aging-and-biomarker-discovery BioBriefs en 2026-07-28T10:31:54Z Aging and biomarker discovery https://biobriefs.com/argenx-forte-acquisition-expands-autoimmune BioBriefs en 2026-07-28T09:31:59Z Argenx–Forte acquisition expands autoimmune pipeline https://biobriefs.com/fda-scrutiny-hits-capricors-dmd BioBriefs en 2026-07-28T09:31:59Z FDA scrutiny hits Capricor’s DMD cell therapy ahead of adcom https://biobriefs.com/freenome-wins-fda-approval-for BioBriefs en 2026-07-28T09:31:59Z Freenome wins FDA approval for blood-based colorectal cancer screening https://biobriefs.com/maplight-faces-mixed-phase-2 BioBriefs en 2026-07-28T09:31:59Z MapLight faces mixed Phase 2 schizophrenia results with dosing split https://biobriefs.com/pairidex-raises-seed-funding-to BioBriefs en 2026-07-28T09:31:59Z Pairidex raises seed funding to commercialize RNA-based MRD test https://biobriefs.com/oak-hill-bio-plans-nasdaq BioBriefs en 2026-07-28T09:31:59Z Oak Hill Bio plans Nasdaq entry via SPAC merger https://biobriefs.com/omniage-compendium-maps-aging-biomarkers BioBriefs en 2026-07-28T09:31:59Z OmniAge compendium maps aging biomarkers to clonal hematopoiesis https://biobriefs.com/cudc-907-combination-extends-temozolomide BioBriefs en 2026-07-28T09:31:59Z CUDC-907 combination extends temozolomide response in resistant glioblastoma models https://biobriefs.com/capricor-legend-leadership-shifts-add BioBriefs en 2026-07-28T09:31:59Z Capricor, Legend leadership shifts add corporate volatility to gene therapy sector https://biobriefs.com/sarepta-names-michael-severino-ceo BioBriefs en 2026-07-28T09:31:59Z Sarepta names Michael Severino CEO as turnaround efforts accelerate https://biobriefs.com/immunology-m-a BioBriefs en 2026-07-28T04:32:01Z Immunology M&A https://biobriefs.com/oncology-clinical-development-and-trial BioBriefs en 2026-07-28T04:32:01Z Oncology clinical development and trial launches https://biobriefs.com/fda-review-and-advisory-committee BioBriefs en 2026-07-28T04:32:01Z FDA review and advisory committee scrutiny in gene therapy https://biobriefs.com/fda-approval-for-cancer-screening BioBriefs en 2026-07-28T04:32:01Z FDA approval for cancer screening diagnostics https://biobriefs.com/schizophrenia-therapy-update-and-competitive BioBriefs en 2026-07-28T04:32:01Z Schizophrenia therapy update and competitive positioning https://biobriefs.com/biomarker-driven-early-detection-in BioBriefs en 2026-07-28T04:32:01Z Biomarker-driven early detection in ALS https://biobriefs.com/regulatory-and-company-leadership-change BioBriefs en 2026-07-28T04:32:01Z Regulatory and company leadership change https://biobriefs.com/biotech-diagnostics-funding BioBriefs en 2026-07-28T04:32:01Z Biotech diagnostics funding https://biobriefs.com/digital-health-and-continuous-monitoring BioBriefs en 2026-07-28T04:32:01Z Digital health and continuous monitoring in Parkinson’s https://biobriefs.com/biosecurity-policy-and-screening-standards BioBriefs en 2026-07-28T04:32:01Z Biosecurity policy and screening standards https://biobriefs.com/regulatory-and-clinical-efficacy-pressure BioBriefs en 2026-07-27T21:32:07Z Regulatory and clinical efficacy pressure points https://biobriefs.com/fda-approvals-expanding-commercial-diagnostics BioBriefs en 2026-07-27T21:32:07Z FDA approvals expanding commercial diagnostics and therapeutics https://biobriefs.com/big-biotech-acquisition-in-immunology BioBriefs en 2026-07-27T21:32:07Z Big biotech acquisition in immunology https://biobriefs.com/late-stage-ovarian-cancer-trial BioBriefs en 2026-07-27T21:32:07Z Late-stage ovarian cancer trial starts https://biobriefs.com/ai-enabled-genomics-access-expands BioBriefs en 2026-07-27T21:32:07Z AI-enabled genomics access expands for rare disease https://biobriefs.com/national-genomic-precision-medicine-program BioBriefs en 2026-07-27T21:32:07Z National genomic precision medicine program scales https://biobriefs.com/funding-for-rapid-bedside-oriented BioBriefs en 2026-07-27T21:32:07Z Funding for rapid, bedside-oriented COPD diagnostics https://biobriefs.com/liquid-biopsy-and-molecular-mrd BioBriefs en 2026-07-27T21:32:07Z Liquid biopsy and molecular MRD testing moves toward commercialization https://biobriefs.com/pharmaceutical-ipo-pipeline-scribe-enters BioBriefs en 2026-07-27T21:32:07Z Pharmaceutical IPO pipeline: Scribe enters public markets https://biobriefs.com/biotech-capital-formation-for-rare BioBriefs en 2026-07-27T21:32:07Z Biotech capital formation for rare genetic disease via SPAC https://biobriefs.com/regulatory-approval-commercialization BioBriefs en 2026-07-27T16:32:32Z Regulatory approval & commercialization https://biobriefs.com/dealmaking-acquisitions-to-expand-immunology BioBriefs en 2026-07-27T16:32:32Z Dealmaking: acquisitions to expand immunology pipeline https://biobriefs.com/clinical-readouts-schizophrenia-trial-results BioBriefs en 2026-07-27T16:32:32Z Clinical readouts: schizophrenia trial results pressure go-forward decisions https://biobriefs.com/clinical-setbacks-regulatory-scrutiny-duchenne BioBriefs en 2026-07-27T16:32:32Z Clinical setbacks & regulatory scrutiny: Duchenne stem-cell therapy questioned by FDA https://biobriefs.com/corporate-leadership-governance-legend-ceo BioBriefs en 2026-07-27T16:32:32Z Corporate leadership & governance: Legend CEO steps down https://biobriefs.com/nasdaq-listing-risk-quantum-si BioBriefs en 2026-07-27T16:32:32Z Nasdaq listing risk: Quantum-Si notified of delisting https://biobriefs.com/strategic-partnership-execution-ra-capital BioBriefs en 2026-07-27T16:32:32Z Strategic partnership execution: RA Capital backs Angelman rival https://biobriefs.com/funding-seed-round-for-rna BioBriefs en 2026-07-27T16:32:32Z Funding: seed round for RNA-based MRD testing startup https://biobriefs.com/regulatory-filings-pipeline-progress-bispecific BioBriefs en 2026-07-27T16:32:32Z Regulatory filings & pipeline progress: bispecific ADC technical milestone https://biobriefs.com/pipeline-progress-oral-tyk2-inhibitor BioBriefs en 2026-07-27T16:32:32Z Pipeline progress: oral TYK2 inhibitor clears Phase 3 psoriasis endpoint https://biobriefs.com/regulatory-and-trial-scrutiny-in BioBriefs en 2026-07-27T14:32:12Z Regulatory and trial scrutiny in Duchenne muscular dystrophy https://biobriefs.com/leadership-shakeups-at-commercial-oncology BioBriefs en 2026-07-27T14:32:12Z Leadership shakeups at commercial oncology and cell therapy companies https://biobriefs.com/immunology-m-a-accelerates-with BioBriefs en 2026-07-27T14:32:12Z Immunology M&A accelerates with Argenx’s acquisition of Forte https://biobriefs.com/corporate-restructuring-and-ceo-change BioBriefs en 2026-07-27T14:32:12Z Corporate restructuring and CEO change at a Duchenne-focused biotech https://biobriefs.com/ai-driven-diagnostics-and-reimbursement BioBriefs en 2026-07-27T14:32:12Z AI-driven diagnostics and reimbursement infrastructure funding https://biobriefs.com/therapeutic-pipeline-revival-in-rare BioBriefs en 2026-07-27T14:32:12Z Therapeutic pipeline revival in rare brain disease funding https://biobriefs.com/nasdaq-listing-compliance-pressures-hit BioBriefs en 2026-07-27T14:32:12Z Nasdaq listing compliance pressures hit protein sequencing and in vitro diagnostics https://biobriefs.com/nasdaq-compliance-notice-adds-pressure BioBriefs en 2026-07-27T14:32:12Z Nasdaq compliance notice adds pressure to diagnostics test portfolio https://biobriefs.com/large-pharma-uses-ai-in BioBriefs en 2026-07-27T14:32:12Z Large pharma uses AI in late-stage development – AZ reports setbacks in pipeline https://biobriefs.com/immunology-licensing-and-biologics-pipeline BioBriefs en 2026-07-27T14:32:12Z Immunology licensing and biologics pipeline repositioning via European foundation funding https://biobriefs.com/immunology-m-a-accelerates-pipeline BioBriefs en 2026-07-27T10:32:07Z Immunology M&A accelerates pipeline https://biobriefs.com/company-finance-ipo-with-pharma BioBriefs en 2026-07-27T10:32:07Z Company finance – IPO with pharma tie-up https://biobriefs.com/clinical-development-funding-pivotal-testing BioBriefs en 2026-07-27T10:32:07Z Clinical development funding – pivotal testing for gout https://biobriefs.com/patient-safety-and-therapeutics-device BioBriefs en 2026-07-27T10:32:07Z Patient safety and therapeutics – device-based monitoring and delivery https://biobriefs.com/artificial-intelligence-in-care-prediction BioBriefs en 2026-07-27T10:32:07Z Artificial intelligence in care prediction https://biobriefs.com/health-systems-rethinking-hospital-preparation BioBriefs en 2026-07-27T10:32:07Z Health systems – Rethinking hospital preparation for treatment continuity https://biobriefs.com/immunotherapy-discovery-spatial-mapping-for BioBriefs en 2026-07-27T10:32:07Z Immunotherapy discovery – spatial mapping for response biology https://biobriefs.com/gene-therapy-economics-aav-cost BioBriefs en 2026-07-27T10:32:07Z Gene therapy economics – AAV cost modeling for access planning https://biobriefs.com/biotech-funding-ai-platform-for BioBriefs en 2026-07-27T10:32:07Z Biotech funding – AI platform for revenue cycle management https://biobriefs.com/drug-discovery-tools-protein-evolution BioBriefs en 2026-07-27T10:32:07Z Drug discovery tools – protein evolution with AI-designed starting points https://biobriefs.com/big-pharma-deal-making-and BioBriefs en 2026-07-27T09:31:52Z Big Pharma deal-making and pipeline funding https://biobriefs.com/biotech-ipo-financing-and-partner BioBriefs en 2026-07-27T09:31:52Z Biotech IPO financing and partner continuity https://biobriefs.com/china-and-global-biotech-positioning BioBriefs en 2026-07-27T09:31:52Z China and global biotech positioning for growth https://biobriefs.com/thrombocytopenia-therapy-safety-signals BioBriefs en 2026-07-27T09:31:52Z Thrombocytopenia therapy safety signals https://biobriefs.com/immunology-discovery-and-tumor-microenvironment BioBriefs en 2026-07-27T09:31:52Z Immunology discovery and tumor microenvironment tuning https://biobriefs.com/cell-therapy-adjacent-platform-expansion BioBriefs en 2026-07-27T09:31:52Z Cell therapy–adjacent platform expansion in pharma https://biobriefs.com/next-gen-immunotherapy-design-with BioBriefs en 2026-07-27T09:31:52Z Next-gen immunotherapy design with safety constraints https://biobriefs.com/viral-host-pathway-screening-for BioBriefs en 2026-07-27T09:31:52Z Viral host-pathway screening for antivirals https://biobriefs.com/diagnostic-and-monitoring-tools-for BioBriefs en 2026-07-27T09:31:52Z Diagnostic and monitoring tools for chronic care https://biobriefs.com/regulatory-and-market-risk-chemotherapy BioBriefs en 2026-07-27T09:31:52Z Regulatory and market risk: chemotherapy shortages https://biobriefs.com/immunology-lactic-acid-dampens-interferon BioBriefs en 2026-07-27T04:31:55Z Immunology: lactic acid dampens interferon antiviral signaling https://biobriefs.com/oncology-ultrasound-based-mechanical-targeting BioBriefs en 2026-07-27T04:31:55Z Oncology: ultrasound-based mechanical targeting of oral cancer cells https://biobriefs.com/neurobiology-neural-stem-cell-exosomes BioBriefs en 2026-07-27T04:31:55Z Neurobiology: neural stem cell exosomes repair the blood-brain barrier after radiation https://biobriefs.com/cancer-immunology-ovarian-cancer-ascites BioBriefs en 2026-07-27T04:31:55Z Cancer immunology: ovarian cancer ascites suppresses T-cell activation via lipid effects https://biobriefs.com/infectious-disease-host-genome-screening BioBriefs en 2026-07-27T04:31:55Z Infectious disease: host-genome screening highlights SARS-CoV-2 pro-viral pathways https://biobriefs.com/clinical-development-funding-crystalys-raises BioBriefs en 2026-07-27T04:31:55Z Clinical development & funding: Crystalys raises $130M for pivotal gout testing https://biobriefs.com/healthcare-operations-chemotherapy-shortages-strain BioBriefs en 2026-07-27T04:31:55Z Healthcare operations: chemotherapy shortages strain oncology delivery https://biobriefs.com/capital-markets-healthcare-it-candid BioBriefs en 2026-07-27T04:31:55Z Capital markets & healthcare IT: Candid Health raises $120M for AI RCM platform https://biobriefs.com/drug-development-delivery-cannabidiol-albumin BioBriefs en 2026-07-27T04:31:55Z Drug development & delivery: cannabidiol-albumin nanoparticles aim to improve brain delivery in Alzheimer’s https://biobriefs.com/immunology-primary-itp-trial-tests BioBriefs en 2026-07-27T04:31:55Z Immunology: primary ITP trial tests low-dose baricitinib plus danazol https://biobriefs.com/immunology-in-cancer BioBriefs en 2026-07-26T21:31:27Z Immunology in cancer https://biobriefs.com/cell-death-and-cancer-biology BioBriefs en 2026-07-26T21:31:27Z Cell death and cancer biology https://biobriefs.com/immune-engineering-platform-design BioBriefs en 2026-07-26T21:31:26Z Immune engineering platform design https://biobriefs.com/liquid-biopsy-and-spatial-immuno BioBriefs en 2026-07-26T21:31:26Z Liquid biopsy and spatial immuno-oncology https://biobriefs.com/virology-and-host-targeted-antivirals BioBriefs en 2026-07-26T21:31:26Z Virology and host-targeted antivirals https://biobriefs.com/gene-therapy-economics BioBriefs en 2026-07-26T21:31:26Z Gene therapy economics https://biobriefs.com/alzheimers-drug-delivery BioBriefs en 2026-07-26T21:31:26Z Alzheimer’s drug delivery https://biobriefs.com/therapeutic-shortages-and-oncology-access BioBriefs en 2026-07-26T21:31:26Z Therapeutic shortages and oncology access risk https://biobriefs.com/diagnostics-and-immunotherapy-tissue-mapping BioBriefs en 2026-07-26T21:31:26Z Diagnostics and immunotherapy tissue mapping https://biobriefs.com/digital-health-funding BioBriefs en 2026-07-26T21:31:26Z Digital health funding https://biobriefs.com/gene-therapy-economics-and-capacity BioBriefs en 2026-07-26T16:32:06Z Gene therapy economics and capacity planning https://biobriefs.com/regulatory-dispute-over-niche-oncology BioBriefs en 2026-07-26T16:32:06Z Regulatory dispute over niche oncology drug https://biobriefs.com/fda-advisory-panel-vote-on BioBriefs en 2026-07-26T16:32:06Z FDA advisory panel vote on compounded peptides https://biobriefs.com/car-t-safety-genomics BioBriefs en 2026-07-26T16:32:06Z CAR-T safety genomics https://biobriefs.com/emerging-antiviral-candidate-for-measles BioBriefs en 2026-07-26T16:32:06Z Emerging antiviral candidate for measles-like spread https://biobriefs.com/cancer-immunotherapy-platform-off-the BioBriefs en 2026-07-26T16:32:06Z Cancer immunotherapy platform: off-the-shelf iPSC-derived cells https://biobriefs.com/liquid-biopsy-to-map-spatial BioBriefs en 2026-07-26T16:32:06Z Liquid biopsy to map spatial antitumor immunity https://biobriefs.com/clinical-and-supply-chemotherapy-shortage BioBriefs en 2026-07-26T16:32:06Z Clinical and supply: chemotherapy shortage risk https://biobriefs.com/virology-and-platform-host-directed BioBriefs en 2026-07-26T16:32:06Z Virology and platform: host-directed SARS-CoV-2 pathways https://biobriefs.com/company-funding-ai-revenue-cycle BioBriefs en 2026-07-26T16:32:06Z Company funding: AI revenue cycle management push https://biobriefs.com/crispr-therapeutics-and-early-commercial BioBriefs en 2026-07-26T14:31:32Z CRISPR therapeutics and early commercial signals https://biobriefs.com/biopharma-financing-and-enzyme-platform BioBriefs en 2026-07-26T14:31:32Z Biopharma financing and enzyme platform economics https://biobriefs.com/car-t-safety-biology-flagged BioBriefs en 2026-07-26T14:31:32Z CAR-T safety biology flagged by patient genomics https://biobriefs.com/fda-advisory-panel-weighs-compounding BioBriefs en 2026-07-26T14:31:32Z FDA advisory panel weighs compounding peptide access https://biobriefs.com/regulatory-standoff-over-rare-disease BioBriefs en 2026-07-26T14:31:32Z Regulatory standoff over rare disease medicine in Europe https://biobriefs.com/sanofi-pulls-back-eczema-indication BioBriefs en 2026-07-26T14:31:32Z Sanofi pulls back eczema indication for OX40-ligand antibody https://biobriefs.com/npc-therapy-attempt-hits-another BioBriefs en 2026-07-26T14:31:32Z NPC therapy attempt hits another EMA gate https://biobriefs.com/measles-like-antiviral-blocks-transmission BioBriefs en 2026-07-26T14:31:32Z Measles-like antiviral blocks transmission in ferrets https://biobriefs.com/gut-targeting-engineering-flips-pancreatic BioBriefs en 2026-07-26T14:31:32Z Gut-targeting engineering flips pancreatic cancer immune context (preclinical) https://biobriefs.com/off-the-shelf-ipsc-derived BioBriefs en 2026-07-26T14:31:32Z Off-the-shelf iPSC-derived γδ T cells for colorectal cancer (preclinical) https://biobriefs.com/european-regulator-decision-reshapes-orphan BioBriefs en 2026-07-26T10:31:36Z European regulator decision reshapes orphan-drug landscape https://biobriefs.com/sanofi-reverses-atopic-dermatitis-strategy BioBriefs en 2026-07-26T10:31:36Z Sanofi reverses atopic dermatitis strategy tied to OX40L program https://biobriefs.com/car-t-safety-genetics-move BioBriefs en 2026-07-26T10:31:36Z CAR-T safety genetics move toward smarter engineering https://biobriefs.com/crispr-therapy-ethics-and-oversight BioBriefs en 2026-07-26T10:31:36Z CRISPR therapy ethics and oversight spotlighted after fatal trial https://biobriefs.com/gene-regulation-science-accelerates-via BioBriefs en 2026-07-26T10:31:36Z Gene regulation science accelerates via NIH 4D Nucleome https://biobriefs.com/biotech-ipo-market-extends-momentum BioBriefs en 2026-07-26T10:31:36Z Biotech IPO market extends momentum with Scribe listing https://biobriefs.com/codexis-secures-23-1m-public BioBriefs en 2026-07-26T10:31:36Z Codexis secures $23.1M public offering to fund enzyme tooling https://biobriefs.com/new-crispr-free-cell-therapy BioBriefs en 2026-07-26T10:31:36Z New CRISPR-free cell therapy angle: off-the-shelf iPSC-derived gamma delta T cells for CRC https://biobriefs.com/transcripta-bio-raises-24m-to BioBriefs en 2026-07-26T10:31:36Z Transcripta Bio raises $24M to advance neuro programs toward the clinic https://biobriefs.com/fda-panel-advances-compounding-peptide BioBriefs en 2026-07-26T10:31:36Z FDA panel advances compounding peptide access—tight split vote https://biobriefs.com/european-orphan-drug-decisions-reshape BioBriefs en 2026-07-26T09:32:15Z European orphan-drug decisions reshape rare disease options https://biobriefs.com/car-t-toxicity-genomics-point BioBriefs en 2026-07-26T09:32:15Z CAR-T toxicity genomics point to patient-specific risk flags https://biobriefs.com/sanofi-reverses-eczema-filing-strategy BioBriefs en 2026-07-26T09:32:15Z Sanofi reverses eczema filing strategy for OX40-ligand antibody https://biobriefs.com/regulators-narrow-access-for-compounding BioBriefs en 2026-07-26T09:32:15Z Regulators narrow access for compounding peptides in FDA advisory vote https://biobriefs.com/ipo-window-stays-open-for BioBriefs en 2026-07-26T09:32:15Z IPO window stays open for CRISPR startup Scribe https://biobriefs.com/biotech-fundraising-continues-as-codexis BioBriefs en 2026-07-26T09:32:15Z Biotech fundraising continues as Codexis sells equity https://biobriefs.com/amgen-and-fda-dispute-over BioBriefs en 2026-07-26T09:32:15Z Amgen and FDA dispute over Tavneos moves to a new evidentiary round https://biobriefs.com/global-approvals-hit-a-strong BioBriefs en 2026-07-26T09:32:15Z Global approvals hit a strong H1 pace https://biobriefs.com/biotech-starts-chasing-new-preclinical BioBriefs en 2026-07-26T09:32:15Z Biotech starts chasing new preclinical targets in preeclampsia via single-cell maps https://biobriefs.com/new-funding-supports-neuro-and BioBriefs en 2026-07-26T09:32:15Z New funding supports neuro and muscle programs at Transcripta Bio https://biobriefs.com/eu-regulator-action-on-rare BioBriefs en 2026-07-26T04:31:53Z EU regulator action on rare disease and peptide therapy https://biobriefs.com/sanofi-retreats-on-atopic-dermatitis BioBriefs en 2026-07-26T04:31:53Z Sanofi retreats on atopic dermatitis filing for amlitelimab https://biobriefs.com/car-t-toxicity-risk-linked BioBriefs en 2026-07-26T04:31:53Z CAR-T toxicity risk linked to patient genetics https://biobriefs.com/biotech-ipo-momentum-continues-with BioBriefs en 2026-07-26T04:31:53Z Biotech IPO momentum continues with CRISPR and new listings https://biobriefs.com/fda-advisory-panel-votes-on BioBriefs en 2026-07-26T04:31:53Z FDA advisory panel votes on compounding peptides https://biobriefs.com/amgen-faces-an-fda-dispute BioBriefs en 2026-07-26T04:31:53Z Amgen faces an FDA dispute over Tavneos continued availability https://biobriefs.com/biopharma-financing-and-public-market BioBriefs en 2026-07-26T04:31:53Z Biopharma financing and public-market activity https://biobriefs.com/royalty-monetization-deal-for-an BioBriefs en 2026-07-26T04:31:53Z Royalty monetization deal for an ATTR-CM antibody in Phase 3 https://biobriefs.com/ai-enabled-platforms-for-sequencing BioBriefs en 2026-07-26T04:31:53Z AI-enabled platforms for sequencing and drug discovery https://biobriefs.com/new-biotech-funding-for-neuro BioBriefs en 2026-07-26T04:31:53Z New biotech funding for neuro programs https://biobriefs.com/gene-editing-and-translational-safety BioBriefs en 2026-07-25T21:31:57Z Gene editing and translational safety/oversight https://biobriefs.com/regulatory-pulse-peptides-and-compounding BioBriefs en 2026-07-25T21:31:57Z Regulatory pulse: peptides and compounding pharmacies https://biobriefs.com/eu-regulation-orphan-drug-wins BioBriefs en 2026-07-25T21:31:57Z EU regulation: orphan drug wins, another NPC submission rejected https://biobriefs.com/us-evidence-car-t-toxicity BioBriefs en 2026-07-25T21:31:57Z US evidence: CAR-T toxicity genetics in Yescarta trials https://biobriefs.com/pipeline-reprioritization-sanofi-reverses-eczema BioBriefs en 2026-07-25T21:31:57Z Pipeline reprioritization: Sanofi reverses eczema filing plans https://biobrie